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Text
Abstract
Chronic widespread pain (CWP) is common and associated with poor health. In general practice 
no morbidity code for CWP exists. By identifying patients in medical records consulting regularly 
over five years with multiple individual regional (axial, upper limb, lower limb) problems, a 
previous study identified patients in one practice with features consistent with CWP. This suggests 
patients regularly consult for regional pains without being recognised, or managed, as having a 
generalised condition. The original criteria for identifying these recurrent regional consulters 
(RRCs) had limitations including a restricted set of musculoskeletal morbidity codes.
This thesis aimed to develop the existing RRC definition, determine characteristics of RRCs, and 
assess the extent of unrecognised CWP in primary care. The study was set in: i) a general 
practice database; ii) a cohort with linked self-reported health and medical records.
RRCs were identified using different code lists, over altered timeframes, and with a varied number 
of recorded body regions. Three-quarters of RRCs were not recorded with a generalised pain 
code related to CWP (e.g. fibromyalgia) and are therefore potentially unrecognised as having a 
generalised pain condition. Recorded prevalence of recognised CWP was lower than community 
CWP prevalence, suggesting CWP is under-recognised in primary care. 
The new approach to identifying RRCs, using all regional musculoskeletal Read codes and 
identifying patients prospectively between three and five years from an index musculoskeletal 
consultation, identified more patients earlier, and returned patients with features consistent with 
self-reporting of CWP (e.g. increased somatic symptoms, frequent consultation, worse general 
health). However, RRC prevalence overestimated CWP prevalence and not all RRCs self-reported 
CWP, suggesting the RRC criteria identified a heterogeneous group of frequent consulters sharing 
features with CWP, including those less severely affected who do not necessarily fit established 
CWP criteria. They nonetheless lie on the spectrum of polysymptomatic distress characteristic of 
CWP.
i
Glossary and abbreviations
Term Definition
ACR-90 The American College of Rheumatology criteria for CWP/FM (Wolfe et al. 1990). 
CWP is defined as pain lasting three months or longer, located axially (cervical 
spine, thoracic spine, anterior chest or low back), above and below the waist, 
and on the left and right sides of the body. FM diagnosis requires CWP and 11 
out of 18 specific tender points.
ACR-2010 The 2010 revised American College of Rheumatology FM criteria (Wolfe et al. 
2010). FM is defined as either: i) WPI≥7 and SS≥5; or ii) WPI 3–6 and SS≥9.
AS Ankylosing spondylitis
CI Confidence interval
CiPCA Consultations in Primary Care Archive. A dataset containing anonymised 
primary care consultation data from 10 to 14 (depending on year) general 
practices in the North Staffordshire area of the UK.
Consultation-based CWP CWP cases defined using primary care consultation patterns for specific 
musculoskeletal pain complaints.
CWP
 
Chronic widespread pain: This refers to unexplained, longstanding, diffuse 
body pain. It is the characteristic feature of fibromyalgia. It has been most 
widely studied using the 1990 ACR criteria (Wolfe et al. 1990) and is often 
associated with multiple somatic symptoms (Aggarwal et al. 2006).
FA Frequent attender/attendance.
FM Fibromyalgia
IQR Inter-quartile range
Manchester criteria Alternative criteria for CWP (Hunt et al. 1999). Like the ACR-90 pain must be 
present in at least two contralateral body quadrants, however, to reflect a more 
diffuse pattern of pain, for a body quadrant to be deemed positive, pain must 
be present in at least two regions of that quadrant.
NES Not elsewhere specified. Used in Read code clinical terms.
NOS Not otherwise specified. Used in Read code clinical terms.
NorStOP North Staffordshire Osteoarthritis Project (Thomas et al. 2004b). A large 
prospective cohort study of people aged 50 and over. Respondents were 
recruited from the registered populations of six general practices from the Keele 
GP Research Partnership which is supported by the North Staffordshire Primary 
Care Research Consortium. Baseline, three-year and six-year demographic, 
generic and musculoskeletal postal questionnaire responses have been 
collected (Thomas et al. 2004a, Thomas et al. 2004b, Thomas et al. 2007, 
Jordan et al. 2008). These responses have been linked to the medical records 
of those respondents who consented.
MS Musculoskeletal
NS Non-specific pain. Used to describe Read codes for non-specific pain which 
could represent CWP coding. Non-specific coding was used as a proxy for 
recognised CWP coding. 
OA Osteoarthritis
OR Odds ratio
PMR Polymyalgia rheumatica
ii
Term Definition
QOF Quality and Outcomes Framework. Following the introduction of the new 
General Medical Services contract in 2004, substantial financial rewards were 
linked to a number of quality indicators (Doran et al. 2006, Sutton & McLean 
2006). The contract increased practice income based on performance in areas 
of ‘quality’ identified in the Quality and Outcomes Framework (QOF). The QOF 
identified 146 clinical and organisational benchmarks (Doran et al. 2008, 
Guthrie et al. 2006). Quality points were accrued by evaluation of a limited list of  
Read codes from practice records (Williams and de Lusignan 2006).
RA Rheumatoid arthritis
Rohrbeck criteria The consultation-based CWP criteria defined by Jens Rohrbeck, (Rohrbeck 
2002, Rohrbeck et al. 2007). Requires a pattern of consultations for specific 
Read codes over a five-year period.
Rohrbeck-2002 First consultation-based CWP criteria proposed by Rohrbeck (2002), uses the 
same consultation pattern as Rohrbeck-2007 criteria and also includes an age 
specification and individuals recorded with FM or fibrositis codes.
Rohrbeck-2007 Using primary care consultation data and a list of 147 Read codes (appendix 
A5.1), Rohrbeck-2007 RRCs need the following consultation pattern:
  In a period of 5 consecutive years fulfil all of i)–iv):
i) at least 1 consultation for a musculoskeletal complaint in the axial skeleton 
(neck & back);
ii) at least 1 consultation for an upper or lower limb complaint
iii) at least 1 consultation for a regional musculoskeletal complaint in each of 3 
separate years;
iv) at least 4 consultations for regional musculoskeletal complaints in total 
during the 5 year period.
RRC Recurrent Regional Consulter. Patients with repeated regional musculoskeletal 
consultations. Defined initially using the Rohrbeck-2007 consultation-based 
CWP criteria. Definition developed throughout this thesis.
RRC-all Recurrent regional consulters identified using a list of all regional 
musculoskeletal Read codes.
RRC-clinician Recurrent regional consulters identified using a list of all regional 
musculoskeletal Read codes excluding those identified by an advisory panel of 
clinicians as being unlikely to represent CWP.
RRC-Rohrbeck Recurrent regional consulters identified using the original list of 147 
musculoskeletal pain Read codes identified by Rohrbeck (2007).
RRC-all-2 Recurrent regional consulters identified using a list of all regional 
musculoskeletal Read codes. Recorded as consulting in two body regions only:  
axial and upper limb, or axial and lower limb.
RRC-all-3 Recurrent regional consulters identified using a list of all regional 
musculoskeletal Read codes. Recorded as consulting in all three body regions: 
axial, upper limb and lower limb.
RRC-clinician-2 Recurrent regional consulters identified using a list of all regional 
musculoskeletal Read codes excluding those identified by an advisory panel of 
clinicians as being unlikely to represent CWP. Recorded as consulting in two 
body regions only: axial and upper limb, or axial and lower limb.
RRC-clinician-3 Recurrent regional consulters identified using a list of all regional 
musculoskeletal Read codes excluding those identified by an advisory panel of 
clinicians as being unlikely to represent CWP. Recorded as consulting in all 
three body regions: axial, upper limb and lower limb.
RRC-Rohrbeck-2 Recurrent regional consulters identified using the original list of 147 
musculoskeletal pain Read codes identified by Rohrbeck (2007). Recorded as 
consulting in two body regions only: axial and upper limb, or axial and lower 
limb.
RRC-Rohrbeck-3 Recurrent regional consulters identified using the original list of 147 
musculoskeletal pain Read codes identified by Rohrbeck (2007). Recorded as 
consulting in all three body regions: axial, upper limb and lower limb.
iii
Term Definition
Search strategy This term is used in two different contexts in this thesis: i) with reference to the 
systematic review it is: the set of search terms used to search for relevant 
papers within a medical reference database such as Medline; and ii) with 
reference to general practice electronic data this refers to this refers to the 
consultation-based definitions of CWP, for example the RRC definition or 
Rohrbeck’s original criteria.
sd Standard deviation
SLE Systemic lupus erythematosus
SS Symptom Severity: 0–12 measure of severity of somatic symptoms used in the 
ACR-2010 criteria. Fatigue, waking unrefreshed and cognitive symptoms are 
assigned a score between zero (no problem) and three (severe problem). The 
number of somatic symptoms reported are also scored from zero (no 
symptoms) to three (a great deal of symptoms). The scores for the three 
individual symptoms (fatigue, waking unrefreshed, cognitive symptoms) are 
added to the score for the number of symptoms reported to produce a figure for 
symptom severity.
WPI Widespread Pain Index: 0–19 measure of diffuse nature of pain used in the 
ACR-2010 criteria. Nineteen body regions are assessed for presence/absence 
of pain symptoms.
iv
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Chapter 1
Introduction
Chronic widespread pain (CWP) is a common condition (estimated to affect 10–11% of the 
population, Chapter Three) characterised by longstanding diffuse musculoskeletal pain and 
frequently associated with other physical symptoms such as fatigue, psychological distress and 
concentration problems. Strictly defined, using the American College of Rheumatology 1990 
definition (Wolfe et al. 1990), CWP is the fundamental feature of fibromyalgia (FM). FM and CWP 
can be considered as points on a spectrum of chronic musculoskeletal pain with FM at the 
extreme (Häuser et al. 2009c, Wolfe et al. 2013). CWP is associated with poor longterm health 
outcomes (section 2.2.4) and patients have been found to be frequent consulters in primary care 
(Kadam et al. 2005). Due to the range of symptoms experienced and recommendations for a 
multidisciplinary approach to treatment, many feel that CWP should be managed in primary care 
(section 2.4). Identifying CWP in general practice is therefore important.
No specific morbidity code exists for CWP in UK primary care. It has been suggested therefore 
that patients who may fulfill the criteria for CWP are often diagnosed and treated in primary care 
on the basis of the regional pain pattern that they present with (for example, elbow pain or knee 
pain) (Rohrbeck et al. 2007). Rohrbeck (2002) proposed that patients who could potentially fit 
established criteria were being coded with multiple regional pain complaints. Using long-term 
recurrent regional musculoskeletal consultation patterns Rohrbeck (2007) then identified a set of 
patients in one practice with features consistent with CWP: more health problems, worse self-
reported general health, more sleep problems, and higher levels of fatigue. This suggests that 
there is a group of patients regularly consulting for regional pains (for example, axial pain, hip 
pain) who are not being recognised, and critically not treated, as having a generalised pain 
condition.
This research aimed to further develop Rohrbeck’s original consultation-based CWP (“recurrent 
regional consulter”) criteria (presented in Table 1.1 and explored in further detail in section 2.) and 
apply a refined recurrent regional consulter (RRC) definition to explore the epidemiology and 
changes in self-reported health over time of patients who consult their general practitioner with 
symptoms suggestive of CWP. 
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Table 1.1 Rohrbeck RRC definition (2007).
In a period of 5 consecutive years a patient fulfils all of i)–iv):
i) At least 1 consultation for a musculoskeletal complaint in the axial skeleton (neck & back);
ii) At least 1 consultation for an upper or lower limb complaint;
iii) At least 1 consultation for a regional musculoskeletal complaint in each of 3 separate years;
iv) At least 4 consultations for regional musculoskeletal complaints in total during the 5 year 
period. 
This chapter provides an overview of the thesis as a whole, an outline of research questions to be 
addressed, and provides a rationale for the inclusion of each phase of the research to draw the 
thesis together as a coherent and logically connected piece of work.
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1.1 Aims and objectives
The aim of this thesis is to investigate the epidemiology of consultation-based CWP (recurrent 
regional musculoskeletal consultation) in primary care.
Specifically:
1. To further develop the criteria for consultation-based CWP (recurrent regional musculoskeletal 
consultation) proposed by Jens Rohrbeck (2007).
2. To assess the quality (efficacy of the search strategy within primary care medical records to 
return patients with CWP) of the refined criteria by:
• Comparison of CWP prevalence figures derived using the consultation-based criteria with:
• Prevalence of CWP in the general population derived from a systematic review;
• Primary care coding prevalences of generalised musculoskeletal pain conditions 
related to CWP.
• Assessing the construct validity of the criteria by examining the features of the patients 
returned by the criteria and comparing them to those expected in patients with self-reported 
CWP.
• Comparison of consultation-based CWP (recurrent regional consultation) status with self-
reported CWP status.
3. To investigate the characteristics of patients with consultation-based CWP (termed in this 
thesis as “recurrent regional consulters”) in terms of: demographics, socio-economic status, 
comorbidity (including consultation rate, frequent attendance, and numbers of recorded 
somatic symptoms), and self-reported mental and physical health.
4. To determine changes in pain and general health status over time in recurrent regional 
consulters.
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1.2 Importance of this research
This research further develops the consultation-based CWP (recurrent regional consultation) 
criteria proposed by Rohrbeck (2007) and employs a refined search strategy to identify patients 
from routinely recorded primary care data. This allows exploration of the characteristics of patients 
who consult their primary care practitioner with symptoms suggestive of CWP.
1.2.1 Increased recognition of CWP in primary care
This study further explores the hypothesis that patients fitting the criteria for CWP are being coded 
by their GPs as having multiple consultations for individual regional pain complaints. There are a 
number of possible explanations for recording CWP patients as multiple consultations for regional 
pain complaints. Since no Read code exists for CWP, it may be that clinicians are simply using the 
code that most closely matches a patient’s main presenting problem. However, research 
(Gallagher et al. 2004, Hughes et al. 2006) suggests that the Read code for FM is under-utilised in 
primary care, implying that should a code for CWP exist it might not be employed. Given that 
effective interventions are available (section 2.2.6), whatever the reason for any under-recognition 
of CWP/FM in primary care, it should be remedied so that patients have access to appropriate 
interventions and therefore limit poor long-term health outcomes. This research has the scope to 
provide justification for: i) the provision of a unique code for CWP; and ii) an education 
programme for primary care practitioners to aid the identification, coding, and management of 
these patients.
If feasible and financially justifiable, the search strategy to identify recurrent regional consulters 
could be integrated into general practice software alerting doctors to potential CWP patients. This 
would allow GPs to implement the appropriate management for the patient, rather than continuing 
to treat them for a number of individual regional pain complaints.
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1.2.2 Epidemiology of CWP
Investigation of the characteristics of consultation-based CWP (recurrent regional consultation) 
offers delineation of the patient groups affected by CWP with consequent insight into possible risk 
factors. Specifically, it offers information regarding those that consult their GPs for their symptoms 
and are perhaps unrecognised as having CWP. Comparison of the sociodemographics of patients 
who self-report CWP, with patients with consultation-based CWP (recurrent regional consulters), 
offers information regarding differences between those who consult for their pain and those who 
do not. This research therefore, is a step towards better recognising and consequently managing 
these pain syndromes in primary care.
1.2.3 Tool for future research
The finalised recurrent regional consulter criteria could be used to identify cases for future 
research using medical record data, either as a way to identify potential study participants or as a 
mechanism for identifying cases in order to evaluate the effectiveness of available interventions.
Chapter 1: Introduction
5
1.3 Overview of methods and datasets
To satisfy the project’s aims and objectives, there are four conceptual stages to the research: 1. 
Preliminary research; 2. Development of the consultation-based CWP criteria; 3. Validation of the 
criteria; and 4. Application of the criteria. 
The preliminary stage identifies alternative prevalence figures to be used as comparisons for 
those generated by the criteria. General population figures for CWP and FM are identified via a 
systematic review of existing literature. Prevalence of recorded non-specific (i.e. with no clear 
established underlying alternative diagnosis) generalised musculoskeletal pain conditions related 
to CWP (e.g. fibromyalgia, generalised osteoarthritis) are calculated from routinely coded general 
practice data to establish a measure of ‘recognised’ CWP in primary care. 
The development and validation stages of the project overlap. The recurrent regional consulter 
(RRC) criteria are developed and tested using primary care consultation data and linked survey 
data. First, three lists of regional musculoskeletal Read codes are tested with the criteria (Table 
1.1), and then the criteria’s consultation patterns (number of regions consulted for and time taken 
to identify RRCs) are explored. 
In the validation stage of the project we test the construct validity of the RRC definition as a 
measure of CWP (by investigating: age and gender distribution, comorbidity, somatic symptom 
count, frequent attendance, and self-reported health status), and we investigate the association of 
RRC status with self-reported CWP status.
Finally, we apply the RRC definition in the final stage of the project to examine the epidemiology of 
consultation-based CWP and to identify changes in health and pain status over time for RRCs.
The study uses two datasets: The Consultations in Primary Care Archive (CiPCA) and the North 
Staffordshire Osteoarthritis Project (NorStOP).
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1.3.1 CiPCA
Routinely recorded primary care morbidity data stored in CiPCA is used to develop and test the 
criteria, and explore the epidemiology of RRCs identified using refined criteria. The CiPCA dataset 
contains anonymised primary care consultation data from 10 to 13 (depending on year) general 
practices in the North Staffordshire area of the UK. Information stored includes a unique patient 
identifier, the event date, the Read code and Read term for the complaint or complaints 
addressed during the consultation, and free text entered by the clinician to document the 
consultation. The practices involved are part of the Keele GP Research Partnership, consequently 
routine clinical data recorded by the practices are regularly audited by the informatics team from 
the Research Institute of Primary Care and Health Sciences at Keele University (Porcheret et al, 
2004). Prevalence of musculoskeletal conditions in CiPCA has been demonstrated to be similar to 
that of larger national primary care consultation databases (Jordan et al. 2007) and international 
databases (Jordan et al. 2013). Further detail is given in Chapter Four, section 4.3.1.
1.3.2 NorStop
The NorStOP project is a large prospective cohort study of people aged 50 and over. 
Respondents were recruited from the registered populations of six general practices from the 
Keele GP Research Partnership which is supported by the North Staffordshire Primary Care 
Research Consortium. Baseline, three-year and six-year demographic, generic and 
musculoskeletal postal questionnaire responses have been collected (Thomas et al. 2004a, 
Thomas et al. 2004b, Thomas et al. 2007, Jordan et al. 2008). These responses have been linked 
to the medical records of those respondents who consented. Medical record linking allows 
comparison of self-reported CWP status against consultation-based CWP (recurrent regional 
consulter) status as one method of validating the criteria. In addition, NorStOP is used to 
determine changes in pain and general health status of RRCs. Further details of the NorStOP 
study are given in Chapter Seven, section 7.3.1.
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1.4 Thesis synopsis
A synopsis of the content of each chapter is provided below:
Chapter 2
Background
Chapter Two provides a summary of the background literature on CWP including a review of the 
original research by Rohrbeck (2007) where the consultation-based CWP criteria were initially 
proposed. The chapter aims to justify the main aims of the thesis, present the challenges faced in 
achieving them, and present the previous work on which the thesis builds.
Chapter 3
A systematic review and meta-analysis of the prevalence of CWP in the general population
Chapter Three describes a systematic review and meta-analysis of the prevalence of CWP in the 
general population. One of the main difficulties in developing a strategy to identify a particular 
group of patients using consultation data is how best to judge the quality of the consultation-
based criteria used. One approach to assess how well the RRC criteria perform is to compare 
prevalence figures for consultation-based CWP (RRC) with population figures derived from a 
systematic review of existing literature. 
The review aims to determine variation in CWP prevalence by age, gender, criteria used to 
defined CWP, and geographical location. Determining age and gender variation offers a profile of 
self-reported CWP in the community to compare with consultation-based CWP (RRC). 
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Chapter 4
Coding prevalence of non-specific generalised musculoskeletal pain in primary care
Chapter Four presents the results of a preliminary study to establish the recorded prevalence of 
non-specific (i.e. with no clear established underlying alternative diagnosis) generalised 
musculoskeletal pain conditions related to CWP. This offers a crude measure of ‘recognised’ CWP 
coding in primary care, and offers figures for comparison with those for ‘unrecognised’ CWP 
determined by the RRC criteria. 
Chapter 5
Code list development
Chapter Five presents work to develop and test the list of morbidity codes used by the RRC 
criteria. The original Rohrbeck recurrent regional consulter (RRC) definition used a list of 147 
morbidity codes. This study aims to test and develop the existing RRC definition by defining RRCs 
using: i) the original short code list (RRC-Rohrbeck); ii) all regional musculoskeletal morbidity 
codes (RRC-all); and iii) the list of all regional codes excluding any identified by clinicians as 
unlikely to represent CWP (RRC-clinician). A case-control study is undertaken. RRCs identified 
using the three lists of morbidity codes are compared with controls. Controls are patients 
consulting for a musculoskeletal problem in one region only (axial, upper limb or lower limb) 
during the five-year study period. RRCs and controls are compared on: five-year prevalence, 
variation in age and sex distribution, number of recorded somatic symptoms, comorbidity, 
consultation rates, frequent attendance, and recording with recognised alternative diagnoses. To 
establish a measure of the degree of ‘recognised’ generalised pain within the three groups of 
cases, the proportion of RRCs recorded with non-specific generalised pain conditions (e.g. 
fibromyalgia, generalised osteoarthritis) is also investigated.
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Chapter 6
Distribution of painful body regions and relationship to recognised generalised pain in 
primary care of RRCs
Using the Rohrbeck criteria RRCs can either be recorded with two (axial and, either upper- or 
lower-limb) or three (axial, upper- and lower-limb) body regions. Chapter Six investigates the 
distribution of two- and three-region consulters in those patients fulfilling the RRC criteria using the 
three code lists developed in Chapter Five. Furthermore, two- and three-region RRCs are 
compared to assess whether patients with consulting for all three sites are more severely affected.
Chapter Six also compares recognised CWP (patients recorded with non-specific generalised 
pain codes) with unrecognised CWP (RRCs) in primary care, to quantify the degree of overlap 
between the two and to establish similarities and differences in patient profiles.
Finally, Chapter Six brings together the estimates for community CWP prevalence from the 
systematic review in Chapter Three, with recorded non-specific generalised pain coding from 
Chapter Four, and its overlap with RRC prevalence established in Chapter Five. This offers scope 
for establishing how much recurrent regional consulting might under- or over-estimate CWP.
Chapter 7
Association of recurrent regional consultation with self-reported pain status
Chapter Seven presents work undertaken to explore the association between self-reported 
widespread pain status and RRC status. In this phase of the project the three groups of RRCs 
identified by the code lists presented in Chapter Five are further validated in two processes. One 
approach tests the association of self-reported CWP status with consultation-based CWP (RRC) 
status. The other approach compares self-reported and consultation-based (number of 
consultations, number of recorded somatic symptoms, frequent attendance) health measures in 
RRCs with those in participants self-reporting CWP. 
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Chapter 8
Time taken to identify recurrent regional consulters
Chapter Eight aims to investigate whether RRCs can be identified over a shorter timeframe than 
the five-year threshold set by Rohrbeck’s original criteria. The first analysis presented in this 
chapter compares RRCs identified after three years, between three and four years, and between 
four and five years. This analysis establishes how many patients might be missed by revising the 
criteria to three or four years, and whether those fulfilling RRC criteria earlier have more severe 
problems. The second analysis presented in this chapter investigates the effect of removing the 
requirement for regional consultations in three separate years from the RRC definition. This 
establishes how much sooner RRCs can be identified, and the number of extra patients picked-up 
by removing the requirement for consultations in three separate years. The extra RRCs identified 
by removing the separate years requirement are compared with established RRCs to determine 
whether the extra patients identified still fit the RRC profile.
Chapter 9
Characteristics of recurrent regional consulters and changes in health over time
Chapter Nine describes the demographic and socioeconomic characteristics of RRCs identified 
using the final criteria, and changes in their self-reported general health and pain over time.
Chapter 10
Discussion
The final chapter draws together all the strands of thesis to present a summary of the findings, a 
discussion of the work as a whole, its conclusions, recommendations for future research, and a 
critical reflection of its strengths and limitations.
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Chapter 2
Background
2.1 Introduction
This chapter aims to present a synopsis of the background literature to: i) justify the central 
objective of this thesis, which is to develop a means of identifying chronic widespread pain (CWP) 
patients in general practice using their routinely recorded primary care data; ii) present the 
challenges faced in achieving this; and iii) present the previous work that this thesis builds upon.
First, we will construct an argument for the importance of identifying CWP in primary care. We will 
define CWP, outline its historical context, controversy about its existence and diagnosis, and 
discuss its natural history and management, to advocate that CWP is a valid diagnosis and that, if 
patients can be identified, then effective interventions are available. Moreover, this chapter will 
show where a new primary care consultation based definition of CWP (developed in this thesis) 
will fit in with existing case phenotypes.
We will then discuss morbidity coding in primary care to understand the challenges of identifying 
a controversial diagnosis using routinely recorded data. We will describe Read codes, the system 
used to record primary care morbidity data in the UK, and we will discuss how specific 
phenotypes may be identified from the data.
Finally, we will present the criteria originally developed by Jens Rohrbeck (2002) to identify CWP 
using primary care data (consultation-based definition of CWP). We will discuss the limitations of 
the criteria in order to present the case for developing them further.
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2.2 Chronic widespread pain
Chronic widespread pain (CWP) is the fundamental symptom of fibromyalgia (FM). Both present 
with longstanding multisite pain that may be associated with additional physical symptoms such 
as fatigue, psychological distress, and concentration problems. CWP and FM have been 
described under the umbrella heading of functional somatic syndromes. The term functional 
somatic syndrome has been used to describe conditions with physical symptoms that have no 
currently accepted biomedical explanation (Nimnuan et al. 2001a). There are a number of 
physical symptoms (such as fatigue, psychological distress and concentration problems) that 
have been observed to appear across the different manifestations of functional somatic 
syndromes (Aggarwal et al. 2006) leading some to suggest a common underlying condition with 
varied presentations (Nimnuan et al. 2001a). 
There has been no extensive review of the reported prevalence of CWP, but it has been estimated 
to affect 10–11% of the general adult population and is seen more frequently in women (Davidson 
2010). It has been defined in a number of ways. A common definition of CWP uses the 1990 
American College of Rheumatology (ACR-90) criteria for FM and defines CWP as pain, lasting 
three months or longer, located axially (cervical spine, thoracic spine, anterior chest or low back), 
above and below the waist, and on the left and right sides of the body (Wolfe et al.1990). Using 
the 1990 ACR criteria, FM diagnosis requires CWP in addition to a minimum of 11 tender-points 
from a possible 18 anatomical sites.
In 2010, the American College of Rheumatology published an alternative set of criteria 
(ACR-2010) (Wolfe et al. 2010), meant to be used clinically, which emphasised the importance of 
the somatic symptoms (e.g. fatigue, waking unrefreshed, cognitive symptoms) which have been 
associated with FM. The ACR-2010 criteria dispensed with tender point examination and instead 
used a measure of the widespread-ness of pain, and a measure of the number of somatic 
symptoms experienced such as fatigue and cognitive impairment. The new criteria place FM at 
one extreme on a spectrum of polysymptomatic distress. 
It is considered by many that the relationship between FM and CWP is one of gradation rather 
than of categorical distinction (Macfarlane 1999b, section 2.2.2), so much of what can be said of 
FM will also be true for CWP. Therefore, due to the intimate relationship of the two conditions, 
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some of the following section presents research and debate around the FM concept rather than 
CWP specifically.
2.2.1 Historical context
Accounts of widespread musculoskeletal pain associated with fatigue and psychological 
disturbances have a long history in medical literature (Reynolds 1983, Inanici and Yunus 2004). 
However, it was not until the second half of the twentieth century that what we might recognise as 
modern fibromyalgia began to be discussed under the name ‘fibrositis’ (Traut 1968, Smythe 
1972), a term first used by William Gower in 1904 to refer to regional musculoskeletal symptoms, 
or ‘muscular rheumatism.’ Fibrositis was used as a catch-all diagnosis for pain of almost any origin 
until the 1950s (Reynolds 1983, Block 1999, Wolfe and Wallit 2013). Then, between the fifties and 
early seventies, first Graham, then Traut and Smythe (Inanici and Yunus 2004) applied the term to 
a syndrome of musculoskeletal pain and tender points, but it was not until 1976 that the term 
fibromyalgia was first used (Hench 1976). 
In fibrositis and fibromyalgia, the late twentieth century researchers had unwittingly revived a 
condition described by the neurologist George Beard in the 1880s as neurasthenia (Beard 1894, 
Wessely 1990). In his treatise on nervous exhaustion, neurasthenia was presented as condition of 
fatigue and multiple physical symptoms (including musculoskeletal pain), which he attributed to 
the daily stress of life.
Over the years, the relative weight attributed to tender points versus somatic symptoms has 
oscillated between case definitions. In the modern literature, Smythe was the first to use tender 
points as a diagnostic standard. In 1972 he described fibrositis as generalised pain, fatigue, poor 
sleep, morning stiffness, emotional distress, and multiple tender points. The tender point sites 
were further clarified in Smythe and Moldofsky’s 1977 publication, where the definition required a 
tender point count of 12 out of 14 sites. 
The first research based definition of FM was published in 1981 by Yunus and colleagues, who 
had undertaken a case-control study of 50 FM patients and 50 matched controls with no history of 
musculoskeletal conditions. The Yunus et al. criteria, in contrast to Smythe’s focus on tender point 
count, put more weight on symptom history than on tender points.
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The publication of the 1990 American College of Rheumatology (ACR-90) definition (Wolfe et al. 
1990) heralded a new era for FM. Developed by a multicentre study and with the backing of a 
respected scientific body, this new definition acquired a credibility, which allowed it to become 
the ‘official’ case definition for FM (Wolfe and Walitt 2013). A more uniformly accepted approach 
to FM diagnosis provided a common language and a framework for researchers to share 
observations and develop theories for understanding FM and CWP. The ACR-90 FM criteria relied 
on widespread pain and a tender point count, dispensing with any need for a symptom history.
2.2.2 Currently used case definitions 
The most frequently used definition of CWP is the ACR-90 definition. However, the ACR-90 
definition has been criticised for being too inclusive and not accurately reflecting truly widespread 
pain. This prompted Macfarlane and colleagues to offer a refinement of the criteria in 1996 
(Macfarlane et al. 1996a). This more strict case definition has been termed the Manchester 
criteria. The Manchester criteria define chronicity as persistent or recurrent pain for more than 
three months of the last year. Like the ACR-90 criteria, pain must be present in at least two 
contralateral body quadrants however, to reflect a more diffuse pattern of pain, for a body 
quadrant to be deemed positive, pain must be present in at least two regions of that quadrant. 
Hunt et al. (1999) suggest that while the ACR-90 criteria are useful in a clinical setting, the 
Manchester definition offers greater comparability between epidemiological studies, since the 
more stringent criteria define a more distinct syndrome. Patients satisfying the Manchester criteria 
are more likely than those satisfying the ACR-90 criteria alone to complain of additional symptoms 
such as psychological disturbance, fatigue, sleep problems and to have tender points 
(Macfarlane et al. 1996a). Those satisfying the ACR-90 criteria alone were argued to be more 
similar to patients with regional pain complaints. This suggests that the Manchester criteria are 
identifying patients more likely to fit the construct of CWP however, there has been little uptake of 
the criteria by the research community. Nevertheless, the importance of the symptoms seen more 
frequently in those satisfying the Manchester criteria has been recognised by their incorporation 
into the new 2010 ACR FM criteria (Wolfe et al. 2010).
Despite their popularity, and while high tender point counts have been associated with distress 
(Croft et al. 1994, McBeth et al. 1999), there have been a number of other criticisms of the ACR-90 
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criteria. Some have suggested that there were difficulties with conducting the tender point count, 
that some clinicians did not use tender points to diagnose FM (Wolfe 2003, Katz et al. 2006) and 
that the pre-eminence of the tender point count ignored other physical symptoms associated with 
FM (Crofford and Clauw 2002, Wolfe 2003). The threshold 11 out of 18 tender points was also 
described as an arbitrarily defined cut-off (Croft et al. 1996, Fitzcharles 1999) that failed to 
recognise a spectrum of pain and distress (Schochat et al. 1994); indeed, ‘by placing diagnosis at 
the end of the severity spectrum we lost the appreciation of the spectrum itself’ (Wolfe 2003, p.
1671).
In 2010 therefore, a new set of case criteria were published (ACR-2010, Wolfe et al.). The 
ACR-2010 criteria removed the need for tender point examination, included somatic symptoms, 
and offered a scale to measure polysymptomatic distress. In removing the need for tender point 
examination, the new criteria are arguably more practical in primary care. The new criteria use a 
‘widespread pain index’ which assesses the presence of pain in 19 body regions, resulting in a 
score between zero and 19. A measure is also made of symptom severity. Fatigue, waking 
unrefreshed, and cognitive symptoms are specifically assessed and each assigned a score 
between zero (no problem) and three (severe problem). The number of somatic symptoms 
reported is also scored from zero (no symptoms) to three (a great deal of symptoms). The scores 
for the three individual symptoms (fatigue, waking unrefreshed, cognitive symptoms) are added to 
the score for the number of symptoms reported to produce a figure for symptom severity between 
zero and 12. For a diagnosis of FM, symptoms should have been present for at least three months 
with no alternative explanation for the pain and either: i) a widespread pain index of seven or over, 
and symptom severity of five or more; or ii) a widespread index of between three and six, and 
symptom severity of nine or more. 
The scoring used in the ACR-2010 definition suggests that FM is part of a spectrum of medically 
unexplained pain disorders rather than a discrete, isolated condition. To investigate this, Wolfe 
and colleagues (2013) summed the 0–19 widespread pain index score with the 0–12 symptom 
severity score to produce a 0–31 polysymptomatic distress score that they used to test the 
association of polysymptomatic distress with various self-reported health and social outcomes. 
Results supported the hypothesis, demonstrated by other studies (Häuser et al. 2009c, Croft et al. 
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1996), that fibromyalgia is a continuum disorder. Seen in this light CWP is a less severe 
manifestation on the same spectrum. 
2.2.3 Recognition and acceptance
a. Controversial diagnosis
With the predominant model applied in medical practice being biomedical (Wade and Halligan 
2004) it is perhaps no surprise that a condition with no pathognomonic markers has been a 
controversial one. The biomedical model of disease focuses on physical (somatic) causes of 
illness and offers no role for psychological or social influences on health. It sees illness as having 
an underlying cause that, once removed, will result in a return to health. In this paradigm a 
syndrome with no objective biomedical markers, such as FM/CWP, simply does not exist. 
However, research has shown that doctors try to rely on a biomedical view when dealing with 
patients experiencing FM (Hellström et al. 1998), choosing to focus on symptoms that are 
manageable within a biomedical context.
The biomedical model is often contrasted with the biopsychosocial model championed by George 
Engel (1977). The biopsychosocial model recognises psychological and social influences on 
health and dissolves the mind-body split. Following a qualitative study of doctors’ attitudes to 
fibromyalgia, Hellström and colleagues (1998) recommended applying a patient-centred 
(biopsychosocial) model to managing interactions with FM patients. They suggest that patients 
would benefit from help to manage difficult life-situations rather than efforts to understand their 
symptoms using a biomedical framework.
Many though, have questioned the validity of a painful condition in the absence of measurable 
clinical abnormality (Ehrlich 2003a, Gordon 2003). In 2009, in what Wolfe (2009a) called the 
‘fibromyalgia wars’, the pages of the Journal of Rheumatology saw a spirited debate on the topic. 
Sarkozi (2009) described FM as ‘the fallacy of the pain from nowhere,’ arguing that spontaneous 
central sensitisation cannot appear without a stimulus. Others countered with examples of widely 
accepted conditions with a similar pattern, including phantom limb syndrome and post herpetic 
neuralgia (Shir and Fitzcharles 2009b), and offered evidence from published research of 
disturbed biomedical markers in FM, including abnormalities in functional magnetic resonance 
imaging, increased substance P in the cerebrospinal fluid, and abnormalities of the hypothalamic 
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pituitary axis (Harth and Nielsson 2009). Meanwhile, others questioned whether a debate about 
the biomedical validity of a disease is relevant, suggesting that, using a biopsychosocial 
approach, illness exists if there is suffering (Wade and Halligan 2004), and few can question that 
there is suffering in chronic pain. 
In an essay on what he termed ‘the medicalization of misery,’ Hadler (2003) argued that 
musculoskeletal pain is a normal experience of the human condition, going on to suggest that 
individuals choose to be patients because their ability to cope with this normal pain is challenged 
by ‘the psychosocial context in which the pain is suffered’ (Hadler 2003, p.1668). This theory is 
supported by the observation of increased rates of CWP and FM in war veterans (The Iowa 
Persian Gulf Study Group 1997, Barrett et al. 2002), survivors of a major train crash (Buskila et al. 
2009), and following childhood trauma (Häuser et al. 2011, Jones et al. 2009). 
If the patient in distress is offered the fibromyalgia label by the physician then Hadler suggests 
that the patient ‘learns to be a patient with fibromyalgia’ (Hadler 2003, p.1669). In this context, 
fibromyalgia may be termed a socially constructed illness; a collusion between doctor, patient, 
academic, and the pharmaceutical industry (Hadler and Greenhalgh 2005, Wolfe 2009a). The 
patient is offered legitimisation, which may lead to social gain, or even medical insurance 
compensation (Thorson 1999, Wolfe 2009a). The doctor, rather than feeling unable to help, can 
offer diagnosis and treatment (Fitzcharles 1999). The academic has a topic to research and 
treatments to develop, and the pharmaceutical industry a market to sell to (Wolfe 2009a). The 
concept of FM as disease is maintained by the interested parties. However, evidence suggests 
that few physicians recognise FM as a valid diagnosis (Blotman et al. 2005, Kumar and Pullar 
2003, Arshad and Ooi 2007, Kamoun et al. 2010), and some contend that, ‘the pharmaceutical 
industry was, until quite recently, conspicuous by its absence’ in fibromyalgia research (Harth and 
Nielson 2009, p.2837). 
Similar arguments of social construction have been levelled at psychiatric illnesses (Eisenberg 
1988). Indeed in labelling FM a social construct, Hadler and Greenhalgh (2005) were seeking to 
place it in a social context and caution against the dangers of labelling. It was Hadler’s (2003) 
hope that if a patient accepted the contribution of their mind to their symptoms, they might be 
afforded some comfort, rather than what he saw as a counterproductive medicalisation of their 
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symptoms. However, White (in Wessely and White 2004) cautions against telling a patient they 
have a psychosomatic disorder, arguing that it is detrimental to the doctor-patient relationship, 
and suggesting that to most patients, ‘psychosomatic means malingering’ or ‘all in the 
mind.’ (Wessely and White 2004, p.96).
Ehrlich (2003a) argued that labelling a patient with FM becomes counterproductive to coping 
since the social context of the label perpetuates the condition, Quintner and Cohen stated that it is 
‘a label so easily abused as to have become meaningless’ (1999, p.1092), and Wolfe (2009a) has 
asserted that the FM label contributes to medicalisation and creates an overall societal burden, 
causing problems including: increasing disability, corrupting scientific research, and increasing 
medical costs and treatments. Contrary to this, research suggests that the FM label does not have 
an adverse long-term effect (White et al. 2002a) and two UK-based studies (Annemans et al. 
2008, Hughes et al. 2006) have found that GP visits, investigations and prescriptions decreased 
initially after diagnosis however, consultations increased again two to three years post-diagnosis. 
There has been much criticism of the ACR-90 criteria due to the circular logic used to arrive at the 
definition (Cohen 1999, Quintner and Cohen 1999). The criteria were developed by ranking 
symptoms and then applying the diagnostic label to reiterations of the same presenting symptoms 
(Hadler 2003). They were judged to offer no insight into possible pathological mechanisms and to 
have been validated by ‘a circular argument in which the evidence on which the construct is 
based is taken as proof of its veracity’ (Cohen and Quintner 1993, p.906). Goldenberg (1995) 
challenges that expert opinion will form the gold standard for any illness without objective clinical 
findings. Psychiatric diseases are defined by ‘validated diagnostic classifications based solely on 
symptoms’ (Goldenberg 2004, p.634) and until we find a reliable biomarker, a clear case 
definition provides a useful framework and a common language for research. 
Most medical specialities have a defined condition for which there has been no clear explanation, 
for example: rheumatology has fibromyalgia, gastroenterology – irritable bowel syndrome, 
neurology – tension headaches, dentistry – temperomandibular joint syndrome, and general 
medicine – chronic fatigue syndrome (Escobar et al. 2002). They have been known under a 
variety of umbrella labels including: medically unexplained syndromes, functional somatic 
syndromes, and psychosomatic or somatoform disorders. Most are seen more commonly in 
Chapter 2: Background
19
women, they often respond to similar interventions (Wessely et al. 1999), often share common 
symptoms such as fatigue, cognitive impairment and psychological distress, and individuals with 
one are at increased risk of developing another (Aaron et al. 2000, Aggarwal et al. 2006). This has 
led some to question a common underlying pathology giving rise to varied clinical presentations 
(Wessely et al. 1999, Aaron et al. 2000). However, others have argued against the uniting of 
functional somatic syndromes into a common condition, asserting that study of the individual 
discrete disorders offers greater insight into aetiology, the development of better treatments, and 
more accurate predictions of prognosis (White in Wessely and White 2004). 
However, Peter White (2010) suggests that the truth may be more complex and maintains that 
future investigation will be enhanced by studying both the similarities and the differences between 
syndromes. The road to our future understanding will therefore come from recognising and 
researching both the commonalities and heterogeneities between these conditions. This idea is 
supported by a recent study (Lacourt et al. 2013) using cluster analysis to define groups within a 
sample of 394 individuals with functional somatic syndromes. Evidence was found to support both 
an overall common condition differentiated by symptom severity, and multiple specific syndromes 
differentiated by symptom specific patterns.
The categorical nature of the FM case definition has provoked debate. Some argue that the 
ACR-90 definition wrongly implies a binary state of presence or absence (Wolfe 2009a). The 
ACR-90 definition has a discrete cut-off point that determines who has FM and who does not. It is 
argued that this dichotomy fails to represent the continuum of polysymptomatic distress felt to be 
part of FM (Wolfe 2003). This theory ties in with the argument of FM as one manifestation of a 
common functional somatic syndrome, since a categorical case definition based only on 
widespread pain does not place FM in context with other functional somatic syndromes. Wolfe 
states that by limiting diagnosis to the extreme we overlook the spectrum, ‘the range of human 
distress that exists across all illness and persons, not just in those with 11 tender points’ (Wolfe 
2003, p.1671). This argument, as well as a perceived problem with conducting tender point 
counts, was part of the rationale for developing the ACR-2010 FM criteria (Wolfe 2010). By using a 
combination of symptom severity and a quantitative measure of widespread pain the ACR-2010 
criteria were intended to offer a FM symptom scale (Wolfe et al. 2011a), rather than simply a 
binary classification.
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There may be controversy regarding the biomedical basis of fibromyalgia, the influence of society 
on its symptoms, the effect of the FM label, the tautology of the ACR-90 definition, and whether FM 
should be considered a discrete clinical entity. However, much of the preceding debate seems to 
conclude that regardless of disagreement, there is a group of people experiencing distress, and 
whether or not current labels and classifications are appropriate, they serve as a useful starting 
point for continued research and debate.
b. Awareness and accuracy of diagnosis
Doctors have reported inadequate formal training in FM (Buskila et al. 1997b, Kamoun et al. 2010, 
Arshad and Ooi 2007). In an international survey (Perrot et al. 2012) of 1,622 doctors, 53% 
admitted to difficulty in diagnosing FM, 54% reported inadequate FM training, and awareness of 
the ACR criteria ranged from 32% for psychiatrists to 83% in rheumatologists.
Surveys investigating awareness of diagnostic criteria have found generally poor levels of 
knowledge. In France (Blotman et al. 2005) 46% of GPs surveyed did not know the ACR-90 
criteria and 17% did not believe widespread pain to be a characteristic feature. In a comparable 
study in Israel (Buskila et al. 1997b), only 55% of GPs knew that FM was associated with 
widespread pain and only a quarter were familiar with the tender point count, while in Tunisia 
(Kamoun et al. 2010) only 14% were familiar with the ACR-90 criteria.
Blotman et al.’s (2005) French survey of clinicians found that while the majority (96–98%) believed 
in the existence of FM, only 23% of rheumatologists and 33% of GPs considered it to be a 
disease. Similarly, in both Scotland (Kumar and Pullar 2003) and Southeast Asia (Arshad and Ooi 
2007) the majority of rheumatologists believe FM to be a distinct clinical entity but not a 
pathological disease. However, in Tunisia, (Kamoun et al. 2010) only 17% of GPs recognised FM 
as a clinical entity. 
Given the controversy surrounding the FM diagnosis, a reported lack of formal training, the limited 
awareness of diagnostic criteria, and the variety of perceptions regarding the status of FM as a 
distinct clinical or pathological entity, it should come as no surprise that the diagnostic accuracy 
of primary care physicians has been low. One study in Canada (Fitzcharles and Boulos 2003) 
found only 34% of patients referred to a rheumatologist with a FM diagnosis were correctly 
diagnosed and another study found only 12% (Gamez-Nava et al. 1998). In contrast, a more 
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recent study in Israel (Shleyfer et al. 2009) found agreement between GPs and rheumatologists in 
71% of FM cases. 
c. Attitudes
While their reasons might be uncertain, physicians are uncomfortable with medically unexplained 
syndromes. Most GPs find patients with medically unexplained symptoms challenging to manage 
(Reid et al. 2001a). Doctors have referred to these patients as ‘difficult’ or ‘heartsink,’ and report 
problems in conducting consultations with them (Ring et al. 2005). Hellström et al. (1998) found 
that doctors struggled with clinical uncertainty and the desire to apply a biomedical paradigm to 
FM, and prioritised a technical diagnostic approach to avoid the risk of missing important 
alternative diagnoses. The primacy of diagnosis was also noted by Ring and colleagues (2004), 
who found that patients with medically unexplained syndromes received disproportionate levels of 
physical intervention, proposed more often by their GPs than by themselves. There has been 
concern that the therapeutic relationship may be damaged by suggesting to a patient that their 
symptoms have a psychological component (White in Wessely and White 2004). However patients 
with medically unexplained symptoms have been shown to offer cues concerning psychological 
difficulties that are not picked-up by their physicians (Salmon et al. 2004). It is possible therefore 
that it is the doctors, not their patients, who are uncomfortable with moving away from the 
biomedical paradigm.
2.2.4 Natural history and long-term health outcomes
Research suggests that musculoskeletal pain exists on a continuum from single- to multisite pain 
(Kamaleri et al. 2008a, 2008b). Multisite chronic pain has been found to be more common than 
single-site chronic pain (Carnes et al. 2007) and evidence suggests that progression from local to 
widespread pain is common (Forseth et al. 1999, Kamaleri et al. 2009, Kindler et al. 2010). 
Increasing numbers of pain sites have been observed to be related to reduction in overall health, 
poor sleep quality, psychological distress (Kamaleri et al. 2008b), and numbers of reported 
somatic symptoms (Coggon et al. 2013). This suggests that CWP and FM exist at the opposite 
end of a spectrum from single-site pain with no additional symptoms.
Evidence suggests that FM and CWP often show a persistent and recurrent pattern. Between a 
third and half of CWP patients reported persistent CWP at follow-up intervals of between one and 
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seven years, and only 11–16% had no pain at follow-up (the remaining patients complain of 
regional pains at follow-up) (Macfarlane et al. 1996b, McBeth et al. 2001a, Bergman et al. 2002, 
Papageorgiou et al. 2002). Risk factors identified for persistent CWP have included increasing 
age (Macfarlane et al. 1996b, Bergman et al. 2002, Papageorgiou et al. 2002), increased number 
of painful regions or high tender point count (Macfarlane et al. 1996b, Bergman et al. 2002), 
psychological distress and fatigue (Macfarlane et al. 1996b, McBeth et al. 2001a), additional 
physical symptoms (Macfarlane et al. 1996b, Papageorgiou et al. 2002), family history of chronic 
pain (Bergman et al. 2002), and illness behaviour characterised by frequent attendance to 
primary care (McBeth et al. 2001a).
Consistent with the spectrum theory of CWP/FM, outlook in FM is worse than in CWP. White and 
Harth (2001) reviewed six follow-up studies of FM and concluded that complete remissions of FM 
are rare. In a recent study (Walitt et al. 2011), 1,555 FM patients under the care of a speciality 
clinic were followed-up biannually for up to 11 years. Overall 10% of patients reported a 
substantial improvement and 15% a moderate improvement in pain however, pain worsened in 
39% of patients. Over the duration of the study period patients fluctuated between positive and 
negative on the ACR-2010 criteria. There was a general trend for continued high levels of self-
reported symptoms and distress for most patients with only slight improvement over time. This is 
consistent with a six-centre study (Wolfe et al. 1997) following up FM patients at seven years. 
Severity of pain, functional disability, sleep disturbance and psychological status varied little over 
time.
Overall prognosis and outcome in FM and CWP are poor. In addition CWP has been associated 
with long-term increased mortality, particularly as a result of cancer (Macfarlane et al. 2001, 
McBeth et al. 2009), although other studies have not found such an association (Andersson 2009, 
Macfarlane et al. 2007).
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2.2.5 Consultation behaviour
Seventy-two percent of individuals with ACR-90 defined CWP reported having consulted their GP 
for their pain (Macfarlane et al. 1999). CWP patients have been found to consult more frequently 
than patients with no pain, independent of their level of psychological distress (Kadam et al. 
2005), suggesting that frequent attendance is a feature of CWP. Indeed research has 
demonstrated an association between CWP and help-seeking behaviour for health problems 
(Gupta et al. 2007).
Frequent attenders are more likely to have musculoskeletal problems than controls (Jyväsjärvi et 
al. 1998, Karlsson et al. 1994) and research demonstrates that 20–30% of frequent attenders have 
medically unexplained symptoms (Smits et al. 2009, Reid et al. 2001a) or are considered to be 
somatisers (Karlsson et al. 1997, Jyväsjärvi et al. 2001). It is estimated that 80% of clinical work is 
taken up by 20% of patients (Smits 2009), therefore, identifying and managing patients with CWP 
appropriately in primary care has the potential to reduce workload.
2.2.6 Management
An extensive systematic review commissioned by EULAR (European League Against 
Rheumatism) (Carville et al. 2008) looked at 146 studies that investigated management 
approaches to FM. A multidisciplinary approach, using an individualised combination of 
pharmacological and non-pharmacological therapies was recommended. Recommended 
pharmacological interventions included tramadol, paracetamol, weak opioids, antidepressants, 
tropistetron, pramipexole, and pregabalin. Recommended non-pharmacological therapies 
included individually tailored exercise programmes, cognitive behavioural therapy, and heated 
pool treatment. The review also highlighted the importance of a comprehensive assessment of 
pain, function, and psychosocial context in the diagnosis and management of FM. Given the 
recommendation of a multidisciplinary tailored approach to management, Glennon (2010) argues 
that GPs are in a strong position to diagnose and select which therapies are best suited to 
individual patients. This highlights the importance of recognising FM and CWP in primary care.
Research suggests that new-onset CWP is increased in individuals with multiple physical 
symptoms, sleep problems, adverse life events, help-seeking behaviour for health problems, 
(Gupta et al. 2007), and other features of somatisation (McBeth et al. 2001b). Further, persistent 
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CWP was also associated with psychological distress, fatigue, and other features of somatisation 
(McBeth et al. 2001a). This suggests that modification of these risk factors may be a useful target 
for intervention. Indeed, a recent trial (McBeth et al. 2012) showed telephone delivered cognitive 
behavioral therapy to offer significant improvements in outcomes (compared to those treated with 
graded exercise, combined intervention, or treatment as usual) for CWP patients. This implies that 
if we were able to identify patients at risk of CWP we might be able to reduce progression of 
symptoms towards the extreme end of the spectrum of polysymptomatic distress.
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2.3 Morbidity Coding
In the UK in order to be able to retrieve meaningful information from the primary care electronic 
medical record, each patient encounter is summarised using codes that correspond to a standard 
set of clinical terminology. This allows electronic medical records to be used for tasks such as: 
clinical decision support, audit, research, and governance (Benson 2002). The majority of UK 
primary care electronic medical record systems use the Read clinical classification or ʻRead 
codesʼ (Simpson et al. 2007, Benson 2002). The codes are alphanumeric strings up to five 
characters long. Each code is a unique identifier to a preferred clinical concept that can also be 
labelled with additional synonymous terms. 
Read codes are organised into chapters, reflected by the first character of the code. The 
numerical chapters (0–9) represent history and examination findings, clinical procedures 
(investigations or therapeutic procedures) and administrative codes. The chapters denoted by 
letters represent diagnostic classifications, for example, Chapter A contains codes for infectious 
diseases and Chapter N for musculoskeletal and connective tissue diseases. Each additional 
character adds more detail, allowing increasing granularity down to five hierarchical levels, so 
each ‘child’ code represents a more detailed diagnosis than its parent code. For example, 
chapter heading G represents circulatory disorders, its ‘child’ code G3 represents ischaemic 
heart disease, G30 acute myocardial infarction, and G300 acute anterolateral infarction.
Studies using routinely recorded medical record data rely on the quality of morbidity coding. 
Quality varies and is subject to the influence of a number of barriers to accurate coding.
2.3.1 Quality of morbidity coding
There are limitations to the coding structure used in UK primary care. In a systematic review of 
studies investigating the quality of primary care medical record data, Thiru and colleagues (2003) 
found the ability of variables recorded (in GP records) to identify specific diagnoses or lifestyle 
factors varied; with sensitivity of recorded variables ranging from 37% for accurate alcohol history 
to 100% for prescribing data. In another systematic review Jordan et al. (2004) again concluded 
that the quality of morbidity coding was variable, noting a higher quality of recording for 
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conditions with clear diagnostic features (e.g. diabetes) than for conditions with more subjective 
criteria (e.g. asthma)
The nature of morbidity coding may change over time. Following the introduction of the new 
General Medical Services contract in 2004, substantial financial rewards were linked to a number 
of quality indicators (Doran et al. 2006, Sutton & McLean 2006). The contract increased practice 
income based on performance in areas of ‘quality’ identified in the Quality and Outcomes 
Framework (QOF). The QOF identified 146 clinical and organisational benchmarks (Doran et al. 
2008, Guthrie et al. 2006). Quality points were accrued by evaluation of a limited list of Read 
codes from practice records (Williams and de Lusignan 2006). As the financial welfare of a 
practice became intimately linked to it, there was new emphasis on coding. While the QOF may 
have led to improvements in data quality in the domains it assesses, these improvements may not 
have occurred in other clinical domains (Bayley 2005). Musculoskeletal morbidity was not 
included in the QOF, so at best, it can only have an indirect effect on the reliability of coding for 
these problems.
Of specific note to this thesis, a recent study (Salisbury et al. 2013), analysing video-recorded 
primary care consultations, found that only 32% of musculoskeletal complaints were Read-coded, 
while 85% were recorded in free-text notes. Problems in primary care frequently do not conform to 
the biomedical framework that coding classifications model. Clinicians interviewed by de 
Lusignan et al. in 2003 felt that applying a label to an unclear diagnosis had the potential to 
stigmatise and failed to leave room for emergent diagnoses. It is also unreasonable to imagine 
that any coding scheme could provide appropriate codes to cover every facet of the complex 
human condition. New conditions may not yet have assigned codes; existing codes may not 
provide the necessary level of detail. 
Peat et al. (2005) suggest that coding may be a reflection of individual GPs’ diagnostic beliefs and 
the patterns and context of their coding behaviour. Pearson et al. (1996) also hold this view, 
arguing that inter-practice variation in coding observed in their study was likely to be due to 
general practitioners’ different diagnostic approaches. In instances of clinical uncertainty, the 
diagnostic practices of an individual clinician are likely to play a role in the codes they assign to 
the patient’s problem. 
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In the UK every time we interact with the health service we generate electronic data. Over 95% of 
the UK population are registered with a GP (Bowling 1997) and in 2008 only 10% of the UK 
population had private health insurance (Hawe et al. 2011, p.69). Consequently, routinely 
recorded NHS data can be considered a fair approximation of the conditions for which the 
general population presents to health care. Our electronic medical records therefore represent a 
rich and pragmatic (since data are collected as part of everyday clinical practice) source of data 
for research. However they must be used with an appreciation of the complexity of the 
environment in which the data are created and entered, recognising that the accuracy of coding 
will vary between patients, clinicians and practices. Specifically, in the context of this thesis, we 
must recognise that evidence suggests many musculoskeletal complaints are not coded 
(Salisbury et al. 2013), and coding of conditions with subjective case definitions is variable 
(Jordan et al. 2004). 
2.3.2 Using routinely recorded data to identify cases
Previous studies have used combinations of Read-codes to identify specific conditions in primary 
care (Gray et al. 2003, Anandarajah et al. 2005, Linsell et al. 2006, Herrett et al. 2013). However, 
while primary care records are indeed ‘goldmines for research’ (de Lusignan et al. 2006), using 
Read-coded data for epidemiological research is not without problems. Like more traditional 
health research, we need to decide exactly who it is we are interested in studying and what 
exactly is the clinical phenotype we are interested in. Using either established disease definitions 
(from existing literature) or expert consensus, we need to clearly define the outcome we are 
interested in. Then we need to decide who has that outcome based on what is recorded in their 
medical records; what combination of information available will represent that phenotype 
(Faulconer and de Lusignan 2004). Sometimes morbidity codes available in the data will restrict 
the individuals we can identify as either there is no specific code (as is the case for CWP) or the 
coding scheme does not offer the level of granularity required. Finally, we need to check whether 
the people our search strategy identifies actually have the phenotype we said we were trying to 
find.
Deciding on code lists that will identify a particular phenotype is not easy and can involve 
laboriously going through long code lists to ensure important codes have not been missed. A 
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2003 study (Gray et al.) of Read codes used in diabetes management illustrates that, even for a 
well-defined disease like diabetes, there is a wide range of codes in use. Twenty-five individual 
diabetes codes were in use across 17 general practices, with only one code in use in all 17 
practices. There are likely to be differences in coding and diagnostic practices, so different codes 
are likely used by different clinicians to record the same clinical scenario (Hobbs and Hawker 
1995). Some studies have made use of consultation patterns for specific codes, rather than 
individual codes, to improve confidence in case identification (Rohrbeck et al. 2007, Marschall et 
al. 2011).
Fortunately there are ways we can check whether the people our search strategy finds match the 
phenotype we were aiming for (Faulconer and de Lusignan 2004). We can examine whether: i) 
incidence or prevalence figures match what the literature predicts; ii) the patients we find have 
profiles similar to those of the clinical phenotype we are intending to find (for example, do they 
have a similar age and gender distribution, and do they have a similar risk profile?). In addition, 
we can check with a relevant standard to see if the patients we are finding match, by: i) reviewing 
a sample of case notes; ii) cross checking with relevant linked disease registries if available 
(Herrett et al. 2013); or, iii) if appropriate, using self-reported data or making a clinical 
assessment.
When interpreting the results of medical record studies we must therefore be aware of: i) the 
challenges involved in phenotyping the symptom, condition, or syndrome of interest; ii) matching 
that phenotype to the data available; iii) the accuracy of the data; iv) whether or not our search 
strategy (the combination of codes or consultation pattern) identifies the phenotype we set out to 
find; and v) how many of the cases we hope to find will have consulted for their problems. Clearly 
there are implications here for our intention to identify a relatively ill-defined and controversial 
condition like CWP using Read-coded data.
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2.4 Identifying CWP in primary care
Due to the range of symptoms experienced and a multidisciplinary approach to treatment, many 
authors have argued that FM and CWP should be managed in primary care (Endresen 2007, Shir 
and Fitzcharles 2009a, Glennon 2010, Ghazan-Shahi et al. 2012). In a survey of 150 Canadian 
rheumatologists 89% felt that GPs should be the main care provider in FM and 71% did not want 
to retain ownership of FM (Ghana-Shahi et al. 2012). A survey of 284 UK GPs (Reid et al. 2001a) 
concluded that, although patients with medically unexplained symptoms are difficult to manage, 
the majority feel they should be managed in primary care. Further, CWP is common (10–11% of 
the population), causes suffering and can be treated (section 2.2), and CWP patients have been 
found to be frequent consulters (Kadam et al. 2005). Identifying CWP in primary care is therefore 
important. However, awareness, acceptance and recognition of FM/CWP by GPs varies (section 
2.2.3).
There is no Read code listed for CWP, but a code does exist for FM. However, the disparity 
between the community prevalence for FM and the number of reported cases of FM in UK primary 
care suggests that the diagnostic label of FM is not often used in general practice (Gallagher et 
al. 2004, Hughes et al. 2006). One explanation might be the controversial nature of FM (see 
section 2.2.3), and another that some GPs are cautious about the wider implications of diagnostic 
labelling (Bedson et al. 2004).
The underuse of the FM code may be justified by insufficient time in a routine primary care 
consultation to undertake a full tender point examination. However, with the introduction of the 
new ACR-2010 criteria, the diagnosis of FM is more accessible in this setting (Glennon, 2010). 
Perhaps as the new criteria become more widely recognised and implemented in primary care, 
the coding prevalence of FM in primary care will increase. Whatever the reason for the observed 
disparity, we are left with the question of how consultations with these patients are being coded. It 
has been suggested that patients who may fulfil the criteria for CWP are often diagnosed, 
recorded and treated in primary care on the basis of the individual regional pain pattern that they 
present with (e.g. shoulder or knee pain), rather than on the basis of an arguably more 
appropriate generalised pain condition (Rohrbeck et al. 2007). Rohrbeck et al. suggested that 
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patients who could potentially fit established criteria were being coded as multiple regional pain 
complaints.
2.4.1 Existing criteria
Jens Rohrbeck, a GP Research Fellow at Keele University, and colleagues set out to map the 
ACR-90 criteria for CWP to primary care consultation patterns for regional musculoskeletal pain 
complaints (2002, 2007). He developed a search strategy to identify patients with CWP using 
consultation patterns for a selected number of Read codes for musculoskeletal pain complaints 
(Table 2.1).
Table 2.1 Rohrbeck RRC definition (2007).
In a period of 5 consecutive years a patient fulfils all of i)–iv):
i) At least 1 consultation for a musculoskeletal complaint in the axial skeleton (neck & back);
ii) At least 1 consultation for an upper or lower limb complaint;
iii) At least 1 consultation for a regional musculoskeletal complaint in each of 3 separate years;
iv) At least 4 consultations for regional musculoskeletal complaints in total during the 5 year 
period. 
Rohrbeck’s criteria can be thought of as having three dimensions:
1. Read codes: A list of regional musculoskeletal problem codes that potentially represent CWP.
2. Numeric limits: The number of episodes of pain consulted for over the specified timeframes. 
These figures attempt to capture both the chronicity and the diffuse nature of pain. Chronicity 
is represented by requiring that patients have at least four consultations for regional 
musculoskeletal complaints during a five-year period, of which at least three must occur in 
separate years. However, no documented rationale was given for the choice of these figures. 
In combination with pain location, the number of episodes of pain offer a means of 
representing the diffuse nature of the pain.
3. Pain location: A measure of the diffuse nature of pain. The criteria specified the need for 
codes representing at least two different anatomical regions (axial pain, and either upper- or 
lower-limb pain). This is justified by the observation that few people consulted with pain in 
three regions.
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a. Application
Rohrbeck applied these criteria to a case-control study set in one practice, in which cases were 
those patients matching his criteria and controls were patients matched for age and gender who 
had not consulted for regional musculoskeletal problems in the preceding five years (Rohrbeck et 
al. 2007). He found that cases identified using the criteria consulted for more health problems, 
and reported worse self-reported general health, more sleep problems, and higher levels of 
fatigue than controls. The findings of the study indicate that Rohrbeck’s criteria had been 
successful in identifying a patient group similar to that identified by the ACR-2010 criteria with 
both widespread unexplained musculoskeletal pain and associated somatic symptoms
b. Limitations
However, Rohrbeck’s criteria did have some limitations in that the criteria: i) used a limited list of 
Read codes; ii) included no codes for generalised pain complaints; iii) required consultations for 
only two body regions based on findings using a limited code set; iv) offered limited 
documentation on the rationale for the numeric limits used; and v) had received limited validation. 
Each of these points will now be considered.
i) Limited Read code set
Rohrbeck identified 232 Read codes for regional musculoskeletal pain by undertaking a series of 
systematic and semantic searches of the Read code directory (Clinical Terminology Browser 
Version 1.0) (2002, p.72). Systematic searches followed the hierarchical tree structure of the Read 
code directory. Semantic searches were undertaken by entering relevant terms into the Read 
code browser. Subsequent examination of a list of Read codes from Chapters 1 (symptoms), N 
(musculoskeletal problems), R (ill-defined conditions or working diagnoses), and S (injury or 
poisoning) reveal a substantial number of regional pain codes which are not included in 
Rohrbeck’s list of codes. From the initial list of 232 codes Rohrbeck’s final criteria employed a list 
of 147 unique codes (Rohrbeck 2002, p.88). There was no documented explanation for how or 
why the list was reduced to this final figure.
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ii) No generalised codes
There are two versions of Rohrbeck’s criteria: i) the original Rohrbeck-2002 criteria added any 
patient receiving a code for FM or fibrositis in addition to those fulfilling the criteria listed in Table 
2.1; and ii) the Rohrbeck-2007 criteria used for the case-control study include only those fulfilling 
the criteria (i.e. excluding those with a code for FM or fibrositis). If Rohrbeck’s criteria aimed to 
identify all patients consulting their GP for symptoms of CWP, then both code lists (including and 
excluding FM and fibrositis pain codes) have the potential to miss patients whose complaints 
have been coded as generalised pain (e.g. those coded with conditions such as ‘general aches 
and pains’ or ‘polyalgia’).
However, using the code list for regional pain complaints only, Rohrbeck et al.’s (2007) case-
control study successfully identified a group of individuals sharing features with CWP patients. 
Individuals identified using only regional codes are potentially unrecognised, and perhaps not 
treated, as having a generalised condition; this group of patients therefore, have a potentially 
unmet need. Consequently, it could be argued that it is more important to identify this group than 
those who have been recognised as having a generalised pain condition. 
iii) Requirement of only two body regions based on findings from limited code set
Rohrbeck justified his requirement for consultation for only two body regions (axial and upper- or 
lower-limb pain) using the rationale that only 4% of 2,348 patients (questionnaire respondents 
recruited from one general practice) were found to have consulted for pain in all three regions 
(axial and upper- and lower-limb pain) during the study period (Rohrbeck 2002, p.79 and p.87). 
However, this finding was based on a limited Read code set that did not include generalised pain 
complaints. A more accurate mapping of the ACR-90 criteria may be possible with a more 
inclusive Read code list. 
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iv) Limited documented rationale for chronicity limits used in the criteria
The original criteria were applied by taking a snapshot of a predefined five-year period. The 1996–
2000 timeframe was selected for convenience, as it was not until 1996 that the study practice was 
routinely recording all consultations electronically (Rohrbeck 2002, p.91). The choice of this five-
year window would therefore seem arbitrary. It could also be argued that the timeframe for 
assessment of a patient should commence with their first consultation with a musculoskeletal pain 
complaint, rather than at a predetermined starting time.
The remaining two specifications that attempt to demonstrate the chronicity of the pain complaints 
are the requirements for: i) at least one consultation for a regional musculoskeletal complaint in 
each of three separate years; and ii) at least four consultations for regional musculoskeletal 
complaints in total during the five year period. There is no documented rationale for the choice of 
these numerical criteria. 
v) Limited criteria validation
The model criteria developed by Rohrbeck were initially tested in a sample of only 20 patients 
from one practice (Rohrbeck, 2002, pp.82–84). Self-reported CWP status was determined using a 
modified version of the Manchester criteria and was used as a reference standard for evaluating 
the performance of the criteria (Rohrbeck 2002, p.70). While it could be argued that the 
characteristics of the patient group returned by the criteria give sufficient validation, this may only 
be true for the practice where the criteria were developed. Given the variety of coding practices in 
use (Tai et al. 2007), it is possible that the criteria may not be transferable to consultation data 
from other general practices. Any further development of the criteria should be tested in a large 
sample of patients, from a number of different primary care practices, using accepted criteria for 
CWP as a reference standard.
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2.4.2 Developing recurrent regional consulter criteria
The original Rohrbeck-2002 criteria aimed to identify ACR-90 CWP by including patients recorded 
with FM as well as those recurrently consulting with regional pain. However, by using regional 
codes only, the 2007 study identified a group of recurrent regional consulters who were potentially 
unrecognised by their doctors as having a more generalised condition. This group of individuals, 
with an arguably unmet need, are therefore an important group to identify. They perhaps sit at a 
less extreme point on the continuum of polysymptomatic distress and express their unmet need 
through repeated consultations. Development in this thesis of what will be termed the recurrent 
regional consulter (RRC) definition therefore aims to identify individuals with unrecognised 
polysymptomatic distress (with the defining symptom being widespread and recurrent 
musculoskeletal pain), based on a consultation pattern for multiple regional musculoskeletal 
complaints.
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2.5 Summary
CWP is a controversial diagnosis. Evidence suggests that it sits within a spectrum of 
polysymptomatic distress and that patients experience suffering that can be alleviated by 
appropriate interventions. Many feel that, due to the broad range of symptoms and 
recommendations for an individually tailored multidisciplinary approach to management, GPs are 
best suited to deliver care. 
CWP patients have been shown to regularly consult for their symptoms. However, with evidence of 
under-diagnosis of FM in primary care, and since there is no specific morbidity code for CWP, 
Rohrbeck (2002) suggested that consultations with these patients were being recorded as 
multiple regional pain complaints. Recurrent consulters for multiple single-site pain complaints are 
likely to be unrecognised as having a more general pain condition, and therefore unlikely to 
access appropriate interventions. Through their consultation behaviour recurrent regional 
consulters are expressing a need that appears to be unmet. Identifying these individuals in 
primary care is therefore important as it has the potential to improve patient outcomes and reduce 
consultation demands. This thesis aims to develop an already established definition for identifying 
a group of recurrent regional musculoskeletal consulters who share features with CWP patients. 
Characteristics of recurrent regional consulters (RRCs) identified using the definition will be 
explored to investigate where they fit within the spectrum of polysymptomatic distress. 
Despite the extensive literature on clinical features, recognition and management of CWP and FM 
there has been no extensive review of the prevalence of CWP and FM to determine just how 
common these are in the general population. The next chapter aims to establish the size of the 
problem by conducting a systematic review of CWP and FM prevalence.
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Chapter 3
Systematic review and meta-analysis of the 
prevalence of CWP in the general population
3.1 Introduction
Many studies have reported the prevalence of chronic widespread pain (CWP) and fibromyalgia 
(FM) in the general population. However, there has been no attempt to consolidate these studies 
to derive a robust prevalence estimate of CWP and FM, and assess how this is influenced by 
socio-demographic factors and the definition of CWP used. Ascertaining the population 
prevalence of CWP has important public health implications. For example, clinicians take into 
account estimates of disease prevalence, and prevalence in different groups of the population 
(age, sex, ethnicity), when formulating differential diagnoses. It is also difficult to justify research 
into interventions for conditions whose prevalence is unknown. In addition, these figures were 
necessary for comparison with coding prevalence figures for non-specific generalised pain 
complaints calculated in the next chapter to investigate whether FM is under-diagnosed in primary 
care.
A search of DARE (Database of Abstracts of Reviews of Effects: contains abstracts for published 
systematic reviews), NHS EED (NHS Economic Evaluation Database: contains abstracts of 
economic evaluation studies), HTA (Health Technology Assessment database: contains 
completed and ongoing health technology assessments), Cochrane (a database of systematic 
reviews) and Medline (contains citations for biomedical literature) databases failed to return any 
previous reviews of general population prevalence estimates for CWP, although three previous 
systematic reviews of the more general term ʻchronic painʼ were identified (Verhaak et al, 1998; 
Nickel and Raspe, 2001; Ospina and Harstall, 2002). Two previous papers have presented a 
narrative review of chronic pain (Reid et al. 2011, Cimmino et al. 2011), a recent paper (McBeth 
and Mulvey 2012) has summarised the reported prevalence of CWP from 16 population studies, 
but is not a systematic review, and another recent paper (Queiroz 2013) has also summarised 
published FM prevalence and incidence but again is not a systematic review and does not offer a 
meta-analysis.
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This chapter builds on a previous ʻmodifiedʼ systematic review undertaken as a 10,000 word 
dissertation for a Masters (MRes) qualification by this researcher under her unmarried name 
(Davidson 2010). Twenty-four papers were included in that review, all were cross-sectional 
studies. Thirteen gave prevalence figures for FM and eight gave prevalence figures for CWP 
(three gave figures for both FM and CWP). Estimates for CWP prevalence ranged from 360 to 
2,300 per 10,000, with the majority at approximately 1,000 per 10,000. Figures for FM ranged from 
6 to 880 per 10,000, with majority between 200 and 400 per 10,000. Twelve papers provided 
prevalence figures by gender. Most of these studies estimated CWP and FM to be at least two 
times more common in women. The majority of the studies used ACR-90 case definition criteria. It 
was not possible to stratify prevalence figures by age due to the variety of presentations of age 
grouping data provided by the papers included. The prevalence figures observed were consistent 
across the geographical locations covered by the included papers.
The previous review was restricted by the time and scope constraints for work at the level of a 
Masters dissertation. It was limited to English language articles and a strict set of eligibility criteria 
to limit the number of papers included in the review. For example, studies where case definition 
criteria were felt to be inadequately defined were excluded and articles with study populations 
restricted by gender, culture, or race were also excluded. No meta-analysis was undertaken.The 
search only went up to 2nd July 2010. This review can be regarded as a scoping study for the 
systematic review reported here.
The objective of the systematic review and meta-analysis presented in this chapter was to 
determine the prevalence of chronic widespread pain in the general population. In the context of 
this review, chronic widespread pain refers to unexplained, longstanding, diffuse body pain. This 
is necessarily a broad description since one of the aims of the review is to identify and explore 
how different definitions of chronic widespread pain might influence the patient groups identified 
and prevalence. Since this is often a vaguely defined and poorly understood condition, it was 
hoped that such a comparison would offer further insight into how to best identify patients with this 
syndrome or to offer a delineation of a severity spectrum. The prevalence of FM, as an arguably 
more severe manifestation of CWP, therefore necessarily formed part of the study. Sub-grouping 
of prevalence data by factors such as age and sex offered further insight into the population 
groups most susceptible to CWP.
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The results from the review were used in a number of related strands of follow-up work: i) The 
community prevalence figures for FM revealed in the review were compared with annual primary 
care recorded prevalence of FM to test the hypothesis that FM is under-reported in primary care 
(Chapter Four), offering evidence to justify the need for an alternative means of identifying FM/
CWP consulters in primary care; and ii) CWP community prevalence figures were used as a 
comparison to consultation prevalence figures of individuals repeatedly consulting for multiple 
regional pain complaints who share features with patients fitting established CWP criteria 
(consultation-based CWP based on our recurrent regional consulter definition: Chapter Five).  
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3.2 Aims and objectives
Primary objective
To estimate the prevalence of chronic widespread pain (CWP) and fibromyalgia (FM) in the 
general population.
Secondary objective
To determine variation in prevalence by age, sex, geographical location, and criteria used to 
define CWP and FM.
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3.3 Methods
A defined set of search criteria was used to conduct a search of relevant bibliographic databases. 
The papers returned by the search were evaluated against eligibility criteria and those meeting 
the criteria were included in the review. The methodological quality of each of the included papers 
was assessed to attribute appropriate weighting to the conclusions drawn from each study. Data 
extracted from the studies were analysed and conclusions drawn concerning the methodological 
quality of each paper. A meta-analysis was then undertaken to calculate pooled prevalence 
figures. 
3.3.1 Reporting
A proposal for reporting the meta-analysis of observational studies in epidemiology (MOOSE) was 
published in 2002 (Stroup et al. 2002). This provides a useful framework for authors of reviews of 
observational studies similar to the one proposed here. The PRISMA statement is a more recent 
27-item checklist for reporting systematic reviews and meta-analyses; it was published in 2009 as 
a result of consensus exercise (Liberati et al. 2009). These frameworks were used in the 
preparation of the final report of this research.
3.3.2 Search strategy
a. Databases searched
The following databases were searched: Medline (Medical Literature Analysis and Retrieval 
System Online), Embase (Excerpta Medica Database), CINAHL (Cumulative Index to Nursing and 
Allied Health Literature) and AMED (Allied and Complementary Medicine Database).
Medline is a large biomedical/health bibliographic database containing more than 23 million 
references from over 5,500 journal titles (National Library of Medicine 2013). The search strategy 
for this review was initially piloted in Medline.
Embase is a database produced by Elsevier and can be considered the European equivalent of 
Medline, it contains over 22 million records from over 7,500 biomedical journals published from 
1974 (Ovid 2013). A study undertaken by Suarez-Almazor in 2000, found only a 30% overlap 
between Medline and Embase. A systematic review must therefore search both databases to 
include all relevant studies.
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CINAHL is an index of journal articles about nursing, allied health, biomedicine and healthcare. It 
indexes more than 3.9 million records from over 5,000 journals from nursing and allied health 
disciplines (EBSCO 2013). AMED is a database produced by the British Library, it contains more 
than 279,000 records from up to 600 allied health and complementary medical journals (National 
Institute for Health and Care Excellence 2013). These two databases were searched in order to 
return any prevalence research published in nursing, complementary medical or allied health 
journals not indexed by Medline or Embase.
b. Search terms
The search strategy developed in the initial scoping study was used to interrogate the selected 
databases; it was piloted and refined with the help of health librarian Rachael Lewis from Keele 
University’s Health Library. Rachael offered guidance on defining the search terms using Boolean 
operators in an hour-long personal tutorial. The search terms were fine-tuned and developed in 
the Medline database. The finalised Medline search strategy was then adapted for each of the 
other databases searched to take into account the equivalent subject headings used in these 
databases. The strategy is documented in Tables 3.1 and 3.2 (the individual search strategy for 
each database is documented in appendix A3.1).
Table 3.1 Keywords included in the search strategy for all four databases; terms searched for in the 
title and abstract of papers
Pain term chronic widespread pain OR fibromyalgia OR chronic pain syndrome OR diffuse pain 
OR fibrositis OR fibromyositis OR myofascial pain syndrome
AND
Study type term epidemiology OR cohort stud* OR cohort analys* OR cross sectional stud* OR cross 
sectional analys* OR observational analys* OR prevalence OR disease frequency
Table 3.2 Database specific subject heading terms
Medline - MeSH 
Headings
CINAHL - Subject 
Headings
AMED - Subject  
Headings
Embase - Emtree 
Subject Headings
Pain term fibromyalgia 
myofascial pain 
syndromes
fibromyalgia 
myofascial pain 
syndromes
fibromyalgia 
pain
fibromyalgia/ 
epidemiology 
myofascial pain/ 
epidemiology
Study type term prevalence cross-
sectional studies 
epidemiology 
epidemiologic methods 
epidemiologic research 
design
epidemiologic studies 
epidemiologic 
measurements
cohort studies
prevalence cross-
sectional studies 
epidemiology 
epidemiological 
research prospective 
studies
epidemiology epidemiology 
prevalence
cross sectional study
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c. Study retrieval and selection
Medline, Embase, CINAHL and AMED were first searched on 4th April 2011 and an updated 
search was undertaken on 6th September 2013. The databases were accessed using the OVID 
search interface (Wolters Kluwer 2013). The titles of the papers returned by the search were 
examined and any that were obviously irrelevant were excluded. The resulting lists of the 
candidate papers from each database were then exported to the bibliographic reference 
management software RefWorks (ProQuest LLC 2013). Here, any duplicate papers were 
removed. The list of candidate papers (excluding duplicate records) was exported to the desktop 
reference management software Papers (Mekentosj 2013). The abstracts of the remaining articles 
were reviewed by this author (Kathryn Mansfield, KM) to find relevant cross-sectional and cohort 
studies for inclusion in the review. Editorials, letters and conference proceedings were excluded. 
The full text of the papers short-listed for inclusion was obtained and reviewed and any papers not 
meeting the eligibility criteria (see section 3.3.3) were excluded. A record was kept of those 
papers excluded and reasons for exclusion. At each stage a second reviewer (Kelvin Jordan, KJ) 
was asked to arbitrate on the suitability of any papers for which eligibility was not clear cut.
The second reviewer also calibrated the primary reviewerʼs application of the eligibility criteria 
during the paper identification process by assessing for inclusion/exclusion:
1. A random selection of 10% of the abstracts identified after title appraisal of the papers 
returned by the search strategy.
2. A random selection of 10 or 10% (whichever was the greater) of the full text of papers 
identified after appraisal of the list of potentially relevant abstracts.
The citations of the retrieved articles were then searched for additional relevant publications.
d. Translation of foreign language publications
Foreign language articles were translated by native speakers. 
e. Hand searching
A hand search of the Journal of Rheumatology from 1990 was conducted to identify any relevant 
articles. This journal was identified as the most frequent contributor of articles to the initial scoping 
study (Davidson 2010).
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3.3.3 Eligibility criteria
The eligibility criteria for the study are documented in Table 3.3.
Table 3.3 Inclusion/exclusion criteria
Inclusion criteria Exclusion criteria
Cohort or cross-sectional observational studies
Set in primary care or the general population 
Studies since 1990
Studies where prevalence data (for FM or CWP) can 
be extracted or calculated
All age ranges
Conference proceedings, editorials and letters.
Studies quoting incidence rather than prevalence 
figures 
Papers in a foreign language, where resources were 
not available for full translation
Studies quoting figures for soft tissue rheumatism
The rationale for the implementation of each of the eligibility criteria will now be considered in turn.
a. Inclusion criteria
Cohort and cross-sectional observational studies
In seeking to answer the question “What is the prevalence of CWP in the general population?”, 
cohort and cross-sectional studies as primary observational studies will return the prevalence 
data necessary. Intervention and case-control studies are likely to use more selective study 
populations, which will not be transferable to determining prevalence in the general population.
Set in primary care or the general population
To assess the prevalence of CWP in the general population, only research in this predefined 
population will return applicable data. In the UK 98% of people are registered with a GP (Bowling, 
1997); consequently, studies of patients registered with a GP can be considered to be 
representative of the general population. Therefore, studies of patients on a GP register were 
selected for inclusion.
Studies published since 1990
The ACR criteria for FM were published in 1990. Prior to this date, extreme heterogeneity in the 
definition of both CWP and FM would make any comparison of prevalence estimates difficult. In 
addition, since the prevalence of a disorder is likely to vary over time, it could be argued that to 
make the results of the review transferable to today’s general population, looking at prevalence 
data from more than 20 years ago may be invalid.
Studies where prevalence data can be extracted, calculated or obtained from the author
To make a judgment regarding the prevalence of CWP/FM these data must be available. 
Chapter 3: A systematic review and meta-analysis of the prevalence of CWP in the general population
44
All age ranges
This study aims to ascertain the prevalence of CWP at all age ranges, and therefore papers 
covering prevalence at any age should be included.
b. Exclusion criteria
Conference proceedings, editorials and letters
Editorials and letters are not primary studies and should therefore be excluded, since articles of 
these types citing primary research would fail to give sufficient information on which to determine 
the robustness of the data given. Conference proceedings may cite primary research; however, 
this is also likely to be published in research papers and proceedings should therefore be 
excluded as inclusion may result in double counting. Nonetheless, an attempt was made to 
ensure that any primary research cited by such publications was included.
Studies quoting incidence rather than prevalence figures
The incidence of a condition is the number of newly diagnosed cases in the population at risk 
during a specific time-period. This review sought to assess the prevalence of CWP rather than the 
incidence. In addition, incidence figures are likely to be unreliable as it is difficult to get an 
accurate measure of incidence when diagnosis is based on symptoms being long-standing.
Papers in a foreign language, where resources are unavailable for full translation
Every effort was made to ensure that foreign language papers were translated as exclusion has 
the potential to introduce bias. There were no foreign language papers that could not be 
translated. 
Studies quoting figures for soft tissue rheumatism
Soft tissue rheumatism is a poorly defined condition that often includes FM along with other 
regional soft tissue complaints such as bursitis and tendonitis (Burkholder-Krommes 2002). While 
the prevalence of soft tissue rheumatism may include FM, it is not restricted to widespread 
unexplained pain complaints. Its prevalence therefore will not reflect the prevalence of CWP or 
FM.
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3.3.4 Methodological quality assessment
The papers selected for inclusion in the review were assessed for methodological quality. A 2007 
review of tools for assessing quality in observational studies concluded that there was a lack of a 
single obvious candidate tool (Sanderson et al. 2007). A modified version of the Newcastle-
Ottawa scale (Wells et al. 2008) was used in the initial scoping study. It was modified because the 
original tool was developed to assess the quality of epidemiological studies examining exposure 
to a potential causative or therapeutic agent of the disease in question, and consequently was not 
completely relevant to the papers in this study. There are clearly issues of validity when an 
existing tool is adapted and the new version is not appropriately tested. In addition, the subjective 
domain based evaluation that this tool employed proved cumbersome in the scoping exercise 
and offered no way of efficiently identifying areas of methodological weakness.
This review therefore made use of two tools to assess methodological quality. The first was a tool 
developed by Walker et al. (2000, cited in Louw et al. 2007) for assessing the quality of low back 
pain prevalence studies. It provides a checklist of responses to eleven questions covering three 
domains of methodological quality: A) study participation (Is the final sample representative of the 
target population?); B) data quality; and C) case definition. The results can be formatted as a 
summary table of quality for all the papers included in the study, offering an easy reference for 
identifying which areas of methodology may be poor. 
The second tool used in this review uses the two domains of the Quality in Prognosis Studies 
(QUIPS) tool (Hayden 2007, Hayden et al. 2013) that are relevant to the appraisal of this sort of 
prevalence study (Domain 1: study participation; Domain 4: outcome measurement). Appraisal of 
each domain requires a more subjective assessment of risk of bias (low, moderate or high) rather 
than a separate assessment of a number of different aspects of quality as offered by the first tool. 
Both tools are included as part of the data extraction sheet in appendix A3.2.
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3.3.5 Data extraction
A data extraction form was used to extract equivalent information from each of the papers 
(appendix A3.2). This form included details regarding the population sampled, the criteria used to 
determine diagnosis, the geographical location of the study, prevalence figures, timeframe (for 
example: point prevalence, annual prevalence) and any subgrouping based on age or gender. It 
also included fields to capture data relevant to methodological quality assessment using the 
Walker et al. tool and the two domains of the QUIPS tool (see next section 3.3.4). Data were drawn 
from the papers using the data extraction tool. For each paper, prevalence figures were extracted 
or calculated from the available data. Where available, 95% confidence intervals for prevalence 
figures were extracted from the papers. If not provided in the paper, confidence intervals were 
calculated using Wilson’s method (Newcombe 1998) using data given in the papers. A 
spreadsheet was created incorporating formulae for calculating the 95% confidence interval for a 
proportion.
3.3.6 Reliability exercise
A second reviewer (KJ) checked the paper selection, data extraction and quality appraisal stages 
of the review. In each instance either 10% of the list of studies to be appraised or 10 studies were 
reviewed, whichever was the larger figure. Any disagreements were discussed. The second 
reviewer was blinded to the primary reviewer’s decisions. A third reviewer (Julius Sim, JS) was 
available to arbitrate any disagreements that remained unresolved following discussion.
Chapter 3: A systematic review and meta-analysis of the prevalence of CWP in the general population
47
3.3.7 Analysis
a. Descriptive analysis
An initial descriptive account of the papers selected for inclusion in the study was undertaken. 
Reference was made to the type of studies included (cross sectional or cohort), the sample size, 
the demographics of the study samples, and the geographical location of the studies. A narrative 
account of the methodological quality of the papers (using the Walker et al. tool and the 
participation and outcome measurement domains of QUIPS tool) was then presented. Prevalence 
figures for CWP and FM were stratified according to the geographical location of the study, case 
definition criteria and, where possible, age and gender. 
b. Meta-analysis
Studies estimating FM or CWP prevalence using the ACR-90 criteria in mixed-gender adults were 
entered into a meta-analysis. Studies using the same diagnostic criteria in similar populations 
were used to ensure comparability. The ACR-90 criteria were selected as an established and 
widely used measure of CWP/FM diagnosis.
Meta-analysis was undertaken using a random-effects model (to account for heterogeneity) and 
conducted in Stata (StataCorp 2011). Prevalence figures for CWP and FM were visualised 
graphically using forest plots to compare variability between studies. Heterogeneity between 
estimates was assessed using the I2 statistic, which describes the percentage of variation not due 
to chance across studies. An I2 value of zero indicates no heterogeneity, values of 25%, 50%, and 
75% indicate low, moderate, and high heterogeneity respectively (Higgins et al. 2003). Pooled 
prevalence figures were calculated with 95% confidence intervals for FM and CWP prevalence. 
The impact of study quality on pooled prevalence was assessed by systematically excluding 
lower-quality studies and studies examining particularly select populations from the meta-analysis. 
Studies scoring a low risk of bias in both domains of the QUIPS tool were classified as high quality 
studies, those scoring a high risk in either domain were classified as low quality, while the 
remaining studies (those scoring either moderate risk in both domains or moderate risk in one and 
low in the other) were termed intermediate quality. A sensitivity analysis was undertaken by 
calculating alternative pooled prevalence figures for: i) high- and intermediate-quality studies only; 
and ii) high-quality studies only.
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3.4 Results
3.4.1 Search results
The search returned a total of 4,051 papers: 1,227 from Medline, 1,679 from Embase, 500 from 
AMED and 645 from CINAHL. Once duplicate records were removed, a total of 2,818 records 
remained. A flow chart to illustrate the process by which the papers were selected or rejected for 
inclusion in the study is show in Figure 3.1. To assist readability, when citing more than one paper 
in this chapter, references are listed in footnotes rather than in the text.
After screening the paper titles, 336 papers were shortlisted for abstract review. During this stage 
it was decided that papers researching study populations that were exclusively composed of 
individuals who had been exposed to specific potential risk factors should not be included. These 
study populations included Holocaust survivors (Ablin et al. 2010b), individuals under chronic 
traumatic exposure (Ablin et al. 2010a), train crash survivors (Buskila et al. 2009), Gulf war 
veterans (Stimpson et al. 2006) and populations in specific occupations (Kim et al. 2008). After 
screening the abstracts of these 336 papers according to the eligibility criteria, 225 papers were 
excluded, leaving 111 papers for full text review. An additional 15 studies were identified from the 
citation lists of these 111 papers. 
Following review of the full text, 47 papers were excluded (appendix A3.3). Of these 47, sixteen 
were excluded because prevalence figures for CWP or FM were not quoted and could not be 
calculated from the information provided in the paper. Eleven of the excluded papers did not 
present primary research: five were editorials or letters and six were either review articles or used 
secondary data presented in other papers already included in the review. The citation lists of 
these papers were scrutinised and any relevant primary research referenced was sourced.
Two studies were excluded because they were neither a cross-sectional nor a cohort study. A 
further six studies were excluded because the study population was not representative of the 
general population.
Twelve papers were excluded because they documented data analysed in other papers included 
in the review. In each instance, the information included in all the available papers has been used 
to critique the methodological quality of the studies that were included in the review.
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Eleven foreign language papers were identified for possible inclusion in the review1 all were 
translated by native speakers (two Norwegian, three German, one Spanish, one Italian, one 
French, one Taiwanese, one Korean and one Russian).
No additional papers were returned by a hand search of the Journal of Rheumatology from 1990. 
Seventy-nine papers were therefore selected for inclusion in the review.
Chapter 3: A systematic review and meta-analysis of the prevalence of CWP in the general population
50
1 Alvarez-Nemegyei et al. 2005 (Spanish), Chen et al. 2008 (Taiwanese), Cimmino et al. 2002 (Italian), Elstad 
1994 (Norwegian), Guermazi et al. 2008 (French), Häuser et al. 2009b (German), Häuser et al. 2013 
(German), Kim et al. 2006 (Korean), Marschall et al. 2011 (German), Stormorken et al. 1994 (Norwegian), 
Storozhenko et al. 2004 (Russian).
Figure 3.1 A flow chart to illustrate the process by which the papers were selected or rejected for 
inclusion in the study.
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3.4.2 Reliability exercise
a. Abstract appraisal
A second reviewer (KJ) independently assessed for inclusion a random sample of 10% (27 
studies) of the 265 abstracts identified from the list of titles selected from the initial search 
conducted in 2011 (an updated search was run for literature published between 2011 and 2013 
on 4th September 2013). As previously discussed, it was decided that studies of populations 
exposed to specific potential risk factors should be excluded.
Conversely, it was decided that papers that identified specific social and cultural groups within 
the general population should be included, as these groups reflected geographically located 
populations. Consequently, studies researching prevalence in the Amish (White et al. 2003), Pima 
Indians (Jacobsson et al. 1996), and areas of low socioeconomic status (Assumpção et al. 2009) 
were included in the review.
b. Full text appraisal
The second reviewer (KJ) then independently assessed the full text of a random sample of 10 
papers identified for possible inclusion after review of the list of abstracts. There was no 
disagreement between the two reviewers regarding the inclusion or exclusion of any of the 10 
papers. 
c. Data extraction and quality appraisal
The second reviewer (KJ) independently extracted data from a random sample of 10 papers 
selected for inclusion to validate the use of the data extraction form and the application of the 
methodological scoring tool. 
Discussion between the two reviewers (KM and KJ) concentrated on assessing outcome 
measurement bias (Domain 4 of the QUIPS tool). It was decided that, if a paper did not present 
sufficient information about how presence of FM or CWP was measured, it should be scored as at 
least at moderate risk of outcome measurement bias. Where studies chose to examine only those 
participants who tested positive to a screening test, it was decided that, if the screening process 
was unlikely to exclude individuals with FM/CWP, then only examining screen positives would be 
unlikely to influence the validity of prevalence figures. Therefore the validity and reliability of the 
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screening process was considered in the assessment for possible outcome measurement bias in 
these papers.
It was decided during data extraction that studies using medical or insurance records to calculate 
coding prevalence needed to be considered separately to community prevalence studies. Coding 
prevalence is unlikely to represent community prevalence since it is reliant on patients’ help-
seeking and consultation behaviour, and clinicians’ diagnostic beliefs and coding practices. 
These studies were therefore given two additional measures on domain four (outcome 
measurement bias) of the QUIPS tool: i) one representing how good the specific code(s) identified 
were as a measure of the recording of the specified condition; and (ii) another representing how 
good the measure was as an assessment of community CWP or FM prevalence. 
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3.4.3 Papers included
Of the 79 papers selected for inclusion, three2 were cohort studies, seventy-six were cross-
sectional. Fifty-eight of the included papers gave prevalence figures for FM, while 36 gave figures 
for CWP (15 papers gave figures for both FM and CWP). Table 3.4 displays the sample size, 
geographical location, age range and gender of the samples studied by papers included in the 
review.
Ten3 of the papers included in the review included estimates for two or more different nationalities 
or different cultural/ethnic groups living in the same regions. One paper (Andersson et al. 1999) 
presented both medical record data and the results of a survey that was reported more fully in 
another paper included in the review (Andersson et al. 1994); only the results of the medical 
record review from this paper were therefore presented in this review. 
The 58 papers presenting figures for FM included one paper (Vincent et al. 2013) providing 
figures from two separate studies, bringing the total of studies estimating FM prevalence to 59. Of 
the studies providing figures for FM, three studies provided figures for children or adolescents 
only, five papers presented figures for adult women only, two papers gave figures for older adults 
aged 60–75 years plus, and the remaining 48 papers (49 studies) presented FM figures for adults 
of both genders.
The 36 papers presenting figures for CWP included the results from a total of 38 studies, as: i) 
Choudhury et al. 2013 presented figures from two studies, a short postal questionnaire and a 
longer face-to-face questionnaire; and ii) Macfarlane et al. 2005 presented figures from two 
surveys, one of female adults only and one of mixed-gender adults. Of the studies presenting 
figures for CWP, four gave figures for women only, one gave figures for men aged 40–79 only, two 
presented CWP prevalence in older age groups only (age 65–70 years plus), one study looked at 
prevalence in 45 year olds from the 1958 British Birth Cohort, and one looked at prevalence in 40 
to 46 year olds from a Norwegian birth cohort. The remaining 29 studies looked at prevalence in 
mixed-gender adults.
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2 Gansky and Plesh 2007, Macfarlane et al. 2009a, and Øverland et al. 2012.
3 Gansky and Plesh 2007, Macfarlane et al. 2005a, Macfarlane et al. 2009b, Branco et al. 2010, Choudhury et  
al. 2013, Farooqi and Gibson 1998, Haq et al. 2005, Kurita et al. 2012, White et al. 2003, Zeng et al. 2010.
Table 3.4 Sample size, age range, gender and geographical location of studies included in the review.
Study 
population
Study Sample 
size
Sample 
Age
Location FM CWP
Children and 
young adults 
(mixed 
gender)
Buskila et al. 1993
Clark et al. 1998
Zapata et al. 2006
Female 
adults
Abusdal et al. 1997a
Cakirbay et al. 2006
Elstad 1994
Forseth & Gran 1992
Gansky & Plesh 2007
African American
Caucasian
Macfarlane et al. 2005 
(survey B)
South Asian
White European
Schochat & Raspe 2003
Topbas et al. 2005
Male adults Macfarlane et al. 2009b
Belgium (Leuven)
England (Manchester)
Estonia (Tartu)
Hungary (Szeged)
Italy (Florence)
Poland (Lodz)
Spain (Santiago)
Sweden (Malmo)
Older adults 
(mixed 
gender)
Eggermont et al. 2010
Santos et al. 2010
Birth cohorts 
(mixed 
gender)
Macfarlane et al. 2009a 
(1958 British birth cohort)
Øverland et al. 2012 (1953–
1957 birth cohort: 
Hordaland Health Study)
Male and 
female adults
Ablin et al. 2012
Aggarwal et al. 2006
Alvarez-Nemegyei et al. 
2005
Alvarez-Nemegyei et al. 
2011
Andersson 1994
Andersson et al. 1999 
(1996 medical record 
figures)
Assumpção et al. 2009
Bazelmans et al. 1999
Bergman et al. 2001
Branco et al. 2010
France
Germany
Italy
Portugal
Spain
Buskila et al. 2000
Cardiel & Serrano 2002
Carmona et al. 2001
338 9–15 Israel ✓
548 9–15 Mexico ✓
359 adolescent São Paulo, Brazil ✓
2,622 25–55 Norway ✓
1,045 18–55 Trabzon City, Turkey – 
urban
✓
3,211 36–55 Norway ✓
2,038 20–49 Arendal, Norway ✓
1,334 21–26 USA ✓ ✓
684
650
18–36 UK ✓
137
121
2,253 35–74 Germany ✓
1,930 20–64 Turkey ✓
3,963 40–79 8 European countries ✓
452 Belgium (Leuven)
590 England (Manchester)
527 Estonia (Tartu)
431 Hungary (Szeged)
484 Italy (Florence)
408 Poland (Lodz)
548 Spain (Santiago)
523 Sweden (Malmo)
585 70+ Boston, USA ✓ ✓
361 65+ Brazil ✓ ✓
9,377 45 UK ✓
17,706 40–46 Hordaland county, 
western Norway
✓
1,019 18+ Israel ✓ ✓
2,299 18–75 Manchester, UK ✓
761 18+ Cantamayec, Yucatán, 
Mexico
✓
3,195 adults Yucatan, Mexico ✓
1,609 25–74 Sweden – rural ✓ ✓
7,474 25–74 Sweden ✓
768 35–60 Sao Paulo, Brazil ✓ ✓
3,881 all The Netherlands ✓
2,425 20–74 Sweden ✓
4,517 15+ Five European countries ✓ ✓
1,014 France
1,002 Germany
1,000 Italy
500 Portugal
1,001 Spain
2,210 18+ Israel ✓
2,500 18+ Mexico – suburban ✓
2,198 20+ Spain ✓
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Study 
population
Study Sample 
size
Sample 
Age
Location FM CWP
Male & 
female adults
Carnes et al. 2007
Chaaya et al. 2012
Chen et al. 2008
Choudhury et al. 2013
Long questionnaire
White British/Irish
British Bangladeshi
Bangladeshi
Short postal survey
White British/Irish
British Bangladeshi
Bangladeshi
other ethnic groups
Croft et al. 1993
Dans et al. 1997
Davatchi et al. 2008 urban
Davatchi et al. 2009a rural
Farooqi & Gibson 1998
Rural
Urban affluent
Urban poor
Guermazi et al. 2008
Hagen et al. 2005
Haq et al. 2005
Rural
Urban affluent
Urban slum
Hardt et al. 2008
Häuser et al. 2009b
Häuser et al. 2013
Hughes et al. 2006
Hunt et al. 1999
Jacobsson et al. 1996
Joshi & Chopra 2009
Kim et al. 2006
Klemp et al. 2002
Kurita et al. 2012
Danish
Other Western
Non-Western
Lindell et al. 2000
Macfarlane et al. 2005 
(survey A)
South Asian
White European
Mäkelä & Heliövaara 1991
Marschall et al. 2011
McNally et al. 2006
Minaur et al. 2004
Papageorgiou et al. 2002
Pelaez-Ballestas et al. 2011
Perrot et al. 2011
Picavet & Hazes 2003
Prescott et al. 1993
Raspe & Baumgartner 1993
2,445 18+ South East, UK ✓
3,520 15+ Lebanon ✓
1,094 all Taiwan ✓
18+ Tower Hamlets, London, 
UK600 ✓
294
158
141
1,223 ✓
571
141
201
310
1,340 18–85 Cheshire, UK ✓
3,006 15+ Philippines ✓
10,291 15+ Iran – urban ✓
1,565 15+ Iran – rural ✓
1,997 15+ Pakistan ✓
683 Rural
608 Urban affluent
706 Urban poor
1,000 15+ Tunisia ✓
35,751 20+ Nord-Trøndelag, Norway ✓
5,211 15+ Bangladesh ✓
2,635 Rural
1,259 Urban affluent
1,317 Urban slum
10,271 20+ USA ✓
2,524 14+ Germany ✓
2,510 14+ Germany ✓
1,255, 556 any UK ✓
1,953 18–65 UK – suburban ✓
105 35–70 Pima Indians ✓
8,145 16+ Pune, India – urban ✓
1,028 no age 
limits
South Korea – rural ✓ ✓
689 12+ New Zealand ✓ ✓
14,925 16+ Denmark ✓
14,033
395
497
2,425 18–74 Sweden ✓ ✓
18–75 UK ✓
1,945 South Asian
932 White European
7,217 30+ Finland ✓
6,897,846 any Germany ✓
131,535 12+ Canada ✓
847 15+ Australia ✓
1,386 27–90 Handforth, UK ✓
19,213 18+ Mexico ✓
3,081 18+ France ✓
3,664 25+ Netherlands ✓
1,219 18–79 Denmark ✓
438 25–74 Bad Sackingen, Germany ✓ ✓
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Study 
population
Study Sample 
size
Sample 
Age
Location FM CWP
Male & 
female adults
Reyes-Llerena et al. 2000
Reyes-Llerena et al. 2009
Rodriquez-Amado et al. 
2011
Salaffi et al. 2005
Sauer et al. 2011
Scudds et al. 2006
Senna et al, 2004
Storozhenko et al. 2004
Svebak et al, 2006
Turhanoglu et al. 2008
Veerapan et al. 2007
Vincent et al. 2013
Self report
Medical record review
White et al. 1999
White et al. 2003
Amish
non-Amish
Wolfe et al. 1995
Wolfe et al. 2013
Zeng et al. 2010
Shantou
Taiyuan
300 adult Cuba ✓
3,155 15+ Cuba ✓
4,713 18+ Mexico ✓
2,155 18+ Italy ✓
1,646,284 all Germany ✓
1,467 18–65 Hong Kong ✓ ✓
3,038 16+ Brazil – urban ✓
120 27–75 Yekaterinburg, Russia ✓
64,690 20+ Norway ✓
600 20+ Turkey – urban ✓
2,594 15+ Malaysia ✓
Olmsted County, 
Minnesota, USA830 21+ ✓
County 
population
21+ ✓
3,395 18+ London, Canada – urban ✓ ✓
18+ London, Canada – rural ✓ ✓
179 Amish
494 non-Amish
3,006 18+ Wichita, USA – urban ✓ ✓
2,445 18+ Germany ✓
16+ China ✓
2,350 Shantou
3,916 Taiyuan
Total number of studies included 59 38
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3.4.4 Methodological quality assessment
a. Walker et al. tool
A summary of the methodological appraisal of the studies included in the review using a tool 
developed from the Walker et al. tool (Louw et al. 2007) is presented in Table 3.5 (a summary of 
the items covered by the tool is provided after the table).
Study participation
Sixty-six percent (n=54) of the studies (n=82) were able to demonstrate that the sample had been 
selected appropriately by: selecting an entire target population, randomly selecting the sample, or 
stating that the sample represented the target population. Assessment of bias due to non-
response and response rate was not applicable to five studies4 that had used the medical and 
health insurance records of an entire population. Of the rest, 32 studies (39%) discussed bias due 
to non-response by: describing reasons for nonresponse; describing non-responders; comparing 
responders and non-responders; or comparison of sample and target population. Response rates 
were recorded by 82% (63 of the 77) of the studies where response rates where appropriate.
Quality of the data
Fifty-two percent (n=43) of the studies used the same method of data collection for all subjects. 
Ninety-three percent (n=76) of the studies collected data directly from the respondent (or, in the 
case of children, the parents). Where a questionnaire was used (n=73), 56% (n=41) of studies 
presented some evidence of its validity. Where an interview was used (n=49), 33% (n=16) of 
studies presented some evidence of interview validity. Where respondents were examined (n=46), 
43% (n=20) presented some evidence of measures taken to validate the examination process. 
Eight-five percent (n=70) of the studies calculated prevalence as a direct estimate from the whole 
sample, the remaining twelve studies (15%) extrapolated prevalence figures using positive 
predictive values derived from other populations (e.g. rheumatology outpatients), or from 
subsamples of responders (e.g. only those examined or only those testing positive on an initial 
screening test). The majority of studies (94%, n=77) provided clear time points (generally point 
prevalence) for prevalence estimates. 
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4 Andersson et al. 1999, Hughes et al. 2006, Marschall et al. 2011, Sauer et al. 2011, Vincent et al. 2013 
(medical records).
Case definition
Eighty-seven percent (n=71) gave clear diagnostic criteria for outcomes measured.
Table 3.5 Methodological quality appraisal of each study included in the review using the Walker et al. 
tool
A1 A2 A3 B4 B5 B6 B7 B8 B9 B10 C11
Albin et al. 2012
Abusdal et al. 1997a
Aggarwal et al. 2006
Alvarez-Nemegyei et al. 2005
Alvarez-Nemegyei et al. 2011
Andersson 1994
Andersson et al. 1999
Assumpção et al. 2009
Bazelmans et al. 1999
Bergman et al. 2001
Branco et al. 2010
Buskila et al. 1993
Buskila et al. 2000
Cakirbay et al. 2006
Cardiel & Serrano 2002
Carmona et al. 2001
Carnes et al. 2007
Chaaya et al. 2012
Chen et al. 2008
Choudhury et al. 2013 (long)
Choudhury et al. 2013 (short)
Clark et al. 1998
Croft et al. 1993
Dans et al. 1997
Davatchi et al. 2008 (urban)
Davatchi et al. 2009a (rural)
Eggermont et al. 2010
Elstad 1994
Farooqi & Gibson 1998
Forseth & Gran 1992
Gansky & Plesh 2007
Guermazi et al. 2008
Hagen et al. 2005
Haq et al. 2005
Hardt et al. 2008
✕ ✕ ✓ ✓ Directly from respondent ✓ NS NS ✕ ✓ ✓
✓ ✕ ✓ ✓ Directly from respondent ✓ N/A N/A ✓ ✓ ✕
✓ ✓ ✓ ✓ Directly from respondent ✓ N/A N/A ✓ ✓ ✓
✕ ✕ ✓ ✕ Directly from respondent ✕ ✕ ✕ ✕ ✓ ✓
✕ ✕ ✕ ✕ Directly from respondent ✓ ✕ ✕ ✕ ✕ ✓
✓ ✓ ✓ ✕ Directly from respondent ✓ N/A ✕ ✕ ✓ ✕
✓ N/A N/A ✓ Physician estimate N/A N/A N/A ✓ ✓ ✓
✕ ✕ ✓ ✕ Directly from respondent NS NS NS ✕ ✕ ✓
✓ ✓ ✓ ✕ Medical records NS N/A N/A ✓ ✕ ✕
✓ ✓ ✓ ✓ Directly from respondent NS N/A N/A ✓ ✓ ✓
✓ ✕ ✕ ✓ Directly from respondent ✓ NS ✕ ✕ ✓ ✓
✕ ✕ ✕ ✓ Directly from respondent 
and parents
N/A ✕ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ Directly from respondent NS NS N/A ✓ ✓ ✓
✓ ✕ ✓ ✕ Directly from respondent N/A NS NS ✓ ✓ ✓
✓ ✓ ✕ ✕ Directly from respondent ✓ ✓ ✕ ✕ ✓ ✓
✓ ✓ ✓ ✓ Directly from respondent ✓ ✓ ✓ ✓ ✓ ✓
✓ ✕ ✓ ✓ Directly from respondent NS N/A N/A ✓ ✓ ✓
✓ ✓ ✓ ✕ Directly from respondent ✓ NS NS ✓ ✓ ✓
✕ ✕ ✕ ✓ Directly from respondent ✕ ✕ N/A ✓ ✓ ✓
✕ ✕ ✓ ✓ Directly from respondent ✓ NS N/A ✓ ✓ ✓
✕ ✕ ✓ ✓ Directly from respondent NS N/A N/A ✓ ✓ ✓
✕ ✕ ✕ ✕ Directly from respondent NS ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ Directly from respondent ✓ N/A N/A ✓ ✓ ✓
✓ ✓ ✓ ✕ Directly from respondent ✓ ✓ ✓ ✓ ✓ ✕
✓ ✓ ✓ ✕ Directly from respondent ✓ ✓ ✕ ✓ ✓ ✕
✓ ✕ ✓ ✕ Directly from respondent ✓ ✓ ✕ ✓ ✓ ✓
✕ ✕ ✕ ✓ Directly from respondent NS ✓ ✓ ✓ ✓ ✓
✓ ✕ ✓ ✓ Directly from respondent NS N/A N/A ✓ ✓ ✕
✕ ✕ ✓ ✕ Directly from respondent ✓ ✕ ✕ ✓ ✓ ✕
✕ ✕ ✓ ✕ Directly from respondent ✕ ✕ ✕ ✕ ✓ ✓
✓ ✕ ✓ ✕ Directly from respondent ✓ ✓ ✓ ✓ ✓ ✓
✓ ✕ ✕ ✕ Directly from respondent ✓ ✓ NS ✓ ✓ ✓
✓ ✓ ✓ ✓ Directly from respondent ✕ N/A N/A ✓ ✓ ✓
✓ ✕ ✓ ✕ Directly from respondent ✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✕ ✓ Directly from respondent NS NS N/A ✓ ✓ ✓
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A1 A2 A3 B4 B5 B6 B7 B8 B9 B10 C11
Häuser et al. 2009b
Häuser et al. 2013
Hughes et al. 2006
Hunt et al. 1999
Jacobsson et al. 1996
Joshi & Chopra 2009
Kim et al. 2006
Klemp et al. 2002
Kurita et al. 2012
Lindell et al. 2000
Macfarlane et al. 2005 
(survey A)
Macfarlane et al. 2005 
(survey B)
Macfarlane et al. 2009a
Macfarlane et al. 2009b
Mäkelä & Heliövaara 1991
Marschall et al. 2011
McNally et al. 2006
Minaur et al. 2004
Øverland et al. 2012
Papageorgiou et al. 2002
Pelaez-Ballestas et al. 2011
Perrot et al. 2011
Picavet & Hazes 2003
Prescott et al. 1993
Raspe & Baumgartner 1993
Reyes-Llerena et al. 2000
Reyes-Llerena et al. 2009
Rodriquez-Amado et al. 2011
Salaffi et al. 2005
Santos et al. 2010
Sauer et al. 2011
Schochat & Raspe 2003
Scudds et al. 2006
Senna et al, 2004
Storozhenko et al. 2004
Svebak et al, 2006
Topbas et al. 2005
Turhanoglu et al. 2008
Veerapan et al. 2007
Vincent et al. 2013 
(Medical records)
Vincent et al. 2013 
(Self-report)
White et al. 1999
White et al. 2003
Wolfe et al. 1995
Wolfe et al. 2013
Zapata et al. 2006
Zeng et al. 2010
✓ ✓ ✓ ✓ Directly from respondent ✕ N/A N/A ✓ ✓ ✓
✓ ✓ ✓ ✓ Directly from respondent ✓ N/A N/A ✓ ✓ ✓
✓ N/A N/A ✓ Medical records N/A N/A N/A ✓ ✓ ✓
✓ ✓ ✓ ✓ Directly from respondent NS N/A N/A ✓ ✓ ✓
✕ ✕ ✕ ✓ Directly from respondent NS NS N/A ✓ ✓ ✓
✕ ✓ ✕ ✕ Directly from respondent ✓ ✓ NS ✓ ✓ ✓
✕ ✕ ✕ ✕ Directly from respondent NS ✕ ✕ ✓ ✓ ✓
✕ ✕ ✓ ✓ Directly from respondent N/A NS ✓ ✓ ✓ ✓
✕ ✕ ✓ ✓ Directly from respondent NS N/A N/A ✓ ✓ ✓
✕ ✓ ✓ ✕ Directly from respondent NS N/A ✓ ✕ ✓ ✓
✕ ✕ ✓ ✓ Directly from respondent NS N/A N/A ✓ ✓ ✓
✕ ✕ ✕ ✓ Directly from respondent NS N/A N/A ✓ ✓ ✓
✓ ✓ ✓ ✓ Directly from respondent NS N/A N/A ✓ ✓ ✓
✓ ✕ ✓ ✓ Directly from respondent ✓ N/A N/A ✓ ✓ ✓
✓ ✕ ✓ ✕ Directly from respondent N/A ✕ ✕ ✕ ✓ ✓
✕ N/A N/A ✓ Medical records N/A N/A N/A ✓ ✓ ✓
✓ ✓ ✓ ✓ Directly from respondent NS ✓ N/A ✓ ✓ ✓
✓ ✕ ✓ ✕ Directly from respondent ✓ NS NS ✓ ✓ ✓
✕ ✕ ✓ ✓ Directly from respondent NS N/A N/A ✓ ✓ ✓
✓ ✕ ✓ ✓ Directly from respondent ✓ N/A N/A ✓ ✓ ✓
✓ ✓ ✓ ✕ Directly from respondent ✓ NS NS ✓ ✓ ✓
✓ ✕ ✓ ✓ Directly from respondent ✓ NS ✓ ✕ ✕ ✓
✓ ✕ ✓ ✓ Directly from respondent ✕ N/A N/A ✓ ✓ ✕
✓ ✓ ✓ ✕ Directly from respondent ✓ ✓ ✓ ✓ ✓ ✓
✓ ✕ ✓ ✕ Directly from respondent ✕ N/A ✓ ✕ ✓ ✓
✕ ✓ ✓ ✕ Directly from respondent ✓ NS NS ✓ ✓ ✕
✓ ✓ ✕ ✕ Directly from respondent ✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✕ Directly from respondent ✓ NS ✓ ✓ ✓ ✓
✓ ✓ ✓ ✕ Directly from respondent NS NS NS ✓ ✓ ✓
✓ ✕ ✓ ✕ Directly from respondent NS NS ✓ ✓ ✓ ✓
✕ N/A N/A ✓ Medical records N/A N/A N/A ✓ ✓ ✓
✕ ✕ ✓ ✓ Directly from respondent ✓ N/A N/A ✓ ✓ ✓
✓ ✕ ✓ ✕ Directly from respondent ✓ ✓ ✓ ✓ ✓ ✓
✓ ✕ ✓ ✕ Directly from respondent ✓ NS NS ✓ ✓ ✓
✓ ✕ ✓ ✓ Directly from respondent ✓ N/A N/A ✓ ✓ ✓
✓ ✓ ✓ ✓ Directly from respondent ✕ N/A N/A ✓ ✓ ✓
✓ ✕ ✓ ✕ Directly from respondent ✓ NS ✓ ✓ ✓ ✓
✓ ✓ ✓ ✕ Directly from respondent NS NS NS ✓ ✓ ✓
✕ ✕ ✓ ✕ Directly from respondent ✓ NS NS ✓ ✓ ✕
✓ N/A N/A ✓ Medical records N/A N/A N/A ✓ ✓ ✓
✓ ✕ ✓ ✓ Directly from respondent ✓ N/A N/A ✓ ✓ ✓
✓ ✓ ✓ ✕ Directly from respondent ✓ ✓ ✓ ✓ ✓ ✓
✓ ✕ ✓ ✕ Directly from respondent ✓ NS NS ✓ ✓ ✓
✓ ✓ ✓ ✕ Directly from respondent ✓ NS ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ Directly from respondent ✓ N/A N/A ✓ ✓ ✓
✕ ✓ ✓ ✓ Directly from respondent ✕ ✕ NS ✓ ✕ ✓
✕ ✕ ✓ ✕ Directly from respondent ✓ NS ✓ ✓ ✓ ✓
NS: No statement; N/A: Not applicable
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Modified Walker et al. quality appraisal tool (Louw et al. 2007)
A. Is the final sample representative of the target population?
1. At least one of the following must apply in the study: an entire target population, randomly selected sample, or 
sample stated to represent the target population.
2. At least one of the following: reasons for nonresponse described, non-responders described, comparison of 
responders and non-responders, or comparison of sample and target population.
3. Response rate and, if applicable, drop-out rate reported.
B. Quality of the data
4. Was the same mode of data collection used for all subjects?
5. Were the data collected from each respondent directly or were they collected from a proxy?
6. In the case of a questionnaire, at least one of the following: a validated questionnaire or at least tested for 
reproducibility.
7. In the case of an interview, at least one of the following: interview validated; tested for reproducibility; or 
adequately described and standardised.
8. In the case of an examination, at least one of the following: Examination validated; tested for reproducibility; or 
adequately described and standardised.
9. Was prevalence calculated as a direct estimate from the whole sample?
10. Was any statement given regarding time points for prevalence figures (point/period prevalence)?
C. Case definition
11. Were clear diagnostic criteria for CWP/FM stated?
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b. QUIPS tool
A summary of the results for the two domains of the QUIPS tool (1. Study participation, 4. 
Outcome measurement) that were used to assess the methodological quality of the papers 
included in the review is provided in Table 3.6. A more detailed justification of the risk of bias 
assigned for each domain is included in the appendix (A3.4 and A3.5).
Table 3.6 Summary of risk of bias in domains 1 and 4 of the QUIPS methodological quality assessment  
tool for all papers included in the review
Study Risk of bias related to study 
participation
Risk of bias related to 
outcome measurement
Aggarwal et al. 2006 low low
Bergman et al. 2001 low low
Buskila et al. 2000 low low
Carmona et al. 2001 low low
Croft et al. 1993 low low
Gansky & Plesh 2007 low low
Häuser et al. 2013 low low
Hunt et al. 1999 low low
Macfarlane et al. 2009a low low
Macfarlane et al. 2009b low low
Papageorgiou et al. 2002 low low
Prescott et al. 1993 low low
Rodriquez-Amado et al. 2011 low low
Topbas et al. 2005 low low
Wolfe et al. 2013 low low
Abusdal et al. 1997a low moderate
Cardiel & Serrano 2002 low moderate
Chaaya et al. 2012 low moderate
Pelaez-Ballestas et al. 2011 low moderate
Reyes-Llerena et al. 2009 low moderate
Salaffi et al. 2005 low moderate
Svebak et al. 2006 low moderate
Turhanoglu et al. 2008 low moderate
Andersson et al. 1999 low high
Cakirbay et al. 2006 low high
Häuser et al. 2009b low high
Mäkelä & Heliövaara 1991 low high
McNally et al. 2006 low high
Hughes et al. 2006 low coding: low/community: high
Vincent et al. 2013 (medical records) low coding: low/community: high
Carnes et al. 2007 moderate low
Dans et al. 1997 moderate low
Eggermont et al. 2010 moderate low
Haq et al. 2005 moderate low
Macfarlane et al. 2005 (survey A) moderate low
Macfarlane et al. 2005 (survey B) moderate low
Schochat & Raspe 2003 moderate low
Scudds et al 2006 moderate low
Storozhenko et al. 2004 moderate low
White et al. 1999 moderate low
White et al. 2003 Amish: low/non-Amish: moderate moderate
Wolfe et al. 1995 moderate low
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Study Risk of bias related to study 
participation
Risk of bias related to 
outcome measurement
Alvarez-Nemegyei et al. 2005 moderate moderate
Andersson 1994 moderate moderate
Davatchi et al. 2009a moderate moderate
Farooqi & Gibson 1998 moderate moderate
Guermazi et al. 2008 moderate moderate
Hagen et al. 2005 moderate moderate
Hardt et al. 2008 moderate moderate
Jacobsson et al. 1996 moderate moderate
Joshi & Chopra 2009 moderate moderate
Kurita et al. 2012 moderate moderate
Minaur et al. 2004 moderate moderate
Santos et al. 2010 moderate moderate
Senna et al. 2004 moderate moderate
Zeng et al. 2010 moderate moderate
Bazelmans et al. 1999 moderate high
Branco et al. 2010 moderate high
Davatchi et al. 2008 moderate high
Elstad 1994 moderate high
Forseth & Gran 1992 moderate high
Picavet & Hazes 2003 moderate high
Choudhury et al. 2013 (short) high low
Clark et al. 1998 high low
Vincent et al. 2013 (self report) high low
Alvarez-Nemegyei et al. 2011 high moderate
Assumpção et al. 2009 high moderate
Buskila et al. 1993 high moderate
Choudhury et al. 2013 (long) high moderate
Kim et al. 2006 high moderate
Klemp et al. 2002 high moderate
Øverland et al. 2012 high moderate
Perrot et al. 2011 high moderate
Zapata et al. 2006 high moderate
Ablin et al. 2012 high high
Chen et al. 2008 high high
Lindell et al. 2000 high high
Marschall et al. 2011 high coding: low/community: high
Raspe & Baumgartner 1993 high high
Reyes-Llerena et al. 2000 high high
Sauer et al. 2011 high coding: low/community: high
Veerapan et al. 2007 high high
Six studies (7%) were felt to be at high risk of bias for both domains of the QUIPS tool (study 
participation and outcome measurement). Three5 of these high risk studies did not employ the 
ACR criteria; one (Chen et al. 2008) failed to adequately operationalise the ACR criteria; one 
(Ablin et al. 2012) had a low response rate (30%), recruited respondents by telephone only 
(thereby systematically excluding those without a home telephone) and extrapolated prevalence 
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5 Reyes-Llerena et al. 2000, Raspe and Baumgartner 1993, Veerapan et al. 2007
figures from data observed in rheumatology outpatients; and one study (Lindell et al. 2000) 
demonstrated non-responders to be different from participants completing the outcome measure 
and may have underestimated prevalence because of long delay between questionnaire and 
examination, and the examination of only a stratified sample of screen positives. A further two 
studies6 used health insurance records to estimate prevalence and were therefore at high risk of 
selection bias and at high risk of outcome measurement bias for estimates of community 
prevalence, but at low risk for estimates of coding prevalence.
Study participation
Using the QUIPS tool, 24% (n=20 out of 82 studies included in 79 papers) of the studies included 
in the review were felt to be at high risk of study participation bias. Thirty-nine percent (n=32) were 
considered to be at moderate risk, and 37% (n=30) were considered to be at low risk of 
participation bias.
The main failings in sample selection noted in the high risk studies were non-random sampling of 
respondents or recruitment from a non-representative sampling frame. Seven used non-random 
selection methods7, and seven took their sample from a non-representative sampling frame8. 
Four9 had to be considered high risk due to low response rates and inadequate documentation 
regarding the representativeness of study sample. 
Of the 82 studies (79 papers) included in the review, 58 used diagnostic criteria based on the 
ACR-90 and two used the ACR-2010 criteria. Of the 58 studies employing the ACR-90 criteria, 
22% (n=13) were deemed to be at high risk of study participation bias. Of the 22 remaining 
studies, which used case definitions other than ACR-90 or ACR-2010, or failed to clearly state any 
diagnostic criteria, 27% (n=6) were found to be at high risk of selection bias.
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6 Marschall et al. 2011, Sauer et al. 2011.
7 Assumpção et al. 2009, Chen et al. 2008, Choudhury et al. 2013 (long interview), Kim et al. 2006, Klemp et 
al. 2002, Reyes-Llerena et al. 2000, Veerapen et al. 2007.
8 Buskila et al. 1993, Clark et al. 1998, Marschall et al. 2011, Øverland et al. 2012, Sauer et al. 2011, 
Veerapen et al. 2007, Zapata et al. 2006. 
9 Ablin et al. 2012, Choudhury et al. 2013 (short postal questionnaire), Perrot et al. 2011, Vincent et al. 2013 
(self-report questionnaire).
Outcome measurement
If we consider our outcome to be community FM/CWP prevalence (rather than coding 
prevalence), then 26% (n=21) of the included studies were at high risk of outcome measurement 
bias using the QUIPS tool. Thirty-nine percent (n=32) of the studies were found to be at moderate 
risk and 35% (n=29) were felt to be at low risk of outcome measurement bias.
For the outcome measurement domain, over half (55%, n=11)10 of the 20 high-risk studies were 
rated as such because they used inadequate case definition criteria. They either employed 
diagnostic criteria that were poorly documented, relied on clinical judgement with no specified 
diagnostic criteria, or asked for patient recall of physician’s diagnosis. Two high-risk11 studies 
failed to operationalise established diagnostic criteria adequately. Four studies12 used non-robust 
methods to establish prevalence estimates, calculating figures from data extrapolated from a sub-
sample or from an unrelated population (e.g. rheumatology outpatients) rather than from the whole 
sample or the target population. One high-risk study (Cakirbay et al. 2006) failed to provide 
sufficient documentation regarding the validity of screening test used and the method of outcome 
measurement and therefore had to be considered high-risk.
Six (7%) of the included studies13 aimed to estimate the prevalence of clinically recognised FM, 
rather than community prevalence. Five of the six studies14 estimating clinically recognised FM 
established coding prevalence used a clear definition of the codes (recorded in medical/health 
insurance records) used to represent a FM diagnosis, while the remaining study (Bazelmans et al. 
1999) asked GPs to self-report the number of FM patients in their practice (no FM case definition 
was documented in the paper). The five studies using medical or health insurance records were 
therefore considered to be at low risk of bias for measuring FM coding as an outcome, but at high 
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10 Albin et al. 2012, Bazelmans et al. 1999, Chen et al. 2008, Davtchi et al. 2008, Elstad et al. 1994, Häuser et 
al. 2009b, McNally et al. 2006, Picavet and Hazes 2003, Raspe and Baumgartner 1993, Reyes-Llerena et al. 
2000, Veerapan et al. 2007.
11 Mäkelä and Heliövaara 1991, Chen et al. 2008.
12 Branco et al. 2010, Raspe and Baumgartner 1993, Forseth and Gran 1992, Lindell et al. 2000.
13 Andersson et al. 1999, Hughes et al. 2006, Marschall et al. 2011, Sauer et al. 2011, Vincent et al. 2013 - 
medical records, Bazelmans et al. 1999.
14 Andersson et al. 1999, Hughes et al. 2006, Marschall et al. 2011, Sauer et al. 2011, Vincent et al. 2013 - 
medical records.
risk for assessing actual community FM burden; while the study asking GPs to self-report FM was 
considered to be at high risk of bias in determining both coding and community prevalence.
Twelve percent (n=7) of the studies using the ACR-90 criteria (n=58) were felt to be at high risk of 
outcome measurement bias, compared to 59% (n=13) of the non-ACR (ACR-90 or ACR-2010) 
studies (n=22).
3.4.5 Prevalence
a. Prevalence estimates
Prevalence estimates for FM ranged from three per 10,000 in China (Zeng et al. 2010) to an upper 
limit of 1,050 per 10,000 in women aged 20–49 in Arendal, Norway (Forseth and Gran 1992). The 
majority of estimates for FM prevalence were between 100 and 400 per 10,000 of the population. 
The majority of figures were either stated or assumed to be point prevalence estimates.
Prevalence estimates for CWP ranged from zero per 10,000, observed in a sample of Pima 
Indians (Jacobsson et al. 1996), to an upper limit of 2,400 for low socioeconomic status 
populations in Brazil (Assumpção et al. 2009). The majority of estimates for CWP prevalence were 
between 1,000 and 1,300 per 10,000 of the population.
A full summary of prevalence estimates and study characteristics is provided in Table A3.8 in the 
appendix (A3.6).
b. Variation by diagnostic criteria
Fibromyalgia
Prevalence estimates for FM stratified by diagnostic criteria used are presented in Table 3.7 for 
the studies included in the review that provided figures for both male and female adults.
Of the 49 studies presenting figures for FM in male and female adults, 30 (61%) used the full 
ACR-90 diagnostic criteria. Three further studies15 used the ACR-90 criteria but did not examine 
for tender points. Two studies16 used the ACR-2010 criteria. Two studies17 gave figures based on 
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15 Chen et al. 2008, Häuser et al. 2009b, Ablin et al. 2012.
16 Wolfe et al. 2013 and Vincent et al. 2013.
17 McNally et al. 2006, Picavet and Hazes 2003.
self-reported FM diagnosis. Six studies18 used diagnostic criteria based on either coding 
prevalence or prevalence based on GPs’ estimates of the prevalence within their practice. One 
study defined a case according to ‘generally accepted definitions among 
rheumatologists’ (Reyes-Llerena et al. 2000). One study used the Yunus et al. criteria (Mäkelä and 
Heliövaara 1991). Finally, four studies19 failed to document clear diagnostic criteria.
Estimates for FM prevalence in studies of male or female adults using the full ACR-90 criteria 
ranged between 3 and 880 per 10,000, with the majority of estimates between 100 and 400 per 
10,000. The two studies20 reporting FM prevalence using the updated ACR-2010 criteria 
estimated prevalence of 210 and 530 per 10,000.
The two studies21 calculating recorded prevalence using insurance records had very low 
prevalence rates when compared with community prevalence figures determined using the 
ACR-90 criteria (28–45 per 10,000 of the population compared with a figure between 100 and 400 
for the majority of studies implementing the ACR-90 criteria). The two studies of FM coding 
prevalence in insurance records both used German insurance company data; the lower estimate 
(28 per 10,000) was found in the study requiring two instances of FM coding, while the study with 
the higher estimate only required one instance of FM coding. Medical record coding prevalence22 
was between 18 and 330 per 10,000.
Prevalence as estimated by GPs (Bazelmans et al. 1999) was very low (16 per 10,000).
The two studies23 using self-reported recollection of FM diagnosis had low prevalence rates of 110 
and 120 per 10,000 of the population. 
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18 Insurance company records: Sauer et al. 2011, Marschall et al. 2011; Medical records: Andersson et al. 
1999, Hughes et al. 2006, Vincent et al. 2013 (medical records); GP estimates: Bazelmans et al. 1999.
19 Andersson 1994, Davatchi et al. 2008, Farooqi and Gibson 1998, Veerapan et al. 2007.
20 Vincent et al. 2013 (self report), Wolfe et al. 2013.
21 Marschall et al. 2011, Sauer et al. 2011.
22 Vincent et al. 2013 (medical records), Hughes et al. 2006, Andersson et al. 1999
23 McNally et al, 2006, Picavet and Hazes 2003.
Table 3.7 Prevalence of FM per 10,000 of the population for male and female adults stratified by 
diagnostic criteria used for case definition.
Diagnostic 
Criteria
Study Prevalence per 10,000 
population (95% CI)
ACR-90 – including tender point 
examination
Zeng et al. 2010
Taiyuan 3 (0, 10)*
Shantou 10 (0, 30)*
Joshi & Chopra 2009 5 (1, 13)
Davatchi et al. 2009a 6 (0, 123)
Minaur et al. 2004 12 (2, 66)*
Alvarez-Nemegyei et al. 2011 20 (10, 40)
Dans et al. 1997 20 (10, 40)*
Reyes-Llerena et al. 2009 22 (9, 40)
Prescott et al. 1993 66 (28, 129)
Pelaez-Ballestas et al. 2011 68 (56, 80)
Rodriquez-Amado et al. 2011 80 (60, 110)
Scudds et al. 2006 82 (35, 129)
Chaaya et al. 2012 100 (60, 130)
White et al. 2003 
Non-Amish (rural) 120 (60, 260)*
Amish 720 (530, 970)
Lindell et al. 2000 130 (80, 170)
Alvarez-Nemegyei et al. 2005 130 (60, 240)
Klemp et al. 2002 130 (10, 240)
Cardiel & Serrano 2002 140 (100, 200)
Perrot et al. 2011 160 (120, 200)
Raspe & Baumgartner 1993 200 (110, 390)*
Wolfe et al. 1995 200 (140, 270)
Salaffi et al. 2005 222 (136, 319)
Kim et al. 2006 224 (150, 333)*
Carmona et al. 2001 240 (150, 320)
Senna et al. 2004 250 (197, 312)
Branco et al. 2010** 290 (240, 360)
France 140 (70, 210)
Portugal 360 (200, 520)
Spain 230 (140, 320)
Germany 320 (210, 430)
Italy 370 (260, 480)
White et al. 1999 (urban) 330 (320, 340)
Haq et al. 2005 360 (310, 410)*
Urban slum 320 (230, 440)
Urban affluent 330 (240, 440)
Rural 440 (370, 530)
Assumpção et al. 2009 440 (270, 630)
Guermazi et al. 2008 670 (530, 840)*
Turhanoglu et al. 2008 880 (680, 1140)*
Based on ACR-90 criteria 
(no examination conducted)
Ablin et al. 2012** 200 (130, 270)
Häuser et al. 2009b 380 (290, 440)*
Chen et al. 2008
Criteria developed from ACR-90 670 (530, 830)*
Criteria based on LFESSQ 980 (820, 1,170)*
ACR-2010 Wolfe et al. 2013 210 (160, 270)
Vincent et al. 2013 
(self report)
530 (385, 712)
Self-reported recall of diagnosis McNally et al. 2006 110 (100, 120)
Picavet & Hazes 2003 120 (90, 160)*
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Diagnostic 
Criteria
Study Prevalence per 10,000 
population (95% CI)
Recorded 
prevalence
Read codes N248, N239 
and N2412
OXMIS code 7339F
Hughes et al. 2006 18 (17, 19)*
ICD-10 diagnosis M79.7 
coded at least twice
Marschall et al. 2011 28 (28, 29)*
ICD-10 diagnosis M79.7 Sauer et al. 2011 45 (43, 46)*
Documented FM 
diagnosis in medical 
records
Vincent et al. 2013 
(medical records)
110 (107, 120)
ICD-8: 7179; ICD-9: 728 Andersson et al. 1999 330 (290, 370)*
Estimate of practice prevalence 
provided by GPs
Bazelmans et al. 1999 16 (7, 34)*
Yunus et al. Mäkelä & Heliövaara 1991 75 (57, 97)*
According to generally accepted 
definitions among 
rheumatologists
Reyes-Llerena et al. 2000 70 (20, 240)*
No criteria stated Davatchi et al. 2008 (urban) 69 (54, 87)*
Veerapan et al. 2007 93 (62, 137)*
Andersson 1994 190 (130, 260)*
Farooqi & Gibson 1998 210 (160, 280)*
Rural 260 (170, 410)*
Urban 320 (220, 480)*
Urban affluent 10 (3, 90)*
*95% CI calculated from sample size and prevalence estimate.
** based on figures for positive screen for LFESSQ-6
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Chronic widespread pain
Prevalence estimates stratified by diagnostic criteria for the 29 studies (28 papers) presenting 
figures for CWP in male and female adults are presented in Table 3.8. Of these 29 studies, 24 
(83%) used the ACR-90 criteria, one study additionally used the Manchester criteria (Hunt et al. 
1999) with the same study sample, one used ACR-2010 criteria, and four studies used study-
specific criteria. In ACR-90 studies CWP prevalence ranged from zero in Pima Indians (Jacobsson 
et al. 1996) to 2,400 per 10,000 in a low socio-economic status population in Brazil (Assumpção et 
al. 2009), with the majority of estimates between 1,000 and 1,300 per 10,000.
The study (Hunt et al. 1999) using both the ACR-90 and Manchester criteria with the same sample 
noted a lower prevalence using the Manchester criteria; 470 per 10,000 compared to 1,290 using 
the ACR-90 criteria.
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Table 3.8 Prevalence of CWP per 10,000 for mixed adults stratified by diagnostic criteria.
Diagnostic criteria Study Prevalence per 10,000 
population (95% CI)
ACR-90 Jacobsson et al. 1996 0 (0, 350)
Klemp et al. 2002 280 (160, 430)
Hardt et al. 2008 360 (310, 420)
Lindell et al. 2000 420 (340, 500)
Scudds et al. 2006 440 (340, 550)*
Ablin et al. 2012 510 (391, 663)*
White et al. 1999 730 (650, 820)*
White et al. 2003
Non-Amish 890 (670, 1,180)*
Amish 1,450 (1,010, 2,040)*
Choudhury et al. 2013
Short postal survey
White British/Irish 1,000 (200, 1,800)
British Bangladeshi 900 (0, 2,500)
Bangladeshi 1,600 (300, 2,800)
Other ethnic groups 900 (0, 2,000)
Long questionnaire
White British/Irish 600 (0, 1,800)
British Bangladeshi 900 (0, 2,400)
Bangladeshi 1,800 (300, 3,300)
Papageorgiou et al. 2002 1,000 (860, 1,170)*
Buskila et al. 2000 1,020 (870, 1,110)
Wolfe et al. 1995 1,060 (950, 1,170)
Croft et al. 1993 1,120 (960, 1,300)*
Bergman et al. 2001 1,140 (1,010, 1,260)
Macfarlane et al. 2005 (survey A)
White European 1,180 (990, 1,400)*
South Asian 1,380 (1,240, 1,550)*
Raspe & Baumgartner 1993 1,200 (940, 1550)
Carnes et al. 2007 1,200 (1,080, 1,330)*
Branco et al. 2010 1,300 (1,200, 1,400)*
France 1,000 (830, 1,200)*
Italy 1,000 (830, 1,200)*
Germany 1,100 (920, 1,310)*
Portugal 1,300 (1,030, 1,620)*
Spain 2,300 (2,050, 2,570)*
Storozhenko et al. 2004 1,330 (838, 2,056)*
Kim et al. 2006 1,401 (1,202, 1,626)*
Aggarwal et al. 2006 1,500 (1,367, 1,647)*
Assumpção et al. 2009 2,400 (2,100, 2,700)
ACR-90 and Manchester Hunt et al. 1999
ACR 1,290 (1,150, 1,450)
Manchester 470 (390, 570)
ACR-2010: WPI ≥ 6 for 3 months Häuser et al. 2013 580 (497, 680)*
Study-specific Hagen et al. 2005 440 (420, 460)*
Kurita et al. 2012
Danish 460 (427, 496)*
Other Western 405 (251, 648)*
Non-Western 1,026 (789, 1,324)*
Andersson 1994 1,070 (930, 1,230)*
Svebak et al. 2006 1,260 (1,230, 1,280)
*95% CI calculated from sample size and prevalence estimate.
WPI: Widespread pain index (Wolfe et al. 2010)
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c. Geographical variation
To ensure comparability for the assessment of geographical variation in prevalence, only adult 
studies using the ACR-90 criteria have been compared. Tables 3.9 and 3.10 present prevalence 
figures stratified by study location for FM and CWP respectively.
Fibromyalgia
The studies conducted by White et al. (1999, 2003) in Ontario Canada compare FM prevalence in 
rural, urban and Amish communities. A substantially higher prevalence of 720 per 10,000 of the 
population is observed in the Amish community, compared to 120 for rural communities and 330 
per 10,000 for the urban population. In contrast, Haq et al. (2005) found a high prevalence in rural 
Bangladesh compared to both urban affluent and slum communities.
In South America, prevalence estimates were lower in the Mexican and Cuban studies compared 
to the Brazilian studies. The Mexican and Cuban studies also presented lower estimates than the 
North American studies.
European estimates ranged from 66 per 10,000 in Denmark (Prescott et al. 1993) to 380 per 
10,000 in Germany (Häuser et al. 2009b), with the majority of the estimates between 200 and 350 
per 10,000 of the population.
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Table 3.9 Prevalence of FM in male and female adults in the general population per 10,000 of the 
population, stratified by geographical location (for studies using ACR-90 criteria).
Geographical region Study Population Prevalence per 
10,000 
population 
(95% CI)
Africa Guermazi et al. 2008 Tunisia 670 (530, 840)*
Asia China Scudds et al. 2006 Hong Kong 82 (35, 129)
China Chen et al. 2008 ✥ China 670 (530, 830)*
Zeng et al. 2010 – Shantou Shantou, China 10 (0, 30)*
Zeng et al. 2010 – Taiyuan Taiyuan, China 3 (0, 10)*
Korea Kim et al. 2006 South Korea 224 (150, 333)*
South East 
Asia
Dans et al. 1997 Philippines 20 (10, 40)*
Indian 
subcontinent
Haq et al. 2005 Bangladesh 360 (310, 410)*
Rural Bangladesh – rural 440 (370, 530)
Urban affluent Bangladesh – urban affluent 330 (240, 440)
Urban slum Bangladesh – urban slum 320 (230, 440)
Joshi & Chopra 2009 Pune, India – urban 5 (1, 13)
Australasia Minaur et al. 2004 Australia – Aboriginal 
community
12 (2, 66)*
Klemp et al. 2002 New Zealand 130 (10, 240)
Middle 
East
Davatchi et al. 2009a Iran – rural 6 (0, 123)
Chaaya et al. 2012 Lebanon 100 (60, 130)
Ablin et al. 2012 Israel 200 (130, 270)
Turhanoglu et al. 2008 Turkey 880 (680, 1140)*
North 
America
Canada White et al. 2003
Rural Amish Ontario, Canada – Amish 720 (530, 970)
Rural non-Amish Ontario, Cananda – rural 120 (60, 260)*
White et al. 1999 Ontario, Canada – urban 330 (320, 340)
USA Wolfe et al. 1995 Wichita, Kansas, USA 200 (140, 270)
South 
America
Brazil Senna et al. 2004 Brazil 250 (197, 312)
Assumpção et al. 2009 Sao Paulo, Brazil – low 
socioeconomic
440 (270, 630)
Cuba Reyes-Llerena et al. 2009 Cuba 22 (9, 40)
Mexico Alvarez-Nemegyei et al. 2011 Yucatan, Mexico 20 (10, 40)
Pelaez-Ballestas et al. 2011 Mexico 68 (56, 80)
Rodriguez-Amado et al. 2011 Mexico 80 (60, 110)
Alvarez-Nemegyei et al. 2005 Cantamayec, Yucatán, Mexico 130 (60, 240)
Cardiel & Serrano 2002 Mexico – suburban 140 (100, 200)
Europe Central/
Western 
Europe
Branco et al. 2010** Europe 290 (240, 360)
Branco et al. 2010 – France France 140 (70, 210)
Perrot et al. 2011 France 160 (120, 200)
Raspe & Baumgartner 1993 Germany 200 (110, 390)*
Branco et al. 2010 – 
Germany
Germany 320 (210, 430)
Häuser et al. 2009b Germany 380 (290, 440)*
Salaffi et al. 2005 Italy 222 (136, 319)
Branco et al. 2010 – Italy Italy 370 (260, 480)
Branco et al. 2010 – Spain Spain 230 (140, 320)
Carmona et al. 2001 Spain 240 (150, 320)
Branco et al. 2010 – Portugal Portugal 360 (200, 520)
Scandinavia Prescott et al. 1993 Denmark 66 (28, 129)
Lindell et al. 2000 Halmstad and Laholm, Sweden 130 (80, 170)
* 95% CI calculated from sample size and prevalence estimate.
** based on figures for positive screen for LFESSQ-6
✥ These figures are based on those calculated using an adapted version of the ACR-90 criteria in Chen et al. 2008.
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Chronic widespread pain
Figures for ACR-90 CWP in Europe ranged from 420 per 10,000 of the population in Sweden 
(Lindell et al. 2000) to 2,300 in Spain (Branco et al. 2010) but the majority were between 10,00 
and 1,400 per 10,000 of the population. In North America, the Amish had a high prevalence of 
1,450 per 10,000 of the population, compared to rural Ontarians with a prevalence of 890 (White 
et al. 2003) and urban Ontarians with a prevalence of 730 per 10,000 (White et al. 1999). In 
contrast to the Amish, the Pima Indians of the Gila River community in Phoenix, Arizona had no 
observed CWP (Jacobsson et al. 1996). The general population in America were found to have a 
prevalence of 360 per 10,000 of the population by Hardt et al. in 2008 and 1,060 by Wolfe et al. in 
1995.
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Table 3.10 Prevalence of CWP in the adult general population per 10,000 of the population, stratified by 
geographical location (for studies using ACR-90 CWP criteria).
Geographical region Study Population Prevalence per 
10,000 population 
(95% CI)
Asia Scudds et al. 2006 Hong Kong 440 (340, 550)*
Kim et al. 2006 South Korea 1,401 (1,202, 1,626)*
Australasia Klemp et al. 2002 New Zealand 280 (160, 430)
Middle East Buskila et al. 2000 Israel 1,020 (870, 1,110)
Ablin et al. 2012 Israel 510 (391, 663)*
South 
America
Assumpção et al. 2009 Sao Paulo, Brazil - low 
socioeconomic status
2,400 (2,100, 2,700)
North 
America
Canada White et al. 2003 Ontario, Canada
Amish 1,450 (1,010, 2,040)*
Non-Amish (rural) 890 (670, 1,180)*
White et al. 1999 Ontario, Canada (urban) 730 (650, 820)*
USA Jacobsson et al. 1996 Pima Indians, Gila River, 
Arizona
0 (0, 350)
Hardt et al. 2008 USA 360 (310, 420)
Wolfe et al. 1995 USA 1,060 (950, 1,170)
Europe Central/
Western 
Europe
Papageorgiou et al. 2002 Handforth, UK 1,000 (860, 1,170)*
Croft et al. 1993 Cheshire, UK 1,120 (960, 1,300)*
Hunt et al. 1999 Manchester, UK 1,290 (1,150, 1,450)
Macfarlane et al. 2005 
(survey A)
UK
White European 1,180 (990, 1,400)*
South Asian 1,380 (1,240, 1,550)*
Aggarwal et al. 2006 Manchester, UK 1,500 (1,367, 1,647)*
Carnes et al. 2007 South East, UK 1,200 (1,080, 1,330)*
Choudhury et al. 2013 East London, UK
Short postal survey White British/Irish 1,000 (200, 1,800)
British Bangladeshi 900 (0, 2,500)
Bangladeshi 1,600 (300, 2,800)
Other ethnic groups 900 (0, 2,000)
Long questionnaire White British/Irish 600 (0, 1,800)
British Bangladeshi 900 (0, 2,400)
Bangladeshi 1,800 (300, 3,300)
Raspe & Baumgartner 1993 Bad Sackingen, Germany 1,200 (940, 1,550)
Branco et al. 2010 Europe 1,300 (1,200, 1,400)*
France France 1,000 (830, 1,200)*
Italy Italy 1,000 (830, 1,200)*
Germany Germany 1,100 (920, 1,310)*
Portugal Portugal 1,300 (1,030, 1,620)*
Spain Spain 2,300 (2,050, 2,570)*
Scandinavia Lindell et al. 2000 Sweden 420 (340, 500)
Bergman et al. 2001 Sweden 1,140 (1,010, 1,260)
Russia Storozhenko et al. 2004 Yekaterinburg, Russia 1,330 (838, 2,056)*
* 95% CI calculated from sample size and prevalence estimate.
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d. Gender variation
Of the 59 studies presenting figures for FM, 35 gave prevalence figures stratified by gender; 30 of 
these were studies of the adult population. Table 3.11 displays FM prevalence data according to 
gender. Male-to-female ratio for FM prevalence ranged from zero to 0.97. The majority of studies 
showed FM to be at least two times more prevalent in women. 
Table 3.11 Prevalence (per 10,000) of FM in the adult general population stratified by gender.
Study Prevalence per 10,000 population (95% CI) Male:female 
ratioFemale Male
Alvarez-Nemegyei et al. 2005
Assumpção et al. 2009
Chaaya et al. 2012
Lindell et al. 2000
Prescott et al. 1993
Senna et al, 2004
White et al. 2003
Amish
Non-Amish rural
Haq et al. 2005
urban affluent
rural
urban slum
Carmona et al. 2001
Vincent et al. 2013
medical records
self report
Cardiel & Serrano 2002
Picavet & Hazes 2003
Veerapan et al. 2007
Sauer et al. 2011
Wolfe et al. 1995
McNally et al, 2006
Kim et al. 2006
Klemp et al. 2002
Reyes-Llerena et al. 2009
White et al. 1999
Pelaez-Ballestas et al. 2011
Guermazi et al. 2008
Ablin et al. 2012
Turhanoglu et al. 2008
Mäkelä & Heliövaara 1991
Chen et al. 2008***
Branco et al. 2010 ✥
Wolfe et al. 2013
Häuser et al. 2009b
260 (140, 480)* 0 (0, 100)* 0.00
780 (500, 1,180)* 0 (0, 60)* 0.00
200 (130, 260) 0 (0, 21)* 0.00
116 (71, 191)* 0 (0, 34)* 0.00
125 (60, 240)* 0 (0, 60)* 0.00
390 (310, 480)* 9 (2, 50)* 0.02
1,040 (610, 1,850)* 30 (7, 89)* 0.03
220 (50, 390)* 0 (0, 194)* 0.00
580 (410, 790) 20 (0, 120) 0.03
750 (610, 910) 120 (70, 200) 0.16
530 (370, 750) 140 (70, 270)* 0.26
420 (320, 560)* 20 (10, 70)* 0.05
200 (188, 212) 14 (11, 18) 0.07
681 (456, 978) 371 (208, 612) 0.54
140 (180, 360)* 10 (40, 60)* 0.07
210 (150, 270) 20 (0, 40) 0.10
155 (103, 233)* 17 (5, 62)* 0.11
40** 5** 0.13
340 (230, 460) 50 (0, 100) 0.15
180 (170, 200) 30 (20, 40) 0.17
310 (200, 470)* 57 (16, 205)* 0.18
200 (80, 390)* 40 (0, 580) 0.20
30 (10, 70)* 8 (1, 50)* 0.27
490 (470, 510) 160 (130, 190) 0.33
100 (82, 118) 34 (21, 47) 0.34
975 (740, 1270)* 374 (240, 580)* 0.38
360 (240, 470) 150 (100, 200) 0.42
1,250 (920, 1,670) 510 (310, 820) 0.41
98 (71, 133)* 48 (29, 78)* 0.49
830 (641, 1,081)* 460 (307, 690)* 0.55
360 (350, 370) 210 (200, 220) 0.58
240 (150, 320) 180 (110, 260) 0.75
370 (270, 470)* 360 (270, 490)* 0.97
95% CI calculated from sample size and prevalence estimate.
**Unable to calculate 95% CI from information provided in the paper.
***These figures are based on those calculated using an adapted version of the ACR-90 criteria in Chen et al. 2008.
✥ Figures based on positive screen in LFESSQ-6
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Of the 38 studies presenting figures for CWP, 17 gave prevalence by gender, 15 of these were 
studies of the adult population. Table 3.12 displays CWP prevalence in adults according to 
gender. Male to female ratio for CWP prevalence in adults ranged from 0.21 to 0.95, with the 
majority between 0.50 and 0.70.
Table 3.12 Prevalence (per 10,000) of CWP in the adult general population stratified by gender.
Study Prevalence per 10,000 population (95% CI) Male:female  
ratioFemale Male
Buskila et al. 2000
Kim et al. 2006
Ablin et al. 2012
Bergman et al. 2001
Klemp et al. 2002
White et al. 1999
Carnes et al. 2007
Croft et al. 1993
Svebak et al. 2006
Aggarwal et al. 2006
Hardt et al. 2008
Hunt et al. 1999**
Storozhenko et al. 2004
Häuser et al. 2013
White et al. 2003 (Amish)
1,400 (1,230, 1,600) 300 (210, 440) 0.21
1,920 (1,640, 2,240)* 400 (240, 660)* 0.21
713 (522, 967)* 300 (183, 489)* 0.42
1,530 (1,320, 1,740) 750 (600, 910) 0.49
350 (190, 580) 180 (10, 410) 0.51
900 (777, 1,023)* 470 (355, 585)* 0.52
1,440 (1,264, 1,636)* 818 (669, 997)* 0.57
1,560 (1,320, 1,840)* 940 (730, 1210)* 0.60
1,550 (1,510, 1,590) 950 (910, 980) 0.61
1,600 (1,230, 1,510)* 1,070 (890, 1,260)* 0.67
430 (350, 530) 290 (230, 370) 0.67
530 (410, 670) 370 (260, 520) 0.70
1,460 (857, 2,386)* 1,050 (417, 2,413)* 0.72
630 (509, 770)* 530 (416, 674)* 0.84
1,490 (920, 2,310)* 1,410 (810, 2,350) 0.95
* 95% CI calculated from sample size and prevalence estimate.
** Manchester criteria
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e. Age variation
Fibromyalgia
Nine of the papers using the ACR-90 case criteria to diagnose FM presented prevalence figures 
in both male and female adults stratified by age. These data are summarised in Figure 3.2. The 
results show the majority of studies demonstrating either increasing FM prevalence with age or a 
peak in middle age with a decline in older age groups. However, figures for a rural population in 
South Korea (Kim et al. 2006) show increasing prevalence with age in women, but declining 
prevalence with age in men.
Figure 3.2 Prevalence of FM (per 10,000) in the adult general population for studies using the ACR-90 
criteria, stratified by age group.
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Chronic widespread pain
Six of the papers presenting figures for ACR-90 CWP in male and female adults presented 
prevalence stratified by age (Figure 3.3). As for FM there is an increase in CWP prevalence with 
increasing age and/or a peak in middle age with some studies suggesting a decline in older age 
groups. Data from Croft et al. (1993) demonstrate two peaks: one in middle age, and another in 
the elderly. For women there is a peak at age 45–54 and again at 75–85, while for men there is a 
peak at 55–64 with another at 75–85. 
Figure 3.3 Prevalence of CWP (per 10,000) in the adult general population for studies using the ACR-90 
criteria, stratified by age group.
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3.4.6 Meta-analysis
Studies examining prevalence in both male and female adults using the ACR-90 criteria were 
included in a meta-analysis. Thirty papers presenting figures for ACR-90 FM prevalence in mixed-
gender adults were identified, representing 38 estimates of FM prevalence in different 
populations. 
CWP estimates from the Lindell et al. (2000) study were excluded from the meta-analysis because 
the paper used a slightly different definition that used data from two different time points a year 
apart. Twenty-two papers presenting figures for CWP were included, representing 34 estimates of 
CWP prevalence in different populations.
a. Fibromyalgia
The random-effects pooled prevalence of FM for all 38 included estimates was 180 per 10,000 
(95% CI 150, 220); this estimate was associated with a high level of heterogeneity (I2 = 99.1%). 
There was little difference if low-quality studies (as defined in section 3.3.7.b) and studies 
estimating prevalence in particularly select populations (White et al. 2003: Amish population) were 
removed from the analysis – pooled prevalence dropped marginally to 170 per 10,000 (95% CI 
120, 210) with a comparable level of heterogeneity (I2 = 99.4%). When only high-quality studies 
(studies scoring at low risk of bias on both domains of the QUIPS tool) were considered, pooled 
prevalence reduced to 120 per 10,000 (95% CI 40, 190), with reduced, but still high, 
heterogeneity (I2 = 85.1%).
A forest plot for all 38 estimates of ACR-90 FM prevalence in the adult population stratified by 
study quality is shown in Figure 3.4.
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Figure 3.4 Forest plot for all FM prevalence estimates for ACR-90 studies in the adult population, 
stratified by study quality.
Pooled prevalence estimates calculated using random effects model.
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b. Chronic widespread pain
The random-effects pooled prevalence of CWP for all 34 included estimates (from 22 papers) was 
1,077 per 10,000 (95% CI 907, 1,249) this estimate was associated with a high level of 
heterogeneity (I2 = 97.0%). There was little difference in pooled prevalence if low-quality studies 
(studies scoring a high risk of bias on either domain one or four of the QUIPS tool) and studies 
estimating prevalence in particularly select populations (Jacobsson et al. 1996: Pima Indians; 
White et al. 2003: Amish population; Macfarlane et al. 2005: white European and South Asian) 
were excluded from the analysis – pooled prevalence dropped to 995 per 10,000 (95% CI 770, 
1,221), with comparable heterogeneity (I2 = 97.8%). When only high-quality studies (studies 
scoring at low risk of bias on both domains of the QUIPS tool) were considered, there was little 
change in pooled prevalence: 1,178 per 10,000 (95% CI 1,025, 1,331), with reduced, but still 
high, heterogeneity (I2 = 85.7%). A forest plot for estimates of ACR-90 CWP prevalence in the 
adult population stratified by study quality is shown in Figure 3.5.
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Figure 3.5 Forest plot for all ACR-90 CWP estimates from studies in the adult population stratified by 
study quality.
Pooled prevalence estimates calculated using random effects model.
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3.5 Discussion
Seventy-nine papers were included in the review including the results from 82 separate studies. 
Fifty-nine studies (58 papers) presented prevalence figures for FM, estimates ranged from three to 
1,050 per 10,000, with the majority between 100 and 400 per 10,000. Thirty-eight studies (36 
papers) presented prevalence figures for CWP: estimates ranged from zero to 2,400 per 10,000, 
with the majority between 1,000 and 1,300 per 10,000. 
Prevalence varied with the diagnostic criteria used to define cases. Generally, recorded 
prevalence (in medical or health insurance records) was lower than self-reported prevalence. In 
studies using ACR-90 criteria there was insufficient evidence to demonstrate any geographic 
variation. However, the papers included in the review suggest that there is appreciable socio-
cultural variation.
Prevalence was higher in women for all studies presenting figures stratified by gender. Prevalence 
was also higher in those over 40 years of age for all studies presenting age stratified figures. 
Papers presenting figures using ACR-90 criteria in mixed-gender adults were included in the 
meta-analysis. The meta-analysis therefore included 30 papers presenting 38 estimates for FM 
prevalence, and 22 papers presenting 34 estimates for CWP prevalence. All pooled prevalence 
estimates were associated with high levels of heterogeneity (I2 ranging from 85% to 99%). Pooled 
prevalence for FM was 180 per 10,000 for all included studies and 120 per 10,000 for only high-
quality studies. Pooled prevalence for CWP was 1,077 per 10,000 for all included studies and 
1,178 per 10,000 for high-quality studies only.
3.5.1 Prevalence
With some exceptions, the prevalence estimates were relatively consistent regardless of the range 
of methodological quality and variation in case definition criteria. For FM estimates for prevalence 
in mixed-gender adults, 21 (33%) estimates were below 100 per 10,000, eight (13%) were over 
400 per 10,000, leaving 54% (n=34) of estimates between 100 and 400 per 10,000. For CWP 
estimates, 13 (30%) were below 800 per 10,000, seven (16%) were above 1,400 per 10,000, 
leaving 55% (n=24) of estimates for prevalence in mixed-gender adults between 800 and 1,400 
per 10,000.
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Particularly low estimates for FM prevalence were found in eleven24 studies. Four25 of these 
studies provided estimates for either recorded (in medical or health insurance records) FM 
prevalence or estimates of practice prevalence provided by GPs. One (Minaur et al. 2004) 
estimated prevalence in a select population (Australian Aborigines). Six26 of these studies did not 
provide enough documentation to exclude participation bias, and five27 did not provide enough 
evidence to exclude outcome measurement bias.
Unusually low estimates for CWP prevalence were found in six28 studies in mixed-gender adults 
using ACR-90 criteria. One (Lindell et al. 2000) used a slightly different application of the case 
definition by using data from two different time points a year apart. Another (Jacobsson et al. 
1996) estimated prevalence in a particularly select population (Pima Indians) and three29 were of 
poor methodological quality. The low estimate in one study (Hardt et al. 2008) might be explained 
by data collection methods.
One possible explanation for outliers with low CWP prevalence estimates could be the method of 
data collection. Of 12 papers30 presenting CWP prevalence estimates for mixed-gender adults 
below 1,000 per 10,000 most collected data using an interview (or, in one case, a questionnaire 
filled in by the respondent with help available from an interviewer) and only three31 used a postal 
questionnaire. This is in contrast to studies reporting CWP prevalence estimates greater than 
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24 Zeng et al. 2010, Joshi and Chopra 2009, Davatchi et al. 2009a, Minaur et al. 2004, Alvarez-Nemegyei et 
al. 2011, Dans et al. 1997, Reyes-Llerena et al. 2009, Hughes et al. 2006, Marschall et al. 2011, Sauer et al. 
2011, and Bazelmans et al. 1999.
25 Hughes et al. 2006, Marschall et al. 2011, Sauer et al. 2011, and Bazelmans et al. 1999.
26 Zeng et al. 2010, Joshi and Chopra 2009, Davatchi et al. 2009a,, Alvarez-Nemegyei et al. 2011, Dans et al. 
1997, and Reyes-Llerena et al. 2009.
27 Zeng et al. 2010, Joshi and Chopra 2009, Davatchi et al. 2009a,, Alvarez-Nemegyei et al. 2011, and 
Reyes-Llerena et al. 2009.
28 Jacobsson et al. 1996, Klemp et al. 2002, Hardt et al. 2008, Lindell et al. 2000, Scudds et al. 2006 and 
Ablin et al. 2012.
29 Scudds et al. 2006, Klemp et al. 2002, Ablin et al. 2012.
30 Jacobsson et al. 1996, Klemp et al. 2002, Hardt et al. 2008, Lindell et al. 2000, Hagen et al. 2005, Scudds 
et al. 2006, Ablin et al. 2012, Häuser et al. 2013, Choudhury et al. 2013 (long questionnaire), White et al. 
1999, White et al. 2003 (Non-Amish), and Kurita et al. 2012.
31 Lindell et al. 2000, Hagen et al. 2005, and Kurita et al. 2012.
1,000 per 10,000 where all but four32 of 19 studies33 (of mixed-gender adults) used a self-
completed questionnaire. The American study by Hardt et al. (2008) ascertained CWP status by 
personal interview, but the other American general population study included in the review (Wolfe 
et al. 1995) used a postal questionnaire and estimated the prevalence of CWP in Wichita at nearly 
three times that found by Hardt (1,060/10,000 population). 
This suggests that pain reporting is higher when ascertained through self-reported questionnaire 
than by personal interview. However, one study (Choudhury et al. 2013) used both a short postal 
survey and longer face-to-face interview using a structured questionnaire to collect data. Findings 
varied between the three ethnic groups studied; in white British/Irish CWP prevalence was higher 
in the postal survey group, in British Bangladeshis prevalence was the same in both postal survey 
and interview groups, and in Bangladeshis prevalence was lower in the postal survey group. This 
suggests that while for many pain reporting might be high when ascertained through self-
reporting, this is not the same in all cultural groups.
Particularly high estimates for FM prevalence were found in three studies34 using ACR-90 criteria 
to estimate prevalence in mixed-gender adults. One of these estimates was from a select 
population (White et al. 2003 Amish). One study investigating FM in Turkey (Turhanoglu et al. 
2008) did not provide sufficient evidence to exclude outcome measurement bias and another 
(Guermazi et al. 2008) investigating FM in Tunisia did not provide enough evidence to exclude 
risk of selection bias.
Two studies provided CWP estimates higher than 2,000 per 10,000 (Assumpção et al. 2009 and 
Branco et al. 2010). The study of the low-socioeconomic status population of São Paulo, Brazil 
(Assumpção et al. 2009) offered the highest prevalence estimate in the review (2,400 per 10,000). 
This high estimate could be the result of study recruitment methods that were likely to have 
resulted in bias, or as a result of low socioeconomic status. The association of CWP with low 
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32 Buskila et al. 2000, Branco et al. 2000, Kim et al. 2006, and Assumpção et al. 2009.
33 White et al. 2003 (Amish), Choudhury et al. 2013 (short postal survey), Papageorgiou et al. 2002, Buskila 
et al. 2000, Wolfe et al. 1995, Croft et al. 1993, Bergman et al. 2001, Macfarlane et al. 2005, Raspe and 
Baumgartner 1993, Carnes et al. 2007, Branco et al. 2010, Storozhenko et al. 2004, Kim et al. 2006, 
Aggarwal et al. 2006, Assumpção et al. 2009, Hunt et al. 1999, Kurita et al. 2012, Andersson 1994, and 
Svebak et al. 2006. 
34 Turhanoglu et al. 2008, White et al. 2003 (Amish), and Guermazi et al. 2008.
socioeconomic status is consistent with findings from a study of the 1958 British Birth Cohort 
(Macfarlane et al. 2009a).
The Spanish arm of the study by Branco et al. (2010) returned a high estimate for CWP 
prevalence of 2,300 per 10,000. Four other countries investigated by this study provide figures 
that sit within the majority of estimates seen in the review. It is noteworthy that in the same study 
FM prevalence for Spain is at the higher end of the estimates for all five countries, but is still lower 
than those of Germany and Italy. It would seem unusual that the prevalence of CWP in Spain 
should be so high, while that for FM sits in a more typical range. The FM figure provided by the 
Branco et al. study was 400 per 10,000, while that in another Spanish study (Carmona et al. 2001) 
is lower at 240 per 10,000. The difference in methods is that Carmona et al. examined all patients 
while Branco et al. calculated prevalence using a positive predictive value established by 
applying the questionnaire to patients in rheumatological outpatient clinics. Since the 2001 study 
used more robust methods, we must assume the lower figure to offer a more reliable estimate.
It could be argued that the two most extreme outliers for CWP prevalence included in the review 
represent select populations rather than the general population. The highest estimate for 
prevalence is for a low socio-economic population (Assumpção et al. 2009), while the lowest 
estimate is in a North American Indian tribal population (Jacobsson et al. 1996). It seems 
reasonable to suggest that the true estimate for a less select population would sit somewhere 
between these two extremes.
Care should be taken in interpreting the results of the meta-analysis due to high levels of 
heterogeneity demonstrated by the high I2 statistics for the overall figure and the subgroup 
analysis. With this caveat in mind, if we compare the overall pooled CWP prevalence figure 
(1,077/10,000) with the pooled figure for high quality studies only (1,178/10,000) there is very little 
difference, and we see a similar pattern when we compare overall and high-quality FM pooled 
prevalence estimates. The high level of heterogeneity in pooled prevalence estimates was 
probably due to methodological differences. Taking a more standard approach to sample 
selection and outcome measurement might lead to greater consistency in prevalence estimates. 
However, with the exception of some notable outliers, the evidence provided in this review 
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suggests that the general population prevalence using ACR-90 criteria for FM is between 100 and 
200 per 10,000 and for CWP is between 1,000 and 1,100 per 10,000.
a. Variation by diagnostic criteria
As might be expected, prevalence varied with case definition. GPs estimates of the prevalence of 
FM in their practice (Bazelmans et al. 1999) were considerably lower than self-reported 
prevalence estimates for FM. An estimate for FM prevalence based on diagnosis according to 
generally accepted definitions among rheumatologists (Reyes-Llerena et al. 2000) was also lower 
than estimates based on standard ACR-90 or ACR-2010 criteria. This is consistent with research 
suggesting that there is a lack of awareness of the FM diagnosis among doctors (section 2.2.3.b).
Results from medical and health insurance record review were also towards the lower end of 
estimates based on standard ACR definitions. In a study in Minnesota (Vincent et al. 2013) FM 
prevalence estimated using ACR-2010 criteria was compared to documented FM diagnosis in 
medical records. ACR-2010 FM diagnosis was nearly five times that of documented FM diagnosis. 
These findings are of particular importance to this thesis, since they appear to support the 
argument that FM is both under-recognised and under-coded.
Two studies reported FM prevalence using the new ACR-2010 criteria, one based in Germany 
(Wolfe et al. 2013) and one in the USA (Vincent et al. 2013). The German study (Wolfe et al. 2013) 
estimated prevalence at 210 per 10,000 which was similar to prevalence estimates from Germany 
based on the earlier ACR-90 criteria. However, the American study (Vincent et al. 2013) estimated 
prevalence with the ACR-2010 criteria at 530 per 10,000 which was higher than both the pooled 
ACR-90 prevalence figure from the meta-analysis and the estimate of 200 per 10,000 from another 
American study that used the ACR-90 criteria (Wolfe et al. 1995).
Another German study (Häuser et al. 2013) used the widespread pain index from the ACR-2010 
criteria to estimate CWP prevalence at 580 per 10,000, this was lower than the pooled prevalence 
estimate from ACR-90 studies.
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b. Geographical variation
On examining prevalence figures stratified by geographical locations it is difficult to establish any 
sort of pattern in the geographical distribution of prevalence estimates. European estimates for 
CWP and FM show general agreement and are consistent with findings from studies in North 
America. Smaller numbers of studies from other locations and diverse methodological 
approaches make comparisons between other regions less straightforward. However, the 
estimates do show some consistency across locations.
Six35 of the included studies made comparisons between different ethnic or cultural groups 
resident in the same regions: All six studies revealed appreciable differences in FM/CWP 
prevalence between the different ethnic or cultural groups. Whether these differences in the 
experience of CWP are attributable to lifestyle or genetics is unclear.
The difference in CWP prevalence between Amish and non-Amish (White et al. 2003) might be 
accounted for by the data collection method used for each population. Non-Amish were assessed 
using a telephone interview (prevalence 890/10,000) while the Amish were assessed using a self-
completed questionnaire (prevalence 1,450/10,000). We have already seen that the majority of 
low estimates of CWP prevalence were based on studies using an interview to collect data.
The study of Maori and European New Zealanders by (Klemp et al. 2002) also had 
methodological problems. Participants were recruited from two sources. Those from Maori tribes 
had to be recruited non-randomly to satisfy cultural beliefs, while the response rate among those 
recruited from European New Zealanders was low (39%). It would seem likely therefore that the 
results of this study were influenced by participation bias. However, the study also presents 
prevalence figures for FM that, unlike the CWP figures, are comparable with FM prevalence 
figures from other studies included in the review, indicating that there may have been a problem 
with CWP case identification in this study.
Another study of a tribal community (Jacobsson et al. 1996) also revealed a difference in 
prevalence compared to other general population estimates. The study identified no cases of 
CWP in 105 Pima Indians of the Gila River Community, Arizona. Other estimates for CWP in the 
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35 Klemp et al. 2002, White et al. 2003, Macfarlane et al. 2005, Gansky and Plesh 2007, Kurita et al. 2012, 
Choudhury et al. 2013.
USA range from 360 to 1,060 per 10,000. The paper did not provide enough evidence regarding 
sample selection to judge whether the sample was representative of the target population. It also 
failed to document any steps taken to validate the questionnaire and interview process. 
Consequently, it is difficult to assess whether the results are an accurate estimate or the result of 
methodological problems.
However, with the caveat of likely methodological problems in both studies, when we compare the 
low prevalence of CWP observed in Maoris (Maori 170/10,000, European 390/10,000) (Klemp et 
al. 2002) with the absence of observed CWP in Pima Indians (Jacobsson et al. 1996) we must 
consider there may be reduced CWP in tribal communities.
A number of other studies36 compared rural and urban regions of the same country, revealing 
noticeable differences in prevalence. Generally, developing countries had increased prevalence 
in rural areas compared to urban areas, while developed countries had higher prevalence in 
urban areas. This suggests that differences in prevalence might be attributable to lifestyle factors.
The study of the low-socioeconomic status population of São Paulo, Brazil offered the highest 
prevalence estimate in the review (2,400 per 10,000). Study recruitment methods were likely to 
have resulted in bias: subjects were recruited non-randomly by telephone, 27% of the target 
population did not have a phone, and 30% of those called did not answer. However, a high rate of 
CWP in association with low socioeconomic status is consistent with a study using the 1958 British 
Birth Cohort (Macfarlane et al. 2009a), which demonstrated that low social class is related to an 
almost threefold increase in CWP risk. Further, another study (Farooqi and Gibson 1998) included 
in the review demonstrated a lower prevalence of FM in affluent urban communities compared to 
urban and rural communities. However, a Bangladeshi study (Haq et al. 2005) found similar levels 
of FM in affluent urban areas and urban slums.
Findings from the review demonstrate cultural and socioeconomic differences in FM/CWP 
prevalence. Methodological variation between studies make it difficult to draw many conclusions 
regarding geographical variation, however, there does appear to be some consistency between 
studies from different locations suggesting limited geographical variation. This suggests that 
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36 Zeng et al. 2010, Haq et al. 2005, Farooqi and Gibson 1998, White et al. 1999 (urban) with White et al. 
2003 (non-Amish rural), and Davatchi et al. 2008 (urban) with Davatchi et al. 2009a (rural).
findings from this thesis, which uses data from individuals in North Staffordshire, UK, may be 
transferable to other populations, particularly other European and North American populations.
c. Gender variation
In all studies providing prevalence by gender, both FM and CWP were observed to be higher in 
women. On the whole there was a more marked difference between the genders noted in the FM 
studies compared to the CWP studies.
In one paper (Vincent et al. 2013) comparing self-reported FM prevalence with the prevalence of 
a diagnosis of FM in medical records, there was a more marked difference between recorded 
male and female FM prevalence than between self-reported male and female prevalence. This 
might represent gender-related differences in help-seeking behaviour. Women have been shown 
to be more likely than men to seek help for symptoms (Cornally and McCarthy 2011, Sayer and 
Britt 1996). Alternatively, clinicians might be more comfortable with diagnosing FM in women than 
men.
d. Age variation
Both FM studies and CWP studies demonstrate low prevalence in younger age groups and 
increasing prevalence towards middle age. It would be reasonable to suggest, therefore, that this 
is a reliable reflection of patterns of FM/CWP up to around 40 years of age. However, there was 
some inconsistency between studies in prevalence trends after middle age, with some studies 
showing prevalence continuing to increase with increasing age, some showing a decline in older 
age, and some showing two peaks, one in middle age and another in older people. It is unclear 
whether these differences in age-related prevalence trends are due to methodological differences 
between studies or true differences in age-related prevalence for different populations. However, 
the higher-quality FM studies37 appear to show a decline in prevalence with increasing age, while 
the higher-quality CWP studies38 show an overall upward trend in prevalence with age, with a 
peak in middle age.
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37 Carmona et al. 2001, Turhanoglu et al. 2008, White et al. 1999, and Wolfe et al 1995.
38 Bergman et al. 2001, Buskila et al 2000, and Croft et al. 1993.
3.5.2 Future research
Agreeing on a standard case definition for CWP/FM would allow more reliable research into 
geographical, age, and gender variability. Future research employing standard case definition 
criteria and using comparable methodology would allow more reliable evaluation of any variation 
observed in prevalence data between studies. Allied to this is the need for a standardised data 
collection tool. The calculation of a pooled prevalence figure would be more appropriate if the 
studies included in the review had implemented equivalent classification criteria and data 
collection methods. Employing standard case definition criteria and collecting data using a 
benchmark tool would mean that any variation could be more plausibly attributed to geographical, 
age, or gender variation, rather than its being as a result of the diagnostic criteria or methodology 
used. Further research into geographical, age, and gender variation has the potential to provide 
insight into aetiological factors and the underlying pathophysiology of these conditions. This 
would have implications for approaches to management.
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3.5.3 Strengths and limitations
a. Search and data extraction
The review searched four major bibliographic databases, using a search strategy that had been 
tested in a pilot study (Davidson 2010), and was able to find reliable translations for all relevant 
foreign language articles. In addition we searched the citation lists of all papers selected for full 
text review and hand searched the Journal of Rheumatology for relevant papers published after 
1990. Moreover, at each step of the review process a reliability exercise was undertaken. A 
second reviewer (KJ) checked the paper selection (title review, abstract appraisal, full-text 
review), data extraction, and quality appraisal stages of the review. Any disagreements were 
discussed and a third reviewer (JS) was available to arbitrate any disagreements that remained 
unresolved following discussion. The second reviewer was blinded to the primary reviewer’s 
decisions. Our search should therefore have identified most relevant papers. However, we did not 
undertake a search of grey literature, so there may be unpublished research that should have 
been included. Nonetheless, with such a large review of a topic where publication bias is unlikely 
it seems reasonable to conclude that the included studies present a reasonable reflection of the 
true general population prevalence of CWP and FM.
b. Inclusion of estimates from medical and health insurance records
It could be argued that in a systematic review of general population prevalence, figures for 
recorded prevalence in medical and health insurance records should not have been included. 
Recorded prevalence reflects a mixture of consultation behaviour, diagnostic beliefs, and 
recording practices. However, since FM and CWP are controversial diagnoses recorded 
prevalence could be argued to provide a measure of the minimum amount of FM/CWP in the 
community. Further, recorded prevalence figures offer a useful comparison to community 
prevalence, with the observed disparity offering a convincing justification for the central aim of this 
thesis. This project is founded on the premise that CWP/FM is unrecognised and unrecorded in 
primary care, necessitating an alternative means of identifying CWP in morbidity coded data. The 
observed disparity between coding and community burden supports the theory that CWP is 
under-recorded.
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c. Methodological quality assessment
A systematic review of tools to assess the quality of observational studies examining incidence or 
prevalence (Shamilyan et al. 2010) concluded that no consensus exists as to which individual 
criteria should be assessed to establish methodological validity or how to rank overall quality (or 
indeed whether an overall quality ‘rank’ is appropriate). It called for a future collaborative effort to 
develop checklists for quality assessment of observational research. This call for a checklist 
specifically would seem to be in conflict with the Cochrane Collaborationʼs advice to assess 
methodological quality on a subjective basis using domain-based evaluation (Higgins and Green, 
2008, section 8.3.1). While the Cochrane Collaboration’s recommendations are aimed at 
systematic reviews of interventions rather than observational studies, their justification for a 
domain-based assessment, based on the argument that the ‘most realistic assessment of the 
validity of a study may involve subjectivity’ (Higgins and Green, 2008, section 8.3.1), still holds 
true when assessing the risk of bias in observational studies. 
Our experience developing and using a tool based on the Newcastle-Ottawa scale (Wells 2008) 
for quality appraisal in the pilot study informed the choice of tool used in this study. Evaluation of 
the strengths and weaknesses of the tool used in the pilot study suggested that both a checklist 
and a tool allowing a subjective assessment of risk of bias in relevant study design domains would 
be helpful. With no consensus tool available we selected two tools. One was a checklist-based 
tool (Walker et al. 2000, cited in Louw et al. 2007) and the other asked for a subjective 
assessment of risk of bias in separate domains (Hayden et al. 2013). Subsequent to the 
assessment of risk of bias undertaken in this review a 2012 paper (Hoy et al.) published a 
modified and validated version of the Walker et al. tool for assessing risk of bias in prevalence 
studies. The modified tool uses both a 10-item checklist (assessing four domains of bias) and a 
summary rating of either low or high risk of bias, and has been demonstrated to have high 
interrater agreement (kappa:0.82, 95% CI: 0.76, 0.86). This new tool has therefore addressed the 
methodological gap that our study sought to address by using two tools. Both of the tools we used 
were useful in assessing possible reasons for outlying prevalence estimates. However, 
methodological appraisal is still a subjective exercise, and it was hoped that involving additional 
reviewers would partially mitigate this.
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d. Meta-analysis
Given the varied methodological approaches of the studies included in the review it could be 
argued that it was not appropriate to calculate pooled prevalence estimates. High heterogeneity 
between the studies illustrated by the high values of the I2 statistic certainly supports this 
argument. However, only studies using the ACR-90 case definition criteria in mixed-gender adults 
were entered into the meta-analysis. The ACR-90 criteria were selected as an established and 
widely used standard for CWP/FM diagnosis. Including studies using the same diagnostic criteria 
in similar populations (male and female adults) ensured some comparability. In addition, 
prevalence figures were generally consistent (albeit with a few outliers), a random effects model 
was used to account for heterogeneity, and the impact of study quality on pooled prevalence was 
assessed by systematically excluding lower-quality studies and studies examining particularly 
select populations from the meta-analysis. 
e. Raw data
No effort was made to contact study authors for raw data. This meant that in some instances, 95% 
confidence intervals for prevalence estimates had to be calculated from information given in the 
paper. It also restricted the ability of the research to fulfil one of its objectives, which was to 
evaluate the variability in prevalence according to age. Of the papers that presented prevalence 
figures according to age, the age groups used varied considerably, preventing more robust 
comparisons between studies from being drawn. However, presenting the age-banded 
prevalence data graphically did allow some useful between-study comparisons to be drawn.
f. Soft tissue rheumatism and myofascial pain syndrome
In the process of conducting the search, three studies returned quoted prevalence figures for soft 
tissue rheumatism (Davatchi et al. 2009b, Andrianakos et al. 2003) or myofascial pain syndrome 
(Chaiamnuay et al. 1998). Soft tissue rheumatism is an ill-defined term, applied to painful or 
inflammatory conditions that are non-articular. It includes both local inflammatory conditions such 
as bursitis and also more generalized pain syndromes such as CWP and FM (Natvig and Picavet 
2002). While the term does not necessarily imply a chronic condition, it certainly encompasses 
both CWP and FM. 
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Myofascial pain syndrome was included as a term in the search strategy, but papers presenting 
prevalence figures for myofascial pain syndrome were excluded from the review. Myofascial pain 
syndrome and FM are distinct conditions, but they share some common features (Wolfe et al. 
1992, Granges and Littlejohn 1993), which was the rationale for including ‘myofascial pain 
syndrome’ in the search strategy, but excluding it from the review. Exploring prevalence figures 
(and variation by geographic location, age, and gender) for myofascial pain would have provided 
an interesting exploration of distinctions between it and FM/CWP. However, excluding papers 
calculating myofascial pain syndrome (rather than CWP/FM) prevalence allowed for comparison 
of individuals identified using comparable criteria for CWP/FM. 
g. Incidence
It could be argued that papers quoting incidence figures should also have been included in the 
study. While incidence is clearly distinct from prevalence, a measure of the number of new cases 
diagnosed may have allowed interesting comparison with prevalence figures. This could 
potentially allow conclusions to be drawn regarding the degree to which new cases account for 
the ongoing burden of disease, and some inferences could therefore be drawn with respect to 
remission rates.
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3.6 Conclusions
CWP is a common problem, women are affected more than men, and those over 40 have a higher 
prevalence. The 79 papers included in this review returned consistent estimates for the 
prevalence of CWP and FM. The majority of estimates for CWP were approximately 1,000 to 1,300 
per 10,000 (about 10–13% of the population), and for FM ranged between 100 and 400 per 
10,000. Pooled CWP prevalence was 1,077 per 10,000 and pooled FM prevalence was 180 per 
10,000. 
Data recorded between 1998 and 2003 from more than 350 general practices in the UK 
(representative of 4.6% of the UK population) estimated the prevalence of FM diagnosis recorded 
in general practice in the UK at 18/10,000 (Hughes et al. 2006). This is substantially lower than the 
community prevalence figures recorded by studies included in the review. This suggests that FM, 
and by inference therefore CWP, are vastly under-diagnosed in general practice in the UK, 
indicating a need for more work to help identify and manage these patients in primary care.
The results from this review were used in a number of related strands of follow-up work. The next 
chapter compares community prevalence figures for FM revealed by this review to annual primary 
care consultation prevalence for FM to further test the hypothesis that FM is under-reported in 
primary care, therefore potentially offering further weight to the argument for developing an 
alternative means of identifying CWP in primary care. Chapters Five and Six use results from the 
review to assess how well RRC criteria perform as a means of identifying CWP consulters in 
primary care. Prevalence figures for consultation-based CWP (RRC) were compared with 
population figures derived from the review, and the age and gender profiles of RRCs were also 
compared with the age and gender distribution of CWP in the general population determined by 
the review, to determine whether RRCs fit the profile for self-reported CWP patients.
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Chapter 4
Coding prevalence of non-specific generalised 
musculoskeletal pain in primary care
4.1 Introduction
In the previous chapter, we established estimates for general population prevalence of FM and 
CWP in a systematic review and meta-analysis. We also synthesised estimates from previous 
studies of recorded FM prevalence in medical and insurance data. We noted that recorded FM 
prevalence estimates were on the whole lower than community prevalence figures, suggesting 
that FM is under-used as a diagnostic label. 
With a possible under-recording of FM in primary care and no specific morbidity code for CWP, it 
is not clear how consultations with CWP patients are recorded in general practice. Rohrbeck’s 
original recurrent regional consultation (RRC) criteria were developed (to identify CWP consulters 
in primary care) based on the theory that consultations with patients fitting established CWP 
criteria were being coded as multiple single-site musculoskeletal complaints (2007). To test the 
argument that consultations with CWP patients are not being recognised as generalised 
conditions, this chapter aims to calculate the recorded prevalence of conditions related to CWP in 
primary care and compare it with annual CWP community prevalence. Community prevalence is, 
of course, not equal to consulting prevalence, since not all CWP patients will consult their GP for 
their symptoms. However, a postal survey (Macfarlane et al. 1999) of 252 individuals with ACR-90 
CWP, estimated that 72% reported consulting a general practitioner regarding their pain at any 
time, hence we might expect prevalence of annual recorded CWP to be approximately 72% of 
community prevalence (i.e. 8% based on reported community prevalence of 11%).
The aim of this chapter is to establish how much CWP is ‘recognised’ in primary care by 
establishing the coding prevalence of non-specific (conditions with no clear established 
underlying alternative diagnosis) generalised pain conditions related to CWP. By estimating any 
shortfall between ‘recognised’ CWP (coding of generalised pain conditions related to CWP) and 
expected CWP consultation prevalence (72% of community prevalence, from Macfarlane et al. 
1999), we aimed to evaluate how much ‘unrecognised’ CWP the RRC criteria would need to 
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account for. However, there is a problem with such a comparison: the Rohrbeck RRC criteria use 
five years of consultation data to identify a case and most estimates of community prevalence 
identified in the systematic review were point estimates. We therefore also aimed to compare both 
annual and five-year coding prevalence of non-specific generalised pain complaints to establish 
how much variation there was between short- and long-term estimates for CWP coding. 
The existence of FM and CWP as disease entities is controversial (see section 2.2.3). The 
frequency of coding of these conditions in primary care is therefore a reflection of three different 
components: i) the population prevalence of the condition; ii) patients’ consultation behaviour; and 
iii) clinicians’ diagnostic beliefs and coding practices. By investigating the coding of five different 
groups of non-specific pain codes (1. FM; 2. FM and myofascial pain; 3. Generalised 
osteoarthritis; 4. All non-specific generalised pain codes excluding generalised osteoarthritis; and 
5. All non-specific generalised pain codes) we were able to explore current coding practices for 
these conditions.
We used Read-coded GP consultation data from 12 general practices in North Staffordshire 
contributing to the Consultations in Primary Care Archive (CiPCA). By investigating practice 
variation we were able to investigate any disparities in coding between practices. We were also 
able to investigate how comparable coding in the CiPCA practices was to other populations, by 
comparing FM coding prevalence estimates derived in this chapter with health care recorded FM 
prevalence from other sources identified in the systematic review (Chapter Three).
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4.2 Aims and objectives
The primary aim of this chapter is to establish the coded consultation prevalence of generalised 
musculoskeletal pain complaints related to CWP in primary care.
Specifically, the objectives of the chapter are:
1. To establish the current coding prevalence of FM in primary care and to compare it with: i) 
community FM prevalence figures (established in the systematic review presented in Chapter 
Three); and with ii) other figures for recorded (in medical or health insurance records) FM 
prevalence reported in the published literature (identified in the systematic review presented in 
Chapter Three).
2. To compare the coding prevalence of generalised musculoskeletal pain complaints related to 
CWP (generalised pain conditions with no clear established underlying alternative diagnosis) 
with general population based estimates for CWP prevalence from a systematic review 
(Chapter Three). This allows estimation of the prevalence of ‘recognised’ CWP (coding of non-
specific generalised pain) in primary care.
3. To analyse differences in non-specific generalised musculoskeletal pain coding prevalence 
across five different groups of generalised musculoskeletal pain codes, to explore the 
prevalence of coding of different conditions related to CWP: 
• Group 1: Fibromyalgia codes.
• Group 2: Fibromyalgia, fibrositis, and myofascial pain syndrome codes.
• Group 3: Generalised osteoarthritis codes.
• Group 4: All non-specific generalised musculoskeletal pain codes excluding any codes for 
osteoarthritis.
• Group 5: All non-specific generalised musculoskeletal pain codes.
4. To analyse trends in annual coding prevalence over time for generalised musculoskeletal 
complaints related to CWP.
5. To assess variation in generalised musculoskeletal pain coding prevalence by age, gender, 
and practice.
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6. To calculate five-year coding period prevalence figures for generalised pain conditions related 
to CWP, to offer data to compare with figures generated using the original Rohrbeck recurrent 
regional consulter criteria, which require a five-year period for case identification. 
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4.3 Methods
4.3.1 Data
Annual coding prevalences were calculated using routinely recorded morbidity data stored in the 
Consultations in Primary Care Archive (CiPCA). The CiPCA dataset contains anonymised primary 
care consultation data for up to 13 (depending on year) general practices in the North 
Staffordshire area of the UK. Although North Staffordshire is generally quite deprived in 
comparison to the average for England, these practices cover both more affluent and more 
deprived areas.
Information stored includes a unique patient identifier, the event date, and the Read code and 
Read term for the complaint or complaints addressed during the consultation. The practices 
involved are part of the Keele GP Research Partnership; consequently routine clinical data 
recorded by the practices is regularly audited by the informatics team from the Research Institute 
of Primary Care and Health Sciences Research at Keele University (Porcheret et al. 2004). The 
data quality has been demonstrated to be similar to that of larger national primary care 
consultation databases giving comparable musculoskeletal consultation prevalences to national 
UK and international databases (Jordan et al. 2007, 2013). At least one morbidity code is required 
to be entered for each contact to the practice.
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4.3.2 Identification of Read codes
Five groups of Read codes representing non-specific (i.e. with no clear established underlying 
alternative diagnosis) generalised pain conditions related to CWP were identified:
• Group 1: Fibromyalgia codes
• Group 2: Fibromyalgia, fibrositis, and myofascial pain syndrome codes
• Group 3: Generalised osteoarthritis codes
• Group 4: All non-specific generalised musculoskeletal pain codes excluding any codes for 
osteoarthritis 
• Group 5: All non-specific generalised musculoskeletal pain codes.
The Read codes to include in the study were identified through a systematic search of all Read 
codes in Chapters 1, N, R, and S. Chapter 1 contains codes for symptoms, N codes for 
musculoskeletal problems, R ill-defined conditions or working diagnoses, and S covers injury or 
poisoning codes. 
In a previous study (Jordan et al. 2010), two research GPs independently identified 5,182 unique 
Read codes (representing 5,908 clinical terms; some Read codes are associated with multiple 
synonymous clinical terms) from Chapters 1, N, R, and S as being musculoskeletal in nature. A 
team of four GPs then allocated each musculoskeletal code to an individual body region (e.g. 
hand, knee, back) where possible. If the codes did not specify an individual body region they 
were classified as ‘site unspecified.’ Using this classification, initially we identified all generalised 
musculoskeletal codes from the list of ‘site unspecified’ codes. Generalised pain codes were 
defined as those for conditions that are generalised by definition (e.g. FM) or had clinical terms 
that included expressions such as: ‘multiple sites’ or ‘generalised.’ In addition, we identified site 
unspecified pain codes that could represent either regional or generalised pain; that is, codes 
with musculoskeletal pain clinical terms that were broad and inclusive, but did not necessarily 
imply a single site (e.g. ‘other tendon disorders’, ‘arthralgia – site unspecified’, ‘rheumatic pain’) 
and therefore had the potential be used to represent generalised pain.
From this list of codes, the aim then was to identify codes that could represent idiopathic diffuse 
pain syndromes. An advisory panel of six GPs and a rheumatologist were approached for their 
advice regarding coding practices for consultations with patients who present to their GPs with 
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symptoms of CWP. Two of the panel had specialist musculoskeletal research interests and 
worked both clinically and within the Arthritis Research UK Primary Care Centre at Keele 
University. The remaining five clinicians were members of the North Staffordshire GP Research 
Network (Porcheret et al. 2004) with no special musculoskeletal interest. In a series of mainly one-
to-one sessions (with KM), the GPs discussed how they would routinely code consultations with 
patients who present with medically unexplained musculoskeletal pains. While there was a 
diversity of coding practices in use among the panel members, there was a clear consensus 
regarding the codes that would be unlikely to identify CWP patients. All agreed that the following 
musculoskeletal complaints were unlikely to represent CWP patients: clearly identified underlying 
pathology (determined via clear investigative evidence, secondary care diagnosis or strong 
clinical indication); injury or trauma; vertebral conditions with myelopathy; structural problems 
(e.g. fractures); and strains or sprains. Codes were therefore excluded from the list of all 
generalised Read codes if they represented any of the conditions agreed by the advisory panel 
as unlikely to represent CWP.
The remaining non-specific generalised codes were then categorised into the five code groups 
outlined above. Full code lists for each group are presented in the appendix (A4.1). Group one 
comprised the only two specific Read codes for fibromyalgia. Group two included eight codes 
covering FM (including the two codes in group one), fibrositis, muscular rheumatism, and 
myofascial pain syndrome. Myofascial pain syndrome and FM are distinct conditions, but they 
share some common features (Wolfe et al. 1992, Granges and Littlejohn 1993). Group three 
included 11 codes for generalised osteoarthritis. Osteoarthritis was included since it was 
considered by the advisory panel as a diagnostic label that might be used for older patients 
presenting with generalised musculoskeletal pain. The remaining two groups comprised all non-
specific generalised pain codes either including (n=110), or excluding (n=99), generalised 
osteoarthritis codes. 
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4.3.3 Analysis
To assess the generalisability of the study population to the general population, the age and 
gender distribution of patients registered with the CiPCA practices were compared with the UK 
general population. Patients registered with the CiPCA practices in each year (mid-year figures) 
from 2005 to 2009 and patients registered with the practices for the full five-year period (2005–
2009: registered both mid-year 2005 and mid-year 2009) were compared with the 2009 UK 
general population (mid-year figures from the Office for National Statistics 2011).
a. Prevalence
The annual and five-year consultation prevalence for each code group was calculated for the 12 
practices in the CiPCA dataset for which there were complete data for the years 2005–2009. 
Prevalence figures were recorded per 10,000 population. Prevalence was calculated only for 
consultations conducted in primary care; coded hospital consultations were not included. Repeat 
codings for the same patient were excluded in order to identify the number of patients coded with 
specific conditions rather than the number of consultations for those conditions. For annual 
prevalence figures the denominator population was the mid-year registered population for all 12 
practices. Five-year prevalence figures for all patients consulting (including those not registered 
for the full five-year period) were calculated using 2009 mid-year registered population as the 
denominator. Finally, five-year figures were also calculated for the fully registered (2005–2009) 
population only, using all patients registered for the duration of the five-year study period as the 
denominator (recorded as registered mid-year 2005 and mid-year 2009).
Confidence intervals for prevalence figures were calculated using Wilson’s method (Newcombe 
1998). A spreadsheet was developed for this purpose, incorporating formulae for calculating 
these intervals at the 95% confidence level. 
Both crude and standardized figures were calculated. Prevalence figures were directly 
standardized to the UK general population age-gender structure (mid-year 2009 figures) provided 
by the Office for National Statistics (2011). A spreadsheet was developed incorporating formulae 
for calculating standardised prevalence estimates with 95% confidence intervals (using direct 
standardization as documented in Altman et al. 2000, p.70–71).
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Prevalence figures for each code grouping were compared with community and recorded 
(medical and insurance records) prevalence figures derived from a systematic review of the 
prevalence of CWP/FM in the general population (see Chapter Three).
b. Annual variation
Trends over time for the recording of each diagnostic code group were examined descriptively by 
determining annual prevalence figures for the years 2005 to 2009. A ratio of 2009 to 2005 figures 
was also calculated to quantify any changes in prevalence over time. 
c. Practice variation
Crude and standardised (standardised directly to the 2009 UK general population) annual 
prevalence figures (and 95% confidence intervals) for 2009 were calculated for each of the 12 
participating practices using the 2009 mid-year registered population as the denominator. Inter-
practice variation was examined descriptively by comparing crude and standardised prevalence 
estimates for each code group across practices
d. Age and gender variation
Annual (2009) and five-year (2005–2009, fully registered only) prevalence was stratified for each 
Read coded grouping by age and gender. The age stratification was in the following age bands: 
14 and under; 15–24; 25–44; 45–64; 65–74; 75 years and over – as used in other studies in the 
Arthritis Research UK Primary Care Centre at Keele University. Confidence intervals were 
calculated at the 95% level, as before.
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4.4 Results
Table 4.1 shows the age and gender distribution of the study population between 2005 and 2009, 
and the UK population in 2009 (Office for National Statistics 2011). Between 2005 and 2009 there 
was a slight increase in the number of patients registered with the 12 practices contributing to 
CiPCA, but the age and gender distribution of the registered population remained stable for the 
five-year period (2005–2009). Patients fully registered with the CiPCA practices for the whole five-
year duration of the study period (2005–2009) were comparable on gender to the total number of 
patients registered in each individual year (2005 to 2009). However, the population fully registered 
for the full five-year period comprised a higher percentage of those over 45 years and a lower 
percentage of under 14s than those registered in each individual year.
Both the total number of patients registered with the CiPCA practices in the individual years from 
2005 to 2009, and those fully registered for the five-year period (2005–2009), were comparable on 
gender distribution with the UK 2009 population. However, the CiPCA population had a higher 
percentage of older people than the UK general population, with a higher percentage aged 45 
and over, and this difference was more marked in the fully registered population.
Table 4.1 Comparative demographic data for the CiPCA registered population 2005–2009 and the UK 
general population for 2009 (source Office for National Statistics, National Records of Scotland, 
Northern Ireland Statistics and Research Agency).
CiPCA population – frequency (%) UK General 
Population 
mid-year 
figures 
2009* 
2005 2006 2007 2008 2009 Fully 
registered 
2005–2009
Age 
group
<14 16,148 (16.1%) 16,021 (15.9%) 16,709 (16.0%) 16,896 (16.1%) 16,883 (16.1%) 8,485 (10.6%) 17.5%
15–24 11,933 (11.9%) 12,110 (12.0%) 12,676 (12.2%) 12,752 (12.1%) 12,764 (12.2%) 9,664 (12.1%) 13.3%
25–44 27,246 (27.2%) 27,124 (26.9%) 27,996 (26.8%) 27,923 (26.6%) 27,720 (26.4%) 19,280 (24.2%) 27.5%
45–64 26,458 (26.4%) 26,930 (26.7%) 27,759 (26.6%) 27,943 (26.6%) 27,941 (26.6%) 24,294 (30.4%) 25.4%
65–74 9,834 (9.8%) 9,810 (9.7%) 10,069 (9.7%) 10,373 (9.9%) 10,471 (10.0%) 9,717 (12.2%) 8.5%
>75 8,593 (8.6%) 8,763 (8.7%) 9,099 (8.7%) 9,078 (8.6%) 9,132 (8.7%) 8,356 (10.5%) 7.8%
Gender
Female 51,158 (51.0%) 51,461 (51.1%) 53,147 (51.0%) 53,414 (50.9%) 53,346 (50.8%) 40,668 (51.0%) 50.8%
Male 49,054 (49.0%) 49,297 (48.9%) 51,161 (49.0%) 51,551 (49.1%) 51,565 (49.2%) 39,128 (49.0%) 49.2%
Total 100,212 100,758 104,308 104,965 104,911 79,796 61,792,000
*Source: Office for National Statistics (2011)
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4.4.1 Prevalence
Table 4.2 shows both crude and standardised annual (2009) and five-year prevalence figures for 
each diagnostic code group. Annual (2009) coding prevalence for generalised pain conditions for 
the 12 practices included in the CiPCA dataset was between 14 per 10,000 for FM codes only, up 
to 243 per 10,000 for all generalised musculoskeletal pain codes (including codes for 
osteoarthritis). Generalised osteoarthritis codes accounted for approximately a quarter of all 
generalised musculoskeletal pain coding. There was little difference in prevalence between group 
one (FM codes only) and group two (FM and myofascial pain syndrome codes), reflecting a lack 
of use of the additional codes included in group two.
There was little difference between the crude and standardised figures for code groups not 
including osteoarthritis. Those that included osteoarthritis however, showed lower standardised 
figures. Five-year period prevalence figures for generalised musculoskeletal coding ranged from 
34 per 10,000 population for FM codes to 794 per 10,000 for all generalised pain complaints. 
Table 4.2 Crude and standardised* annual (2009) and five-year (2005–2009) prevalence figures (per 
10,000 population) (95% CI) for diagnostic code groups for all patients consulting 2005 to 2009.
Annual prevalence 
(95% CI)
Five-year prevalence (95% CI)
All patients consulting Only those fully registered 
(2005–2009)
Code Group Crude Standardised Crude Standardised Crude Standardised
Group 1
FM codes only
14 (12, 17) 14 (12, 17) 34 (31, 38) 34 (30, 37) 36 (32, 41) 35 (31, 39)
Group 2
FM and myofascial 
pain codes
15 (13, 17) 14 (12, 17) 35 (32, 39) 34 (31, 38) 37 (33, 42) 36 (32, 40)
Group 3
Generalised 
osteoarthritis codes
60 (56, 65) 55 (50, 59) 208 (199, 217) 188 (181, 196) 220 (210, 230) 179 (170, 187)
Group 4
All generalised 
codes excluding OA
188 (180, 196) 180 (172, 188) 628 (613, 642) 605 (591, 619) 638 (621, 655) 599 (582, 616)
Group 5
All generalised 
codes
243 (234, 253) 230 (222, 239) 794 (778, 811) 756 (741, 772) 810 (792, 829) 739 (720, 757)
*Standardised to UK general population figures for 2009, source: Office for National Statistics (2011)
There was little difference between five-year prevalence estimates for all patients consulting, and 
only those fully registered (2005–2009).
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4.4.2 Annual variation
Overall there was little annual variation in prevalence of all five code groups between 2005 and 
2009 (Table 4.3). Generalised osteoarthritis (group 3) showed a slight decrease from 74 per 
10,000 in 2005, to 60 per 10,000 in 2009. For all other generalised pain complaints there was a 
slight dip in coding between 2005 and 2006 with an otherwise very slight upward trend to 2009. 
Changes over the five-year period were small – ranging from an increase of one per 10,000 for FM 
coding (group 1) between 2005 and 2009, to 35 per 10,000 for coding of all generalised pain 
complaints excluding osteoarthritis (group 4).
Table 4.3 Variation in coding prevalence (per 10,000 population) of non-specific generalised 
musculoskeletal complaints by code group over time (95% CI) for all patients registered with CiPCA 
practices.
Annual prevalence per 10,000 (95% CI)
Code Group
2005 2006 2007 2008 2009 2009:2005 
ratio
Group 1
FM codes only
13 
(11, 15)
12
(10, 15)
14 
(12, 16)
13
(11, 16)
14
 (12, 17)
1.1
Group 2
FM and myofascial 
pain
13
(11, 15)
12 
(10, 15)
14
(12, 16)
13
(11, 16)
15
 (13, 17)
1.2
Group 3
Generalised OA
74
 (69, 80)
62
(57, 67)
66
(61, 71)
62
(57, 67)
60
(56, 65)
0.8
Group 4
All generalised codes 
exc. OA
153
(146, 161)
140
(133, 147)
166
(158, 174)
175
(167, 183)
188
(180, 196)
1.2
Group 5
All generalised codes
222
(213, 232)
197 
(189, 206)
226 
(217, 235)
231
(222, 240)
243 
(234, 253)
1.1
exc. OA: excluding osteoarthritis
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4.4.3 Practice variation
Coding behaviour varied between practices (Table 4.4). Annual FM (group one codes) coding 
crude prevalence in 2009 ranged from 3 to 29 per 10,000 depending on practice, and coding of 
all non-specific generalised pain codes ranged from 159 to 369 per 10,000 depending on 
practice.
There was little difference between crude and standardised prevalences for each code group 
across practices.
Table 4.4 Variation in annual coding prevalence (per 10,000 population) (95% CI) for each code group 
by practice for 2009 (all patients).
GP
Code Group
Group 1
FM codes
Group 2
FM and myofascial 
pain
Group 3
Generalised OA
Group 4
All generalised pain 
exc. OA
Group 5
All generalised pain
Crude Stand. Crude Stand. Crude Stand. Crude Stand. Crude Stand.
1
2
3
4
5
6
7
8
9
10
11
12
3 
(1, 10)
2 
(0, 5)
3 
(1, 10)
2 
(0, 5)
78 
(61, 100)
69 
(51, 87)
83 
(65, 106)
78 
(58, 97)
159 
(133, 189)
144 
(118, 170)
29 
(20, 43)
32 
(19, 45)
32 
(22, 46)
34 
(21, 47)
41 
(29, 57)
49 
(32, 65)
138 
(115, 165)
150 
(123, 177)
174 
(148, 204)
193 
(162, 225)
9 
(5, 16)
9 
(3, 14)
9
 (5, 16)
9 
(3, 14)
35 
(26, 47)
28 
(20, 37)
150 
(130, 173)
140 
(120, 160)
185 
(162, 210)
168 
(146, 189)
19
 (12, 30)
18 
(10, 27)
19
 (12, 30)
18 
(10, 27)
51 
(38, 67)
42 
(30, 54)
157 
(134, 183)
148 
(124, 171)
205 
(179, 234)
187 
(161, 214)
14
 (8, 22)
14 
(7, 21)
14
 (9, 23)
15 
(8, 23)
48 
(37, 62)
50 
(37, 63)
167 
(145, 191)
174 
(149, 198)
209 
(185, 236)
218 
(191, 245)
14
 (8, 25)
13 
(5, 20)
14
 (8, 25)
13 
(5, 20)
51 
(37, 69)
42 
(29, 55)
181 
(154, 212)
164 
(137, 191)
229 
(198, 264)
203 
(173, 233)
15 
(7, 30)
14 
(4, 24)
15 
(7, 30)
14
 (4, 24)
44 
(29, 67)
46 
(26, 66)
191 
(156, 234)
188 
(149, 227)
227 
(188, 273)
226 
(184, 269)
29 
(19, 43)
29 
(17, 41)
29
 (19, 43)
29 
(17, 41)
70 
(54, 92)
65 
(47, 82)
223 
(192, 259)
223 
(189, 257)
290 
(254, 330)
284 
(246, 322)
8 
(4, 17)
8 
(2, 14)
8 
(4, 17)
8 
(2, 14)
59 
(45, 78)
52 
(37, 66)
228 
(198, 262)
216 
(185, 247)
281 
(248, 319)
263 
(229, 296)
2 
(0, 12)
2 
(0, 7)
2 
(0, 12)
2 
(0, 7)
37 
(24, 59)
34 
(18, 49)
229 
(190, 275)
213 
(173, 253)
258 
(217, 307)
239 
(197, 281)
11
 (6, 19)
11 
(4, 17)
11
 (6, 19)
11 
(4, 17)
90 
(74, 110)
82 
(65, 98)
243 
(215, 274)
234 
(205, 263)
328 
(296, 364)
311 
(278, 344)
17
 (11, 27)
17 
(9, 25)
17 
(11, 27)
17 
(9, 25)
107 
(89, 129)
84 
(68, 100)
271 
(242, 304)
250 
(220, 279)
369 
(334, 407)
326 
(293, 359)
GP: General practice
OA: osteoarthritis
exc. OA: excluding osteoarthritis
Stand.: standardised to UK general population figures for 2009 (source: Office for National Statistics 2011).
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4.4.4 Age and sex variation
Table 4.5 shows age and gender variation for both annual (for consultations with all CiPCA 
patients in 2009) and five-year prevalence (for consultations with patients fully registered with the 
CiPCA practices 2005–2009) for all five code groups. Variation in annual prevalence by age and 
gender is illustrated in Figure 4.1. For clarity, and owing to little variation between groups one (FM 
codes only) and two (FM and myofascial pain codes), only group two is shown on the graph in 
Figure 4.1."
Table 4.5 Annual (2009) and five-year prevalence (2005–2009, fully registered patients only) (per 10,000 
population) by age and gender.
Code 
Grp
Age 
Grp
Annual prevalence (2009) Five-year prevalence 
(fully registered 2005–2009)
Female Male Total Female Male Total
1 <14 0 (0, 4) 0 (0, 2) 0 (0, 5) 0 (0, 9) 2 (1, 8) 1 (0, 12)
15–24 2 (0, 9) 0 (0, 3) 1 (0, 8) 13 (6, 27) 0 (0, 4) 6 (2, 19)
25–44 28 (20, 38) 4 (2, 8) 16 (10, 24) 75 (60, 94) 9 (6, 15) 42 (31, 57)
45–64 59 (47, 73) 4 (2, 7) 31 (23, 42) 121 (103, 142) 17 (12, 23) 69 (56, 85)
65–75 22 (12, 39) 4 (2, 10) 13 (7, 27) 45 (30, 69) 9 (4, 17) 28 (17, 47)
75+ 7 (2, 23) 0 (0, 4) 4 (1, 14) 12 (5, 31) 3 (1, 10) 8 (3, 21)
Total 26 (22, 30) 3 (2, 4) 14 (12, 17) 63 (55, 71) 9 (7, 11) 36 (32, 41)
2 <14 0 (0, 4) 0 (0, 2) 0 (0, 5) 0 (0, 9) 2 (1, 8) 1 (0, 12)
15–24 2 (0, 9) 0 (0, 3) 1 (0, 8) 13 (6, 27) 0 (0, 4) 6 (2, 19)
25–44 28 (21, 39) 4 (2, 8) 16 (11, 25) 75 (60, 94) 9 (6, 15) 42 (31, 57)
45–64 59 (48, 74) 4 (2, 7) 32 (24, 43) 124 (106, 146) 17 (13, 23) 71 (58, 88)
65–75 22 (12, 39) 4 (2, 10) 13 (7, 27) 47 (31, 72) 9 (4, 17) 29 (17, 48)
75+ 7 (2, 23) 0 (0, 4) 4 (1, 14) 12 (5, 31) 3 (1, 10) 8 (3, 21)
Total 26 (22, 31) 3 (2, 4) 15 (13, 17) 64 (57, 72) 9 (7, 12) 37 (33, 42)
3 <14 0 (0, 4) 0 (0, 2) 0 (0, 5) 0 (0, 9) 0 (0, 5) 0 (0, 9)
15–24 0 (0, 6) 0 (0, 3) 0 (0, 6) 0 (0, 8) 0 (0, 4) 0 (0, 8)
25–44 5 (2, 10) 3 (1, 6) 4 (2, 9) 20 (13, 31) 8 (5, 13) 14 (8, 24)
45–64 90 (75, 107) 40 (33, 48) 65 (53, 80) 332 (302, 366) 158 (143, 175) 246 (220, 275)
65–75 244 (205, 291) 139 (119, 164) 194 (160, 234) 785 (711, 866) 362 (326, 401) 582 (521, 650)
75+ 336 (281, 402) 141 (118, 167) 262 (223, 307) 852 (762, 953) 408 (367, 452) 677 (611, 750)
Total 85 (78, 94) 35 (31, 38) 60 (56, 65) 309 (292, 326) 128 (120, 136) 220 (210, 230)
4 <14 31 (22, 46) 16 (11, 24) 24 (15, 37) 163 (130, 205) 132 (110, 159) 147 (115, 189)
15–24 101 (79, 128) 51 (40, 65) 76 (57, 101) 357 (309, 412) 190 (165, 220) 270 (227, 321)
25–44 216 (193, 242) 96 (85, 108) 155 (136, 177) 731 (680, 784) 381 (355, 409) 555 (511, 603)
45–64 406 (374, 440) 194 (178, 211) 300 (273, 329) 1,171 (1,115, 1,230) 609 (579, 639) 892 (842, 943)
65–75 349 (302, 403) 281 (251, 314) 316 (273, 366) 1,094 (1,008, 1,187) 704 (655, 756) 908 (832, 990)
75+ 276 (227, 336) 218 (190, 250) 254 (216, 298) 811 (722, 909) 529 (483, 579) 700 (633, 774)
Total 243 (230, 257) 130 (123, 137) 188 (180, 196) 819 (792, 846) 450 (436, 464) 638 (621, 655)
5 <14 31 (22, 46) 16 (11, 24) 24 (15, 37) 163 (130, 205) 132 (110, 159) 147 (115, 189)
15–24 101 (79, 128) 51 (40, 65) 76 (57, 101) 357 (309, 412) 190 (165, 220) 270 (227, 321)
25–44 221 (198, 246) 98 (87, 111) 159 (139, 181) 746 (696, 800) 387 (360, 415) 565 (521, 613)
45–64 482 (447, 518) 230 (213, 248) 356 (326, 388) 1,424 (1,363, 1,487) 741 (709, 775) 1,085 (1,031, 1,141)
65–75 573 (512, 640) 412 (376, 452) 496 (441, 557) 1,690 (1,585, 1,800) 986 (928, 1,047) 1,353 (1,262, 1,450)
75+ 598 (524, 682) 353 (317, 393) 505 (451, 565) 1,489 (1,372, 1,615) 867 (809, 929) 1,245 (1,157, 1,338)
Total 321 (306, 337) 162 (155, 170) 243 (234, 253) 1,057 (1,027, 1,088) 554 (538, 570) 810 (792, 829)
Grp: Group
Code groups: 1: FM; 2. FM and myofascial pain; 3. Generalised osteoarthritis; 4. All non-specific generalised pain codes 
excluding osteoarthritis; 5. All non-specific generalised pain codes.
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Figure 4.1 Variation in annual prevalence (per 10,000) by age & gender for code groups 2–5 in 2009.
NB: Y-axis scale varies.
MF: Myofascial pain; OA: osteoarthritis.
For all code groups there is an increased prevalence in women (see Table 4.6). The gender 
disparity is most marked in code groups one and two (FM and myofascial pain codes). For the 
code groups that exclude osteoarthritis codes (one, two, and four) there is a peak in women in the 
45–64 age group. For the code groups that include osteoarthritis (groups three and five) there is 
an increase in prevalence with age. Five-year prevalence figures for fully registered (2005–2009) 
patients are higher than annual prevalence figures, but show similar age and gender trends.
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Table 4.6 Male:female ratio for annual (2009, all patients) and five-year prevalence (2005–2009, fully 
registered patients only) for all five code groups.
Male:female ratio
Code Group
Annual (2009) Five-year fully 
registered 
(2005–2009)
Group 1
FM codes only
0.12 0.14
Group 2
FM and myofascial pain codes
0.12 0.14
Group 3
Generalised osteoarthritis codes
0.41 0.41
Group 4
All generalised codes excluding OA
0.53 0.55
Group 5
All generalised codes
0.50 0.52
! OA: osteoarthritis.
4.4.5 Comparison with general population prevalence estimates
We estimated annual FM coding prevalence at 14 per 10,000 (95% CI: 12, 17); other estimates for 
medical record and health insurance coded FM prevalence have ranged from 18 to 45 per 10,000 
(see section 3.4.5.b). One study (Hughes et al. 2006) calculated five-year FM coding prevalence 
in a large UK primary care consultation dataset (GPRD, General Practice Research Database39) at 
18 per 10,000, which is lower than our estimate for five-year prevalence (34 per 10,000), but 
comparable to the annual coding prevalence of 14 per 10,000 that we calculated.
Annual and five-year coding prevalence for all five groups of codes (14 to 819 per 10,000) was 
lower than community CWP pain prevalence estimates (1,077 per 10,000, from meta-analysis in 
Chapter Three). The annual coding prevalence of FM (14/10,000, 95% CI: 12, 17) calculated for 
the CiPCA practices was 8% of the pooled community point prevalence (180/10,000, 95% CI: 150, 
200) calculated in the meta-analysis presented in the previous chapter. The annual coding 
prevalence of all non-specific generalised pain codes related to CWP (243/10,000, 95% CI: 234, 
253) was 23% of the pooled community point prevalence of CWP (1,077 per 10,000, 95% CI: 907, 
1,249).
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39 Now known as the Clinical Practice Research Database; http://www.cprd.com/intro.asp.
4.5 Discussion
Annual recorded prevalence of non-specific generalised pain complaints related to CWP ranged 
from 14 to 243 per 10,000, depending on code group. Coded prevalence of FM was comparable 
to figures from another UK primary care study (Hughes et al. 2006). Overall, there was little 
variation in coding prevalence over time, but coding behaviour varied between practices. 
Prevalence was higher in women for all code groups. Prevalence of FM coding peaked in middle 
age and then declined, prevalence for generalised osteoarthritis and all non-specific generalised 
pain codes including osteoarthritis increased with increasing age, and prevalence of all non-
specific pain codes excluding osteoarthritis showed an initial upward trend with age with a peak 
at middle age.
4.5.1 Prevalence
We need to be aware when we compare period coding prevalence figures with point community 
prevalence estimates (from the systematic review), that period and point prevalence are unlikely 
to be equivalent. Research demonstrates that CWP prevalence is stable over time (Croft et al. 
1993, Hunt et al. 1999, McBeth et al. 2001a, Aggarwal et al. 2006) but for half of CWP cases 
symptoms resolve within a year (McBeth et al. 2001a). This suggests a dynamic picture with equal 
numbers of new and resolving cases over the course of a year giving a stable point prevalence. 
Since period prevalence based on a single consultation during that period will encompass all 
those with symptoms during the specified timeframe (including new cases, those with continuous 
symptoms, and those whose symptoms have resolved) period prevalence is likely to over-
estimate point prevalence. 
Annual coding figures will represent the number of people recognised with a generalised 
condition in a year. Five-year period prevalence figures should pickup most people in a practice 
with the condition who consult for their symptoms during that period (and are recognised as 
having a generalised condition), but not all will still have the condition at the end of the five-year 
period. Five-year figures are therefore even more likely than annual figures to over-estimate point 
community prevalence. This is consistent with the observation from this study that five-year coding 
prevalence was higher than annual coding prevalence for both FM and ‘recognised’ CWP (i.e. 
coding of all non-specific generalised pain codes related to CWP). However, neither annual nor 
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five-year period coding prevalence can be robustly compared to general population point 
prevalence estimates (from the systematic review), but, if we keep in mind the caveats discussed 
above we can draw some useful conclusions regarding how much CWP/FM might be recognised 
in primary care.
For FM, both annual (14 per 10,000) and five-year (34 per 10,000) estimates were lower than point 
estimates for general population (180 per 10,000). Annual FM coding prevalence was 8% of 
general population prevalence, and five-year FM coding prevalence was 28% of general 
population prevalence. Not all those with FM will consult for their symptoms, but, given that FM/
CWP has been associated with help-seeking behaviour (section 2.2.5) it seems reasonable to 
suggest that more than a third of those with FM will consult their GP for their symptoms. Further, 
given that we would expect period prevalence to over-estimate point prevalence this suggests FM 
is under-recorded and possibly under-recognised in primary care.  
Given a CWP community point prevalence of 11% (Chapter Three) of whom an estimated 72% 
have consulted for their pain at any time (Macfarlane et al. 1999), we might expect an annual CWP 
consultation prevalence of around 8%. In fact the annual prevalence for all non-specific 
generalised pain (including osteoarthritis) was 2.4% (243/10,000). The five-year prevalence was 
8%, but not everyone recorded over five years with a non-specific generalised pain code would 
still report CWP up to five years later, so we would expect the five-year prevalence to be higher. 
Moreover, including generalised osteoarthritis codes means not all those identified will fulfil CWP 
criteria. While some generalised osteoarthritis coding could be a label given to CWP in older 
patients, the majority should reflect appropriate osteoarthritis diagnoses and not fulfil CWP criteria, 
therefore, recording of all non-specific generalised pain codes (including osteoarthritis codes) is 
likely to over-estimate ‘recognised’ CWP. True recognised CWP coding prevalence is likely to be 
closer to the lower prevalence estimate for non-specific pain excluding osteoarthritis (annual 
prevalence 1.9%, five-year prevalence 6.4%). Consequently, we can argue that our results 
suggest that both FM and CWP are under-recognised in primary care. 
The under-recording of FM in primary care is consistent with what we might expect given the 
contention surrounding FM as valid diagnoses (section 2.2.3), the lack of awareness of the FM 
diagnosis by clinicians (section 2.2.3), the evidence suggesting that coding is not a neutral 
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activity (de Lusignan et al. 2003), the evidence that many musculoskeletal complaints are not 
coded (Salisbury et al. 2013), and that coding of conditions with subjective case definitions is 
variable (Jordan et al. 2004).
Figures for FM annual coding prevalence from the CiPCA dataset were comparable with those 
established from a large, quality controlled, database of UK primary care medical records 
(Hughes et al. 2006). This suggests that the findings in this thesis, established using the CiPCA 
dataset, are generalisable to the rest of the UK population. However, the prevalence estimates 
from the GPRD (General Practice Research Database) are five-year period prevalence figures 
and are much lower than the five-year prevalence estimates calculated in this study.
We saw very little difference in prevalence when comparing coding prevalence of two specific FM 
codes (group one) with eight codes for FM and myofascial pain syndrome (group two), 
suggesting that the extra six codes were rarely used. This is consistent with the findings of 
Hughes et al. (2006), who noted a preferential use of some codes over others. Out of 2,260 new 
FM diagnoses, 2,257 were labelled with ‘fibromyalgia’ (Read codes N248 and N239), and only 
three were labelled ‘fibromyalgia not otherwise specified’ (Read code N2412).
There was little difference between crude and standardised figures for code groups not including 
osteoarthritis. However, for code groups including osteoarthritis, standardised figures were lower 
than crude estimates. This reflects the older population covered by the CiPCA dataset and the 
increased prevalence of osteoarthritis in older age groups.
4.5.2 Annual variation
Our results demonstrated very little annual variation in coding between 2005 and 2009 across all 
five groups of generalised pain codes. This suggests that coding practices for the groups of 
codes studied are reasonably static. This contrasts with findings from an earlier study (Gallagher 
et al. 204) using the GPRD which indicated a trend for increased FM coding between 1990 and 
2001.
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4.5.3 Practice variation
Consistent with research suggesting heterogeneity in coding practices (Gray et al. 2003, Hobbs 
and Hawker 1995, Tai et al. 2007), we saw differences in coding prevalence between practices. 
This suggests that, to account for differences in coding behaviour, when using routinely recorded 
clinical data to identify cases we need to use a broad and inclusive range of morbidity codes. This 
is of relevance to this thesis if we consider that the original RRC criteria were developed in only 
one practice using a list of 147 Read codes for regional musculoskeletal problems. There are over 
5,000 musculoskeletal Read codes and 4,482 of these represent regional musculoskeletal 
problems.
4.5.4 Age and sex variation
As would be predicted by general population figures (section 3.4.5.d) both FM-related codes and 
osteoarthritis codes are either not used or have very limited usage in the lower age groups.
Studies have shown FM to largely affect those in middle age (section 3.4.5.d), so it is not 
surprising to see a peak of FM coding in the 45–64 year age group. Examining the generalised 
osteoarthritis codes only, as would be expected with a degenerative condition, there is a clear 
increase in prevalence with increasing age, which is reflected in the higher prevalence for the 
group five codes (all generalised codes including osteoarthritis). 
The age distributions observed for those recorded with all generalised pain codes, both including 
and excluding osteoarthritis (groups 4 and 5), demonstrate similar patterns to those observed in 
studies of general population CWP prevalence – either a peak in middle age or increase in older 
ages (section 3.4.5.d). This suggests that these codes lists are identifying individuals who have a 
similar age profile to patients with self-reported CWP.
For all code groups prevalence was higher in women. This is consistent with general population 
findings for CWP from the systematic review (section 3.4.5.c). Further, in the systematic review we 
noted a more marked difference between genders in FM than in CWP. This is mirrored in our 
findings here, where there was a more marked disparity between genders in those recorded with 
FM codes (group one) than those recorded with all generalised pain codes (groups four and five).
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4.5.5 Future application
This chapter has developed a list of Read codes that could be used to represent ‘recognised’ 
CWP in primary care. The overlap of recognised CWP (coding of non-specific generalised pain 
codes) with unrecognised CWP coding (represented by Rohrbeck’s RRC criteria) will be explored 
in the next chapter (section 5.4.6.a), and in Chapter Six the features of recognised CWP (section 
6.3.3) and the combined coding prevalence of recognised and unrecognised CWP (section 6.3.4) 
will be explored in further detail.
4.5.6 Strengths and limitations
a. Study population
While generalisability may be reduced by the geographical limitation of the CiPCA study to one 
area of the UK (North Staffordshire), the CiPCA database has been demonstrated to give similar 
musculoskeletal consultation prevalence figures to a larger national general practice database 
(Jordan et al. 2007) and international databases (Jordan et al. 2013). Moreover, compared to the 
UK general population, the CiPCA population was comparable on gender distribution. However, 
the study population was demonstrated to have a higher percentage of older people than the UK 
general population. To account for this we standardised annual and five-year prevalence 
estimates to UK general population figures. In addition, the systematic review did not show great 
geographical variation accross Europe in CWP prevalence, so restricting the study geographically 
may only have a small influence on the ability to transfer the results to other populations.
b. Variation by age and gender
It is important to note that observed variations in prevalence by age, gender, and practice may 
reflect different clinicians coding practices rather than genuine population variation. However, 
variation in prevalence by age and gender for the codes investigated in the chapter appear to 
mirror the age and gender distribution of CWP in the general population observed in the previous 
chapter.
c. Read codes
Read codes for non-specific generalised pain complaints with the potential to be used to record 
consultations with CWP patients were identified from a list of ‘site unspecified’ codes identified in 
a previous study (Jordan et al. 2010). Identification of musculoskeletal codes was undertaken by 
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two GPs independently and a team of four GPs then allocated each code to an individual body 
region. Generalised pain codes and ambiguous codes with the potential to represent either 
regional or generalised pain (e.g. arthralgia, rheumatic pain) were then identified from the list of 
‘site unspecified’ codes. This process was unlikely to have missed any relevant codes. 
Codes selected for inclusion in the study were then established from this list after consultation (in 
a series of mainly one-to-one interviews) with an advisory panel of six GPs and a rheumatologist. 
All agreed on the codes unlikely to be used for CWP and these were therefore excluded from the 
list of codes used in the study. However, this was a limited and select group of clinicians. Only 
seven clinicians were approached. All seven clinicians had an interest in research. Two had a 
specialist musculoskeletal research interest, and consequently their opinions regarding coding 
practices may reflect how they hope these conditions are coded rather than how they are coded. 
Five of the panel were from the North Staffordshire GP Research Network. The Research Network 
was established in 1997 by the Primary Care Research Centre at Keele University (Porcheret et al. 
2004). Practices with previous audit participation, particularly using electronic data, were 
approached for inclusion in the network. Prior research involvement using electronic data by the 
five GPs from the research network might suggest an enhanced Read code literacy and a greater 
value on accurate coding practices. In addition, the one-to-one interview format may have 
compelled the clinicians to provide what they felt to be correct answers, rather than providing a 
more accurate picture of their coding practices. However, in seeking to identify ‘recognised CWP’, 
by identifying codes that might be used to record consultations for idiopathic pain syndromes, it 
would seem both reasonable and medically sound to follow the advice of the clinicians who apply 
those codes in practice and exclude conditions with: i) clearly identified underlying pathology; ii) 
injury or trauma; iii) vertebral conditions with myelopathy; iv) structural problems (e.g. fracture); 
and v) strains or sprains.
d. Inclusion of generalised osteoarthritis codes
Osteoarthritis is an ‘active repair process that takes place in all joint tissues and involves localised 
loss of cartilage and remodelling of adjacent bone’ (National Institute for Health and Care 
Excellence 2008, p.1). It could be argued therefore that, given recommendations by the advisory 
panel to exclude conditions with clearly identified pathology, generalised osteoarthritis codes 
should not have been included on the list of codes with the potential to represent CWP. However, 
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research (Graven-Nielsen et al. 2012) suggests that there is a subgroup of osteoarthritis patients 
with abnormalities of pain processing consistent with central sensitisation, which is one of the 
theories proposed to explain the pathophysiology of FM (Clauw and Crofford 2003). In addition it 
is possible that a clinical label of osteoarthritis may be given to older patients presenting with 
musculoskeletal pain who might better fit a CWP/FM diagnosis. To counter concerns about 
including osteoarthritis codes we presented figures both for generalised osteoarthritis alone 
(group 3), and for all non-specific generalised pain codes both including (group 5) and excluding 
(group 4) osteoarthritis codes.
e. Exclusion of coded hospital consultations
It could be argued that coded hospital consultations should have been included in order to better 
establish the burden of CWP in primary care. However, the aim was to establish how much CWP 
is recognised in primary care, not as a secondary care diagnosis. Coded hospital consultations 
were therefore excluded.
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4.6 Conclusions
Age and gender patterns for individuals recorded with non-specific generalised pain codes were 
similar to those seen in CWP in the general population. Comparison of coding prevalence figures 
for non-specific generalised pain codes (recognised CWP) with general population prevalence of 
CWP reveal some disparity between community burden and CWP recording in primary care, 
particularly regarding recent (annual) consultation. The results of this study therefore suggest an 
under-recording of CWP in primary care which implies that CWP consulters may not all be 
recognised as having a generalised condition. The next chapter will consequently start to assess 
an approach to identifying these potentially unrecognised CWP patients.
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Chapter 5
Code list development
5.1 Introduction
In the previous two chapters we postulated that, given there is no primary care morbidity code for 
CWP, GPs might be recording patients presenting with CWP with a non-specific generalised pain 
complaint. However, there was a marked disparity between the number of CWP patients expected 
to consult (estimated at approximately 8% of the population: calculated as 72% (Macfarlane et al. 
1999) of the community CWP prevalence of 11%, estimated in Chapter Three) and the observed 
annual consultation prevalence of non-specific pain complaints (2.4%, section 4.4.1). The 
question arising from this disparity is: if only a small proportion of the CWP consulters are 
recorded with generalised pain conditions, what codes are being recorded for consultations by 
the remaining CWP patients? 
As suggested earlier, one hypothesis is that GPs record and therefore treat individual regional 
pain complaints (e.g. hip or elbow pain) rather than the underlying CWP (Rohrbeck 2002). Based 
on this hypothesis, Rohrbeck used primary care consultation patterns to identify a set of patients 
with repeated consultations for pain in different body regions. Patients fulfilling the recurrent 
regional consulting (RRC) criteria had more health problems, worse self-reported general health, 
more sleep problems, and more fatigue (Rohrbeck et al 2007). These features have also been 
observed in CWP/FM patients (Hunt et al. 1999, Aggarwal et al. 2006), suggesting that the RRC 
criteria successfully identified CWP patients from their regional pain consultation patterns. Further, 
in a study using primary care consultation data, Jordan et al. (2010) found that the coding 
prevalence of patients consulting for a musculoskeletal complaint over one year in more than one 
body region was nearly 6%. The RRCs identified by Rohrbeck might therefore go some way to 
explaining the observed gap between estimated CWP consulting prevalence and recorded CWP 
prevalence (non-specific generalised pain coding); that is, identifying patients with CWP currently 
unrecognised in primary care.
The Rohrbeck-2007 RRC criteria used a list of 147 musculoskeletal pain morbidity codes 
developed through analysis of the medical records of one general practice. There are nearly 
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6,000 musculoskeletal Read codes (Jordan et al. 2010) and recognised variation in morbidity 
recording between practices (section 2.3.1). The first aim of this chapter was therefore to develop 
further the list of codes used to define RRCs to allow the RRC definition to be implemented 
outside the original practice in which it was developed, prior to further validation of the definition. 
Alternative code sets were tested within the established RRC criteria to decide which code list 
should be taken into the next stage of development.  
Two code lists were tested in addition to Rohrbeck et al’s (2007) original limited code list. The first 
code list comprised all regional musculoskeletal morbidity codes. The second excluded from the 
list of all regional codes any identified by clinicians on an advisory panel as unlikely to represent 
CWP. 
The second aim was to assess whether the application of the RRC criteria returned a patient 
group who fitted the construct of CWP. Cases fulfilling the criteria were compared to a control 
group on prevalence, age and sex distribution, comorbidity, recorded somatic symptoms, 
alternative diagnoses (rheumatoid arthritis, systemic lupus erythematosus, etc), and frequent 
attendance. The degree of overlap of RRCs with those recorded with generalised pain conditions 
was also explored.
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5.2 Aims and objectives
The overall aim of this chapter was to test candidate sets of regional musculoskeletal Read codes 
with the existing RRC consultation pattern definition (Rohrbeck-2007 criteria) in primary care 
consultation data, and to assess whether patients returned by the Rohrbeck criteria appeared to 
fit with the known characteristics of CWP.
Specifically:
1. To apply the Rohrbeck-2007 criteria for recurrent regional musculoskeletal consulters (RRC) 
using the following three code lists:
A. Rohrbeck (2007) original short code list (RRC-Rohrbeck)
B. All regional musculoskeletal codes (RRC-all)
C.The codes in B) having excluded all those codes identified by clinicians as being 
unlikely to represent CWP (RRC-clinician).
2. To explore similarities and differences in age and gender distribution, prevalence, number of 
recorded somatic symptoms, comorbidity, levels of frequent attendance, and degree of 
overlap with non-specific generalised pain recording, between RRCs returned using the three 
alternative code sets. 
3. Establish how much ‘unrecognised’ CWP the RRC definition identifies by exploring the overlap 
between recurrent regional pain consultation (RRC) and recorded non-specific generalised 
pain consultation (‘recognised’ CWP e.g. FM).
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4. To establish the construct validity of the RRC definition as a measure of CWP in primary care 
using each of the code lists by investigating the following hypotheses:
4.1. The consulting prevalence of RRCs approximates the estimated consultation 
prevalence of CWP (8%).
4.2. The age and gender distributions of RRCs more closely resembles those expected 
from patients with CWP than those of a control group who consult only for single-site 
musculoskeletal problems. Specifically, cases are hypothesised to be older and with a 
higher female proportion than controls.
4.3. Comorbidity is higher in RRCs than in controls.
4.4. The number of somatic symptoms in RRCs is higher than in controls.
4.5. The percentage of RRCs who are frequent attenders is higher than for controls.
4.6. The percentage of frequent attenders who are also RRCs is consistent with that 
expected from patients with CWP (20–30% of frequent attenders have medically 
unexplained symptoms (Karlsson et al. 1997, Jyväsjärvi et al. 2001, Reid et al. 2001b, 
Smits et al. 2009); CWP is a subset of medically unexplained symptoms, therefore, less 
than 30% of frequent attenders should fulfil CWP criteria).
4.7. The percentage of patients recorded with differential diagnoses for FM/CWP (e.g. 
rheumatoid arthritis, systemic lupus erythematosus) is similar for cases and controls.
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5.3 Methods
Overarching aims addressed throughout:
1. To apply the Rohrbeck-2007 criteria for recurrent regional musculoskeletal 
consulters (RRC) using the following three code lists: A. Rohrbeck (2007) original 
short code list (RRC-Rohrbeck); B. All regional musculoskeletal codes (RRC-all); 
and C. excluding from B) all those codes identified by clinicians as being unlikely 
to represent CWP (RRC-clinician).
2. To explore similarities and differences in age and gender distribution, 
prevalence, number of recorded somatic symptoms, comorbidity, levels of 
frequent attendance, and degree of overlap with non-specific generalised pain 
recording, between RRCs returned using the three alternative code sets. 
5.3.1 Cases and controls
Cases and controls were identified from all patients (no age restriction) fully registered with the 12 
primary care practices in the CiPCA dataset between the years 2005 and 2009. 
Three non-mutually exclusive groups of cases were identified using the RRC criteria (see Table 
5.1) with three code lists (illustrated in Figure 5.1):
A. Rohrbeck (2007) original short code list (RRC-Rohrbeck)
B. All regional musculoskeletal codes (RRC-all)
C.The codes in B) having excluded all those codes identified by clinicians as being 
unlikely to represent CWP (RRC-clinician).
Table 5.1 Rohrbeck RRC definition (2007).
In a period of 5 consecutive years fulfil all of i)–iv):
i) at least 1 consultation for a musculoskeletal complaint in the axial skeleton (neck & back);
ii) at least 1 consultation for an upper or lower limb complaint;
iii) at least 1 consultation for a regional musculoskeletal complaint in each of 3 separate years;
iv) at least 4 consultations for regional musculoskeletal complaints in total during the 5 year 
period.
Controls were patients with musculoskeletal consultations in only one of the three regions defined 
in the RRC criteria (axial, upper limb or lower limb) over the five-year period between 2005 and 
2009. 
Cases and controls were compared on: five-year prevalence (using patients fully registered 
between 2005 and 2009 as denominator), age and sex distribution, number of somatic symptoms, 
all-cause morbidity, frequent attendance, and the proportion of patients with alternative diagnoses 
(e.g. rheumatoid arthritis, systemic lupus erythematosus). We also calculated the proportion of 
RRCs with recorded generalised conditions (e.g. FM, generalised osteoarthritis).
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Ambiguous codes that may reflect either regional or generalised problems, for example, codes 
simply labeled ‘arthralgia’ or ‘joint pain’ with no region specified, were excluded from code lists B 
(all regional musculoskeletal codes) and C (clinician defined regional musculoskeletal codes). 
This research aimed to identify a subset of CWP consulters who are unrecognised as having a 
generalised pain condition; ambiguous codes were excluded to ensure that RRC criteria identified 
patients on the basis of their consultation patterns for regional (not generalised) complaints only. 
Codes that represent musculoskeletal complaints are located across four Read code chapters: 
Chapter 1 – History/Symptoms; Chapter N – Musculoskeletal/connective tissue diseases; Chapter 
R – Symptoms, signs and ill-defined conditions; and Chapter S – Injury and poisoning.
In a previous study (Jordan et al. 2010), two research GPs independently identified 5,182 unique 
Read codes (representing 5,908 clinical terms) from Chapters 1, N, R, and S as being 
musculoskeletal in nature. A team of four GPs then allocated each musculoskeletal code to an 
individual body region (e.g. hand, knee, back) where possible.
We assigned the musculoskeletal Read codes identified by the Jordan et al. (2010) study to one 
of three categories: regional, generalised, or ambiguous (Figure 5.1):
1. Regional musculoskeletal complaints: Includes all codes assigned to individual body regions 
and regional musculoskeletal complaints where a site is not specified (e.g. N23y4: Spasm of 
muscle).
2. Generalised musculoskeletal complaints: Includes codes with clinical terms that include the 
words ‘generalised’ or ‘multiple site’, or codes for conditions that are widespread by definition 
(e.g. FM).
3. Ambiguous clinical terms: Broad clinical terms for musculoskeletal problems; includes site 
unspecified codes that could represent either regional or generalised conditions. These codes 
tend to be non-specific, inclusive terms such as ‘musculoskeletal diseases’ or ‘joint disorders’.
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Figure 5.1 Flow chart to show the Read code lists.
MS: Musculoskeletal
a. Rohrbeck (2007) original short code list - RRC-Rohrbeck
The original code list developed by Rohrbeck consists of 147 codes, including 132 regional 
musculoskeletal codes (including code one code from Chapter 2 – examination findings), 13 
ambiguous codes, and two generalised codes (see appendix A5.1: Tables A5.1 and A5.2). 
Twenty-eight represented axial complaints (including two classified as both axial and lower 
extremity complaints), 42 represented lower extremity complaints (including two classified as both 
axial and lower extremity complaints), and 64 upper extremity codes (see appendix 5.1 for code 
list and Figure 5.1). The remaining codes, whether regional, generalised, or ambiguous, were 
counted as ‘regional’ complaints when used with the Rohrbeck-RRC definition, i.e. used only for 
criteria iii) and iv) (see Table 5.1) (see appendix A5.1, Table A5.2 for the regional or ambiguous 
codes included on Rohrbeck’s original code list). The regional musculoskeletal codes on the 
Rohrbeck list includes one code (2H23: on examination painful arc) from Read code Chapter 2 
(codes relating to clinical examination findings). No Chapter 2 codes were included in code lists B 
or C.
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b. All regional musculoskeletal codes - RRC-all
The list of all regional musculoskeletal complaints was used to identify the RRC-all group of 
codes. Using the body regions defined by Jordan et al. (2010), regional complaints with a 
specified site were assigned to the following three categories: axial, upper limb or lower limb. The 
body regions allocated to each category are listed below:
1. Axial: includes codes allocated to the following regions: back, chest, neck, head/neck, lower 
back and lower limb, lower back and pelvis/lower limb, neck, neck and back, neck and trunk, 
neck and upper back, neck and upper limb, trunk and pelvis, and upper back. Abdominal 
codes were excluded from this category as the ACR-90 criteria define axial pain as being 
located in the cervical spine, anterior chest, thoracic spine, or low back. Codes allocated to 
the ‘pelvis’ region were evaluated individually and categorised as being either axial (sacral, 
sacroiliac, or coccygeal complaints) or appendicular (complaints not specifying sacral, 
coccygeal, or sacroiliac region). Axial pelvic codes were included in this category. 
2. Upper limb: includes codes allocated to the following regions: elbow, forearm, hand, neck and 
upper limb, shoulder girdle, shoulder girdle/upper arm, shoulder girdle/upper limb, shoulder 
girdle/upper limb, shoulder, upper limb, upper arm, wrist, wrist/hand.
3. Lower limb: includes codes allocated to the following regions: ankle, ankle/foot, buttock, foot, 
hip, hip/thigh, knee, lower back and lower limb, lower back and pelvis/lower limb, lower leg, 
lower limb, pelvis/hip, pelvis/thigh, thigh, trunk and pelvis. Codes allocated to the ‘pelvis’ 
region were evaluated individually and categorised as being axial (sacral, sacroiliac, or 
coccygeal complaints) or appendicular (complaints not specifying sacral, sacroiliac, or 
coccygeal region). Pelvic codes identifying sacral, coccygeal or sacroiliac complaints were 
excluded from this category; all other pelvic codes were included.
Where a code for a regional complaint was identified as both an axial and a limb complaint (for 
example acute back pain and sciatica), it was assigned to both categories, as pain was 
determined to be simultaneously present in both body regions. Codes associated with multiple 
clinical terms located in conflicting regions (for example code N245 is associated with 17 
separate terms located in both upper and lower extremity) were assigned to categories 
individually on the basis of the associated clinical term used in the consultation data. Codes with 
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no specified site were recorded as regional complaints only and contributed only to criteria iii) and 
iv) of the Rohrbeck definition (Table 5.1).
Of the list of 5,182 unique codes, 4,482 were identified as regional musculoskeletal problems, 101 
as generalised problems, and 584 as ambiguous (see Figure 5.1). The remaining 15 codes did 
not represent consultations for current problems; they included terms such as ‘at risk of,’ or ‘family 
history of.’ The 4,482 codes representing regional musculoskeletal problems were used to identify 
the RRC-all group. There were 1,040 axial codes, 1,509 lower extremity codes,1,638 upper 
extremity codes, and 308 regional codes with no site specified40 (see appendix 5.2 for code list).
c. Clinician defined code list - RRC-clinician
The codes to be excluded from the list of all regional musculoskeletal codes (to generate code list 
C) were established after consultation with an advisory panel of six GPs and a rheumatologist (see 
also section 4.3.2). Two of the panel had specialist musculoskeletal research interests and worked 
both clinically and within the Arthritis Research UK Primary Care Research Centre at Keele 
University. The remaining five clinicians were members of the North Staffordshire GP Research 
Network (Porcheret et al. 2004) with no special musculoskeletal interest.
All the clinicians were approached for their advice regarding coding practices for consultations 
with patients who present to their GPs with symptoms of CWP. In a series of mainly one-to-one 
sessions (with KM), the GPs discussed how they would routinely code consultations with patients 
who present with medically-unexplained musculoskeletal pains.
Across the seven panel members there was no consistent approach to the coding of CWP 
patients. Of the five GPs from the North Staffordshire GP Research Network (i.e. non 
musculoskeletal specialists external to the Arthritis UK Primary Care Centre, Keele University), four 
expressed a reluctance to give precise diagnostic codes to patients without a secondary care 
diagnosis, some sort of clear investigative evidence, or strong clinical indication (relating to any 
condition not just FM or CWP). There seemed to be very much a 'watch and wait' policy, with 
caution about the implications of diagnostic labels. Most preferred to use a looser description of a 
'reason for attendance' rather than a 'diagnosis' for patients who could potentially meet accepted 
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40 Please note that these numbers will not sum to the total 4,482 regional codes as some codes are 
simultaneously classified as both limb and axial (e.g. acute back pain and sciatica).
criteria for CWP, citing the wider implications of labelling and the need to exclude self-limiting 
conditions before assigning a diagnostic label. The remaining GP was much more confident to 
assign labels, largely because he seemed more positive about what this could offer a patient.
As highlighted in section 4.3.2, while there was a diversity of coding practices in use among the 
panel members, there was a clear consensus regarding what codes would be unlikely to identify 
CWP patients. All agreed that the following musculoskeletal complaints were unlikely to represent 
CWP patients: clearly identified underlying pathology (determined via clear investigative 
evidence, secondary care diagnosis, or strong clinical indication); injury or trauma; vertebral 
condition with myelopathy; structural problem (e.g. meniscal tear); strain/sprain. To form code list 
C (RRC-clinician), consultations classified in categories identified by the advisory panel as being 
unlikely to represent a patient with CWP were excluded from the list of all regional musculoskeletal 
Read codes.
From the list of all regional musculoskeletal codes, 736 remained after exclusion of those felt to be 
unlikely (by the advisory panel) to be used in patients presenting with unexplained 
musculoskeletal symptoms (i.e. unlikely to be used for CWP patients). Of these 736 codes, 594 
were regional pain codes, 26 were generalised pain, and 116 were ambiguous. The 594 regional 
codes were used to identify the RRC-clinician group (see Figure 5.1). Of the regional complaints, 
there were 205 axial, 189 lower extremity, and 162 upper extremity codes (see appendix 5.2 for 
code list). The remaining regional codes had no site specified.
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d. Application of code lists 
Rohrbeck’s 2007 code list (A. RRC-Rohrbeck) and the two new code sets (B. RRC-all: all regional 
musculoskeletal codes; C. RRC-clinician: clinician defined regional musculoskeletal codes) were 
used with Rohrbeck’s 2007 criteria (as presented in Table 5.1). All consultations for the period 
2005 to 2009 with patients fully registered with the CiPCA practices during that five-year period 
(2005 to 2009) were searched using the criteria to identify RRCs. No age limitations were set.
The codes were applied to the Rohrbeck-2007 criteria using the following rationale:
• One consultation for a musculoskeletal complaint in the axial skeleton: correlates with one 
consultation coded with an axial code.
• One consultation for an upper- or lower-limb complaint: correlates with one consultation 
with an upper-limb or lower-limb code.
• One consultation for a regional musculoskeletal complaint coded in each of three separate 
years: correlates with one regional (axial, upper-limb, lower-limb, or site unspecified) 
musculoskeletal complaint in each of three separate years.
• At least four consultations for regional musculoskeletal complaints in total during the five-
year period: correlates with four consultations with a regional musculoskeletal code during 
the five-year period.
Controls were patients (fully registered between 2005 to 2009) recorded with a musculoskeletal 
problem in only one region (axial, upper limb or lower limb) during the five-year period (2005–
2009). Controls had no musculoskeletal consultations recorded with codes classified as either 
generalised or ambiguous.
Chapter 5: Code list development
132
5.3.2 Calculation of prevalence figures
Specific aims addressed:
4. To establish the construct validity of the RRC definition as a measure of CWP in 
primary care using each of the code lists by investigating the following 
hypotheses: 4.1) The consulting prevalence of RRCs approaches the estimated 
consultation prevalence of CWP (8%); and 4.2) The age and gender distributions 
of RRCs more closely resembles those expected from patients with CWP than 
those of a control group who consult only for single site musculoskeletal 
problems. Specifically, cases are more likely to be older and female than 
controls.
Five-year consultation period prevalences for recurrent regional consulting using each of the three 
RRC codes lists, and the prevalence for controls, were calculated. Prevalence was calculated 
only for consultations conducted in primary care; coded hospital consultations were not included. 
The denominator population was patients fully registered between 2005 and 2009 with practices 
in the CiPCA archive. Prevalence figures were recorded per 10,000 population. Prevalence 
figures were calculated for the 12 practices in the CiPCA dataset for which there were complete 
data for the years 2005–2009. Both crude and standardised figures were calculated. Prevalence 
figures were standardised by the direct method to the UK general population age-gender 
structure provided by the Office for National Statistics (2011). Overall prevalence and prevalence 
by age, gender, and primary care practice was compared between controls and cases returned 
using each of the three codes lists.
Prevalence was stratified by age and gender. The age stratification was in the following age 
bands: 14 and under; 15–24; 25–44; 45–64; 65–74; and 75+.
Five-year prevalence and age and gender distribution of any musculoskeletal consultation was 
calculated to offer a comparison to the prevalence of RRC and of single-region consultation 
(controls). Musculoskeletal consultation prevalence was determined for those fully registered 
between 2005 and 2009, this population was used as the denominator in calculations.  
The percentage of individuals recorded with any musculoskeletal code over the five-year period 
(2005–2009) who were also identified as RRCs was calculated to investigate the overlap of RRC 
consultation pattern with all regional musculoskeletal coding.
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Confidence intervals for prevalence figures were calculated using Wilson’s method (Newcombe 
1998). A spreadsheet was developed for this purpose, incorporating formulae for calculating 
these intervals at the 95% confidence level.
5.3.3 Comorbidity
Specific aims addressed:
4. To establish the construct validity of the RRC definition as a measure of CWP in 
primary care using each of the code lists by investigating the following 
hypothesis: 4.3) Comorbidity is higher in RRCs than in controls.
All cause comorbidity was measured using consultation counts for non-musculoskeletal 
conditions, and consultations stratified by Read code chapter. For each case group and the 
control group the mean number of non-musculoskeletal consultations in the five years between 
2005 and 2009 was calculated. Non-musculoskeletal consultations were those not coded with the 
musculoskeletal Read codes identified by Jordan et al. (2010). For each case group and the 
control group the percentage of the group recorded as consulting in each diagnostic (A–Z) Read 
code chapter was also calculated to establish the burden of disease in each of the body systems 
defined by the Read code chapter structure.
5.3.4 Somatic symptom count
Specific aims addressed:
4. To establish the construct validity of the RRC definition as a measure of CWP in 
primary care using each of the code lists by investigating the following 
hypothesis: 4.4) The number of somatic symptoms in RRCs is higher than in 
controls.
Physical symptoms itemised in the ACR-2010 criteria for FM (Wolfe et al. 2010) were used to 
conduct a systematic search of the Read code browser (NHS Clinical Terminology Browser, 
version 1.04, 2000) to identify corresponding Read codes. Three hundred and forty codes were 
identified corresponding to 40 of the 42 somatic symptoms. No codes relating to ‘sun sensitivity’ 
or ‘waking unrefreshed’ were found. The list of somatic symptoms and associated Read codes is 
included in appendix A5.3.
For each patient the number of somatic symptoms recorded in the period 2005–2009 was 
calculated. Mean and median somatic symptom counts were compared for cases and controls. 
The odds of being recorded with at least one somatic symptom was calculated for each RRC 
group against controls. Logistic regression was used to calculate an adjusted odds ratio for each 
Chapter 5: Code list development
134
case group relative to the control group, controlling for age, gender and frequent attender status 
(using SPPS version 20, IBM 2011). Frequent attender status was defined as stated in the next 
section (5.3.5).
5.3.5 Frequent attenders
Specific aims addressed:
4. To establish the construct validity of the RRC definition as a measure of CWP in 
primary care using each of the code lists by investigating the following 
hypotheses: 4.5) The percentage of RRCs who are frequent attenders is higher 
than for controls; and 4.6) The percentage of frequent attenders who are also 
RRCs is consistent with that expected from patients with CWP (20–30% of 
frequent attenders have medically unexplained symptoms (Karlsson et al. 1997, 
Jyväsjärvi et al. 2001, Reid et al. 2001b, Smits et al. 2009); CWP is a subset of 
medically unexplained symptoms, therefore, less than 30% of frequent attenders 
should fulfil CWP criteria).
Frequent attendance was defined using consultations for non-musculoskeletal consultations only. 
By definition, RRCs are likely to have a higher number of musculoskeletal consultations than 
controls.
A systematic review of frequent attenders in primary care found disparity in the definition of 
frequent attendance (Vedsted and Christensen 2005). Given the lack of consensus, for the 
purposes of this study, non-musculoskeletal frequent attenders were defined as the top 5% and 
10% of consulters for non-musculoskeletal problems (identified from those fully registered 
between 2005 and 2009) in each of the CiPCA practices for the five-year period 2005 to 2009. 
Non-musculoskeletal problems were defined as consultations coded with any Read code 
(including numeric Chapters 0–9: history, examination, procedural and administrative codes; and 
Chapters A–Z: diagnostic codes) except the musculoskeletal codes identified by Jordan et al. 
(2010). The percentage of frequent attenders who were case/controls, and the percentage of 
cases/controls who were frequent attenders was calculated. Frequent attendance defined in this 
way is also an indirect measure of comorbidity.
The relative odds of being a frequent attender (top 10% of consulters) were calculated for each 
RRC group against controls. Logistic regression was used to calculate an adjusted odds ratio for 
each case group relative to the control group controlling for age and gender.
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5.3.6 Generalised pain
Specific aims addressed:
3. Establish how much ‘unrecognised’ CWP the RRC definition identifies by 
exploring the overlap between recurrent regional pain consultation (RRC) and 
recorded non-specific generalised pain consultation (‘recognised’ CWP e.g. FM).
4. To establish the construct validity of the RRC definition as a measure of CWP in 
primary care using each of the code lists by investigating the following 
hypothesis: 4.7) The percentage of patients recorded with differential diagnoses 
for FM/CWP (e.g. rheumatoid arthritis, SLE) is similar for cases and controls.
a. Overlap with non-specific generalised pain coding (recognised CWP)
The degree of overlap between recurrent regional pain consultation (RRC) and recorded non-
specific generalised pain consultation (‘recognised’ CWP) was explored. The percentage of RRCs 
recorded as also recorded as consulting for non-specific generalised pain complaints related to 
CWP (e.g. fibromyalgia, identified using Read codes identified in the previous chapter, see 
appendix 4.1: Table A4.4) between the years 2005 and 2009 was calculated. Controls, by 
definition, had not consulted for generalised pain complaints and were therefore excluded from 
this analysis. The percentage of non-specific pain consulters who were also RRCs was calculated.
b. Overlap with specific widespread pain conditions (CWP differential diagnoses)
To explore the specificity of the RRC criteria for CWP/FM, the percentage of cases and controls 
also coded with conditions that might be included in a differential diagnosis of FM/CWP was 
investigated. Patients recorded in the five-year study period with Read codes for the following 
conditions were identified: rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), 
Sjögren’s syndrome, polymyalgia rheumatica (PMR), ankylosing spondylitis (AS), and 
hypothyroidism. These conditions were identified by Goldenberg (2009) as potential differential 
diagnoses for FM. Read codes were identified via a systematic search for clinical terms (identified 
using medical subject headings (MeSH) in Medline) related to the conditions listed using the 
Read-code browser (NHS Clinical Terminology Browser, version 1.04, 2000). The Read codes 
identified are presented in Table A5.4 in the appendix. The number of RRCs and controls 
recorded as consulting for defined widespread pain conditions was used to calculate the 
percentage of cases and controls with alternative explanations (other than CWP) for their 
symptoms. It should be noted that a diagnosis of FM/CWP does not exclude alternative comorbid 
diagnoses. Therefore, a patient identified as a RRC and recorded as consulting for one of the 
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alternative conditions listed above, may have both conditions (for example a patient could have 
both rheumatoid arthritis and CWP). 
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5.4 Results
Overarching aims addressed throughout:
1. To apply the Rohrbeck-2007 criteria for recurrent regional musculoskeletal 
consulters (RRC) using the following three code lists: A. Rohrbeck (2007) original 
short code list (RRC-Rohrbeck); B. All regional musculoskeletal codes (RRC-all); 
and C. excluding from B) all those codes identified by clinicians as being unlikely 
to represent CWP (RRC-clinician).
2. To explore similarities and differences in age and gender distribution, 
prevalence, number of recorded somatic symptoms, comorbidity, levels of 
frequent attendance, and degree of overlap with non-specific generalised pain 
recording, between RRCs returned using the three alternative code sets. 
5.4.1 Denominator population
The study population (patients fully registered with practices in the CiPCA archive between 2005 
and 2009) were comparable on gender distribution with the UK 2009 population. However, the 
study population had a higher proportion of older people than the UK general population, with 
more aged 45 and over (see Chapter Four, Table 4.1).
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5.4.2 Prevalence
Specific aims addressed:
4. To establish the construct validity of the RRC definition as a measure of CWP in 
primary care using each of the code lists by investigating the following 
hypotheses: 4.1) The consulting prevalence of RRCs approaches the estimated 
consultation prevalence of CWP (8%); and 4.2) The age and gender distributions 
of RRCs more closely resembles those expected from patients with CWP than 
those of a control group who consult only for single site musculoskeletal 
problems. Specifically, cases are more likely to be older and female than 
controls.
a. Prevalence and age/gender variation
The number of cases identified ranged from 3,523 using the Rohrbeck short code list (RRC-
Rohrbeck) to 9,172 using all regional musculoskeletal codes (RRC-all). 20,499 controls were 
identified (Table 5.2, Figure 5.2).
Five-year prevalence of recurrent regional consultation varied between 442 per 10,000 for RRC-
Rohrbeck (cases identified using the Rohrbeck-2007 short code list C), to 1,149 for RRC-all 
(cases identified using all regional musculoskeletal codes, code list A) (Table 5.3 and Figure 5.2). 
Prevalence of patients meeting the control criteria (single-region consultation only) was 
substantially higher than for cases, at 2,569 per 10,000. RRC prevalence was higher in females 
than males for all age groups. The control group prevalence was similar by gender in the younger 
age groups, but, higher in men aged 45 years and over. RRC prevalence increased with age, 
while for controls there was a peak prevalence in those aged 25 to 44. 
Table 5.2 Age and gender distribution in fully registered (2005–2009) cases and controls.
Patient group
Variable RRC-all RRC-clinician RRC-Rohrbeck Control
Age group
<14 39 (0.4%) 21 (0.3%) 5 (0.1%) 1,346 (6.6%)
15–24 304 (3.3%) 149 (2.0%) 55 (1.6%) 2,467 (12.0%)
25–44 1,639 (17.9%) 1,157 (15.8%) 454 (12.9%) 5,709 (27.9%)
45–64 3,652 (39.8%) 3,005 (41.1%) 1,452 (41.2%) 6,564 (32.0%)
65–74 1,793 (19.5%) 1,537 (21.0%) 775 (22.0%) 2,411 (11.8%)
>75 1,745 (19.0%) 1,438 (19.7%) 782 (22.2%) 2,002 (9.8%)
Total 9,172 7,307 3,523 20,499
Gender
Female 5,522 (60.2%) 4460 (61.0%) 2,262 (64.2%) 10,215 (49.8%)
Male 3,650 (39.8%) 2847 (39.0%) 1,261 (35.8%) 10,284 (50.2%)
Male:female ratio 0.66 0.64 0.56 1.01
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Figure 5.2 Five-year prevalence (per 10,000 population) in cases and controls for patients fully 
registered 2005–2009.
Age-gender standardised figures were slightly lower than crude figures for cases, and similar for 
controls (see Table 5.4).
Table 5.4 Crude and standardised five-year prevalence figures per 10,000 population (95% CI) for 
cases and controls.
Patient group Crude (95% CI) Standardised* (95% CI)
RRC - all 1,149 (1,127, 1,171) 987 (966, 1,007)
RRC - Clinician 916 (896, 936) 774 (756, 792)
RRC - Rohrbeck 442 (428, 456) 367 (354, 379)
Controls 2,569 (2,539, 2,599) 2,516 (2,480, 2,551)
*Standardised to UK general population figures for 2009, source: Office for National Statistics (2011)
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b. Practice variation
There was some variation in prevalence across the 12 general practices included in the study 
(see Table 5.5). For example, RRC-all prevalence ranged from 882 to 1,435 per 10,000 across 
practices; although seven practices had a narrower range with prevalences of between 1,000 and 
1,300 per 10,000.
Table 5.5 Five-year prevalence figure per 10,000 population (95% CI) for cases and controls, stratified 
by practice.
Practice RRC-all RRC-Clinician RRC-Rohrbeck Control
9
7
6
8
1
11
3
12
4
5
2
10
882 (817, 952) 636 (581, 697) 299 (261, 342) 2,420 (2,320, 2,524)
933 (842, 1,033) 771 (688, 863) 339 (284, 404) 2,558 (2,418, 2,704)
1,003 (928, 1,084) 750 (685, 821) 394 (347, 448) 2,698 (2,584, 2,814)
1,023 (942, 1,112) 829 (755, 910) 253 (213, 301) 2,451 (2,333, 2,574)
1,068 (994, 1,148) 777 (713, 847) 357 (313, 406) 2,544 (2,437, 2,654)
1,078 (1,013, 1,147) 840 (782, 902) 226 (196, 261) 2,459 (2,366, 2,553)
1,136 (1,076, 1,198) 958 (903, 1,016) 514 (473, 558) 2,722 (2,637, 2,808)
1,171 (1,104, 1,242) 949 (888, 1,014) 571 (523, 623) 2,471 (2,380, 2,565)
1,279 (1,209, 1,353) 1,017 (954, 1,084) 500 (455, 549) 2,660 (2,566, 2,756)
1,334 (1,260, 1,410) 1,072 (1,006, 1,142) 529 (482, 581) 2,448 (2,354, 2,544)
1,397 (1,309, 1,490) 1,140 (1,060, 1,226) 647 (585, 714) 2,706 (2,592, 2,824)
1,435 (1,331, 1,546) 1,211 (1,114, 1,315) 601 (532, 678) 2,715 (2,581, 2,854)
c. Five-year musculoskeletal coding prevalence 
The five-year coding prevalence for any musculoskeletal problem was considerably higher (5,963 
per 10,000) than that observed for RRCs (442 to 1,149 per 10,000) and controls (2,569 per 
10,000) (see Table 5.6). However, the age and gender distributions were similar to those 
observed in RRCs. Prevalence of musculoskeletal coding increased with age and was higher in 
women.
Table 5.6 Five-year coding prevalence per 10,000 population (95% CI) for any musculoskeletal Read 
code in those fully registered with the CiPCA practices 2005–2009.
Prevalence per 10,000 population (95% CI)
Age group Female Male Total 
<14 2,396 (2,268, 2,529) 2,501 (2,375, 2,631) 2,450 (2,360, 2,543)
15–24 4,561 (4,418, 4,705) 4,155 (4,020, 4,292) 4,349 (4,250, 4,448)
25–44 6,212 (6,614, 6,309) 5,457 (5,358, 5,556) 5,832 (5,762, 5,901)
45–64 7,237 (7,157, 7,316) 6,364 (6,278, 6,449) 6,803 (6,744, 6,862)
65–74 7,559 (7,439, 7,675) 7,000 (6,867, 7,130) 7,291 (7,202, 7,378)
>75 8,041 (7,929, 8,148) 7,210 (7,054, 7,361) 7,714 (7,623, 7,803)
Total 6,343 (6,296, 6,390) 5,569 (5,520, 5,618) 5,963 (5,929, 5,997)
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5.4.3 Comorbidity
Specific aims addressed:
4. To establish the construct validity of the RRC definition as a measure of CWP in 
primary care using each of the code lists by investigating the following 
hypothesis: 4.3) Comorbidity is higher in RRCs than in controls.
a. Consultation count
Mean non-musculoskeletal consultation counts varied from 20 consultations in the period 2005 to 
2009 for controls, to between 39 and 42 consultations in the five-year period for cases. The 
distribution of figures in all groups was positively skewed, with the majority of patients having a 
lower number of consultations and a few individuals attending much more frequently (Table 5.7).
Controls were not age-matched with cases and there was a difference in the age distribution of 
cases and controls. Cases were older than controls; between 78 and 85% of cases were 45 years 
or over compared to only 54% of controls (Table 5.2). However, the disparity between cases and 
controls in mean and median number of non-musculoskeletal consultations persisted when 
restricting the analysis to those aged 45 and over.
Table 5.7 Non-musculoskeletal consultation count for the 5 years period 2005–2009 for each patient 
group.
Patient Group
Total number of non-MS consultations 
2005–2009
Mean (sd) Median (IQR) Min No Max No n
All age groups
RRC - All regional MS codes
RRC - Clinician defined codes
RRC - Rohrbeck-2007 code list
Controls
Cases/controls aged 45+
RRC - All regional MS codes
RRC - Clinician defined codes
RRC - Rohrbeck-2007 code list
Controls
39 (26) 35 (21, 51) 0 344 9,172
41 (26) 36 (22, 53) 0 344 7,307
42 (26) 37 (24, 54) 0 344 3,523
20 (17) 16 (8, 28) 0 254 20,499
41 (26) 37 (23, 53) 0 344 7,190
42 (26) 37 (24, 54) 0 344 5,980
43 (26) 38 (25, 55) 0 344 3,009
23 (17) 20 (10, 32) 0 254 10,977
IQR: Inter quartile range
sd: standard deviation
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b. Consultation by Read code chapter
The percentage of cases and controls recorded with a consultation in each Read code chapter is 
displayed in Figure 5.3 (excluding chapters with low consultation rates: Chapters Q, P, L, U and 
D) to aid interpretation of the figures presented in Table 5.8. 
Figure 5.3 Percentage of patients consulting in each Read code chapter (2005–2009) for cases and 
controls. Excluding chapters with low consultation rates (Chapters Q, P, L, U and D) and numerical 
chapters.
Table 5.8 Number (%) of patients consulting in each Read code chapter (excluding Chapter N and 
numeric chapters) for cases and controls between 2005 and 2009.
Read code chapter
Number of patients recorded in Read code 
chapter (%)
RRC-all RRC-
clinician
RRC-
Rohrbeck
Control
R [D] Symptoms, signs and ill-defined conditions*
H Respiratory system diseases
M Skin/subcutaneous tissue diseases
F Nervous system/sensory organ diseases
G Circulatory system diseases
J Digestive system diseases
K Genitourinary system diseases
E Mental disorders
S Injury and poisoning*
Z Other disease/injury
C Endocrine/nutritional/metabolic/immunological diseases
A Infectious/parasitic diseases
B Neoplasms
T Causes of injury/poisoning
D Blood/blood forming organ diseases
U [X]External causes morbidity/mortality
L Pregnancy/childbirth/puerperium
P Congenital anomalies
Q Perinatal conditions
8,389 (92) 6,763 (93) 3,225 (92) 14,139 (69)
6,337 (69) 5,094 (70) 2,471 (70) 10,649 (52)
5,393 (59) 4,359 (60) 2,146 (61) 8,355 (41)
5,329 (58) 4,329 (59) 2,166 (62) 8,264 (40)
4,599 (50) 3,838 (53) 1,873 (53) 5,710 (28)
4,395 (48) 3,639 (50) 1,790 (51) 4,782 (23)
4,217 (46) 3,420 (47) 1,664 (47) 6,029 (29)
3,932 (43) 3,182 (44) 1,566 (45) 5,165 (25)
3,906 (43) 2,461 (34) 1,255 (36) 4,182 (20)
3,267 (36) 2,610 (36) 1,306 (37) 5,266 (26)
3,161 (35) 2,628 (36) 1,352 (38) 3,429 (17)
3,104 (34) 2,499 (34) 1,227 (35) 4,869 (24)
1,293 (14) 1,066 (15) 548 (16) 1,847 (9)
1,175 (13) 933 (13) 488 (14) 1,142 (6)
634 (7) 531 (7) 259 (7) 641 (3)
338 (4) 264 (4) 144 (4) 335 (2)
125 (1) 89 (1) 44 (1) 335 (2)
102 (1) 82 (1) 36 (1) 189 (1)
10 (0) 7 (0) 6 (0) 13 (0)
NB: Musculoskeletal codes from Chapters R and S are included in the code lists used to identify cases and controls.
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The percentage of patients consulting was lower for controls across all Read code chapters. 
There was a reasonably similar percentage of patients consulting in each chapter for each case 
group. Using just the Rohrbeck short code list (RRC-Rohrbeck) gave a slightly higher percentage 
of people consulting for most chapters. However, there was a higher percentage of patients 
consulting in Chapter S (Injury and poisoning) in the RRC-all group (cases identified using all 
regional musculoskeletal codes). 
5.4.4 Somatic symptoms
Specific aims addressed:
4. To establish the construct validity of the RRC definition as a measure of CWP in 
primary care using each of the code lists by investigating the following 
hypothesis: 4.4) The number of somatic symptoms in RRCs is higher than in 
controls.
Between 88 and 90% of cases were recorded with one or more somatic symptoms compared to 
63% of controls. The mean number of somatic symptoms for the five-year period 2005 to 2009 
was lower in controls compared to cases, ranging from 1.22 in control patients to 2.89 in the RRC-
Rohrbeck group (RRCs identified using the Rohrbeck-2007 code list). The mean number of 
somatic symptoms was similar across the three groups of cases (range from 2.75 to 2.89). 
Looking at somatic symptom count in only those cases/controls aged 45 years and over, there 
was little difference compared to that seen for all ages. Mean somatic symptom count figures are 
shown in Table 5.9 and the distribution of somatic symptom counts is illustrated in Figure 5.4.
Table 5.9 Somatic symptom count for the 5 year period 2005–2009 for cases and controls.
Patient Group
Number of somatic symptoms 2005–2009 Number (%) with 
one or more 
somatic 
symptoms
Mean (sd) Median (IQR) Min No Max No n
All age groups
RRC-all
RRC-clinician
RRC-Rohrbeck
Controls
Cases/controls aged 45+
RRC-all
RRC-clinician
RRC-Rohrbeck
Controls
2.75 (2.13) 2 (1,4) 0 16 8,104 (88%) 9,172
2.88 (2.16) 2 (1,4) 0 16 6,560 (90%) 7,307
2.89 (2.27) 2 (1,4) 0 16 3,118 (89%) 3,523
1.22 (1.35) 1 (0, 2) 0 10 12,977 (63%) 20,499
2.76 (2.12) 2 (1,4) 0 16 6,370 (89%) 7,190
2.87 (2.14) 2 (1,4) 0 16 5,374 (90%) 5,980
2.88 (2.25) 2 (1,4) 0 16 2,663 (89%) 3,009
1.20 (1.35) 1 (0, 2) 0 10 6,872 (63%) 10,977
sd: standard deviation
IQR: Inter quartile range
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Figure 5.4 Distribution of number of recorded somatic symptoms (2005–2009) for cases/controls.
As Table 5.10 shows, the odds ratio for the association of RRC group with the recording of one or 
more somatic symptoms was 4.40 for the RRC-all group, 5.09 for RRC-clinician, and 4.46 for the 
RRC-Rohrbeck group compared to the control group. Adjustment for age and gender reduced the 
odds ratios slightly to 4.20 for the RRC-all group, 4.84 for RRC-clinician, and 4.14 for RRC-
Rohrbeck but there remained a strong and significant association between RRC status and having 
a recorded somatic symptom. Adjusting for frequent attender status in addition to age and gender 
reduced the odds of being recorded with a somatic symptom further, but again a strong and 
significant association between RRC status and somatic symptom recording remained.
Table 5.10 Odds ratios (95% confidence interval) for the recording of one or more somatic symptoms 
in each group of cases.
Patient group
Odds ratio (95% CI)
Crude Adjusted* (age & 
gender)
Adjusted* (age, 
gender and 
frequent attender 
status)
RRC-all
RRC-clinician
RRC-Rohrbeck
4.40 (4.10, 4.72) 4.20 (3.90, 4.51) 3.44 (3.20, 3.70)
5.09 (4.70, 5.52) 4.84 (4.46, 5.26) 3.91 (3.59, 4.25)
4.46 (4.01, 4.97) 4.14 (3.71, 4.62) 3.26 (2.92, 3.65)
* Adjusted using logistic regression compared to controls.
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5.4.5 Frequent attenders
Specific aims addressed:
4. To establish the construct validity of the RRC definition as a measure of CWP in 
primary care using each of the code lists by investigating the following 
hypotheses: 4.5) The percentage of RRCs who are frequent attenders is higher 
than for controls; and 4.6) The percentage of frequent attenders who are also 
RRCs is consistent with that expected from patients with CWP (20–30% of 
frequent attenders have medically unexplained symptoms (Karlsson et al. 1997, 
Jyväsjärvi et al. 2001, Reid et al. 2001b, Smits et al. 2009); CWP is a subset of 
medically unexplained symptoms, therefore, less than 30% of frequent attenders 
should fulfil CWP criteria).
In the fully-registered CiPCA population the mean consultation count over the five-year period 
2005–2009 for frequent attenders was between 69 when defined as the top 10% of consulters, 
and 82 when defined as the top 5% (see Table 5.11). Minimum consultation count was 38 in the 
top 10% of consulters to a maximum of 398. The mean age of frequent attenders was between 60 
and 61 for both frequent (top 10%) and very frequent attenders (top 5%). Women were more than 
twice as likely as men to be frequent attenders. Somatic symptom count ranged from a mean of 
3.4 for frequent attenders (top 10%) to 3.9 for very frequent attenders (top 5%).
Table 5.11 Mean age, mean five-year consultation count and male:female ratio for non-musculoskeletal 
frequent attenders (identified from fully registered population 2005–2009 only).
Mean 
age 
(sd)
male: 
female 
ratio
Consultation 
count
Mean non-
MS 
consultation 
count (sd)
Mean MS 
consultation 
count (sd)
Mean 
somatic 
symptom 
count 
(sd)
Total
Mean 
(sd)
Min Max
Top 10% non-MS 
FAs*
60 (19) 0.48 69 (24) 38 398 64 (22) 7 (8) 3.4 (2.2) 7,691
Top 5% non-MS 
FAs*
61 (19) 0.46 82 (26) 47 398 77 (24) 8 (9) 3.9 (2.4) 3,850
*non-MS FAs: non-musculoskeletal frequent attenders
MS: musculoskeletal
RRC cases were more likely to be frequent attenders than controls (see Table 5.12). The 
percentage of RRCs who were also frequent attenders (10% definition) was between 31% and 
35% across the three case groups, with higher proportions seen in RRC-Rohrbeck cases, 
followed by the RRC-clinician, with RRC-all having the lowest proportion of frequent attenders. 
Frequent attenders accounted for substantially less of the control group (7% based on the 10% 
definition for frequent attendance). Similar results were observed when case/controls were limited 
to those aged 45 years an over (see appendix 5.5, Table A5.6). 
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Cases accounted for between 16% and 37% of all frequent attenders (10% definition). Reflecting 
the group sizes, the RRC-Rohrbeck cases accounted for the smallest number of frequent 
attenders, followed by RRC-clinician, with the RRC-all group of cases accounting for the highest 
percentage of frequent attenders. The RRC-all group accounted for up to 43% of the top 5% of 
consulters. 
Controls accounted for 18% of non-musculoskeletal frequent attenders (10% definition).
Table 5.12 Cases and controls by frequent attendance status.
number of patients (% cases/controls also frequent attenders, 
% frequent attenders identified as cases/controls)
RRC - All RRC - Clinician RRC - Rohrbeck Controls n
Top 10% non-MS FAs*
Top 5% non-MS FAs*
n
2,868 (31%, 37%) 2,418 (33%, 31%) 1,241 (35%, 16%) 1,416 (7%, 18%) 7,691
1,670 (18%, 43%) 1,429 (20%, 37%) 758 (22%, 20%) 597 (3%, 16%) 3,850
9,172 7,307 3,523 20,499
*non-MS FAs: non-musculoskeletal frequent attenders
As Table 5.13 shows, the odds ratio associating RRC group with frequent attendance (top 10%) 
was 6.13 for the RRC-all group, 6.67 for RRC-clinician and 7.33 for the RRC-Rohrbeck group 
compared to controls. Adjustment for age and gender reduced the odds ratio noticeably to 4.83 
for the RRC-all group, 5.16 for RRC-clinician, and 5.33 for RRC-Rohrbeck but still showed strong 
and significant associations between RRC status and frequent attendance.
Table 5.13 Odds ratios (95% confidence interval) for frequent attendance (top 10% of attenders) in 
each group of cases.
Patient Group
Odds ratio (95% CI)
Crude Adjusted* (age & 
gender)
RRC-all
RRC-clinician
RRC-Rohrbeck
6.13 (5.72, 6.57) 4.83 (4.49, 5.19)
6.67 (6.20, 7.17) 5.16 (4.78, 5.57) 
7.33 (6.71, 8.00) 5.33 (4.85, 5.84)
* Adjusted using logistic regression compared to controls.
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5.4.6 Generalised pain
Specific aims addressed:
3. Establish how much ‘unrecognised’ CWP the RRC definition identifies by 
exploring the overlap between recurrent regional pain consultation (RRC) and 
recorded non-specific generalised pain consultation (‘recognised’ CWP e.g. FM).
4. To establish the construct validity of the criteria using each of the code lists by 
investigating the following hypothesis: 4.7) The percentage of patients recorded 
with differential diagnoses for FM/CWP (e.g. rheumatoid arthritis, SLE) is similar 
for cases and controls.
a. Overlap with non-specific generalised pain coding (recognised CWP)
The degree of overlap between non-specific generalised pain coding and RRCs is shown in Table 
5.14. Patients recorded with non-specific pain complaints accounted for up to 26% of RRCs 
(depending on non-specific pain definition). There were similar proportions of non-specific pain 
consulters across all three groups of RRCs for each subgroup of non-specific pain coding (FM, 
generalised osteoarthritis, non-specific generalised pain). The RRC-all code list identified 42% of 
all patients with a record of fibromyalgia, whereas RRC-Rohrbeck identified approximately half 
that number (22%). This pattern was similar for generalised osteoarthritis, and all non-specific 
generalised pain.
Table 5.14 Number of RRCs consulting for non-specific pain complaints (percentage of RRCs with 
non-specific pain coding, percentage of non-specific pain consulters identified as RRCs).
Number of patients 
(% RRCs with NS pain coding, % NS pain consulters also RRCs)
RRC - All RRC - Clinician RRC - Rohrbeck n
FM*
Generalised OA**
All NS pain (exc. OA)
All NS pain (inc. OA)
n
123 (1%, 42%) 107 (1%, 37%) 64 (2%, 22%) 290
672 (7%, 38%) 577 (8%, 33%) 303 (9%, 17%) 1,756
1,637 (18%, 32%) 1,407 (19%, 28%) 731 (21%, 14%) 5,089
2,106 (23%, 33%) 1,803 (25%, 28%) 929 (26%, 14%) 6,466
9,172 7,307 3,523
*FM = fibromyalgia
**OA = osteoarthritis
NS = non-specific
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b. Overlap with specific widespread pain conditions (CWP differential diagnoses)
The degree of overlap between patients coded with specified alternative widespread pain 
diagnoses and cases/controls is shown in Table 5.15. The percentage of patients with alternative 
diagnoses recorded is low for both cases and controls, with the percentage with any alternative 
diagnoses ranging from 3% in controls to 8-9% for RRCs. Hypothyroidism accounted for the 
majority of alternative diagnoses, with 6-7% of RRCs also recorded with hypothyroidism.
Table 5.15 Number (%) of RRCs/controls recorded with differential diagnoses.
Number of patients
 (% cases/controls with alternative diagnoses)
RRC - all RRC - clinician RRC - Rohrbeck Controls n
Rheumatoid arthritis
SLE*
Polymyalgia rheumatica
Ankylosing spondylitis
Sjögren’s syndrome
Hypothyroidism
Any listed (above) differential 
diagnosis
n
82 (1%) 65 (1%) 31 (1%) 0 (0%) 476
5 (0%) 4 (0%) 4 (0%) 0 (0%) 24
125 (1%) 108 (1%) 56 (2%) 0 (0%) 360
18 (0%) 5 (0%) 2 (0%) 28 (0%) 60
8 (0%) 5 (0%) 2 (0%) 0 (0%) 33
524 (6%) 418 (6%) 233 (7%) 515 (3%) 2,162
734 (8%) 581 (8%) 318(9%) 543 (3%) 3,029
9,172 7,307 3,523 20,499
*SLE = systemic lupus erythematosus
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5.5 Discussion
We found recurrent multi-region consulters (RRCs) to be consistently different from single-site 
consulters (controls). RRCs were older, more likely to be female, had higher consultation rates for 
both musculoskeletal and non-musculoskeletal complaints, were more likely to be frequent 
attenders, had more recorded physical symptoms, and were more likely to be coded with non-
specific generalised musculoskeletal pain codes, or codes for FM/CWP differential diagnoses. 
However, the percentage recorded with differential diagnosis codes were low.
Increasing the number of codes used to define a RRC increased the number of patients identified. 
However, increases in RRC prevalence were not in proportion to increased numbers of identifying 
codes. There were few differences in the profile of the patients in each group. The patients 
identified using all regional musculoskeletal codes has a similar age and gender distribution to the 
subgroups identified by the clinician-defined code list and the original Rohrbeck short code list. 
All three groups had similar non-musculoskeletal consultation rates, numbers of somatic 
symptoms, levels of comorbidity, frequent attendance, and recorded non-specific generalised 
pain and specific differential diagnoses. The only notable difference between the three groups of 
cases was the observation of a higher proportion of RRC-all patients recorded with consultations 
in Read code Chapter S – injury and poisoning. This might be accounted for by a higher number 
of injury codes included on the list of codes used to identify the RRC-all group compared to the 
other two groups of RRCs.
RRCs accounted for up to 42% of patients with a recorded non-specific generalised pain 
condition. The percentage of patients recorded with alternative diagnoses for FM/CWP was low for 
both RRCs and controls, but was higher in RRCs (8-9%) than controls (3%). 
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5.5.1 Prevalence
a. Total prevalence
The study population is older than the standard UK population (Table 5.2), however age and 
gender standardisation did not greatly change the estimated prevalence figures.
The requirement for a minimum of four musculoskeletal consultations to meet RRC criteria 
compared to only one consultation to define a control may account for the observation that 
prevalence in controls is at least double that in cases. However, it might also reflect population 
differences in single- and multi-site pain prevalence (Carnes et al. 2007, Clark 2002). The RRC 
criteria’s requirement for a specific number of consultations over time suggests chronicity of 
musculoskeletal complaints in cases. Meanwhile, with a requirement for only one consultation, we 
might expect to see more acute problems in controls. Differences observed might therefore also 
be accounted for by differences in acute and chronic pain prevalence. 
The RRC definition identified a group of people who consult regularly for multi-site 
musculoskeletal pain with prevalence ranging from 449 to 1,149 per 10,000 registered population 
depending on the code list used. Estimated figures for community CWP prevalence (1,077 per 
10,000 see Chapter Three) and expected annual consultation rate (in a cross-sectional study 72% 
of CWP patients were shown to consult for their pain, Macfarlane et al. 1999) suggest some of 
these RRCs, particularly using the RRC-all code list, might not have CWP. However, we are 
comparing five-year consultation prevalence with annual or point community prevalence, and 
previous research (Carnes et al. 2007) suggests that only a third of chronic multi-site pain patients 
would fit strict CWP criteria (Carnes et al. 2007). Therefore a RRC prevalence higher than 
expected based on community CWP prevalence does not mean that RRCs do not have long-term 
multi-site pain.
Differences in prevalence observed across the three groups of cases is undoubtedly explained by 
the increased numbers of codes used to identify patients. The Rohrbeck code list comprised 147 
codes, the clinician defined code list comprised 736, and all regional codes numbered 4,481. 
However, the increases in prevalence are not in proportion to the increase in numbers of codes. 
For example, comparing the RRC-all and RRC-clinician codes lists we might anticipate a more 
substantial increase in prevalence given an increase of 3,745 codes (RRC-all: 1,149/10,000 
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population compared to RRC-clinician: 916/10,000). This suggests that many of the additional 
codes added by the alternative code lists were not used for this type of patient. This might imply 
that clinicians have a reasonable picture of the type of coding that might be used for 
unrecognised CWP.  
b. Variation in prevalence with age 
Community studies show increasing CWP prevalence with increasing age and/or a peak in middle 
age with some studies suggesting a decline in older age groups (see section 3.4.5.d). The pattern 
of age distribution in the RRCs identified in this study is not entirely consistent with population 
patterns for CWP; however, RRCs do show an increasing prevalence with increasing age, which 
we would expect from some general population studies, and any inconsistencies between RRCs 
and community CWP may be due to systematic differences in this subgroup of unrecognised 
CWP consulters. The demographics of RRCs will be explored further in Chapter Nine.
c. Variation in prevalence with sex
Fifteen papers included in the systematic review (presented in Chapter Three) provided 
prevalence figures for CWP stratified by gender. CWP was more common in women in all 15 
papers, with the majority showing prevalence in women to be at least twice that in men. Male-to-
female ratios observed for RRCs in this study are comparable to those observed in the systematic 
review, ranging from 0.56 (RRC-Rohrbeck) to 0.66 (RRC-all). With respect to gender distribution, 
controls were substantially different from cases. The control group showed an overall equal 
number of men and women, but with higher prevalence in men at older ages.
The gender distribution of RRCs is also comparable to that found in the non-specific generalised 
musculoskeletal pain consulters (recognised CWP) investigated in the previous chapter (see 
Table 5.13), with the exception of FM consulters where coding prevalence was almost nine times 
more frequent in women. 
While the gender variation observed in this study appears to support the construct of CWP, we 
must take into account that women have been shown to be more likely than men to seek help for 
symptoms (Cornally and McCarthy 2011, Sayer and Britt 1996). Therefore, while the results of the 
study show more female RRCs, this may partially be due to gender differences in help-seeking 
behaviour.
Chapter 5: Code list development
153
d. Practice variation
While there were some outlying practices in terms of prevalence of RRCs, there was some 
consistency in the figures (see Figure 5.2). The consistency across practices supports the RRC 
criteria as a useful measure since it appears to show little variation with the different coding habits 
and diagnostic beliefs in use in the 12 practices included in the study.
In contrast, the prevalence of patients with a recorded non-specific generalised pain complaint 
(see Chapter Four, section 4.4.1) showed substantial variability between practices. Non-specific 
generalised pain consulters were identified based on one or more consultations coded with 
specific Read codes, while RRCs were identified using consultation patterns for multiple codes. 
The observation of variability where codes alone are used to identify patient groups versus less 
variation when consultation patterns are used supports the RRC criteria as a useful tool to identify 
patients, since the consultation pattern may smooth out differences in coding practices.
e. Comparison with five-year musculoskeletal coding prevalence
The age and gender distributions for the prevalence of any musculoskeletal consultation mirrored 
those seen in RRCs with a higher prevalence in women and increasing prevalence with age. 
However, only 19% of patients recorded with any musculoskeletal code over five years were 
identified as RRC-all patients, demonstrating that the RRC consultation pattern is successfully 
identifying a subset of musculoskeletal consulters who consult repeatedly with multi-region 
complaints.
5.5.2 Comorbidity
Research has consistently demonstrated overlap between FM/CWP and other conditions for which 
there is no clearly defined pathology such as chronic fatigue and irritable bowel syndrome (Aaron 
et al. 2000, Aggarwal et al. 2006). There has also been a documented association between FM/
CWP and psychiatric comorbidity (Benjamin et al. 2000). While greater psychological distress has 
been observed in FM patients than in CWP (White et al. 2002b), one in four CWP consulters has 
been shown to have a mental disorder (Macfarlane et al. 1999). FM/CWP patients have been 
shown to have worse self-reported general health (Bergman 2005, Rohrbeck et al. 2007) and 
CWP patients have also been shown to consult more frequently for both musculoskeletal and non-
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musculoskeletal complaints (Kadam et al. 2005). These findings might lead us to expect higher 
levels of comorbidity in CWP patients. 
In the original paper presenting the ‘consultation-based widespread pain’ criteria, Rohrbeck et al. 
used consultations for excessive earwax and cough as ‘indicators of a general propensity to 
consult about common problems’ (Rohrbeck et al. 2007, p.111). Consultations for these 
conditions were observed to be higher in consultation-based widespread pain cases than in 
controls, indicating a lower threshold for consultation. In this study we demonstrated that RRCs 
have higher non-musculoskeletal consultation rates and a higher percentage of people consulting 
in each Read code chapter than controls: findings that are consistent with CWP.
Cases identified using the Rohrbeck code list had the highest non-musculoskeletal consultation 
counts, followed by the clinician-defined code list, while the all-code list identified patients with the 
lowest consultation count. This suggests the original Rohrbeck code list identifies patients who 
might better fit strict CWP criteria. However, while using the inclusive all regional musculoskeletal 
codes list might result in less specificity, it identifies more patients, therefore potentially increasing 
its sensitivity. However, differences between the three case groups on number of comorbidities 
were small.
If we compare the percentage of cases/controls consulting in each Read code chapter, we see a 
similar relative pattern across the three case groups. For all chapters, the proportion of patients 
consulting is lower for controls than for cases. There is a substantially higher prevalence of 
consultations in Chapter S (injury and poisoning) in the RRC-all group. This reflects the higher 
proportion of Chapter S codes in the RRC-all code list and the consequent identification of more 
patients coded using Chapter S. The question arising from this observation is: Does this imply that 
the RRC-all patients are less likely to fit established criteria for CWP, as the RRC-all group might 
include more patients with acute musculoskeletal injury and its sequelae? A study by Buskila et al. 
(1997a) found that 22% of patients with acute neck soft-tissue injury were subsequently 
diagnosed with FM, compared to 2% of patients with leg fractures, suggesting that site-specific 
trauma might be involved in the aetiology of FM. We might therefore expect there to be more CWP 
following some types of injury; this is certainly consistent with osteopathic theory regarding distant 
biomechanical compensation for primary local dysfunction (Stone 1999, p.20–21). The 
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observation of a higher proportion of Chapter S coding for a group of cases does not generally 
indicate that they are less likely to fit criteria for CWP. 
5.5.3 Somatic symptoms
The introduction of the somatic symptom scale to the ACR-2010 criteria for FM (Wolfe et al. 2010) 
emphasised the importance of somatic symptoms in CWP/FM. An alternative set of diagnostic 
criteria for FM, developed using evidence-based and consensus methods by a German 
interdisciplinary committee, also includes a requirement for somatic symptoms (Häuser et al. 
2009a, 2010). Using the Somatic Symptom Checklist (SSC), a screening test of six items for 
somatization (McBeth et al. 2001b), one study has shown 53% of CWP patients to have one or 
more somatic symptoms (Aggarwal et al. 2006). Using the same checklist Gupta et al. (2007) 
demonstrated that 33% of patients with new CWP had one or more somatic symptoms.
In this study, the finding that there was a substantially lower number of somatic symptoms in 
control subjects compared to RRC cases suggests that RRC criteria are successfully identifying 
CWP patients. This observation is consistent with the findings of the original paper presenting the 
consultation-based widespread pain criteria (Rohrbeck et al. 2007). In terms of somatic symptom 
count there is little to differentiate between the three groups of cases. 
5.5.4 Frequent attenders
Previous research has shown that 20–30% of frequent attenders have medically unexplained 
symptoms (Smits et al. 2009, Reid et al. 2001b) or can be considered to be somatizers (Karlsson 
et al. 1997, Jyväsjärvi et al. 2001). Frequent attenders are also more likely to have musculoskeletal 
problems (Jyväsjärvi et al. 1998, Karlsson et al. 1994, Foster et al. 2006). Persistent CWP has 
been found to be associated with frequent attendance (McBeth et al. 2001b), help-seeking 
behaviour for health problems has been demonstrated to be a risk factor for CWP onset (Gupta et 
al. 2007), and CWP patients have been found to consult more frequently than patients with no 
pain, independent of their level of psychological distress (Kadam et al. 2005), suggesting that 
frequent attendance is a feature of CWP. Our study found that RRCs were more likely to be 
frequent attenders, and to have more musculoskeletal and non-musculoskeletal consultations than 
controls, which is consistent with the construct of CWP. 
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However, a case can be made for there being a disproportionately high percentage of frequent 
attenders in the RRC groups. Our study showed that up to 37% of frequent attenders (top 10%) 
were RRCs. If up to 30% of frequent attenders have medically unexplained symptoms (Smits et al. 
2009, Reid et al. 2001b), then, since those who exhibit recurrent regional consulting comprise a 
subgroup of CWP, which is, in turn, a subgroup of medically unexplained symptoms, we would 
perhaps expect fewer RRC frequent attenders than we found. However, variety in the definitions 
for frequent attendance and medically unexplained symptoms across published studies makes 
meaningful comparisons between them questionable, and after controlling for age and gender the 
odds of RRCs being frequent attenders reduces, suggesting that the age and gender profiles of 
RRCs influence frequent attender rate. We must also take into account that the RRC definition is 
based on recurrent consultations, making frequent attendance a self-fulfilling feature of RRC, 
although for this reason we removed musculoskeletal consultations from the definition of frequent 
attendance.
A third (31–35%) of RRCs are frequent attenders (top 10%). This might be higher than research 
predicts (Smits et al. 2009, Reid et al. 2001b), but the profile of frequent attenders identified in the 
CiPCA database is different from that of RRCs, with frequent attenders having an exaggerated 
version of the RRC profile. Where RRCs are older, more likely to be female, and have more 
consultations and more recorded somatic symptoms than controls, frequent attenders are even 
older, more likely to be female, and have higher numbers of consultations and recorded somatic 
symptoms than RRCs (mean 3.4 in frequent attenders versus 2.8-2.9 for RRCs). We can conclude, 
therefore, that the proportion of RRCs who are frequent attenders supports the argument that 
RRCs fit the construct for CWP. The number of RRCs who are also frequent attenders might be 
higher than that expected in CWP patients, but perhaps it is not unexpected in this subgroup of 
CWP. The RRC definition specifically identifies frequent attenders with musculoskeletal symptoms 
whom we consider to be unrecognised as having CWP. The implication is that since their 
condition is unrecognised they have an unmet need which drives repeated consultations. 
Moreover, the profile of RRCs is not the same as that of frequent attenders and only a third of 
RRCs are frequent attenders, suggesting that the definition is not simply identifying frequent 
attenders with musculoskeletal symptoms – a situation where we would expect the profile of RRCs 
to more closely match that of frequent attenders, and more RRCs to be frequent attenders. 
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5.5.5 Generalised pain
a. Non-specific generalised pain
Approximately 25% of RRCs were also recorded as consulting for non-specific generalised pain 
and this was similar between case definitions. 
The proportion of non-specific generalised consulters who were also identified as RRCs varied 
from 14% to 33% by case group definition. This suggests that the non-specific pain codes 
identified in the previous chapter show a reasonable degree of overlap with RRCs and therefore 
supports the use of non-specific generalised pain coding as a rough measure of recognised 
CWP.
If we add patients with recognised CWP, measured using non-specific generalised pain coding 
(identified in Chapter Four), to those with unrecognised CWP, measured using RRCs without non-
specific pain coding, we obtain prevalences ranging from 1,000 to 1,400 per 10,000 by case 
group definition. These figures are much higher than we would expect given community 
prevalence (1,077 per 10,000 population) figures for CWP (established in Chapter Three). This 
might mean that either high numbers of RRCs or high numbers of patients coded with generalised 
pain are not CWP patients based on strict ACR criteria. 
The overlap between recognised (non-specific pain coding) and unrecognised CWP (RRCs 
without a generalised pain code) will be explored in more detail in the next chapter.
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b. Differential diagnoses
The percentage of RCCs recorded with differential diagnoses for CWP is low (8–9%), suggesting 
that the RRC definition is successfully identifying patients without alternative explanations for their 
symptoms. There is evidence that FM/CWP prevalence is higher in patients with some differential 
diagnoses (Ostuni et al. 2002, Wolfe et al. 2009), suggesting that a higher percentage of cases 
than controls with recorded alternative diagnoses also supports the CWP construct.
It might be argued that patients recorded with alternative explanations for their widespread pain 
symptoms should be specifically excluded in further iterations of the RRC definition. However, 
CWP/FM can coexist with its differentials (Wolfe et al. 2011b, Wolfe and Michaud 2004, Middleton 
et al. 1994, Iannuccelli et al. 2012, Aloush et al. 2007, Wolfe and Cathey 1983, Kato et al. 2006, 
Bazzichi et al. 2007). In fact thyroid autoimmunity has been postulated as a predisposition for 
fibromyalgia (Bazzichi et al. 2012), and it would therefore seem unwise to exclude such diagnoses 
from the RRC definition since a diagnosis with one of FM/CWP’s differentials does not exclude 
concomitant FM/CWP. 
None of these validations (prevalence estimates, age and gender distribution, recorded somatic 
symptoms, comorbidity, frequent attendance, and overlap with non-specific generalised pain and 
differential diagnosis coding) proves that RRCs would fulfil established CWP criteria, but taken as 
a whole they provide persuasive evidence that this group of patients appear to fit the 
‘characteristics’ of someone with CWP.
5.5.6 Strengths and limitations
a. Study population
The existing Rohrbeck-2007 RRC criteria require a minimum of three years consultation data for 
case identification. In order to define a case, consultation patterns during a five-year window are 
examined. It could be argued that the five-year window for an individual should start with his or 
her first regional musculoskeletal consultation; however, for the purposes of this development 
study, a set timeframe from 2005 to 2009 was chosen for convenience. 
It is possible that a patient could be wrongly identified as not being a RRC due to incomplete 
medical records. For example, a patient might consult for only one musculoskeletal complaint 
before moving house and re-registering with another, non-CiPCA, practice. It was decided 
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therefore to limit the study population to those fully registered with the CiPCA practices between 
2005 and 2009. To ensure comparability of cases and controls, the control group was also 
selected from the fully registered population. Members of a more fluid and mobile population are 
likely to be systematically different from those remaining resident in a fixed place for at least five 
years. Limiting the study population to patients fully registered during a five-year period is 
therefore likely to introduce bias and reduce the generalisabilty of the study results. 
Generalisability may also be reduced by the geographical limitation of the CiPCA study to one 
area of the UK (North Staffordshire). The CiPCA population has already been demonstrated to be 
older than the UK general population (Table 4.1) and it is likely that other features may also be 
systematically different. However, differences in age and gender of the study population were 
accounted for by standardising prevalence figures to the UK general population (Table 5.4). The 
control group were also younger than the case groups and therefore subgroup analyses were 
done for case and controls aged 45 and over, and, when assessing differences in somatic 
symptom count and frequent attender status, age and gender were controlled for (Tables 5.9 and 
5.12). European geographical variation in CWP prevalence was demonstrated to be limited in the 
systematic review presented in Chapter Three, so limiting the study geographically may only have 
a small influence on generalisability. In addition the CiPCA database has been demonstrated to 
give similar musculoskeletal consultation prevalence figures to a larger national general practice 
database (Jordan et al. 2007).
b. Ambiguous codes
Only regional musculoskeletal Read codes were included on code lists B (all regional 
musculoskeletal codes) and C (clinician defined regional musculoskeletal codes). Ambiguous 
codes with the potential to represent either regional or generalised problems (for example, codes 
simply labeled ‘arthralgia’ or ‘joint pain’ with no region specified) were excluded from the RRC-all 
and RRC-clinician code lists. However, the original Rohrbeck short code list (Rohrbeck et al. 
2007) included 16 ambiguous or generalised codes (see appendix A5.1, Table A5.2 for 
ambiguous codes). Despite this, the RRC-Rohrbeck code lists did not identify any patients who 
were not identified by the other two RRC definitions. This research aimed to identify unrecognised 
CWP consulters. Ambiguous codes were therefore excluded to ensure that RRC criteria identified 
patients on the basis of their consultation patterns for regional (not generalised) complaints only. 
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The results of a sensitivity analysis (see appendix A5.6) investigating the impact of including 
ambiguous codes revealed only a very limited increase in RRC-all and RRC-clinician prevalence 
when ambiguous codes were included, suggesting that the ambiguous codes are used 
infrequently and their exclusion had little effect. 
c. Clinician defined codes
As previous discussed (section 4.5.6.d) the clinician-defined codes were arrived at through 
discussion with a limited and select group of clinicians. To account for the diversity between 
clinicians the decision was made to exclude only codes agreed by all panel members to be 
unlikely to represent CWP. The alternative would have been to include only those codes on which 
there was unanimity, which would have resulted in a short list of codes excluding many likely to be 
in use. The clinician defined code list is therefore a large and inclusive list that will accommodate 
heterogeneous coding practices and diagnostic beliefs.  
d. Control group
Membership of the control group was defined by patients consulting for pain in only one of three 
body regions in a five-year period. It does not therefore exclude individuals experiencing pain in 
more than one area. However, since the hypothesis being tested is that RRCs would be likely to fit 
established criteria for CWP, the control group was selected in order to compare patients who 
consult for pain in one body region versus those who consult for pain in multiple body regions.
e. Prevalence figures
While possibly missing short term CWP cases, the RRC definition arguably identifies a group of 
individuals with greater clinical need, since the need for consultations in at least three of the five 
years required for RRC status will identify those with truly chronic musculoskeletal pain who are 
repeatedly consulting for help with their pain symptoms.
f. Comorbidity
This study used non-musculoskeletal consultation count and consultation by Read-code chapter 
as a measure of comorbidity rather than specific diseases. The use of coding by chapter provides 
a useful proxy for establishing the extent of illness by diagnostic classification and the use of 
consultation count provides an indication of illness burden. However, both these measures are 
strongly influenced by illness and consulting behaviour (Sensky et al. 1996), and clinicians’ 
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diagnostic and coding practices (Fink et al. 1999), and are therefore not absolute measures of 
comorbidity.
g. Somatic symptoms
The list of symptoms (itemised in the ACR-2010 criteria, Wolfe et al. 2010) that were used to 
identify Read codes for the study is not an exhaustive list of all somatic symptoms. The measure 
shares the problems associated with using any type of morbidity coding as a proxy for community 
burden. It relies on patients’ consulting practices and clinicians’ diagnostic beliefs and coding 
practices. The somatic symptom count used in this study is therefore only used as an indicator of 
the relative burden of somatic symptoms in cases versus that in controls. 
h. Frequent attenders
Previous studies have used a diversity of approaches to defining frequent attenders (Gill et al. 
1999). The majority of studies have defined frequent attenders using either a minimum number of 
consultations in a defined timeframe (e.g. 9–14 per year), or a more relative approach (e.g. top 
10–25% of attenders) (Vedsted et al. 2005, Gill et al. 1999). Given conflicting recommendations 
for frequent attender definition, this study defined frequent attenders using two approaches (the 
top 5% and 10% of consulters), which showed similar conclusions. 
i. Generalised pain
Care should be taken with the measure for non-specific generalised pain used in this study. It 
does not represent CWP known to be recognised by their GP, but represents patients coded with 
pain conditions that could fit CWP criteria or could fit alternative differential diagnoses for CWP/
FM. Consequently, it is likely to include patients recognised by their GP as having CWP, in 
addition to a number of false positives. It is therefore likely to overestimate recognised CWP in 
primary care. 
The list of possible differential diagnoses used in this study is not exhaustive. Morbidity coding 
relies on consulting behaviour, and on diagnostic and coding practices. The measure for 
differential diagnoses should be used as a relative measure to compare the proportion of patients 
coded with selected differential diagnoses between cases and controls, rather than an absolute 
measure of disease prevalence.
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5.6 Conclusions
The three definitions for RRC have identified groups of people who have similar characteristics 
and who appear to fit many of the recognised features of CWP, including identifying patients 
apparently unrecognised by GPs as having a generalised pain condition. However, consultation 
prevalence of RRC is perhaps higher than that expected based on published data, which may 
suggest not all these patients fulfil the stricter definitions of CWP. 
There is little difference, other than prevalence, in the characteristics of the patients returned by 
the three code lists. This suggests that RRC-all, which uses a wider coding list, may be more 
sensitive without necessarily losing specificity. However, the RRC-all group identifies more 
patients with Chapter S (injury) codes. This difference is likely accounted for by more Chapter S 
codes in the RRC-all code list, but it might also be explained by more single limb injuries in the 
RRC-all group. The next chapter will therefore investigate the distribution of single limb versus 
dual upper and lower limb problems in each group of RRCs.
The RRC definition appears to pick up individuals that GPs are not identifying as having a 
generalised pain condition. The next chapter also investigates the difference between recognised 
and unrecognised CWP by exploring the overlap between being a RRC and recorded non-
specific pain.
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Chapter 6
Distribution of painful body regions and 
relationship to recognised generalised pain in 
primary care of RRCs
6.1 Aims and objectives
The overall aim of this chapter is to further investigate recurrent regional consulters (RRCs) 
identified using the three codes lists to: 1) provide further evidence for which code list(s) should 
be used in an updated version of the Rorhbeck-2007 RRC criteria; 2) start developing a severity 
scale for RRC; and 3) to investigate the intersection of recognised CWP in primary care (those 
with non-specific generalised pain labels) with unrecognised CWP to test the RRC definition as a 
means of identifying unrecognised CWP consulters.
The previous chapter showed that the patient groups returned by the three RRC definitions (RRC-
all: identified using all regional musculoskeletal codes, RRC-clinician: identified using clinician 
defined regional musculoskeletal codes, RRC-Rohrbeck: defined using the original Rohrbeck 
short code list) appeared similar with similar overall levels of somatic symptoms, frequent 
attendance, non-musculoskeletal consultation rates, and comorbidity. Partly this reflects the fact 
that the RRC-Rohrbeck and RRC-clinician groups are both subgroups of the much larger RRC-all 
group of patients. The two things differentiating the three groups of RRCs were the number of 
patients identified (more codes identified more patients) and the slightly increased prevalence of 
Chapter S (injury and poisoning) coding in the RRC-all group. One explanation for the higher level 
of Chapter S coding is that there are more inury codes on the RRC-all code list. An excess of 
injury coding suggests the RRC-all group includes more patients with acute musculoskeletal injury 
and its sequelae. Since RRCs are defined as having a documented upper- or lower-limb 
complaint, if there is more acute injury in the RRC-all group we might expect there to be more 
patients with only one limb affected rather than both arm and leg complaints. 
Objective 1: To determine if the RRC-all list identified a smaller proportion of people consulting for 
problems in all three (axial and upper- and lower-limb) body regions.
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Epidemiological evidence suggests that FM and CWP exist on a continuum of idiopathic pain 
syndromes (Forseth and Gran 1993, Wolfe 1997, Macfarlane 1999) rather than as discrete 
disease entities. If this is the case we would expect a grading of severity from patients recorded 
as consulting for a single region complaint (our ‘control’ group), through two-region RRCs 
(recorded with axial and either upper- or lower-limb complaints), to three-region RRCs (recorded 
with axial and both upper- and lower-limb complaints). Further, we saw in the previous chapter 
that RRC prevalence is higher than estimates of CWP community prevalence. If CWP exists on a 
spectrum, the RRC definition has the potential to identify both patients fitting established CWP 
criteria (requiring all three regions) and patients who may not necessarily fit ACR-90 criteria, but 
who experience a level of ‘fibromyalgianess’ or polysymptomatic distress (Wolfe 2009c). 
Objective 2: To investigate whether a grading of severity exists by comparing the rate of somatic 
symptoms, consultation and frequent attendance in two- and three-region RRCs.
In the previous chapter we showed that a third of patients recorded with non-specific generalised 
pain codes were also RRCs (see Figure 6.1). If we consider patients recorded with non-specific 
generalised pain codes as having a recognised widespread pain condition in primary care, then 
investigating the overlap between RRCs and those recorded with non-specific pain complaints 
offers insights into the differences between recognised and unrecognised CWP in primary care. 
This allows assessment of whether unrecognised CWP consulters have a less ‘severe’ condition or 
whether they are a group with similar characteristics to CWP patients fitting established criteria 
who have been missed by GPs.
Objective 3: To determine how similar recognised (patients with non-specific pain coded 
consultation) and unrecognised (RRCs without non-specific pain coded consultation) CWP 
consulters are on characteristics of CWP.
Objective three was addressed by comparing the age, gender, number of recorded body regions 
(two or three), number of recorded somatic symptoms, and consultation and frequent attender 
rates between those only fulfilling the RRC definition (‘unrecognised’ CWP, area C in Figure 6.1), 
those who had a non-specific pain code but did not fulfill the RRC definition (area E in Figure 6.1), 
and those who fulfilled the RRC definition and had a non-specific pain code in their primary care 
record (area D in Figure 6.1).
Chapter 6: Distribution of painful body regions and relationship to recognised generalised pain in primary care of RRCs
165
Figure 6.1. Venn diagram to show the overlap between non-specific generalised pain code recording 
and RRC-all.
A. RRC-all (blue circle, A = C + D)
B. Non-specific pain (red square, B = D + E)
C. RRC-all patients not recorded with non-specific pain codes (blue circle not overlapping with red circle, C = A - D)
D. RRC-all and non-specific pain (intersection of red and blue circles, D = A ∩ B)
E. Non-specific pain not RRC-all (red circle not overlapping with blue circle, E = B - D)
Objective 4: The final objective was to refine the estimate of CWP in primary care using both the 
RRC criteria and non-specific generalised pain coding to investigate how much consultation-
defined measures might over- or under-estimate CWP. 
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6.2 Methods
As described in section 5.3.1, RRCs were identified from all patients fully registered (no age 
restrictions) with the CiPCA practices between 2005 and 2009 using the Rohrbeck-2007 criteria 
and the following three lists of regional musculoskeletal Read codes:
1. RRC-all: all regional musculoskeletal Read codes (documented in appendix A5.2).
2. RRC-clinician: excluding from the list of all regional musculoskeletal Read codes those 
felt by clinicians to be unlikely to be used for CWP patients (documented in appendix 
A5.2).
3. RRC-Rohrbeck: Rohrbeck’s (2007) original short code list (documented in appendix 
A5.1).
6.2.1 Number of body regions
Objective 1: To determine if the RRC-all list identified a smaller proportion of people consulting for 
problems in all three (axial and upper- and lower-limb) body regions.
The percentage of patients recorded with complaints in only two of three body regions (recorded 
with axial plus upper- or lower-limb codes) rather than problems in all three body regions 
(recorded with axial plus upper- and lower-limb codes) was determined for each of the three 
groups of RRCs (RRC-all, RRC-clinician, RRC-Rohrbeck). The RRC-all group includes all people 
returned by the RRC-Rohrbeck criteria. In order to assess if the extra people returned by the RRC-
all criteria differed from those identified using the RRC-Rohrbeck criteria, those identified by the 
RRC-Rohrbeck criteria were excluded from the RRC-all group for this analysis. Differences in the 
distribution of recorded body regions between the RRC-Rohrbeck group and the extra patients 
returned by the RRC-all criteria were tested using the chi-squared test.
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6.2.2 Comparison of two- and three-region RRCs
Objective 2: To investigate whether a grading of severity exists by comparing the rate of somatic 
symptoms, consultation and frequent attendance in two- and three-region RRCs.
For this objective we present methods and results solely for the RRC-all group. Similar analyses 
were performed for the other two RRC groups with similar results.
RRC-all patients were divided into two groups:
• 2-region RRC-all: RRC-all patients recorded with codes during the five years for two 
body regions (axial + upper or lower limb).
• 3-region RRC-all: RRC-all patients recorded with codes during the five years for three 
body regions (axial + upper and lower limb).
Controls were those identified previously (with a single region musculoskeletal problem – axial, 
upper limb or lower limb – during the five-year period (2005–2009)), see section 5.3.1. Controls 
were compared descriptively with the two- and three-region RRC-all groups on mean number of 
somatic symptoms, percentage who were non-musculoskeletal frequent attenders, and mean 
number of musculoskeletal and non-musculoskeletal consultations. 
Somatic symptoms were calculated as described previously using 340 Read codes 
corresponding to 40 physical symptoms (see section 5.3.4, Read codes presented in appendix 
A5.3, Table A5.4). For each patient the number of somatic symptoms consulted for in the period 
2005 to 2009 was calculated. Non-musculoskeletal frequent attenders were defined, as 
previously, as the top 10% of attenders in each practice for non-musculoskeletal problems. Non-
musculoskeletal problems were defined as consultations coded with any Read code except those 
identified by Jordan et al. (2010) as being musculoskeletal in nature. The percentage who were 
non-musculoskeletal frequent attenders, and the mean number of musculoskeletal and non-
musculoskeletal consultations between 2005 and 2009 was calculated for each group of patients.
Differences between two- and three-region RRCs were assessed using chi-squared tests to 
investigate differences in gender and frequent attendance, and with t-tests to investigate 
differences in mean age, somatic symptom count, and musculoskeletal and non-musculoskeletal 
consultation counts.
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6.2.3 Non-specific generalised pain
Objective 3: To determine how similar recognised (with non-specific pain coded consultation) and 
unrecognised (RRCs without non-specific pain coded consultation) CWP consulters are on 
characteristics of CWP.
Non-specific pain consulters were identified using 108 non-specific pain (including osteoarthritis) 
codes with the potential to represent CWP detailed in Chapter Four (section 4.3.2, codes listed in 
appendix A4.1, Table A4.5). Patients were identified from those fully registered with the CiPCA 
practices beween 2005 and 2009 (these are the same non-specific pain consulters as those 
identified in Chapters Four and Five).
Age and gender were compared across the RRC groups, controls and non-specific pain 
consulters. For the rest of this objective we present methods and results solely for the RRC-all 
group. Similar analyses were performed for the other two RRC groups, with similar results.
a. Overlap between RRC and non-specific pain coding
To explore the overlap between recognised CWP consulters and unrecognised CWP consulters, 
the intersection between patients recorded with non-specific pain codes (recognised CWP) and 
those identified as RRC-all (unrecognised CWP) was investigated. 
The two main groups of patients (A. RRC-all and B. non-specific pain consulters) were compared 
with the following three subgroups (see Figure 6.1):
1. RRC-all patients excluding any recorded with non-specific pain codes (C. unrecognised 
RRCs).
2. Patients identified as both RRC-all and recorded with a non-specific pain code (D. recognised 
RRCs).
3. Patients recorded with non-specific pain codes excluding those also identified as RRC-all (E).
The five patient groups and subgroups (illustrated in Figure 6.1) were compared descriptively on 
mean age, gender distribution, mean number of somatic symptoms, proportion who were non-
musculoskeletal frequent attenders, and mean number of musculoskeletal and non-
musculoskeletal consultations. 
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Somatic symptom count, non-musculoskeletal frequent attendance, and consultation rates 
(musculoskeletal and non-musculoskeletal) were evaluated using the same measures as detailed 
in section 6.3.2. 
To test for differences between the three subgroups (C: RRC-all not NS; D: RRC-all also NS; and 
E: NS not RRC-all) unadjusted and adjusted odds ratios for age group, gender, frequent attender 
status (top 10% of attenders for non-musculoskeletal complaints), recording of one or more 
somatic symptoms and recording of three body regions (axial, upper limb and lower limb) were 
calculated using multinomial logistic regression with NS/RRC subgroup as the dependent variable 
using SPSS (IBM 2011). Group E (NS not RRC-all) was used as the reference category. Age 
group was defined using the following age bands 14 and under; 15–24; 25–44; 45–64; 65–74; and 
75+. Working age adults (25–44) constituted the reference category. 
b. Non-specific generalised pain and two- and three-region RRCs
The RRCs subgroups (C: RRC-all not NS; and D: RRC-all and NS) will have been recorded with 
either two or three body regions, while subgroup E (NS not RRC-all, reference category) will have 
been recorded with between zero to three body regions. Therefore, the percentages of two- and 
three-region RRCs in groups C (RRC-all not NS, unrecognised RRCs) and D (RRC-all and NS, 
recognised RRCs) were calculated and compared further. A chi-squared test was used to 
investigate the association between additional recording of non-specific pain codes and number 
of body regions recorded in RRCs.
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6.2.4. CWP coding prevalence
Objective 4: To refine the estimate of CWP in primary care using both the RRC criteria and non-
specific generalised pain coding to investigate how much consultation-defined measures might 
over- or under-estimate CWP.
A comparison was made between the community prevalence of CWP, the expected consultation 
prevalence of CWP, and the combined coding prevalence of RRCs and non-specific pain 
consulters. The meta-analysis, detailed in Chapter Three, provided the pooled community 
prevalence figure (1,077/10,000). Expected consulting prevalence for CWP was calculated using 
this estimated community prevalence and the CWP consultation rate observed in a study 
conducted by Macfarlane et al. (1999). The results of a postal survey of the general population 
(patients registered with one general practice in a Manchester suburb) aged 18 to 65 (n=1,953) 
suggested that approximately 72% of CWP patients (n=181) reporting consulting for their pain at 
any time. This gives an expected consultation prevalence of 775 per 10,000.
If RRCs offer a measure of unrecognised CWP and non-specific generalised pain coding offers a 
measure of recognised CWP, then a combination of the two offers a measure of overall CWP 
consulting. We identified all those fulfilling RRC criteria and/or recorded with non-specific pain 
codes (non-specific generalised pain including osteoarthritis, see section 4..4.1) over the five-year 
period (2005–2009) to determine a combined measure of CWP consulting (number of patients 
recorded with a non-specific generalised pain code and/or fulfiling the RRC criteria during the five 
years). Prevalence was calculated per 10,000 population using the number of patients fully 
registered with the CiPCA practices between 2005 and 2009 as the denominator. This figure was 
compared with the expected point consulting prevalence of CWP of 775 per 10,000.
To test the impact of excluding differential diagnoses, coding prevalence was further calculated 
excluding those patients also recorded with one or more specified alternative diagnoses. Patients 
recorded with alternative diagnoses were identified using the methods outlined in Chapter Five 
(section 5.3.5.b).
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6.3 Results
6.3.1 Number of body regions
Objective 1: To determine if the RRC-all list identified a smaller proportion of people consulting for 
problems in all three (axial and upper- and lower-limb) body regions.
The RRC-all group had a higher proportion of patients recorded with problems in only two regions 
(axial plus upper- or lower-limb, 54%) than the RRC-Rohrbeck group (45%) (Table 6.1).
Table 6.1 Distribution of body regions affected in each group of cases. Data are numbers (%).
2-region 3-region
Axial + one of upper or lower limb 
coding
Axial + upper and lower limb 
coding 
Total
RRC-all 4,991 (54%) 4,181 (46%) 9,172
RRC-clinician 3,800 (52%) 3,507 (48%) 7,307
RRC-Rohrbeck 1,577 (45%) 1,946 (55%) 3,523
Examining the additional cases identified by the RRC-all definition compared to the original RRC-
Rohrbeck group (Table 6.2) there were a significantly higher percentage of two-region consulters 
in the RRC-all patients not identified by the RRC-Rohrbeck definition compared to those identified 
by the RRC-Rohrbeck criteria (!2 (1) = 214.86, p<0.001, OR = 1.89, 95% CI 1.73, 2.05).
Table 6.2 Distribution of body regions affected in RRC-Rohrbeck compared to the RRC-all group 
excluding those identified using the RRC-Rohrbeck definition. Data are numbers (%).
2-region 3-region
Axial + one of upper or lower 
limb coding
Axial + upper and lower 
limb coding 
Total
RRC-Rohrbeck 1,577 (45%) 1,946 (55%) 3,523
RRC-all not RRC-Rohrbeck 3,414 (60%) 2,235 (40%) 5,649
Chapter 6: Distribution of painful body regions and relationship to recognised generalised pain in primary care of RRCs
172
6.3.2 Comparison of two- and three-region RRCs
Objective 2: To investigate whether a grading of severity exists by comparing the rate of somatic 
symptoms, consultation and frequent attendance in two- and three-region RRCs.
There was an increase in age, number of somatic symptoms, consultation count, and percentage 
who were frequent attenders from controls, through two-region RRCs to three-region RRCs (Table 
6.3). The proportion of women was similar for both groups of RRCs (!2 (1) = 0.54, p=0.46) and 
higher than that observed in the control group. A similar pattern was observed in the RRC-
clinician and RRC-Rohrbeck groups (results presented in appendix A6.1, Table A6.1).
The percentage who were frequent attenders was significantly higher in the three-region 
compared to the two-region RRC group (35% vs 28%; !2 (1) = 56.11, p<0.001). There were 
significant differences in mean age (57 vs 59; t (9170) = -6.00, p<0.001), somatic symptom count 
(2.61 vs 2.92; t (9170) = -6.82, p<0.001), musculoskeletal (9 vs 11; t (9170) = -17.53, p<0.001) 
and non-musculoskeletal (37 vs 42; t (9170) = -9.87, p<0.001) consultation counts between two- 
and three-region RRCs.
Table 6.3 Comparison of 2- and 3-region RRC-all patients and controls on age, gender, recorded 
somatic symptoms, MS and non-MS consultation count and percentage who are in the top 10% of 
attenders (non-MS consultations only). 
Patient group Mean 
age 
(sd)
% 
female
Mean 
somatic 
symptom 
count (sd)
Mean non-MS 
consultation 
count (sd)
Mean MS 
consultation 
count (sd)
% FAs Total
3-region RRC-all 59 (16) 60% 2.92 (2.20) 42 (27) 11 (7) 35% 4,181
2-region RRC-all 57 (18) 61% 2.61 (2.05) 37 (24) 9 (6) 28% 4,991
Control 46 (21) 50% 1.22 (1.35) 20 (17) 2 (2) 7% 20,499
MS: musculoskeletal
FA: Top 10% non-musculoskeletal frequent attender
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6.3.3 Non-specific generalised pain
Objective 3: To determine how similar recognised (with non-specific pain coded consultation) and 
unrecognised (RRCs without non-specific pain coded consultation) CWP consulters are on 
characteristics of CWP.
a. Demographics of recognised and unrecognised CWP coding
The age and gender distribution for the three RRC groups, non-specific generalised pain 
consulters, and controls are shown in Table 6.4. All three groups of RRCs showed a similar age 
and gender distribution, with more women and more affected in the 45–64 year age group. Non-
specific pain coding was also higher in women and increased with age for those recorded with 
generalised osteoarthritis and all generalised pain codes including osteoarthritis; however for the 
FM and all generalised pain excluding osteoarthritis groups, there was a peak in the 45–64 year 
age groups. In contrast to RRCs and non-specific pain consulters, the number of men and women 
in the control group was almost equal and there was a peak in the 25–44 year age group.
Table 6.4 Age and sex distribution of RRCs and controls, and non-specific pain consulters (2005–2009, 
as defined in Chapter Four).
Number (%)
RRCs Control Non-specific generalised pain consulters 
(as defined in Chapter 4)
Variable RRC-all RRC-clinician RRC-
Rohrbeck
FM Generalised 
OA
All 
generalised 
pain (exc. 
OA)
All generalised 
pain
Age 
group
<14 39 (0.4) 21 (0.3) 5 (0.1) 1,346 (6.6) 1 (0.3) 0 (0.0) 125 (2.5) 125 (1.9)
15–24 304 (3.3) 149 (2.0) 55 (1.6) 2,467 (12.0) 6 (2.1) 0 (0.0) 261 (5.1) 261 (4.0)
25–44 1,639 (17.9) 1,157 (15.8) 454 (12.9) 5,709 (27.9) 81 (27.9) 27 (1.5) 1,070 (21.0) 1,090 (16.9)
45–64 3,652 (39.8) 3,005 (41.1) 1,452 (41.2) 6,564 (32.0) 168 (57.9) 597 (34.0) 2,166 (42.6) 2,635 (40.8)
65–74 1,793 (19.5) 1,537 (21.0) 775 (22.0) 2,411 (11.8) 27 (9.3) 566 (32.2) 882 (17.3) 1,315 (20.3)
>75 1,745 (19.0) 1,438 (19.7) 782 (22.2) 2,002 (9.8) 7 (2.4) 566 (32.2) 585 (11.5) 1,040 (16.1)
Total 9,172 7,307 3,523 20,499 290 1,756 5,089 6,466
Gender
Female 5,522 (60) 4,460 (61) 2,262 (64) 10,215 (50) 255 (88) 1,255 (72) 3,329 (65) 4,299 (67)
Male 3,650 (40) 2,847 (39) 1,261 (36) 10,284 (50) 35 (12) 501 (28) 1,760 (35) 2,167 (33)
Male: 
female 
ratio
0.66 0.64 0.56 1.01 0.14 0.40 0.53 0.50
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b. Overlap between RRC and non-specific pain coding
As shown in Chapter Five, RRC-all patients accounted for 33% of all patients recorded with a non-
specific generalised pain code during the same time period, while non-specific generalised pain 
consulters represented 23% of RRC-all patients. A comparison of the two index patient groups (A. 
RRC-all and B. non-specific generalised pain consulters) with the three subgroups representing 
their overlap (C. RRC-all not NS, D. RRC-all and NS, E. NS not RRC-all) is presented in Table 6.5. 
Similar results were found in the overlap between non-specific pain consulters and the remaining 
two RRC groups (RRC-clinician and RRC-Rohrbeck), these are presented in appendix A6.2 
(Tables A6.2 and A6.3).
Table 6.5 Comparison of RRC-all and patients recorded with non-specific pain.
Somatic 
symptom count
Consultation count
Non-MS MS
Patient group Mean 
age 
(sd)
% 
female
% 
FAs 
Mean 
(sd)
Median
(IQR)
Mean 
(sd)
Median 
(IQR)
Mean 
(sd)
Median 
(IQR)
Total
 A. RRC-all 58 (17) 60% 31% 2.8 (2.1) 2 (1, 4) 39 (26) 35 (21, 51) 10 (6) 8 (6, 12) 9,172
B. NS 60 (18) 67% 27% 2.4 (2.1) 2 (1, 3) 37 (25) 32 (19, 48) 8 (7) 6 (3, 11) 6,466
C. RRC-all not NS 57 (17) 57% 28% 2.5 (2.0) 2 (1, 4) 37 (25) 32 (19, 49) 9 (5) 7 (5, 11) 7,066
D. RRC-all also NS 63 (15) 71% 43% 3.5 (2.4) 3 (2, 5) 47 (28) 42 (29, 60) 14 (8) 12 (9, 17) 2,106
E. NS not RRC-all 58 (19) 64% 19% 1.9 (1.8) 2 (1, 3) 31 (21) 28 (16, 42) 6 (5) 4 (2, 7) 4,360
sd: standard deviation
IQR: Interquartile range
NS: non-specific pain consulter (including OA)
MS: musculoskeletal
FA: Top 10% non-musculoskeletal frequent attender
Recognised versus unrecognised CWP consulters
Comparing unrecognised CWP consulters (C. RRC-all not NS) with recognised CWP consulters 
(B. patients recorded with non-specific generalised pain codes), we see that unrecognised CWP 
consulters (C) were younger and more likely to be male, but comprise a similar percentage who 
were frequent attenders, and have similar numbers of somatic symptoms, musculoskeletal 
consultation counts and rates of non-musculoskeletal consultation.
Recognised RRCs versus unrecognised RRCs
Comparing unrecognised RRCs (C. RRC-all patients not recorded with non-specific pain codes) 
with recognised RRCs (D. RRC-all patients recorded with non-specific pain codes), unrecognised 
RRCs (C) are younger, more likely to be male, less likely to be frequent attenders, and have fewer 
recorded somatic symptoms, musculoskeletal and non-musculoskeletal consultation counts.
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RRCs versus recognised CWP consulters who are not RRCs
Results of a multinomial logistic regression analysis comparing group C (RRC-all not NS) and D 
(RRC-all and NS) with group E (NS not RRC-all) as the reference category are shown in Table 6.6.
Recognised (D. RRC and NS) and unrecognised (C. RRC not NS) RRCs were more likely to be 
frequent attenders, to have at least one recorded somatic symptom and to be recorded with 
codes for all three body regions than recognised CWP consulters not identified as RRCs (E. NS 
not RRC). Recognised RRCs (D. NS and RRC) were more likely to be female (OR = 1.20, 95% CI 
1.06, 1.35) and older than recognised CWP consulters who were not RRCs (E. NS not RRC), while 
unrecognised RRCs (C. RRC not NS) were more likely to be male (OR = 0.70, 95% CI 0.64, 0.76) 
and of working age.
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c. Non-specific generalised pain and two- and three-region RRCs
The distribution of two- and three-region RRCs is shown in Table 6.7. Of the 33% of RRC-all 
patients (n=2,106) also recorded with non-specific pain codes (D. RRC-all and NS, recognised 
widespread pain) 49% consulted for only two of the three body regions. While for RRCs not 
recorded with non-specific pain codes (C. RRC-all not NS, unrecognised widespread pain, 
n=7,066) a slightly higher percentage (56%) were recorded as consulting for complaints in only 
two body regions. In RRCs there was a small but significant association between additional non-
specific pain coding and whether RRCs were recorded with two or three body regions (!2 (1) = 
35.18, p<0.001, OR = 1.3, 95% CI 1.2, 1.5).
Table 6.7 Number (%) of 2- and 3-region RRCs in groups C (RRC-all not NS) and D (RRC-all also NS).
RRC-all-2 RRC-all-3
Patient group (identified from fully 
registered patients in CiPCA 
population 2005-2009)
Axial + one of upper 
or lower limb coding
Axial + upper and 
lower limb coding 
Total
C. RRC-all not NS 3,964 (56%) 3,102 (44%) 7,066
D. RRC-all also NS 1,027 (49%) 1,079 (51%) 2,106
NS: non-specific pain consulter (including OA)
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6.3.4 CWP coding prevalence
Objective 4: To refine the estimate of CWP in primary care using both the RRC criteria and non-
specific generalised pain coding to investigate how much consultation-defined measures might 
over- or under-estimate CWP.
Table 6.8 displays recorded consultation, community and expected consultation prevalence 
figures for CWP. 
The consultation prevalence figures for RRC-all (1,149 per 10,000 population) and RRC-clinician 
(916/10,000) derived in Chapter Five are similar to that for estimated community prevalence 
(1,077 per 10,000 population). RRC-all and RRC-clinician prevalence estimates are higher than 
expected consulting prevalence (775/10,000). RRC-Rohrbeck prevalence (442/10,000) is much 
lower than the community (1,077 per 10,000 population) or expected consulting prevalence 
(775/10,000).
Combining RRCs (unrecognised CWP) with non-specific pain consulters (recognised CWP) we 
see prevalence ranging from 1,019 to 1,432 per 10,000 population, depending on the code list 
used to define RRCs; this is a narrower spread than figures based on RRCs alone. Prevalence of 
RRC-all or non-specific pain (1,432/10,000) is higher than community prevalence (1,077/10,000), 
while the related estimates based on the other two RRC definitions (RRC-Rohrbeck and RRC-
clinician) are similar to the community CWP prevalence.
Removing differential diagnoses gives prevalence figures ranging from 921 to 1,318 per 10,000 of 
the population depending on the code list used to determine RRC status. These figures are still 
higher than the expected CWP consultation rate (775 per 10,000 population) but are similar to 
community prevalence (1,077/10,000).
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Table 6.8 Five-year CWP coding, and annual community and consulting prevalence figures (per 10,000 
population).
Patient group n Prevalence per 10,000 population (95% CI)
Recorded 
prevalence
RRC RRC-all 9,172 1,149 (1,127, 1,171)
RRC-clinician 7,307 916 (896, 936)
RRC-Rohrbeck 3,523 442 (428, 456)
RRCs + NS 
consulters
RRC-all + NS pain 11,426 1,432 (1,408, 1,456)
RRC-clinician + NS pain 10,167 1,274 (1,251, 1,297)
RRC-Rohrbeck + NS pain 8,131 1,019 (998, 1,040)
RRCs + NS 
consulters and 
excluding 
alternative 
diagnoses
RRC-all + NS pain excluding patients with 
DDx
10,520 1,318 (1,295, 1,342)
RRC-clinician + NS pain excluding patients 
with DDx
9,311 1,167 (1,145, 1,189)
RRC-Rohrbeck + NS pain excluding DDx 7,347 921 (901, 941)
Community prevalence* CWP - using ACR-90 criteria in adults only 1,077 (907, 1,249)
Consulting prevalence CWP patients expected to consult for pain 
symptoms = 72% of community prevalence 
(from Macfarlane et al. 1999)
775
NS = Non-specific pain coding 
DDx = specific differential diagnoses
*Community prevalence: Results from meta-analysis presented in Chapter Three (excluding those scoring a moderate or 
high risk of bias on domains 1 or 4 of the QUIPS methodological quality tool).
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6.4 Discussion
A comparison of the three groups of RRCs on number of recorded body regions showed the RRC-
all group had a lower proportion of patients consulting in all three body regions (axial, upper and 
lower limb) compared to the other two RRC groups. 
There is a disparity between expected annual CWP consulting prevalence (775/10,000) and the 
recorded five-year combined prevalence of non-specific pain and RRCs (RRC-all: 1,432/10,000 
RRC-clinician:1,274/10,000 RRC-Rohrbeck:1,019/10,000). If we consider non-specific pain coding 
to represent recognised CWP, and RRCs (RRC-all) to represent unrecognised CWP, then the 
prevalence of the combination (1,432 per 10,000) of these two groups is higher than estimated 
community point prevalence of CWP of 1,077 per 10,000 (identified in Chapter Three). When 
patients recorded with differential diagnoses are removed, coding prevalence figures remain 
higher (1,318 per 10,000) than we would anticipate from the general population prevalence of 
CWP. This suggests that one or both groups (RRCs and non-specific pain) are identifying patients 
who do not fit established CWP criteria (e.g. ACR-90) at the end of the five-year period.
The RRC-all definition identified 33% (n=2,106) of recognised generalised pain consulters. Based 
on differences in mean somatic symptoms, frequent attendance and consultations rates, there 
appeared to be an increasing order of severity when moving from recognised CWP who did not 
fulfil the RRC definition (group E. NS not RRC), through to RRCs with unrecognised CWP (group 
C. RRC no NS), and finally to recognised RRCs (group D. RRC and NS). However, unrecognised 
RRCs (i.e. without a recorded non-specific generalised pain code) were more likely to be male 
and of working age.
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6.4.1 Two- and three-region RRCs
The two notable differences between the three RRC groups identified in Chapter Five were: 1. a 
higher proportion of Chapter S (injury and poisoning) coding in the RRC-all group, and 2. the 
number of patients identified: more codes identified more patients. 
An excess of injury (Chapter S) coding suggests that the RRC-all group includes more patients 
with acute musculoskeletal injury and its sequelae than the other two RRC groups; hence, we 
might expect there to be more patients with only one limb affected rather than both arm and leg 
complaints. Compared to the other two groups of RRCs, the RRC-all group did indeed have a 
higher proportion of patients recorded with single limb problems (two body regions: axial + upper 
or lower limb).
Our study showed increases in the number of somatic symptoms, consultation rate, and frequent 
attender rate when moving from controls, through 2-region RRCs to 3-region RRCs. This finding is 
consistent with the concept that FM and CWP exist within a spectrum of chronic idiopathic pain 
syndromes (Forseth and Gran 1993, Wolfe 1997, Macfarlane 1999). It could be argued that the 
more stringent three-region RRC definition identifies patients better fitting the CWP construct. Two-
region RRCs have a profile suggesting less distress (fewer consultations, fewer symptoms) than 
three-region RRCs, but they are more similar to three-region RRCs than they are to controls. This 
suggests a grading of severity when moving from those recorded with single region 
musculoskeletal problems to those recurrently consulting for multi-site musculoskeletal pain. 
The RRC-Rohrbeck group had a slightly higher percentage of 3-region RRCs (axial + upper limb 
+ lower limb) which corresponds with the ACR-90 requirement for problems in both upper and 
lower limbs. It could be argued therefore that the RRC-Rohrbeck code list captures patients 
slightly more likely to fit ACR-90 CWP criteria. However, the updated ACR-2010 criteria 
emphasises a continuum of polysymptomatic distress (Wolfe et al. 2011a, 2013) and research 
suggests that pain exists on a continuum from localised to widepsread pain (Kamaleri et al. 
2008a), implying that, even if two-region RRCs do not meet ACR-90 criteria for CWP, given poor 
consultation-based health in RRCs, they are still likely to sit at the more severe end of the 
spectrum of polysymptomatic distess.
Chapter 6: Distribution of painful body regions and relationship to recognised generalised pain in primary care of RRCs
182
6.4.2 Non-specific generalised pain
Our study showed the age and gender distribution of RRCs and non-specific pain consulters to 
be more similar to each other than to that observed in single-site controls. We have already shown 
(Chapter Five) that RRCs have many of the same features as CWP. In addition, patients recorded 
with non-specific pain codes have been shown to be more similar to RRCs than controls on 
somatic symptom count, consultation rate, and percentage of frequent attenders (Table 6.5 and 
Chapter Five). This suggests non-specific pain codes are being used for a group of patients 
sharing a similar profile to both RRC and community CWP patients. This supports the idea that 
non-specific pain coding represents recognised CWP.
However, there is a disparity between the combined recorded prevalence of recognised (non-
specific pain) and unrecognised (RRC) CWP in primary care, and the expected CWP consulting 
prevalence, even when differential diagnoses are taken into account. Indeed the recorded 
prevalence of all non-specific pain and RRC-all (1,432/10,000) is substantially higher than 
community prevalence obtained from our meta-analysis (1,077/10,000). These comparisons are 
being made between five-year recorded prevalence versus annual or point community prevalence 
figures, which might account for the disparity observed. Further, our recorded five-year 
consultation prevalence figures represent patients’ consulting practices and clinicians’ diagnostic 
and coding behaviour. Community prevalence figures are based on strict ACR-90 CWP criteria 
that, we can argue, represent patients fitting an arbitrary definition with a diagnostic cut-off, which 
while useful for research, might be less useful clinically in a spectrum condition (Wolfe et al. 
2010). So, while, the RRC definition may over-estimate CWP prevalence, suggesting that it is not 
specific to strict ACR-90 CWP, it does identify a group of patients who share features with CWP 
and who, through repeated consultations, are seeking help for their symptoms. The RRC definition 
is arguably therefore identifying a group of individuals who, while they may not meet established 
definitions of CWP, have a clinical need.
Unrecognised CWP patients (C. RRC-all not NS) had higher consultation rates, more somatic 
symptoms, and were more likely to be male than recognised CWP patients not fulfilling the RRC 
criteria (E. NS not RRC-all). The RRC-all definition identifies 33% (n=2,106) of recognised 
generalised pain consulters and these RRCs had higher consultation demands and were more 
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likely to be older and female than their unrecognised counterparts (C. RRC-all not NS). If we were 
interested in identifying all CWP consulters from their medical records then it would be important 
to consider including non-specific generalised pain consulters in the definition, however, the RRC 
criteria we are developing aim to identify a subgroup of CWP consulters who recurrently consult 
with regional pain and are unrecognised by their GPs as having a widespread pain condition.
The RRC phenotype appears to be a patient with a high consultation rate due to either poor health 
(increased need for consultation) or consultation behaviour (patient or clinician determined). The 
RRC definition identifies more patients than identified using solely non-specific generalised pain 
codes. The non-specific generalised pain consulters who are not identified by RRC criteria (E. NS 
not RRC-all) are patients with lower consultation rates, who are arguably less important to identify, 
(given that they have already been recognised as having a generalised pain condition and, 
therefore, their clinical need is likely to have been met), than those with the higher consultation 
demands whose clinical need may not have been met. We can conclude that consultation 
patterns, based on repeated consulting for regional musculoskeletal problems, are more 
important in identifying a group of musculoskeletal patients with high clinical need than specific 
morbidity codes for non-specifc generalised pain.
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6.4.3 Strengths and limitations
a. Study population
The study population is the same as that used in Chapter Five, where we have already discussed 
the limitations of studying only those fully registered for a five year period. We have also 
discussed the geographical limitations of the CiPCA dataset and suggested that since community 
CWP prevalence has been shown to be consistent in Europe (Chapter Three) and the dataset has 
been demonstrated to give similar musculoskeletal consultation prevalence figures to a larger 
national database (Jordan et al. 2007), this may only have a small influence on generalisability.
b. Body regions
In this study we compared the number of recorded body regions consulted for and attempted to 
equate them to the ACR-90 CWP criteria. We argued that patients recorded as consulting for three 
body regions were more likely to fit self-reported CWP criteria. We must remember that coding will 
not present an accurate impression of the lived experience of chronic pain. The medical record 
captures coding practices and clinician and patient beliefs rather than the actuality of an 
individual’s experience of pain. However, the number of recorded body regions present a 
measure of body pain distribution and therefore serves as a useful index of ‘widespread-ness’ and 
it is fair to say that those recorded with pain in at least three different body regions are more likely 
to have self-reported widespread pain. We will explore the association of RRC status with self-
reported pain status in the next chapter.
c. Recognised and unrecognised CWP
We have used non-specific pain coding as a measure of recognised CWP. However, being 
recorded with one of the codes identified by our clinician advisory panel as likely to represent 
unexplained generalised musculoskeletal pain does not mean that a patient has CWP. Non-
specific pain coding does, however, represent a patient for whom the clinician has recognised 
and recorded a generalised musculoskeletal pain condition not explained by inflammation, 
infection or injury and is therefore a useful proxy measure.
Those RRCs not coded with non-specific pain complaints, that we have termed unrecognised 
CWP, might have been recognised by their GPs has having generalised conditions but not 
recorded using one of the non-specific pain codes we have identified. However, we have 
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demonstrated differences (in age and gender distribution, somatic symptom count, frequent 
attender rate and consultation rate) between recognised and unrecognised RRCs.
d. Prevalence
We are attempting to compare RRC prevalence figures based on five years of consultation data 
with point prevalence estimates for CWP community prevalence. Research suggests that, for CWP 
patients who recover, there are an equal or higher number of incident cases (McBeth et al. 2001a, 
Papageorgiou et al. 2002). Since CWP prevalence remains consistent or increases over time 
(Croft et al. 1993, Hunt et al. 1999, McBeth et al. 2001a, Aggarwal et al. 2006) we might expect 
point prevalence estimates for CWP to be relatively similar to that based on five years of 
consultation data. However, care must be taken in making such comparisons, since not all 
patients included in five-year estimates will still self-report CWP at the end of the five-year period, 
five-year period prevalence is likely to over-estimate point prevalence.
The expected CWP consulting figure has been calculated by extrapolating from community 
prevalence figures using a consultation rate derived from one study that asked for self-reported 
recall of consultations (Macfarlane et al. 1999). Research has shown a disparity between self-
reported consultation and medical records (Jordan et al. 2006) suggesting this estimate can only 
approximate recorded consultation prevalence.
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6.5 Conclusions
The RRC-Rohrbeck group could be argued to perform slightly better by identifying a higher 
proportion of patients consulting for three body regions, as this is closer to the ACR-90 criteria for 
CWP. However RRC-all criteria also seem to reflect CWP characteristics. The distribution of body 
regions might serve as a useful starting point for the future development of a RRC severity scale.
RRC-all criteria identify a third of apparently recognised CWP in primary care. The remaining two-
thirds of non-specific pain consulters have lower consultation rates and arguably, therefore, less 
clinical need. The RRC consultation pattern identifies a group of similar patients who are high 
users of primary care and findings from this chapter suggest that the RRC criteria are useful in 
identifying unrecognised CWP consulters with clinical need.
However, there continues to be a circular logic problem in developing the RRC definition since we 
define unrecognised CWP consulters based on consultation patterns requiring high consultation 
rates and then we test our definition using consultation metrics. In addition it appears the RRC 
definition identifies more patients than are likely to fit established CWP criteria. The next chapter 
therefore compares self-reported CWP status and general health with RRC status using a cohort 
of older adults with linked survey and medical record data. 
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Chapter 7
Association of recurrent regional consultation 
with self-reported pain status
7.1 Introduction
In the previous two chapters we have shown that recurrent regional consulters (RRCs) returned by 
three different lists of regional musculoskeletal Read codes (RRC-all: all regional codes; RRC-
clinician: excluding from the list of all regional codes those felt by clinicians to be unlikely to 
represent CWP; RRC-Rohrbeck: original 2007 short codes list) have similar levels of recorded 
somatic symptoms, comorbidity, consultation rates and frequent attendance. The RRC-all 
definition identified over 60% more patients than the RRC-Rohrbeck definition but a higher 
percentage (55% of RRC-Rohrbeck, 46% of RRC-all) of patients identified using the RRC-
Rohrbeck codes were recorded as consulting for all three body regions (axial, upper- and lower-
limbs), and therefore possibly more likely to fit ACR-90 CWP criteria. The aim of this chapter was 
to investigate further how well the three RRC definitions may identify patients with CWP by 
assessing their association with self-reported CWP status. This was performed using health survey 
data with linked medical record data from a prospective three-year study of pain in the older 
population (Thomas et al. 2004b).
Since not all CWP patients will consult for their symptoms the RRC definition will not identify all 
self-reported CWP patients. Conversely, it is likely that the RRC consultation pattern will identify 
patients who do not satisfy the strict self-report ACR-90 CWP criteria. The hypothesis is therefore 
that there will be a substantial overlap between patients self-reporting CWP and RRCs, but that 
there will be some differences between the two patient groups, particularly in consultation profile 
(RRCs are more likely to consult frequently) and severity (due to the strictness of its criteria, 
ACR-90 CWP patients are more likely to have increased severity of symptoms).
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7.2 Aims and objectives
The primary aim of this chapter was to test the association between fulfilling the RRC criteria and 
self-reported chronic widespread pain status.
Specifically:
1. To test the hypothesis that there is an association between having self-reported pain and 
being identified as a RRC by assessing the sensitivity, specificity, positive (PPV) and negative 
(NPV) predictive values of the RRC criteria in identifying self-reported widespread pain 
patients.
2. To test the hypothesis that RRCs who do not self-report CWP have a more similar profile to 
patients with self-reported widespread pain than patients consulting for single region pain 
(control group) do on age, gender, recorded somatic symptoms, consultation rate 
(musculoskeletal and non-musculoskeletal), frequent attendance, and self-reported general 
health, psychological dysfunction, and cognitive and sleep complaints.
3. To test the hypothesis that self-reported CWP patients who do not fulfil the RRC definition are 
less likely than RRCs to be frequent attenders (lower consultation rates and levels of frequent 
attendance) but more likely to have severe symptoms (worse self-reported mental and 
physical health, cognitive impairment, sleep complaints and psychological dysfunction).
Chapter 7: Association of recurrent regional consultation with self-reported pain status
189
7.3 Methods
This chapter compares self-reported chronic widespread pain status to RRC status. A comparison 
was made between RRCs and patients with self-reported widespread pain on age and gender, 
self-reported health status, consultation frequency, recorded number of somatic symptoms and 
frequent attendance. 
7.3.1 Study population
The study population was drawn from the North Staffordshire Osteoarthritis Project (NorStOP), a 
prospective epidemiological study of pain and general health in community-dwelling adults aged 
50 years and over (Thomas et a. 2004b). The study sample were those who had responded to 
both baseline and three-year postal health surveys from three identically recruited and measured 
cohorts (NorStOP 1: 2002, NorStOP 2: 2003, NorStOP 3: 2004, 2005), and who had consented to 
medical record review and had a minimum of five years of medical record data available. The 
cohorts were recruited through postal surveys of all patients aged 50 years and over registered 
with eight North Staffordshire general practices. In the United Kingdom it has been estimated that 
98% of the population are registered with a GP (Bowling 1997); practice registers therefore 
provide a representative sample of local populations. Consenting responders were followed up at 
three years with a repeat postal health survey. Questionnaires were mailed with a letter from the 
GP practice, accompanied by a study information leaflet, and reminders were sent to non-
responders after two and four weeks. Mailing lists were checked by GPs prior to mailing to 
exclude unsuitable patients (for example, patients with terminal illnesses or dementia). Full details 
of the study protocol and data collection have been published previously (Thomas et al. 2004b). 
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7.3.2 Self-reported pain status
Self-reported pain status was collected by postal questionnaire at baseline and three-year follow 
up. A self-completed body manikin was used to establish the location of body pain lasting for one 
day or longer in the past four weeks. Pain diagrams have been demonstrated to be a reliable 
means of classifying widespread pain based on existing criteria (Lacey et al. 2005). 
ACR-90 widespread pain is defined as axial pain, pain in the left and right sides of the body, and 
pain above and below the waist (Wolfe et al. 1990). A more strict definition, proposed by 
Macfarlane et al. (1996a), has been termed the ʻManchesterʼ definition. Like the ACR-90 criteria, 
pain must be present in at least two contralateral body quadrants, however, to reflect a more 
diffuse pattern of pain, for a body quadrant to be deemed positive, pain must be present in at 
least two regions of that quadrant (Hunt et al. 1999). Both definitions define chronicity as 
widespread pain of three months duration or longer. Due to the limitations of the self-reported data 
we have been unable to ascertain chronicity using this standard. Widespread pain at both 
baseline and three years has therefore been used here as a marker of ‘persistent’ widespread 
pain.
Self-reported widespread pain was classified into four non-mutually exclusive categories as: 
1. ACR-90 widespread pain at baseline or three years.
2. ACR-90 widespread pain at baseline and three years (persistent widespread pain).
3. Manchester widespread pain at baseline or three years.
4. Manchester widespread pain at baseline and three years (persistent widespread pain).
Group two (ACR-90 widespread pain at baseline and three years) was a subgroup of group one 
(ACR-90 widespread pain at baseline or three years). Similarly, group four (Manchester 
widespread pain at baseline and three years) was a subgroup of group three (Manchester 
widespread pain at baseline or three years). Patients defined using the Manchester criteria 
(groups three and four) were subgroups of those defined using the ACR-90 criteria (groups one 
and two), reflecting the more stringent requirements of the Manchester definition.
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7.3.3 Consultation-based pain status
Consultation-based pain status was established using linked medical record data for the five-year 
period starting two years prior to the baseline health questionnaire. Single-region controls and 
those fulfilling the RRC criteria were identified from data for the five-year study period. 
Consultation-based pain was classified into three non-mutually exclusive RRC categories and 
single-region controls:
1. Single-region controls recorded as consulting in just one of the three defined body regions 
(axial, upper limb or lower limb) during the five-year study period (see Chapter Five, section 
5.3.1 for the Read codes used).
2. RRCs defined using the existing Rohrbeck-2007 regional musculoskeletal pain consultation 
criteria and the following three lists of regional musculoskeletal Read codes (see Chapter Five 
for further details):
i. RRC-all: all regional musculoskeletal Read codes (documented in appendix A5.2).
ii. RRC-clinician: excluding from the list of all regional musculoskeletal Read codes those felt 
by clinicians to be unlikely to be used for CWP patients (documented in appendix A5.2).
iii. RRC-Rohrbeck: Rohrbeck’s (2007) original short code list (documented in appendix 
A5.1).
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7.3.4 Outcome measures
Self-reported and consultation-based widespread pain status were compared on self-reported 
health and consultation-based measures. 
Self-reported health status was collected from baseline health questionnaire responses (see Table 
7.1). General health was assessed using the SF-12 physical and mental health component 
summary scores (Ware et al. 1996) and the SF-36 physical function score (Ware et al. 1992). 
Psychological health was assessed using the Hospital Anxiety and Depression Scale (HADS 
Zigmond and Snaith 1983). Cognitive impairment was measured using the alertness subscale of 
the Sickness Impact Profile (SIP, Bergner et al. 1981). Sleep was assessed by four questions, in 
which respondents were asked if they had the following sleep problems on most nights: i) trouble 
falling asleep; ii) waking at night; iii) trouble staying asleep; and iv) waking up tired. A positive 
response to any of the four sleep questions was used to indicate a reported sleep problem.
Table 7.1 Measures of self-reported health at baseline.
Outcome measure Score range High score Reference
SF-12
SF-36
HADS
SIP
12 item short form health survey 
physical and mental component  
summary scores
General population mean 
score is 50 (SD 10). 
Scores higher than 50 are 
better than the general 
population.
Best health Ware et al. 1996
36 item short form health survey 
physical functioning subscale.
0–100 Best health Ware et al. 1992
Hospital anxiety and depression 
scale.
0–21 Worst health Zigmond and Snaith 1983
Sickness impact profile 
alertness subscale.
0–100 Worst health Bergner et al. 1981
Consultation-based measures comprised somatic symptom count, frequent attendance, and 
musculoskeletal and non-musculoskeletal consultation counts in the same five-year period as 
used to define RRCs. These have been defined previously (see Chapter Five, section 5.3). 
Somatic symptoms were calculated using 340 Read codes (presented in Chapter Five, section 
5.3.4) corresponding to 40 physical symptoms documented in the ACR-2010 fibromyalgia criteria 
(Wolfe et al. 2010). For each patient the number of somatic symptoms consulted for in the five 
years was calculated. 
Non-musculoskeletal frequent attenders were defined as the top 10% of attenders for non-
musculoskeletal problems (as in Chapter Five, section 5.3.5). Non-musculoskeletal problems were 
defined as consultations coded with any Read code (including administrative or process of care 
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Read codes from numerical Read code chapters) except those identified by Jordan et al. (2010) 
as being musculoskeletal in nature. The percentage who were non-musculoskeletal frequent 
attenders and the mean number of musculoskeletal and non-musculoskeletal consultations for the 
five years was calculated.
7.3.5 Analysis
a. Participation bias
Potential participation bias was examined by comparing three groups: i) non-responders at 
baseline; ii) incomplete responders who either responded to baseline only, or responded at 
baseline and three-years but did not consent to medical record review or had less than five years 
of medical record data; and iii) those included in this analysis (the ‘study population’). Differences 
observed between the study population and non-responders or incomplete responders would 
suggest participation bias. Non-responders (group i) and those included in this analysis (group iii) 
were compared descriptively on gender distribution and on mean age.
Those included in this analysis (group iii) and incomplete responders (group ii) were compared on 
baseline deprivation score (measured using ranked Index of Multiple Deprivation 2004, Payne 
and Abel 2012), marital status, current employment status, social class (Office for National 
Statistics, 2005), SF-12 mental and physical health component scores, SF-36 physical function 
score, HADs anxiety and depression scores, cognitive impairment (SIP alertness sub-scale), 
percentage of patients with any self-reported pain at baseline, and ACR-90 or Manchester 
widespread pain at baseline.
b. Association of consultation-based pain status with self-reported pain status
The association of consultation-based pain status with self-reported pain status was assessed. 
We first calculated the percentage of individuals with at least one recorded musculoskeletal 
consultation in primary care during the five-year period who also self-reported pain on the body 
manikin. The three RRC definitions (RRC-all, RRC-clinician and RRC-Rohrbeck) were then 
evaluated against the self-reported pain definitions (any pain, and the four ACR-90 and 
Manchester widespread pain definitions given in section 7.3.2) by calculating sensitivity, 
specificity, positive (PPV) and negative (NPV) predictive values of the RRC definitions for each of 
these self-reported pain definitions. Sensitivity measures the proportion of actual positives that are 
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correctly identified by a test. So, using the ACR-90 CWP criteria as the example, here it is the 
percentage of respondents fulfilling the ACR-90 criteria who were identified using the RRC 
definition. Specificity measures the proportion of true negatives who are correctly identified by a 
test (the percentage of respondents not fulfilling the ACR-90 criteria who were not identified as 
RRCs). PPV is the proportion of those with positive test results who have the condition (the 
percentage of RRCs who fulfilled the ACR-90 criteria). Conversely, NPV is the proportion of 
patients with a negative test result who do not have the condition (the percentage of non-RRCs 
who did not fulfill the ACR-90 criteria).
Confidence intervals for sensitivity, specificity, PPV and NPV were calculated using Wilson’s 
method (Newcombe 1998). A spreadsheet was developed incorporating formulae for calculating 
the 95% confidence interval for a proportion.
c. Comparison of consultation-based pain and self-reported pain patients
Mean age, percentage who were women, mean five-year somatic symptom count, 
musculoskeletal and non-musculoskeletal consultation counts, and percentage who were non-
musculoskeletal frequent attenders were determined for each RRC and control group, and for 
respondents fulfilling the self-reported pain definitions. 
Measures of self-reported general health status at baseline were also determined for each RRC 
and control group, and for responders fulfilling the self-reported pain definitions. These were the 
mean SF-12 mental and physical health components, SF-36 physical function, psychological 
dysfunction (measured using HADS anxiety and depression measure), and cognitive complaints 
(measured using Sickness Impact Profile alertness behaviour scale) scores. We also determined 
the percentage reporting any sleep problem.
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For the main analysis, we used the RRC-all definition only to compare RRC status with self-
reported CWP status defined as having ACR-90 widespread pain at both baseline and three 
years. Specifically we compared the following four mutually exclusive groups of patients:
A. RRC and CWP: RRC-all patients who also fulfilled the self-reported ACR-90 widespread pain 
criteria at both baseline and three years.
B. RRC not CWP: RRC-all patients who did not fulfill the ACR-90 widespread pain criteria at both 
baseline and three years.
C. CWP not RRC: Respondents who fulfilled the ACR-90 widespread pain criteria at both baseline 
and three years but who did not meet the RRC-all criteria.
D. Controls not CWP: Controls recorded as consulting for a musculoskeletal problem in a single 
region only (axial or upper-limb or lower-limb) for the five-year period from two years prior to 
baseline to three years after baseline, and who did not fulfill the ACR-90 criteria at baseline and 
three years.
These four groups (A to D) were first compared descriptively on age, gender, somatic symptoms, 
musculoskeletal and non-musculoskeletal consultation count, percentage who were frequent 
attenders and self-reported mental and physical health status (measured using SF-12 mental and 
physical health component summary scores, SF-36 physical function score, HADS anxiety and 
depression scores, SIP cognitive impairment score and one or more sleep problems reported on 
most nights). 
The four groups were compared to test the hypotheses that: i) RRCs not self-reporting CWP 
(Group B) were more similar to CWP patients who were not identified as RRCs (Group C) than to 
controls who did not self-report CWP (Group D) (objective 2); and ii) self-reported CWP patients 
who were not RRCs (Group C) have better consultation-based health (lower consultation rates and 
levels of frequent attendance), but worse self-reported health (worse self-reported mental and 
physical health, cognitive impairment, sleep complaints and psychological dysfunction) than self-
reported CWP patients who are RRCs (Group A) (objective 3). Differences between the groups 
were tested by fitting nine separate regression models to the data. Logistic regression, controlling 
for age and gender, was used to assess association of group membership with the dichotomous 
outcome variables of frequent attendance, recording of one or more somatic symptoms and 
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reporting of one or more sleep problems on most nights (with group D: controls not reporting CWP 
as the reference category). Linear regression was used to assess the association of group 
membership with the continuous outcome variables of SF-12 mental and physical component 
scores, SF-36 physical function, SIP cognitive impairment score, and HADs anxiety and 
depression scores again controlling for age and gender.
Chapter 7: Association of recurrent regional consultation with self-reported pain status
197
7.4 Results
7.4.1 Study population
Of 26,129 eligible participants (adults aged 50 or over and registered with one of the eight 
practices in the NorStOP study) at baseline, 71% (n=18,497) responded to the baseline health 
survey questionnaire. Of those consenting to follow-up and still registered with the GP (n=11,900), 
81% (n=9,665) responded to the three-year follow up questionnaire. Of the 9,665 people 
responding to both baseline and three-year questionnaires, 9% (n=831) did not consent to 
medical record review and 6% (n=548) had access to less than five years of medical record data, 
leaving 8,286 participants who returned both baseline and 3-year questionnaires and had access 
to a minimum of five years of medical record data and hence were eligible for inclusion in this 
analysis (see Figure 7.1).
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Figure 7.1. Participation flowchart.
Chapter 7: Association of recurrent regional consultation with self-reported pain status
199
a. Participation bias
Table 7.2 presents a baseline comparison of non-responders, incomplete responders (either 
baseline only responders or baseline and three-year responders without access to five years of 
medical record data), and the study population (those eligible for the study analysis).
Non-responders at baseline were older, although mean difference was less than one year (mean 
difference = 0.86 years, 95% CI: 0.53, 1.18), and more likely to be male (non-responders: 49% 
male; study population: 46% male, percentage difference: 3%) than the study population.
Incomplete responders (either baseline only responders, or baseline and three-year responders 
without access to five years of medical record data) showed generally small differences from the 
study population on all baseline variables assessed (see Tables 7.2 and 7.3). Complete 
responders (the study population) were younger (mean difference = 3.13 years, 95% CI 2.84, 
3.43), less likely to be female (OR 0.88, 95% CI 0.83, 0.93), were less deprived (deprivation score 
mean difference = 1,118, 95% CI: 900, 1,335), and more likely to be married or cohabiting (OR 
1.49, 95% CI 1.40, 1.58), to self-report pain (any self-reported pain: OR 1.34, 95% CI 1.26, 1.42; 
ACR-90 widespread pain: OR 1.26, 95% CI 1.18, 1.36; Manchester widespread pain: OR 1.34, 
95% CI 1.14, 1.36), be in paid employment (OR: 1.44, 95% CI 1.35, 1.54), and of a high social 
class (OR 1.70, 95% CI 1.57, 1.85) than incomplete responders. When compared to incomplete 
responders, the study population (complete responders), had better baseline self-reported mental 
(SF-12 mental component score mean difference = 1.69, 95% CI 1.34, 2.03; HADS anxiety mean 
difference = -0.33, 95 % CI -0.46, -0.21; HADS depression mean difference = -0.81, 95% CI -0.92, 
-0.70) and physical health (SF-12 physical component score mean difference = 1.91, 95% CI 
1.53, 2.31; SF-36 physical function score mean difference = 6.82, 95% CI 5.87, 7.76) and less 
cognitive impairment (SIPS mean difference = -3.95, 95% CI -4.65, -3.25).
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Table 7.2 Comparison of responders and non-responders
Non-responders Incomplete 
responders**
Study population 
(n = 7,632) (n =10,211) (n = 8,286)
Gender
Female
Male
Age, mean (sd)
Marital status*
Married or cohabiting
Not married or cohabiting
Current employment status*
Paid employment
Not in paid employment (unemployed, retired, ill 
health, housewife, other)
Social classa *
High
Middle
Low
Deprivation score b, mean (sd)*
Self-reported health at baseline
SF-12 physical component score (0-100)c, mean (sd)*
SF-12 mental component score (0-100)c, mean (sd)*
SF-36 physical function score (0-100)d, mean (sd)*
Anxiety (0-21)e, mean (sd)*
Depression (0-21)e, mean (sd)*
Cognitive impairment (0-100)f, mean (sd)*
Baseline self-reported pain (%)*
Baseline ACR-90 widespread pain (%)*
Baseline Manchester widespread pain (%)*
3,883 (51%) 5,834 (57%) 4,477 (54%)
3,7469 (49%) 4,377 (43%) 3,809 (46%)
65.3 (11.7) 67.6 (10.8) 64.5 (9.1)
- 6,493 (65%) 6,007 (72%)
- 3,540 (35%) 2,203 (27%)
2,348 (24%) 2,513 (30%)
7,434 (73%) 5,522 (67%)
- 1,357 (13%) 1,701 (21%)
- 1,471 (14%) 1,546 (19%)
- 6,181 (61%) 4,546 (55%)
- 12,836 (7,574) 13,953 (7,451)
- 40.5 (12.6) 42.4 (12.2)
- 48.5 (11.2) 50.2 (10.8)
- 59.2 (33.1) 66.0 (29.9)
- 6.8 (4.2) 6.5 (4.1)
- 5.1 (3.8) 4.3 (3.5)
- 16.3 (25.2) 12.4 (20.9)
- 6,750 (66%) 5,989 (72%)
- 1,892 (19%) 1,850 (22%)
- 1,145 (11%) 1,125 (14%)
a. Higher = higher managerial, higher professional or lower managerial/professional. Middle = intermediate occupations or 
self-employed. Lower = lower supervisory/technical, semi-routine or routine occupations (Office for National Statistics 
2005).
b. Rank index of multiple deprivation (Payne and Abel 2012) (low score = high deprivation)
c. 12 item short form health survey – physical and mental component summary scores (Ware et al. 1996) (100 best health)
d. 36 item short form health survey – physical functioning subscale (Ware et al. 1992) (100 best health)
e. Hospital Anxiety and Depression Scale (Zigmond and Snaith 1983) (21 worst health)
f. Sickness Impact Profile – alertness subscale (Bergner et al. 1981) (100 worst health)
sd. standard deviation
*Data on these variables were incomplete with n ranging from 8,456 to 10,210 for incomplete responders and 7,444 to 
8,283 for the study population.
** Baseline only responders or responders to baseline and 3 years with either no consent to medical record review or 
access to less than 5 years of medical record data.
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Table 7.3 Comparison of incomplete responders (reference group) to the study population.
Female
Married or cohabiting
Any self-reported pain
ACR-90 widespread pain
Manchester widespread pain
Paid employment
Social class*
Age
Deprivation score
SF-12 physical component score 
SF-12 mental component score
SF-36 physical function score
HADS anxiety
HADS depression
SIP cognitive impairment
OR (95% CI)
0.88 (0.83, 0.93)
1.49 (1.40, 1.58)
1.34 (1.26, 1.42)
1.26 (1.18, 1.36)
1.24 (1.14, 1.36)
1.44 (1.35, 1.54)
Low 1
Middle 1.43 (1.32, 1.55)
High 1.70 (1.57, 1.85)
Mean difference (95% CI)
-3.13 (-3.43, -2.84)
1,118 (900, 1,335)
1.91 (1.53, 2.31)
1.69 (1.34, 2.03)
6.82 (5.87, 7.76)
-0.33 (-0.46, -0.21)
-0.81 (-0.92, -0.70)
-3.95 (-4.65, -3.25)
*Odds ratios from logistic regression with low social class as the reference category.
All self-reported health and pain measures from baseline health survey responses.
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b. Study population
Of the 8,286 individuals included in the study population, 54% were female, the majority (70%, 
n=5,811) were between 50 and 69 years of age, 72% (n=5,848) were married, 30% (n=2,513) 
were employed, and 51% (n=4,220) were retired. 
c. Prevalence of pain
Seventy-two percent of the study population self-reported musculoskeletal pain at baseline. 
Eighty-five percent (n=7,076) reported pain at either baseline or three years. Fifty-seven percent 
(n=4,740) reported two-region pain (axial pain at baseline and/or three years and pain in either 
upper- or lower-limb at baseline and/or three years). Forty-one percent (n=3,437) reported three-
region pain (axial pain at baseline and/or three years and pain in both upper- and lower-limbs at 
baseline and/or three years). Two thousand, eight hundred and seventy-three people (37%) 
reported ACR-90 widespread pain at baseline or three years – of which 1,190 (14% of all the 
study population) reported ACR-90 widespread pain at baseline and three years. One thousand, 
eight hundred and sixty-two people (22%) reported Manchester widespread pain at baseline or 
three years – of which 658 (8% of all the study population) reported Manchester widespread pain 
at baseline and three years.
Eighty percent (n=6,611) of the study population had a recorded musculoskeletal consultation in 
the five-year period starting two years before the baseline health survey. RRC prevalence ranged 
from 905 per 10,000 population for RRC-Rohrbeck, to 1,737 for RRC-clinician, and 2,155 for RRC-
all. Control prevalence was 2,388 per 10,000 population.
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7.4.2 Association of consultation-based pain status with self-reported pain status
Ninety percent of patients with a recorded musculoskeletal consultation also self-reported pain at 
baseline or three years (see Table 7.4). Virtually all RRCs (97% to 99% by definition used) had 
self-reported pain. Between 53% and 57% of RRCs, depending on RRC definition, reported 
ACR-90 widespread pain at either baseline or three years, while 37% to 41% reported Manchester 
definition widespread pain at either baseline or three years. For reporting widespread pain at both 
baseline and three years, figures ranged by RRC definition from 25% to 29% for ACR-90 
widespread pain, and 14% to 16% for Manchester definition widespread pain. Controls recorded 
with single-region (axial, upper or lower limb) pain reported less widespread pain than RRCs – 
with between 16% (Manchester) and 27% (ACR-90) reporting widespread pain at baseline or 
three years, and 5% (Manchester) and 10% (ACR-90) reporting widespread pain at both baseline 
and three years. 
Table 7.4 Primary care musculoskeletal consultation by self-reported pain (n, column %’s).
Self reported pain
Primary care recorded pain
Any recorded 
MS 
consultation
Control RRC-all RRC-
clinician
RRC-
Rohrbeck
Total 
Any musculoskeletal pain
ACR-90 widespread pain 
(baseline or 3 years)
ACR-90 widespread pain 
(baseline and 3 years)
Manchester widespread pain 
(baseline or 3 years)
Manchester widespread pain 
(baseline and 3 years)
Total 
5,933 (90) 1,648 (83) 1,727 (97) 1,399 (97) 741 (99) 7,076
2,603 (39) 532 (27) 942 (53) 782 (54) 424 (57) 2,873
1,112 (17) 194 (10) 445 (25) 384 (27) 214 (29) 1,190
1,705 (26) 314 (16) 652 (37) 553 (38) 304 (41) 1,862
625 (9) 98 (5) 249 (14) 249 (14) 121 (16) 658
6,611 1,979 1,786 1,439 750
NB: Column %’s represent positive predictive values.
Sensitivity, specificity, positive and negative predictive values of RRC definitions for the measures 
of self-reported pain (from any self-reported pain to the most severe widespread pain definition –
Manchester widespread pain at baseline and three years) are presented in Table 7.5. Sensitivity 
and NPV were highest for the RRC-all definition (for example, sensitivity: 37% and NPV: 89% for 
ACR-90 widespread pain at baseline and three years) and lowest for the RRC-Rohrbeck definition 
(sensitivity: 18% and NPV: 87% for ACR-90 widespread pain at baseline and three years). 
Specificity and PPV demonstrated the opposite trend, with the highest figures observed in the 
RRC-Rohrbeck definition (specificity: 92% and PPV: 29% for ACR-90 widespread pain at baseline 
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and three years) and the lowest in the RRC-all group (specificity: 81% and PPV: 25% for ACR-90 
widespread pain at baseline and three years). 
Sensitivity and NPV were higher for the more stringent self-reported pain definitions; with 
sensitivity for RRC-all ranging from 24% for any self-reported pain to 38% for Manchester 
widespread pain at baseline and three years. Specificity and PPV demonstrated the reverse 
relationship with higher figures seen in the broader self-reported pain definitions; with specificity 
ranging from 80% for Manchester definition widespread pain at baseline and three years to 95% 
for any self-reported pain.
Table 7.5 Sensitivity, specificity, positive predictive value and negative predictive value for RRC status 
as a means of identifying self-reported pain.
Consultation-
based pain
Self-reported pain Sensitivity 
(95% CI)
Specificity
(95% CI)
PPV 
(95% CI)
NPV
(95% CI)
RRC-all Any 
(baseline or 3 years)
ACR-90 widespread pain 
(baseline or 3 years)
ACR-90 widespread pain 
(baseline and 3 years)
Manchester widespread pain
(baseline or 3 years)
Manchester widespread pain
(baseline and 3 years)
RRC-clinician Any 
(baseline or 3 years)
ACR-90 widespread pain 
(baseline or 3 years)
ACR-90 widespread pain 
(baseline and 3 years)
Manchester widespread pain
(baseline or 3 years)
Manchester widespread pain
(baseline and 3 years)
RRC-
Rohrbeck
Any 
(baseline or 3 years)
ACR-90 widespread pain 
(baseline or 3 years)
ACR-90 widespread pain 
(baseline and 3 years)
Manchester widespread pain
(baseline or 3 years)
Manchester widespread pain
(baseline and 3 years)
24 (23, 25) 95 (94, 96) 97 (96, 97) 18 (17, 19)
33 (31, 35) 84 (83, 85) 53 (50, 55) 70 (69, 71)
37 (35, 40) 81 (80, 82) 25 (23, 27) 89 (88, 89)
35 (33, 37) 82 (81. 83) 37 (34, 39) 81 (80, 82)
38 (34, 42) 80 (79, 81) 14 (12, 16) 94 (93, 94)
20 (19, 21) 97 (96, 98) 97 (96, 98) 17 (16, 18)
27 (26, 29) 88 (87, 89) 54 (52, 57) 69 (68, 71)
32 (30, 35) 85 (84, 86) 27 (24, 29) 88 (87, 89)
30 (28, 32) 86 (85, 87) 38 (36, 41) 81 (80, 82)
32 (29, 36) 84 (83, 85) 15 (13, 17) 93 (93, 94)
10 (10, 11) 99 (99, 100) 99 (98, 99) 16 (15, 17)
15 (14, 16) 94 (93, 95) 57 (53, 60) 68 (66, 69)
18 (16, 20) 92 (92, 93) 29 (16, 20) 87 (86, 88)
16 (15, 18) 93 (92, 94) 41 (37, 44) 79 (78, 80)
18 (16, 22) 92 (91, 92) 16 (14, 19) 93 (92, 93)
PPV: Positive predictive value
NPV: Negative predictive value
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7.4.3 Comparison of consultation-based and self-reported pain status
a. Descriptive comparison of patients with consultation-based and self-reported pain
Age, gender and consultation-based measures of health in RRCs, controls and participants with 
any self-reported pain or widespread pain are presented in Table 7.6 (note that RRC and self-
reported widespread pain groups are not mutually exclusive in this analysis). Mean age was 
similar in all groups. The percentage of women was lowest in the consultation-based control 
group (49%) and ranged from 60% to 66% for patients with self-reported widespread pain, which 
was similar to the figure of 61% observed in RRCs. Recorded number of somatic symptoms was 
higher in RRCs (mean 2.66) than in controls (mean 1.24). Mean somatic symptom count in 
patients self-reporting widespread pain (ranging from 2.01 for ACR-90 widespread pain at 
baseline or three years to 2.36 for Manchester widespread pain at baseline and three years) 
approached, but was not as high as, that in RRCs (2.66). Similarly, the percentage who were 
frequent attenders, and the mean musculoskeletal and non-musculoskeletal consultation counts 
were higher for those defined as RRCs than for both controls and for respondents with self-
reported widespread pain however, figures for those self-reporting widespread pain were closer 
to RRCs than to controls.
Table 7.6 Age, gender, mean number of somatic symptoms, musculoskeletal and non-musculoskeletal 
consultations and percentage who were frequent attenders for cases/controls and self-reported pain.
n Mean 
age 
(sd)
Female 
(%)
Mean 
somatic 
symptom 
count (sd)
Mean non-
MS 
consultation 
count (sd)
Mean MS 
consultation 
count (sd)
 FAs 
(%)
Consultation 
based pain
RRC-all
Control
Self-reported 
pain
Any self-reported MS pain 
(baseline or 3 years)
ACR-90 widespread pain 
(baseline or 3 years)
ACR-90 widespread pain 
(baseline and 3 years)
Manchester widespread 
pain (baseline or 3 years)
Manchester widespread 
pain (baseline and 3 years)
1,786 65 (9) 61 2.66 (2.10) 44 (27) 12 (8) 23
1,979 64 (9) 49 1.24 (1.41) 26 (20) 2 (2) 5
7,076 64 (9) 55 1.71 (1.79) 33 (25) 6 (7) 12
2,873 64 (8) 60 2.01 (1.95) 37 (26) 7 (8) 15
1,190 64 (9) 64 2.21 (1.99) 39 (25) 8 (9) 18
1,862 64 (9) 62 2.08 (1.95) 38 (26) 8 (9) 17
658 64 (9) 66 2.36 (2.06) 41 (25) 9 (8) 20
FA: Top 10% of non-musculoskeletal attenders.
MS: Musculoskeletal
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Measures of self-reported mental and physical health and sleep problems for RRCs, controls and 
patients with self-reported pain are presented in Table 7.7. In patients self-reporting widespread 
pain all measures were worse for the subgroup with widespread pain at both baseline and three 
years than for the total group who reported pain at either baseline or three years, and all 
measures were worse for those fulfilling Manchester criteria than for those fulfilling ACR-90 criteria 
at corresponding time points (baseline or three years versus baseline and three years). All 
measures were worse for widespread pain patients than for those with any self-reported pain.
The three groups of RRCs were similar to one another on baseline self-reported health measures. 
However, although the differences between RRC groups are small, the RRC-Rohrbeck subgroup 
reported slightly lower standards of health on all measures, except cognitive impairment.
Respondents with self-reported widespread pain had worse self-reported health than those 
defined as RRCs on all measures. 
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b. Consultation-based health of RRCs and CWP patients
Twenty-five percent (n=445) of RRC-all patients self-reported CWP (defined here as ACR-90 
widespread pain at both baseline and three years), while RRCs represented 37% of CWP 
patients. Table 7.8 presents age, gender, and consultation-based measures for the following four 
mutually exclusive groups:
A. RRC-all and self-reported CWP
B. RRC-all and not self-reported CWP
C. Self-reported CWP and not RRC
D. Controls and not self-reported CWP
Table 7.8 Age, gender and consultation-based measures by RRC and self-reported CWP status 
(ACR-90 at baseline and three years).
Mean age 
(sd)
Female (%) Mean somatic 
symptom 
count (sd)
Mean non-MS 
consultation 
count (sd)
Mean MS 
consultation 
count (sd)
FAs 
(%) 
n
A. RRC and CWP
B. RRC not CWP
C. CWP not RRC
D. Controls not CWP
64 (9) 67 2.90 (2.16) 47 (26) 13 (8) 27 445
65 (9) 59 2.58 (2.07) 44 (28) 11 (8) 21 1,341
64 (9) 62 1.80 (1.75) 34 (23) 6 (9) 12 745
64 (9) 48 1.21 (1.39) 26 (20) 2 (2) 5 1,785
The results of two binary logistic regression analyses assessing the association of group 
membership with: i) frequent attendance; and ii) recording of one or more somatic symptoms, 
adjusted for age and gender are shown in Table 7.9. The two groups of RRCs (A. RRC and CWP; 
B. RRC not CWP) had the highest odds of frequent attendance (A. RRC and CWP, OR 7.07, 95% 
CI 5.21, 9.58; B. RRC not CWP, OR 4.99, 95% CI 3.87, 6.43) compared to the control group, and 
being recorded with one or more somatic symptoms (A. RRC and CWP, OR 4.73, 95% CI 3.45, 
6.47; B. RRC not CWP, OR 4.03, 95% CI 3.34, 4.86). 
The group of patients self-reporting CWP who were not identified as RRCs (Group C) had over 
twice the odds (OR 2.55, 95% CI 1.86, 3,48) of the control group (D. Control not CWP) of being 
frequent attenders, and nearly twice (OR 1.89, 95% CI 1.55, 2.30) the odds of having at least one 
recorded somatic symptom.
Chapter 7: Association of recurrent regional consultation with self-reported pain status
209
Table 7.9 Results of two logistic regression analyses to assess the association of: i) frequent 
attendance; and ii) recording of one or more somatic symptoms, with group membership (with group 
D as the reference category), controlling for age and gender. 
Number (%) p-value OR 
(95% CI)
Frequent attendancea
Group A. RRC and CWP
Group B. RRC not CWP
Group C. CWP not RRC
Group D. Controls not CWP (reference)
One or more somatic symptomsb
Group A. RRC and CWP
Group B. RRC not CWP
Group C. CWP not RRC
Group D. Controls not CWP (reference)
121 (27%) <0.001 7.07 (5.21, 9.58)
284 (21%) <0.001 4.99 (3.87, 6.43)
88 (12%) <0.001 2.55 (1.86, 3.48)
87 (5%) 1
396 (89%) <0.001 4.73 (3.45, 6.47)
1,171 (87%) <0.001 4.03 (3.34, 4.86)
567 (76%) <0.001 1.89 (1.55, 2.30)
1,111 (62%) 1
a. Frequent attendance model !2 (5) = 334.96, p<0.001
b. One or more somatic symptoms model !2 (5) = 373.65, p<0.001
OR: odds ratio
p-values in bold are less than or equal to 0.05.
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c. Self-reported health of RRCs and CWP patients
Table 7.10 presents self-reported health measures for the same four mutually exclusive patient 
groups analysed in the previous section: A) RRC and CWP; B) RRC not CWP; C) CWP not RRC; 
and D) Controls not CWP. The two groups of patients self-reporting CWP (A. RRC and CWP; C. 
CWP not RRC) had the most severe self-reported health on all measures. The controls (Group D. 
Controls not CWP) had the best self-reported health and RRCs not self-reporting CWP had more 
severe self-reported health than the control group, but were not as severely affected as the two 
groups self-reporting CWP (A. RRC and CWP; C. CWP not RRC). 
Table 7.10 Mean (sd) of baseline self-reported health measures* by RRC and CWP status.
SF-12 mcsa SF-12 pcsa SF-36 pfsb Anxietyc Depression
c
Cognitive 
impairmentd
Sleep 
problems 
on most 
nights (%)
n
A. RRC and CWP
B. RRC not CWP
C. CWP not RRC
D. Controls not CWP
45.1 (12.5) 30.3 (9.5) 37.0 (26.7) 8.8 (4.3) 6.6 (3.6) 22.6 (26.1) 60 445
48.4 (11.3) 39.0 (11.7) 59.2 (29.5) 7.0 (4.0) 4.7 (3.3) 13.9 (21.2) 41 1,341
46.2 (12.2) 32.6 (11.1) 41.3 (29.3) 8.4 (4.4) 6.3 (4.0) 21.2 (25.6) 59 745
51.6 (10.1) 45.7 (11.1) 74.7 (25.9) 5.9 (3.9) 3.7 (3.1) 9.9 (19.0) 32 1,785
a. 12 item short form health survey – physical and mental component summary scores (Ware et al. 1996)
b. 36 item short form health survey – physical functioning subscale (Ware et al. 1992)
c. Hospital Anxiety and Depression Scale (Zigmond and Snaith 1983)
d. Sickness Impact Profile – Alertness subscale (Bergner et al. 1981)
sd. Standard deviation
* Data on these variables were incomplete with n ranging from: 391 to 439 for group A; 1,159 to 1,302 for group B; 665 to 
739 for group C; and 1,633 to 1,753 for group D.
The data were analysed with: 1) logistic regression to assess the association of group 
membership with reporting sleep problems on most nights, adjusted for age and gender (Table 
7.11); and 2) six separate multiple linear regression analyses to assess the association (adjusted 
for age and gender) of group membership with: i) SF-12 mental component score; ii) SF-12 
physical health component score; iii) SF-36 physical function score; iv) cognitive impairment (SIPS 
alertness subscale); v) HADS anxiety score; and vi) HADS depression score (Table 7.12). Group 
membership was shown to be significantly associated with all seven baseline self-reported health 
measures. 
The two groups self-reporting CWP (A. RRC and CWP; C. CWP not RRC) had the highest odds of 
reporting a sleep problem on most nights, with odds three times (A. RRC and CWP, OR 3.07, 95% 
CI 2.47, 3.81; C. CWP not RRC, OR 2.97, 95% CI 2.48, 3.54) that of the control group (D. Controls 
not CWP), while RRCs not self-reporting CWP (B. RRC not CWP) had 1.4 times the odds of the 
control group to report sleep problems (OR 1.42, 95% CI 1.22, 1.64).
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Table 7.11 Results of logistic regression analyses to assess the association of reporting of sleep 
problems on most nights, with group membership (with group D as the reference category), 
controlling for age and gender. 
Number (%) p-value OR 
(95% CI)
Reporting of sleep problems on most 
nights*
Group A. RRC and CWP
Group B. RRC not CWP
Group C. CWP not RRC
Group D. Controls not CWP (reference)
269 (60%) <0.001 3.07 (2.47, 3.81)
549 (41%) <0.001 1.42 (1.22, 1.64)
441 (59%) <0.001 2.97 (2.48, 3.54)
573 (32%) 1
* Reporting of sleep problems on most nights !2 (5) = 246.72, p<0.001
OR: odds ratio
p-values in bold are less than or equal to 0.05.
Compared to the control group (D. Controls not CWP), all three groups (A. RRC and CWP; B. RRC 
not CWP; and C. CWP not RRC) were more likely to have worse self-reported mental and physical 
health (SF-12 mental and physical component scores, SF-36 physical function), more 
psychological dysfunction (HADs anxiety and depression), and more cognitive impairment. The 
differences between controls and the other three groups were most marked on the two physical 
health measures (SF-12 physical component score and SF-36 physical function score). The two 
groups of patients with self-reported CWP (A. RRC and CWP; C. CWP not RRC) demonstrated 
worse self-reported health on all measures relative to the control group than for a similar 
comparison of group B patients (RRCs who did not self-report CWP) to the control group. 
However, group B patients still demonstrated a significant difference to the control group on self-
reported health measures. Individuals both self-reporting CWP and identified as RRCs (Group A. 
RRC and CWP) were the most severely affected on all measures. 
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Table 7.12 Results of six multiple linear regression analyses to test for association of group 
membership with baseline self-reported mental and physical health (SF-12 mental and physical health 
component scores, SF-36 physical function), cognitive impairment (SIP alertness subscale) and 
psychological dysfunction (HADS anxiety and depression), controlling for age and gender.
Beta coefficient 
(95% CI)
t-statistic 
for Beta 
coefficient
p-value 
for t-test
SF-12 mental component score
Control vs group A
Control vs group B
Control vs group C
SF-12 physical component score
Control vs group A
Control vs group B
Control vs group C
SF-36 physical function
Control vs group A
Control vs group B
Control vs group C
HADS anxiety
Control vs group A
Control vs group B
Control vs group C
HADS depression
Control vs group A
Control vs group B
Control vs group C
Cognitive impairment
Control vs group A
Control vs group B
Control vs group C
-6.17 (-7.40, -4.94) -9.85 <0.001
-3.09 (-3.93, -2.25) -7.24 <0.001
-5.16 (-6.16, -4.16) -10.09 <0.001
-15.53 (-16.72, -14.34) -25.61 <0.001
-6.42 (-7.23, -5.61) -15.56 <0.001
-13.18 (-14.15, -12.21) -26.65 <0.001
-36.63 (-39.43, -33.83) -25.65 <0.001
-13.93 (-15.84, -12.02) -14.28 <0.001
-32.75 (-35.05, -30.45) -27.93 <0.001
2.72 (2.30, 3.15) 12.66 <0.001
1.07 (0.78, 1.36) 7.24 <0.001
2.34 (1.99, 2.69) 13.26 <0.001
2.95 (2.60, 3.31) 16.25 <0.001
1.00 (0.75, 1.24) 8.01 <0.001
2.65 (2.36, 2.94) 17.76 <0.001
12.79 (10.45, 15.12) 10.75 <0.001
3.99 (2.41, 5.57) 4.94 <0.001
11.46 (9.54, 13.38) 11.71 <0.001
Group A. RRC and CWP.
Group B. RRC not CWP.
Group C. CWP not RRC.
Group D. Controls not CWP (reference category).
p-values in bold are less than or equal to 0.05.
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7.5 Discussion
The RRC-all definition identified over a third of patients self-reporting persistent widespread pain 
(baseline and three years: 37% ACR-90, 38% Manchester definition). Between 75% and 86% of 
RRCs did not report persistent widespread pain (depending on widespread pain and RRC 
definition) but only a maximum of 3% reported no musculoskeletal pain. The RRC-all definition 
identified twice as many self-reported widespread pain participants as the RRC-Rohrbeck 
definition. 
For all three RRC definitions sensitivity for self-reported chronic widespread pain was low (RRC-
all: 37%–38%; RRC-clinician: 32%; RRC-Rohrbeck: 18%) and specificity high (RRC-all: 80%–81%; 
RRC-clinician: 84%–85%; RRC-Rohrbeck: 92%). The RRC-all definition was the most sensitive for 
self-reported CWP, while the RRC-Rohrbeck the most specific.
Respondents who were both RRCs and fulfilled the self-reported CWP criteria had the worst self-
reported physical and mental health status, consulted most frequently and were more likely to 
have somatic symptom consultations. Those fulfilling the CWP criteria who were not RRCs had 
worse self-reported health status than RRCs who did not fulfill the CWP criteria. However, RRCs 
who did not fulfill the CWP criteria consulted more frequently and had more somatic symptom 
consultations than those fulfilling the CWP criteria who were not RRCs.
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7.5.1 Association of consultation-based pain status with self-reported pain status 
Our first hypothesis was that there is an association between fulfilling RRC criteria and self-
reporting chronic widespread pain. Half (53%) of the patients identified by the RRC-all definition 
had self-reported widespread pain (ACR-90) at either baseline or three years, and a quarter (25%, 
the positive predictive value) had persistent widespread pain (ACR-90) at both baseline and three 
years. Thirty-seven percent of respondents with persistent widespread pain (ACR-90 pain at 
baseline and three years) fulfilled RRC-all criteria. However, 86% of patients not fulfilling the RRC-
all definition did not have persistent self-reported widespread pain (ACR-90 at baseline and three 
years).  
The observation that the RRC definition correctly identifies most of those without self-reported 
CWP (persistent ACR-90 widespread pain on baseline and three year questionnaires) but is less 
effective at identifying CWP patients, and has a low positive predictive value, might be accounted 
for by three explanations: i) the self-reported widespread pain definitions used in the study; ii) the 
spectrum of the chronic pain experience; and iii) the consultation behaviour of CWP patients. 
Firstly, the widespread pain definitions used in this study. Self-reported chronic widespread pain 
was determined at two discrete time points separated by a three-year interval potentially missing 
some widespread pain cases. As the self-reported definition becomes more stringent 
(widespread pain at baseline or three years progressing to a requirement for baseline and three 
years, or ACR-90 widespread pain progressing to Manchester widespread pain) it becomes more 
likely that cases will be missed. Since RRC status is determined by a continuous five-year review 
of medical record data it is likely that the RRC definition identifies true CWP patients missed by the 
self-reported pain measure. This suggests that the sensitivity reported here might be an under-
estimate for true CWP.  
Secondly, another explanation for the low positive predictive value of RRC status as a measure of 
widespread pain is related to the theory that ACR-90 defined CWP and FM occupy the more 
severe end of a spectrum of pain conditions (McBeth and Mulvey 2012). This explanation is 
supported by the observation that RRCs not reporting persistent widespread pain had fewer 
somatic symptoms, lower consultation counts, were less likely to be frequent attenders and had 
better self-reported health than those who did. Further, if we compare patients self-reporting 
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ACR-90 persistent widespread pain with those satisfying the more exacting Manchester 
widespread pain definition, we see that the Manchester widespread pain patients have higher 
consultation rates, more frequent attendance, more recorded somatic symptoms (Table 7.6) and 
worse self-reported health (Table 7.7). This finding of worse consultation-based and self-reported 
health in Manchester versus ACR-90 widespread pain patients supports the theory (Macfarlane et 
al. 1996a) that patients fitting more stringent widespread pain definitions occupy the more severe 
end of the spectrum of chronic pain syndromes. RRC criteria may identify patients experiencing 
longstanding diffuse pain who might not necessarily meet the more stringent established CWP 
criteria. 
Finally, consultation behaviour may also explain the low sensitivity of the RRC definition for self-
reported widespread pain. The RRC definition only has the capacity to identify those who present 
to primary care with their musculoskeletal symptoms. Because there is still a group in the general 
population who do not consult, RRC criteria cannot hope to identify all self-reported widespread 
pain patients. 
By identifying more patients, the RRC-all definition has a higher sensitivity than the RRC-clinician 
or RRC-Rohrbeck definitions. However, increased sensitivity comes at the cost of reduced 
specificity. For all three RRC definitions sensitivity is low (less than 40%) and specificity high (over 
80%). In order to identify a higher proportion of self-reported CWP cases who are probably at the 
more severe end of the CWP scale, it would be prudent therefore, to accept a small reduction in 
specificity as a trade-off for increasing a low sensitivity. This is a potentially persuasive argument 
for discarding the RRC-clinician and RRC-Rohrbeck code lists in favour of the RRC-all list in future 
iterations of the RRC definition. However, it is important to consider here the context in which the 
RRC definition will be applied. In a clinical setting it could be argued that it is more important to 
identify the maximum number of cases, while in a research setting it may be more important to be 
sure that those identified fit an established case definition. Consequently, in clinical practice a 
higher sensitivity may be more important, while in a research setting a high specificity may be the 
priority.
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7.5.2 Comparison of consultation-based and self-reported pain status
Our second hypothesis was that RRCs and CWP patients were more similar to each other than 
controls. Both consultation-based and self-reported measures of health were worse for RRCs and 
self-reported CWP (ACR-90 pain at baseline and three years) patients than for consultation-based 
controls. This suggests that patients fulfilling either consultation-based or self-reported CWP 
criteria have worse subjective health than patients who only consult for problems in a single 
region. The consistency between the health profile of RRCs and that of self-reported widespread 
pain patients supports the RRC definition as a measure of CWP. 
Our final hypothesis was that individuals with self-reported CWP (ACR-90 pain at baseline and 
three years) not fulfilling the RRC definition would be more likely than RRCs not fulfilling the CWP 
criteria to have more severe symptoms (worse self-reported health, cognitive impairment, sleep 
complaints and psychological dysfunction) and less likely to be frequent attenders (lower 
consultation rates and levels of frequent attendance). This was found to be the case. The 
improved self-reported health of these RRCs without self-reported CWP might indicate a group of 
patients with a less severe form of CWP. Cognitive impairment and sleep problems are features 
associated with FM and CWP (Glass 2006, Mease et al. 2005, Wolfe et al. 2010). Our finding of 
better cognitive function and fewer sleep problems in RRCs not self-reporting CWP compared to 
CWP patients might suggest that either some RRCs are less likely to fit the FM/CWP profile, or that 
these RRCs represent either a less severe point on the chronic pain spectrum, or a pre-disease 
manifestation of CWP.
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7.5.3 Strengths and limitations
a. Study population
The study population was taken from a sampling frame of those aged 50 years and over only. This 
is likely to limit the generalisability of the findings. RRC prevalence was higher for the over 50 age 
group presented (2,155 per 10,000 population) in this study than that observed in the previous 
chapter for all ages (1,149 per 10,000). This finding is consistent with the observations of the 
systematic review (Chapter Three), where it was noted that CWP prevalence increased from 
middle-age. In Chapter Five we demonstrated that RRCs aged over 45 had similar numbers of 
non-musculoskeletal consultations (section 5.4.3.a) and somatic symptoms (section 5.4.4) than 
RRCs of all age groups, suggesting that the findings of this chapter may be relevant to all age 
groups; however, we must be cautious in attributing our findings to all those with or at risk of CWP.
Less than a third of the eligible population (i.e. all those invited to take part in the baseline study) 
were included in the analysis, we cannot therefore exclude the risk of participation bias. However, 
differences between the study population, and non- or partial-responders were demonstrated to 
be small on all variables assessed.
Non-responders at baseline were older (mean difference = 0.86, 95% CI: 0.53, 1.18) and more 
likely to be male (non-responders: 49% male; study population: 46% male) than the study 
population, however differences were small and unlikely to affect the generalisability of the 
findings. 
There were small differences between the study population and incomplete responders 
(responders to baseline only, or responders to baseline and three years without access to five 
years of medical record data). Compared to incomplete responders the study population was 
younger, more likely to be married or cohabiting, more likely to be in paid employment, with less 
deprivation, from a higher social class, with better self-reported mental and physical health (SF-12 
mental and physical component score, SF-36 physical function, HADS anxiety and depression 
score, and SIPS cognitive impairment score) and more self-reported pain. However, the small 
magnitude of the observed differences suggests that they are unlikely to affect the generalisability 
of the findings. 
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b. Outcome measures
The body-pain manikin included in the health questionnaires asked patients to note the location of 
any body pain experienced in the last four weeks. Without a measure of chronicity we measured 
widespread pain at a two levels: i) widespread pain at baseline or three years; and ii) persistent 
widespread pain at both baseline and three years. Neither provides an accurate measure of 
chronicity. However, the prevalence of ACR-90 widespread pain (defined as at baseline and three 
years) in the study population was 1,400 per 10,000, which is comparable to CWP prevalence 
estimates for the older population from previous studies (Eggermont et al. 2010: 910 per 10,000 in 
those over 70; Santos et al. 2010: 1,400 per 10,000 in those over 65). Further, patients with 
widespread pain at baseline or three years demonstrated similar levels of anxiety and depression 
to those found in CWP patients in another study (McBeth et al. 2005).
Comparing widespread pain measured at discrete time points against a continuous measure of 
consultation-based widespread pain also presents problems. While truly persistent widespread 
pain will be picked up by the two measures at a three-year interval, new CWP patients or patients 
with relapsing and remitting CWP might be missed. This suggests estimates of sensitivity and PPV 
may therefore be higher than those observed in this study.
Problems with using consultation-based measures of health (consultation count, somatic symptom 
count, frequent attendance) were discussed in Chapter Five (section 5.5.6 f–h). While these 
measures are not a true reflection of health, they do offer a useful indicator of the relative burden 
of ill-health and a picture of consulting practices. Similarly, self-reported health measures can only 
offer a subjective assessment of health status not a true reflection of health, but again they offer a 
useful indicator in this instance for subjective distress. 
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7.6 Conclusions
Fulfilling the RRC criteria was associated with worse consultation-based health (more 
consultations, more frequent attendance) than CWP status, but CWP status was associated with 
worse self-reported health than RRC status. This suggests that RRCs are frequent consulters who 
share features with CWP patients, but perhaps some may be less severely affected and therefore 
do not necessarily fit established and strict CWP criteria. 
However, these patients still have a clinical need, as demonstrated by their high consultation 
demands. We could argue therefore that the RRC definition is a more useful means of identifying a 
clinically important group of patients than whether they meet the arbitrary cut-off point set by 
established CWP criteria. The diagnostic cut-off of established criteria fails to recognise the 
continuum of the pain experience and therefore excludes some of the less severe cases (who are 
still expressing an arguably unmet need) picked up by the RRC definition. Indeed recognising the 
less severe cases identified by the RRC definition might offer us an opportunity of providing 
effective management before a patient progresses to meeting the more strict established CWP 
definitions. Previous research (McBeth et al. 2001a and 2001b) has identified risk factors 
associated with persistent CWP, and modifying these risk factors in patients with ‘pre-CWP’ may 
halt the progression to persistent CWP.
If the RRC definition is to be used clinically we must be very clear about the patient group that is 
being identified. A low sensitivity means that many of those with self-reported CWP will be missed 
by the RRC definition, while a low PPV means that many RRCs will not meet strict ACR-90 CWP 
criteria. The RRC definition identifies a heterogeneous group of frequent consulters with 
predominantly musculoskeletal symptoms, including those less severely affected who do not 
therefore necessarily fit established and strict CWP criteria. They nonetheless still exist on the 
spectrum of polysymptomatic distress characteristic of CWP and FM. The RRC definition might 
therefore have an important application as a tool to identify high-risk patients (i.e. patients at risk 
of progression towards the more severe end of the CWP/FM spectrum) in situations where 
reduced continuity of care may hinder a clinician’s ability to perceive a history of repeated 
musculoskeletal consultations as evidence of a more generalised condition.
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Identifying and offering appropriate management for currently unrecognised generalised pain 
conditions has the potential to improve patient outcomes and reduce consultation rates. The next 
chapter will therefore establish whether RRCs can be identified in a shorter timeframe and 
continue work to develop a severity scale for use within the existing RRC definition.
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Chapter 8
Time taken to identify recurrent regional 
consulters
8.1 Introduction
In the previous chapter we demonstrated that RRCs had similar characteristics to individuals with 
self-reported CWP. However, since RRCs without self-reported CWP had better self-reported 
health than people self-reporting CWP but not fulfilling the RRC criteria, we postulated that fulfilling 
the RRC criteria might represent a less severe point on the chronic pain spectrum. If this is the 
case it is hoped that identifying RRCs early and before their condition becomes severe would 
provide the opportunity to intervene to manage risk factors and halt the progression to persistent 
CWP, which may be associated with greater health problems (McBeth et al. 2001a). It would be 
helpful therefore to identify RRCs earlier than the current five-year period needed in the case 
definition. Previously the RRC criteria have been used retrospectively to identify how many 
patients in the previous five years have fulfilled the criteria. It would be useful to establish how 
quickly RRCs can be identified prospectively as patients could then be followed forward until they 
fulfilled the criteria at which point their status could be flagged to their GP.
This chapter therefore first aims to determine the proportion of RRCs who can be identified after 
three and four years and to compare RRCs identified after three and four years with those 
identified in the five years imposed by the Rohrbeck-2007 RRC definition. 
Current RRC criteria require a minimum of three years to identify a RRC, based on need for a 
regional consultation in three separate years, if this requirement were removed then RRCs could 
potentially be identified more quickly. This chapter therefore also investigates how much adapting 
the established criteria (by removing the requirement for regional consultation in three separate 
years) influences the time taken to identify a RRC and how many false positives are then identified 
(i.e. the number of extra patients fulfilling the criteria when the requirement for a regional 
consultation in three separate years is removed). 
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8.2 Aims and objectives
The primary aim of this chapter is to establish whether RRCs can be identified in less time than the 
five years required by the established RRC definition to allow for earlier identification.
Specifically, the objectives of the chapter are:
1. To assess how many patients fulfilling the RRC criteria would be missed if the criteria were 
revised to three or four years rather than five years.
2. To establish whether those fulfilling RRC criteria earlier are those with more severe problems.
3. To establish how much sooner RRCs can be identified if the requirement for regional 
consultations in each of three separate years were removed from the RRC criteria 
4. To investigate how many more patients would be identified if the requirement for regional 
musculoskeletal consultations in each of three separate years were removed.
5. To compare the consultation-based health profile of the extra RRCs identified by removing the 
separate years criterion to that of RRCs identified using the established Rohrbeck-2007 
definition, to establish whether the extra patients identified still fit the RRC profile. 
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8.3 Methods
8.3.1 Study population
RRCs were identified from all patients (no age restriction) fully registered with the 12 primary care 
practices in the CiPCA dataset between the years 2005 and 2009. To fulfil the aim of this analysis 
to assess the feasibility of earlier identification of RRCs, as a slight variation to previous chapters, 
we only considered patients who had a regional musculoskeletal complaint in 2005 (the first year 
of the five-year period). The first such regional consultation in 2005 was labelled as the index 
consultation. RRCs were identified using the Rohrbeck-2007 criteria (see Table 8.1) with the list of 
all regional musculoskeletal Read codes (RRC-all). RRCs were identified from those recorded as 
consulting for a regional musculoskeletal complaint in 2005.
Table 8.1 RRC definition used in this analysis.
From and including their index regional musculoskeletal consultation, fulfil all of i)–iv).
i) at least 1 consultation for a musculoskeletal complaint in the axial skeleton (neck & back);
ii) at least 1 consultation for an upper or lower limb complaint;
iii) at least 1 consultation for a regional musculoskeletal complaint in each of 3 separate years;
iv) at least 4 consultations for regional musculoskeletal complaints in total during the 5 year 
period.
8.3.2 Analysis 1: RRCs identified in shorter timeframes
RRCs were identified over the five-year period who had an index regional musculoskeletal 
consultation in 2005. We determined the percentage of these RRC patients who fulfilled the RRC 
criteria: i) within three years; ii) between three and four years; and iii) after four years from their 
index regional musculoskeletal consultation date in 2005. These three groups were then 
compared on age, gender, mean number of somatic symptoms, percentage who were non-
musculoskeletal frequent attenders, and their mean number of musculoskeletal and non-
musculoskeletal consultations. 
Somatic symptom count was calculated as before (see Chapter Five, section 5.3.4) using 340 
Read codes corresponding to 40 physical symptoms (Read codes presented in appendix 5.3, 
Table A5.4). For each patient, the number of somatic symptoms consulted for in the period 2005 
to 2009 was calculated. The mean number of somatic symptoms was then calculated for each 
patient group.
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Non-musculoskeletal frequent attenders were defined as before (see Chapter Five, section 5.3.5) 
as the top 10% of attenders in each practice for non-musculoskeletal problems. The percentage 
of non-musculoskeletal frequent attenders and the mean number of musculoskeletal and non-
musculoskeletal consultations between 2005 and 2009 was calculated for each group of patients.
To test for differences between the RRCs identified within three years, between three and four 
years, and between four and five years, unadjusted and adjusted odds ratios for age group, 
gender, frequent attender status (top 10% of attenders for non-musculoskeletal complaints) and 
recording of one or more somatic symptoms were calculated using multinomial logistic regression 
with three subgroups of RRCs defined by the time at which RRC criteria are fulfilled (i. at 3 years; 
ii. 3–4 years; and iii. 4–5 years) as the dependent variable. Analyses were undertaken using SPSS 
(IBM 2011). RRCs identified between four and five years (i.e. those taking the longest to fulfill 
criteria) were used as the reference category. Age group was defined using the following age 
bands 14 and under; 1524; 25–44 (reference); 45–64; 65–74; and 75+.  
8.3.3 Analysis 2: Removing requirement for regional consultations in three 
separate years
a. Extra RRCs identified
This analysis removed the requirement for regional consultations in each of three separate years. 
RRCs were again identified from an index regional musculoskeletal consultation in 2005 but 
without the requirement of regional complaints in three separate years. The number of extra 
patients identified by removing the requirement for consultations in three separate years was 
determined. 
To establish whether removing the separate years requirement influenced how soon RRCs were 
identified we categorised RRCs identified using adapted criteria (without the requirement for 
consultations in three separate years) into yearly intervals based on the time to fulfillment of 
criteria (from one year from index consultation to five years from index consultation). We cross-
tabulated these categories against the classification used in analysis one based on the full criteria 
(fulfilled within: three years; three to four years; and four to five years of index consultation). This 
allowed us to calculate what percentage of RRCs identified using established criteria would be 
identified at yearly intervals if the requirement for consultation in separate years were removed.
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b. Comparison of established RRCs with extra RRCs
RRCs identified using the established Rohrbeck-2007 criteria were compared descriptively with 
the extra RRCs identified by removing the separate years criterion, and with a control group. The 
following groups were compared on age, gender, mean number of somatic symptoms, 
percentage of non-musculoskeletal frequent attenders, and mean number of musculoskeletal and 
non-musculoskeletal consultations:
A. RRCs identified using established criteria.
B. The additional patients added to those identified using established Rohrbeck-2007 criteria (A) 
by removing the requirement for regional consultations in separate years.
C. Controls recorded as consulting for a musculoskeletal problem in only one of three body 
regions (axial, upper limb or lower limb) during the five-year period (2005–2009) (described in 
section 5.3.1).
Consultation-based health measures (somatic symptom count, frequent attendance, and 
musculoskeletal and non-musculoskeletal consultation count) were measured as described above 
(section 8.3.2).
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8.4 Results
8.4.1 Analysis 1: RRCs identified in shorter timeframes
A total of 6,088 RRCs with an index regional musculoskeletal consultation in 2005 were identified 
using established RRC Rohrbeck-2007 criteria over the five-year period. Forty-eight percent 
(n=2,900) of RRCs were identified within three years of the index musculoskeletal consultation and 
83% (n=5,062) were identified within four years of the index consultation date.
RRCs identified at three or four years had higher non-musculoskeletal consultation counts and 
more recorded somatic symptoms than those identified over the full five years (see Table 8.2).
Table 8.2 Age and gender distribution, and consultation-based health of RRCs identified at 3, 4 and 5 
years from index consultation.
Mean 
age 
(sd)
Female 
(%)
FAs
(%)
Somatic 
symptom count
Non-MS 
consultation 
count
MS 
consultation 
count
Total
Mean 
(sd)
Median 
(IQR)
Mean 
(sd)
Median 
(IQR)
Mean 
(sd)
Median 
(IQR)
RRC within 3 years
RRC after 3 and before 
4 years
RRC after 4 and before 
5 years
RRC using established 
Rohrbeck-2007 criteria 
(2005 to 2009)*
60 (16) 63% 40% 3.19 (2.29) 3 (1, 5) 56 (38) 50 (30, 74) 14 (9) 12 (8, 18) 2,900
59 (17) 59% 30% 2.72 (2.09) 2 (1, 4) 49 (33) 42 (25, 64) 10 (6) 9 (6, 12) 2,162
57 (17) 60% 26% 2.41 (1.95) 2 (1, 3) 44 (30) 37 (23, 58) 8 (5) 7 (5, 10) 1,026
59 (17) 61% 34% 2.89 (2.19) 2 (1, 4) 52 (35) 44 (27, 68) 12 (8) 10 (7, 15) 6,088
*RRCs identified in the five years from index consultation in 2005, includes all RRCs identified in the three rows above.
FA: top 10% of non-musculoskeletal frequent attenders.
MS: musculoskeletal
sd: standard deviation
IQR: interquartile range
Results of a multinomial logistic regression analysis comparing RRCs identified within three years, 
between three and four years, and between four and five years are shown in Table 8.3. Adjusting 
for age and gender, RRCs identified within three years had nearly twice the odds (OR = 1.76, 95% 
CI 1.49, 2.08), compared to those identified between four and five years, of being frequent 
attenders, and were more likely to have a least one recorded somatic symptom (OR=1.36, 95% CI 
1.09, 1.69). RRCs identified between three and four years were also more likely to be frequent 
attenders (OR = 1.18, 95% CI 0.99, 1.40) and to have at least one recorded somatic symptom 
(OR = 1.26, 95% CI 1.01, 1.58) than those identified after four years. There was no significant 
difference in age and gender between RRCs identified before four years, and those identified 
after four years.
Chapter 8: Time taken to identify RRCs
227
Ta
bl
e 
8.
3 
M
ul
tin
om
ia
l l
og
is
tic
 re
gr
es
si
on
 a
na
ly
si
s 
of
 R
RC
s 
id
en
tif
ie
d 
wi
th
in
 3
 y
ea
rs
 a
nd
 b
et
we
en
 3
 a
nd
 4
 y
ea
rs
 w
ith
 R
RC
s 
id
en
tif
ie
d 
be
tw
ee
n 
4 
an
d 
5 
ye
ar
s 
as
 th
e 
re
fe
re
nc
e 
ca
te
go
ry
 –
 a
dj
us
te
d 
an
d 
un
ad
ju
st
ed
 o
dd
s 
ra
tio
s.
Re
fe
re
nc
e 
gr
ou
p 
          
RR
C 
id
en
tif
ie
d 
be
tw
ee
n 
4 
an
d 
5 
ye
ar
s
RR
C 
id
en
tif
ie
d 
be
tw
ee
n 
3 
an
d 
4 
ye
ar
s
RR
C 
id
en
tif
ie
d 
be
tw
ee
n 
3 
an
d 
4 
ye
ar
s
RR
C 
id
en
tif
ie
d 
be
tw
ee
n 
3 
an
d 
4 
ye
ar
s
RR
C 
id
en
tif
ie
d 
wi
th
in
 3
 y
ea
rs
RR
C 
id
en
tif
ie
d 
wi
th
in
 3
 y
ea
rs
RR
C 
id
en
tif
ie
d 
wi
th
in
 3
 y
ea
rs
n 
(%
) 
n 
(%
)
Un
ad
ju
st
ed
 O
R 
(9
5%
 C
I)
Ad
ju
st
ed
 O
R*
 
(9
5%
 C
I)
n 
(%
)
Un
ad
ju
st
ed
 O
R 
(9
5%
 C
I) 
Ad
ju
st
ed
 O
R*
 (9
5%
 
CI
) 
Ge
nd
er
M
al
e
Fe
m
al
e
FA
 s
ta
tu
s
No
FA
 s
ta
tu
s
Ye
s
So
m
at
ic
 
sy
m
pt
om
s
No
So
m
at
ic
 
sy
m
pt
om
s
Ye
s
Ag
e 
gr
ou
p
<1
4
15
–2
4
25
–4
4
45
–6
4
65
–7
4
75
+
41
6 
(4
0%
)
89
2 
(4
1%
)
1
1
1,
07
6 
(3
7%
)
1
1
61
0 
(6
0%
)
1,
27
0 
(5
9%
)
0.
97
 (0
.8
3,
 1
.1
3)
0.
93
 (0
.7
9,
 1
.0
8)
1,
82
4 
(6
3%
)
1.
16
 (1
.0
0,
 1
.3
4)
1.
04
 (0
.8
9,
 1
.2
0)
76
0 
(7
4%
)
1,
51
1 
(7
0%
)
1
1
1,
73
8 
(6
0%
)
1
1
26
6 
(2
6%
)
65
1 
(3
0%
)
1.
23
 (1
.0
4,
 1
.4
6)
1.
18
 (0
.9
9,
 1
.4
0)
1,
16
2 
(4
0%
)
1.
91
 (1
.6
3,
 2
.2
4)
1.
76
 (1
.4
9,
 2
.0
8)
14
4 
(1
4%
)
24
0 
(1
1%
)
1
1
26
9 
(9
%
)
1
1
88
2 
(8
6%
)
1,
92
2 
(8
9%
)
1.
31
 (1
.0
5,
 1
.6
3)
1.
26
 (1
.0
1,
 1
.5
8)
2,
63
1 
(9
1%
)
1.
60
 (1
.2
9,
 1
.9
8)
1.
36
 (1
.0
9,
 1
.6
9)
5 
(1
%
)
5 
(0
%
)
0.
52
 (0
.1
5,
 1
.8
2)
0.
53
 (0
.1
5,
 1
.8
6)
3 
(0
%
)
0.
26
 (0
.6
1,
 1
.0
9)
0.
30
 (0
.0
7,
 1
.2
5)
38
 (4
%
)
85
 (4
%
)
1.
15
 (0
.7
6,
 1
.7
5)
1.
16
 (0
.7
6,
 1
.7
7)
54
 (2
%
)
0.
61
 (0
.3
9,
 0
.9
6)
0.
64
 (0
.4
1,
 1
.0
0)
19
3 
(1
9%
)
37
1 
(1
7%
)
1
1
44
9 
(1
6%
)
1
1
42
6 
(4
2%
)
84
8 
(3
9%
)
1.
04
 (0
.8
4,
 1
.2
8)
1.
04
 (0
.8
4,
 1
.2
8)
1,
17
6 
(4
1%
)
1.
19
 (0
.9
7,
 1
.4
5)
1.
18
 (0
.9
7,
 1
.4
5)
18
5 
(1
8%
)
44
2 
(2
05
)
1.
24
 (0
.9
7,
 1
.5
9)
1.
23
 (0
.9
5,
 1
.5
6)
61
1 
(2
1%
)
1.
42
 (1
.1
2,
 1
.8
0)
1.
33
 (1
.0
5,
 1
.6
8)
17
9 
(1
7%
)
41
2 
(1
9%
)
1.
20
 (0
.9
4,
 1
.5
3)
1.
15
 (0
.9
0,
 1
.4
8)
60
7 
(2
1%
)
1.
46
 (1
.1
5,
 1
.8
5)
1.
26
 (0
.9
9,
 1
.6
0)
FA
: T
op
 1
0%
 n
on
-m
us
cu
los
ke
let
al 
fre
qu
en
t a
tte
nd
er
OR
: o
dd
s r
at
io
* A
dj
us
te
d 
fo
r a
ll p
re
se
nt
ed
 va
ria
bl
es
.
Chapter 8: Time taken to identify RRCs
228
8.4.2 Analysis 2: Removal of requirement for regional consultations in three 
separate years
a. Extra RRCs identified
An additional 1,618 RRCs were identified when the requirement for a regional musculoskeletal 
consultation in each of three separate years was removed, representing a 27% (1,618/6,088) 
increase on the RRCs identified using the established Rohrbeck-2007 RRC criteria. Seventy-nine 
percent (6,088/7,706) of RRCs identified when the separate years requirement was removed met 
established Rohrbeck-2007 criteria.
Table 8.4 cross-tabulates the Rohrbeck-2007 RRCs identified at: i) three years; ii) between three 
and four years; and iii) between four and five years, against RRCs identified without the 
requirement for regional complaints in three separate years who were identified at: i) one year; ii) 
between one and two years; iii) between two and three years; iv) between three and four years; 
and v) between four and five years. This shows that the adapted criteria identify RRCs sooner.
Table 8.4 Cross tabulation of Rohrbeck-2007 RRCs identified at yearly intervals from 3 to 5 years with 
RRCs identified without the requirement for regional consultations in separate years identified at 
yearly intervals from 1 to 5 years (row percentages).
RRCs identified without the requirement for regional 
consultations in each of three separate years
At 1 year At 1 to 2 
years
At 2 to 3 
years
At 3 to 4 
years
 At 4 to 5 
years
Total
Not Rohrbeck-2007 RRC
Rohrbeck-2007 RRC:
   At 3 years
   At 3 to 4 years
   At 4 to 5 years
   Subtotal: all RRCs
Total
562 (35%) 331 (20%) 281 (17%) 312 (19%) 132 (8%) 1,618
807 (28%) 1,188 (41%) 905 (31%) 0 (0%) 0 (0%) 2,900
401 (19%) 351 (16%) 413 (19%) 997 (46%) 0 (0%) 2,162
126 (12%) 107 (10%) 81 (8%) 128 (12%) 584 (57%) 1,026
1,334 (22%) 1,646 (27%) 1,399 (23%) 1,125 (18%) 584 (10%) 6,088
1,896 (25%) 1,977 (26%) 1,680 (22%) 1,437 (19%) 716 (9%) 7,706
At one year the criteria without the requirement for regional consultations in separate years 
identified 28% of Rohrbeck-2007 RRCs who would not have been identified until three years with 
established criteria, 19% of those who would not have been identified until four years, and 12% 
who would not have been identified until five years. This increases to 69%, 35%, and 22% 
(cumulative percentages) respectively at two years.
If the requirement for regional consultations in separate years is removed, then 22% of all 
established RRCs (i.e. RRCs identified using the established Rohrbeck-2007 criteria, including the 
separate years requirement) were identified one year from an index musculoskeletal consultation, 
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and this would include those RRCs most severely affected (see analysis 1), but at the cost of an 
extra 562 (35%) of patients who do not fulfil the full criteria. Further, of all established RRCs, if the 
requirement for regional consultations in separate years were removed, 49% were found within 
two years, 72% in three, and 90% in four (see Table 8.5).
For all RRCs identified by removing the requirement for regional consultations in three separate 
years, 25% of RRCs were found within a year, 50% in two years, 72% in three (contrasted with 
48% of established RRCs identified using full criteria found at three years), and 91% in four 
(contrasted with 83% of established RRCs identified using full criteria found at four years).
Table 8.5 Cumulative number (%) of RRCs identified by year from earliest time point for identification.
Number (%) of RRCs identified by year
Within 1 year At 2 years At 3 years At 4 years At 5 years Total
Rohrbeck-2007 RRC
RRCsa identified when 
separate years 
requirement removed
RRC-amended-criterab
- - 2,900 (48%) 5,062 (83%) 6,088 (100%) 6,088
1,334 (22%) 2,980 (49%) 4,379 (72%) 5,505 (90%) 6,088 (100%) 6,088
1,896 (25%) 3,873 (50%) 5,553 (72%) 6,990 (91%) 7,706 (100%) 7,706
a. Those RRCs fulfilling the original criteria only;
b. All RRCs identified when removing separate years requirement.
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b. Comparison of established RRCs with extra RRCs
The additional patients identified by removing the requirement for regional musculoskeletal 
consultations in each of three separate years were slightly younger, less likely to be female, less 
likely to be frequent attenders, and had fewer somatic symptoms and lower consultation rates 
than RRCs identified using established criteria (see Table 8.6). However, they were clearly 
different from the control group on these variables.
Table 8.6 Age and gender distribution, frequent attendance, somatic symptom count and five-year 
musculoskeletal and non-musculoskeletal consultation counts for RRCs identified using established 
Rohrbeck-2007 RRC criteria and additional patients identified by removing the requirement for 
regional musculoskeletal consultations in three separate years.
Mean 
age 
(sd)
Female 
(%)
FAs
(%)
Somatic 
symptom count
Non-MS 
consultation 
count
MS 
consultation 
count
Total
Mean 
(sd)
Median 
(IQR)
Mean 
(sd)
Median 
(IQR)
Mean 
(sd)
Median 
(IQR)
A. RRC using 
established 
Rohrbeck-2007 
criteria
B. Additional RRCs 
added to A if 
separate years 
criterion removed
C. Control (single-
region consulters)
59 (17) 61% 34% 2.89 (2.19) 2 (1, 4) 52 (35) 44 (27, 68) 12 (8) 10 (7, 15) 6,088
56 (17) 55% 20% 2.06 (1.81) 2 (1, 3) 39 (30) 32 (17, 52) 7 (4) 6 (4, 8) 1,618
46 (21) 50% 7% 1.22 (1.35) 1 (0, 2) 20 (17) 16 (8, 28) 2 (2) 1 (1, 2) 20,499
FA: top 10% of non-musculoskeletal frequent attenders.
MS: musculoskeletal
sd: standard deviation
IQR: interquartile range
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8.5 Discussion
Nearly half (48%) of all RRCs could be identified within three years of an initial regional 
musculoskeletal consultation and 83% identified within four. RRCs identified earlier had more 
severe consultation-based health (more recorded somatic symptoms, more consultations, and 
more likely to be a frequent attender). 
If the requirement for regional consultations in three separate years is removed from the RRC 
definition 27% more RRCs are identified. Removing the requirement for regional consultations in 
separate years leads to earlier identification of RRCs; 72% of RRC-all are identified within three 
years in contrast to only 48% using the established Rohrbeck-2007 criteria. However, the extra 
RRCs identified by adapting the RRC consultation pattern have a different consultation-based 
health profile from that of RRCs identified using established criteria; they have fewer somatic 
symptoms, are less likely to be frequent attenders, and have fewer non-musculoskeletal 
consultations. 
8.5.1 RRCs identified in shorter timeframes
The high percentage of patients identified within three to four years of the index musculoskeletal 
consultation suggests that the timeframe for RRC identification can be shortened. Whether the 
timeframe for identification should be shortened, however, depends on the context in which the 
criteria are used. If the intention is to use the criteria retrospectively (to identify research subjects 
or patients at the practice currently unrecognised as having CWP with a view to clinical 
intervention), then reducing the timeframe over which RRCs are identified could potentially halve 
the number of RRCs picked up. Without the need for a speedy diagnosis, there seems no 
justification for reducing the timeframe over which a RRC can be identified. However, since RRCs 
identified over shorter timeframes have been demonstrated to have more severe consultation-
based health (and therefore greater clinical need) than those identified over longer timeframes, it 
is therefore arguably important in a clinical setting to identify patients (perhaps via an electronic 
flag in the computer system) as soon as they meet the RRC consultation criteria. Previous 
research (McBeth et al. 2001a) has shown that patients with features of somatisation are more 
likely to have persistent widespread pain and that persistent widespread pain patients are more 
likely to make more frequent consultations for disruptive symptoms; this suggests that the RRCs 
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we found in shorter timeframes, who had more recorded somatic symptoms and more frequent 
attendance, are perhaps those at most risk of developing persistent widespread pain. Clinically, 
therefore, identifying these more severe early RRCs promptly, before their condition becomes truly 
chronic, is a priority. Earlier identification would allow more timely clinical evaluation and if 
necessary therapeutic intervention as soon as the criteria permit, and potentially halt progression 
to a more persistent state.
8.5.2 Regional consultations in separate years
Removing the requirement for regional consultations in three separate years decreases the time 
taken to identify a RRC, but it identifies extra patients (27% more RRCs are identified) who do not 
necessarily fit the RRC consultation profile. Again, the important consideration here is the context 
in which the RRC criteria will be applied. When using the RRC definition to identify individuals for 
participation in research the focus should be on identifying patients accurately. In a research 
setting the time necessary to identify a RRC will be less important than the ability to identify a 
patient accurately fitting the RRC/CWP profile. However, in a clinical context, flagging a patient 
with potential CWP quickly is perhaps more important than definitive diagnosis. A software prompt 
would serve as an indication to a doctor to use their clinical judgement to consider a CWP/FM 
diagnosis in patients fulfilling RRC criteria, offering an opportunity for timely intervention if 
appropriate. 
Removing the separate years criterion might therefore be appropriate in clinical practice as an 
electronic flag for clinicians to consider a CWP diagnosis, but inappropriate in a research context.
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8.5.3 Strengths and limitations
a. Study population
The study population is the same as that used in Chapters Five and Six where we have already 
discussed the limitations of studying only those fully registered for a five-year period and the 
geographical limitations of the CiPCA dataset and suggested that this may only have a small 
influence on generalisability.
b. RRC identification 
In this study we have identified RRCs from an index consultation in 2005. This has allowed us to 
compare RRCs identified within different periods of time from an index musculoskeletal 
consultation. We have also been able to evaluate what proportion of RRCs can be identified 
earlier by adapting RRC criteria by removing the separate years criterion.
However, by identifying RRCs based on consultations in one specific five-year period we may 
have missed patients already fulfilling RRC criteria based on their earlier consultation patterns. By 
not examining data from 2001 to 2005 we have no way of knowing if patients had already fulfilled 
RRC criteria. Ideally this analysis should have been undertaken in a group known to yet to fulfil 
RRC criteria.
c. Consultation-based health measures
The consultation-based measures of health (consultation count, somatic symptom count, frequent 
attendance) we have used in this chapter have been used previously in Chapters Five, Six and 
Seven. We have therefore already discussed that these measures are not a true reflection of 
actual health, but offer a useful indicator of the relative burden of disease and consultation 
behaviour. 
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8.6 Conclusions
RRCs identified earlier appear to be affected more severely, with more recorded somatic 
symptoms and higher consultation frequency. 
Current criteria require a minimum of three years for RRC identification; this can be reduced by 
removing the need for regional consultations in three separate years. However, while generally 
more similar to established RRCs than to single-region consulters, the extra 27% of patients 
identified by removal of this part of the criteria have a less severe consultation profile than 
established Rohrbeck-2007 RRCs, and as a result might be less likely to self-report CWP. It could 
be argued that the benefits of earlier identification of RRCs in clinical practice are worth the price 
of reduced specificity. However, in a research context, where there is less need for early 
diagnosis, the emphasis should remain on accurate patient identification using the full criteria.
The next chapter will use the full updated RRC definition (Rohrbeck-2007 consultation pattern with 
all regional musculoskeletal Read codes) to further characterise RRCs in terms of demographics 
and changes in health and pain over time.
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Chapter 9
Characteristics of recurrent regional consulters 
and changes in health over time
9.1 Introduction
Previous chapters have developed and validated the RRC definition. This chapter aims to apply 
the RRC definition to further explore the characteristics of RRCs and their changes in health over 
time. With the intention of further investigating whether RRCs fit the profile of CWP patients, and to 
help us better understand RRCs to offer insights into how best to intervene to improve their health. 
We aimed to investigate whether RRCs share socio-demographic and self-reported health 
features with CWP patients, in order to provide further evidence to support the hypothesis that 
RRCs fit the profile for CWP. Additionally, to note in what respects the profile of RRCs might differ 
from that of CWP to better understand where RRCs fit within a spectrum of chronic pain and 
polysymptomatic distress which is characteristic of FM and CWP (Häuser et al. 2009c).
Previous studies of self-reported FM and CWP have shown that the following features are 
associated with CWP: increased reporting of sleep problems (Aggarwal et al. 2006), cognitive 
impairment (Wolfe et al. 2013), increased body mass index (Macfarlane et al. 2009a, Walitt et al. 
2011), low socioeconomic status (Macfarlane et al. 2009a, Assumpção et al. 2009, Wolfe et al. 
2013), poor social function (Wolfe et al. 2013), poor self-reported mental and physical health 
(Häuser et al. 2009c, Walitt et al. 2011, Wolfe et al. 2013), and little change in self-reported pain 
and health over time (Walitt et al. 2011). The research presented in this chapter therefore aimed to 
test these characteristics of CWP patients in RRCs in order to explore similarities and differences 
to better appreciate where recurrent regional consulters sit in relation to CWP.
To help us better understand RRCs, in order to offer insight into possible risk factors and perhaps 
suggest how best to intervene to improve their health, we also aimed to explore the profile of 
RRCs in more detail. Specifically whether RRCs experience more social inequality (e.g. tend to be 
more deprived), their perceptions regarding the causes of disease, whether their health continues 
to deteriorate or has plateaued, and whether there are modifiable factors (e.g. social isolation, 
social inequalities, illness perceptions) which might prevent RRC.
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In this chapter therefore, we used the RRC-all definition (original Rohrbeck-2007 criteria with all 
regional musculoskeletal Read codes) to identify RRCs, and we compared their socio-
demographic status, their illness perceptions, and how their self-reported health and pain change 
over time to a control group who were recorded as consulting for single-site problems.
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9.2 Aims and objectives
The primary aims of this chapter were to investigate the socio-demographic characteristics of 
RRCs and their changes in self-reported health and pain over time.
Specifically:
1. To test whether demographic (age, gender, marital status, living alone status) and 
socioeconomic (social class, employment status, social network and deprivation) 
characteristics of RRCs fit those observed in CWP patients.
2. To determine the baseline body mass index of RRCs, since research has identified an 
association between increased body mass index (BMI) and CWP (VanDenKerkhof et al. 2011)
3. To explore RRCs’ perceptions regarding the causes of disease at baseline.
4. To investigate how self-reported mental and physical health of RRCs changes over the time. 
5. To investigate changes in self-reported pain in RRCs over time. 
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9.3 Methods
This chapter, like Chapter Seven, uses data from the North Staffordshire Osteoarthritis Project 
(NorStOP), a prospective cohort study of community-dwelling adults aged 50 years and over 
(Thomas et al. 2004). Three cohorts (NorStOP 1: 2002; NorStOP 2: 2003; NorStOP 3: 2004, 2005) 
were identically recruited and measured via postal surveys of all patients aged 50 years and over 
registered with eight North Staffordshire general practices (see Chapter Seven, section 7.3.1 for 
further information). Health surveys were sent at baseline and consenting responders were 
followed up with repeat questionnaire at three years and six years. Responders were asked for 
consent for medical record review. 
Responders to baseline and three year follow-up health surveys were used to investigate the 
demographics and illness perceptions of RRCs. Changes over time in self-reported health and 
pain in RRCs were assessed in those who responded at baseline, three, and six years. 
9.3.1 Analysis 1: Demographics, socioeconomic characteristics and illness 
perceptions at baseline
This part of the study uses the same sample of the NorStOP cohort used in Chapter Seven, that is: 
responders to baseline and three-year health surveys consenting to medical record review with 
access to a minimum of five years of medical record data. The study sample was investigated for 
possible participation bias in Chapter Seven (section 7.4.1.a) and it was concluded that while 
non-responders at baseline were significantly older and more likely to be male than the study 
population, differences were small and unlikely to affect generalisability. 
We identified RRCs using the established Rohrbeck-2007 criteria (see Chapter Five, section 5.3.1, 
Table 5.1) using all regional musculoskeletal Read codes (see appendix A5.2) applied to the five 
years of medical record data starting two years prior to the baseline health questionnaire. Controls 
were those used in previous chapters, that is, individuals recorded as consulting for only one of 
the three body regions specified in the RRC criteria (axial, upper limb or lower limb) over the five 
years starting two years prior to the baseline health questionnaire.
RRCs and controls were compared on age, gender, marital status, whether they lived alone, 
current employment status, social class, deprivation, body mass index (BMI), social network, and 
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illness perceptions at baseline (Table 9.1). RRCs have already been compared to controls on 
SF-12 mental and physical component summary scores, SF-36 physical function score and HADS 
anxiety and depression scores in Chapter Seven, section 7.4.3. 
Table 9.1 Measures of self-reported health, social networks and illness perceptions.
Outcome measure Score 
range
High score Reference
SF-12
SF-36
HADS
Berkman-Syme 
SNI
IPQ(R)
12 item short form health survey physical 
and mental component summary scores.
0–100 Best health Ware et al. 1996
8 item short form health survey physical 
functioning subscale.
0–100 Best health Ware et al. 1992
Hospital anxiety and depression scale. 0–21 Worst health Zigmond and Snaith 1983
Social network index, 4 levels of social 
connection: ‘Most integrated’ to ‘Most 
isolated.’
1–4 Most 
integrated
Berkman and Syme 1979
The revised illness perceptions 
questionnaire, causal component. 
Separated into scores for four different 
causes of illness: psychological attributes,  
risk factors, immunity, and accident or 
chance.
Moss-Morris et al. 2002
• Risk factor attribution score 7–35 Belief in 
specified 
attributes 
causing 
condition
• Psychological attribution score 6–30
• Immunity attribution score 3–15
• Accident/chance attribution score 2–10
Body mass index (BMI) is a crude measure used to establish if an individual is under or over 
weight. BMI is calculated as self-reported mass in kilograms divided by height in metres squared. 
A BMI between 19 and 25 is considered a healthy weight and one over 30 is considered obese 
(WHO 2000). Deprivation was measured using the Index of Multiple Deprivation (Payne and Abel 
2012).
Marital status, employment status, social class, and living alone were established by calculating 
the percentage of RRCs or controls married or cohabiting, in paid employment, living alone, and 
in high, middle or low social class. Social class was determined using Office for National Statistics 
(ONS) social class definitions (2005). High social class was determined to be those fitting ONS 
defined higher managerial or higher professional classifications. Middle class were those in ONS 
intermediate self-employed occupations, and low class were those fitting lower supervisory/
technical, semi-routine or routine occupations.
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Level of social connection was assessed using the Berkman-Syme social network index (1979) 
which evaluates four levels of social connection from the 'most integrated' to the 'most isolated.' 
The social network index considers the number of social ties and their relative importance, for 
example contact with friends and relatives is weighted more heavily than group membership. We 
calculated the percentage of RRCs and controls who were in the two most isolated groups 
(groups one and two) and those in groups with the most social integration (groups three and four).
Illness perceptions of RRCs and controls were investigated using the revised illness perceptions 
questionnaire (IPQ(R) Moss-Morris et al. 2002) causal component. This provides scores for beliefs 
about four different causes of illness: psychological, risk factors, immunity, and accident or 
chance.
Differences in baseline age, BMI, deprivation score, and the four causes of illness from the IPQ(R) 
for RRCs and controls were tested using t-tests. Differences between RRCs and controls on the 
dichotomous outcomes: marital status, employment status, living alone, and social network were 
investigated using chi-squared tests. Social class differences between RRCs and controls were 
investigated with logistic regression.
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9.3.2 Analysis 2: Changes in self-reported health and pain over time
For this section of the study we restricted the analysis to the subgroup of those included in 
Analysis One above who also responded to the six year follow-up questionnaire (i.e. responders 
to baseline, three- and six-year health surveys, and consenting to medical record review with 
access to a minimum of five years of medical record data).
As for Analysis One, RRCs and single-region controls were defined using medical records for the 
five years starting two years prior to the baseline health questionnaire.
a. Participation bias
Potential participation bias was examined by comparing those in Analysis One who also 
responded at six years to those who did not. Comparisons were made on age, gender, marital 
status, employment status, deprivation, and baseline self-reported health and pain.
b. Changes in self-reported health
We investigated changes in SF-36 physical function score, SF-12 mental and physical component 
scores, and HADs anxiety and depression scores over time, by calculating the mean difference 
between: i) baseline and three-year scores; and ii) between baseline and six-year scores for 
RRCs and controls. We tested for differences between RRCs and controls by comparing the mean 
difference between baseline and three-year scores, and baseline and six-years scores, using 
independent t-tests for each self-reported health variable.
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c. Changes in self-reported pain
We evaluated changes in self-reported pain over time by making a descriptive comparison of the 
prevalence of: i) any self-reported pain; ii) ACR-90 widespread pain; and iii) Manchester 
widespread pain at baseline, three-years and six-years in RRCs and controls.
To investigate self-reported pain trajectories for RRCs and controls we defined five widespread 
pain journeys for the six years covered by the study:
A. No widespread pain reported.
B. Persistent widespread pain.
C. Widespread pain resolving during the study.
D. Onset of widespread pain during the study.
E. Episodic widespread pain.
How the five pain trajectories are mapped to ACR-90 widespread pain reporting at baseline, 
three-years and six-years is shown in Table 9.2.
Table 9.2 Definitions of self-reported widespread pain trajectories in the six years from baseline.
ACR-90 widespread pain reporting
Baseline 3 years 6 years
A. No widespread pain reported
B. Persistent widespread pain
C. Widespread pain improving
D. Onset of widespread pain during study
E. Episodic widespread pain
X X X
✓ ✓ ✓
✓ X X
✓ ✓ X
X ✓ ✓
X X ✓
✓ X ✓
X ✓ X
We investigated pain trajectories for RRCs and controls by calculating the percentage of RRCs 
and controls identified by each of the five pain trajectories.
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9.4 Results
9.4.1 Analysis 1: Demographics, socioeconomic characteristics and illness 
perceptions at baseline
As in Chapter Seven, of the 8,286 responders to NorStOP baseline and three-year surveys 
consenting to medical record review with a minimum of five years of medical record data, 24% 
(n=1,979) of individuals were identified as single-region controls, and 22% (n=1,786) were 
identified as RRCs.
Baseline socio-demographics and illness perceptions for controls and RRCs and the results of 
statistical testing for differences between RRCs and controls are shown in Table 9.3. 
RRCs were significantly older (mean difference=0.97 years, 95% CI 0.39, 1.55), with a higher BMI 
(mean difference=0.88, 95% CI: 0.59, 1.17), more deprived (mean difference=-656, 95% CI: 
-1,137, -174), more likely to be female (percentage difference: 12%, 95% CI: 9, 15), and less likely 
to be in paid employment (percentage difference: -9%, 95% CI: -12, -6) than controls. 
RRCs were similar to controls on marital/cohabiting status (percentage difference in married/
cohabiting: 3%, 95% CI: 0, 6), social networks (percentage difference most isolated: 3%, 95% CI: 
-1, 6), and whether they lived alone (percentage difference: 3%, 95% CI: 1, 6). There were no 
significant differences between RRCs and controls in perceiving psychological problems as 
causes of ill-health (mean difference= 0.03 95% CI: -0.17, 0.22), or accident or chance as causes 
of ill-health (mean difference=0.02, 95% CI: -0.07, 0.10), nor on whether they considered risk 
factors (mean difference=-0.18, 95% CI: -0.38, 0.04) or immunity (mean difference=-0.05, 95% CI: 
-0.12, 0.08) as causes of ill-health.
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Table 9.3 Comparison of RRCs and controls on demographics and self-reported social network index 
and illness perceptions.
Controls RRCs Mean/percentage 
difference
(95% CI) 
p-value
(n =1,979) (n = 1,786)
Gender
Female
Male
Age, mean (sd)
Marital status*
Married or cohabiting
Not married or cohabiting
Lives alone*
Yes
No
Current employment status*
Paid employment
Not in paid employment (unemployed, 
retired, ill health, housewife, other)
Social classa *
High
Middle
Low
Deprivation scoreb, mean (sd)*
BMI, mean (sd)*
Berkman-Syme social network indexc*
Most isolated (index I or II)
Most integrated (index III or IV)
Illness perception questionnaire, causal 
componentd*
Risk factor attribution score, mean (sd)
Psychological attribution score, mean (sd)
Immunity attribution score, mean (sd)
Accident/chance attribution score, mean (sd)
<0.001
959 (49%) 1,084 (61%) 12% (9, 15)
1,020 (52%) 702 (39%)
64.0 (9.1) 65.0 (9.1) 0.97 (0.39,1.55) 0.001
0.58
1,462 (75%) 1,268 (72%) -3% (-6, 0)
500 (25%) 499 (28%)
0.18
384 (20%) 399 (23%) 3% (1, 6)
1,524 (80%) 1,309 (77%)
<0.001
672 (35%) 452 (26%) -9% (-12, -6)
1,255 (65%) 1,265 (74%)
0.001**
420 (22%) 310 (19%) -4% (-6, -1)
398 (21%) 304 (18%) -3% (-5, 0)
1,069 (57%) 1,043 (63%) 6% (3, 10)
14,044 (7,667) 13,953 (7,451) -656 (-1,137, -175) 0.008
26.6 (4.3) 27.5 (4.7) 0.88 (0.59, 1.17) <0.001
0.11
972 (60%) 939 (63%) 3% (-1, 6)
636 (40%) 545 (37%)
27.3 (3.1) 27.1 (3.3) -0.18 (-0.38, 0.04) 0.102
23.1 (3.0) 23.1 (3.0) 0.03 (-0.17, 0.22) 0.778
12.2 (1.5) 12.2 (1.6) -0.05 (-0.12, 0.08) 0.71
6.8 (1.3) 6.8 (1.3) 0.02 (-0.07, 0.10) 0.726
a. Higher = higher managerial, higher professional or lower managerial/professional. Middle = intermediate occupations or 
self-employed. Lower = lower supervisory/technical, semi-routine or routine occupations (Office for National Statistics 
2005).
b. Rank index of multiple deprivation (Payne and Abel 2012) (low score = high deprivation)
c. Berkman-Syme social network index (Berkman and Syme, 1979)
d. Illness perception questionnaire (Moss-Morris et al. 2002) (high score = belief in specified attribute causing condition, 
Risk factor attribution 7-35; Psychological attribution 6-30; Immunity attribution 3-15; Accident/chance attribtion: 2-10).
sd. standard deviation
*Data on these variables were incomplete with n ranging from 1,608 to 1,962 for controls and 1,484 to 1,767 for RRCs.
**Calculated using logistic regression (low social class as reference category).
All self-reported health and pain measures from baseline health survey responses.
p-values in bold are less than or equal to 0.05.
Chapter 9: Characteristics of recurrent regional consulters and changes in health over time
245
9.4.2 Analysis 2: Changes in self-reported health and pain over time
Of the 8,286 responders to baseline and three-year surveys, 5,650 (68%) consented to follow-up 
(Figure 9.1). Of those consenting to follow-up, 389 (7%) were either excluded by GPs (for example 
patients with terminal illnesses or dementia) or during the mailing (deaths, departures, unwell, or 
returned addressee unknown). Of those eligible for follow-up, 83% (n = 4,389) responded to the 
six-year health survey and were therefore eligible for inclusion in this analysis. The same 
percentage (53%) of both RRCs (n=957), and controls (n=1,043) responding at baseline and 
three years (study population from Analysis One) also responded at six-year follow-up. 
Figure 9.1 Participation flowchart for changes in health over time analysis.
a. Participation bias
The baseline demographics and self-reported health and pain of responders to baseline and 
three-year health surveys only (incomplete responders), and responders to baseline, three-year 
and six-year health surveys (study sample for Analysis Two) is shown in Table 9.4. Differences 
between responders to baseline and three years only, and responders to baseline, three years 
and six years were small for all variables tested. 
However, while differences were small, the study sample (responders to baseline, three years and 
six years) were younger (mean difference=-2.64 years, 95% CI: 3.03, -2.25), less deprived (mean 
difference=-1,036, 95% CI: -1,357, -715), more likely to be married or cohabiting (percentage 
difference: 3%, 95% CI: 1, 4), and in paid employment (percentage difference: 6%, 95% CI: 4, 8), 
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of a high social class (percentage difference: 4, 95% CI: 2, 6), with better self-reported baseline 
physical health (SF-12 physical component score: mean difference=1.74, 95% CI: 1.18, 2.29; 
SF-36 physical function score: mean difference=5.09, 95% CI: 3.76, 6.41), less depression (mean 
difference on HADS depression scale=-0.38, 95% CI: -0.53, -0.23), and less cognitive impairment 
(mean difference=-1.15, 95% CI: -2.08, -0.22) than those not-responding to six-year follow-up. 
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Table 9.4 Comparison of baseline demographics and self-reported health and pain in responders to 
baseline and three years and responders to baseline, three years and six years.
Incomplete 
responders 
(Responders to 
baseline and 3 years 
only)
Study sample 
(Responders to 
baseline, 3 years 
and 6 years)
Mean/percentage 
difference
(95% CI) 
n = 3,897 n = 4,389
Gender
Female
Male
Age, mean (sd)
Marital status*
Married or cohabiting
Not married or cohabiting
Current employment status*
Paid employment
Not in paid employment (unemployed, retired, ill 
health, housewife, other)
Social classa *
High
Middle
Low
Deprivation score b, mean (sd)*
Self-reported health at baseline
SF-12 physical component score (0-100)c, mean (sd)*
SF-12 mental component score (0-100)c, mean (sd)*
SF-36 physical function score (0-100)d, mean (sd)*
Anxiety (0-21)e, mean (sd)*
Depression (0-21)e, mean (sd)*
Cognitive impairment (0-100)f, mean (sd)*
Baseline self-reported pain (%)*
Baseline ACR-90 widespread pain (%)*
Baseline Manchester widespread pain (%)*
2,068 (53%) 2,409 (55%) 2% (0, 4)
1,829 (47%) 1,980 (45%)
65.9 (9.6) 63.2 (8.5) -2.64 (3.03, -2.25) 
2,774 (72%) 3,233 (74%) 3% (1, 4)
1,089 (28%) 1,114 (26%)
1,049 (28%) 1,464 (34%) 6% (4, 8)
2,709 (72%) 2,813 (66%)
716 (20%) 985 (24%) 4% (2, 6)
682 (19%) 864 (21%) 2% (0, 4)
2,217 (61%) 2,329 (56%) -6% (-8, -3)
14,502 (7,590) 13,466 (7,292) -1,036 (-1,357, -715)
41.5 (12.4) 43.3 (12.1) 1.74 (1.18, 2.29)
49.9 (10.8) 50.4 (10.8) 0.43 (0.64, 0.92)
63.3 (31.3) 68.4 (28.5) 5.09 (3.76, 6.41)
6.4 (4.1) 6.5 (4.2) 0.09 (-0.09, 0.27)
4.5 (3.5) 4.1 (3.4) -0.38 (-0.53, -0.23)
13.0 (21.9) 11.8 (20.0) -1.15 (-2.08, -0.22)
2,806 (72%) 3,183 (73%) 1% (-1, 2)
853 (22%) 997 (23%) 1% (-1, 3)
516 (13%) 609 (14%) 1% (-1, 2)
a. Higher = higher managerial, higher professional or lower managerial/professional. Middle = intermediate occupations or 
self-employed. Lower = lower supervisory/technical, semi-routine or routine occupations (Office for National Statistics 
2005).
b. Rank index of multiple deprivation (Payne and Abel 2012) (low score = high deprivation)
c. 12 item short form health survey – physical and mental component summary scores (Ware et al. 1996) (100 best health)
d. 36 item short form health survey – physical functioning subscale (Ware et al. 1992) (100 best health)
e. Hospital Anxiety and Depression Scale (Zigmond and Snaith 1983) (21 worst health)
f. Sickness Impact Profile – alertness subscale (Bergner et al. 1981) (100 worst health)
sd. standard deviation
*Data on these variables were incomplete with n ranging from 3,615 to 3,863 for baseline and three-year only responders 
and 4,178 to 4,347 for the study sample.
All self-reported health and pain measures from baseline health survey responses.
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b. Changes in self-reported health
In the six years from baseline, for both RRCs and controls, self-reported health (SF-12 mental and 
physical component score, and SF-36 physical function score) declined, while there was an 
improvement in self-reported anxiety but little change in self-reported depression (HADS) (Table 
9.5). The highest magnitude of change was observed in physical function score (SF-36), with 
mean reductions from baseline scores: at three years of 3.1 for RRCs, and 3.6 for controls; and at 
six years of 5.7 for RRCs, and 7.6 for controls. Changes in self-reported health over time for all 
other variables examined were small. 
Controls had slightly higher levels of decline in self-reported physical health (SF-12 physical 
component and SF-36 physical function scores) than RRCs. However, the only significant mean 
difference between RRCs and controls was change between baseline and six-years on the SF-12 
physical component score (p=0.012, mean difference=1.22, 95% CI 0.27, 2.18); although controls 
still had much better self-reported physical health at six years than RRCs. Changes in 
psychological measures (SF-12 mental component score, and HADS anxiety and depression) 
over time for RRCs and controls were similar (Table 9.6).
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Table 9.5 Changes in mean self-reported health (sd) over time for RRCs and controls.
Outcome Control RRC Mean difference 
between controls 
and RRCs 
(95% CI)
p-value**
n=1,043 n=957
SF-36 physical function score* 
(High score = best health)
Baseline
3 years
6 years
Mean difference between BL and 3-year scores
Mean difference between BL and 6-year scores
SF-12 physical component score*
(High score = best health)
Baseline
3 years
6 years
Mean difference between BL and 3-year scores
Mean difference between BL and 6-year scores
SF-12 mental component score*
(High score = best health)
Baseline
3 years
6 years
Mean difference between BL and 3-year scores
Mean difference between BL and 6-year scores
HADs anxiety*
(High score = worst health)
Baseline
3 years
6 years
Mean difference between BL and 3-year scores
Mean difference between BL and 6-year scores
HADs depression*
(High score = worst health)
Baseline
3 years
6 years
Mean difference between BL and 3-year scores
Mean difference between BL and 6-year scores
75.3 (25.2) 55.3 (29.1)
71.7 (27.0) 52.0 (29.8)
67.8 (29.1) 49.2 (30.7)
-3.6 (15.9) -3.1 (19.1) 0.55 (-1.04, 2.14) 0.494
-7.6 (19.5) -5.7 (21.3) 1.81 (-0.27, 3.65) 0.053
45.8 (11.2) 37.1 (11.6)
44.8 (11.2) 36.8 (11.2)
43.7 (11.6) 36.6 (11.5)
-1.0 (8.5) -0.5 (8.9) 0.47 (-0.37, 1.32) 0.271
-1.9 (9.5) -0.7 (10.2) 1.22 (0.27, 2.18) 0.012
51.4 (10.3) 48.3 (11.7)
50.9 (9.7) 47.7 (11.2)
50.5 (9.8) 47.2 (10.9)
-0.5 (9.5) -0.9 (10.5) -0.36 (-1.34, 0.61) 0.465
-1.0 (10.5) -1.2 (11.3) -0.25 (-1.29, 0.82) 0.663
5.96 (3.95) 7.53 (4.12)
5.39 (3.96) 6.86 (4.24)
5.12 (3.86) 6.46 (4.24)
-0.61 (2.88) -0.71 (3.12) -0.10 (-0.37, 0.17) 0.470
-0.90 (3.15) -1.07 (3.43) -0.17 (-0.47, 0.13) 0.259
3.66 (3.12) 4.96 (3.42)
3.59 (3.26) 4.89 (3.54)
3.65 (3.34) 4.92 (3.63)
-0.10 (2.39) -0.08 (2.58) 0.01 (-0.21, 0.23) 0.917
-0.01 (2.69) -0.04 (2.95) -0.03 (-0.29, 0.22) 0.794
*Data on these variables were incomplete with n ranging from 899 to 1,034 for controls and 757 to 941 for RRCs.
**p-value for independent t-test testing for differences between control and RRC means.
BL: Baseline
p-values in bold are less than or equal to 0.05.
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c. Changes in self-reported pain
Table 9.6 shows frequency of self-reported pain in RRCs and controls at baseline, three years, 
and six years. For controls prevalence of self-reported pain increased with time from baseline to 
six-year follow-up; prevalence of any pain rose from 33% to 70%, and ACR-90 widespread pain 
increased from 15% to 22%. For RRCs widespread pain prevalence increased from baseline to 
six years, with ACR-90 widespread pain prevalence 37% at baseline and 43% and 42% at three 
and six years respectively. Prevalence of any self-reported pain in RRCs was 90% both at 
baseline and three years, reducing to 86% at six years.
Self-reported pain was higher in RRCs than controls for all self-reported pain definitions at each 
time point. There was approximately twice as many RRCs than controls reporting ACR-90 
widespread pain at each time point. 
Table 9.6 Number (%) of cases and controls self-reporting pain at baseline, 3 years and 6 years.
Control
n=1,043
RRC
n=957
Baseline 3 years 6 years Baseline 3 years 6 years
Any self-reported pain 
ACR-90 widespread pain
Manchester widespread pain
346 (33%) 730 (70%) 731 (70%) 858 (90%) 858 (90%) 825 (86%)
161 (15%) 218 (21%) 231 (22%) 355 (37%) 413 (43%) 404 (42%)
89 (9%) 137 (13%) 144 (14%) 224 (23%) 269 (28%) 273 (29%)
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Table 9.7 shows self-reported ACR-90 widespread pain trajectories over the six years of the study 
for RRCs and controls. Only 37% (n=354) of RRCs, compared to 67% (n=695) of controls, did not 
report ACR-90 widespread pain on any of the three health surveys (baseline, three years or six 
years). Thirty-seven percent of RRCs either reported widespread pain on all three surveys (B. 
Persistent ACR-90 pain), or reported the onset of widespread pain at three or six years (D. Onset 
of ACR-90 pain during the study). Twenty-five percent either had widespread pain that resolved 
(C. ACR-90 pain improving) or episodic widespread pain (E).
Table 9.7 Self-reported widespread pain trajectories over six years.
Control
n=1,043
RRC
n=957
A. No ACR-90 pain reported
B. Persistent ACR-90 pain
C. ACR-90 pain improving
D. Onset of ACR-90 pain during study
E. Episodic ACR-90 pain
695 (67%) 354 (37%)
76 (7%) 186 (19%)
67 (6%) 125 (13%)
137 (13%) 174 (18%)
68 (7%) 118 (12%)
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9.5 Discussion
As shown previously across all ages, RRCs were older, and more likely to be female in this 
population aged 50 and over. We found that they also had an increased BMI, and a lower 
socioeconomic status (more deprived, less likely to be in paid employment and, a lower social 
class) than controls recorded as consulting for problems in a single musculoskeletal region (axial, 
lower limb or upper limb). However, differences between RRCs and controls were small, and there 
was no significant difference between RRCs and controls on marital/cohabiting status, social 
isolation, living alone, or perceptions regarding the causes of illness. 
In the six years from baseline there was little change in self-reported health status for both RRCs 
and controls. Mean self-reported physical health declined slightly, depression was stable, while 
self-reported anxiety improved slightly. The largest changes were seen in self-reported physical 
function (SF-36) with a mean fall between baseline and six-year scores of -5.7 for RRCs, and -7.6 
for controls.
Prevalence of self-reported widespread pain in RRCs showed a five to six percent increase 
between baseline and three years; whereas between three years and six years, there was a one 
percent increase in ACR-90 widespread pain and a one percent decrease in Manchester 
widespread pain. Single-region controls demonstrated a lower prevalence of self-reported pain 
than RRCs, but demonstrated increased pain reporting over time.
Thirty-seven percent of RRCs had either persistent widespread pain or onset of widespread pain 
during the study compared to 20% of controls.
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9.5.1 Demographics, socioeconomic characteristics and illness perceptions
In the following interpretation of the baseline differences between RRCS and controls we must 
keep in mind the caveat that differences were small for the majority of variables assessed.
RRCs were older and more likely to be female than single-site musculoskeletal consulters, 
consistent with findings from the systematic review reported in Chapter Three – where we noted 
increased prevalence of CWP in women and older people.
We found that RRCs lived in more deprived areas, were more likely to be in a low social class, and 
less likely to be in paid employment than controls – this is consistent with the findings from the 
British Birth Cohort (Macfarlane et al. 2009a), a 2009 study (Davies et al. 2009a) demonstrating 
that low socioeconomic status is related to new onset of CWP, and a Brazilian study (Assumpçao 
et al. 2009) suggesting higher CWP prevalence in a low socioeconomic population. However, 
RRCs were slightly older than controls, so retirement may account for fewer RRCs being in paid 
employment than controls, but age differences were small, so these findings appear to support 
the theory that the RRC definition identifies patients from the CWP/FM spectrum.
Increased rates of divorce have been seen in FM patients (Wolfe et al. 1995), CWP has been 
shown to be associated with insecure attachment styles (Davies et al. 2009b), and more pain sites 
have been noted in individuals who are separated or divorced (Kamaleri et al. 2008b). 
Conversely, in this study marital status was similar in RRCs and controls, and in a group of over 
50s, it is likely that mortality rather than divorce is the reason for being single.
A 2002 (Bergman et al.) study suggested that personal social support reduced the risk of CWP 
onset, suggesting that our finding of more social isolation than integration in RRCs is consistent 
with the RRC definition identifying individuals with CWP. However, we found similar levels of social 
isolation in controls, suggesting that increased social isolation is not specific to RRCs.
Research has shown that, compared to those with acute pain, patients with chronic pain have 
higher scores for all four causal attributions on the illness perceptions questionnaire (Moss-Morris 
et al. 2002) and a recent study (Cedraschi et al. 2013) suggested that 50% of patients with FM 
attributed their condition to psychological problems. In accord with this we found a moderate to 
high score for belief in psychological causes of disease in RRCs (mean score: 23, sd 3, range of 
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possible scores: 6–30), however, the other three causal attributions on the illness perceptions 
questionnaire also scored towards the higher end of score ranges, and RRCs and controls had 
similar perceptions regarding the causes of ill-health. Being aware of, and addressing patients 
beliefs regarding the possible cause for their condition may help in tailoring treatment, and 
helping patients understand the onset of their condition and manage their future behaviour.
Our finding of an increased BMI in RRCs is consistent with findings in CWP patients from the 1958 
British Birth Cohort (Van Den Kerkhof et al. 2011) and consequently, since it might be a risk factor, 
diet and lifestyle advice should be considered when managing these patients.
9.5.2 Changes in self-reported health and pain over time
RRCs showed little deterioration in their generally already poor self-reported health, suggesting 
that this is a group who have already reached a level of chronic ill-health. This is consistent with 
research (Walitt et al. 2011) demonstrating little change in self-reported pain and health over time 
for FM patients. However, there was a moderate decline in physical function suggesting a 
continuing deterioration albeit at a similar rate to controls. SF-36 physical function score has been 
shown to be correlated to a FM symptom scale based on the widespread pain index and 
symptom severity score from the ACR-2010 criteria (Wolfe et al. 2011a). The lower SF-36 physical 
function score in RRCs than controls is therefore consistent with RRCs fitting the construct for 
CWP. This, and the moderate decline in physical function over time, underline the importance of 
identifying this group early and attempting to intervene before they progress to a more severe 
state. However, the older age group analysed by this study may also account for limited changes 
in health over time and the small differences observed between RRCs and controls.
Changes in self-reported mental health for RRCs over the six years of the study were small and 
somewhat conflicting. SF-12 mental component score deteriorated slightly over the duration of the 
study, but anxiety scores improved, and depression scores remained stable. The limited changes 
again suggest a group who have already reached a poor level of health, however, slight 
improvements in anxiety might reflect an adaptation to chronic pain (von Korff and Simon 1996), 
but it would be imprudent to draw conclusions from such small changes.
Over 60% of RRCs reported ACR-90 widespread pain on one or more of the three questionnaires 
administered over the six years of the study. Since RRCs are defined by primary care consultation 
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patterns favoring repeat consulters this is consistent with previous research (McBeth et al. 2001a) 
suggesting that frequent primary care attendance for symptoms disrupting daily living is a risk 
factor for persistent CWP.
The increase in widespread pain prevalence and deterioration in physical function in RRCs 
between baseline and three years might represent increasing pain and disability in RRCs over 
time, or may be as a result of the timeframe used to define RRCs in this study. RRCs were 
identified using five years of medical record data starting two years before the baseline health 
survey. Therefore, since RRCs are identified by a minimum of three years of health record data, at 
baseline some RRCs may not yet be symptomatic, but by three years all RRCs will, by definition, 
have had multisite symptoms sufficient to seek primary care advice, thereby making it more 
probable that the RRCs we identified for this study will report widespread pain at three years than 
at baseline. Evidence from the pain trajectories of RRCs might support the theory that increases in 
prevalence between baseline and three years were as a result of new onset of symptoms. 
Eighteen percent of RRCs reported onset of CWP at either three or six years. However, 13% of 
controls also reported new onset of widespread pain during the six year study period. Future work 
could elucidate the relationship between time of RRC ‘diagnosis’ (i.e. point at which RRC criteria 
fulfilled) and onset of self-reported widespread pain symptoms. This is important as, if RRC 
criteria are met before patients fulfil strict self-reported CWP criteria, this could be a useful early 
recognition mechanism with the possibility for intervening to modify risk factors and thereby 
reducing the progression to a more severe and persistent form of CWP (McBeth et al. 2001a).
The plateauing of self-reported widespread pain prevalence figures between three and six years 
also suggests the increased prevalence seen between baseline and three years is partly a result 
of the timeframe used to identify RRCs. We can postulate that the initial increase in prevalence at 
three years is at least partially due to the RRCs who fulfilled criteria after baseline, and then the 
levelling of prevalence between three and six years could be due to either a static picture, where 
patients have settled into stable pain patterns, or a more dynamic situation with equal numbers of 
relapsing and remitting RRCs. The second, more dynamic situation, is supported by the 
observation that 18% of the RRCs had onset of widespread pain during the study, and 25% had 
self-reported widespread pain that either resolved during the six years of the study or was 
episodic. Further, this is consistent with previous research (Croft et al. 1993, Hunt et al. 1999, 
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McBeth et al. 2001a, Aggarwal et al. 2006) demonstrating a stable prevalence of CWP over time 
and the resolution of symptoms in half of CWP cases within a year (McBeth et al. 2001a).
Of note in the control group, is the large increase from 33% to 70% in self-reported pain between 
baseline and three-years. This is likely to be partially due to the timeframe over which controls 
were identified. Controls were individuals recorded as consulting for only one of the three body 
regions specified in the RRC criteria (axial, upper limb or lower limb) over the five years starting 
two years prior to the baseline health questionnaire. Consequently some controls might not have 
had symptoms at baseline, but developed their symptoms and consulted for them in the three 
years following the baseline questionnaire. 
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9.5.3 Strengths and limitations
a. Study population
As previously discussed in Chapter Seven (section 7.5.3.a) the two study samples used in this 
chapter are taken from a cohort of people aged 50 years and over which may limit whether we 
can apply our findings to the general population. 
In Chapter Seven (section 7.5.3.a) we demonstrated that any differences between the sample for 
Analysis One and either non-responders or incomplete responders were small and unlikely to 
affect the generalisability of findings.
We used a subsample to investigate changes in self-reported health and pain over time (Analysis 
Two) who responded to six-year follow-up questionnaire. We tested for participation bias by 
investigating the differences between responders to baseline and three-year follow-up only 
(incomplete responders), and those who also responded to six-year follow-up (the study sample). 
The study sample were younger, more likely to be female, more likely to be married or cohabiting, 
less deprived, more likely to be in paid employment and in a high social class, with better self-
reported physical health, less depression, less cognitive impairment, worse self-reported mental 
health, more anxiety, and more likely to report baseline pain. However, the generally small mean 
and percentage differences suggest that they are unlikely to affect the generalisability of the 
findings.
While differences between study samples and non- or partial-responders were small for all 
variables assessed, findings must be treated with caution as, for both analyses, less than a third 
of the eligible population (i.e. all those invited to take part in the baseline study) were included.
b. Changes in self-reported health over time
Defining changes in self-reported health over time by calculating the differences between three 
isolated assessments of self-reported health over a period of six years will miss fluctuating health 
between those measurements. The measures we used to assess changes in self-reported health 
over time will therefore miss some of the nuances of an individual’s changing health status, 
however taken together they offer us means of establishing trends in self-reported health of the 
sample.
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c. Changes in pain over time
Prevalence figures for self-reported widespread pain are likely to be influenced by the five-year 
period in which RRCs are identified. As discussed above (section 9.5.2) for this study RRCs were 
identified using the five years of medical record data starting two years before baseline health 
questionnaire, which means that prevalence at three years is likely to be higher than baseline 
prevalence because not all RRCs identified were likely to be symptomatic at the time of the 
baseline questionnaire. 
Defining pain trajectories based on pain reporting at baseline, three-year and six-year health 
questionnaires is also problematic. Extrapolating a continuous pain experience from information 
given at three isolated time points is unlikely to represent the true course of pain. In addition, the 
episodic pain trajectory is perhaps a little misleading since it may represent either an individual 
with an isolated and now resolved episode of widespread pain, or someone with more relapsing 
and remitting pattern. It therefore has the potential to include both those with a new episode and 
those with a resolved episode of widespread pain. Our figures for onset and improving 
widespread pain trajectories might therefore be underestimates. However, despite their 
limitations, the pain trajectories used do provide us with a crude assessment of how an 
individual’s pain might change over time. 
d. Control group 
We used a group of patients recorded as consulting for musculoskeletal problems in a single 
region (axial, upper limb or lower limb) in the five years starting two years before baseline health 
questionnaire as a control group. Since single-region pain is a risk factor for progression to CWP 
(Gupta et al. 2007) it is perhaps not surprising that our single-region control group showed more 
deterioration in self-reported health and similar levels of change in widespread pain reporting than 
the RRCs under investigation. In addition, differences between RRCs and single-region consulters 
are likely to be less than those between RRCs and those who do not consult for musculoskeletal 
conditions.
An alternative would have been to use a group of non-musculoskeletal consulters as a 
comparison. However, this approach would have made it impossible to determine whether any 
differences observed were due to being a RRC or simply consulting for a musculoskeletal 
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problem. Using a group of single-region musculoskeletal consulters as a control group meant that 
differences in changes in health and pain over time between cases and controls were small, but 
we did observe higher levels of anxiety and depression, worse self-reported physical health, and 
lower socio economic status in RRCs. In addition the slightly higher deterioration in the control 
group served to highlight the relatively small changes in self-reported health of our RRCs. The 
control group are a group of musculoskeletal consulters who did not develop as RRCs and there 
are some baseline differences (e.g. worse self-reported health and lower socioeconomic status) 
between controls and RRCs which may indicate factors related to a greater risk of moving from 
single-region to multi-region pain.
Chapter 9: Characteristics of recurrent regional consulters and changes in health over time
260
9.6 Conclusions
RRCs have been shown to be older and more likely to be female, with low socioeconomic status, 
and increased BMIs, findings that are consistent with previous research into CWP. In addition, 
over 60% of RRCs reported ACR-90 widespread pain on one or more of the health questionnaires 
between baseline and six years. This suggests that RRC criteria are effectively identifying 
individuals from the CWP/FM spectrum.
RRCs have poor self-reported health and report little deterioration in health over time suggesting 
that this is a group with already poor health; highlighting the importance (discussed in Chapter 
Eight) of identifying RRCs early. Evaluation of changes in pain reporting over time supports 
previous research suggesting that CWP prevalence remains constant over time with equal 
numbers of relapsing and remitting CWP cases.
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Chapter 10
Discussion
10.1 Introduction
This thesis aimed to develop an approach to identifying primary care consulters with chronic 
widespread pain (CWP) from their medical records using the existing consultation-based 
definition of CWP developed by Jens Rohrbeck as a starting point. The characteristics of the 
recurrent consulters for regional musculoskeletal complaints identified by the modified definition 
were then described. This chapter presents a discussion of the main findings of this thesis, the 
contribution of this project to the existing knowledge in the field, the implications of the work for 
future research and clinical practice, and a critical reflection on its strengths and limitations.
10.2 Summary of findings
There is a group of patients who regularly consult for multiple regional pain complaints (RRCs) 
who may not be recognised by their GPs as having a generalised pain condition. The new 
approach to identifying RRCs (using all regional musculoskeletal Read codes rather than the 
original limited code list developed by Rohrbeck et al. 2007) increased the number of patients 
identified and returned a similar group of patients with features consistent with patients self-
reporting CWP. However, not all RRCs self-reported CWP and fulfilling the RRC criteria was 
associated with worse consultation-based health (more consultations, more frequent attendance) 
than self-reported CWP status, but self-reported CWP status was associated with worse self-
reported health than RRC status alone. This suggests that RRCs are frequent consulters who 
share features with CWP patients, but include those perhaps less severely affected and therefore 
do not necessarily fit established and strict CWP criteria, but are likely to sit towards the end of a 
spectrum of polysymptomatic distress.
Key findings from the thesis are presented in Table 10.1.
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Table 10.1 Key findings from the thesis.
Findings relevant to chronic widespread pain conditions
Prevalence
• The general population prevalence of FM is 1–2% and CWP is 10–11%
• The annual recorded prevalence of non-specific generalised pain conditions likely to be related to CWP 
in primary care is 0.1–2.3%.
• Annual primary care recorded prevalence of Read codes with the potential to record CWP (e.g. 
fibromyalgia, fibrositis) is substantially lower than community CWP prevalence estimates, suggesting 
that CWP is under-diagnosed or under-recognised in primary care.
• Five-year prevalence for RRCs is 442 to 1,149 per 10,000 depending on code list used to define RRCs. 
• Five-year prevalence using the final code list (RRC-all) and codes likely to represent CWP combined is 
1,432/10,000. This is higher than community prevalence of CWP (1,077/10,000) and that predicted by 
estimated consultation prevalence of CWP (775/10,000).
Code lists
• It is possible to use a list of all regional musculoskeletal Read codes with existing Rohrbeck-2007 RRC 
criteria to identify patients resembling those identified using the original restricted code list. Using all 
regional codes identifies more RRCs, but the extra RRCs identified still fit the RRC profile
• RRCs identified using a list of all regional musculoskeletal Read codes were more likely to be recorded 
as consulting for a problem in only one limb (plus axial problem), and have an injury code recorded 
than RRCs identified using the original Rohrbeck short code list.
Overlap of RRCs with non-specific generalised pain coding
• Three-quarters of RRCs are not recorded with a non-specific generalised pain code and are therefore 
potentially unrecognised as having a generalised pain condition.
• A third of patients recorded with a non-specific generalised pain code were identified by the RRC-all 
definition. Non-specific pain consulters not identified as RRCs had lower consultation demands.
• RRCs also recorded with a non-specific generalised pain codes had worse consultation-based health 
than those RRCs who were not. 
Association with self-reported CWP
• The RRC-all definition identified over a third of patients self-reporting persistent widespread pain 
however, up to 89% of RRCs did not report persistent widespread pain.
• Fulfilling RRC criteria was associated with worse consultation-based health than self-reported CWP 
status, but self-reported CWP status was associated with worse self-reported health than RRC status. 
This suggests RRCs are frequent consulters who share features with CWP patients, but include those 
less severely affected and who therefore do not necessarily fit established and strict CWP criteria, but 
are likely to sit towards the end of a spectrum of polysymptomatic distress.
Time to identify RRCs
• It is possible to identify RRCs up to two years earlier than the five-year period specified in the RRC 
definition. Those identified earlier have more severe consultation-based health.
• It is possible to remove the separate-years criterion and therefore capture RRCs as soon as they have 
been recorded with four separate regional musculoskeletal consultations, one axial consultation, and 
one for an upper or lower limb complaint. Removing the separate-years criterion identifies more RRCs, 
but the extra RRCs are possibly less likely to fit the RRC profile.
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Findings relevant to chronic widespread pain conditions
Characteristics of RRCs
• RRCs are more likely to be female, older, more deprived, not in paid employment, and with higher BMIs 
than controls recorded as consulting for single-region musculoskeletal problems.
• RRCs have worse consultation-based health than controls recorded as consulting for single-region 
musculoskeletal problems, with more frequent attendance, higher rates of primary care consultation, 
and more recorded somatic symptoms.
• RRCs have more sleep problems, worse self-reported mental and physical health than controls 
recorded as consulting for single-region musculoskeletal problems.
• RRCs show little change in self-reported health and pain over time.
Severity Scale
• RRCs are more severely affected if: i) they are recorded as consulting for problems in all three body 
regions (axial, upper- and lower-limb) defined in the RRC criteria; ii) they are identified earlier; iii) they 
are also recorded with a non-specific generalised pain code; and iv) they fulfil the requirement as in the 
original definition for regional musculoskeletal consultations in each of three separate years.
• There is potential to develop a severity scale for RRCs using number of body regions consulted for, time 
to identification, concomitant recording of non-specific generalised pain codes, and requirement for 
regional consultations in each of three separate years.
Methodological findings
• Patterns of consultation for specific morbidity codes can be used in primary care data to identify a well 
defined patient group.
• When aiming to identify a specified patient group from Read-coded data, the group identified can be 
validated by: i) comparing coding prevalence with prevalence figures predicted by existing literature; 
and ii) matching the profile (for example, age/gender distribution, measures of health status) of the 
patients identified to those of the clinical phenotype intending to be identified.
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10.3 Discussion of findings
10.3.1 Under-recognition of CWP in primary care
a. Community, consulting and coding prevalence of CWP
Research (Faulconer and de Lusignan 2004) has recommended comparing expected community 
prevalence of a condition with its recorded prevalence as an indicator of diagnostic data quality 
(in primary care). However, in this case, rather than assessing coding quality, we were attempting 
to investigate whether the RRC definition (our diagnostic test) was successfully identifying 
individuals with CWP. In a sense we were testing how well our measures of ‘recognised 
CWP’ (non-specific generalised pain coding), and ‘unrecognised CWP’ (RRC criteria), identified 
CWP consulters. Even so, since research (Macfarlane et al. 1999) suggests 28% of CWP will not 
consult for their pain, we would not expect community and consulting prevalence figures to be 
equal. 
There is a distinction to be made between the actual community prevalence of a condition, the 
prevalence of patients who consult their GP for that condition, and the prevalence of patients 
recorded as having the condition. Not all patients with a specific problem will consult their GP for 
it consequently, consultation prevalences will be lower than community population prevalence 
estimates. Additionally, for chronic conditions, a diagnostic label for a repeatedly consulted 
complaint may only be coded once, for example at the time of diagnosis (Jordan et al. 2004). 
Consequently, when calculating prevalence using dated event-based data, there is potential for a 
patient to be missed if the diagnostic label was assigned during a consultation event that 
occurred before or after the period for which consultation prevalence is assessed. 
Coding prevalence will offer some measure of consulting prevalence but will also reflect the 
coding practices and diagnostic beliefs of the clinician (Jordan et al. 2007). Prevalence based on 
morbidity coding relies on what is recorded by clinicians during a consultation. Problems in 
primary care frequently do not conform to the biomedical framework of coding classification 
models, CWP being a good example. As described in section 2.3.1 in instances of clinical 
uncertainty, the diagnostic and recording practices of an individual clinician are likely to play a 
role in the codes they assign to the patient’s problem, particularly if, like CWP/FM, the diagnosis is 
a controversial one.
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We found the primary care coding prevalence of FM to be considerably lower than predicted by 
community prevalence, even accounting for a proportion of patients not consulting for their 
symptoms. This is consistent with findings from two large database studies (Gallagher et al. 2004, 
Hughes et al. 2006) that found FM coding to be considerably lower than general population 
figures would predict. 
We found that codes for conditions related to CWP (for example fibromyalgia, muscular 
rheumatism) were under-recorded in primary care when compared to what we might expect from 
general population prevalence figures and also given that research suggests that CWP is 
associated with ‘a pattern of illness behaviour characterised by frequent visits to a medical 
practitioner’ (McBeth 2001b, p.95). The under-recording of CWP in primary care is consistent with 
what we might expect, given: the contention surrounding FM and CWP as valid diagnoses 
(section 2.2.3); the evidence suggesting that coding is not a neutral activity (section 2.3.2); 
evidence that many musculoskeletal complaints are not coded (Salisbury et al. 2013); and 
evidence that completeness of coding of conditions with subjective case definitions is variable 
(Jordan et al. 2004).
b. Recognised and unrecognised CWP consulting prevalence
It was hoped that Rohrbeck’s (2002) theory that CWP patients were being recorded with multiple 
consultations for regional pain (for example, elbow pain, knee pain) would account for the missing 
CWP consulters (the observed disparity between community prevalence of CWP and recorded 
prevalence of conditions related to CWP). We hypothesised that RRCs represented unrecognised 
CWP in primary care, and individuals with a recorded generalised condition related to CWP (non-
specific generalised pain codes) represented recognised CWP. By investigating the overlap 
between recognised and unrecognised CWP we hoped to be able to estimate the amount of CWP 
in primary care. However, the combined prevalence of RRCs and individuals coded with non-
specific pain complaints was higher than general population estimates for CWP prevalence. While 
this suggests that all those fulfilling the RRC criteria might not meet strict CWP criteria, this finding 
is consistent with evidence suggesting FM/CWP exists at the extreme end of a spectrum of 
polysymptomatic distress (Häuser et al. 2009c, Wolfe et al. 2013) with the excess RRC prevalence 
a result of inclusion of less severe cases.
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10.3.2 Association of RRCs with CWP
In discussing the association between RRCs and self-reported CWP we will consider two themes: 
a) the evidence that RRCs share features with self-reported CWP; and b) the association between 
RRC status and self-reported CWP status. 
a. Evidence for RRCs sharing features with self-reported CWP
Throughout this thesis we have accumulated observations suggesting that RRCs share features 
with those self-reporting CWP. For ease of reference, these are collated and considered below.
We have demonstrated that recurrent regional consulting is associated with: i) female gender and 
increasing age; ii) frequent attendance; iii) comorbidity (including increased recording of 
generalised pain conditions and CWP and FM differential diagnoses); iv) increased numbers of 
recorded somatic symptoms, self-reported sleep problems and cognitive impairment; v) poor self-
reported health; vi) little change in pain and health status over time; and vii) poor socioeconomic 
status. Whilst none of these on their own are conclusive evidence that people fulfilling the RRC 
criteria have CWP, these are all features consistent with a diagnosis of CWP. 
The age and gender distribution of RRCs was consistent with that of CWP in the general 
population observed in the systematic review (section 3.4.5.c and d). In addition, RRCs were 
shown to have high rates of consultation (for musculoskeletal and non-musculoskeletal problems) 
and to be more likely to be frequent attenders, which is consistent with research linking frequent 
attendance to both CWP (McBeth et al. 2001b, Kadam et al. 2005, Gupta et al. 2007) and 
medically unexplained syndromes (Smits et al. 2009, Reid et al. 2001b). However, it may also be a 
feature of the self-fulfilling nature of a definition that requires repeated consultation, although we 
excluded musculoskeletal conditions from our definition of frequent attendance. Further, although 
a third of RRCs were frequent attenders, the profile of RRCs was not the same as that of all 
frequent attenders. 
RRCs were shown to have higher levels of comorbidity, compared to a group of controls recorded 
as consulting for single-site musculoskeletal problems. This is consistent with research 
suggesting an association between CWP and long-term increased mortality, particularly as a 
result of cancer (Macfarlane et al. 2001, McBeth et al. 2009), although other studies have not 
found such an association (Andersson 2009, Macfarlane et al. 2007).
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Research suggests that CWP/FM can coexist with its differentials such as rheumatoid arthritis 
(Wolfe et al. 2009), Sjögren’s syndrome (Ostuni et al. 2002), systemic lupus erythematosus 
(Middleton et al. 1994), and hypothyroidism (Bazzichi et al. 2007). Research has even postulated 
thyroid autoimmunity as a predisposition for FM (Bazzichi et al. 2012). Therefore, our finding of 
increased coding of rheumatoid arthritis, systematic lupus erythematosus, Sjögren’s syndrome, 
and hypothyroidism in RRCs is consistent with a diagnosis of CWP.
RRCs had more recorded somatic symptoms, self-reported sleep problems, and cognitive 
impairment than single-region controls. Many studies have shown an association between somatic 
symptoms and CWP/FM (McBeth et al. 2001a and 2001b, Aggarwal et al. 2006, Häuser et al. 
2009c, Wolfe et al. 2013). Somatic symptoms are now a part of the ACR-2010 definition for FM, 
and fatigue, waking unrefreshed, and cognitive symptoms are the three somatic symptoms 
individually scored in the definition (Wolfe et al. 2010), suggesting that RRCs share important 
features with CWP/FM patients.
Research has shown FM and CWP to be associated with poor self-reported mental and physical 
health (Walitt et al. 2011, Wolfe et al. 2013), and little change in self-reported pain and health over 
time (Walitt et al. 2011). This is consistent with our findings for RRCs.
We showed that recurrent regional consulting was linked to low socioeconomic status. RRCs were 
more likely to be in a low social class than controls, more deprived, and less likely to be in paid 
employment (however, RRCs were identified from a cohort of over 50s, who were therefore more 
likely to be retired). This is consistent with other studies of CWP (Macfarlane et al. 2009a, 
Assumpção et al. 2009, Wolfe et al. 2013). 
Clearly, RRCs share many characteristics with CWP. Taken together, the features of RRCs offer a 
persuasive argument that they fit the profile for CWP. However, as we have already discussed 
(section 10.3.1.b), RRCs and non-specific generalised pain coding over-estimate CWP, 
suggesting that not all RRCs would fulfil strict criteria for CWP.
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b. Association between RRC and CWP status
We found that half of RRCs did not self-report CWP at either of the two survey points three years 
apart and only a third of those self-reporting persistent widespread pain fulfilled the RRC definition 
(37%). In addition, fulfilling RRC criteria was associated with worse consultation-based health than 
self-reporting CWP, but CWP status was associated with worse self-reported health than RRC 
status. This suggests that RRCs are frequent consulters who share features with CWP patients, 
but include those less severely affected and therefore do not necessarily fit established and strict 
CWP criteria. Considered together with the observation that there are more RRCs than community 
prevalence would predict, this again suggests that RRC criteria are capturing a group of 
consulters some of whom may not be affected enough to reach the diagnostic threshold for CWP, 
but still fit within the spectrum of CWP and polysymptomatic distress suggested by research, with 
FM at the extreme end (Häuser et al. 2009c, Wolfe et al. 2013). 
Rather than identifying all CWP patients who consult their GP, as originally intended by the 
criteria, the RRC definition identifies a specific group of patients who are perhaps unrecognised 
as having a generalised condition, and therefore, through their consultation behaviour, are 
expressing a need that is likely to be unmet. This group is consequently an important one, since 
identifying them and managing them appropriately has the potential to improve their health (using 
interventions presented in section 2.2.6) and reduce consultation demands.
10.3.3 Identifying RRCs: developing the RRC definition
We tested a number of aspects of Rorhbeck’s original definition. Specifically, we investigated 
three variables in the definition: i) the list of Read-codes; ii) the number of body regions they are 
required to be recorded as consulting for (axial, and upper and/or lower limb); and iii) the 
timeframe required for identification (three to five years, and number of separate years in which 
they must have a recorded musculoskeletal consultation).
a. Code lists
By investigating the profile of RRCs returned by three separate code lists (Rohrbeck original short 
code list, all regional musculoskeletal codes, and excluding from the list of all regional codes 
those felt by clinicians to be unlikely to represent CWP) we have shown the code list can be 
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expanded. This is important because the original short code list was developed in only one GP 
practice. Research (Gray et al. 2003) suggests that, even for a well defined disease like diabetes, 
there is a wide range of codes in use across different general practices. This suggests that it 
would be unlikely for the limited list of codes identified by Rohrbeck (2002) to be the same ones 
used in other practices, and implies that a broad range of codes needs to be used to identify a 
specific phenotype using routinely recorded data from multiple practices.
The three code lists generally returned similar groups of RRCs. However, the list of all regional 
musculoskeletal codes identified 60% more patients than Rohrbeck’s original list of codes, and 
twice as many self-reported CWP patients. These findings and the diversity of coding approaches 
in use across different clinicians and different practices is a good argument for accepting the 
RRC-all list over the other two code lists. However, a comparison of the three groups of RRCs 
showed that the RRC-all group had more injuries coded, and lower proportions of patients 
consulting in all three body regions (axial, upper and lower limb) compared to the other two RRC 
groups.
b. Body regions
When we compared single-region controls with RRCs recorded as consulting in either two body 
regions (axial + upper or lower limb) or all three body regions (axial + upper and lower limb), we 
found an increasing severity (increased number of somatic symptoms, more consultations and 
more identified as frequent attenders) when moving from controls, through two-region RRCs, to 
three-region RRCs. With more two-region consulters in the RRC-all group, the gradation of severity 
from two- to three-region consulters suggests that the RRC-Rohrbeck and RRC-clinician groups 
are identifying a more severe group of RRCs who might be more likely to fit established ACR-90 
CWP criteria. The RRC-all group might identify more of those who sit towards the less severe end. 
However, injury has been shown to be a risk factor for CWP (Buskila et al. 1997a) and research 
has shown a progression from single region to multisite pain (Kamaleri et al. 2008a), suggesting 
that fewer sites of pain should be considered a matter of gradation of severity. Some of those 
fulfilling RRC-all criteria may be on a pathway towards the more severe end of the spectrum, 
further longitudinal research would be needed to test this hypothesis.
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We can conclude that given diversity in coding practice, the increased numbers of RRCs 
identified who still fit the expected RRC profile by the RRC-all definition, and the higher 
percentage of CWP patients identified by the RRC-all definition, the list of all regional codes 
should be used with the RRC definition and there is no argument for increasing number of body 
regions required by the definition to from two to three. 
c. Timeframe
We were able to show that RRCs can be identified prospectively within three years of an index 
musculoskeletal consultation by investigating the profile of RRCs returned: i) in timeframes shorter 
than the five years required by the original criteria, and ii) by removing the requirement for 
musculoskeletal consultations in each of three separate years. 
Nearly half of RRCs could be identified within three years of an index musculoskeletal consultation 
and those identified earlier were more severely affected. In clinical practice, this allows 
identification of severely affected individuals more promptly. 
However, whilst removing the requirement for regional musculoskeletal consultations in each of 
three separate years resulted in earlier identification of RRCs, it identified extra individuals who no 
longer fit the RRC profile (lower consultation rates, fewer somatic symptoms). This implies that 
removing the requirement for consultations in each of three separate years would not be 
appropriate for identifying RRCs for research purposes, but that if the criteria were to be used 
prospectively in a clinical setting, then, if the separate years requirement were removed, clinicians 
should review patients on a case-by-case basis to determine whether they fit the CWP profile 
clinically.
We can conclude that for the RRC definition to be used prospectively for clinical practice it should 
be revised to identify individuals between three and five years from an index regional 
musculoskeletal consultation. For research purposes, involving retrospective identification of 
RRCs, the previous RRC definition with all regional musculoskeletal codes will suffice, although to 
identify the most severe RRC cases the timeframe could be reduced to three years.
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d. The new RRC definition for clinical practice
Our definition of RRCs to be used in clinical practice therefore only changes two dimensions of 
the existing definition: the code list, and a requirement for prospective identification between three 
and five years from an index musculoskeletal consultation rather than a retrospective review of 
five years of consultation data. Our new RRC definition is shown in Table 10.2.
Table 10.2 New RRC definition for clinical practice.
Using a list of all regional musculoskeletal read codes.
In a period from between 3 and 5 years following an index regional musculoskeletal consultation fulfil 
all of i)–iv):
i) At least 1 consultation for a musculoskeletal complaint in the axial skeleton (neck & back);
ii) At least 1 consultation for an upper or lower limb complaint;
iii) At least 1 consultation for a regional musculoskeletal complaint in each of 3 separate years;
iv) At least 4 consultations for regional musculoskeletal complaints in total.
10.3.4 The RRC phenotype
We have suggested that RRCs represent a subgroup of consulters with chronic pain as the 
prevailing symptom of their polysymptomatic distress who are often not recognised as having a 
more generalised pain condition associated with somatic symptoms. RRCs might not necessarily 
fit strict ACR-90 CWP criteria where there is a clear cutoff for diagnosis, but they are likely to fit on 
the scale of polysymptomatic distress presented in the ACR-2010 criteria (see Figure 10.1). The 
RRC definition therefore identifies a heterogeneous group of frequent consulters with 
predominantly musculoskeletal symptoms, including those less severely affected who do not 
therefore necessarily fit established and strict CWP criteria but nonetheless still exist at the less 
severe end of the spectrum of polysymptomatic distress characteristic of CWP and FM. 
Figure 10.1 The RRC phenotype within the spectrum of chronic pain and polysymptomatic distress
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10.4 Implications
10.4.1 Clinical practice
The new RRC definition suggested for clinical practice in Table 10.2 allows the use of routinely 
recorded data to identify a group of patients with potentially unmet needs. Many feel that due to 
the range of symptoms experienced and a multidisciplinary approach to treatment, CWP and FM 
should be managed in primary care (Endresen 2007, Shir and Fitzcharles 2009a, Glennon 2010, 
Ghazan-Shahi et al. 2012). This group of ‘unrecognised’ CWP patients is therefore important to 
identify in this setting. Their symptoms have reached a level where they are asking for help, and 
those symptoms are unlikely to be managed appropriately if they are treated for the specific 
isolated regional pain complaints with which they are being coded. Further, RRCs have high 
consultation demands which may be reduced by appropriate interventions. However, since the 
RRC criteria identify a group including those less severely affected, rather than advocating that all 
RRCs need immediate specific treatment, the definition might be used as a tool to identify high-
risk patients who would benefit from monitoring and potentially intervening before they progress 
towards the more extreme end of the spectrum. 
The utility of the RRC definition might be about highlighting the existence a group of high-risk 
patients with unmet needs rather than as a case identification tool. Given an under-recognition of 
CWP in primary care – suggested both by disparity between community and coding prevalences, 
and by the evidence that RRCs represent unrecognised CWP consulters (section 10.3.2), along 
with the controversy regarding the validity of CWP/FM (section 2.2.3) – it possible that even if a 
specific morbidity code for CWP existed, it would not be used. Therefore, before we can argue 
that there should be a Read code for CWP, there needs to be an improved awareness of FM/CWP 
in primary care. This suggests a need for specific training in identifying, coding, and managing 
these conditions for GPs. This is consistent with reports from doctors of inadequate formal training 
(Buskila et al. 1997b, Arshad and Ooi 2007, Kamoun et al. 2010) and difficulty in diagnosing FM 
(Perrot et al. 2012), and research suggesting limited awareness of diagnostic criteria (Buskila et 
al. 1997b, Blotman et al. 2005, Kamoun et al. 2010, Perrot et al. 2012).
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Until there is an improved awareness of CWP/FM in primary care (potentially prompting a need for 
a specific morbidity code for CWP), the RRC definition could serve as a useful electronic flag (that 
is, a built-in software prompt alerting clinicians when a patient fulfils the definition) in primary care 
software for identifying individuals at risk to their doctors. GPs could then decide clinically whether 
a specific patient might benefit being more closely monitored or from an intervention aimed at 
CWP/FM. An electronic flag may also be useful as a tool to identify patients at risk of progressing 
to the more severe end of the CWP/FM spectrum in situations where reduced continuity of care 
hinders a clinician’s ability to perceive a history of repeated musculoskeletal consultations as 
evidence of a more generalised condition.
10.4.2 Research implications
Some of the methods used in this study have important implications for other research using 
primary care consultation data. In developing and applying the RRC definition we have been able 
to demonstrate that it is possible to use consultation patterns for specific morbidity codes in 
primary care data to identify a unique group of consulters who share features with a clearly 
defined clinical group. By using consultation patterns to identify patients with high consultation 
demands, we demonstrated the potential for identifying clinically meaningful groups of frequent 
consulters who can be preferentially targeted in an attempt to help reduce consultation rates.
We have also shown that when aiming to identify a specified clinical phenotype from Read-coded 
data, the group identified can be validated using: i) prevalence figures predicted by existing 
literature; and ii) matching the profile (for example age/gender distribution, measures of health 
status) of the patients identified to those of the clinical phenotype intending to be identified. 
There has been much criticism levelled at the ACR-90 criteria due to the circular logic used to 
arrive at the definition (Cohen 1999, Quintner and Cohen 1999). The RRC definition, while 
originally intended to identify ACR-90 CWP, is identifying a group defined by their consultation 
patterns rather than ‘a circular argument in which the evidence on which the construct is based is 
taken as proof of its veracity’ (Cohen and Quintner 1993, p.906). Using routinely recorded data, 
rather than a clinical trial or expert consensus, we have identified a group of individuals who 
appear to sit within a spectrum of polysymptomatic distress (section 10.3.2) and demonstrate 
differing gradations of severity related, for example, to the number of body regions recorded. 
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Using real-world data relying on help seeking behaviour we have therefore offered evidence to 
support the ACR-2010 severity scale definition of FM (Wolfe et al. 2010, 2011). In finding 
individuals who do not necessarily fulfil strict ACR-90 criteria, who have a less severe symptom 
profile, but still share many characteristics with self-reported CWP patients (ACR-90), the RRC 
definition offers weight to the argument that the ACR-90 criteria implemented an arbitrarily defined 
cut-off that failed to recognise a spectrum of pain and distress (Schochat et al. 1994, Croft et al. 
1996, Wolfe 2003). 
The RRC definition offers a pragmatic way of identifying a clinically meaningful group of 
individuals for future research. Identifying effective interventions for this group has the potential 
not only to improve patient health but also to reduce consultation demands.
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10.5 Future work
Future work with the RRC definition has two broad strands: i) continued development of the RRC 
definition; and ii) application of the definition to identify a group of individuals for continued 
investigation.
10.5.1 Developing the RRC definition
There are a number of avenues open both for the continued development of the RRC definition 
and as a means of identifying all CWP consulters: i) developing a severity scale using variables in 
the existing criteria; ii) using the framework of the ACR-2010 widespread pain index and somatic 
symptom severity score to develop an alternate RRC definition incorporating a severity scale; iii) 
incorporation of non-Read coded data; iv) identifying all CWP consulters; and v) further validation 
of the existing definition.
a. Severity scale
During development of the RRC definition we have identified a number of variables linked to 
severity that could offer scope for developing a severity scale for RRCs: i) the number of body 
regions consulted for; ii) the time taken to fulfil RRC criteria; iii) the recording of non-specific 
generalised pain codes; and iv) the requirement for regional musculoskeletal consultations in 
each of three separate years. 
In addition, our development of the RRC definition did not address the requirement for four 
regional musculoskeletal consultations. Research suggests an increasing number of pain sites is 
related to reduction in overall health, poor sleep quality, psychological distress (Kamaleri et al. 
2008b), and number of reported somatic symptoms (Coggon et al. 2013). This suggests that 
varying the number of regional musculoskeletal consultations has the potential to offer another 
marker of RRC severity.
The heterogeneity of the RRC phenotype and identification of common subgroups of RRC could 
be assessed further by using cluster or latent class analysis to group patients fulfilling the RRC 
criteria based on characteristics such as: number of recorded somatic symptoms, number of 
recorded body regions, number of musculoskeletal and non-musculoskeletal consultations, and 
time to fulfilment of RRC criteria.
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b. Developing an expanded RRC definition incorporating somatic symptoms
The ACR-2010 criteria use a combination of the number of the affected pain sites (widespread 
pain index) and a measure of the number of somatic symptoms (somatic symptom severity) 
experienced (Wolfe et al. 2010) to calculate an overall polysymptomatic distress score (Wolfe et 
al. 2011 and 2013). The RRC criteria could be redeveloped using a count of the number of body 
sites recorded (similar to the ACR-2010 widespread pain index), and a count of the number of 
somatic symptoms recorded (similar to the ACR-2010 somatic symptom severity score). In much 
the same way as the ACR-2010 polysymptomatic distress score, the new RRC definition (based 
on number of pain sites and number of somatic symptoms) would result in a score, rather than the 
individuals needing to fulfil a set of criteria, and therefore needing to meet a diagnostic threshold. 
This has the potential to offer a means of identifying CWP consulters who might be recorded with 
somatic symptoms (e.g. fatigue) rather than regional musculoskeletal complaints, and who may 
be more affected by somatic problems.
The RRC definition is based on Read-coded data only, therefore, the definition could be 
developed by incorporating prescribing data or information from free-text entries.
While there are no prescriptions that are used exclusively for FM/CWP, pharmacological 
interventions are used for chronic pain and FM, including tramadol, antidepressants, tropistetron, 
pramipexole, and pregabalin (Carville et al. 2008). Prescriptions for drugs like these, as well as 
existing RRC criteria, might serve as useful markers for CWP.
Research (Salisbury et al. 2013) suggests only 32% of musculoskeletal complaints are Read-
coded, while 85% are recorded in free-text notes. This suggests that more RRCs may be ‘hidden’ 
in the free-text of the consultation. Natural language processing could be used to access 
information contained in the free text that may not be coded (Pakhomov et al. 2007). However, 
natural language processing may not yet be able to reliably extract nuanced medical meaning 
from free-text (Anandarajah et al. 2005).
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c. Further validation
The RRC definition could be tested further by investigating the association between RRC status 
and the ACR-2010 polysymptomatic distress score (Wolfe et al. 2013). This would require a study 
linking medical records with individual patient assessment using the distress score. 
Prior to incorporation of the RRC definition in primary care software, the clinical relevance of the 
definition needs to be assessed by qualitative exploration with clinicians. Discussion with 
clinicians could be used to assess whether RRC status is a clinically useful concept: whether 
identifying a patient as a RRC would prompt further assessment of the patient with possible 
intervention (using managements aimed at CWP), or, given the controversy around the FM/CWP 
diagnosis, the prompt would be ignored. If the RRC criteria are clinically acceptable to GPs, given 
the possibility for a severity scale, it would be useful to discuss what diagnostic threshold doctors 
feel it clinically meaningful to be alerted to a patient’s RRC status.
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10.5.2 Applying the RRC definition
The RRC definition could be used to identify a clinically relevant group of high users of primary 
care for continued research. The effectiveness of specific interventions for RRCs could be tested 
by conducting a clinical trial (for example, to test cognitive behavioural therapy in RRCs). 
Since we found little deterioration in self-reported health for RRCs over six years, it may be that 
this is a group who do not deteriorate further. Perhaps the reason they are not coded with 
generalised pain conditions is because they have a stable level of poor health and the GP is 
reluctant to offer a label that might be counterproductive to coping (Ehrlich 2003a). Our study did 
not investigate the timing of non-specific generalised pain coding in relation to the point at which 
RRCs fulfil the RRC criteria. It would therefore be helpful to investigate whether initially 
‘unrecognised’ RRCs, are ‘recognised’ over time, by investigating the timing of both generalised 
pain coding and secondary care referral patterns. It would also be useful to investigate the 
relationship between fulfilling RRC criteria and self-reporting CWP, to assess whether the RRC 
criteria identify patients before they meet strict CWP criteria. If they do, this would offer a means of 
investigating whether implementing interventions in an at-risk population (i.e. before patients 
progress to a more severe form of polysymptomatic distress) reduces their risk of their condition 
deteriorating. Longitudinal data could be used to assess whether there are specific risk factors for 
recurrent regional consulting, thereby offering a rationale for attempting to modify specific risk 
factors in an at-risk population.
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10.6 Strengths and limitations
10.6.1 Validation of RRC criteria
In attempting to validate the RRC criteria we used three approaches: i) comparing coding 
prevalence with prevalence figures predicted by existing literature; ii) matching the consultation 
profile of RRCs to that expected from patients with self-reported CWP; and iii) matching the 
demographic, socioeconomic, self-reported health and pain status of RRCs to that of CWP 
patients.
We have already discussed how differences between community, consulting, and coding 
prevalence for a controversial condition like CWP makes such comparisons problematic (section 
2.2.1.a). Additionally, we were comparing point estimates for community prevalence with five-year 
estimates for CWP coding prevalence (RRC and non-specific pain coding combined). However, 
we were able to derive some useful information about the recognition of CWP in primary care from 
these data.
There is a circular logic to defining a group of individuals based on their consultation pattern and 
then validating that definition using consultation patterns. However, we attempted to mitigate this 
problem by defining frequent attendance based on non-musculoskeletal consultations (the RRC 
definition was based on repeated musculoskeletal consultations) and we were able to 
demonstrate that self-reported CWP patients had a similar pattern of non-musculoskeletal frequent 
attendance, somatic symptom recording, and consultation rates.
The main problem we had in validating the RRC criteria was that we were attempting to define a 
phenotype that has previously not been identified; that is, a group of recurrent consulters in 
primary care, with a prevailing symptom of chronic musculoskeletal pain, who are potentially 
unrecognised by their GPs as having a generalised condition associated with somatic symptoms. 
We therefore had no reference standard against which to compare the RRCs identified by our 
criteria. However, the RRC phenotype is closely related to FM/CWP, and these conditions have 
been studied extensively using the ACR-90 definition. We were able to demonstrate that RRCs 
share many characteristics with CWP, and taken together, the features of RRCs offer a persuasive 
argument that they fit the profile for CWP (see section 10.3.2).
Chapter 10: Discussion
280
10.6.2 CWP versus recurrent regional consulting
The RRC definition does not identify all CWP patients, and it does not even identify all CWP 
consulters. However, the definition does identify an important group of patients with potentially 
unmet needs and high consultation demands.
10.6.3 Data
The study used two datasets: The Consultations in Primary Care Archive (CiPCA) and the North 
Staffordshire Osteoarthritis Project (NorStOP). 
a. CiPCA
The CiPCA dataset contains anonymised primary care consultation data from up to 13 (depending 
on year) general practices in the North Staffordshire area of the UK. Although North Staffordshire 
is generally quite deprived in comparison to the average for England, these practices cover both 
more affluent and more deprived areas. The practices involved are part of the Keele GP Research 
Partnership, consequently, routine clinical data recorded by the practices are regularly audited by 
the informatics team from the Primary Care and Health Sciences Research Institute at Keele 
University (Porcheret et al. 2004). The data quality has been demonstrated to be similar to that of 
larger national primary care consultation databases giving comparable musculoskeletal 
consultation prevalences to national UK and international databases (Jordan et al. 2007, 2013). At 
least one morbidity code is required to be entered for each contact to the practice.
Generalisability may be reduced by the geographical limitation of the CiPCA study to one area of 
the UK (North Staffordshire). The CiPCA population is older than the UK general population (Table 
4.1) and it is likely that other features may also be systematically different. However, differences in 
the age and gender distribution of the study population were accounted for by standardising 
prevalence figures to the UK general population. European geographical variation in CWP 
prevalence has been demonstrated to be limited (section 3.4.5.b), so limiting the study 
geographically may only have a small influence on generalisability. 
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b. NorStOP
The North Staffordshire Osteoarthritis Project (NorStOP), is a prospective epidemiological study of 
pain and general health in community-dwelling adults aged 50 years and over (Thomas et al. 
2004b). Using an older population is likely to limit the generalisability of the findings from Chapters 
Seven and Nine. While we were able to demonstrate minimal differences between RRCs from all 
age groups, and the subgroup aged 45 and over on number of recorded somatic symptoms 
(section 5.4.4) and number of musculoskeletal consultations (5.4.3.a), we must be cautious about 
extrapolating our findings to all age groups.
Less than a third of the eligible population (i.e. all those invited to take part in the baseline study) 
were included in analyses using NorStOP data, and we cannot therefore exclude the risk of 
participation bias. However, differences between study samples, and non- or partial-responders 
were demonstrated to be small on all variables assessed (sections 7.4.1.a and 9.4.2.a).
10.6.4 Read codes
a. Musculoskeletal
By including most musculoskeletal Read codes, the RRC-all definition is unlikely to miss RRCs, as 
it accounts for diversity in coding practices. However, not all the codes represent musculoskeletal 
pain (for example, N0967: unstable ankle), and the list includes codes for conditions that 
clinicians on the advisory panel felt were inappropriate for use in CWP, such as structural 
derangements (e.g. meniscal tears, haemarthrosis, and fracture), infections, and inflammatory 
arthropathies. However, the consultation pattern required for RRCs appears to have successfully 
filtered out individuals not sharing features with CWP.
There may be codes with the potential to represent musculoskeletal problems outside the Read 
code chapters we used that should have been included on the list of all regional musculoskeletal 
codes – such as mastalgia, which is included in Chapter K (genitourinary system diseases), and 
codes from Chapter 2 (codes relating to clinical examination findings) representing 
musculoskeletal pain on examination, for example, Rohrbeck’s original code list included one 
code (2H23: on examination painful arc) from Read code Chapter 2.
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b. Somatic symptoms 
The new ACR-2010 criteria emphasise the importance of somatic symptoms in identifying CWP/
FM patients. By identifying patients consulting for regional musculoskeletal complaints only, the 
criteria may not be identifying all ‘unrecognised’ CWP since it is not picking up consultations with 
these patients that are coded only with somatic symptoms, such as, fatigue and difficulty 
concentrating. However, being recorded with a somatic symptom might imply that the patient has 
actually been recognised as having a functional somatic syndrome, and the intention of the RRC 
definition was to identify CWP patients who were hiding behind multiple single-region 
presentations in primary care. 
10.6.5 Non Read-coded primary care data
In using only Read-coded data, the RRC definition may be missing some unrecognised CWP 
consulters. Research (Salisbury et al. 2013) suggests only 32% of musculoskeletal complaints are 
Read-coded, while 85% are recorded in free-text notes, suggesting, as noted earlier, that 
evidence of widespread pain and somatic symptoms may be ‘hidden’ in the free-text of the 
consultation.
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10.7 Conclusions
The new approach to identifying RRCs, using all regional musculoskeletal Read codes and 
identifying patients prospectively after a minimum of three to a maximum of five years from an 
index musculoskeletal consultation, identifies more patients earlier, and returns a similar group of 
patients with features consistent with patients self-reporting CWP. However, RRC prevalence 
overestimates CWP prevalence and not all RRCs self-report CWP. This suggests that the RRC 
criteria identify a heterogenous group of frequent consulters who generally share features with 
CWP patients, include those less severely affected and therefore do not necessarily fit established 
and strict CWP criteria. They nonetheless still exist on the spectrum of polysymptomatic distress 
characteristic of CWP and FM. RRCs therefore represent a subgroup of consulters, with chronic 
pain as the prevailing symptom of their polysymptomatic distress, who are often not recognised 
as having a more generalised pain condition associated with somatic symptoms. 
There an under-recognition of CWP in primary care, implying a need for specific training for GPs 
on this condition. The RRC definition could be used clinically as an electronic flag in primary care 
software to identify individuals who might benefit from being more closely monitored or from an 
intervention aimed at CWP/FM, or as a research tool to identify a clinically important group of 
chronic pain consulters. Whilst there appear to be effective treatments for patients with 
widespread pain, we do not yet understand how best to help those recurrently consulting with 
regional musculoskeletal problems.
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Appendix
Chapter 3 appendix
A3.1 Database specific search strategies
Table A3.1 Medline – limit to human, 1990–current.
Pain term Keywords 
searched for in 
abstract and title
(TI “chronic widespread pain” OR “fibromyalgia” OR “chronic pain 
syndrome” OR “diffuse pain” OR “fibrositis” OR “fibromyositis” OR 
“myofascial pain syndrome”)
OR
(AB “chronic widespread pain” OR “fibromyalgia” OR “chronic pain 
syndrome” OR “diffuse pain” OR “fibrositis” OR “fibromyositis” OR 
“myofascial pain syndrome”)
OR
MeSH headings (MH "Fibromyalgia") OR (MH "Myofascial Pain Syndromes")
AND
Study type 
term
Keywords 
searched for in 
abstract and title
“epidemiology” OR “cohort stud*” OR “cohort analys*” OR “cross sectional 
stud*” OR “cross sectional analys*” OR “observational analys*” OR 
“prevalence” OR “disease frequency”
OR
MeSH headings (MH "Prevalence") OR (MH "Cross-Sectional Studies") OR (MH 
"Epidemiologic Measurements") OR (MH "Epidemiologic Methods") OR (MH 
"Epidemiologic Research Design") OR (MH "Epidemiology") OR (MH "Cohort 
Studies")
Table A3.2 AMED – 1990–current.
Pain term Keywords 
searched for in 
abstract and title
(TI “chronic widespread pain” OR “fibromyalgia” OR “chronic pain syndrome” 
OR “diffuse pain” OR “fibrositis” OR “fibromyositis” OR “myofascial pain 
syndrome”)
OR
(AB “chronic widespread pain” OR “fibromyalgia” OR “chronic pain 
syndrome” OR “diffuse pain” OR “fibrositis” OR “fibromyositis” OR 
“myofascial pain syndrome”)
OR
Subject 
headings
(DE "FIBROMYALGIA") OR (DE "PAIN") 
AND
Study type 
term
Keywords 
searched for in 
abstract and title
“epidemiology” OR “cohort stud*” OR “cohort analys*” OR “cross sectional 
stud*” OR “cross sectional analys*” OR “observational analys*” OR 
“prevalence” OR “disease frequency”
OR
Subject 
headings
(DE "EPIDEMIOLOGY") 
A1
Table A3.3 EMBASE – limit to human, 1990–current.
Pain term Keywords 
searched for in 
abstract and title
(chronic widespread pain OR fibromyalgia OR chronic pain syndrome OR 
diffuse pain OR fibrositis OR fibromyositis OR myofascial pain 
syndrome).ab,ti.
OR
Emtree subject 
headings
(fibromyalgia/epidemiology OR myofascial pain/epidemiology).sh.
AND
Study type 
term
Keywords 
searched for in 
abstract and title
(epidemiology OR cohort stud* OR cohort analys* OR cross sectional stud* 
OR cross sectional analys* OR observational analys* OR prevalence OR 
disease frequency).ab,ti.
OR
Emtree subject 
headings
(epidemiology OR prevalence OR cross sectional study).sh.
Table A3.4 CINAHL – limit to human, 1990–current.
Pain term Keywords 
searched for in 
abstract and title
(TI “chronic widespread pain” OR “fibromyalgia” OR “chronic pain syndrome” 
OR “diffuse pain” OR “fibrositis” OR “fibromyositis” OR “myofascial pain 
syndrome”)
OR
(AB “chronic widespread pain” OR “fibromyalgia” OR “chronic pain 
syndrome” OR “diffuse pain” OR “fibrositis” OR “fibromyositis” OR 
“myofascial pain syndrome”)
OR
Subject 
headings
(MH "Fibromyalgia") OR (MH "Myofascial Pain Syndromes") 
AND
Study type 
term
Keywords 
searched for in 
abstract and title
“epidemiology” OR “cohort stud*” OR “cohort analys*” OR “cross sectional 
stud*” OR “cross sectional analys*” OR “observational analys*” OR 
“prevalence” OR “disease frequency”
OR
Subject 
headings
(MH "Prevalence") OR (MH "Cross Sectional Studies") OR (MH "Epidemiology") 
OR (MH "Epidemiological Research") OR (MH "Prospective Studies")
A2
A3.2 Data extraction sheet and quality appraisal tool
A3
A4
A5
A6
A3.3 Studies excluded after review of full text
Table A3.5 Papers excluded after review of full text.
Reason for exclusion Paper
Prevalence figures for 
CWP/FM not quoted 
or could not be 
calculated from the 
information provided 
in the paper (n=16)
No prevalence figures for FM/
CWP
Davies et al. 2009a
Fleckenstein et al. 2010
Zeng et al. 2008
Identified widespread pain 
but gave no measure of 
chronicity
Adamson et al. 2007
Harkness et al. 2005
Lascuevas et al. 1995
Leveille et al. 2005
Mikkelsson et al. 1997
Palmer et al. 2007
Thomas et al. 2004a
Gerdle et al. 2008
Cho et al. 2012
Häuser et al. 2012
Identified chronic pain but 
provided no measure of pain 
location
Rustøen et al. 2004
Figures for myofascial pain 
syndrome
Chaiamnuay et al. 1998
Figures for soft tissue 
rheumatism
Andrianakos et al. 2003
Not primary research 
(n=11)
Editorials or letters Felson 2008
Russell 2006
Ganuza & Sotillos 1992
Jacobsen & Bredkjaer 1992 
Montanes et al. 1995
Review articles or used 
secondary data presented in 
other papers already 
included in the review.
Blanco et al. 2007
Cavalcante et al. 2006
Lawrence et al. 2008 
Lawrence et al. 1998
Wolfe et al. 1993
Zeng et al. 2010
Not cross-sectional or cohort study (n=2) Marrie et al. 2012 
Stormorken et al. 1994
Study population was not representative of the 
general population (n=6)
Cimmino et al. 2002
Kim et al. 2008
Kim et al. 2012
Kleinman et al. 2009
Kurita et al. 2012 
Lydell and Meyers 2009 (conference abstract)
Document data analysed in other papers included in 
the review (paper included in review) (n=13)
Abusdal et al.1997b (Abusdal et al.1997a) 
Atherton et al. 2009 (Macfarlane et al. 2009b)
Bannwarth et al. 2009 (Branco et al. 2010)
Bazelmans et al.1997 (Bazelmans et al.1999)
Bergman et al. 2002 (Bergman et al. 2001)
Davatchi et al. 2009b (Davatchi et al. 2008)
Gedalia et al.1993 (Buskila et al. 1993)
Jones et al. 2009 (Macfarlane et al. 2009b)
Mas et al.2008 (Carmona et al. 2001)
McBeth et al. 2001b (Hunt et al. 1999)
Schochat and Raspe 1995 (Schochat and Raspe 2003)
Wenzel et al. 2009 (Svebak et al. 2006)
A7
A3.4 Methodological quality: justification of ratings for QUIPS tool domain 1
Table A3.6 Risk of selection bias and justification for rating using domain 1 of the QUIPS 
methodological quality assessment tool.
Study Risk of 
bias
Rating Justification
Ablin et al. 2012 high Very small response rate (30%) and respondents recruited by telephone which 
systematically excludes those without a home telephone. In addition no 
information is provided regarding the time of day of the call (daytime only calls 
systematically exclude daytime workers) or any effort made to reach those not 
answering a call first time. There is no information provided regarding the target 
population or non-responders to compare with the study sample to establish if 
the study sample is different to non-responders or the target population. 
Estimates of prevalence using extrapolation from data observed in 
rheumatology outpatients in not a robust estimate of general population 
prevalence as rheumatology outpatients are likely to be systematically different 
to the general population.
Abusdal et al. 1997a low Moderate response rate (response rate 65%), but there is evidence that 
participation was not likely to bias outcome as 'the sample is considered 
representative for Norwegian women in Oslo'.
Aggarwal et al. 2006 low High participation rate, clear comparison of responders vs non-responders. 
Only question is whether residents of Handforth, Manchester are representative 
of the UK general population.
Alvarez-Nemegyei et al. 2005 moderate High participation rates, but unclear how sample selected and unclear if 
sample is representative of target population and population parameters 
estimated based on extrapolation from figures observed in screen positives 
only.
Alvarez-Nemegyei et al. 2011 high Unclearly defined target population (age not stated), sampling frame not 
stated, insufficient detail regarding sampling process, no information regarding 
response rate, possible disparity in gender distribution in sample vs population 
suggests selection bias.
Andersson 1994 moderate Incomplete participation, but there is evidence that participation was not 
related to outcome. Evidence suggests that the sample is representative of the 
residents of Bromölla and Simrishamn, however unclear if sample reflective of 
the 'rural population of Sweden' as stated in the title. Figures for FM 
extrapolated from examination of sample of those that responded positively to 
CWP.
Andersson et al. 1999 low Representative nature of primary care registered population, participation not 
likely to be related to outcome (however, possibility for bias here as no 
comparison given of responders vs non-responders, but assume small 
influence)
Assumpção et al. 2009 high Non-random sample selection for screening phase; recruitment of sample by 
telephone when 27% of target population do not have a telephone and 30% of 
those called did not answer the phone; recruitment to examination phase 
based on participant agreement – highly likely to lead to a systematically 
different group of patients.
Bazelmans et al. 1999 moderate Likelihood of sample being non-representative of GPs. If we consider this a 
measure of 'diagnostic prevalence' (interplay of clinical opinion and consulting 
behaviour) then a response rate of 60% would seem reasonable, however, it 
would seem fair to suggest that those that didn't not return the questionnaire 
were likely to be Drs who did not agree with the diagnosis, therefore making 
their estimates of prevalence lower, resulting in an over-estimation of coding (or 
diagnostic) prevalence.
Bergman et al. 2001 low Random selection from appropriate sampling frame (however, unclear if two 
regions selected are representative of the whole of the general population of 
Sweden), good response rate and clear description of non-responders 
sufficient to provide evidence that participation unrelated to outcome measure.
Branco et al. 2010 moderate Unclear sampling frame, insufficient information presented regarding non-
responders, recruitment conducted by telephone (excludes those without a 
landline and those not in at the time of call > responders likely to be 
systematically different to non-responders) – however, sample stated to be 
representative of the general population – therefore moderate rather than high 
risk of selection bias.
A8
Study Risk of 
bias
Rating Justification
Buskila et al. 1993 high Sample selected non-randomly from one school only, cannot generalise the 
results to all children. Insufficient information available to decide whether it's 
possible to even generalise to other schools in the same area, as no 
information is given regarding the school population or location. Insufficient 
evidence provided to determine whether the sample is reflective of the 
sampling frame population since no information given regarding response rate/
non-responders vs responders.
Buskila et al. 2000 low Good participation rate, non-responders described, responders compared with 
1993 Israel census data, gender distribution of sample found to deviate from 
census data, however analysis takes this into account (figures adjusted for age 
and gender).
Cakirbay et al. 2006 low Good participation rate and participants likely to be reflective of the target 
population, however unclear who was examined in the examination phase.
Cardiel & Serrano 2002 low While no response rate is given and there is no description of non responders, 
evidence from comparison with year 2000 Mexican national census shows 
comparable age and gender distribution in sample. 
Carmona et al. 2001 low Sample demonstrated to be comparable to general population. While response 
rate moderate at 73%, there is clear comparison of the study sample to 
Spanish general population data derived from Institute of National Statistics 
1999 or 1997, on age, gender, urban/city residence, level of education, type of 
employment, social class, employment status, showing sample to be 
representative of the general population. Non-responders are demonstrated to 
be similar to responders, with the exception of place of residence, higher 
response rate in villages.
Carnes et al. 2007 moderate A reasonable, but not ideal response rate of 60%. The study population is 
demonstrated to be older (mean age 52 years) and more likely to be female 
(56% female). No discussion regarding non-responders is provided. Must 
therefore conclude at least a moderate risk of selection bias.
Chaaya et al. 2012 low Sample selected using random multistage cluster selection and stated to be 
representative of the general population of Lebanon. Selected from main 
centers and randomly selected villages from all 26 Lebanese districts. Study 
sample stated to be representative of general population on age and gender 
distribution. High response rate to initial screening (83%) and reasonable 
response rate to follow-up examination of screen positives.
Chen et al. 2008 high Participants self selected by responding to an advert offering free health 
checks to participants. No information provided allowing comparison of sample 
demographics to population demographics to judge the representative nature 
of the sample.
Choudhury et al. 2013 (long) high While response rate was high (94%), patients were recruited from a GP waiting 
room thereby automatically selecting a group of the population more likely to 
be unwell. Quota sampling was used to help ensure a representative sample, 
but who to approach was still at the discretion of the interviewer and was 
therefore likely to be biased. 
The paper argues that since the aim of the study was not to calculate robust 
prevalence estimates, but to make comparisons between prevalence in the 
white and Bangladeshi populations thereby making some of my arguments 
irrelevant however, I would counter that to make meaningful comparisons 
between prevalence estimates for groups from different ethnic backgrounds 
sampling of these groups needs to be representative.
Choudhury et al. 2013 (short) high Very low response rate (27%) and the exclusion of patients with pain due 
established pathophysiological diagnoses, since CWP can coexist with its 
differential diagnoses. There is insufficient documentation regarding non-
responders and no comparison made between study sample and target 
population, therefore given the very low response rate we must consider this 
study to be at high risk of participation bias.
Clark et al. 1998 high Children selected from 3 schools in one area, might not be representative of 
the whole Mexican population. Children selected from public schools only, 
excludes privately educated children. Participants recruited by attendance on 
the days of the study, excludes children who were not at school, systematically 
selects only well students.
Croft et al. 1993 low Good (corrected) response rate, comparison been responders and non-
responders shows some difference (responders were more likely to be female 
and in current employment). Short questionnaire completed by a sample of 
non-responders showed that they were less likely to have chronic pain 
compared to those who did (suggests that study may slightly overestimate 
prevalence) but examination of rates of consultation for pain complaints shows 
little difference between responders and non-responders so effect of 
participation bias unlikely to be large.
A9
Study Risk of 
bias
Rating Justification
Dans et al. 1997 moderate While we can assume that recruitment to the screening phase will have led to a 
representative sample (high response rate, assuming sample selection process 
valid), however responders to examination phase shown to be systematically 
different to non-responders (non-responders more likely to be male, younger 
and less likely to have any physical limitation).
Davatchi et al. 2008 moderate Good response rate and study participants selected randomly, however 
recruitment of participants on a weekend may have lead to participation bias, 
this is supported by the finding of a different age and gender distribution when 
study sample was compared with results from a 1996 census. However, 
comparison of 2004–2006 study to 1996 data (results have been standardised 
to 1996 population) might not be appropriate.
Davatchi et al. 2009a moderate Random selection of participants from sampling frame, with a reasonable 
response rate, however, unclear how sampling frame arrived at, unclear if 
sampling frame representative of rural Iran. While a description of the baseline 
study population is given this is not compared with target population.
Eggermont et al. 2010 moderate Little documentation provided in this paper regarding sample selection and 
non-responders. It is assumed that this information is provided in another 
publication, but must assume at least a moderate risk of bias as the study only 
includes the first 600 participants enrolled in the MOBILIZE Boston study, 
therefore need to assume that there is a possibility of first responders being 
systematically different from all participants enrolled.
Elstad 1994 moderate Sample is selected randomly for a variety of regions in Norway. However, 
response rate is low (54%) and no description is provided of non-responders. 
Comparison is made between study sample and Statistics Norway Living 
Conditions Survey 1991 (which had a drop-out rate of 22%), the study samples 
were felt to be comparable, however, this is not sufficient evidence to give a 
low risk of selection bias. 
Farooqi & Gibson 1998 moderate While response rates are high, it is unclear how/why the 3 areas were selected 
and whether they are representative of the target populations, no comparison is 
made between target and sample populations to make this judgement and no 
information is provided regarding the demographics of the sample to be able to 
research this. Recruitment strategy is unclear, however seem to have 
attempted to recruit all residents of the selected area with a good response 
rate, so perhaps the detail of the recruitment strategy is less important in this 
instance.Forseth & Gran 1992 moderate While there is a high response rate, there is no description of non-responders 
or comparison of responders to the population. It may be likely that the 
questionnaire study sample is representative of the target population, however, 
it may be that the random sample of positive responders are not representative. 
Insufficient information about how the sample selected for examination was 
selected. Overall must conclude that there is a moderate risk of bias since 
insufficient information documented to say low risk.
Gansky & Plesh 2007 low Sample stated to be representative of the target population, cohort has high 
retention rate.
However, unlikely to be representative of the general population as a whole, 
since limited population in terms of age, gender and race.
Guermazi et al. 2008 moderate Sample selected from one city, which while in the opinion of the authors was 
felt to be representative of the general population of Tunisia, there was no 
objective measure of. No response rate is given and no description of non 
responders is provided. There was no general population data available on 
which to base the proportion selected for inclusion. Unclear sampling frame, no 
register/list of residents given as source of sample. Therefore must conclude at 
least a moderate risk of selection bias.
Hagen et al. 2005 moderate Responders in this study need to have responded to two postal surveys (over a 
decade apart) and completed 2 questionnaires in the second survey, there is 
therefore likely to be bias due to loss to follow up. However, the study has large 
sample size. Information in other publications may have compared responders 
to non-responders, however, the information is not provided in this paper, so 
must conclude at least a moderate risk of bias.
Haq et al. 2005 moderate While the study has high response rates, there is no description provided of 
non-responders, so unable to judge if non-response may have lead to bias. In 
addition no comparison is made between study populations (rural, urban slum, 
urban affluent) and the rest of the Bangladeshi population to judge how 
representative these populations are of the Bangladeshi population as a whole. 
Study is very likely to provide a fair measure of prevalence in sampling frame, 
but unclear if this can be extrapolated to the country as a whole.
A10
Study Risk of 
bias
Rating Justification
Hardt et al. 2008 moderate The cohort from which the large sample is drawn is stated to be representative 
of the US general population with an oversampling of ethnic minorities. This is 
accounted for in analysis by standardising the figures to the US population. 
This would seem a reasonable approach to take, however, no evidence is 
provided regarding the representativeness of the study sample, neither are 
response rates or recruitment strategies documented, it is assumed that these 
are provided in the publications referenced in the paper, however, since 
sample is stated to oversample ethnic minorities it cannot be taken to be 
representative of the whole population. There is also a lack of documentation 
regarding what constitutes a 'personal' interview, if this is conducted by phone 
it may systematically systematically exclude individuals without a phone.
Häuser et al. 2009b low While response rate is low and no description is provided of non-responders, 
the sample is stated to be representative of the German population based on 
statistics from German Federal Statistics for 2007 with respect to age, gender, 
and educational qualifications. 
Häuser et al. 2013 low While response rate is low (56%), reasons for non-participation are given and 
while the sample is stated to differ from the general population on age and 
gender distribution and education it is not significantly different from the 
general population.
Hughes et al. 2006 low This study uses the GPRD (General Practice Research Database) which 
contains the medical records from more than 350 general practices in the UK, 
and represents approximately 4.6% of the UK population. Since it is estimated 
that 95% of the UK population are registered with a GP this data offers a good 
representation of the UK population.
Hunt et al. 1999 low Sample selected randomly, reasonable response rate, description of 
responders provided and comparison of figures derived from sample against 
figure standardised to the UK general population show little difference, there is 
no evidence that any differences in the study sample will influence the 
outcome.
Jacobsson et al.1996 moderate No documented details are given regarding sample selection, recruitment 
methods, response rate, non-responders or baseline study population (with the 
exception of gender and diabetic status). No comparison is made to the target 
population. Must therefore conclude at least a moderate risk of selection bias, 
since insufficient information to make the judgement.
Joshi & Chopra 2009 moderate Insufficient documentation regarding: sample selection, recruitment approach 
and response rate. However, comparison is made between study sample and 
Indian general population in terms of age distribution. Study sample found to 
be older than general population, prevalence figures standardised by age and 
gender to Indian 2001 census population.
Kim et al. 2006 high Non-random voluntary recruitment is highly likely to lead to participation 
bias.This is supported by the observation that 66% of the sample are female, 
this is unlikely to be representative of the underlying population. Response rate 
is not applicable since participants were recruited by voluntary response to a 
mass health screening. 
Klemp et al. 2002 high Non-random recruitment by tribal elders of tribal constituent of the study, while 
necessary due to cultural beliefs, will nonetheless lead to bias. Effort has been 
made to counter this by adjusting figures for age (would result in a moderate 
risk of bias), however, in addition, the study had very poor response rates and 
there was no analysis of non-responders and no comparison made with target 
population, must therefore conclude a high risk of participation bias.
Kurita et al. 2012 moderate Moderate response rate of 61%. No description of non-responders is provided 
and there is no comparison of the sample to the target population, therefore we 
are unable to judge whether the sample is representative of the target 
population, however, the results are adjusted for non-response using weighting 
based on information available in the Danish Civil Register (sex, age, 
residence, education level, income, employment status, country of origin and 
health care utilisation), so this may not be a problem.
Lindell et al. 2000 high While response rate is reasonable, and sample selection would seem to be fair, 
there seems to be a problem with response-bias: non-participants are shown to 
be different to participants with respect to the outcome measure (non-
responders shown to be less likely to complain of chronic pain). No comparison 
is made to target population. Study only examines a stratified sample of 
positive responders.
A11
Study Risk of 
bias
Rating Justification
Macfarlane et al. 2005 
(survey A)
moderate Using GP registered population to reflect general population of the UK is valid 
due to high proportion of individuals registered with a GP in the UK, however, 
GP practices were chosen for high density of South Asian population, therefore 
unlikely to represent the general population of the UK. Response rates are 
relatively poor. Comparison of age/gender distribution in the two study groups 
demonstrate that samples not similar, therefore also unlikely to be 
representative of the underlying population. However, prevalence figures 
standardised for age and gender. 
Macfarlane et al. 2005 
(survey B)
moderate Sample taken from GP register, which is a valid approach in the UK. However, 
there is insufficient documentation regarding sample selection/response rate/
baseline study population/non-responders provided to judge risk of selection 
bias. Must therefore conclude at least moderate risk of bias, possibly high risk 
given low sample size and use of only one geographical area to recruit 
participants from.
Macfarlane et al. 2009a low Clear documented details (in another publication) showing that sample broadly 
representative of surviving cohort. However, only representative of those age 
45yrs.
Macfarlane et al. 2009b low Sample selected using stratified sampling from appropriate population 
registers, low participation rates in some centres may be a concern, but 
prevalence not observed to be related to participation rate, so it was concluded 
that decision not to participate was not importantly influenced by CWP.
Mäkelä & Heliövaara 1991 low While no detail is given regarding how sample selected, it is stated to be 
representative of the Finnish population, and has a high response rate. 
However, prevalence calculated after examination of screen positives only, 
therefore moderate risk of bias as a result of possibly missing some individuals 
who were not examined.
Marschall et al. 2011 high Sample includes only one insurance provider. Does not include AOK which is 
the largest of Germany’s roughly 180 statutory health insurance funds and does 
not include private insurance funds.
McNally et al. 2006 low This a large size survey with a sample selected to be representative. 
Mandatory completion ensured complete response rate. Sample stated to be 
representative of the general population of Canada.
Minaur et al. 2004 moderate The study had a good response rate (80%) and the study sample seems 
comparable with 2001 census data for the region in terms of age and gender, 
however, no description is provided regarding sample selection and 
recruitment methods and there is no discussion of how representative the 
Aboriginal population in this region is of the Aboriginal population in the rest of 
Australia. No description is provided on non-responders. Therefore must 
conclude a moderate risk of selection bias.
Øverland et al. 2012 high There is insufficient information about non-responders and no comparison of 
responders to the baseline population, so we are unable to judge whether the 
sample is representative of the general population and a limited age range (40–
46) is unlikely to be representative.
Papageorgiou et al. 2002 low Reasonable response rate and sample selected randomly from GP register 
which is felt to be representative of the general population in the UK, however, 
need to be careful with generalising this prevalence to the population as a 
whole, since only used one general practice in Handford.
Pelaez-Ballestas et al. 2011 low Sample selected using random sampling techniques, subjects recruited at 
times they were likely to be home, up to 4 repeat visits to a household to ensure 
participation. However, some regions have very poor response rates and 
baseline study population shown to be have high density of women. While 
methods of sampling should ensure a random sample, participation bias may 
be a problem as indicated by poor response rates in some regions and 
baseline study population being different to underlying general population. 
However, perhaps large sample size may account for this therefore low risk of 
bias.
Perrot et al. 2011 high There are low response rates to both screening interview (51%) and follow up 
physical examination of screen positives (41%). There is no information 
provided comparing responders to the target population or to non-responders 
to judge the effect of the low response rate. Identifying patients from the 
telephone directory systematically excludes those without a telephone and 
those not included in the telephone directory. These individuals are likely to be 
systematically different to those in the sampling frame. There is no statement 
made regarding the time of day calls were made, if calls were only made 
during the day this would systematically exclude daytime workers. Finally, 
prevalence estimates were extrapolated from FM rates observed in screen 
positives attending for physical examination.
A12
Study Risk of 
bias
Rating Justification
Picavet & Hazes 2003 moderate Sample selected via stratified sampling from 1998 population census, which is 
a reasonable approach, however, low response rate of 47% leading to a 
sample with higher proportions of women, middle aged and married people, 
therefore likely to be at least a moderate risk of selection bias.
Prescott et al. 1993 low Study sample drawn from the responders to another survey. The sampling 
frame is shown to be representative of the target population and the study 
sample shown to be representative of the sampling frame with respect to age 
and gender (study participants more likely to be married and live in a rural 
area). However, response rate is reasonable, therefore there is evidence that 
participation is not likely to be related to outcome.
Raspe & Baumgartner 1993 high The sample is selected randomly, there is a reasonable response rate of 81% 
to the initial postal questionnaire and a reasonable response of 76% to 
examination, however, there is no evidence provided that the sample is 
representative of the target population and no information is provided 
regarding non-responders to both the questionnaire and examination phase. 
Must therefore conclude at least a moderate risk of sample selection bias, 
however, the assumptions that have been made in the estimation of population 
parameters mean this study must be rated at high risk of bias. The assumptions 
made in the calculation of prevalence are very likely to result in inaccurate 
estimates. It is not appropriate to assume that non-responders are the same to 
responders, cannot therefore assume that there is an equal frequency of 
widespread pain in non-responders, cannot therefore extrapolate anything 
regarding FM prevalence among those who have not responded.
Reyes-Llerena et al. 2000 high Sample selected non-randomly and stated to have an over representation of 
individuals of Caucasian and African origin. No clear documentation of sample 
selection and recruitment. 100% response rate seems unrealistic and therefore 
suspicious. Have to conclude a high risk of bias. 
Reyes-Llerena et al. 2009 low Sample selected randomly from an area which is stated to be representative of 
the general population of Cuba. While no response rate is provided and no 
description is given of non-responders, sociodemographic data for the sample 
is provided and the age distribution of the sample is compared with that of the 
national population derived from a recent national census. 
Rodriquez-Amado et al. 2011 low Sample selected using stratified sampling from national census data, 94% 
response rate, details of baseline study population provided.
Salaffi et al. 2005 low The sample was selected using random stratified sampling, however, GPs were 
given the power to veto some selections, most of these decisions seem 
reasonable (e.g. died, no longer register, dementia, etc) however, there are 99 
patients excluded by GPs with no reason given, it’s unclear if these patients 
were systematically different from others. Description of baseline study 
population provided and non-responders were investigated, so while there is a 
question regarding the 99 patient excluded, the study sample would seem 
representative of the target population, at least with respect to age and gender.
Santos et al. 2010 moderate Sampling frame likely to be representative (no statement given in this paper, 
references to another 2 publications). Good response rate, baseline study 
sample described. Non-responders unlikely to be a problem due to high 
response rate. Moderate risk of bias as a result of exclusion criteria, excluding 
individuals on antidepressants, analgesics or anti-inflammatories (regularly 
used treatment medication for CWP/FM) likely to systematically exclude those 
with FM/CWP, also excluding those with other rheumatic disease will exclude 
patients who also have FM/CWP. Study likely to be an underestimation of 
population prevalence.
Sauer et al. 2011 high Sample includes only one insurance provider. Does not include AOK which is 
the largest of Germany’s roughly 180 statutory health insurance funds and does 
not include private insurance funds.
Schochat & Raspe 2003 moderate Participants recruited from all women aged 35–74 on the state register in one 
area in Germany, there is a reasonable response rate of 74%. There is no 
evidence provided that this area is representative of the German population 
(this is a very select population, in terms of age, gender and location), no 
information is provided regarding non-responders and no description of the 
baseline study population is offered or comparison made with the target 
population, must therefore conclude a least a moderate risk of participation 
bias.
A13
Study Risk of 
bias
Rating Justification
Scudds et al 2006 moderate Sample selected randomly from telephone directory, with reasonable response 
rate of 60%. Sample stated to be representative of Hong Kong census in terms 
of age. No other comparisons offered. No information provided regarding non-
responders. Low response rate to examination phase also a problem. Sampling 
frame excludes those without a telephone and those who have chosen not to 
have their numbers in the telephone directory, therefore likely to lead to a 
systematically different set of individuals in the sample. 
Senna et al. 2004 moderate The sample was selected using cluster sampling, there was a high response 
rate to both the interview phase and the examination phase. There is a 
possibility that since all subjects were not examined there might be an 
underestimation of prevalence. The baseline study population is described and 
the sample is compared to the sociodemographics of the target population. No 
description is provided of non-responders. This study must be considered 
moderate risk of participation bias, since it is unclear how representative the 
Montes Claros region is of urban Brazil as a whole.
Storozhenko et al. 2004 moderate Good response rate of 76% and the age and gender distribution of the sample 
is provided however, no statement is made regarding whether Yekaterinburg is 
representative of the general population of Russian and no comparison made 
with target population and no description of non-responders provided.
Svebak et al. 2006 low All residents of one region were invited to participate, there was a 70% 
response rate. Participants are more likely to be female and aged 60–69. Non 
responders were described. Prevalence figures were standardised for age and 
gender.
Topbas et al. 2005 low High response rate from a sample selected randomly from health care 
registration records. Only reservations I have are how many of the Turkish 
population are registered with a GP? (are these registration records 
representative of the general population?) and how generalisable is the 
population of Trabzon to the rest of Turkey?
Turhanoglu et al. 2008 low Sample selected to represent Turkish population, baseline sample described, 
complete response rate for screening phase. However, no response rate 
quoted for examination phase.
Veerapan et al. 2007 high Unclear description of recruitment process, inadequate description by which to 
judge bias, this would result in a moderate risk of bias, however the paper itself 
describes the difficulty in finding one community which represents the 
multiethnic population of Malaysia – therefore would seem very unlikely that in 
recruiting the sample from one suburb that it will be representative of the 
general population.
Vincent et al. 2013 
(medical records)
low This study uses the medical records of all those registered with the Rochester 
Epidemiology Project, which has been shown to capture 'virtually the entire' 
target population. 
Vincent et al. 2013 
(self report)
high While the sampling frame and random selection of study sample appears 
appropriate, the very low overall response rate (28%) and particularly low 
response rate in the 21–39 year age group (16%) suggests that the sample is 
unlikely to be representative of the target population. In addition, no details 
comparing responders with non-responders or responders and the target 
population are provided to help assess how much the poor response rate might 
have influenced the prevalence estimate. In addition an unexpectedly high 
prevalence rate in the 21–39 year age group suggests that prevalence 
estimates may be biased.
White et al. 1999 moderate Sample shown to be different to census data, while figures are standardised 
against census data, this does not remove possible systematic bias as a result 
of telephone interviewing (excludes those without a home phone).
White et al. 2003 low 
(Amish) 
moderate 
(non-
Amish)
Amish arm of study low risk of selection bias due to 74% participation by those 
eligible to participate. Amish community in Aylmer likely to be representative of 
other Canadian Amish.
Non-Amish rural arm of study moderate risk of selection bias due to telephone 
recruitment of participants excluding those without a telephone and those not in 
at the time of a call, no information about non-responders, and figure for FM 
likely to be biased due to low participation rate for examination arm of study 
(42%)
Wolfe et al. 1995 moderate While the study samples the general population of Wichita city, with a good 
response rate of 86% for questionnaire and a reasonable response of 61% to 
the examination phase, it is not clear how representative Wichita city is of the 
general population in the US, must therefore conclude a moderate risk of 
selection bias.
A14
Study Risk of 
bias
Rating Justification
Wolfe et al. 2013 low While response rate is low (56.7%), details of non-participants are provided 
and the study sample is demonstrated to be comparable to the target 
population on age and gender.
Zapata et al. 2006 high Only private school students in one city investigated. No clear age of 
participants given. Only a subset of participants examined.
Select group of participants and low response rate.
Zeng et al. 2010 moderate No detail is provided of sampling frame or sampling strategy by which to judge 
possibility of selection bias, must therefore conclude at least a moderate risk of 
bias
A15
A3.5 Methodological quality: justification of ratings for QUIPS tool domain 4
Table A3.7 Risk of outcome measurement bias and justification for rating using domain 4 of the QUIPS 
methodological quality assessment tool.
Study Risk of 
bias
Rating Justification
Ablin et al. 2012 high Used positive predictive value (PPV) ascertained from a different population to 
that under investigation to calculate prevalence. Therefore unlikely to be a 
reliable measure of prevalence. Also no statement made regarding validation of 
examination used in the rheumatology outpatients department to determine FM 
status and therefore calculate the PPV used to calculate community prevalence.
Abusdal et al. 1997a moderate Measurement of the outcome is similar for all subjects. However, unclear 
documentation regarding case definition and unclear if testing of retest reliability 
of questionnaire is done appropriately.
Aggarwal et al. 2006 low Measurement of outcome is valid, reliable and similar for all subjects. Might be 
some underestimation of ACR-90 CWP status due to exclusion of head pain from 
case criteria, however, likely to be small.
Alvarez-Nemegyei et al. 
2005
moderate Insufficient information to determine whether outcome measurement is valid and 
reliable, since no reported evidence of questionnaire validation, or reliability of 
junior doctors' diagnosis. Method and setting of outcome measurement not 
similar for all subjects. Prevalence estimates based on extrapolation from figures 
observed in screen positives only.
Alvarez-Nemegyei et al. 
2011
moderate While screening questionnaire has been validated there is no documentation 
regarding any efforts taken to ensure that those administering the questionnaire 
are doing so reliably. Only screen positive are examined. Unclear if measurement 
of outcome is valid as no information given regarding test-retest reliability of 
physicians conducting examination. 
Andersson 1994 moderate CWP: Moderate risk of bias as clear diagnostic criteria stated, measured using a 
validated instrument in a similar setting for all participants, however diagnostic 
criteria are not accepted CWP criteria.
FM: Moderate risk of bias as no clear diagnostic criteria stated, no stated 
measures taken to ensure validity/reliability of diagnosis. Only examined a sub-
sample of CWP positive responders.
Andersson et al. 1999 high Coding: Low
Community: High due to variation in diagnostic and coding practices among 
clinicians and variation in consulting behaviour between patients, therefore 
prevalence estimate will likely underestimate community prevalence
Assumpção et al. 2009 moderate Clear operationalisation of outcome measure but unclear validation of 
examination/diagnosis and not all participants examined. Insufficient information 
about screening questionnaire to judge validity.
Bazelmans et al. 1999 high Coding: High. No clear, constant diagnostic approach taken between clinicians. 
Paper doesn’t state FM diagnostic criteria.
Community: High. Relies on the clinicians diagnostic beliefs and the patients 
consulting behaviour.
Bergman et al. 2001 low Measurement of outcome is similar for all subjects. While the questionnaire is not 
validated is uses a standard approach to assessing self-reported CWP status 
which has been used by other studies (i.e. question regarding pain duration and 
body mannikin to locate pain).
Branco et al. 2010 high Uses positive predictive value (PPV) ascertained from a different population to 
that under investigation to calculate prevalence, this is unlikely to lead to a 
reliable prevalence estimate. Also no statement made regarding validation of 
examination used in the rheumatology outpatient department to determine FM 
status and therefore calculate the PPV used to calculate prevalence.
Buskila et al. 1993 moderate Method and setting of measurement is standard for all subjects using standard 
approach, however, no evidence is provided of reliability of outcome 
measurement. No statement is made regarding test-retest reliability of interview/
examination.
Buskila et al. 2000 low Outcome measurement conducted in a similar way for all participants using an 
accepted approach to measurement and using clearly documented case criteria.
Cakirbay et al. 2006 high Screening questionnaire not validated. No steps taken to validate examination or 
blind examiners to screening status. No statement given regarding method or 
setting of screening questionnaire or follow-up examination. Examination of only 
screen positives may lead to bias. Insufficient information given to judge risk of 
bias in measurement of outcome measure, therefore must conclude high risk of 
bias.
Cardiel & Serrano 2002 moderate While all subjects were screened in a consistent manner using a validated 
instrument, not all subjects were examined, and little evidence is provided for 
validity/reliability of clinical examination.
A16
Study Risk of 
bias
Rating Justification
Carmona et al. 2001 low Use of previously validated instruments which have been pilot tested. Data 
collectors instructed in standard interview/examination protocol prior to study. 
Data collection monitored during the study for consistency. Similar method and 
setting of outcome measurement for all participants. 
Carnes et al. 2007 low Measure of outcome similar for all subjects, criteria are clearly stated and while 
the questionnaire is unvalidated it uses a standard approach to assessing pain 
location using a blank body manikin. However, there is no detail provided 
regarding how chronicity of pain was elicited, it is assumed that patients were 
asked a simple question about pain duration given the use of the chronic pain 
grade scale.
Chaaya et al. 2012 moderate We must conclude at least a moderate risk of outcome measurement bias 
because no information is provided regarding and measures taken to ensure the 
reliability of the interview, and no information is given regarding whether the 
examination was standardised or tested for reliability.
Chen et al. 2008 high Poor operationalisation of ACR-90 criteria using a questionnaire only. Study uses 
two questionnaires which have not been validated as a means of determining FM 
prevalence without an associated examination. High likelihood of overestimation 
of prevalence. 
Choudhury et al. 2013 
(long)
moderate While the questionnaire uses a standard method of ascertaining CWP status 
(body mannikin) and the setting is the same for all participants, there is no 
statement regarding the interview validity and it is unclear how much a possible 
lack of confidentiality in the interview setting (GPs waiting rooms) might have 
influenced participants responses.
Choudhury et al. 2013 
(short)
low Measure of outcome similar for all subjects (although some were assessed with 
postal questionnaire, late responders were assessed using a telephone 
questionnaire), criteria are clearly stated and while the questionnaire is 
unvalidated it uses a standard approach to assessing pain location using a blank 
body manikin. 
Clark et al. 1998 low While the questionnaire used is not validated is uses a standard approach used 
by other studies. Screening process unlikely to have excluded individuals with 
FM, therefore examination of only screen positives unlikely to be a problem. 
Examiners not blinded to screening status, but examinations conducted in a 
systematic way.
Croft et al. 1993 low Clear operationalisation of CWP criteria, use of a study specific questionnaire that 
while not stated to have been validated or tested for reproducibility, uses a 
standard approach to assessing CWP. Measurement of outcome is similar for all 
subjects.
Dans et al. 1997 low Measurement of outcome is similar for all subjects, clear diagnostic criteria given, 
clinicians given standardised training in diagnosis prior to study. 
Davatchi et al. 2008 high The study uses a validated and back translated questionnaire that has been pilot 
tested, the interviews are conducted by trained interviewers, and test for 
reliability with frequent quality control, however, the examination is not validated, 
adequately described or tested for reproducibility and diagnosis is based on 
'clinical judgement' and therefore not a robust measure.
Davatchi et al. 2009a moderate While questionnaires and interviews appear to be valid and tested for reliability. 
Examination has not been validated or tested for reproducibility and while 
diagnostic criteria are given (WHO-ILAR criteria, assume this means ACR-90) 
diagnosis is based on 'expert opinion'.
Eggermont et al. 2010 low Clearly defined outcome measures, recorded in a standardised fashion. 
Possibility that case definition may not accurately represent ACR-90 criteria, 
however case definition criteria are given sufficiently that it offers a useful figure 
to compare with prevalence figures derived using alternative criteria.
Elstad 1994 high Case definition based on patient recollection of physician diagnosis. This relies 
on patient recall and understanding, physician communication, physician's 
diagnostic practices and beliefs. There are too many other variables contributing 
to definition of a 'case' to provide an accurate measure of FM diagnosis in the 
community. In addition there is no statement made regarding the reliability/
validity of the questionnaire. 
Farooqi & Gibson 1998 moderate Insufficient information regarding examination procedure, validity and reliability 
and no statement of diagnostic criteria.
Forseth & Gran 1992 high Unreliability of unvalidated clinical judgement of one clinician only and 
unvalidated postal questionnaire used to determine positive responders. Random 
sample of positive responders selected for follow-up examination. Not robust to 
extrapolate the prevalence found in random sample of screen positives to the 
population as a whole.
Gansky & Plesh 2007 low Measurement of outcome is valid, reliable and similar for all subjects. 
A17
Study Risk of 
bias
Rating Justification
Guermazi et al. 2008 moderate The study uses a previously validated questionnaire that has been translated and 
back translated and then tested in a pilot of 30 subjects. However, the 
examination procedure is not documented and there is no statement made 
regarding any reliability testing of the examination process, therefore must 
conclude at least a moderate risk of outcome measurement bias.
Hagen et al. 2005 moderate Measure of outcome similar for all subjects, but questionnaire unvalidated and 
while criteria are clearly stated, there is a question about the validity of the case 
definition.
Haq et al. 2005 low Measurement of outcome is similar for all subjects. Interviewers and examiners 
trained for standard application of interview/examination. Review of all 
questionnaires and examination sheets by rheumatologists ensures reliability of 
diagnosis. Only worry would be that tender point examination might not have 
been carried out appropriately since no documentation, however, training of 
examiners should ensure that this is carried out according to standard protocols.
Hardt et al. 2008 moderate Due to insufficient documentation of interview process and validity/reliability of 
questionnaire unable to give this study a low risk of outcome measurement bias 
and must conclude a moderate risk of bias.
Häuser et al. 2009b high Non-standard criteria for FM based on self-report only with no examination, 
however, questionnaire stated to have good concordance with FM diagnosis in a 
rheumatology clinic.
Häuser et al. 2013 low Validated measure of outcome used, applied in a consistent method to all 
participants.
Hughes et al. 2006 high Community prevalence: High risk of bias since coding prevalence will be 
influenced by consulting behaviour and diagnostic beliefs of clinician.
Coding prevalence: Low risk of bias.
Hunt et al. 1999 low Measurement of outcome is similar for all subjects, it uses a standard approach 
and the coder of manikins is blinded to patient's psychosocial status.
Jacobsson et al. 1996 moderate The operationalisation of the outcome measure is reasonable, but no statement is 
made regarding any validity/reliability testing of the questionnaire/interview 
process, must therefore conclude moderate risk of outcome measurement bias.
Joshi & Chopra 2009 moderate Study uses a widely used and pre-validated questionnaire. The questionnaire is 
administered by personnel trained over two days (therefore assume good inter-
rater reliability). Concern over use of screening question to determine 
questionnaire administration, since this is not used in other studies using 
COPCORD questionnaire, however, unlikely to exclude cases, so probably valid. 
No documentation regarding examination procedure or steps taken to ensure 
reliability/validity of examination process so must therefore conclude a moderate 
risk of bias.
Kim et al. 2006 moderate Clear case criteria have been used, but there is insufficient documentation 
regarding the reliability of the screening questionnaire and setting of outcome 
measurement to infer low risk of bias. There is also inadequate documentation 
regarding testing for reliability of interviewers and examinations, so must 
conclude at least moderate risk of bias.
Klemp et al. 2002 moderate While there is clear documentation of the examination procedure and the 
examination process is shown to be reliable and reproducible by pre-study 
standardisation, there is no documentation regarding the validity/reliability of the 
interview procedure to ascertain CWP status, must therefore conclude a 
moderate risk of outcome measurement bias.
Kurita et al. 2012 moderate While the outcome is defined as pain in 4 or more sites lasting 6 months or 
longer, this is a non-standard definition for CWP and it is unclear how the number 
of body sites were measured (no information about whether the study used a 
body mannikin, a list of body regions or the free text of the respondents).
Lindell et al. 2000 high Long delay between questionnaire and examination, may have resulted in 
resolution of symptoms for some subjects leading to underestimation of 
prevalence. In addition only examining a stratified sample of screen positives 
and extrapolating to the rest of the population is not robust.
Macfarlane et al. 2005 
(survey A)
low Measurement of outcome is similar for all subjects, while study makes no 
statement regarding validity/reliability of questionnaire, it uses a standard 
approach to assessing CWP. 
Macfarlane et al. 2005 
(survey B)
low Measurement is similar for all subjects. While there is no statement regarding 
questionnaire validity it uses a standard approach to assessing the outcome, so 
unlikely to lead to systematic bias.
Macfarlane et al. 2009a low Clear case definition, outcome measured in a standardised way, no statement 
made regarding validity of questionnaire, however takes a standard approach 
(question about pain duration and blank body manikin to record location of pain).
A18
Study Risk of 
bias
Rating Justification
Macfarlane et al. 2009b low Measurement of outcome is valid (standard approach) and similar for all 
subjects. 
Mäkelä & Heliövaara 1991 high Examination not designed to test for FM therefore tender points not tested for 
using accepted methodology, therefore likely to underestimate prevalence. 
In addition only screen positives examined.
Marschall et al. 2011 high Community prevalence: High risk of bias since coding prevalence will be 
influenced by consulting behaviour and diagnostic beliefs of clinician.
Coding prevalence: Low risk of bias, particularly since it requires the recording of 
the FM code twice in the medical records.
McNally et al. 2006 high Relying on patient recall of physician diagnosis is not an accurate assessment of 
community prevalence of a disease since it relies on: patent recall, consulting 
behaviour, diagnostic beliefs of clinician, communication between clinician and 
patient. Highly likely to be an under representation of prevalence.
Minaur et al. 2004 moderate While a widely used and validated screening tool is used, there is no statement 
made regarding the reliability of the interview process and the examination 
procedure, must therefore conclude at least a moderate risk of outcome 
measurement bias.
Øverland et al. 2012 moderate The same method of assessment is used for all participants and the outcome is 
clearly defined, however, case definition for CWP is non-standard since it makes 
no assessment of contralateral limb pain and no statement is made regarding 
any efforts to validate the questionnaire.
Papageorgiou et al. 2002 low The study uses a stand method of outcome measurement and is similar for all 
subjects.
Pelaez-Ballestas et al. 2011 moderate The study clearly defines diagnostic criteria and outcome measurement is similar 
for all subjects, however, only screen positives are examined. The COPCORD 
questionnaire has been used in many other studies and is validated. However, no 
description is provided regarding the reliability of the interview/examination 
process. Must therefore conclude a moderate risk of bias due to inadequate 
reporting of data collection.
Perrot et al. 2011 moderate While the study uses a screening questionnaire that has been widely used and 
validated in other studies, no statement is made regarding any efforts to 
standardise its administration. Further, only those screen positives who accepted 
were examined. We must conclude therefore that there is at least a moderate risk 
of outcome measurement bias.
Picavet & Hazes 2003 high Relying on self reported diagnosis of FM is not an accurate assessment of 
community prevalence of a disease since it relies on: patent recall, consulting 
behaviour, diagnostic beliefs of clinician, communication between clinician and 
patient, patient self diagnosis. Highly unlikely to be an accurate representation of 
community prevalence.
Prescott et al. 1993 low Measurement of outcome is valid and reliable – uses clear diagnostic criteria and 
2 examiners independently examining all screen positives. The examination of 
only screen positives is unlikely to exclude any patients with FM. 
Raspe & Baumgartner 
1993
high Definition of outcome not adequately documented. Unclear if questionnaire is 
capable of picking up all subjects with CWP, therefore only examining those that 
are defined as having multi location chronic pain according to the questionnaire 
may miss relevant patients. Examination is well documented, with the exception 
of the location of the control points. 
Reyes-Llerena et al. 2000 high While the study uses a widely used and validated screening questionnaire, the 
interview and examination process are not documented and no clear diagnostic 
criteria are provided, it is unlikely therefore that the results of the study are 
reproducible.
Reyes-Llerena et al. 2009 moderate While the study uses clearly defined diagnostic criteria and a validated and 
widely used questionnaire, the paper itself suggests the possibility of a low index 
of suspicion for FM by the interviewers, leading to examinations that did not 
specifically look for tender points and might therefore have missed FM diagnosis, 
possibly underestimating FM prevalence, must therefore conclude at least a 
moderate risk of measurement bias.
Rodriquez-Amado et al. 
2011
low Cases are defined using standard criteria. Screening unlikely to exclude cases 
(uses widely used and validated instrument), potential cases all reviewed by a 
rheumatologist. 
Salaffi et al. 2005 moderate While the study uses accepted and clear case criteria, and a similar method of 
outcome measurement for all subjects, no statement is made regarding the 
validity/reliability of questionnaire, interview or examination. The reliability of the 
screening questionnaire is unclear, therefore unable to judge whether any 
subjects could have been missed by the screening questionnaire. Unable to 
judge reliability/validity of diagnosis and must therefore conclude a moderate risk 
of outcome measurement bias.
A19
Study Risk of 
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Rating Justification
Santos et al. 2010 moderate While case criteria and examination procedures are clearly documented, there is 
insufficient documentation to judge the validity of the screening questionnaire 
used to determine whether a participant is examined or not. Must therefore 
conclude at least a moderate risk of outcome measurement bias. 
Sauer et al. 2011 high Community prevalence: High risk of bias since coding prevalence will be 
influenced by consulting behaviour and diagnostic beliefs of clinician.
Coding prevalence: Low risk of bias.
Schochat & Raspe 2003 low Outcome measurement is similar and uses a standard approach (question about 
pain duration and blank body manikins to capture pain location) for all subjects.
Scudds et al 2006 low The study uses clearly defined case definition criteria and uses a back translated 
version of a validated instrument to screen participants for CWP. Interviews are 
standardised and examination protocol clearly documented.
Senna et al. 2004 moderate While the COPCORD screening questionnaire is validated and has been widely 
used, there is insufficient documentation regarding the reliability of the interview 
and examination processes, must therefore conclude at least a moderate risk of 
outcome measurement bias.
Storozhenko et al. 2004 low Method and setting of outcome measurement similar for all respondents. 
Questionnaire based on validated questionnaires. Russian and English speakers 
translated and back translated from a validated questionnaire.
Svebak et al. 2006 moderate Definition of CWP is non standard, the questionnaire has not been validated for 
determining estimates of widespread pain, must therefore conclude a moderate 
risk of outcome measurement bias.
Topbas et al. 2005 low Screening test uses a validated questionnaire which has been used in other 
studies. Examination is conducted according to a clearly documented protocol.
Turhanoglu et al. 2008 moderate Measurement of outcome is similar for all subjects and uses standard case 
definition criteria, however no statement is made regarding the reliability/validity 
of the questionnaire, interview or examination process, must therefore conclude 
at least a moderate risk of bias.
Veerapan et al. 2007 high While the study uses the pre-validated and widely used COPCORD tool, it is 
unclear if the administrators of the tool were adequately trained to use it, and 
there is no statement made regarding the examination procedure used or any 
measures taken to check for reliability of examination procedure. This would 
result in only a moderate risk of bias, however, in addition, no statement has 
been made regarding diagnostic criteria used for case determination, this study 
must therefore be considered at high risk of outcome measurement bias since it 
is unclear if robust case definitions are used and unclear if interview and 
examination valid and reliable. In addition only those with pain in "the last week" 
were examined, therefore potential to exclude FM patients who were currently 
pain free.
Vincent et al. 2013 
(medical records)
high Coding prevalence: low risk of bias. The means of identifying diagnosed FM 
through medical record review is unlikely have missed cases. 
Community prevalence: high risk of bias since medical record review will only 
capture those who consult for symptoms and those that the clinician diagnoses 
as having FM.
Vincent et al. 2013 (self 
report)
low The study uses a new, but clearly documented, classification criteria for FM. FM 
status is assessed using a questionnaire whose development is clearly 
documented in another paper. The same method and setting of outcome 
measurement is used for all participants.
White et al. 1999 low Study uses validated questionnaire, interviews are quality controlled and 
examination is clearly documented and consensus between examiners checked.
White et al. 2003 moderate There is insufficient documentation regarding the reliability of the examination 
phase of the study, must therefore conclude at least a moderate risk of outcome 
measurement bias.
Wolfe et al. 1995 low Questionnaire used is not validated but uses a standard approach, examination 
is standardised and clearly documented.
Wolfe et al. 2013 low The study uses a new, but clearly documented, classification criteria for FM. FM 
status is assessed using a questionnaire whose development is clearly 
documented in another paper. The same method and setting of outcome 
measurement is used for all participants. The only criticism might be that the new 
criteria do not measure FM prevalence, however, with no gold standard 
measurement for FM, and with the new criteria aiming to better capture the 
continuum of the FM experience, it might be argued that these criteria better 
identify FM patients, in addition figures are given for how many cases meet 
established ACR-90 criteria (82.7% overall).
Zapata et al. 2006 moderate Clear outcome criteria measured in a consistent manner, however, no statement 
regarding validation of questionnaire or examination, therefore must conclude at 
least a moderate risk of bias.
A20
Study Risk of 
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Rating Justification
Zeng et al. 2010 moderate Study makes uses of validated and widely used COPCORD screening 
questionnaire and examination of suspected cases was undertaken by 3 
rheumatologists to ensure consensus, however, no statement is made regarding 
the validity/reliability of the screening interview, must therefore conclude a least a 
moderate risk of outcome measurement bias.
A21
A3.6 Summary of included studies
Table A3.8 Summary of studies included in the systematic review, including: sample size, age and sex, geographical location of the study, diagnostic criteria, and 
prevalence estimates.
Study 
population
Study Sample 
size
Sample 
Age
Location Diagnostic criteria FM CWP
Children, 
adolescents & 
young adults
Buskila et al. 1993
Clark et al. 1998
Zapata et al. 2006
Female adults Abusdal et al. 1997a
Cakirbay et al. 2006
Elstad 1994
Forseth & Gran 1992
Gansky & Plesh 2007
African American
Caucasian
Macfarlane et al. 2005 
(survey B)
South Asian
White European
Schochat & Raspe 2003
Topbas et al. 2005
338 9–15 Israel ACR-90 – including tender point 
examination
620 (410, 930)*
548 9–15 Mexico ACR-90 – including tender point 
examination
120 (60, 260)*
359 adolescent São Paulo, Brazil ACR-90 – including tender point 
examination
100 (20, 130)*
2,622 25–55 Norway Generalised pain for 3 months or longer 
with everyday life influenced by a great 
extent.
290 (230, 350)
1,045 18–55 Trabzon City, Turkey 
– urban
ACR-90 – including tender point 
examination
680 (540, 850)*
3,211 36–55 Norway Self-reported recall of diagnosis 440 (370, 520)*
2,038 20–49 Arendal, Norway ACR-90 – including tender point 
examination
1,050 (640, 1,460)
1,334 21–26 USA ACR-90 – including tender point 
examination
240 (170, 350) 560 (440, 690)*
684 300 (200, 460)
650 200 (120, 340)*
18–36 UK ACR-90 CWP criteria
137 940 (560, 1560)*
121 570 (280, 1150)*
2,253 35–74 Germany ACR-90 – including tender point 
examination
1350 (1210, 1500)*
1,930 20–64 Turkey ACR-90 – including tender point 
examination
360 (280, 440)*
A22
Study 
population
Study Sample 
size
Sample 
Age
Location Diagnostic criteria FM CWP
Male adults Macfarlane et al. 2009b
Belgium (Leuven)
England (Manchester)
Estonia (Tartu)
Hungary (Szeged)
Italy (Florence)
Poland (Lodz)
Spain (Santiago)
Sweden (Malmo)
Older adults Eggermont et al. 2010
Santos et al. 2010
Birth cohorts 
(mixed gender)
Macfarlane et al. 2009a 
(1958 British Birth Cohort)
Øverland et al. 2012
(1953–1957 Birth Cohort: 
Hordaland Health Study)
Male & female 
adults
Ablin et al. 2012
Aggarwal et al. 2006
Alvarez-Nemegyei et al. 
2005
Alvarez-Nemegyei et al. 
2011
Andersson 1994
3,963 40–79 8 European countries ACR-90 CWP criteria 830 (750, 930)
452 Belgium (Leuven) 690 (490, 960)*
590 England (Manchester) 520 (360, 730)*
527 Estonia (Tartu) 1530 (1230, 1870)*
431 Hungary (Szeged) 1040 (780, 1380)*
484 Italy (Florence) 460 (300, 690)*
408 Poland (Lodz) 900 (650, 1220)*
548 Spain (Santiago) 870 (660, 1140)*
523 Sweden (Malmo) 700 (510, 960)*
585 70+ Boston, USA FM: ACR-90 – including tenderpoint 
examination.
CWP: Using McGill pain questionnaire or 
positive response to the Q “during the 
past year have you had pain, aching or 
discomfort all over for 3 months or 
longer?”
30 (10, 123)* 910 (700, 1,070)*
361 65+ Brazil ACR-90 – including tender point 
examination
550 (540, 570) 1,410 (1,050, 1,770)
9,377 45 UK ACR-90 CWP criteria 1,180 (1,120, 1,250)*
17,706 40–46 Norway Pain lasting 3 months or longer in trunk, 
lower limbs and upper limbs. No 
assessment of contralateral body pain.
1,240 (1,193, 1,290)*
1,019 18+ Israel Based on ACR-90 criteria, no examination 
conducted
200 (130, 270) 510 (391, 663)*
2,299 18–75 Manchester, UK ACR-90 CWP criteria 1,500 (1,367, 1,647)*
761 18+ Cantamayec, 
Yucatán, Mexico
ACR-90 – including tender point 
examination
130 (60, 240)
3,195 adults Yucatan, Mexico ACR-90 – including tender point 
examination
20 (10, 40)
1,609 25–74 Sweden – rural FM: No criteria stated.
CWP: pain > 3 months in more than 3 
locations in upper and lower body.
190 (130, 260)* 1,070 (930, 1,230)*
A23
Study 
population
Study Sample 
size
Sample 
Age
Location Diagnostic criteria FM CWP
Male & female 
adults
Andersson et al. 1999 
(1996 figures)
Assumpção et al. 2009
Bazelmans et al. 1999
Bergman et al. 2001
Branco et al, 2010
France
Germany
Italy
Portugal
Spain
Buskila et al. 2000
Carnes et al. 2007
Cardiel & Serrano 2002
Carmona et al. 2001
Chaaya et al.2012
Chen et al. 2008
7,474 25–74 Sweden Coding prevalence of ICD-8: 7179; ICD-9:  
728 codes for fibrositis/fibromyalgia in 
primary care.
330 (290, 370)*
768 35–60 Sao Paulo, Brazil – 
low socioeconomic 
status
ACR-90 – including tender point 
examination
440 (270, 630) 2,400 (2,100, 2,700)
3,881 all The Netherlands Practice prevalence estimated by GPs 16 (7, 34)*
2,425 20–74 Sweden ACR-90 CWP criteria 1,140 (1,010, 1,260)
4,517 15+ Five European 
countries
ACR-90 – including tender point 
examination
290 (240, 360) 1,300 (1,200, 1,400)*
1,014 France 140 (70, 210) 1,000 (830, 1,200)*
1,002 Italy 370 (260, 480) 1,000 (830, 1,200)*
1,000 Germany 320 (210, 430) 1,100 (920, 1,310)*
500 Portugal 360 (200, 520) 1,300 (1,030, 1,620)*
1,001 Spain 230 (140, 320) 2300 (2,050, 2,570)*
2,210 18+ Israel ACR-90 CWP criteria 1,020 (870, 1,110)
2,445 18+ South East, UK ACR-90 CWP criteria 1,200 (1,080, 1,330)*
2,500 18+ Mexico – suburban ACR-90 – including tender point 
examination
140 (100, 200)
2,198 20+ Spain ACR-90 – including tender point 
examination
240 (150, 320)
3,530 15+ Lebanon ACR-90 – including tender point 
examination
100 (60, 130)
1,094 all Taiwan
Based on ACR-90 Criteria developed from ACR-90 670 (530, 830)*
Based on LFESSQ** Criteria based on LFESSQ 980 (820, 1,170)*
A24
Study 
population
Study Sample 
size
Sample 
Age
Location Diagnostic criteria FM CWP
Male & female 
adults
Choudhury et al. 2013
Short postal survey
White British/Irish
British Bangladeshi
Bangladeshi
Other ethnic groups
Long questionnaire
White British/Irish
British Bangladeshi
Bangladeshi
Croft et al. 1993
Dans et al. 1997
Davatchi et al. 2008
Davatchi et al. 2009a
Farooqi & Gibson 1998
Rural
Urban affluent
Urban poor
Guermazi et al. 2008
Hagen et al. 2005
Haq et al. 2005
Rural
Urban affluent
Urban slum
Hardt et al. 2008
18+ Tower Hamlets, 
London, UK
ACR-90 CWP criteria
1,223 Short postal survey
571 White British/Irish 1,000 (200, 1,800)
141 British Bangladeshi 900 (0, 2,500)
201 Bangladeshi 1,600 (300, 2,800)
310 Other ethnic groups 900 (0, 2,000)
600 Long questionnaire
294 White British/Irish 600 (0, 1,800)
158 British Bangladeshi 900 (0, 2,400)
141 Bangladeshi 1,800 (300, 3,300)
1,340 18–85 Cheshire, UK ACR-90 CWP criteria 1,120 (960, 1,300)*
3,006 15+ Philippines ACR-90 – including tender point 
examination
20 (10, 40)*
10,291 15+ Iran – urban No criteria stated 69 (54, 87)*
1,565 15+ Iran – rural ACR-90 including tender point 
examination
6 (0, 123)
1,997 15+ Pakistan No criteria stated 210 (160, 280)*
683 Rural 260 (170, 410)*
608 Urban affluent 10 (3, 90)*
706 Urban poor 320 (220, 480)*
1,000 15+ Tunisia ACR-90 – including tender point 
examination
670 (530, 840)*
35,751 20+ Nord-Trøndelag, 
Norway
Pain complaints for at least 3 months 
during the last year and 15 days+ with 
pain during the last month from 3 different 
regions (neck or shoulder, hip or back, 
wrist/hands, knees or ankles/feet)
440 (420, 460)*
5,211 15+ Bangladesh ACR-90 – including tender point 
examination
360 (310, 410)*
2,635 Rural 440 (370, 530)
1,259 Urban affluent 330 (240, 440)
1,317 Urban slum 320 (230, 440)
10,271 20+ USA ACR-90 CWP criteria 360 (310, 420)
A25
Study 
population
Study Sample 
size
Sample 
Age
Location Diagnostic criteria FM CWP
Male & female 
adults
Häuser et al. 2009b
Häuser et al. 2013
Hughes et al. 2006
Hunt et al. 1999
ACR-90
Manchester
Jacobsson et al. 1996
Joshi & Chopra 2009
Kim et al. 2006
Klemp et al. 2002
Kurita et al. 2012
Danish
Other Western
Non-Western
Lindell et al. 2000
Macfarlane et al. 2005 
(survey A)
South Asian
White European
Mäkelä & Heliövaara 
1991
Marschall et al. 2011
McNally et al. 2006
2,524 14+ Germany Based on ACR-90 criteria, no examination 
conducted
380 (290, 440)*
2,510 14+ Germany CWP is defined as a ACR-2010 
widespread pain index of 6 or over lasting 
a minimum of three months.
580 (497, 680)*
1,255, 556 no age 
limits
UK Read codes N248, N239 and N2412, 
OXMIS code 7339F
18 (17, 19)*
1,953 18–65 Manchester, UK –
suburban
ACR-90 ACR-90 CWP criteria 1,290 (1,150, 1,450)
Manchester Manchester criteria 470 (390, 570)
105 35–70 Pima Indians ACR-90 CWP criteria 0 (0, 350)
8,145 16+ Pune, India – urban ACR-90 – including tender point 
examination
5 (1, 13)
1,028 no age 
limits
South Korea – rural ACR-90 – including tender point 
examination
224 (150, 333)* 1,401 (1,202, 1,626)*
689 12+ New Zealand ACR-90 – including tender point 
examination
130 (10, 240) 280 (160, 430)
14,925 16+ Denmark Pain in 4 or more sites lasting 6 months or 
longer.
14,033 Danish 460 (427, 496)*
395 Other Western 405 (251, 648)*
497 Non-Western 1,026 (789, 1,324)*
147 18–74 Sweden ACR-90 – including tender point 
examination
130 (80, 170) 420 (340, 500)
18–75 UK ACR-90 CWP criteria
1945 South Asian 1,380 (1,240, 1,550)*
932 White European 1,180 (990, 1,400)*
7,217 30+ Finland Yunus et al. criteria 75 (57, 97)*
6,897,846 any Germany ICD-10 diagnosis M79.7 coded at least 
twice
28 (28, 29)*
131,535 12+ Canada Self-reported recall of diagnosis 110 (100, 120)
A26
Study 
population
Study Sample 
size
Sample 
Age
Location Diagnostic criteria FM CWP
Male & female 
adults
Minaur et al. 2004
Papageorgiou et al. 2002
Pelaez-Ballestas et al. 
2011
Perrot et al. 2011
Picavet & Hazes 2003
Prescott et al. 1993
Raspe & Baumgartner 
1993
Reyes-Llerena et al. 2000
Reyes-Llerena et al. 2009
Rodriguez-Amado et al. 
2011
Salaffi et al. 2005
Sauer et al. 2011
Scudds et al. 2006
Senna et al, 2004
Storozhenko et al. 2004
Svebak et al, 2006
Turhanoglu et al. 2008
Veerapan et al. 2007
Vincent et al. 2013
Self report
Medical records
847 15+ Australia – Aboriginal 
community
ACR-90 – including tender point 
examination
12 (2, 66)*
1,386 27–90 Handforth, UK ACR-90 CWP criteria 1,000 (860, 1,170)*
19,213 18+ Mexico ACR-90 – including tender point 
examination
68 (56, 80)
3,081 18+ France ACR-90 – including tender point 
examination
160 (120, 200)
3,664 25+ Netherlands Self-reported recall of diagnosis 120 (90, 160)*
1,219 18–79 Denmark ACR-90 – including tender point 
examination
66 (28, 129)
438 25–74 Bad Sackingen, 
Germany
ACR-90 – including tender point 
examination
200 (110, 390)* 1,200 (940, 1,550)
300 adult Cuba According to ‘generally accepted case 
definitions among rheumatologists’
70 (20, 240)*
3,155 15+ Cuba ACR-90 – including tender point 
examination
22 (9, 40)
4,713 18+ Mexico ACR-90 – including tender point 
examination
80 (60, 110)
2,155 18+ Italy ACR-90 – including tender point 
examination
222 (136, 319)
1,646,284 all Germany Coding prevalence of ICD-10 diagnosis 
M79.7 in insurance company database.
45 (43, 46)*
1,467 18–65 Hong Kong ACR-90 – including tender point 
examination
82 (35, 129) 440 (340, 550)*
3,038 16+ Brazil – urban ACR-90 – including tender point 
examination
250 (197, 312)
120 27–75 Yekaterinburg, Russia ACR-90 CWP criteria 1,330 (838, 2,056)*
64,690 20+ Norway Chronic (>3 months) axial skeletal pain 
and pain above and below the waist
1,260 (1,230, 1,280)
600 20+ Turkey – urban ACR-90 – including tender point 
examination
880 (680, 1140)*
2,594 15+ Malaysia No criteria stated 93 (62, 137)*
21+ Olmsted county, 
Minnesota
830 Self report ACR-2010 530 (385, 712)
County 
population
Medical records Documented FM diagnosis in medical 
records
110 (107, 120)
A27
Study 
population
Study Sample 
size
Sample 
Age
Location Diagnostic criteria FM CWP
Male & female 
adults
White et al. 1999
White et al. 2003
Amish
non-Amish
Wolfe et al. 1995
Wolfe et al. 2013
Zeng et al. 2010
Shantou
Taiyuan
3,395 18+ London, Canada –
urban
ACR-90 – including tender point 
examination
330 (320, 340)
18+ London, Canada – 
rural
ACR-90 – including tender point 
examination
179 Amish 720 (530, 970) 1,450 (1,010, 2,040)*
494 non-Amish 120 (60, 260)* 890 (670, 1180)*
3,006 18+ Wichita, USA – urban ACR-90 – including tender point 
examination
200 (140, 270) 1060 (950, 1170)
2,445 18+ Germany ACR-2010 210 (160, 270)
16+ China ACR-90 – including tender point 
examination2,350 Shantou 3 (0, 10)*
3,916 Taiyuan 10 (0, 30)*
*95% CI calculated from sample size and prevalence estimate.
**LFESSQ: London Fibromyalgia Epidemiology Survey Screening Questionnaire (White et al. 1999).
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Chapter 4 appendix
A4.1 Read codes for non-specific generalised pain
Table A4.1 Group 1 – FM Read codes.
Read Code Read Term
N239 Fibromyalgia
N248 Fibromyalgia
Table A4.2 Group 2 – FM & myofascial pain syndrome Read codes.
Read Code Read Term
N2480 Myofascial pain syndrome
N2401 Fibrositis unspecified
N2402 Muscular rheumatism
N240z Rheumatism/fibrositis NOS
N2412 Fibromyositis NOS
N248 Fibromyalgia
N239 Fibromyalgia
N240 Rheumatism/fibrositis unspecified
Table A4.3 Group 3 – Generalised osteoarthritis Read codes.
Read Code Read Term
N05 Osteoarthritis
N050 Generalised osteoarthritis - OA
N0500 Generalised OA-site unspecified
N0502 Generalised OA-multiple sites
N0504 Primary general osteoarthrosis
N0505 Secondary multiple arthrosis
N050z Generalised osteoarthritis NOS
N05z Joint degeneration
N05z0 Osteoarthritis NOS-site unspecified
N05z8 Osteoarthritis NOS-other specified
N05zz Osteoarthritis NOS
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Table A4.4 Group 4 – ALL non-specific generalised musculoskeletal pain Read codes excluding OA.
Read Code Read Term Read Code Read Term
1D12 C/O: stiffness N39 Nonallopathic lesions, NEC
1DCC Aching muscles N39z Nonallopathic lesion NEC NOS
N04y1 Sero negative arthritis N3y Musculoskeletal disorders OS
N096 Musculoskeletal pain - joints N3z Other musculoskeletal dis. NOS
N0968 Other joint sympt.-other spec. Ny Musculoskeletal diseases OS
N0969 Other joint sympt.-multip.site Nyu3 [X]Other joint disorders
N096z Other joint symptoms NOS Nyu8 [X]Disorders of muscles
N09y Other spec. joint disorders Nyu80 [X]Other myositis
N09y0 Other joint dis.-site unspec. Nyu85 [X]Oth spcf disorders/muscle
N09y8 Other joint dis.-other specif. Nyu8A [X]Oth disordrs/muscle/dis CE
N09y9 Other joint dis.-multiple site Nyu8B [X]Disorder of muscle, unspec
N09yz Other joint disorders NOS Nyu9 [X]Disorders/synovium+tendon
N248 Fibromyalgia NyuA [X]Other soft tissue disorders
N24z Polyalgia NyuAA [X]Oth sft tis diso/oth dis CE
N06 Other/unspecif. arthropathies NyuAF [X]Oth spcf soft tissu disords
N063 Menopausal arthritis NyuAG [X]Uns sof tis d,use/overu/prs
N0630 Climacteric arthr.-site unsp. Nz Musculoskeletal diseases NOS
N0638 Climacteric arthr.-other spec. R00z2 [D]General aches and pains
N0639 Climacteric arthr.-multip.site R01 [D]Musculoskeletal symptoms
N063z Climacteric arthr.-NOS R01z [D]Nerv/musculoskel.symp.other
N065 Polyarthropathy NEC R01z2 [D]Musculoskeletal pain
N0650 Unsp.polyarthr.-site unspecif. R01zz [D]Nerv/musculoskel.sympt.NOS
N0658 Unsp.polyarthr.-other specif. Ryu70 [X]Other chronic pain
N0659 Unsp.polyarthr.-multiple site N2480 Myofascial pain syndrome
N065A Generalised arthritis N06y9 Other spec.arthr.-multipl.site
N065z Polyarthritis N06yz Other specif.arthropathy NOS
N2y Nonarticular rheumatism OS N09z8 Joint disord.NOS-other specif.
N2z Nonarticular rheumatism NOS N09z9 Joint disord.NOS-multiple site
N06z Arthritis N09zz Joint disorders NOS
N06z0 Arthropathy NOS-site unspecif. N0z Arthropathies NOS
N06z8 Arthropathy NOS-other specif. N2 Rheumatism, excl.the back
N06z9 Arthropathy NOS-multiple sites N22yz Other tendon disorder NOS
N06zB Chronic arthritis N22z Synovium/tendon/bursa dis.NOS
N06zz Arthropathy NOS N23 Muscle/ligament/fascia disord.
N09 Other/unspecif.joint disorders N233z Other specif.musc.disorder NOS
N094 Ache in joint N239 Fibromyalgia
N0940 Arthralgia - site unspecified N23y Other muscle/ligament/fascia
N0948 Arthralgia - other specified N23yz Other musc./lig./fasc.dis.NOS
N0949 Arthralgia of multiple joints N23z Muscle/ligament/fascia dis.NOS
N094z Arthralgia NOS N24 Other soft tissue disorders
N095 Joint stiffness NEC N240 Rheumatism/fibrositis unspecif
N0950 Stiff joint NEC-site unspecif. N2400 Rheumatism unspecified
N0958 Stiff joint NEC-other specif. N2401 Fibrositis unspecified
N0959 Multiple stiff joints N2402 Muscular rheumatism
N095z Joint stiffness NEC NOS N2403 Rheumatic pain
N2412 Fibromyositis NOS N240z Rheumatism/fibrositis NOS
N241z Myalgia/myositis NOS N241 Myalgia/myositis unspecified
N247 Other musculoskel.limb sympts. N2410 Muscle pain
N2411 Myositis unspecified N09z0 Joint disord.NOS-site unspecif
N09z Joint disorders NOS
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Table A4.5 Group 5 – ALL generalised musculoskeletal pain Read codes (including OA).
Read Code Read Term Read Code Read Term
1D12 C/O: stiffness N39 Nonallopathic lesions, NEC
1DCC Aching muscles N39z Nonallopathic lesion NEC NOS
N04y1 Sero negative arthritis N3y Musculoskeletal disorders OS
N05 Osteoarthritis N3z Other musculoskeletal dis. NOS
N050 Generalised osteoarthritis - OA Ny Musculoskeletal diseases OS
N0500 Generalised OA-site unspecif. Nyu3 [X]Other joint disorders
N0502 Generalised OA-multiple sites Nyu8 [X]Disorders of muscles
N0504 Primary general osteoarthrosis Nyu80 [X]Other myositis
N0505 Secondary multiple arthrosis Nyu85 [X]Oth spcf disorders/muscle
N050z Generalised osteoarthritis NOS Nyu8A [X]Oth disordrs/muscle/dis CE
N05z Joint degeneration Nyu8B [X]Disorder of muscle, unspec
N05z0 Osteoarthritis NOS-site unspec Nyu9 [X]Disorders/synovium+tendon
N05z8 Osteoarthritis - other joint NyuA [X]Other soft tissue disorders
N05zz Osteoarthritis NOS NyuAA [X]Oth sft tis diso/oth dis CE
N06 Other/unspecif. arthropathies NyuAF [X]Oth spcf soft tissu disords
N063 Menopausal arthritis NyuAG [X]Uns sof tis d,use/overu/prs
N0630 Climacteric arthr.-site unsp. Nz Musculoskeletal diseases NOS
N0638 Climacteric arthr.-other spec. R00z2 [D]General aches and pains
N0639 Climacteric arthr.-multip.site R01 [D]Musculoskeletal symptoms
N063z Climacteric arthr.-NOS R01z [D]Nerv/musculoskel.symp.other
N065 Polyarthropathy NEC R01z2 [D]Musculoskeletal pain
N0650 Unsp.polyarthr.-site unspecif. R01zz [D]Nerv/musculoskel.sympt.NOS
N0658 Unsp.polyarthr.-other specif. Ryu70 [X]Other chronic pain
N0659 Unsp.polyarthr.-multiple site N2480 Myofascial pain syndrome
N065A Generalised arthritis N06y9 Other spec.arthr.-multipl.site
N065z Polyarthritis N06yz Other specif.arthropathy NOS
N2y Nonarticular rheumatism OS N09z8 Joint disord.NOS-other specif.
N2z Nonarticular rheumatism NOS N09z9 Joint disord.NOS-multiple site
N06z Arthritis N09zz Joint disorders NOS
N06z0 Arthropathy NOS-site unspecif. N0z Arthropathies NOS
N06z8 Arthropathy NOS-other specif. N2 Rheumatism, excl.the back
N06z9 Arthropathy NOS-multiple sites N22yz Other tendon disorder NOS
N06zB Chronic arthritis N22z Synovium/tendon/bursa dis.NOS
N06zz Arthropathy NOS N23 Muscle/ligament/fascia disord.
N09 Other/unspecif.joint disorders N233z Other specif.musc.disorder NOS
N094 Ache in joint N239 Fibromyalgia
N0940 Arthralgia - site unspecified N23y Other muscle/ligament/fascia
N0948 Arthralgia - other specified N23yz Other musc./lig./fasc.dis.NOS
N0949 Arthralgia of multiple joints N23z Muscle/ligament/fascia dis.NOS
N094z Arthralgia NOS N24 Other soft tissue disorders
N095 Joint stiffness NEC N240 Rheumatism/fibrositis unspecif
N0950 Stiff joint NEC-site unspecif. N2400 Rheumatism unspecified
N0958 Stiff joint NEC-other specif. N2401 Fibrositis unspecified
N0959 Multiple stiff joints N2402 Muscular rheumatism
N095z Joint stiffness NEC NOS N2403 Rheumatic pain
N096 Musculoskeletal pain - joints N240z Rheumatism/fibrositis NOS
N0968 Other joint sympt.-other spec. N241 Myalgia/myositis unspecified
N0969 Other joint sympt.-multip.site N2410 Muscle pain
N096z Other joint symptoms NOS N2411 Myositis unspecified
N09y Other spec. joint disorders N2412 Fibromyositis NOS
N09y0 Other joint dis.-site unspec. N241z Myalgia/myositis NOS
N09y8 Other joint dis.-other specif. N247 Other musculoskel.limb sympts.
N09y9 Other joint dis.-multiple site N248 Fibromyalgia
N09yz Other joint disorders NOS N24z Polyalgia
N09z Joint disorders NOS N09z0 Joint disord.NOS-site unspecif
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A5.1 Rohrbeck-2007 Read code list
Table A5.1 Read codes used in the original Rohrbeck-2007 criteria. 
Read 
code
Clinical term Axial Upper 
Limb
Lower 
Limb
16A2
16AZ
16C
16C2
16C3
16C4
16C5
16C6
16C7
16CZ
2H23
N0511
N0512
N0513
N0515
N0516
N0519
N051B
N051F
N0521
N0522
N0523
N0525
N0526
N0531
N0532
N0533
N0535
N0536
N0541
N0542
N0543
N0544
N0545
N0546
N05z1
N05z2
N05z3
N05z5
N05z6
N05z9
N05zA
N05zB
N05zC
N05zE
N05zJ
N05zL
N06
N063
N06y
N06z
N06z8
Stiff neck ✓ ✕ ✕
Stiff neck symptom NOS ✓ ✕ ✕
Backache symptom ✓ ✕ ✕
Backache ✓ ✕ ✕
Backache with radiation ✓ ✕ ✕
Back pain worse on sneezing ✓ ✕ ✕
C/O - low back pain ✓ ✕ ✕
Back pain without radiation NOS ✓ ✕ ✕
C/O - upper back ache ✓ ✕ ✕
Backache symptom NOS ✓ ✕ ✕
O/E - painful arc ✕ ✓ ✕
Local primary OA-shoulder regn ✕ ✓ ✕
Local primary OA-upper arm ✕ ✓ ✕
Local primary OA-forearm ✕ ✓ ✕
Local primary OA-pelvic/thigh ✕ ✕ ✓
Local primary OA-lower leg ✕ ✕ ✓
Primary coxarthrosis, bilat ✕ ✕ ✓
Primary gonarthrosis, bilat ✕ ✕ ✓
Local prim osteoarth elbow ✕ ✓ ✕
Local secondary OA-shoulder ✕ ✓ ✕
Local secondary OA-upper arm ✕ ✓ ✕
Local secondary OA-forearm ✕ ✓ ✕
Local secondary OA-pelv./thigh ✕ ✕ ✓
Local secondary OA-lower leg ✕ ✕ ✓
Local OA unsp. -shoulder region ✕ ✓ ✕
Local OA unsp.-upper arm ✕ ✓ ✕
Local OA unsp.-forearm ✕ ✓ ✕
Hip osteoarthritis NOS ✕ ✕ ✓
Local.OA unsp.-lower leg ✕ ✕ ✓
Oligoartic OA, unspec-shoulder ✕ ✓ ✕
Oligoartic OA, unspec-upp arm ✕ ✓ ✕
Oligoartic OA, unspec-forearm ✕ ✓ ✕
Oligoartic OA, unspec-hand ✕ ✓ ✕
Oligoartic OA, unspec-pelvic/thi ✕ ✕ ✓
Oligoartic OA, unspec-leg ✕ ✕ ✓
Osteoarthritis NOS-shoulder ✕ ✓ ✕
Elbow osteoarthritis NOS ✕ ✓ ✕
Osteoarthritis NOS-forearm ✕ ✓ ✕
Hip osteoarthritis NOS ✕ ✕ ✓
Knee osteoarthritis NOS ✕ ✕ ✓
Osteoarthritis NOS, shoulder ✕ ✓ ✕
OA NOS-sternoclavicular joint ✕ ✓ ✕
OA NOS-acromioclavicular joint ✕ ✓ ✕
OA NOS-elbow ✕ ✓ ✕
OA NOS-wrist ✕ ✓ ✕
OA NOS-hip ✕ ✕ ✓
Osteoarthritis NOS, of knee ✕ ✕ ✓
Other/unspecif. Arthropathies ✕ ✕ ✕
Climacteric arthritis ✕ ✕ ✕
Other specified arthropathy ✕ ✕ ✕
Arthritis ✕ ✕ ✕
Arthropathy NOS-other specif. ✕ ✕ ✕
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Read 
code
Clinical term Axial Upper 
Limb
Lower 
Limb
N06z9
N06zB
N06zz
N066
N06z1
N06z2
N06z3
N06z5
N06z6
N06z7
N0948
N095
N095z
N0941
N0942
N0943
N0944
N0945
N0946
N0947
N094A
N094B
N094C
N094D
N094E
N094F
N094K
N094L
N094M
N094N
N094P
N094W
N0950
N0951
N0952
N0953
N0955
N0956
N0957
N0958
N0959
N095A
N095C
N095D
N095E
N095F
N095K
N095L
N095M
N095N
N095P
N0960
N11
N110
N119
N11z
N131
N135z
N13y2
Arthropathy NOS-multiple sites ✕ ✕ ✕
Chronic arthritis ✕ ✕ ✕
Arthropathy NOS ✕ ✕ ✕
Coxitis ✕ ✕ ✓
Shoulder arthritis NOS ✕ ✓ ✕
Elbow arthritis NOS ✕ ✓ ✕
Wrist arthritis NOS ✕ ✓ ✕
Hip arthritis NOS ✕ ✕ ✓
Arthropathy NOS-lower leg ✕ ✕ ✓
Ankle arthritis NOS ✕ ✕ ✓
Arthralgia of other specified site ✕ ✕ ✕
Joint stiffness NEC ✕ ✕ ✕
Joint stiffness NEC, NOS ✕ ✕ ✕
Arthralgia - shoulder ✕ ✓ ✕
Arthralgia -upper arm ✕ ✓ ✕
Arthralgia - forearm ✕ ✓ ✕
Arthralgia - hand ✕ ✓ ✕
Arthralgia - pelvic/thigh ✕ ✕ ✓
Arthralgia - lower leg ✕ ✕ ✓
Ankle joint pain ✕ ✕ ✓
Arthralgia of shoulder ✕ ✓ ✕
Arthralgia - sternoclav joint ✕ ✓ ✕
Arthralgia - acromioclav joint ✕ ✓ ✕
Arthralgia of elbow ✕ ✓ ✕
Arthralgia of distal radio-ulnar joint ✕ ✓ ✕
Arthralgia of wrist ✕ ✓ ✕
Hip pain ✕ ✕ ✓
Arthralgia of sacro-iliac joint NEC ✕ ✕ ✓
Arthralgia of knee ✕ ✕ ✓
Arthralgia of tibio-fibular joint ✕ ✕ ✓
Arthralgia of ankle ✕ ✕ ✓
Anterior knee pain ✕ ✕ ✓
Stiff joint NEC-site unspecif. ✕ ✕ ✕
Shoulder stiff ✕ ✓ ✕
Elbow stiff ✕ ✓ ✕
Stiff joint NEC-forearm ✕ ✓ ✕
Hip stiff ✕ ✕ ✓
Knee stiff ✕ ✕ ✓
Ankle stiff ✕ ✕ ✓
Stiff joint NEC-other specif. ✕ ✕ ✕
Multiple stiff joints ✕ ✕ ✕
Stiff shoulder NEC ✕ ✓ ✕
Stiff acromioclavic joint NEC ✕ ✓ ✕
Stiff elbow NEC ✕ ✓ ✕
Stiff distal radio-ulnar joint NEC ✕ ✓ ✕
Stiff wrist NEC ✕ ✓ ✕
Stiff hip NEC ✕ ✕ ✓
Stiff sacro-iliac joint NEC ✕ ✕ ✓
Stiff knee NEC ✕ ✕ ✓
Stiff tibio-fibular joint NEC ✕ ✕ ✓
Stiff ankle NEC ✕ ✕ ✓
Other joint sympt.-site unspec ✕ ✕ ✕
Arthritis of spine ✓ ✕ ✕
Cervical spond. -no myelopathy ✓ ✕ ✕
Cx spondylosis + radiculopathy ✓ ✕ ✕
Osteoarthritis spine ✓ ✕ ✕
Cervicalgia - pain in neck ✓ ✕ ✕
Stiff neck NOS ✓ ✕ ✕
Crick in neck ✓ ✕ ✕
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Read 
code
Clinical term Axial Upper 
Limb
Lower 
Limb
N13yz
N13z
N14
N141
N142
N1420
N143
N145
N149
N210
N211
N2110
N2111
N2112
N2113
N2116
N2117
N2118
N211z
N2120
N2121
N2125
N2131
N2132
N2151
N2160
N220S
N220z
N2452
N2453
N2454
N2457
R04zz
S50
S5700
S570z
Other cervical syndromes NOS ✓ ✕ ✕
Cervical/neck disorder NOS ✓ ✕ ✕
Other/unspecif.back disorder ✓ ✕ ✕
Acute back pain - thoracic ✓ ✕ ✕
Acute back pain - lumbar ✓ ✕ ✕
Lumbago with sciatica ✓ ✕ ✓
Acute back pain + sciatica ✓ ✕ ✓
Backache, unspecified ✓ ✕ ✕
Back stiffness ✓ ✕ ✕
Adhesive capsulitis - shoulder ✕ ✓ ✕
Rotator cuff shoulder syndrome ✕ ✓ ✕
Rotator cuff syndrome, unspecified ✕ ✓ ✕
Calcifying tendinitis of the shoulder ✕ ✓ ✕
Bicipital tenosynovitis ✕ ✓ ✕
Supraspinatus tendinitis ✕ ✓ ✕
Subacromial bursitis ✕ ✓ ✕
Subdeltoid bursitis ✕ ✓ ✕
Bursitis of shoulder ✕ ✓ ✕
Rotator cuff syndrome NOS ✕ ✓ ✕
Periarthritis of shoulder ✕ ✓ ✕
Scapulohumeral fibrositis ✕ ✓ ✕
Shoulder tendonitis ✕ ✓ ✕
Medial epicondylitis of the elbow ✕ ✓ ✕
Lateral epicondylitis - elbow ✕ ✓ ✕
Bursitis of hip ✕ ✕ ✓
Bursitis of knee NOS ✕ ✕ ✓
Synovitis of hip ✕ ✕ ✓
Shoulder synovitis ✕ ✓ ✕
Pain in leg ✕ ✕ ✓
Pain in arm ✕ ✓ ✕
Calf pain ✕ ✕ ✓
Shoulder pain ✕ ✓ ✕
[D] Head and neck symptoms NOS ✕ ✓ ✕
Sprain of shoulder and upper arm ✕ ✓ ✕
Neck sprain, unspecified ✓ ✕ ✕
Neck sprain NOS ✓ ✕ ✕
Table A5.2. Ambiguous codes that could represent regional or generalised conditions included in the 
original 2007 Rohrbeck criteria.
Read code Clinical term
N06
N063
N06y
N06z
N06z8
N06zB
N06zz
N0948
N095
N0950
N0958
N095z
N0960
Other/unspecif. Arthropathies
Climacteric arthritis
Other specified arthropathy
Arthritis
Arthropathy NOS-other specif.
Chronic arthritis
Arthropathy NOS
Arthralgia of other specified site
Joint stiffness NEC
Stiff joint NEC-site unspecif.
Stiff joint NEC-other specif.
Joint stiffness NEC, NOS
Other joint sympt.-site unspec
A34
 A35 
A5.2 All regional musculoskeletal Read codes 
Table A5.3 All regional musculoskeletal Read codes. 
Read 
Code 
Read Term Axial Lower 
Limb 
Upper 
Limb 
Clinician 
Defined 
Read 
Code 
Read Term Axial Lower 
Limb 
Upper 
Limb 
Clinician 
Defined 
14G3 H/O: knee problem ✕ ✓ ✕ ✕ S1103 Clsd # C1-C4 cent cord lesion ✓ ✕ ✕ ✕ 
14G4 H/O: back problem ✓ ✕ ✕ ✕ S1104 Clsd # C1-C4 post cord lesion ✓ ✕ ✕ ✕ 
14G7 H/O: hip fracture ✕ ✓ ✕ ✕ S1105 Clsd # C1-C4 incomp cord les ✓ ✕ ✕ ✕ 
14G8 H/O: vertebral fracture ✓ ✕ ✕ ✕ S1106 Clsd # C5-C7 unspec cord les ✓ ✕ ✕ ✕ 
14H5 H/O: cong. dislocation - hip ✕ ✓ ✕ ✕ S1107 Clsd # C5-C7 complete cord les ✓ ✕ ✕ ✕ 
14J1 H/O: head injury ✕ ✕ ✕ ✕ S1108 Clsd # C5-C7 ant cord lesion ✓ ✕ ✕ ✕ 
14J2 H/O: facial injury ✕ ✕ ✕ ✕ S1109 Clsd # C5-C7 cent cord lesion ✓ ✕ ✕ ✕ 
14N30 H/O Spinal surgery ✓ ✕ ✕ ✕ S110A Clsd # C5-C7 post cord lesion ✓ ✕ ✕ ✕ 
14V50 H/0: arthrodesis toe ✕ ✓ ✕ ✕ S110B Clsd # C5-C7 incomp cord les ✓ ✕ ✕ ✕ 
16A Stiff neck symptom ✓ ✕ ✕ ✓ S110z Closed cervical#+cord lesn.NOS ✓ ✕ ✕ ✕ 
16A1 No stiff neck ✓ ✕ ✕ ✕ S111 Open cervical #+cord lesion ✓ ✕ ✕ ✕ 
16A2 Stiff neck ✓ ✕ ✕ ✓ S1110 Op # C1-C4 unspec cord les ✓ ✕ ✕ ✕ 
16A3 Torticollis - symptom ✓ ✕ ✕ ✓ S1111 Op # C1-4 compl cord lesion ✓ ✕ ✕ ✕ 
16AZ Stiff neck symptom NOS ✓ ✕ ✕ ✓ S1112 Op # C1-4 ant cord lesion ✓ ✕ ✕ ✕ 
16C Backache symptom ✓ ✕ ✕ ✓ S1113 Op # C1-4 cent cord lesion ✓ ✕ ✕ ✕ 
16C1 No backache ✓ ✕ ✕ ✕ S1114 Op # C1-4 post cord lesion ✓ ✕ ✕ ✕ 
16C2 Backache ✓ ✕ ✕ ✓ S1115 Op # C1-4 cord les. NOS ✓ ✕ ✕ ✕ 
16C3 Backache with radiation ✓ ✕ ✕ ✓ S1116 Op # C5-7 unspec cord lesion ✓ ✕ ✕ ✕ 
16C4 Back pain worse on sneezing ✓ ✕ ✕ ✓ S1117 Op # C5-7 compl cord lesion ✓ ✕ ✕ ✕ 
16C5 C/O - low back pain ✓ ✕ ✕ ✓ S1118 Op # C5-7 anterior cord les ✓ ✕ ✕ ✕ 
16C6 Back pain without radiat NOS ✓ ✕ ✕ ✓ S1119 Op # C5-7 central cord les ✓ ✕ ✕ ✕ 
16C7 C/O - upper back ache ✓ ✕ ✕ ✓ S111A Op # C5-7 posterior cord lesn ✓ ✕ ✕ ✕ 
16C9 Chronic low back pain ✓ ✕ ✕ ✓ S111B Op # C5-7 incomp cord les NOS ✓ ✕ ✕ ✕ 
16CA Mechanical low back pain ✓ ✕ ✕ ✓ S111z Open cervical#+cord lesion NOS ✓ ✕ ✕ ✕ 
16CZ Backache symptom NOS ✓ ✕ ✕ ✓ S112 Closed thoracic #+cord lesion ✓ ✕ ✕ ✕ 
16J0 Swollen calf ✕ ✓ ✕ ✕ S1120 Cl sp #+unsp thor crd lsn,T1-6 ✓ ✕ ✕ ✕ 
16J1 Swollen toe ✕ ✓ ✕ ✕ S1121 Cl sp #+cmpl thor crd lsn,T1-6 ✓ ✕ ✕ ✕ 
16J2 Swollen thumb ✕ ✕ ✓ ✕ S1122 Cl spn #+ant thor crd lsn,T1-6 ✓ ✕ ✕ ✕ 
16J3 Swollen joint ✕ ✕ ✕ ✕ S1123 Cl spn #+cnt thor crd lsn,T1-6 ✓ ✕ ✕ ✕ 
16J4 Swollen knee ✕ ✓ ✕ ✕ S1124 Cl spn #+pst thor crd lsn,T1-6 ✓ ✕ ✕ ✕ 
16J5 Facial swelling ✕ ✕ ✕ ✕ S1125 Cl # T1-6 incmpl cord lesn NOS ✓ ✕ ✕ ✕ 
16J6 Swollen hand ✕ ✕ ✓ ✕ S1126 Cl sp #+unsp thor cd lsn,T7-12 ✓ ✕ ✕ ✕ 
16J7 Swollen foot ✕ ✓ ✕ ✕ S1127 Cl sp #+cmp thor crd lsn,T7-12 ✓ ✕ ✕ ✕ 
182 Chest pain ✓ ✕ ✕ ✓ S1128 Cl sp #+ant thor crd lsn,T7-12 ✓ ✕ ✕ ✕ 
1822 Central chest pain ✓ ✕ ✕ ✓ S1129 Cl sp #+cnt thor crd lsn,T7-12 ✓ ✕ ✕ ✕ 
1823 Precordial pain ✓ ✕ ✕ ✓ S112A Cl sp #+pst thor crd lsn,T7-12 ✓ ✕ ✕ ✕ 
1824 Anterior chest wall pain ✓ ✕ ✕ ✓ S112B Cl # T7-12incomp cord lsn NOS ✓ ✕ ✕ ✕ 
1826 Parasternal pain ✓ ✕ ✕ ✓ S112z Closed thoracic#+cord lesn.NOS ✓ ✕ ✕ ✕ 
1828 Atypical chest pain ✓ ✕ ✕ ✓ S113 Open thoracic #+cord lesion ✓ ✕ ✕ ✕ 
182B Rib pain ✓ ✕ ✕ ✓ S1130 Op sp #+unsp thor crd lsn,T1-6 ✓ ✕ ✕ ✕ 
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182B0 Costal margin chest pain ✓ ✕ ✕ ✓ S1131 Op sp #+cmpl thor crd lsn,T1-6 ✓ ✕ ✕ ✕ 
182C Chest wall pain ✓ ✕ ✕ ✓ S1132 Op spn #+ant thor crd lsn,T1-6 ✓ ✕ ✕ ✕ 
182Z Chest pain NOS ✓ ✕ ✕ ✓ S1133 Op spn #+cnt thor crd lsn,T1-6 ✓ ✕ ✕ ✕ 
1832 Ankle swelling ✕ ✓ ✕ ✕ S1134 Op spn #+pst thor crd lsn,T1-6 ✓ ✕ ✕ ✕ 
1833 Leg swelling ✕ ✓ ✕ ✕ S1135 Op # T1-6 incomp cord lsn NOS ✓ ✕ ✕ ✕ 
1834 Finger swelling ✕ ✕ ✓ ✕ S1136 Op sp #+unsp thor cd lsn,T7-12 ✓ ✕ ✕ ✕ 
19690 Abdominal wall pain ✕ ✕ ✕ ✓ S1137 Op sp #+cmp thor crd lsn,T7-12 ✓ ✕ ✕ ✕ 
197 Flank pain ✕ ✕ ✕ ✓ S1138 Op sp #+ant thor crd lsn,T7-12 ✓ ✕ ✕ ✕ 
1974 Right subcostal pain ✓ ✕ ✕ ✓ S1139 Op sp #+cnt thor crd lsn,T7-12 ✓ ✕ ✕ ✕ 
1975 Left flank pain ✕ ✕ ✕ ✓ S113A Op sp #+pst thor crd lsn,T7-12 ✓ ✕ ✕ ✕ 
1976 Right flank pain ✕ ✕ ✕ ✓ S113B Op # T7-12incomp cord lsn NOS ✓ ✕ ✕ ✕ 
1A53 C/O - loin pain ✓ ✕ ✕ ✓ S113z Open thoracic #+cord lesn.NOS ✓ ✕ ✕ ✕ 
1A59 C/O pelvic pain ✕ ✓ ✕ ✓ S114 Closed lumbar # + cord lesion ✓ ✕ ✕ ✕ 
1D130 C/O - pain in toes ✕ ✓ ✕ ✓ S1140 Cls spn # + unsp lumb crd lesn ✓ ✕ ✕ ✕ 
1D131 C/O - pain in big toe ✕ ✓ ✕ ✓ S1141 Cls spn # + comp lumb crd lesn ✓ ✕ ✕ ✕ 
1D22 C/O - a chest wall symptom ✓ ✕ ✕ ✓ S1142 Cls spn # + ant lumbr crd lesn ✓ ✕ ✕ ✕ 
1D24 Symptom: trunk posterior ✓ ✕ ✕ ✓ S1143 Cls spn # + cent lumb crd lesn ✓ ✕ ✕ ✕ 
1M00 Elbow pain ✕ ✕ ✓ ✓ S1144 Cls spn # + post lumb crd lesn ✓ ✕ ✕ ✕ 
1M1 Pain in lower limb ✕ ✓ ✕ ✓ S1145 Cls spn # + cauda equina lesn ✓ ✕ ✕ ✕ 
1M10 Knee pain ✕ ✓ ✕ ✓ S115 Open lumbar # + cord lesion ✓ ✕ ✕ ✕ 
1M11 Foot pain ✕ ✓ ✕ ✓ S1150 Opn spn # + unsp lumb crd lesn ✓ ✕ ✕ ✕ 
1M12 Anterior knee pain ✕ ✓ ✕ ✓ S1151 Opn spn # + comp lumb crd lesn ✓ ✕ ✕ ✕ 
N0100 Pyogenic arthr.-site unspecif. ✕ ✕ ✕ ✕ S1152 Opn spn # + ant lumbr crd lesn ✓ ✕ ✕ ✕ 
N0101 Pyogenic arthr.-shoulder regn. ✕ ✕ ✓ ✕ S1153 Opn spn # + cent lumb crd lesn ✓ ✕ ✕ ✕ 
N0102 Pyogenic arthr.-upper arm ✕ ✕ ✓ ✕ S1154 Opn spn # + post lumb crd lesn ✓ ✕ ✕ ✕ 
N0103 Wrist pyogenic arthritis ✕ ✕ ✓ ✕ S1155 Opn spn # + cauda equina lesn ✓ ✕ ✕ ✕ 
N0104 Pyogenic arthr.-hand ✕ ✕ ✓ ✕ S115z Op spn # incmp lmb crd lsn NOS ✓ ✕ ✕ ✕ 
N0105 Pyogenic arthr.-pelvic/thigh ✕ ✓ ✕ ✕ S116 Closed sacral # + cord lesion ✓ ✕ ✕ ✕ 
N0106 Pyogenic arthr.-lower leg ✕ ✓ ✕ ✕ S1160 Closed sacral#+cord lesn.unsp. ✓ ✕ ✕ ✕ 
N0107 Pyogenic arthr.-ankle/foot ✕ ✓ ✕ ✕ S1161 Cl.sacral#+compl.cauda equ.les ✓ ✕ ✕ ✕ 
N0111 Sex acqd reac arthrop-shoulder ✕ ✕ ✓ ✕ S1162 Cl.sacral#+other cauda equ.inj ✓ ✕ ✕ ✕ 
N0112 Sex acqd reac arthrop-upp arm ✕ ✕ ✓ ✕ S1163 Closed sacral#+other cord inj. ✓ ✕ ✕ ✕ 
N0113 Sex acqd reac arthrop-forearm ✕ ✕ ✓ ✕ S116z Closed sacral#+cord lesion NOS ✓ ✕ ✕ ✕ 
N0114 Sex acqd reac arthrop-hand ✕ ✕ ✓ ✕ S117 Open sacral # + cord lesion ✓ ✕ ✕ ✕ 
N0115 Sex acqd reac arthrop-pelv/thi ✕ ✓ ✕ ✕ S1170 Open sacral#+cord lesion unsp. ✓ ✕ ✕ ✕ 
N0116 Sex acqd reac arthrop-leg ✕ ✓ ✕ ✕ S1171 Op.sacral#+compl.cauda equ.les ✓ ✕ ✕ ✕ 
N0117 Sex acqd reac arthrop-ank/foot ✕ ✓ ✕ ✕ S1172 Op.sacral#+other cauda equ.inj ✓ ✕ ✕ ✕ 
N0121 Arthrop+Behcet's synd-shoulder ✕ ✕ ✓ ✕ S1173 Open sacral#+other cord injury ✓ ✕ ✕ ✕ 
N0122 Arthrop+Behcet's synd-upp arm ✕ ✕ ✓ ✕ S117z Open sacral#+cord lesion NOS ✓ ✕ ✕ ✕ 
N0123 Arthrop+Behcet's synd-forearm ✕ ✕ ✓ ✕ S118 Closed coccyx # + cord lesion ✓ ✕ ✕ ✕ 
N0124 Arthrop+Behcet's synd-hand ✕ ✕ ✓ ✕ S1180 Closed coccyx#+cord lesn.unsp. ✓ ✕ ✕ ✕ 
N0125 Arthrop+Behcet's synd-pelv/thi ✕ ✓ ✕ ✕ S1181 Cl.coccyx#+compl.cauda equ.les ✓ ✕ ✕ ✕ 
N0126 Arthrop+Behcet's synd-leg ✕ ✓ ✕ ✕ S1182 Cl.coccyx#+other cauda equ.inj ✓ ✕ ✕ ✕ 
N0127 Arthrop+Behcet's synd-ank/foot ✕ ✓ ✕ ✕ S1183 Closed coccyx#+other cord inj. ✓ ✕ ✕ ✕ 
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N0131 Postdys react arthrop-shoulder ✕ ✕ ✓ ✕ S118z Closed coccyx#+cord lesion NOS ✓ ✕ ✕ ✕ 
N0132 
N0133 Postdys react arthrop-upp arm Postdys react arthrop-forearm ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✕ S119 S1190 Open coccyx # + cord lesion Open coccyx#+cord lesion unsp. ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✕ 
N0134 Postdys react arthrop-hand ✕ ✕ ✓ ✕ S1191 Op.coccyx#+compl.cauda equ.les ✓ ✕ ✕ ✕ 
N0135 Postdys react arthrop-pelv/thi ✕ ✓ ✕ ✕ S1192 Op.coccyx#+other cauda equ.inj ✓ ✕ ✕ ✕ 
N0136 Postdys react arthrop-leg ✕ ✓ ✕ ✕ S1193 Open coccyx#+other cord inj. ✓ ✕ ✕ ✕ 
N0137 Postdys react arthrop-ank/foot ✕ ✓ ✕ ✕ S119z Open coccyx#+cord lesion NOS ✓ ✕ ✕ ✕ 
N0141 Arthr.+oth.bact.dis-shoulder ✕ ✕ ✓ ✕ S11x Closed #spine+cord lesn.unsp. ✓ ✕ ✕ ✕ 
N0142 Arthr.+oth.bact.dis-upper arm ✕ ✕ ✓ ✕ S11y Open #spine+cord lesion unsp. ✓ ✕ ✕ ✕ 
N0143 Arthr.+oth.bact.dis-forearm ✕ ✕ ✓ ✕ S11z #Spine + cord lesion NOS ✓ ✕ ✕ ✕ 
N0144 Arthr.+oth.bact.dis-hand ✕ ✕ ✓ ✕ S12 #Rib/sternum/larynx/trachea ✓ ✕ ✕ ✕ 
N0145 Arthr.+oth.bact.dis-pelv/thigh ✕ ✓ ✕ ✕ S120 Closed fracture rib ✓ ✕ ✕ ✕ 
N0146 Arthr.+oth.bact.dis-lower leg ✕ ✓ ✕ ✕ S1200 Closed #rib unspecified ✓ ✕ ✕ ✕ 
N0147 Arthr.+oth.bact.dis-ankle/foot ✕ ✓ ✕ ✕ S1201 Closed #one rib ✓ ✕ ✕ ✕ 
N0150 Arthr.+oth.viral dis-site unsp ✕ ✕ ✕ ✕ S1202 Closed # two ribs ✓ ✕ ✕ ✕ 
N0151 Arthr.+oth.viral dis-shoulder ✕ ✕ ✓ ✕ S1203 Closed # three ribs ✓ ✕ ✕ ✕ 
N0152 Arthr.+oth.viral dis-upper arm ✕ ✕ ✓ ✕ S1204 Closed # four ribs ✓ ✕ ✕ ✕ 
N0153 Arthr.+oth.viral dis-forearm ✕ ✕ ✓ ✕ S1205 Closed # five ribs ✓ ✕ ✕ ✕ 
N0154 Arthr.+oth.viral dis-hand ✕ ✕ ✓ ✕ S1206 Closed # six ribs ✓ ✕ ✕ ✕ 
N0155 Arthr+oth.viral dis.pelv/thigh ✕ ✓ ✕ ✕ S1207 Closed # seven ribs ✓ ✕ ✕ ✕ 
N0156 Arthr+oth.viral dis.lower leg ✕ ✓ ✕ ✕ S1208 Closed # eight or more ribs ✓ ✕ ✕ ✕ 
N0157 Arthr+oth.viral dis-ankle/foot ✕ ✓ ✕ ✕ S1209 Closed fracture multiple ribs ✓ ✕ ✕ ✕ 
N0160 Arthr.+mycoses-site unspecif. ✕ ✕ ✕ ✕ S120A Cough fracture ✓ ✕ ✕ ✕ 
N0161 Arthr.+mycoses-shoulder region ✕ ✕ ✓ ✕ S120z Closed #rib(s) NOS ✓ ✕ ✕ ✕ 
N0162 Arthr.+mycoses-upper arm ✕ ✕ ✓ ✕ S121 Open fracture rib ✓ ✕ ✕ ✕ 
N0163 Arthr.+mycoses-forearm ✕ ✕ ✓ ✕ S1210 Open #rib unspecified ✓ ✕ ✕ ✕ 
N0164 Arthr.+mycoses-hand ✕ ✕ ✓ ✕ S1211 Open #one rib ✓ ✕ ✕ ✕ 
N0165 Arthr.+mycoses-pelvic/thigh ✕ ✓ ✕ ✕ S1212 Open #two ribs ✓ ✕ ✕ ✕ 
N0166 Arthr.+mycoses-lower leg ✕ ✓ ✕ ✕ S1213 Open #three ribs ✓ ✕ ✕ ✕ 
N0167 Arthr.+mycoses-ankle/foot ✕ ✓ ✕ ✕ S1214 Open #four ribs ✓ ✕ ✕ ✕ 
N0170 Arthr.+helminth.-site unspec. ✕ ✕ ✕ ✕ S1215 Open #five ribs ✓ ✕ ✕ ✕ 
N0171 Arthr.+helminth.-shoulder regn ✕ ✕ ✓ ✕ S1216 Open #six ribs ✓ ✕ ✕ ✕ 
N0172 Arthr.+helminth.-upper arm ✕ ✕ ✓ ✕ S1217 Open #seven ribs ✓ ✕ ✕ ✕ 
N0173 Arthr.+helminth.-forearm ✕ ✕ ✓ ✕ S1218 Open #eight or more ribs ✓ ✕ ✕ ✕ 
N0174 Arthr.+helminth.-hand ✕ ✕ ✓ ✕ S1219 Open fracture multiple ribs ✓ ✕ ✕ ✕ 
N0175 Arthr.+helminth.-pelvic/thigh ✕ ✓ ✕ ✕ S121z Open #rib(s) NOS ✓ ✕ ✕ ✕ 
N0176 Arthr.+helminth.-lower leg ✕ ✓ ✕ ✕ S122 Closed fracture sternum ✓ ✕ ✕ ✕ 
N0177 Arthr.+helminth.-ankle/foot ✕ ✓ ✕ ✕ S123 Open fracture sternum ✓ ✕ ✕ ✕ 
N01w0 Reactive arthropathy-shoulder ✕ ✕ ✓ ✕ S124 Flail chest ✓ ✕ ✕ ✕ 
N01w1 Reactive arthr-acromioclav jt ✕ ✕ ✓ ✕ S1240 Closed flail chest ✓ ✕ ✕ ✕ 
N01w2 Reactive arthrop-sternoclav jt ✕ ✕ ✓ ✕ S1241 Open flail chest ✓ ✕ ✕ ✕ 
N01w3 Reactive arthropathy of elbow ✕ ✕ ✓ ✕ S125 Closed # larynx and trachea ✓ ✕ ✕ ✕ 
N01w4 Reac arthrop-distal rad-uln jt ✕ ✕ ✓ ✕ S1250 Closed fracture larynx ✓ ✕ ✕ ✕ 
N01w5 Reactive arthropathy of wrist ✕ ✕ ✓ ✕ S1251 Closed #hyoid bone ✓ ✕ ✕ ✕ 
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N01w6 Reactive arthropathy of MCPJ ✕ ✕ ✓ ✕ S1252 Closed #thyroid cartilage ✓ ✕ ✕ ✕ 
N01w7 Reactive arthropathy-PIPJ-fing ✕ ✕ ✓ ✕ S1253 Closed #trachea ✓ ✕ ✕ ✕ 
✕ 
✕ N01w8 N01w9 Reactive arthropathy-DIPJ-fing Reactive arthropathy of hip 
✕ 
✕ ✕ ✓ ✓ ✕ ✕ ✕ S125z S126 Closed #larynx/trachea NOS Open # larynx and trachea 
✓ 
✓ ✕ ✕ ✕ ✕ 
N01wA Reactive arthropathy-SI joint ✓ ✕ ✕ ✕ S1260 Open fracture larynx ✓ ✕ ✕ ✕ 
N01wB Reactive arthropathy of knee ✕ ✓ ✕ ✕ S1261 Open #hyoid bone ✓ ✕ ✕ ✕ 
N01wC Reactive arthrop of tib-fib jt ✕ ✓ ✕ ✕ S1262 Open #thyroid cartilage ✓ ✕ ✕ ✕ 
N01wD Reactive arthropathy of ankle ✕ ✓ ✕ ✕ S1263 Open #trachea ✓ ✕ ✕ ✕ 
N01wE Reactive arthrop-subtal joint ✕ ✓ ✕ ✕ S126z Open #larynx/trachea NOS ✓ ✕ ✕ ✕ 
N01wF Reactive arthrop-talonav joint ✕ ✓ ✕ ✕ S127 Fracture of rib ✓ ✕ ✕ ✕ 
N01wG Reactive arthrop-oth tarsal jt ✕ ✓ ✕ ✕ S1270 Multiple fractures of ribs ✓ ✕ ✕ ✕ 
N01wH Reactive arthropathy-1st MTPJ ✕ ✓ ✕ ✕ S1271 Cough fracture of ribs ✓ ✕ ✕ ✕ 
N01wJ Reactive arthropathy-less MTPJ ✕ ✓ ✕ ✕ S128 Fracture of sternum ✓ ✕ ✕ ✕ 
N01wK Reactive arthropathy-IPJ-toe ✕ ✓ ✕ ✕ S12X Fract bony thor, part unsp ✓ ✕ ✕ ✕ 
N01y0 Arth+oth.inf/para-site unspec. ✕ ✕ ✕ ✕ S12X0 Cl fract bony thorax part unsp ✓ ✕ ✕ ✕ 
N01y1 Arth+oth.inf/para-shoulder reg ✕ ✕ ✓ ✕ S12X1 Op fract bony thorax part unsp ✓ ✕ ✕ ✕ 
N01y2 Arth+oth.inf/para-upper arm ✕ ✕ ✓ ✕ S12y Fract oth parts of bony thorax ✓ ✕ ✕ ✕ 
N01y3 Arth+oth.inf/para-forearm ✕ ✕ ✓ ✕ S12y0 Cl frac oth parts bony thorax ✓ ✕ ✕ ✕ 
N01y4 Arth+oth.inf/para-hand ✕ ✕ ✓ ✕ S12y1 Op fract oth parts bony thorax ✓ ✕ ✕ ✕ 
N01y5 Arth+oth.inf/para-pelvic/thigh ✕ ✓ ✕ ✕ S12z #Rib/sternum/larynx/trach.NOS ✓ ✕ ✕ ✕ 
N01y6 Arth+oth.inf/para-lower leg ✕ ✓ ✕ ✕ S13 Fracture or disruption of pelvis ✕ ✓ ✕ ✕ 
N01y7 Arth+oth.inf/para-ankle/foot ✕ ✓ ✕ ✕ S130 Closed fracture acetabulum ✕ ✓ ✕ ✕ 
N01z0 Infect.arthr.NOS-site unspecif ✕ ✕ ✕ ✕ S1300 Cls # acetabulum,ant lip alone ✕ ✓ ✕ ✕ 
N01z1 Infect.arthr.NOS-shoulder reg ✕ ✕ ✓ ✕ S1301 Cls # acetabulm,post lip alone ✕ ✓ ✕ ✕ 
N01z2 Infect.arthr.NOS-upper arm ✕ ✕ ✓ ✕ S1302 Cls # acetabulum,ant column ✕ ✓ ✕ ✕ 
N01z3 Infect.arthr.NOS-forearm ✕ ✕ ✓ ✕ S1303 Cls # acetabulum,post column ✕ ✓ ✕ ✕ 
N01z4 Infect.arthr.NOS-hand ✕ ✕ ✓ ✕ S1304 Cls # acetabulum, floor ✕ ✓ ✕ ✕ 
N01z5 Infect.arthr.NOS-pelvic/thigh ✕ ✓ ✕ ✕ S1305 Cls # acetabulm,dbl col transv ✕ ✓ ✕ ✕ 
N01z6 Infect.arthr.NOS-lower leg ✕ ✓ ✕ ✕ S1306 Cls # acetabulum,dbl col unsp ✕ ✓ ✕ ✕ 
N01z7 Infect.arthr.NOS-ankle/foot ✕ ✓ ✕ ✕ S130y Othr spec cls # acetabulum ✕ ✓ ✕ ✕ 
N01z8 Infec arthritis NOS-shoulder ✕ ✕ ✓ ✕ S130z Closed fracture acetabulum NOS ✕ ✓ ✕ ✕ 
N01z9 Infec arthr NOS-sternoclav jt ✕ ✕ ✓ ✕ S131 Open fracture acetabulum ✕ ✓ ✕ ✕ 
N01zA Infec arth NOS-acromioclav jt ✕ ✕ ✓ ✕ S1310 Opn # acetabulum,ant lip alone ✕ ✓ ✕ ✕ 
N01zB Infec arthritis NOS-elbow ✕ ✕ ✓ ✕ S1311 Opn # acetabulm,post lip alone ✕ ✓ ✕ ✕ 
N01zC Infec arth NOS-dis rad-uln jt ✕ ✕ ✓ ✕ S1312 Opn # acetabulum,ant column ✕ ✓ ✕ ✕ 
N01zD Infec arthritis NOS-wrist ✕ ✕ ✓ ✕ S1313 Opn # acetabulum,post column ✕ ✓ ✕ ✕ 
N01zE Infec arthritis NOS-MCPJ ✕ ✕ ✓ ✕ S1314 Opn # acetabulum, floor ✕ ✓ ✕ ✕ 
N01zF Infec arthritis NOS-PIPJ-fing ✕ ✕ ✓ ✕ S1315 Opn # acetabulm,dbl col transv ✕ ✓ ✕ ✕ 
N01zG Infec arthritis NOS-DIPJ-fing ✕ ✕ ✓ ✕ S1316 Opn # acetabulum,dbl col unsp ✕ ✓ ✕ ✕ 
N01zH Infec arthritis NOS-hip ✕ ✓ ✕ ✕ S131y Othr spec opn # acetabulum ✕ ✓ ✕ ✕ 
N01zJ Infec arthritis NOS-SI joint ✓ ✕ ✕ ✕ S131z Open fracture acetabulum NOS ✕ ✓ ✕ ✕ 
N01zK Infec arthritis NOS-knee ✕ ✓ ✕ ✕ S132 Closed fracture pubis ✕ ✓ ✕ ✕ 
N01zL Infec arth NOS, tib-fib joint ✕ ✓ ✕ ✕ S1320 Cls # pelvis,sngle pubic ramus ✕ ✓ ✕ ✕ 
N01zM Infec arthritis NOS-ankle ✕ ✓ ✕ ✕ S1321 Cls # plvs,mlti pbc rami-stble ✕ ✓ ✕ ✕ 
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N01zN Infec arth NOS-subtalar joint ✕ ✓ ✕ ✕ S1322 Cls # plvs,mlti pbc rami-unstb ✕ ✓ ✕ ✕ 
N01zP Infec arth NOS-talonavic joint ✕ ✓ ✕ ✕ S132y Other spec closed # pubis ✕ ✓ ✕ ✕ 
N01zQ Infec arth NOS-oth tars joint ✕ ✓ ✕ ✕ S132z Closed fracture pubis NOS ✕ ✓ ✕ ✕ 
N01zR 
N01zS Infec arthritis NOS-1st MTPJ Infec arthritis NOS-less MTPJ ✕ ✕ ✓ ✓ ✕ ✕ ✕ ✕ S133 S1330 Open fracture of pubis Opn # plvs,sngle pubic ramus ✕ ✕ ✓ ✓ ✕ ✕ ✕ ✕ 
N01zT Infec arthritis NOS-IPJ of toe ✕ ✓ ✕ ✕ S1331 Opn # plvs,mlti pbc rami-stble ✕ ✓ ✕ ✕ 
N0200 Chondroc.-dical.ph.-site unsp. ✕ ✕ ✕ ✕ S1332 Opn # plvs,mlti pbc rami-unstb ✕ ✓ ✕ ✕ 
N0201 Chondroc.-dical.ph.-shoulder ✕ ✕ ✓ ✕ S133y Other spec open # pubis ✕ ✓ ✕ ✕ 
N0202 Chondroc.-dical.ph.-upper arm ✕ ✕ ✓ ✕ S133z Open fracture of pubis NOS ✕ ✓ ✕ ✕ 
N0203 Chondroc.-dical.ph.-forearm ✕ ✕ ✓ ✕ S134 Othr/multi clsd # pelvis ✕ ✓ ✕ ✕ 
N0204 Chondroc.-dical.ph.-hand ✕ ✕ ✓ ✕ S1340 Closed # ilium, unspec ✕ ✓ ✕ ✕ 
N0205 Chondroc.-dical.ph.-pelv/thigh ✕ ✓ ✕ ✕ S1341 Closed # pelvis, ischium ✕ ✓ ✕ ✕ 
N0206 Chondroc.-dical.ph.-lower leg ✕ ✓ ✕ ✕ S1342 Clsd multi disrptions pelvis ✕ ✓ ✕ ✕ 
N0207 Chondroc.-dical.ph.-ankle/foot ✕ ✓ ✕ ✕ S1343 Cls # plvs, ischial tuberosity ✕ ✓ ✕ ✕ 
N0210 Chondroc.-pyrophos.-site unsp. ✕ ✕ ✕ ✕ S1344 Cls # plvs,ant sup iliac spn ✕ ✓ ✕ ✕ 
N0211 Chondroc.-pyrophos.-shoulder ✕ ✕ ✓ ✕ S1345 Cls # plvs,ant inf iliiac spn ✕ ✓ ✕ ✕ 
N0212 Chondroc.-pyrophos.-upper arm ✕ ✕ ✓ ✕ S1346 Clsd # pelvis, iliac wing ✕ ✓ ✕ ✕ 
N0213 Chondroc.-pyrophos.-forearm ✕ ✕ ✓ ✕ S1347 Clsd vertical # ilium ✕ ✓ ✕ ✕ 
N0214 Chondroc.-pyrophos.-hand ✕ ✕ ✓ ✕ S1348 Clsd # dislocatn sac-iliac jnt ✓ ✕ ✕ ✕ 
N0215 Chondroc.-pyrophos.-pelv/thigh ✕ ✓ ✕ ✕ S134z Othr/mlti clsd # pelvis NOS ✕ ✓ ✕ ✕ 
N0216 Chondroc.-pyrophos.-lower leg ✕ ✓ ✕ ✕ S135 Othr/mlti open # pelvis ✕ ✓ ✕ ✕ 
N0217 Chondroc.-pyrophos.-ankle/foot ✕ ✓ ✕ ✕ S1350 Open # ilium, unspec ✕ ✓ ✕ ✕ 
N0220 Chondrocalc.unsp.-site unspec. ✕ ✕ ✕ ✕ S1351 Open fracture pelvis, ischium ✕ ✓ ✕ ✕ 
N0221 Chondrocalc.unsp.-shoulder reg ✕ ✕ ✓ ✕ S1352 Open multi disruptns pelvis ✕ ✓ ✕ ✕ 
N0222 Chondrocalc.unsp.-upper arm ✕ ✕ ✓ ✕ S1353 Opn # pelvs,ischial tuberosity ✕ ✓ ✕ ✕ 
N0223 Chondrocalc.unsp.-forearm ✕ ✕ ✓ ✕ S1354 Opn # pelvs,ant sup iliac spn ✕ ✓ ✕ ✕ 
N0224 Chondrocalc.unsp.-hand ✕ ✕ ✓ ✕ S1355 Opn # pelvs,ant inf iliac spn ✕ ✓ ✕ ✕ 
N0225 Chondrocalc.unsp.-pelv/thigh ✕ ✓ ✕ ✕ S1356 Opn # pelvis, iliac wing ✕ ✓ ✕ ✕ 
N0226 Chondrocalc.unsp.-lower leg ✕ ✓ ✕ ✕ S1357 Open vertical # ilium ✕ ✓ ✕ ✕ 
N0227 Chondrocalc.unsp.-ankle/foot ✕ ✓ ✕ ✕ S1358 Opn # disloctn sac-iliac jnt ✓ ✕ ✕ ✕ 
N0230 Gouty arthritis-site unspecif. ✕ ✕ ✕ ✕ S135y Other open #pelvis ✕ ✓ ✕ ✕ 
N0231 Gouty arthritis-shoulder ✕ ✕ ✓ ✕ S135z Othr/mlti opn # pelvis NOS ✕ ✓ ✕ ✕ 
N0232 Gouty arthritis-upper arm ✕ ✕ ✓ ✕ S136 Clsd comp rupture pelvic ring ✕ ✓ ✕ ✕ 
N0233 Gouty arthritis-forearm ✕ ✕ ✓ ✕ S1360 Cls comp rupture pbc symphysis ✕ ✓ ✕ ✕ 
N0234 Gouty arthritis-hand ✕ ✕ ✓ ✕ S1361 Cls comp rupture sac-ili jnt ✓ ✕ ✕ ✕ 
N0235 Gouty arthritis-pelvic/thigh ✕ ✓ ✕ ✕ S137 Opn comp rupture pelvic ring ✕ ✓ ✕ ✕ 
N0236 Gouty arthritis-lower leg ✕ ✓ ✕ ✕ S1370 Opn comp rupture pbc symphysis ✕ ✓ ✕ ✕ 
N0237 Gouty arthritis-ankle/foot ✕ ✓ ✕ ✕ S1371 Opn comp rupture sac-iliac jnt ✓ ✕ ✕ ✕ 
N02y0 Other crystal arth.-site unsp. ✕ ✕ ✕ ✕ S138 Traumat ruptur/symphysis pubis ✕ ✓ ✕ ✕ 
N02y1 Other crystal arth.-shoulder ✕ ✕ ✓ ✕ S13y Closed #pelvis NOS ✕ ✓ ✕ ✕ 
N02y2 Other crystal arth.-upper arm ✕ ✕ ✓ ✕ S13z Open #pelvis NOS ✕ ✓ ✕ ✕ 
N02y3 Other crystal arth.-forearm ✕ ✕ ✓ ✕ S14 #Ill-defined bones of trunk ✓ ✕ ✕ ✕ 
N02y4 Other crystal arth.-hand ✕ ✕ ✓ ✕ S140 Closed #ill-defined trunk bone ✓ ✕ ✕ ✕ 
N02y5 Other crystal arth.-pelv/thigh ✕ ✓ ✕ ✕ S141 Open #ill-defined trunk bone ✓ ✕ ✕ ✕ 
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N02y6 Other crystal arth.-lower leg ✕ ✓ ✕ ✕ S14z #Ill-defined trunk bone NOS ✓ ✕ ✕ ✕ 
N02y7 Other crystal arth.-ankle/foot ✕ ✓ ✕ ✕ S15 Fracture of thoracic vertebra ✓ ✕ ✕ ✕ 
N02z0 Crystal arthr.NOS-site unspec. ✕ ✕ ✕ ✕ S150 Multi fractures/thoracic spine ✓ ✕ ✕ ✕ 
N02z1 Crystal arthr.NOS-shoulder ✕ ✕ ✓ ✕ S1500 Cl multi fractur of thor spine ✓ ✕ ✕ ✕ 
N02z2 
N02z3 Crystal arthr.NOS-upper arm Crystal arthr.NOS-forearm ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✕ S1501 S1z Op multi fractur of thor spine Fracture of neck and trunk NOS ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✕ 
N02z4 Crystal arthr.NOS-hand ✕ ✕ ✓ ✕ S2 Arm fracture ✕ ✕ ✓ ✕ 
N02z5 Crystal arthr.NOS-pelvic/thigh ✕ ✓ ✕ ✕ S20 #Clavicle ✕ ✕ ✓ ✕ 
N02z6 Crystal arthr.NOS-lower leg ✕ ✓ ✕ ✕ S200 Closed # clavicle ✕ ✕ ✓ ✕ 
N02z7 Crystal arthr.NOS-ankle/foot ✕ ✓ ✕ ✕ S2000 Closed #clavicle unspecified ✕ ✕ ✓ ✕ 
N02z8 Crys arthr NOS-shoulder ✕ ✕ ✓ ✕ S2001 Clsd # clavicle, medial end ✕ ✕ ✓ ✕ 
N02z9 Cryst arthr NOS-sternoclav jt ✕ ✕ ✓ ✕ S2002 Clsd # clavicle, shaft ✕ ✕ ✓ ✕ 
N02zA Cryst arthr NOS-acromioclav jt ✕ ✕ ✓ ✕ S2003 Clsd # clavical, lateral end ✕ ✕ ✓ ✕ 
N02zB Crystal arthropathy NOS-elbow ✕ ✕ ✓ ✕ S200z Closed #clavicle NOS ✕ ✕ ✓ ✕ 
N02zC Crys arthr NOS-dist rad-uln jt ✕ ✕ ✓ ✕ S201 Open # clavicle ✕ ✕ ✓ ✕ 
N02zD Crystal arthropathy NOS-wrist ✕ ✕ ✓ ✕ S2010 Open #clavicle unspecified ✕ ✕ ✓ ✕ 
N02zE Crystal arthropathy NOS-MCPJ ✕ ✕ ✓ ✕ S2011 Open # clavicle, medial end ✕ ✕ ✓ ✕ 
N02zF Crystal arthrop NOS-PIPJ-fing ✕ ✕ ✓ ✕ S2012 Open fracture clavicle, shaft ✕ ✕ ✓ ✕ 
N02zG Crystal arthrop NOS-DIPJ-fing ✕ ✕ ✓ ✕ S2013 Open # clavicle, lateral end ✕ ✕ ✓ ✕ 
N02zH Crystal arthropathy NOS-hip ✕ ✓ ✕ ✕ S201z Open #clavicle NOS ✕ ✕ ✓ ✕ 
N02zJ Crystal arthropathy NOS-SIJ ✓ ✕ ✕ ✕ S20z #Clavicle NOS ✕ ✕ ✓ ✕ 
N02zK Crystal arthropathy NOS-knee ✕ ✓ ✕ ✕ S21 #Scapula ✕ ✕ ✓ ✕ 
N02zL Cryst arthr NOS, tib-fib joint ✕ ✓ ✕ ✕ S210 Closed # scapula ✕ ✕ ✓ ✕ 
N02zM Crystal arthropathy NOS-ankle ✕ ✓ ✕ ✕ S2100 Closed #scapula-unspecified ✕ ✕ ✓ ✕ 
N02zN Cryst arthr NOS-subtalar joint ✕ ✓ ✕ ✕ S2101 Clsd # scapula, acromion ✕ ✕ ✓ ✕ 
N02zP Crys arthr NOS-talonavic joint ✕ ✓ ✕ ✕ S2102 Clsd # scapula, coracoid ✕ ✕ ✓ ✕ 
N02zQ Cryst arthr NOS-oth tarsal jt ✕ ✓ ✕ ✕ S2103 Clsd # scapula, glenoid ✕ ✕ ✓ ✕ 
N02zR Cryst arthr NOS-1st MTPJ ✕ ✓ ✕ ✕ S2104 Closed fracture scapula, blade ✕ ✕ ✓ ✕ 
N02zS Cryst arthr NOS-lesser MTPJ ✕ ✓ ✕ ✕ S2105 Closed fracture scapula, spine ✕ ✕ ✓ ✕ 
N02zT Crystal arthrop NOS-IPJ of toe ✕ ✓ ✕ ✕ S2106 Closed fracture scapula, neck ✕ ✕ ✓ ✕ 
N03x0 Arthr assoc oth dis-shoulder ✕ ✕ ✓ ✕ S210z Closed #scapula NOS ✕ ✕ ✓ ✕ 
N03x1 Arthr ass oth dis-sternoclav j ✕ ✕ ✓ ✕ S211 Open # scapula ✕ ✕ ✓ ✕ 
N03x2 Arthr ass oth dis-acromioclv j ✕ ✕ ✓ ✕ S2110 Open #scapula-unspecified ✕ ✕ ✓ ✕ 
N03x3 Arthr assoc oth dis-elbow ✕ ✕ ✓ ✕ S2111 Open # scapula, acromion ✕ ✕ ✓ ✕ 
N03x4 Arthr assoc oth dis-dist RUJ ✕ ✕ ✓ ✕ S2112 Open # scapula, coracoid ✕ ✕ ✓ ✕ 
N03x5 Arthr assoc oth dis-wrist ✕ ✕ ✓ ✕ S2113 Open fracture scapula, glenoid ✕ ✕ ✓ ✕ 
N03x6 Arthr assoc oth dis-MCPJ ✕ ✕ ✓ ✕ S2114 Open fracture scapula, blade ✕ ✕ ✓ ✕ 
N03x7 Arthr assoc oth dis-PIPJ-fing ✕ ✕ ✓ ✕ S2115 Open fracture scapula, spine ✕ ✕ ✓ ✕ 
N03x8 Arthr assoc oth dis-DIPJ-fing ✕ ✕ ✓ ✕ S2116 Open fracture scapula, neck ✕ ✕ ✓ ✕ 
N03x9 Arthr assoc oth dis-hip ✕ ✓ ✕ ✕ S211z Open #scapula NOS ✕ ✕ ✓ ✕ 
N03xA Arthr assoc oth dis-SIJ ✓ ✕ ✕ ✕ S21z #Scapula NOS ✕ ✕ ✓ ✕ 
N03xB Arthr assoc oth dis-knee ✕ ✓ ✕ ✕ S22 #Humerus ✕ ✕ ✓ ✕ 
N03xC Arthr assoc oth dis, tib-fib j ✕ ✓ ✕ ✕ S220 Clsd # proximal humerus ✕ ✕ ✓ ✕ 
N03xD Arthr assoc oth dis-ankle ✕ ✓ ✕ ✕ S2200 Cls # proxim humerus unsp part ✕ ✕ ✓ ✕ 
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N03xE Arthr assoc oth dis-subtalar j ✕ ✓ ✕ ✕ S2201 Clsd # proxim humerus, neck ✕ ✕ ✓ ✕ 
N03xF Arthr assoc oth dis-talonav jt ✕ ✓ ✕ ✕ S2202 Cls # prxm humerus,anatom neck ✕ ✕ ✓ ✕ 
N03xG Arthr assoc oth dis-oth tars j ✕ ✓ ✕ ✕ S2203 Clsd # prxm hmrs,grtr tubrsity ✕ ✕ ✓ ✕ 
N03xH Arthr assoc oth dis-1st MTPJ ✕ ✓ ✕ ✕ S2204 Clsd # proxim humerus,head ✕ ✕ ✓ ✕ 
N03xJ Arthr assoc oth dis-less MTPJ ✕ ✓ ✕ ✕ S2205 Closed #humerus-upper epiphys. ✕ ✕ ✓ ✕ 
N03xK 
N0400 Arthr assoc oth dis-IPJ of toe Rheumatoid arthritis-Cx spine ✕ ✓ ✓ ✕ ✕ ✕ ✕ ✕ S2206 S2207 Cls # prxm humerus,three part Cls # prxm humerus,four part ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✕ 
N0401 Oth rheumatoid arthritis-spine ✓ ✕ ✕ ✕ S220z Clsd # proxim humerus NOS ✕ ✕ ✓ ✕ 
N0402 Rheumatoid arthritis-shoulder ✕ ✕ ✓ ✕ S221 Shoulder fracture - open ✕ ✕ ✓ ✕ 
N0403 Rheumatoid arthr-sternoclav jt ✕ ✕ ✓ ✕ S2210 Opn # proxim humerus unsp part ✕ ✕ ✓ ✕ 
N0404 Rheumatoid arthr-acromioclav j ✕ ✕ ✓ ✕ S2211 Opn # proxim humerus, neck ✕ ✕ ✓ ✕ 
N0405 Rheumatoid arthritis of elbow ✕ ✕ ✓ ✕ S2212 Opn # prxm humerus,anatom neck ✕ ✕ ✓ ✕ 
N0406 Rheumatoid arthritis-dist RUJ ✕ ✕ ✓ ✕ S2213 Opn # prxm hmrs,grtr tubrsity ✕ ✕ ✓ ✕ 
N0407 Rheumatoid arthritis of wrist ✕ ✕ ✓ ✕ S2214 Opn # proxim humerus,head ✕ ✕ ✓ ✕ 
N0408 Rheumatoid arthritis-MCP joint ✕ ✕ ✓ ✕ S2215 Open #humerus-upper epiphysis ✕ ✕ ✓ ✕ 
N0409 Rheumatoid arthritis-PIPJ-fing ✕ ✕ ✓ ✕ S2216 Opn # prxm humerus,three part ✕ ✕ ✓ ✕ 
N040A Rheumatoid arthritis-DIPJ-fing ✕ ✕ ✓ ✕ S2217 Opn # prxm humerus,four part ✕ ✕ ✓ ✕ 
N040B Rheumatoid arthritis of hip ✕ ✓ ✕ ✕ S221z Opn # proxim humerus NOS ✕ ✕ ✓ ✕ 
N040C Rheumatoid arthritis of SIJ ✓ ✕ ✕ ✕ S222 Closed #humerus-shaft/unspec. ✕ ✕ ✓ ✕ 
N040D Rheumatoid arthritis of knee ✕ ✓ ✕ ✕ S2220 Closed # humerus NOS ✕ ✕ ✓ ✕ 
N040E Rheumatoid arthr of tib-fib jt ✕ ✓ ✕ ✕ S2221 Closed # humerus-shaft ✕ ✕ ✓ ✕ 
N040F Rheumatoid arthritis of ankle ✕ ✓ ✕ ✕ S222z Closed #humerus-shaft/unsp.NOS ✕ ✕ ✓ ✕ 
N040G Rheumatoid arthr-subtalar jnt ✕ ✓ ✕ ✕ S223 Open #humerus-shaft/unspecif. ✕ ✕ ✓ ✕ 
N040H Rheumatoid arthr-talonav joint ✕ ✓ ✕ ✕ S2230 Open # humerus NOS ✕ ✕ ✓ ✕ 
N040J Rheumatoid arthr-oth tarsal jt ✕ ✓ ✕ ✕ S2231 Open # humerus-shaft ✕ ✕ ✓ ✕ 
N040K Rheumatoid arthr-1st MTP joint ✕ ✓ ✕ ✕ S223z Open #humerus shaft/unspec.NOS ✕ ✕ ✓ ✕ 
N040L Rheumatoid arthr-lesser MTP jt ✕ ✓ ✕ ✕ S224 Clsd # distal humerus ✕ ✕ ✓ ✕ 
N040M Rheumatoid arthr-IP joint-toe ✕ ✓ ✕ ✕ S2240 Closed # elbow unspecified ✕ ✕ ✓ ✕ 
N0433 Monarticular juvenile R.A. ✕ ✕ ✕ ✕ S2241 Cls # dist humrs,supracondylar ✕ ✕ ✓ ✕ 
N0450 Juv ankylosing spondylitis ✓ ✕ ✕ ✕ S2242 Cls # dist humerus,lat condyle ✕ ✕ ✓ ✕ 
N0501 Generalised OA-hand ✕ ✕ ✓ ✓ S2243 Cls # dist humerus,med condyle ✕ ✕ ✓ ✕ 
N0503 Bouchard's nodes with arthrop ✕ ✕ ✓ ✕ S2244 Cls # dist humrs,condyle(unsp) ✕ ✕ ✓ ✕ 
N0507 Heberden's nodes + arthropathy ✕ ✕ ✓ ✕ S2245 Cls # dist humerus, trochlea ✕ ✕ ✓ ✕ 
N051 Local.primary osteoarthritis ✕ ✕ ✕ ✓ S2246 Cls # dist hmrs,lat epicondyle ✕ ✕ ✓ ✕ 
N0510 Local.primary OA-site unspec. ✕ ✕ ✕ ✓ S2247 Cls # dist hmrs,med epicondyle ✕ ✕ ✓ ✕ 
N0511 Local.primary OA-shoulder regn ✕ ✕ ✓ ✓ S2248 Cls # dist humerus,capitellum ✕ ✕ ✓ ✕ 
N0512 Local.primary OA-upper arm ✕ ✕ ✓ ✓ S2249 Cls # dist hmrs,bicond(T-Y #) ✕ ✕ ✓ ✕ 
N0513 Local.primary OA-forearm ✕ ✕ ✓ ✓ S224x Cls # dist humerus,multi ✕ ✕ ✓ ✕ 
N0514 Local.primary OA-hand ✕ ✕ ✓ ✓ S224z Cls # dist humerus NOS ✕ ✕ ✓ ✕ 
N0515 Local.primary OA-pelvic/thigh ✕ ✓ ✕ ✓ S225 Elbow fracture - open ✕ ✕ ✓ ✕ 
N0516 Local.primary OA-lower leg ✕ ✓ ✕ ✓ S2250 Open #elbow unspecified ✕ ✕ ✓ ✕ 
N0517 Local.primary OA-ankle/foot ✕ ✓ ✕ ✓ S2251 Opn # dist humrs,supracondylar ✕ ✕ ✓ ✕ 
N0518 Local.primary OA-other specif ✕ ✕ ✕ ✓ S2252 Opn # dist humerus,lat condyle ✕ ✕ ✓ ✕ 
N0519 Primary coxarthrosis, bilat ✕ ✓ ✕ ✓ S2253 Opn # dist humerus,med condyle ✕ ✕ ✓ ✕ 
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N051A Coxarthr from dysplasia, bilat ✕ ✓ ✕ ✓ S2254 Opn # dist humrs,condyle(unsp) ✕ ✕ ✓ ✕ 
N051B Primary gonarthrosis, bilat ✕ ✓ ✕ ✓ S2255 Opn # dist humerus, trochlea ✕ ✕ ✓ ✕ 
N051C Pr arth 1st carpometcp jts,bil ✕ ✕ ✓ ✓ S2256 Opn # dist hmrs,lat epicondyle ✕ ✕ ✓ ✕ 
N051D Local prim osteoarth wrist ✕ ✕ ✓ ✓ S2257 Opn # dist hmrs,med epicondyle ✕ ✕ ✓ ✕ 
N051E Local prim osteoarth toe ✕ ✓ ✕ ✓ S2258 Opn # dist humerus,capitellum ✕ ✕ ✓ ✕ 
N051F Local prim osteoarth elbow ✕ ✕ ✓ ✓ S2259 Opn # dist hmrs,bicond(T-Y #) ✕ ✕ ✓ ✕ 
N051z 
N052 Localised primary OA NOS Local.secondary osteoarthritis ✕ ✕ ✕ ✕ ✕ ✕ ✓ ✓ S225x S225z Opn # dist humerus,multi Opn # dist humerus NOS ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✕ 
N0520 Local.secondary OA-site unsp. ✕ ✕ ✕ ✓ S226 Fracture/upper end of humerus ✕ ✕ ✓ ✕ 
N0521 Local.secondary OA-shoulder ✕ ✕ ✓ ✓ S227 Fracture of shaft of humerus ✕ ✕ ✓ ✕ 
N0522 Local.secondary OA-upper arm ✕ ✕ ✓ ✓ S228 Fracture/lower end of humerus ✕ ✕ ✓ ✕ 
N0523 Local.secondary OA-forearm ✕ ✕ ✓ ✓ S22z Fracture of humerus NOS ✕ ✕ ✓ ✕ 
N0524 Local.secondary OA-hand ✕ ✕ ✓ ✓ S23 #Radius and ulna ✕ ✕ ✓ ✕ 
N0525 Local.secondary OA-pelv./thigh ✕ ✓ ✕ ✓ S230 Cls # prox radius + ulna ✕ ✕ ✓ ✕ 
N0526 Local.secondary OA-lower leg ✕ ✓ ✕ ✓ S2300 Clsd # prox forearm unsp part ✕ ✕ ✓ ✕ 
N0527 Local.secondary OA-ankle/foot ✕ ✓ ✕ ✓ S2301 Clsd # olecranon,extra-articlr ✕ ✕ ✓ ✕ 
N0528 Local.secondary OA-other spec. ✕ ✕ ✕ ✓ S2302 Clsd # ulna, coronoid ✕ ✕ ✓ ✕ 
N0529 Post-traum coxarthrosis, bilat ✕ ✓ ✕ ✓ S2303 Closed Monteggia's fracture ✕ ✕ ✓ ✕ 
N052A Post-traum gonarthrosis, bilat ✕ ✓ ✕ ✓ S2304 Clsd # prox ulna, comminuted ✕ ✕ ✓ ✕ 
N052B Pst-tr art 1 carpometcp jt bil ✕ ✕ ✓ ✓ S2305 Clsd # proximal ulna ✕ ✕ ✓ ✕ 
N052C Post-trauma gonarth, unilat ✕ ✓ ✕ ✓ S2306 Closed fracture radius head ✕ ✕ ✓ ✕ 
N052z Localised secondary OA NOS ✕ ✕ ✕ ✓ S2307 Closed fracture radius, neck ✕ ✕ ✓ ✕ 
N053 Localised OA unspecified ✕ ✕ ✕ ✓ S2308 Clsd # prox radius, comminuted ✕ ✕ ✓ ✕ 
N0530 Local.OA unsp.-site unspecif. ✕ ✕ ✕ ✓ S2309 Clsd # proximal radius ✕ ✕ ✓ ✕ 
N0531 Local.OA unsp.-shoulder region ✕ ✕ ✓ ✓ S230A Clsd # radius+ulna, proximal ✕ ✕ ✓ ✕ 
N0532 Local.OA unsp.-upper arm ✕ ✕ ✓ ✓ S230B Clsd # olecranon,intra-articlr ✕ ✕ ✓ ✕ 
N0533 Local.OA unsp.-forearm ✕ ✕ ✓ ✓ S230z Clsd # proximal forearm NOS ✕ ✕ ✓ ✕ 
N0534 Local.OA unsp.-hand ✕ ✕ ✓ ✓ S231 Opn # proximal radius+ulna ✕ ✕ ✓ ✕ 
N0535 Hip osteoarthitis NOS ✕ ✓ ✕ ✓ S2310 Opn # proximal forearm, unsp ✕ ✕ ✓ ✕ 
N0536 Local.OA unsp.-lower leg ✕ ✓ ✕ ✓ S2311 Opn # olecranon,extra-artclr ✕ ✕ ✓ ✕ 
N0537 Local.OA unsp.-ankle/foot ✕ ✓ ✕ ✓ S2312 Opn # ulna, coronoid ✕ ✕ ✓ ✕ 
N0538 Local.OA unsp.-other specified ✕ ✕ ✕ ✓ S2313 Open Monteggia's fracture ✕ ✕ ✓ ✕ 
N0539 Arthros 1st CMC joint, unspec ✕ ✕ ✓ ✓ S2314 Opn # prox ulna, comminuted ✕ ✕ ✓ ✕ 
N053z Localised OA unspecified NOS ✕ ✕ ✕ ✓ S2315 Open # proximal ulna ✕ ✕ ✓ ✕ 
N054 Oligoarticular OA, unspecified ✕ ✕ ✕ ✓ S2316 Open fracture radial head ✕ ✕ ✓ ✕ 
N0540 Oligoartic OA, unsp-unsp sites ✕ ✕ ✕ ✓ S2317 Open fracture radial neck ✕ ✕ ✓ ✕ 
N0541 Oligoartic OA, unspec-shoulder ✕ ✕ ✓ ✓ S2318 Open # prox radius,comminuted ✕ ✕ ✓ ✕ 
N0542 Oligoartic OA, unspec-upp arm ✕ ✕ ✓ ✓ S2319 Opn # proximal radius ✕ ✕ ✓ ✕ 
N0543 Oligoartic OA, unspec-forearm ✕ ✕ ✓ ✓ S231A Opn # radius+ulna,proximal ✕ ✕ ✓ ✕ 
N0544 Oligoartic OA, unspec-hand ✕ ✕ ✓ ✓ S231B Opn # olecranon,intra-artclr ✕ ✕ ✓ ✕ 
N0545 Oligoartic OA, unspec-pelv/thi ✕ ✓ ✕ ✓ S231z Open #forearm-upper end NOS ✕ ✕ ✓ ✕ 
N0546 Oligoartic OA, unspec-leg ✕ ✓ ✕ ✓ S232 Closed #radius/ulna-shaft ✕ ✕ ✓ ✕ 
N0547 Oligoartic OA, unspec-ank/foot ✕ ✓ ✕ ✓ S2320 Closed #radius-shaft unspecif. ✕ ✕ ✓ ✕ 
N0548 Oligoartic OA, unspec-oth site ✕ ✕ ✕ ✓ S2321 Closed # radial shaft ✕ ✕ ✓ ✕ 
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N054z OA,1 site +,unspecified NOS ✕ ✕ ✕ ✓ S2322 Closed # ulnar shaft ✕ ✕ ✓ ✕ 
N05z0 Osteoarthritis NOS-site unspec ✕ ✕ ✕ ✓ S2323 Clsd # radius + ulna, middle ✕ ✕ ✓ ✕ 
N05z1 Osteoarthritis NOS-shoulder ✕ ✕ ✓ ✓ S232z Closed #radius/ulna shaft NOS ✕ ✕ ✓ ✕ 
N05z2 Elbow osteoarthritis NOS ✕ ✕ ✓ ✓ S233 Open #radius/ulna-shaft ✕ ✕ ✓ ✕ 
N05z3 Osteoarthritis NOS of the forearm ✕ ✕ ✓ ✓ S2330 Open #radius-shaft unspecified ✕ ✕ ✓ ✕ 
N05z4 Finger osteoarthritis NOS ✕ ✕ ✓ ✓ S2331 Open # radial shaft ✕ ✕ ✓ ✕ 
N05z5 Hip osteoarthritis NOS ✕ ✓ ✕ ✓ S2332 Open # ulnar shaft ✕ ✕ ✓ ✕ 
N05z6 
N05z7 Knee osteoarthritis NOS Ankle osteoarthritis NOS 
✕ 
✕ ✓ ✓ ✕ ✕ ✓ ✓ S2333 S233z Open # radius+ulna, middle Open #radius/ulna shaft NOS 
✕ 
✕ ✕ ✕ ✓ ✓ ✕ ✕ 
N05z9 Osteoarthritis NOS, shoulder ✕ ✕ ✓ ✓ S234 Closed #radius/ulna-lower end ✕ ✕ ✓ ✕ 
N05zA OA NOS-sternoclavicular joint ✕ ✕ ✓ ✓ S2340 Closed #forearm-lower end unsp ✕ ✕ ✓ ✕ 
N05zB OA NOS-acromioclavicular joint ✕ ✕ ✓ ✓ S2341 Closed Colles fracture ✕ ✕ ✓ ✕ 
N05zC OA NOS-elbow ✕ ✕ ✓ ✓ S2342 Clsd # distal radius unspec ✕ ✕ ✓ ✕ 
N05zD OA NOS-dist radio-ulnar joint ✕ ✕ ✓ ✓ S2343 Closed #ulna-styloid process ✕ ✕ ✓ ✕ 
N05zE OA NOS-wrist ✕ ✕ ✓ ✓ S2344 Closed #ulna-lower epiphysis ✕ ✕ ✓ ✕ 
N05zF OA NOS-MCP joint ✕ ✕ ✓ ✓ S2345 Closed fract dist ulna,unspec ✕ ✕ ✓ ✕ 
N05zG OA NOS-PIP joint of finger ✕ ✕ ✓ ✓ S2346 Clsd # radius+ulna, distal ✕ ✕ ✓ ✕ 
N05zH OA NOS-DIP joint of finger ✕ ✕ ✓ ✓ S2347 Closed Smith's fracture ✕ ✕ ✓ ✕ 
N05zJ OA NOS-hip ✕ ✓ ✕ ✓ S2348 Closed Galeazzi fracture ✕ ✕ ✓ ✕ 
N05zK OA NOS-SI joint ✓ ✕ ✕ ✓ S2349 Closed volar Barton's fracture ✕ ✕ ✓ ✕ 
N05zL Osteoarthritis NOS of knee ✕ ✓ ✕ ✓ S234A Closd dorsal Barton's fracture ✕ ✕ ✓ ✕ 
N05zM OA NOS tibio-fibular joint ✕ ✓ ✕ ✓ S234B Closed fracture radial styloid ✕ ✕ ✓ ✕ 
N05zN OA NOS-ankle ✕ ✓ ✕ ✓ S234C Cl # dist rad,int-art,die-pnch ✕ ✕ ✓ ✕ 
N05zP OA NOS-subtalar joint ✕ ✓ ✕ ✓ S234D Cl # dist rad,ext-art,oth type ✕ ✕ ✓ ✕ 
N05zQ OA NOS-talonavicular joint ✕ ✓ ✕ ✓ S234E Cl # dist rad,int-art,oth type ✕ ✕ ✓ ✕ 
N05zR OA NOS-other tarsal joint ✕ ✓ ✕ ✓ S234F Closed Barton's fracture ✕ ✕ ✓ ✕ 
N05zS OA NOS-1st MTP joint ✕ ✓ ✕ ✓ S234z Closed #forearm-lower end NOS ✕ ✕ ✓ ✕ 
N05zT OA NOS-lesser MTP joint ✕ ✓ ✕ ✓ S235 Wrist fracture - open ✕ ✕ ✓ ✕ 
N05zU OA NOS-IP joint of toe ✕ ✓ ✕ ✓ S2350 Open #forearm-lower end unsp. ✕ ✕ ✓ ✕ 
N0600 Kaschin-Beck dis.-site unspec. ✕ ✕ ✕ ✕ S2351 Smith's fracture - open ✕ ✕ ✓ ✕ 
N0601 Kaschin-Beck dis.-shoulder ✕ ✕ ✓ ✕ S2352 Opn # distal radius, unspec ✕ ✕ ✓ ✕ 
N0602 Kaschin-Beck dis.-upper arm ✕ ✕ ✓ ✕ S2353 Open #ulna-styloid process ✕ ✕ ✓ ✕ 
N0603 Kaschin-Beck dis.-forearm ✕ ✕ ✓ ✕ S2354 Open #ulna-lower epiphysis ✕ ✕ ✓ ✕ 
N0604 Kaschin-Beck dis.-hand ✕ ✕ ✓ ✕ S2355 Opn # distal ulna - other ✕ ✕ ✓ ✕ 
N0605 Kaschin-Beck dis.-pelvic/thigh ✕ ✓ ✕ ✕ S2356 Opn # radius + ulna, distal ✕ ✕ ✓ ✕ 
N0606 Kaschin-Beck dis.-lower leg ✕ ✓ ✕ ✕ S2357 Open Smith's fracture ✕ ✕ ✓ ✕ 
N0607 Kaschin-Beck dis.-ankle/foot ✕ ✓ ✕ ✕ S2358 Open Galeazzi fracture ✕ ✕ ✓ ✕ 
N0610 Traumatic arthr.-site unspecif ✕ ✕ ✕ ✕ S2359 Open volar Barton's fracture ✕ ✕ ✓ ✕ 
N0611 Traumatic arthr.-shoulder ✕ ✕ ✓ ✕ S235A Open dorsal Barton's fracture ✕ ✕ ✓ ✕ 
N0612 Traumatic arthr.-upper arm ✕ ✕ ✓ ✕ S235B Open fracture radial styloid ✕ ✕ ✓ ✕ 
N0613 Traumatic arthr.-forearm ✕ ✕ ✓ ✕ S235C Op # dist rad,int-art,die-pnch ✕ ✕ ✓ ✕ 
N0614 Traumatic arthr.-hand ✕ ✕ ✓ ✕ S235D Op # dist rad,ext-art oth type ✕ ✕ ✓ ✕ 
N0615 Traumatic arthr.-pelvic/thigh ✕ ✓ ✕ ✕ S235E Op # dist rad,int-art oth type ✕ ✕ ✓ ✕ 
N0616 Traumatic arthr.-lower leg ✕ ✓ ✕ ✕ S235F Open Barton's fracture ✕ ✕ ✓ ✕ 
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N0617 Traumatic arthr.-ankle/foot ✕ ✓ ✕ ✕ S235z Open #forearm-lower end NOS ✕ ✕ ✓ ✕ 
N061A Traumatic arthropathy-shoulder ✕ ✕ ✓ ✕ S236 Fracture of upper end of ulna ✕ ✕ ✓ ✕ 
N061B Traumat arthrop-sternoclav jt ✕ ✕ ✓ ✕ S237 Fracture/upper end of radius ✕ ✕ ✓ ✕ 
N061C Traumat arthrop-acromioclav jt ✕ ✕ ✓ ✕ S238 Fracture of shaft of ulna ✕ ✕ ✓ ✕ 
N061D Traumatic arthropathy-elbow ✕ ✕ ✓ ✕ S239 Fracture of shaft of radius ✕ ✕ ✓ ✕ 
N061E Traumatic arthropathy-dist RUJ ✕ ✕ ✓ ✕ S23A Fractur/shaft/both ulna+radius ✕ ✕ ✓ ✕ 
N061F Traumatic arthropathy-wrist ✕ ✕ ✓ ✕ S23B Fracture / lower end of radius ✕ ✕ ✓ ✕ 
N061G Traumatic arthropathy-MCPJ ✕ ✕ ✓ ✕ S23C Fractr/lw end/both ulna+radius ✕ ✕ ✓ ✕ 
N061H 
N061J Traumatic arthrop-PIPJ-fing Traumatic arthrop-DIPJ-fing 
✕ 
✕ ✕ ✕ ✓ ✓ ✕ ✕ S23x S23x0 Closed #radius/ulna unspecif. Closed #forearm unspecified 
✕ 
✕ ✕ ✕ ✓ ✓ ✕ ✕ 
N061K Traumatic arthropathy-hip ✕ ✓ ✕ ✕ S23x1 Closed #radius alone unspecif. ✕ ✕ ✓ ✕ 
N061L Traumatic arthropathy-SIJ ✓ ✕ ✕ ✕ S23x2 Fracture of ulna NOS ✕ ✕ ✓ ✕ 
N061M Traumatic arthropathy-knee ✕ ✓ ✕ ✕ S23x3 Clsd # radius + ulna ✕ ✕ ✓ ✕ 
N061N Traumatic arthrop, tib-fib jnt ✕ ✓ ✕ ✕ S23xz Closed #radius/ulna NOS ✕ ✕ ✓ ✕ 
N061P Traumatic arthropathy-ankle ✕ ✓ ✕ ✕ S23y Open #radius/ulna unspecified ✕ ✕ ✓ ✕ 
N061Q Traumatic arthrop-subtalar jnt ✕ ✓ ✕ ✕ S23y0 Open #forearm unspecified ✕ ✕ ✓ ✕ 
N061R Traumatic arthrop-talonav jnt ✕ ✓ ✕ ✕ S23y1 Open #radius alone unspecified ✕ ✕ ✓ ✕ 
N061S Traumatic arthrop-oth tars jnt ✕ ✓ ✕ ✕ S23y2 Open #ulna alone unspecified ✕ ✕ ✓ ✕ 
N061T Traumatic arthropathy-1st MTPJ ✕ ✓ ✕ ✕ S23y3 Opn # radius + ulna ✕ ✕ ✓ ✕ 
N061U Traumatic arthrop-less MTPJ ✕ ✓ ✕ ✕ S23yz Open #radius/ulna NOS ✕ ✕ ✓ ✕ 
N061V Traumatic arthropathy-IPJ-toe ✕ ✓ ✕ ✕ S23z #Radius/ulna NOS ✕ ✕ ✓ ✕ 
N0620 Allergic arthritis-site unsp. ✕ ✕ ✕ ✕ S24 Hand fracture - carpal bone ✕ ✕ ✓ ✕ 
N0621 Allergic arthritis-shoulder ✕ ✕ ✓ ✕ S240 Closed #carpal bone ✕ ✕ ✓ ✕ 
N0622 Allergic arthritis-upper arm ✕ ✕ ✓ ✕ S2400 Closed #carpal bone unspecif. ✕ ✕ ✓ ✕ 
N0623 Allergic arthritis-forearm ✕ ✕ ✓ ✕ S2401 Closed fracture of the scaphoid ✕ ✕ ✓ ✕ 
N0624 Allergic arthritis-hand ✕ ✕ ✓ ✕ S2402 Closed fracture lunate ✕ ✕ ✓ ✕ 
N0625 Allergic arthritis-pelv./thigh ✕ ✓ ✕ ✕ S2403 Closed fracture triquetral ✕ ✕ ✓ ✕ 
N0626 Allergic arthritis-lower leg ✕ ✓ ✕ ✕ S2404 Closed fracture pisiform ✕ ✕ ✓ ✕ 
N0627 Allergic arthritis-ankle/foot ✕ ✓ ✕ ✕ S2405 Closed fracture trapezium ✕ ✕ ✓ ✕ 
N0630 Climacteric arthr.-site unsp. ✕ ✕ ✕ ✓ S2406 Closed fracture trapezoid ✕ ✕ ✓ ✕ 
N0631 Climacteric arthr.-shoulder ✕ ✕ ✓ ✓ S2407 Closed fracture capitate ✕ ✕ ✓ ✕ 
N0632 Climacteric arthr.-upper arm ✕ ✕ ✓ ✓ S2408 Closed fracture hamate ✕ ✕ ✓ ✕ 
N0633 Climacteric arthr.-forearm ✕ ✕ ✓ ✓ S2409 Closed fracture hamate, hook ✕ ✕ ✓ ✕ 
N0634 Climacteric arthr.-hand ✕ ✕ ✓ ✓ S240A Cls # scaphoid, prox pole ✕ ✕ ✓ ✕ 
N0635 Climacteric arthr.-pelv./thigh ✕ ✓ ✕ ✓ S240B Cls # scaphoid,waist,transv ✕ ✕ ✓ ✕ 
N0636 Climacteric arthr.-lower leg ✕ ✓ ✕ ✓ S240C Cls # scaphoid,waist,oblique ✕ ✕ ✓ ✕ 
N0637 Climacteric arthr.-ankle/foot ✕ ✓ ✕ ✓ S240D Cls # scaphoid,waist,commintd ✕ ✕ ✓ ✕ 
N0640 Transient arthr.-site unspecif ✕ ✕ ✕ ✓ S240E Cls # scaphoid, tuberosity ✕ ✕ ✓ ✕ 
N0641 Transient arthr.-shoulder ✕ ✕ ✓ ✓ S240F Cls # carpal bones, multiple ✕ ✕ ✓ ✕ 
N0642 Transient arthr.-upper arm ✕ ✕ ✓ ✓ S240y Closed #other carpal bone ✕ ✕ ✓ ✕ 
N0643 Transient arthr.-forearm ✕ ✕ ✓ ✓ S240z Closed #carpal bone NOS ✕ ✕ ✓ ✕ 
N0644 Transient arthr.-hand ✕ ✕ ✓ ✓ S241 Open #carpal bone ✕ ✕ ✓ ✕ 
N0645 Transient arthr.-pelvic/thigh ✕ ✓ ✕ ✓ S2410 Open #carpal bone unspecified ✕ ✕ ✓ ✕ 
N0646 Transient arthr.-lower leg ✕ ✓ ✕ ✓ S2411 Open fracture of the scaphoid ✕ ✕ ✓ ✕ 
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N0647 Transient arthr.-ankle/foot ✕ ✓ ✕ ✓ S2412 Open fracture lunate ✕ ✕ ✓ ✕ 
N064A Transient arthropathy-shoulder ✕ ✕ ✓ ✓ S2413 Open fracture triquetral ✕ ✕ ✓ ✕ 
N064B Transient arthrop-sternoclav j ✕ ✕ ✓ ✓ S2414 Open fracture pisiform ✕ ✕ ✓ ✕ 
N064C Transient arthr-acromioclav jt ✕ ✕ ✓ ✓ S2415 Open fracture trapezium ✕ ✕ ✓ ✕ 
N064D Transient arthropathy-elbow ✕ ✕ ✓ ✓ S2416 Open fracture trapezoid ✕ ✕ ✓ ✕ 
N064E Transient arthropathy-dist RUJ ✕ ✕ ✓ ✓ S2417 Open fracture capitate ✕ ✕ ✓ ✕ 
N064F Transient arthropathy-wrist ✕ ✕ ✓ ✓ S2418 Open fracture hamate ✕ ✕ ✓ ✕ 
N064G Transient arthropathy-MCPJ ✕ ✕ ✓ ✓ S2419 Open fracture hamate, hook ✕ ✕ ✓ ✕ 
N064H Transient arthrop-PIPJ-fing ✕ ✕ ✓ ✓ S241A Opn # scaphoid, proxim pole ✕ ✕ ✓ ✕ 
N064J 
N064K Transient arthrop-DIPJ-fing Transient arthropathy-hip ✕ ✕ ✕ ✓ ✓ ✕ ✓ ✓ S241B S241C Opn # scaphoid,waist,transv Opn # scaphoid,waist,oblique ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✕ 
N064L Transient arthropathy-SIJ ✓ ✕ ✕ ✓ S241D Opn # scaphoid,waist,commintd ✕ ✕ ✓ ✕ 
N064M Transient arthropathy-knee ✕ ✓ ✕ ✓ S241E Opn # scaphoid, tuberosity ✕ ✕ ✓ ✕ 
N064N Transient arthrop, tib-fib jnt ✕ ✓ ✕ ✓ S241F Opn # carpal bones, multiple ✕ ✕ ✓ ✕ 
N064P Transient arthropathy-ankle ✕ ✓ ✕ ✓ S241y Open #other carpal bone ✕ ✕ ✓ ✕ 
N064Q Transient arthrop-subtalar jnt ✕ ✓ ✕ ✓ S241z Open #carpal bone NOS ✕ ✕ ✓ ✕ 
N064R Transient arthrop-talonav jnt ✕ ✓ ✕ ✓ S242 Fracture at wrist and hand level ✕ ✕ ✓ ✕ 
N064S Transient arthrop-oth tars jnt ✕ ✓ ✕ ✓ S2420 Fracture of scaphoid ✕ ✕ ✓ ✕ 
N064T Transient arthropathy-1st MTPJ ✕ ✓ ✕ ✓ S2421 Fracture/1st metacarpal bone ✕ ✕ ✓ ✕ 
N064U Transient arthrop-less MTPJ ✕ ✓ ✕ ✓ S2422 Fracture of other metacarpal bone ✕ ✕ ✓ ✕ 
N064V Transient arthropathy-IPJ-toe ✕ ✓ ✕ ✓ S2423 Mult fracture/metacarpal bones ✕ ✕ ✓ ✕ 
N0651 Unsp.polyarthr.-shoulder ✕ ✕ ✓ ✓ S24z #Carpal bone NOS ✕ ✕ ✓ ✕ 
N0652 Unsp.polyarthr.-upper arm ✕ ✕ ✓ ✓ S25 #Metacarpal bone ✕ ✕ ✓ ✕ 
N0653 Unsp.polyarthr.-forearm ✕ ✕ ✓ ✓ S250 Closed #metacarpal bone ✕ ✕ ✓ ✕ 
N0654 Unsp.polyarthr.-hand ✕ ✕ ✓ ✓ S2500 Closed #metacarpal bone unsp. ✕ ✕ ✓ ✕ 
N0655 Unsp.polyarthr.-pelvic/thigh ✕ ✓ ✕ ✓ S2501 Cls # thmb mtcarp base Bennett ✕ ✕ ✓ ✕ 
N0656 Unsp.polyarthr.-lower leg ✕ ✓ ✕ ✓ S2502 Cls # finger metacarp base ✕ ✕ ✓ ✕ 
N0657 Unsp.polyarthr.-ankle/foot ✕ ✓ ✕ ✓ S2503 Cls # finger metacarp shaft ✕ ✕ ✓ ✕ 
N066 Unspecified monoarthritis ✕ ✕ ✕ ✓ S2504 Cls # finger metacarp neck ✕ ✕ ✓ ✕ 
N0660 Unsp.monoarthr.-site unspecif. ✕ ✕ ✕ ✓ S2505 Cls # finger metacarp head ✕ ✕ ✓ ✕ 
N0661 Unsp.monoarthr.-shoulder ✕ ✕ ✓ ✓ S2506 Closed fracture finger metacarpal ✕ ✕ ✓ ✕ 
N0662 Unsp.monoarthr.-upper arm ✕ ✕ ✓ ✓ S2507 Cls # finger metacarp, multi ✕ ✕ ✓ ✕ 
N0663 Unsp.monoarthr.-forearm ✕ ✕ ✓ ✓ S2508 Cls # thumb metacarpal ✕ ✕ ✓ ✕ 
N0664 Unsp.monoarthr.-hand ✕ ✕ ✓ ✓ S2509 Cls # thmb mtcarp base Rolando ✕ ✕ ✓ ✕ 
N0665 Unsp.monoarthr.-pelvic/thigh ✕ ✓ ✕ ✓ S250A Cls # thumb metacarpal shaft ✕ ✕ ✓ ✕ 
N0666 Unsp.monoarthr.-lower leg ✕ ✓ ✕ ✓ S250B Cls # thumb metacarpal neck ✕ ✕ ✓ ✕ 
N0667 Unsp.monoarthr.-ankle/foot ✕ ✓ ✕ ✓ S250C Cls # thumb metacarpal head ✕ ✕ ✓ ✕ 
N0668 Unsp.monoarthr.-other specif. ✕ ✕ ✕ ✓ S250x Cls # mlti sites unsp mtcarpus ✕ ✕ ✓ ✕ 
N066z Unspecified monoarthritis NOS ✕ ✕ ✕ ✓ S250z Closed #metacarpal bone NOS ✕ ✕ ✓ ✕ 
N06y0 Other spec.arthr.-site unspec. ✕ ✕ ✕ ✓ S251 Open #metacarpal bone ✕ ✕ ✓ ✕ 
N06y1 Other spec.arthr.-shoulder ✕ ✕ ✓ ✓ S2510 Open #metacarpal bone unspec. ✕ ✕ ✓ ✕ 
N06y2 Other spec.arthr.-upper arm ✕ ✕ ✓ ✓ S2511 Op # thmb mtcarp base Bennett ✕ ✕ ✓ ✕ 
N06y3 Other spec.arthr.-forearm ✕ ✕ ✓ ✓ S2512 Opn # finger mtcarpal base ✕ ✕ ✓ ✕ 
N06y4 Other spec.arthr.-hand ✕ ✕ ✓ ✓ S2513 Opn # finger metacarpal shaft ✕ ✕ ✓ ✕ 
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N06y5 Other spec.arthr.-pelvic/thigh ✕ ✓ ✕ ✓ S2514 Opn # finger metacarpal neck ✕ ✕ ✓ ✕ 
N06y6 Other spec.arthr.-lower leg ✕ ✓ ✕ ✓ S2515 Opn # finger metacarpal head ✕ ✕ ✓ ✕ 
N06y7 Other spec.arthr.-ankle/foot ✕ ✓ ✕ ✓ S2516 Opn fracture finger metacarpal ✕ ✕ ✓ ✕ 
N06z0 Arthropathy NOS-site unspecif. ✕ ✕ ✕ ✓ S2517 Opn # finger metacarpal, multi ✕ ✕ ✓ ✕ 
N06z1 Shoulder arthritis NOS ✕ ✕ ✓ ✓ S2518 Open # thumb metacarpal ✕ ✕ ✓ ✕ 
N06z2 Arthropathy NOS-upper arm ✕ ✕ ✓ ✓ S2519 Op # thmb mtcarp base Rolando ✕ ✕ ✓ ✕ 
N06z3 Arthropathy NOS-forearm ✕ ✕ ✓ ✓ S251A Opn # thumb metacarpal shaft ✕ ✕ ✓ ✕ 
N06z4 Arthropathy NOS of the hand ✕ ✕ ✓ ✓ S251B Opn # thumb metacarpal neck ✕ ✕ ✓ ✕ 
N06z5 Hip arthritis NOS ✕ ✓ ✕ ✓ S251C Opn # thumb metacarpal head ✕ ✕ ✓ ✕ 
N06z6 Knee arthritis NOS ✕ ✓ ✕ ✓ S251x Opn # multi sites unsp mtcrpus ✕ ✕ ✓ ✕ 
N06z7 
N07 Ankle arthritis NOS Internal derangement of knee ✕ ✕ ✓ ✓ ✕ ✕ ✓ ✕ S251z S252 Open #metacarpal bone NOS Clsd # sesamoid bone hand ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✕ 
N070 Medial meniscus derangement ✕ ✓ ✕ ✕ S253 Opn # sesamoid bone hand ✕ ✕ ✓ ✕ 
N0700 Medial menisc.derang.unspecif ✕ ✓ ✕ ✕ S26 #Phalanges of hand ✕ ✕ ✓ ✕ 
N0701 Old bucket handle tear-medial ✕ ✓ ✕ ✕ S260 Closed #phalanges of hand ✕ ✕ ✓ ✕ 
N0702 Medial menisc.ant.horn derang. ✕ ✓ ✕ ✕ S2600 Closed #palanges of hand unsp. ✕ ✕ ✓ ✕ 
N0703 Medial menisc.post.horn derang ✕ ✓ ✕ ✕ S2601 Cl # md/prx phln/phlns,unsp pt ✕ ✕ ✓ ✕ 
N0704 Parr beak tear-post/med menisc ✕ ✓ ✕ ✕ S2602 Cls # dstl phlnx/ges unsp part ✕ ✕ ✓ ✕ 
N0705 Periph detach-medial meniscus ✕ ✓ ✕ ✕ S2603 Cls # thumb proximal phalanx ✕ ✕ ✓ ✕ 
N0706 Radial tear of medial meniscus ✕ ✓ ✕ ✕ S2604 Cls # thumb prox phalanx,base ✕ ✕ ✓ ✕ 
N0707 Horiz cleavage tear-med menisc ✕ ✓ ✕ ✕ S2605 Cls # thumb prox phalnx,shaft ✕ ✕ ✓ ✕ 
N0708 Multiple tears-medial meniscus ✕ ✓ ✕ ✕ S2606 Cls # thumb prox phalanx,neck ✕ ✕ ✓ ✕ 
N0709 Cyst of medial meniscus ✕ ✓ ✕ ✕ S2607 Cls # thumb prox phalanx,head ✕ ✕ ✓ ✕ 
N070A Old tear of medial meniscus ✕ ✓ ✕ ✕ S2608 Cls # thumb distal phalanx ✕ ✕ ✓ ✕ 
N070B Old tear post horn med menis ✕ ✓ ✕ ✕ S2609 Cls # thumb dist phalanx, base ✕ ✕ ✓ ✕ 
N070z Medial meniscus derange.NOS ✕ ✓ ✕ ✕ S260A Cls # thumb dist phalanx,shaft ✕ ✕ ✓ ✕ 
N071 Lateral meniscus derangement ✕ ✓ ✕ ✕ S260B Cls # thumb distl phalanx,tuft ✕ ✕ ✓ ✕ 
N0710 Lateral menisc.derang.unspecif ✕ ✓ ✕ ✕ S260C Cls # thumb dist phlnx,mallet ✕ ✕ ✓ ✕ 
N0711 Old bucket handle tear-lat men ✕ ✓ ✕ ✕ S260D Cls # finger proximal phalanx ✕ ✕ ✓ ✕ 
N0712 Lateral menisc.ant.horn derang ✕ ✓ ✕ ✕ S260E Cls # finger prox phlanx,base ✕ ✕ ✓ ✕ 
N0713 Lateral menisc.post.horn deran ✕ ✓ ✕ ✕ S260F Cls # finger prox phlnx,shaft ✕ ✕ ✓ ✕ 
N0714 Lateral meniscus derangem.NOS ✕ ✓ ✕ ✕ S260G Cls # finger prox phlnx neck ✕ ✕ ✓ ✕ 
N0715 Parr beak tear-post/lat menisc ✕ ✓ ✕ ✕ S260H Cls # finger prox phlnx,head ✕ ✕ ✓ ✕ 
N0716 Periph detach-lateral meniscus ✕ ✓ ✕ ✕ S260J Cls # finger prox phlnx,mlti ✕ ✕ ✓ ✕ 
N0717 Radial tear-lateral meniscus ✕ ✓ ✕ ✕ S260K Cls # finger middle phalanx ✕ ✕ ✓ ✕ 
N0718 Horiz cleavage tear-lat menisc ✕ ✓ ✕ ✕ S260L Cls # finger mid phalanx,base ✕ ✕ ✓ ✕ 
N0719 Multiple tears-lat meniscus ✕ ✓ ✕ ✕ S260M Cls # finger mid phlanx,shaft ✕ ✕ ✓ ✕ 
N071A Cyst of lateral meniscus ✕ ✓ ✕ ✕ S260N Cls # finger mid phalanx,neck ✕ ✕ ✓ ✕ 
N071B Discoid lateral meniscus ✕ ✓ ✕ ✕ S260P Cls # finger mid phalanx,head ✕ ✕ ✓ ✕ 
N071C Old tear of lateral meniscus ✕ ✓ ✕ ✕ S260Q Cls # finger mid phalanx,mlti ✕ ✕ ✓ ✕ 
N072 Meniscus derangement NEC ✕ ✓ ✕ ✕ S260R Cls # finger distal phalanx ✕ ✕ ✓ ✕ 
N0720 Old torn meniscus of knee ✕ ✓ ✕ ✕ S260S Cls # finger dist phlanx,base ✕ ✕ ✓ ✕ 
N0721 Degen lesion artic cart knee ✕ ✓ ✕ ✕ S260T Cls # finger dist phlnx,shaft ✕ ✕ ✓ ✕ 
N0722 Cyst of semilunar cartilage ✕ ✓ ✕ ✕ S260U Cls # finger dist phlanx,tuft ✕ ✕ ✓ ✕ 
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N073 Loose body in knee ✕ ✓ ✕ ✕ S260V Cls # finger dist phlnx,mallet ✕ ✕ ✓ ✕ 
N074 Chondromalacia patellae ✕ ✓ ✕ ✕ S260W Cls # finger dist phalanx,mlti ✕ ✕ ✓ ✕ 
N07y Oth. internal knee derangement ✕ ✓ ✕ ✕ S260x Closed #phalanges-multiple ✕ ✕ ✓ ✕ 
N07y0 Old lat.collat.lig.disruption ✕ ✓ ✕ ✕ S260z Closed #phalanges of hand NOS ✕ ✕ ✓ ✕ 
N07y1 Old med.collat.lig.disruption ✕ ✓ ✕ ✕ S261 Open #phalanges of hand ✕ ✕ ✓ ✕ 
N07y2 Old ant.cruciate lig.disrupt. ✕ ✓ ✕ ✕ S2610 Open #phalanges of hand unsp. ✕ ✕ ✓ ✕ 
N07y3 Old post.cruciate lig.disrupt. ✕ ✓ ✕ ✕ S2611 Op # md/prx phln/phlns,unsp pt ✕ ✕ ✓ ✕ 
N07y4 Old capsular knee lig.disrupt. ✕ ✓ ✕ ✕ S2612 Op # dist phln/phlns,unsp part ✕ ✕ ✓ ✕ 
N07y5 Locked knee ✕ ✓ ✕ ✕ S2613 Opn # thumb proximal phalanx ✕ ✕ ✓ ✕ 
N07y6 Patellofemoral maltracking ✕ ✓ ✕ ✕ S2614 Opn # thumb prox phlnx, base ✕ ✕ ✓ ✕ 
N07y7 Old part tear lat collat lig ✕ ✓ ✕ ✕ S2615 Opn # thumb prox phlnx, shaft ✕ ✕ ✓ ✕ 
N07y8 
N07y9 Old compl tear lat collat lig Old post/lat caps complex tear ✕ ✕ ✓ ✓ ✕ ✕ ✕ ✕ S2616 S2617 Opn # thumb prox phlnx, neck Opn # thumb prox phlnx, head ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✕ 
N07yA Old part tear med collat lig ✕ ✓ ✕ ✕ S2618 Open fracture thumb distal phalanx ✕ ✕ ✓ ✕ 
N07yB Old compl tear med collat lig ✕ ✓ ✕ ✕ S2619 Opn # thumb dist phlnx, base ✕ ✕ ✓ ✕ 
N07yC Old med capsular complex tear ✕ ✓ ✕ ✕ S261A Opn # thumb dist phlnx, shaft ✕ ✕ ✓ ✕ 
N07yD Old part tear ant cruciate lig ✕ ✓ ✕ ✕ S261B Opn # thumb dist phlnx tuft ✕ ✕ ✓ ✕ 
N07yE Old comp tear ant cruciate lig ✕ ✓ ✕ ✕ S261C Opn # thumb dist phlnx, mallet ✕ ✕ ✓ ✕ 
N07yF Old part tear post cruciat lig ✕ ✓ ✕ ✕ S261D Opn # finger prox phalanx ✕ ✕ ✓ ✕ 
N07yG Old comp tear post cruciat lig ✕ ✓ ✕ ✕ S261E Opn # finger prox phlnx, base ✕ ✕ ✓ ✕ 
N07yH Locking knee ✕ ✓ ✕ ✕ S261F Opn # finger prox phlnx, shaft ✕ ✕ ✓ ✕ 
N07yy Other knee lig. old disruption ✕ ✓ ✕ ✕ S261G Opn # finger prox phlnx, neck ✕ ✕ ✓ ✕ 
N07yz Other intern.knee derang.NOS ✕ ✓ ✕ ✕ S261H Opn # finger prox phlnx, head ✕ ✕ ✓ ✕ 
N07z Internal knee derangement NOS ✕ ✓ ✕ ✕ S261J Opn # finger prox phlnx, mlti ✕ ✕ ✓ ✕ 
N08 Other derangement of joint ✕ ✕ ✕ ✕ S261K Opn # finger mid phalanx ✕ ✕ ✓ ✕ 
N0800 Artic.cart.dis.-site unspecif. ✕ ✕ ✕ ✕ S261L Opn # finger mid phlnx, base ✕ ✕ ✓ ✕ 
N0801 Artic.cart.dis.-shoulder ✕ ✕ ✓ ✕ S261M Opn # finger mid phlnx, shaft ✕ ✕ ✓ ✕ 
N0802 Artic.cart.dis.-upper arm ✕ ✕ ✓ ✕ S261N Opn # finger mid phlnx, neck ✕ ✕ ✓ ✕ 
N0803 Artic.cart.dis.-forearm ✕ ✕ ✓ ✕ S261P Opn # finger mid phlnx, head ✕ ✕ ✓ ✕ 
N0804 Artic.cart.dis.-hand ✕ ✕ ✓ ✕ S261Q Opn # finger mid phlnx, mlti ✕ ✕ ✓ ✕ 
N0805 Artic.cart.dis.-pelvic/thigh ✕ ✓ ✕ ✕ S261R Opn # finger dist phalanx ✕ ✕ ✓ ✕ 
N0806 Artic.cart.dis.-ankle/foot ✕ ✓ ✕ ✕ S261S Opn # finger dist phlnx, base ✕ ✕ ✓ ✕ 
N0809 Hill-Sachs lesion ✕ ✕ ✓ ✕ S261T Opn # finger dist phlnx, shaft ✕ ✕ ✓ ✕ 
N080A Reverse Hill-Sachs lesion ✕ ✕ ✓ ✕ S261U Opn # finger dist phlnx, tuft ✕ ✕ ✓ ✕ 
N080B Artic cart disord oth j-should ✕ ✕ ✓ ✕ S261V Opn # finger dist phlnx,mallet ✕ ✕ ✓ ✕ 
N080C Chondrolysis-femoral head ✕ ✓ ✕ ✕ S261W Opn # finger dist phlnx, mlti ✕ ✕ ✓ ✕ 
N081 Loose body in joint-excl.knee ✕ ✕ ✕ ✕ S261x Open #phalanges-multiple sites ✕ ✕ ✓ ✕ 
N0810 Loose body in joint - unspec. ✕ ✕ ✕ ✕ S261z Open #phalanges of hand NOS ✕ ✕ ✓ ✕ 
N0811 Loose body joint-shoulder ✕ ✕ ✓ ✕ S262 Fracture of thumb ✕ ✕ ✓ ✕ 
N0812 Loose body in joint upper arm ✕ ✕ ✓ ✕ S263 Fracture of other finger ✕ ✕ ✓ ✕ 
N0813 Wrist joint loose body ✕ ✕ ✓ ✕ S264 Multiple fractures of fingers ✕ ✕ ✓ ✕ 
N0814 Loose body joint-hand ✕ ✕ ✓ ✕ S26z #Phalanges of hand NOS ✕ ✕ ✓ ✕ 
N0815 Loose body joint-pelvic/thigh ✕ ✓ ✕ ✕ S27 Multiple #hand bones ✕ ✕ ✓ ✕ 
N0816 Loose body joint-ankle/foot ✕ ✓ ✕ ✕ S270 Closed multiple #hand bones ✕ ✕ ✓ ✕ 
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N0817 Loose body in joint, joint OS ✕ ✕ ✕ ✕ S271 Open multiple #hand bones ✕ ✕ ✓ ✕ 
N0819 Loose body in shoulder joint ✕ ✕ ✓ ✕ S27z Multiple #hand bones NOS ✕ ✕ ✓ ✕ 
N081A Loose body, oth joint-shoulder ✕ ✕ ✓ ✕ S28 Ill-defined fracture of arm ✕ ✕ ✓ ✕ 
N081B Loose body in elbow joint ✕ ✕ ✓ ✕ S280 Closed ill-defined #upper limb ✕ ✕ ✓ ✕ 
N081C Loose body in wrist joint ✕ ✕ ✓ ✕ S281 Open ill-defined #upper limb ✕ ✕ ✓ ✕ 
N081D Loose body in hip joint ✕ ✓ ✕ ✕ S28z Ill-defined #upper limb NOS ✕ ✕ ✓ ✕ 
N081E Loose body, oth joint-pelvis ✕ ✓ ✕ ✕ S290 Closed mult.#arms/ribs/sternum ✓ ✕ ✓ ✕ 
N081F Loose body in ankle joint ✕ ✓ ✕ ✕ S291 Open mult.#arms/ribs/sternum ✓ ✕ ✓ ✕ 
N081G Loose body in foot joint ✕ ✓ ✕ ✕ S292 Mult fract/clav,scapula+humrus ✕ ✕ ✓ ✕ 
N081z Loose joint body (ex.knee)NOS ✕ ✕ ✕ ✕ S2920 Clsd mult fract clav scap hum ✕ ✕ ✓ ✕ 
N082 Spontaneous joint dislocation ✕ ✕ ✕ ✕ S2921 Open mult fract clav scap hum ✕ ✕ ✓ ✕ 
N0820 Patholog.disloc.-site unspecif ✕ ✕ ✕ ✕ S293 Multiple fractures of forearm ✕ ✕ ✓ ✕ 
N0821 
N0822 Patholog.disloc.-shoulder Patholog.disloc.-upper arm 
✕ 
✕ ✕ ✕ ✓ ✓ ✕ ✕ S294 S2940 Frac inv mult reg both up limb Cl fr inv mult reg both up lmb 
✕ 
✕ ✕ ✕ ✓ ✓ ✕ ✕ 
N0823 Wrist pathological dislocation ✕ ✕ ✓ ✕ S2941 Op fr inv mult reg both up lmb ✕ ✕ ✓ ✕ 
N0824 Patholog.disloc.-hand ✕ ✕ ✓ ✕ S29z Mult.#arms/ribs/sternum NOS ✓ ✕ ✓ ✕ 
N0825 Patholog.disloc.-pelvic/thigh ✕ ✓ ✕ ✕ S2A Fractur/upper limb,lev unspec ✕ ✕ ✓ ✕ 
N0826 Patholog.disloc.-lower leg ✕ ✓ ✕ ✕ S2z Fracture of upper limb NOS ✕ ✕ ✓ ✕ 
N0827 Patholog.disloc.-ankle/foot ✕ ✓ ✕ ✕ S3 Fracture of lower limb ✕ ✓ ✕ ✕ 
N0828 Patholog.disloc.-other specif. ✕ ✕ ✕ ✕ S30 #Neck of femur ✕ ✓ ✕ ✕ 
N082A Path disloc-shoulder joint ✕ ✕ ✓ ✕ S300 Cls # prox femur,transcerv ✕ ✓ ✕ ✕ 
N082B Path disloc-oth joint-shoulder ✕ ✕ ✓ ✕ S3000 Cl # prx fem,intrcp sctn,unsp ✕ ✓ ✕ ✕ 
N082C Path disloc humero-ulnar joint ✕ ✕ ✓ ✕ S3001 Cls # prox fmur,transepiphys ✕ ✓ ✕ ✕ 
N082D Path disloc-superior RUJ ✕ ✕ ✓ ✕ S3002 Cls # prox fmur,midcerv sctn ✕ ✓ ✕ ✕ 
N082E Path disloc-radial head ✕ ✕ ✓ ✕ S3003 Cls # prox fmur,basicervical ✕ ✓ ✕ ✕ 
N082F Path disloc-inferior RUJ ✕ ✕ ✓ ✕ S3004 Closed fracture head of femur ✕ ✓ ✕ ✕ 
N082G Path disloc-wrist joint ✕ ✕ ✓ ✕ S3005 Cl # prx fem,sbcp,Gdn grd unsp ✕ ✓ ✕ ✕ 
N082H Path disloc-1st CMC joint ✕ ✕ ✓ ✕ S3006 Cl # prx fem,sbcap,Gdn grd I ✕ ✓ ✕ ✕ 
N082J Path disloc-other CMC joint ✕ ✕ ✓ ✕ S3007 Cl # prx fem,sbcap,Gdn grd II ✕ ✓ ✕ ✕ 
N082K Path disloc-MCP joint ✕ ✕ ✓ ✕ S3008 Cl # prx fem,sbcap,Gdn grd III ✕ ✓ ✕ ✕ 
N082L Path disloc-PIP joint ✕ ✕ ✓ ✕ S3009 Cl # prx fem,sbcap,Gdn grd IV ✕ ✓ ✕ ✕ 
N082M Path disloc-DIP joint ✕ ✕ ✓ ✕ S300y Subcapital closed # femur ✕ ✓ ✕ ✕ 
N082N Neuromuscular disloc-hip ✕ ✓ ✕ ✕ S300z Cls # prox fmur,transcerv NOS ✕ ✓ ✕ ✕ 
N082P Other acquired Path disloc-hip ✕ ✓ ✕ ✕ S301 Opn # prox fmur,transcerv ✕ ✓ ✕ ✕ 
N082Q Path disloc-knee joint ✕ ✓ ✕ ✕ S3010 Op # prox fem,intcap sctn,unsp ✕ ✓ ✕ ✕ 
N082R Path disloc-patellofem joint ✕ ✓ ✕ ✕ S3011 Opn # prox fmur,transepiphys ✕ ✓ ✕ ✕ 
N082S Path disloc-ankle joint ✕ ✓ ✕ ✕ S3012 Opn # prox femur,midcerv sctn ✕ ✓ ✕ ✕ 
N082T Path disloc-subtalar joint ✕ ✓ ✕ ✕ S3013 Opn # prox femur, basicervical ✕ ✓ ✕ ✕ 
N082U Path disloc-midtarsal joint ✕ ✓ ✕ ✕ S3014 Open fracture head, femur ✕ ✓ ✕ ✕ 
N082V Path disloc-TMT joint ✕ ✓ ✕ ✕ S3015 Op # prx fem subcap,Gdn gd uns ✕ ✓ ✕ ✕ 
N082W Path disloc-1st MTP joint ✕ ✓ ✕ ✕ S3016 Op # prx fem,subcap,Gdn grd I ✕ ✓ ✕ ✕ 
N082X Path disloc-lesser MTP joint ✕ ✓ ✕ ✕ S3017 Op # prx fem,subcap,Gdn grd II ✕ ✓ ✕ ✕ 
N082Y Path disloc-toe IP joint ✕ ✓ ✕ ✕ S3018 Op # prx fem,subcp,Gdn grd III ✕ ✓ ✕ ✕ 
N083 Redislocation of joint ✕ ✕ ✕ ✕ S3019 Op # prx fem,subcap,Gdn grd IV ✕ ✓ ✕ ✕ 
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N0830 Recurr.joint disloc.-site unsp ✕ ✕ ✕ ✕ S301y Subcapital open # femur ✕ ✓ ✕ ✕ 
N0831 Recurr.joint disloc.-shoulder ✕ ✕ ✓ ✕ S301z Opn # prox femur,transcerv NOS ✕ ✓ ✕ ✕ 
N0832 Recurr.joint disloc.-upper arm ✕ ✕ ✓ ✕ S302 Cls # prox femur,pertrochntrc ✕ ✓ ✕ ✕ 
N0833 Wrist - recurrent dislocation ✕ ✕ ✓ ✕ S3020 Closed #femur-lesser troch. ✕ ✓ ✕ ✕ 
N0834 Recurr.joint disloc.-hand ✕ ✕ ✓ ✕ S3021 Cl # prx fem-intrtrchntrc-2 pt ✕ ✓ ✕ ✕ 
N0835 Recurr.joint disloc-pelv/thigh ✕ ✓ ✕ ✕ S3022 Cls # prox fmur-subtrchntrc ✕ ✓ ✕ ✕ 
N0836 Patella-recurrent dislocation ✕ ✓ ✕ ✕ S3023 Cl # prx fem-intertroch-commin ✕ ✓ ✕ ✕ 
N0837 Recurr.joint disloc-ankle/foot ✕ ✓ ✕ ✕ S3024 Closed # femur intertrochant ✕ ✓ ✕ ✕ 
N083a Carpal instability, V.I.S.I. ✕ ✕ ✓ ✕ S302z Cl # prx fem-prtrchntr sct NOS ✕ ✓ ✕ ✕ 
N083A Recurrent disloc shoulder-ant ✕ ✕ ✓ ✕ S303 Op # prox fem,pertrochanteric ✕ ✓ ✕ ✕ 
N083b Carpal instab, ulnar transloc ✕ ✕ ✓ ✕ S3030 Open #femur-lesser trochanter ✕ ✓ ✕ ✕ 
N083B Recurrent disloc shoulder-post ✕ ✕ ✓ ✕ S3031 Op # prx fem,intrtrchntr,2 prt ✕ ✓ ✕ ✕ 
N083c Carpal instab, dorsal sublux ✕ ✕ ✓ ✕ S3032 Opn # prox fmur-subtrochntrc ✕ ✓ ✕ ✕ 
N083C 
N083d Recurrent sublux shoulder-ant Carpal instability, other 
✕ 
✕ ✕ ✕ ✓ ✓ ✕ ✕ S3033 S3034 Op # prx fem,intrtrchnt,cmmntd Open # femur, intertrochant 
✕ 
✕ ✓ ✓ ✕ ✕ ✕ ✕ 
N083D Recurrent sublux shoulder-post ✕ ✕ ✓ ✕ S303z Opn # prox fmur-prtrchntrc NOS ✕ ✓ ✕ ✕ 
N083e Recurrent disloc - CMC joint ✕ ✕ ✓ ✕ S304 Pertrochanteric fracture ✕ ✓ ✕ ✕ 
N083E Recurrent disloc shoulder-inf ✕ ✕ ✓ ✕ S305 Subtrochanteric fracture ✕ ✓ ✕ ✕ 
N083f Recurrent sublux - CMC joint ✕ ✕ ✓ ✕ S30w Cls # unsp proximal femur ✕ ✓ ✕ ✕ 
N083F Recurrent sublux shoulder-inf ✕ ✕ ✓ ✕ S30x Opn # unsp proximal femur ✕ ✓ ✕ ✕ 
N083g Recurrent disloc - MCP joint ✕ ✕ ✓ ✕ S30y Hip fracture NOS ✕ ✓ ✕ ✕ 
N083G Recurrent disloc shoulder-ant ✕ ✕ ✓ ✕ S30z Open #neck of femur NOS ✕ ✓ ✕ ✕ 
N083h Recurrent sublux - MCP joint ✕ ✕ ✓ ✕ S31 Other #femur ✕ ✓ ✕ ✕ 
N083H Recurrent sublux shoulder-ant ✕ ✕ ✓ ✕ S310 Closed #femur-shaft/unspecif. ✕ ✓ ✕ ✕ 
N083j Recurrent disloc - IP joint ✕ ✕ ✓ ✕ S3100 Upper leg fracture NOS ✕ ✓ ✕ ✕ 
N083J Recur disloc shoulder-multidir ✕ ✕ ✓ ✕ S3101 Closed fracture shaft of femur ✕ ✓ ✕ ✕ 
N083k Recurrent sublux - IP joint ✕ ✕ ✓ ✕ S310z Closed #femur-shaft/unsp.NOS ✕ ✓ ✕ ✕ 
N083K Recur sublux shoulder-multidir ✕ ✕ ✓ ✕ S311 Open #femur-shaft/unspecified ✕ ✓ ✕ ✕ 
N083l Recurrent disloc - hip ✕ ✓ ✕ ✕ S3110 Open #femur-unspecified ✕ ✓ ✕ ✕ 
N083L Habitual disloc shoulder ✕ ✕ ✓ ✕ S3111 Open fracture shaft of femur ✕ ✓ ✕ ✕ 
N083m Recurr disloc - other pelvis ✕ ✓ ✕ ✕ S311z Open #femur-shaft/unspecif.NOS ✕ ✓ ✕ ✕ 
N083M Habitual sublux shoulder ✕ ✕ ✓ ✕ S312 Closed fracture distal femur ✕ ✓ ✕ ✕ 
N083n Recurrent disloc - knee ✕ ✓ ✕ ✕ S3120 Cls # distal femur, unsp ✕ ✓ ✕ ✕ 
N083N Recurrent dislocation of elbow ✕ ✕ ✓ ✕ S3121 Cls # femoral condyle unsp ✕ ✓ ✕ ✕ 
N083p Recurrent disloc - patella ✕ ✓ ✕ ✕ S3122 Closed #femur-lower epiphysis ✕ ✓ ✕ ✕ 
N083P Recurrent subluxation of elbow ✕ ✕ ✓ ✕ S3123 Cls # dist femur supracndyar ✕ ✓ ✕ ✕ 
N083q Recurrent sublux - patella ✕ ✓ ✕ ✕ S3124 Cls # dist femur,mdial condyle ✕ ✓ ✕ ✕ 
N083Q Recurr disloc, sup rad-uln jt ✕ ✕ ✓ ✕ S3125 Cls # dist femur,latrl condyle ✕ ✓ ✕ ✕ 
N083r Habitual disloc - patella ✕ ✓ ✕ ✕ S3126 Cls # dist fmur,bicndylr(T-Y#) ✕ ✓ ✕ ✕ 
N083R Recurr sublux, sup rad-uln jt ✕ ✕ ✓ ✕ S312x Cls # dist fem,cmmntd/intr-art ✕ ✓ ✕ ✕ 
N083s Recurrent disloc - ankle ✕ ✓ ✕ ✕ S312z Cls # dist femur NOS ✕ ✓ ✕ ✕ 
N083S Recurrent disloc-radial head ✕ ✕ ✓ ✕ S313 Open fracture distal femur ✕ ✓ ✕ ✕ 
N083t Recurrent sublux - ankle ✕ ✓ ✕ ✕ S3130 Opn # distal femur, unspec ✕ ✓ ✕ ✕ 
N083T Recurrent sublux-radial head ✕ ✕ ✓ ✕ S3131 Opn # femoral condyle, unspec ✕ ✓ ✕ ✕ 
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N083u Recurrent disloc - foot joint ✕ ✓ ✕ ✕ S3132 Open #femur-lower epiphysis ✕ ✓ ✕ ✕ 
N083U Recurr disloc, inf rad-uln jt ✕ ✕ ✓ ✕ S3133 Opn # dist femur,supracndylr ✕ ✓ ✕ ✕ 
N083v Recurrent sublux-subtal joint ✕ ✓ ✕ ✕ S3134 Opn # dist femur,mdial condyle ✕ ✓ ✕ ✕ 
N083V Recurr sublux, inf rad-uln jt ✕ ✕ ✓ ✕ S3135 Opn # dist femur,latrl condyle ✕ ✓ ✕ ✕ 
N083w Recurrent sublux-oth foot jt ✕ ✓ ✕ ✕ S3136 Opn # dist fem, bicondyl(T-Y#) ✕ ✓ ✕ ✕ 
N083W Recurrent dislocation of wrist ✕ ✕ ✓ ✕ S313x Op # dist fem,commntd/intr-art ✕ ✓ ✕ ✕ 
N083x Recurrent subluxation hip ✕ ✓ ✕ ✕ S313z Opn # of distal femur NOS ✕ ✓ ✕ ✕ 
N083X Carpal instability ✕ ✕ ✓ ✕ S314 Fracture of shaft of femur ✕ ✓ ✕ ✕ 
N083Y Recurrent subluxation of wrist ✕ ✕ ✓ ✕ S315 Fracture of lower end of femur ✕ ✓ ✕ ✕ 
N083Z Carpal instability, D.I.S.I. ✕ ✕ ✓ ✕ S31z #Femur NOS ✕ ✓ ✕ ✕ 
N084 Contracture of joint ✕ ✕ ✕ ✕ S32 #Patella ✕ ✓ ✕ ✕ 
N0840 Joint contracture-site unspec ✕ ✕ ✕ ✕ S320 Closed fracture of the patella ✕ ✓ ✕ ✕ 
N0841 Joint contracture-shoulder ✕ ✕ ✓ ✕ S3200 Closed # patella transverse ✕ ✓ ✕ ✕ 
N0842 Joint contracture-upper arm ✕ ✕ ✓ ✕ S3201 Closed # patella,proximal pole ✕ ✓ ✕ ✕ 
N0843 
N0844 Wrist joint contracture Joint contracture-hand ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✕ S3202 S3203 Closed # patella, distal pole Closed # patella, vertical ✕ ✕ ✓ ✓ ✕ ✕ ✕ ✕ 
N0845 Joint contracture-pelvic/thigh ✕ ✓ ✕ ✕ S3204 Cls # patella, stellate ✕ ✓ ✕ ✕ 
N0846 Knee joint contracture ✕ ✓ ✕ ✕ S321 Open fracture of the patella ✕ ✓ ✕ ✕ 
N0847 Joint contracture-ankle/foot ✕ ✓ ✕ ✕ S3210 Open # patella, transverse ✕ ✓ ✕ ✕ 
N084a Flexion contracture-knee ✕ ✓ ✕ ✕ S3211 Open # patella, proximal pole ✕ ✓ ✕ ✕ 
N084A Flexion contracture-shoulder ✕ ✕ ✓ ✕ S3212 Open # patella, distal pole ✕ ✓ ✕ ✕ 
N084b Equinus contracture of the ankle ✕ ✓ ✕ ✕ S3213 Open # patella, vertical ✕ ✓ ✕ ✕ 
N084B Extension contracture-shoulder ✕ ✕ ✓ ✕ S3214 Open # patella, stellate ✕ ✓ ✕ ✕ 
N084c Calcaneus contracture-ankle ✕ ✓ ✕ ✕ S32z #Patella NOS ✕ ✓ ✕ ✕ 
N084C Abduction contracture-shoulder ✕ ✕ ✓ ✕ S33 #Tibia and fibula ✕ ✓ ✕ ✕ 
N084d Flexion contracture of MTPJ ✕ ✓ ✕ ✕ S330 Cls # tibia + fibula, proximal ✕ ✓ ✕ ✕ 
N084D Adduction contracture-shoulder ✕ ✕ ✓ ✕ S3300 Tibial tuberosity closed # ✕ ✓ ✕ ✕ 
N084e Extension contracture of MTPJ ✕ ✓ ✕ ✕ S3301 Closed # proximal fibula ✕ ✓ ✕ ✕ 
N084E Int rotat contracture-shoulder ✕ ✕ ✓ ✕ S3302 Cls # tibia + fibula, proximal ✕ ✓ ✕ ✕ 
N084f Flexion contracture of toe IPJ ✕ ✓ ✕ ✕ S3303 Cl # prx tib,med cndyle(plat) ✕ ✓ ✕ ✕ 
N084F Ext rotat contracture-shoulder ✕ ✕ ✓ ✕ S3304 Cl # prx tib,ltrl cndyle(plat) ✕ ✓ ✕ ✕ 
N084g Exten contracture of toe IPJ ✕ ✓ ✕ ✕ S3305 Cls # prox tibia, bicondylar ✕ ✓ ✕ ✕ 
N084G Flexion contracture - elbow ✕ ✕ ✓ ✕ S3306 Closed fracture spine, tibia ✕ ✓ ✕ ✕ 
N084H Extension contracture - elbow ✕ ✕ ✓ ✕ S3307 Closed # tubercle, tibia ✕ ✓ ✕ ✕ 
N084J Pronation contracture-forearm ✕ ✕ ✓ ✕ S3308 Closed fracture fibula, head ✕ ✓ ✕ ✕ 
N084K Supination contracture-forearm ✕ ✕ ✓ ✕ S3309 Closed fracture fibula, neck ✕ ✓ ✕ ✕ 
N084L Flexion contracture - wrist ✕ ✕ ✓ ✕ S330z Cls # tibia + fibula, prox NOS ✕ ✓ ✕ ✕ 
N084M Extension contracture- wrist ✕ ✕ ✓ ✕ S331 Opn # tibia + fibula, proximal ✕ ✓ ✕ ✕ 
N084N Uln deviat contracture-wrist ✕ ✕ ✓ ✕ S3310 Tibial tuberosity open # ✕ ✓ ✕ ✕ 
N084P Rad deviat contracture-wrist ✕ ✕ ✓ ✕ S3311 Open fracture proximal fibula ✕ ✓ ✕ ✕ 
N084Q Flexion contracture of MCPJ ✕ ✕ ✓ ✕ S3312 Opn # tibia + fibula, proximal ✕ ✓ ✕ ✕ 
N084R Extension contracture of MCPJ ✕ ✕ ✓ ✕ S3313 Op # prox tib,med cndyle(plat) ✕ ✓ ✕ ✕ 
N084S Flexion contracture of PIPJ ✕ ✕ ✓ ✕ S3314 Opn # prox tibia,ltrl condyle ✕ ✓ ✕ ✕ 
N084T Flexion contracture of DIPJ ✕ ✕ ✓ ✕ S3315 Open # prox tibia, bicondylar ✕ ✓ ✕ ✕ 
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N084U Flexion contracture of hip ✕ ✓ ✕ ✕ S3316 Open fracture spine, tibia ✕ ✓ ✕ ✕ 
N084V Extension contracture of hip ✕ ✓ ✕ ✕ S3317 Open fracture tubercle, tibia ✕ ✓ ✕ ✕ 
N084W Abduction contracture of hip ✕ ✓ ✕ ✕ S3318 Open fracture fibula, head ✕ ✓ ✕ ✕ 
N084X Adduction contracture of hip ✕ ✓ ✕ ✕ S3319 Open fracture fibula, neck ✕ ✓ ✕ ✕ 
N084Y Int rotation contracture-hip ✕ ✓ ✕ ✕ S331z Opn # tibia + fibula, prox NOS ✕ ✓ ✕ ✕ 
N084Z Ext rotation contracture-hip ✕ ✓ ✕ ✕ S332 Closed # tibia/fibula shaft ✕ ✓ ✕ ✕ 
N085 Ankylosis of joint ✕ ✕ ✕ ✕ S3320 Closed fracture shaft of tibia ✕ ✓ ✕ ✕ 
N0850 Joint ankylosis-site unspecif. ✕ ✕ ✕ ✕ S3321 Closed # shaft of fibula ✕ ✓ ✕ ✕ 
N0851 Joint ankylosis-shoulder ✕ ✕ ✓ ✕ S3322 Cls # tibia and fibula shaft ✕ ✓ ✕ ✕ 
N0852 Joint ankylosis-upper arm ✕ ✕ ✓ ✕ S332z Closed #tibia/fibula-shaft,NOS ✕ ✓ ✕ ✕ 
N0853 Wrist joint ankylosis ✕ ✕ ✓ ✕ S333 Open # of tibia/fibula, shaft ✕ ✓ ✕ ✕ 
N0854 Joint ankylosis-hand ✕ ✕ ✓ ✕ S3330 Open fracture shaft of tibia ✕ ✓ ✕ ✕ 
N0855 Joint ankylosis-pelvic/thigh ✕ ✓ ✕ ✕ S3331 Open fracture shaft of fibula ✕ ✓ ✕ ✕ 
N0856 Knee joint ankylosis ✕ ✓ ✕ ✕ S3332 Open # tibia and fibula, shaft ✕ ✓ ✕ ✕ 
N0857 Joint ankylosis-ankle/foot ✕ ✓ ✕ ✕ S333z Open #tibia/fibula-shaft,NOS ✕ ✓ ✕ ✕ 
N085A 
N085B Ankylosis of shoulder joint Ankylosis other joint-shoulder ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✕ S334 S3340 Closed fracture distal tibia Cls # dist tibia, extra-art ✕ ✕ ✓ ✓ ✕ ✕ ✕ ✕ 
N085C Ankylosis of the elbow joint ✕ ✕ ✓ ✕ S3341 Cls # distal tibia, intra-art ✕ ✓ ✕ ✕ 
N085D Ankylosis of superior RUJ ✕ ✕ ✓ ✕ S335 Open fracture distal tibia ✕ ✓ ✕ ✕ 
N085E Ankylosis of inferior RUJ ✕ ✕ ✓ ✕ S3350 Opn # dist tibia, extra-art ✕ ✓ ✕ ✕ 
N085F Ankylosis of the wrist joint ✕ ✕ ✓ ✕ S3351 Opn # dist tibia, intra-art ✕ ✓ ✕ ✕ 
N085G Ankylosis of the 1st CMC joint ✕ ✕ ✓ ✕ S336 Fracture of upper end of tibia ✕ ✓ ✕ ✕ 
N085H Ankylosis of other CMC joint ✕ ✕ ✓ ✕ S337 Fracture of shaft of tibia ✕ ✓ ✕ ✕ 
N085J Ankylosis of MCP joint ✕ ✕ ✓ ✕ S338 Fracture of lower end of tibia ✕ ✓ ✕ ✕ 
N085K Ankylosis of PIP joint ✕ ✕ ✓ ✕ S339 Fracture of fibula alone ✕ ✓ ✕ ✕ 
N085L Ankylosis of DIP joint ✕ ✕ ✓ ✕ S3390 Closed fracture distal fibula ✕ ✓ ✕ ✕ 
N085M Ankylosis of the hip joint ✕ ✓ ✕ ✕ S3391 Open fracture of distal fibula ✕ ✓ ✕ ✕ 
N085N Ankylosis of other pelv joint ✕ ✓ ✕ ✕ S33x Lower leg fracture NOS ✕ ✓ ✕ ✕ 
N085P Ankylosis of the knee joint ✕ ✓ ✕ ✕ S33x0 Closed #tibia-unspecified NOS ✕ ✓ ✕ ✕ 
N085Q Ankylosis of the ankle joint ✕ ✓ ✕ ✕ S33x1 Closed #fibula-unspecified NOS ✕ ✓ ✕ ✕ 
N085R Ankylosis of subtalar joint ✕ ✓ ✕ ✕ S33x2 Cls # of tib + fib, unsp part ✕ ✓ ✕ ✕ 
N085S Ankylosis - other tarsal joint ✕ ✓ ✕ ✕ S33xz Closed #tibia/fibula-unsp.NOS ✕ ✓ ✕ ✕ 
N085T Ankylosis of MTP joint ✕ ✓ ✕ ✕ S33y Open #tibia/fibula-unspec.NOS ✕ ✓ ✕ ✕ 
N085U Ankylosis of toe joint ✕ ✓ ✕ ✕ S33y0 Open #tibia-unspecified NOS ✕ ✓ ✕ ✕ 
N086 Unsp.intrapelv.protr.acetabul. ✕ ✓ ✕ ✕ S33y1 Open #fibula-unspecified NOS ✕ ✓ ✕ ✕ 
N0860 Protrusio acetabuli ✕ ✓ ✕ ✕ S33y2 Opn # of tib + fib, unsp part ✕ ✓ ✕ ✕ 
N0861 Protrus.acetabuli-pelvic/thigh ✕ ✓ ✕ ✕ S33yz Open #tibia/fibula-unspec.NOS ✕ ✓ ✕ ✕ 
N086z Protrusio acetabuli NOS ✕ ✓ ✕ ✕ S33z #Tibia/fibula NOS ✕ ✓ ✕ ✕ 
N087 Fibrocartilage lesion of joint ✕ ✕ ✕ ✕ S34 #Ankle ✕ ✓ ✕ ✕ 
N0870 Bankart lesion ✕ ✕ ✓ ✕ S340 Cls # ankle medial malleolus ✕ ✓ ✕ ✕ 
N0871 Reverse Bankart lesion ✕ ✕ ✓ ✕ S341 Opn # ankle, medial malleolus ✕ ✓ ✕ ✕ 
N0872 Glenoid labrum detachment ✕ ✕ ✓ ✕ S342 Cls # ankle lateral malleolus ✕ ✓ ✕ ✕ 
N0873 Glenoid labrum tear ✕ ✕ ✓ ✕ S3420 Cls # ankle,ltrl malleolus-low ✕ ✓ ✕ ✕ 
N0874 Triangular fibrocartilage tear ✕ ✕ ✓ ✕ S3421 Cls # ankle,ltrl malleolus,hgh ✕ ✓ ✕ ✕ 
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N0875 Triangular fibrocartil detach ✕ ✕ ✓ ✕ S343 Opn # ankle, lateral malleolus ✕ ✓ ✕ ✕ 
N0876 Acetabular labrum detachment ✕ ✓ ✕ ✕ S3430 Opn # ankle,ltrl malleolus-low ✕ ✓ ✕ ✕ 
N0877 Acetabular labrum tear ✕ ✓ ✕ ✕ S3431 Opn # ankle,ltrl malleolus-hgh ✕ ✓ ✕ ✕ 
N0878 Snapping shoulder ✕ ✕ ✓ ✕ S344 Closed fracture ankle bimalleolar ✕ ✓ ✕ ✕ 
N08y0 Oth.joint deran.NEC-site unsp. ✕ ✕ ✕ ✕ S3440 Cls # ankle,bimall,low fib # ✕ ✓ ✕ ✕ 
N08y1 Oth.joint deran.NEC-shoulder ✕ ✕ ✓ ✕ S3441 Cls # ankle,bimall,hgh fib # ✕ ✓ ✕ ✕ 
N08y2 Oth.joint deran.NEC-upper arm ✕ ✕ ✓ ✕ S345 Opn # ankle, bimalleolar ✕ ✓ ✕ ✕ 
N08y3 Oth.joint deran.NEC-forearm ✕ ✕ ✓ ✕ S3450 Opn # ankle,bimall,low fib # ✕ ✓ ✕ ✕ 
N08y4 Oth.joint deran.NEC-hand ✕ ✕ ✓ ✕ S3451 Opn # ankle,bimall,hgh fib # ✕ ✓ ✕ ✕ 
N08y5 Oth.joint deran.NEC-pelv/thigh ✕ ✓ ✕ ✕ S346 Cls # ankle trimalleolar ✕ ✓ ✕ ✕ 
N08y6 Oth.joint deran.NEC-lower leg ✕ ✓ ✕ ✕ S3460 Cls # ankle,trimall,low fib # ✕ ✓ ✕ ✕ 
N08y7 Oth.joint deran.NEC-ankle/foot ✕ ✓ ✕ ✕ S3461 Cls # ankle,trimall,hgh fib # ✕ ✓ ✕ ✕ 
N08yA Flail joint ✕ ✕ ✕ ✕ S347 Open fracture ankle trimalleolar ✕ ✓ ✕ ✕ 
N08z0 Joint derange.NOS-site unspec. ✕ ✕ ✕ ✕ S3470 Opn # ankle,trimall,low fib # ✕ ✓ ✕ ✕ 
N08z1 Joint derange.NOS-shoulder ✕ ✕ ✓ ✕ S3471 Opn # ankle,trimall,hgh fib # ✕ ✓ ✕ ✕ 
N08z2 Joint derange.NOS-upper arm ✕ ✕ ✓ ✕ S348 Fracture of medial malleolus ✕ ✓ ✕ ✕ 
N08z3 
N08z4 Joint derange.NOS-forearm Joint derange.NOS-hand ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✕ S349 S34x Fracture of lateral malleolus Closed fracture ankle unspecified ✕ ✕ ✓ ✓ ✕ ✕ ✕ ✕ 
N08z5 Joint derange.NOS-pelvic/thigh ✕ ✓ ✕ ✕ S34y Open fracture ankle unspecified ✕ ✓ ✕ ✕ 
N08z6 Joint derange.NOS-ankle/foot ✕ ✓ ✕ ✕ S34z #Ankle NOS ✕ ✓ ✕ ✕ 
N090 Swelling of joint - effusion ✕ ✕ ✕ ✕ S35 Metatarsal bone fracture ✕ ✓ ✕ ✕ 
N0900 Joint effusion-site unspecif. ✕ ✕ ✕ ✕ S350 Closed #calcaneus ✕ ✓ ✕ ✕ 
N0901 Joint effusion-shoulder region ✕ ✕ ✓ ✕ S3500 Cls # calcaneus, extra-art ✕ ✓ ✕ ✕ 
N0902 Joint effusion-upper arm ✕ ✕ ✓ ✕ S3501 Cls # calcaneus, intra-art ✕ ✓ ✕ ✕ 
N0903 Joint effusion of the forearm ✕ ✕ ✓ ✕ S351 Open #calcaneus ✕ ✓ ✕ ✕ 
N0904 Joint effusion of the hand ✕ ✕ ✓ ✕ S3510 Opn #s calcaneus, extra-art ✕ ✓ ✕ ✕ 
N0905 Joint effusion-pelvic/thigh ✕ ✓ ✕ ✕ S3511 Opn #s calcaneus, intra-art ✕ ✓ ✕ ✕ 
N0906 Knee joint effusion ✕ ✓ ✕ ✕ S352 March fracture ✕ ✓ ✕ ✕ 
N0907 Joint effusion-ankle/foot ✕ ✓ ✕ ✕ S3520 Closed #tarsal bone unspecif. ✕ ✓ ✕ ✕ 
N090A Effusion of shoulder ✕ ✕ ✓ ✕ S3521 Closed fracture of astragalus ✕ ✓ ✕ ✕ 
N090B Effusion of sternoclav joint ✕ ✕ ✓ ✕ S3522 Closed fracture navicular ✕ ✓ ✕ ✕ 
N090C Effusion of acromioclav joint ✕ ✕ ✓ ✕ S3523 Closed fracture cuboid ✕ ✓ ✕ ✕ 
N090D Effusion of elbow ✕ ✕ ✓ ✕ S3524 Closed # medial cuneiform ✕ ✓ ✕ ✕ 
N090E Effusion of distal RUJ ✕ ✕ ✓ ✕ S3525 Cls # intermediate cuneiform ✕ ✓ ✕ ✕ 
N090F Effusion of wrist ✕ ✕ ✓ ✕ S3526 Cls # lateral cuneiform ✕ ✓ ✕ ✕ 
N090G Effusion of MCP joint ✕ ✕ ✓ ✕ S3527 Closed fracture metatarsal ✕ ✓ ✕ ✕ 
N090H Effusion of PIP joint - finger ✕ ✕ ✓ ✕ S3528 Closed fracture talus, head ✕ ✓ ✕ ✕ 
N090J Effusion of DIP joint - finger ✕ ✕ ✓ ✕ S3529 Closed fracture talus, neck ✕ ✓ ✕ ✕ 
N090K Effusion of hip ✕ ✓ ✕ ✕ S352A Closed fracture talus, body ✕ ✓ ✕ ✕ 
N090L Effusion of sacro-iliac joint ✓ ✕ ✕ ✕ S352B Closed # metatarsal base ✕ ✓ ✕ ✕ 
N090M Effusion of knee ✕ ✓ ✕ ✕ S352C Closed # metatarsal shaft ✕ ✓ ✕ ✕ 
N090N Effusion, tibio-fibular joint ✕ ✓ ✕ ✕ S352D Closed # metatarsal neck ✕ ✓ ✕ ✕ 
N090P Effusion of ankle ✕ ✓ ✕ ✕ S352E Closed # metatarsal head ✕ ✓ ✕ ✕ 
N090Q Effusion of subtalar joint ✕ ✓ ✕ ✕ S352F Closed # metatarsal, multiple ✕ ✓ ✕ ✕ 
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N090R Effusion, talonavicular joint ✕ ✓ ✕ ✕ S352G Closed tarsal #s, multiple ✕ ✓ ✕ ✕ 
N090S Effusion of other tarsal joint ✕ ✓ ✕ ✕ S352H Closed fracture of cuneiforms ✕ ✓ ✕ ✕ 
N090T Effusion of 1st MTP joint ✕ ✓ ✕ ✕ S352z Closed #tarsal/metatarsal NOS ✕ ✓ ✕ ✕ 
N090U Effusion of lesser MTP joint ✕ ✓ ✕ ✕ S353 Open #other tarsal/metatarsal ✕ ✓ ✕ ✕ 
N090V Effusion of IP joint of toe ✕ ✓ ✕ ✕ S3530 Open #tarsal bone unspecified ✕ ✓ ✕ ✕ 
N090X Chronic joint effusion ✕ ✕ ✕ ✕ S3531 Open fracture of astragalus ✕ ✓ ✕ ✕ 
N090Y Acute joint effusion ✕ ✕ ✕ ✕ S3532 Open fracture navicular ✕ ✓ ✕ ✕ 
N090z Effusion of joint NOS ✕ ✕ ✕ ✕ S3533 Open fracture cuboid ✕ ✓ ✕ ✕ 
N0910 Haemarthrosis-site unspecified ✕ ✕ ✕ ✕ S3534 Open fracture medial cuneiform ✕ ✓ ✕ ✕ 
N0911 Haemarthrosis-shoulder ✕ ✕ ✓ ✕ S3535 Open # intermediate cuneiform ✕ ✓ ✕ ✕ 
N0912 Haemarthrosis-upper arm ✕ ✕ ✓ ✕ S3536 Open # lateral cuneiform ✕ ✓ ✕ ✕ 
N0913 Wrist haemarthrosis ✕ ✕ ✓ ✕ S3537 Open fracture metatarsal ✕ ✓ ✕ ✕ 
N0914 Haemarthrosis-hand ✕ ✕ ✓ ✕ S3538 Open fracture talus, head ✕ ✓ ✕ ✕ 
N0915 Hip haemarthrosis ✕ ✓ ✕ ✕ S3539 Open fracture talus, neck ✕ ✓ ✕ ✕ 
N0916 Haemarthrosis of the knee ✕ ✓ ✕ ✕ S353A Open fracture talus, body ✕ ✓ ✕ ✕ 
N0917 Haemarthrosis of the ankle ✕ ✓ ✕ ✕ S353B Open fracture metatarsal base ✕ ✓ ✕ ✕ 
N091A Haemarthrosis of shoulder ✕ ✕ ✓ ✕ S353C Open fracture metatarsal shaft ✕ ✓ ✕ ✕ 
N091B 
N091C Haemarthrosis-sternoclav joint Haemarthrosis-acromioclav jt 
✕ 
✕ ✕ ✕ ✓ ✓ ✕ ✕ S353D S353E Open fracture metatarsal neck Open fracture metatarsal head 
✕ 
✕ ✓ ✓ ✕ ✕ ✕ ✕ 
N091D Haemarthrosis of elbow ✕ ✕ ✓ ✕ S353F Open # metatarsal, multiple ✕ ✓ ✕ ✕ 
N091E Haemarthrosis of distal RUJ ✕ ✕ ✓ ✕ S353G Open tarsal #s, multiple ✕ ✓ ✕ ✕ 
N091F Haemarthrosis of wrist ✕ ✕ ✓ ✕ S353H Open fracture cuneiforms ✕ ✓ ✕ ✕ 
N091G Haemarthrosis of MCP joint ✕ ✕ ✓ ✕ S353z Open #tarsal/metatarsal NOS ✕ ✓ ✕ ✕ 
N091H Haemarthrosis, PIPJ-finger ✕ ✕ ✓ ✕ S354 Fracture of calcaneus ✕ ✓ ✕ ✕ 
N091J Haemarthrosis, DIPJ-finger ✕ ✕ ✓ ✕ S355 Fracture of talus ✕ ✓ ✕ ✕ 
N091K Haemarthrosis of hip ✕ ✓ ✕ ✕ S356 Fracture of metatarsal bone ✕ ✓ ✕ ✕ 
N091L Haemarthrosis of SIJ ✓ ✕ ✕ ✕ S35z #Tarsal/metatarsal bones NOS ✕ ✓ ✕ ✕ 
N091M Haemarthrosis of knee ✕ ✓ ✕ ✕ S36 #Phalanges of foot ✕ ✓ ✕ ✕ 
N091N Haemarthrosis of tib-fib joint ✕ ✓ ✕ ✕ S360 Closed #phalanges of foot ✕ ✓ ✕ ✕ 
N091P Haemarthrosis of ankle ✕ ✓ ✕ ✕ S3600 Cls # proximal phalanx, toe ✕ ✓ ✕ ✕ 
N091Q Haemarthrosis - subtalar joint ✕ ✓ ✕ ✕ S3601 Cls # middle phalanx, toe ✕ ✓ ✕ ✕ 
N091R Haemarthrosis - talonav joint ✕ ✓ ✕ ✕ S3602 Cls # distal phalanx, toe ✕ ✓ ✕ ✕ 
N091S Haemarthrosis-oth tarsal joint ✕ ✓ ✕ ✕ S3603 Cls # multiple phalanges, toe ✕ ✓ ✕ ✕ 
N091T Haemarthrosis-1st MTPJ ✕ ✓ ✕ ✕ S361 Open #phalanges of foot ✕ ✓ ✕ ✕ 
N091U Haemarthrosis of les MTP joint ✕ ✓ ✕ ✕ S3610 Open # proximal phalanx, toe ✕ ✓ ✕ ✕ 
N091V Haemarthrosis of IP joint-toe ✕ ✓ ✕ ✕ S3611 Open # middle phalanx, toe ✕ ✓ ✕ ✕ 
N0920 Villonod.synovitis-site unspec ✕ ✕ ✕ ✕ S3612 Open # distal phalanx, toe ✕ ✓ ✕ ✕ 
N0921 Villonod.synovitis-shoulder ✕ ✕ ✓ ✕ S3613 Open # multiple phalanges, toe ✕ ✓ ✕ ✕ 
N0922 Villonod.synovitis-upper arm ✕ ✕ ✓ ✕ S362 Fracture of great toe ✕ ✓ ✕ ✕ 
N0923 Villonod.synovitis-forearm ✕ ✕ ✓ ✕ S3620 Closed fracture of great toe ✕ ✓ ✕ ✕ 
N0924 Villonod.synovitis-hand ✕ ✕ ✓ ✕ S3621 Open fracture of great toe ✕ ✓ ✕ ✕ 
N0925 Villonod.synovitis-pelv./thigh ✕ ✓ ✕ ✕ S363 Fracture of other toe ✕ ✓ ✕ ✕ 
N0926 Villonod.synovitis-lower leg ✕ ✓ ✕ ✕ S36z #Phalanges of foot NOS ✕ ✓ ✕ ✕ 
N0927 Villonod.synovitis-ankle/foot ✕ ✓ ✕ ✕ S37 Fractur/lower limb,levl unspec ✕ ✓ ✕ ✕ 
 A54 
Read 
Code 
Read Term Axial Lower 
Limb 
Upper 
Limb 
Clinician 
Defined 
Read 
Code 
Read Term Axial Lower 
Limb 
Upper 
Limb 
Clinician 
Defined 
N092A Villonod synovitis-shoulder ✕ ✕ ✓ ✕ S370 Closed frac/lower limb,lev uns ✕ ✓ ✕ ✕ 
N092B Villonod synovitis-sternclav j ✕ ✕ ✓ ✕ S371 Open frac/lower limb,lev uns ✕ ✓ ✕ ✕ 
N092C Villonod synovitis-acromclav j ✕ ✕ ✓ ✕ S3x Other/multiple #lower limb ✕ ✓ ✕ ✕ 
N092D Villonodular synovitis-elbow ✕ ✕ ✓ ✕ S3X Other/multiple #lower limb ✕ ✓ ✕ ✕ 
N092E Villonod synovitis-dist RUJ ✕ ✕ ✓ ✕ S3x0 Other/mult.closed #lower limb ✕ ✓ ✕ ✕ 
N092F Villonodular synovitis - wrist ✕ ✕ ✓ ✕ S3x1 Other/mult.open #lower limb ✕ ✓ ✕ ✕ 
N092G Villonodular synovitis of MCPJ ✕ ✕ ✓ ✕ S3x2 Multiple fractures of femur ✕ ✓ ✕ ✕ 
N092H Villonod synovitis PIPJ finger ✕ ✕ ✓ ✕ S3x3 Multiple fractures/lower leg ✕ ✓ ✕ ✕ 
N092J Villonod synovitis DIPJ finger ✕ ✕ ✓ ✕ S3x4 Multiple fractures of foot ✕ ✓ ✕ ✕ 
N092K Villonodular synovitis of hip ✕ ✓ ✕ ✕ S3xz Other/mult.#lower limb NOS ✕ ✓ ✕ ✕ 
N092L Villonodular synovitis of SIJ ✓ ✕ ✕ ✕ S3yz Mult.#legs/arms/ribs/stern.NOS ✓ ✕ ✓ ✕ 
N092M Villonodular synovitis of knee ✕ ✓ ✕ ✕ S3z Fracture NOS ✕ ✕ ✕ ✕ 
N092N Villonod synovitis, tib-fib jt ✕ ✓ ✕ ✕ S3z00 Greenstick fracture ✕ ✕ ✕ ✕ 
N092P Villonod synovitis-ankle ✕ ✓ ✕ ✕ S40 Temporomandibular joint disloc ✕ ✕ ✕ ✕ 
N092Q Villonod synovitis-subtalar jt ✕ ✓ ✕ ✕ S400 Closed dislocation of jaw ✕ ✕ ✕ ✕ 
N092R Villonod synovitis-talonav jt ✕ ✓ ✕ ✕ S401 Open dislocation of jaw ✕ ✕ ✕ ✕ 
N092S Villonod synovitis-oth tars jt ✕ ✓ ✕ ✕ S402 Closed subluxation jaw ✕ ✕ ✕ ✕ 
N092T Villonod synovitis-1st MTPJ ✕ ✓ ✕ ✕ S403 Open subluxation jaw ✕ ✕ ✕ ✕ 
N092U 
N092V Villonod synovitis-lesser MTPJ Villonod synovitis, IPJ-toe 
✕ 
✕ ✓ ✓ ✕ ✕ ✕ ✕ S40z S41 Dislocation of jaw NOS Disloctn/subluxation shoulder 
✕ 
✕ ✕ ✕ ✕ ✓ ✕ ✕ 
N0930 Palindromic rheum.-site unspec ✕ ✕ ✕ ✕ S410 Cls traumtc disloctn shoulder ✕ ✕ ✓ ✕ 
N0931 Palindromic rheum.-shoulder ✕ ✕ ✓ ✕ S4100 Cls traum disloctn shouldr jnt ✕ ✕ ✓ ✕ 
N0932 Palindromic rheum.-upper arm ✕ ✕ ✓ ✕ S4101 Cl tr dis shd jt ant (sub-cor) ✕ ✕ ✓ ✕ 
N0933 Palindromic rheum.-forearm ✕ ✕ ✓ ✕ S4102 Posterior dislocation shoulder ✕ ✕ ✓ ✕ 
N0934 Palindromic rheum.-hand ✕ ✕ ✓ ✕ S4103 Inferior dislocation shoulder ✕ ✕ ✓ ✕ 
N0935 Palindromic rheum.-pelv./thigh ✕ ✓ ✕ ✕ S4104 Cls tmtc disl acromio-clav jt ✕ ✕ ✓ ✕ 
N0936 Palindromic rheum.-lower leg ✕ ✓ ✕ ✕ S4105 Cls traumatic disloctn scapula ✕ ✕ ✓ ✕ 
N0937 Palindromic rheum.-ankle/foot ✕ ✓ ✕ ✕ S410y Othr cls trmtc disloc shoulder ✕ ✕ ✓ ✕ 
N094 Ache in joint ✕ ✕ ✕ ✓ S410z Cls trmtc dislctn shoulder NOS ✕ ✕ ✓ ✕ 
N0940 Arthralgia - site unspecified ✕ ✕ ✕ ✓ S411 Opn traumtc disloctn shoulder ✕ ✕ ✓ ✕ 
N0941 Arthralgia - shoulder ✕ ✕ ✓ ✓ S4110 Opn trmtc dislctn shoulder jnt ✕ ✕ ✓ ✕ 
N0942 Elbow joint pain ✕ ✕ ✓ ✓ S4111 Op tr dis shld jt,ant(sub-cor) ✕ ✕ ✓ ✕ 
N0943 Arthralgia - forearm ✕ ✕ ✓ ✓ S4112 Opn trmtc dslctn shldr jt,post ✕ ✕ ✓ ✕ 
N0944 Arthralgia - hand ✕ ✕ ✓ ✓ S4113 Op tr ds shd jt,inf(infr-glen) ✕ ✕ ✓ ✕ 
N0945 Arthralgia - pelvic/thigh ✕ ✓ ✕ ✓ S4114 Opn trm dislc acromio-clav jt ✕ ✕ ✓ ✕ 
N0946 Arthralgia - lower leg ✕ ✓ ✕ ✓ S4115 Opn traumatic disloctn scapula ✕ ✕ ✓ ✕ 
N0947 Ankle joint pain ✕ ✓ ✕ ✓ S411y Othr opn trmtc disloctn shlder ✕ ✕ ✓ ✕ 
N094A Arthralgia of shoulder ✕ ✕ ✓ ✓ S411z Opn trmtc disloctn shouldr NOS ✕ ✕ ✓ ✕ 
N094B Arthralgia - sternoclav joint ✕ ✕ ✓ ✓ S4120 Cls trmtc subluxatn shldr jnt ✕ ✕ ✓ ✕ 
N094C Arthralgia - acromioclav joint ✕ ✕ ✓ ✓ S4121 Cls trm sublux acromio-clav jt ✕ ✕ ✓ ✕ 
N094D Arthralgia of elbow ✕ ✕ ✓ ✓ S412z Cls traumtc sublux shldr NOS ✕ ✕ ✓ ✕ 
N094E Arthralgia of distal RUJ ✕ ✕ ✓ ✓ S413 Opn traumtc subluxatn shoulder ✕ ✕ ✓ ✕ 
N094F Arthralgia of wrist ✕ ✕ ✓ ✓ S4130 Opn traumtc sublux shouldr jnt ✕ ✕ ✓ ✕ 
N094G Arthralgia of MCP joint ✕ ✕ ✓ ✓ S4131 Opn trm sublux acromio-clav jt ✕ ✕ ✓ ✕ 
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N094H Arthralgia of PIPJ of finger ✕ ✕ ✓ ✓ S413z Opn trmtc sublux shoulder NOS ✕ ✕ ✓ ✕ 
N094J Arthralgia of DIPJ of finger ✕ ✕ ✓ ✓ S41z Dislocation of shoulder NOS ✕ ✕ ✓ ✕ 
N094K Arthralgia of hip ✕ ✓ ✕ ✓ S42 Disloctn/subluxation elbow ✕ ✕ ✓ ✕ 
N094L Arthralgia of sacro-iliac joint ✓ ✕ ✕ ✓ S420 Cls traumtc disloctn elbow jnt ✕ ✕ ✓ ✕ 
N094M Arthralgia of knee ✕ ✓ ✕ ✓ S4200 Cls trmtc disloctn elbow,unsp ✕ ✕ ✓ ✕ 
N094N Arthralgia of tib-fib joint ✕ ✓ ✕ ✓ S4201 Cls trmtc dislc elbow jnt, ant ✕ ✕ ✓ ✕ 
N094P Arthralgia of ankle ✕ ✓ ✕ ✓ S4202 Cls trmtc dislc elbow jnt,post ✕ ✕ ✓ ✕ 
N094Q Arthralgia of subtalar joint ✕ ✓ ✕ ✓ S4203 Cls trmtc dislc elbow jnt,medl ✕ ✕ ✓ ✕ 
N094R Arthralgia of talonavic joint ✕ ✓ ✕ ✓ S4204 Cls trmtc dislc elbow jt,ltrl ✕ ✕ ✓ ✕ 
N094S Arthralgia of oth tarsal joint ✕ ✓ ✕ ✓ S4205 Cls trm dislc elbow jt,divrgnt ✕ ✕ ✓ ✕ 
N094T Arthralgia of 1st MTP joint ✕ ✓ ✕ ✓ S4206 Cls trm disl sup radio-ulnr jt ✕ ✕ ✓ ✕ 
N094U Arthralgia of lesser MTP joint ✕ ✓ ✕ ✓ S420y Othr cls trmtc disloctn elbow ✕ ✕ ✓ ✕ 
N094V Arthralgia of IP joint of toe ✕ ✓ ✕ ✓ S420z Cls traumtc disloctn elbow NOS ✕ ✕ ✓ ✕ 
N094W Anterior knee pain ✕ ✓ ✕ ✓ S421 Opn traumtc disloctn elbow jnt ✕ ✕ ✓ ✕ 
N0950 Stiff joint NEC-site unspecif. ✕ ✕ ✕ ✓ S4210 Opn trmtc disloctn elbow,unsp ✕ ✕ ✓ ✕ 
N0951 Stiff joint NEC-shoulder ✕ ✕ ✓ ✓ S4211 Opn trmtc dislc elbow jt,ant ✕ ✕ ✓ ✕ 
N0952 Stiff joint NEC-upper arm ✕ ✕ ✓ ✓ S4212 Opn trmtc disloc elbow jt,post ✕ ✕ ✓ ✕ 
N0953 Wrist stiff ✕ ✕ ✓ ✓ S4213 Opn trmtc dslctn elbow jt,medl ✕ ✕ ✓ ✕ 
N0954 Stiff joint NEC-hand ✕ ✕ ✓ ✓ S4214 Opn trmtc dslctn elbow jt,ltrl ✕ ✕ ✓ ✕ 
N0955 
N0956 Stiff joint NEC-pelvic/thigh Knee stiff ✕ ✕ ✓ ✓ ✕ ✕ ✓ ✓ S4215 S4216 Opn trmtc dslc elbow jt,dvrgnt Opn trmt dslc sup radio-uln jt ✕ ✕ ✕ ✕ ✓ ✓ ✕ ✕ 
N0957 Stiff joint NEC-ankle/foot ✕ ✓ ✕ ✓ S421y Othr opn trmtc disloctn elbow ✕ ✕ ✓ ✕ 
N095A Stiff shoulder NEC ✕ ✕ ✓ ✓ S421z Opn traumtc disloctn elbow NOS ✕ ✕ ✓ ✕ 
N095B Stiff sternoclavic joint NEC ✕ ✕ ✓ ✓ S422 Cls traumtc subluxation elbow ✕ ✕ ✓ ✕ 
N095C Stiff acromioclavic joint NEC ✕ ✕ ✓ ✓ S4220 Cls traumtc sublux elbow jnt ✕ ✕ ✓ ✕ 
N095D Stiff elbow NEC ✕ ✕ ✓ ✓ S4221 Cls trm sublux sup rad-uln jnt ✕ ✕ ✓ ✕ 
N095E Stiff distal rad-uln joint NEC ✕ ✕ ✓ ✓ S423 Opn traumtc sublux elbow ✕ ✕ ✓ ✕ 
N095F Stiff wrist NEC ✕ ✕ ✓ ✓ S4230 Opn traumtc sublux elbow jnt ✕ ✕ ✓ ✕ 
N095G Stiff MCP joint NEC ✕ ✕ ✓ ✓ S4231 Op trm sublux sup radio-uln jt ✕ ✕ ✓ ✕ 
N095H Stiff PIP joint of finger NEC ✕ ✕ ✓ ✓ S424 Dislocation of radial head ✕ ✕ ✓ ✕ 
N095J Stiff DIP joint of finger NEC ✕ ✕ ✓ ✓ S42z Dislocation of elbow NOS ✕ ✕ ✓ ✕ 
N095K Stiff hip NEC ✕ ✓ ✕ ✓ S43 Disloctn/subluxation wrist ✕ ✕ ✓ ✕ 
N095L Stiff sacro-iliac joint NEC ✓ ✕ ✕ ✓ S430 Cls traumtc disloctn wrist ✕ ✕ ✓ ✕ 
N095M Stiff knee NEC ✕ ✓ ✕ ✓ S4300 Dislocation of radius - distal ✕ ✕ ✓ ✕ 
N095N Stiff tibio-fibular joint NEC ✕ ✓ ✕ ✓ S4301 Radioulnar dislocation- distal ✕ ✕ ✓ ✕ 
N095P Stiff ankle NEC ✕ ✓ ✕ ✓ S4302 Cls trm dslc radiocarpal jnt ✕ ✕ ✓ ✕ 
N095Q Stiff subtalar joint NEC ✕ ✓ ✕ ✓ S4303 Cls trmtc dslct mid carpal jnt ✕ ✕ ✓ ✕ 
N095R Stiff talonavicular joint NEC ✕ ✓ ✕ ✓ S4304 Cls traumatic disloctn CMCJ ✕ ✕ ✓ ✕ 
N095S Stiff other tarsal joint NEC ✕ ✓ ✕ ✓ S4305 Cls trmtc dislct prox metacarp ✕ ✕ ✓ ✕ 
N095T Stiff 1st MTP joint NEC ✕ ✓ ✕ ✓ S4306 Cls trm disloc lunate (volar) ✕ ✕ ✓ ✕ 
N095U Stiff lesser MTP joint NEC ✕ ✓ ✕ ✓ S4307 Cls trm disl peri-lunate(dors) ✕ ✕ ✓ ✕ 
N095V Stiff IP joint of toe NEC ✕ ✓ ✕ ✓ S4308 Cls trmtc dislc othr carpal jt ✕ ✕ ✓ ✕ 
N095W Stiff finger ✕ ✕ ✓ ✓ S430y Othr cls traumtc dislctn wrist ✕ ✕ ✓ ✕ 
N0961 Other joint sympt.-shoulder ✕ ✕ ✓ ✓ S430z Cls traumtc disloctn wrist NOS ✕ ✕ ✓ ✕ 
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N0962 Other joint sympt.-upper arm ✕ ✕ ✓ ✓ S431 Opn traumtc disloctn the wrist ✕ ✕ ✓ ✕ 
N0963 Other joint sympt.-forearm ✕ ✕ ✓ ✓ S4310 Opn trmtc disloctn wrist,unsp ✕ ✕ ✓ ✕ 
N0964 Other joint sympt.-hand ✕ ✕ ✓ ✓ S4311 Opn trm disl dist radio-uln jt ✕ ✕ ✓ ✕ 
N0965 Other joint sympt.-pelv./thigh ✕ ✓ ✕ ✓ S4312 Opn trmtc dislctn radiocarp jt ✕ ✕ ✓ ✕ 
N0966 Knee gives way ✕ ✓ ✕ ✓ S4313 Opn trmtc disloct mid carp jnt ✕ ✕ ✓ ✕ 
N0967 Unstable ankle ✕ ✓ ✕ ✓ S4314 Opn traumatic disloctn CMCJ ✕ ✕ ✓ ✕ 
N096A Other symptoms - shoulder ✕ ✕ ✓ ✓ S4315 Opn trm disloct prox metacarpl ✕ ✕ ✓ ✕ 
N096B Other symptoms - sternoclav jt ✕ ✕ ✓ ✓ S4316 Opn trm disloct lunate (volar) ✕ ✕ ✓ ✕ 
N096C Other symptoms - acromioclav j ✕ ✕ ✓ ✓ S4317 Opn trm dslc peri-lunate(dors) ✕ ✕ ✓ ✕ 
N096D Other symptoms - elbow ✕ ✕ ✓ ✓ S4318 Opn trm disloc othr carpal jnt ✕ ✕ ✓ ✕ 
N096E Other symptoms - distal RUJ ✕ ✕ ✓ ✓ S431y Othr opn trmtc disloctn wrist ✕ ✕ ✓ ✕ 
N096F Other symptoms - wrist ✕ ✕ ✓ ✓ S431z Opn traumtc disloctn wrist NOS ✕ ✕ ✓ ✕ 
N096G Other symptoms - MCPJ ✕ ✕ ✓ ✓ S432 Cls traumtc subluxation wrist ✕ ✕ ✓ ✕ 
N096H Other symptoms - PIPJ, finger ✕ ✕ ✓ ✓ S4320 Cls traumtc sublux wrist,unsp ✕ ✕ ✓ ✕ 
N096J Other symptoms - DIPJ, finger ✕ ✕ ✓ ✓ S4321 Cls traumatic sublux DRUJ ✕ ✕ ✓ ✕ 
N096K Other symptoms - hip ✕ ✓ ✕ ✓ S4322 Cls trmtc sublux radiocarp jt ✕ ✕ ✓ ✕ 
N096L Other symptoms - SIJ ✓ ✕ ✕ ✓ S4323 Cls trmtc sublux mid carp jt ✕ ✕ ✓ ✕ 
N096M Other symptoms - knee ✕ ✓ ✕ ✓ S4324 Cls traumatic subluxation CMCJ ✕ ✕ ✓ ✕ 
N096N Other symptoms - tib-fib joint ✕ ✓ ✕ ✓ S4325 Cls trm sublux lunate (volar) ✕ ✕ ✓ ✕ 
N096P Other symptoms - ankle ✕ ✓ ✕ ✓ S4326 Cls trm sublux peri-lun(dors) ✕ ✕ ✓ ✕ 
N096Q Other symptoms - subtal joint ✕ ✓ ✕ ✓ S432y Cls trmtc sublux other carp jt ✕ ✕ ✓ ✕ 
N096R Other symptoms - talonav joint ✕ ✓ ✕ ✓ S433 Opn traumtc sublux wrist ✕ ✕ ✓ ✕ 
N096S Other symptoms - oth tarsal jt ✕ ✓ ✕ ✓ S4330 Opn trm sublux wrist, unspec ✕ ✕ ✓ ✕ 
N096T Other symptoms - 1st MTPJ ✕ ✓ ✕ ✓ S4331 Opn traumatic sublux DRUJ ✕ ✕ ✓ ✕ 
N096U Other symptoms - lesser MTPJ ✕ ✓ ✕ ✓ S4332 Opn trmtc sublux radiocarp jt ✕ ✕ ✓ ✕ 
N096V Other symptoms - IPJ of toe ✕ ✓ ✕ ✓ S4333 Opn trmtc sublux mid carp jt ✕ ✕ ✓ ✕ 
N0971 Walking diffic.-pelvic/thigh ✕ ✓ ✕ ✕ S4334 Opn traumtc subluxation CMCJ ✕ ✕ ✓ ✕ 
N0972 Walking difficulty-lower leg ✕ ✓ ✕ ✕ S4335 Opn trm sublux lunate (volar) ✕ ✕ ✓ ✕ 
N0973 Walking difficulty-ankle/foot ✕ ✓ ✕ ✕ S4336 Opn trm sublux peri-lun(dors) ✕ ✕ ✓ ✕ 
N0980 Synov osteochondromat-shoulder ✕ ✕ ✓ ✕ S433y Opn trmtc sublux other carp jt ✕ ✕ ✓ ✕ 
N0981 Synov osteochondromat st-cla j ✕ ✕ ✓ ✕ S43z Dislocation of wrist NOS ✕ ✕ ✓ ✕ 
N0982 Synov osteochondromat ac-cla j ✕ ✕ ✓ ✕ S44 Dislocation of thumb ✕ ✕ ✓ ✕ 
N0983 Synov osteochondromat-elbow ✕ ✕ ✓ ✕ S440 Cls traumtc disloctn digit ✕ ✕ ✓ ✕ 
N0984 Synov osteochondromat-dist RUJ ✕ ✕ ✓ ✕ S4400 Cls trmtc disloctn finger,unsp ✕ ✕ ✓ ✕ 
N0985 Synov osteochondromat-wrist ✕ ✕ ✓ ✕ S4401 Cls traumatic disloctn MCPJ ✕ ✕ ✓ ✕ 
N0986 Synov osteochondromat-MCPJ ✕ ✕ ✓ ✕ S4402 Cls trmtc interphalangl dislc ✕ ✕ ✓ ✕ 
N0987 Synov osteochondromat PIPJ-fin ✕ ✕ ✓ ✕ S4403 Cls traumatic disloctn DIPJ ✕ ✕ ✓ ✕ 
N0988 Synov osteochondromat DIPJ-fin ✕ ✕ ✓ ✕ S4404 Cls traumatic disloctn PIPJ ✕ ✕ ✓ ✕ 
N0989 Synov osteochondromat-hip ✕ ✓ ✕ ✕ S4405 Cls trmtc disloct IP jnt thumb ✕ ✕ ✓ ✕ 
N098A Synov osteochondromat-SIJ ✓ ✕ ✕ ✕ S4406 Cls trmtc disloct multi digits ✕ ✕ ✓ ✕ 
N098B Synov osteochondromat-knee ✕ ✓ ✕ ✕ S440z Cls trmtc disloctn finger NOS ✕ ✕ ✓ ✕ 
N098C Synov osteochondromat-tibfib j ✕ ✓ ✕ ✕ S441 Opn traumatic disloctn digit ✕ ✕ ✓ ✕ 
N098D Synov osteochondromat-ankle ✕ ✓ ✕ ✕ S4410 Opn trmtc disloctn finger,unsp ✕ ✕ ✓ ✕ 
N098E Synov osteochondromat-subtal j ✕ ✓ ✕ ✕ S4411 Open traumatic dislocation MPJ ✕ ✕ ✓ ✕ 
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N098F Synov osteochondromat-talnav j ✕ ✓ ✕ ✕ S4412 Opn trmtc interphalangeal dslc ✕ ✕ ✓ ✕ 
N098G Synov osteochondromat-oth ta j ✕ ✓ ✕ ✕ S4413 Opn trmtc dislocation DIPJ ✕ ✕ ✓ ✕ 
N098H Synov osteochondromat-1st MTPJ ✕ ✓ ✕ ✕ S4414 Opn trmtc dislocation PIPJ ✕ ✕ ✓ ✕ 
N098J Synov osteochondromat-les MTPJ ✕ ✓ ✕ ✕ S4415 Opn trmtc dslctn IP jnt thumb ✕ ✕ ✓ ✕ 
N098K Synov osteochondromat-IPJ-toe ✕ ✓ ✕ ✕ S4416 Opn trmtc dslctn multi digits ✕ ✕ ✓ ✕ 
N099 Clicking joint ✕ ✕ ✕ ✕ S441z Opn trmtc dslctn finger NOS ✕ ✕ ✓ ✕ 
N0990 Clicking shoulder ✕ ✕ ✓ ✕ S442 Cls trmtc subluxation digit ✕ ✕ ✓ ✕ 
N0991 Clicking sternoclavic joint ✕ ✕ ✓ ✕ S4420 Cls trmtc sublux digit, unsp ✕ ✕ ✓ ✕ 
N0992 Clicking acromioclavic joint ✕ ✕ ✓ ✕ S4421 Cls trmtc subluxation MPJ ✕ ✕ ✓ ✕ 
N0993 Clicking elbow ✕ ✕ ✓ ✕ S4422 Cls trmtc subluxation DIPJ ✕ ✕ ✓ ✕ 
N0994 Clicking distal rad-uln joint ✕ ✕ ✓ ✕ S4423 Cls trmtc subluxation PIPJ ✕ ✕ ✓ ✕ 
N0995 Clicking wrist ✕ ✕ ✓ ✕ S4424 Cls trmtc sublux IPJ thumb ✕ ✕ ✓ ✕ 
N0996 Clicking MCP joint ✕ ✕ ✓ ✕ S4425 Cls trmtc sublux multi digits ✕ ✕ ✓ ✕ 
N0997 Clicking PIP joint of finger ✕ ✕ ✓ ✕ S443 Opn trmtc subluxation digit ✕ ✕ ✓ ✕ 
N0998 Clicking DIP joint of finger ✕ ✕ ✓ ✕ S4430 Opn trmtc sublux digit, unsp ✕ ✕ ✓ ✕ 
N0999 Clicking hip ✕ ✓ ✕ ✕ S4431 Open traumatic subluxation MPJ ✕ ✕ ✓ ✕ 
N099B Clicking sacro-iliac joint ✓ ✕ ✕ ✕ S4432 Opn trmtc sublux IPJ thumb ✕ ✕ ✓ ✕ 
N099C Clicking knee ✕ ✓ ✕ ✕ S4433 Opn traumatic subluxation DIPJ ✕ ✕ ✓ ✕ 
N099D Clicking tibio-fibular joint ✕ ✓ ✕ ✕ S4434 Opn traumatic subluxation PIPJ ✕ ✕ ✓ ✕ 
N099E Clicking ankle ✕ ✓ ✕ ✕ S4435 Opn trmtc sublux multi digits ✕ ✕ ✓ ✕ 
N099F Clicking subtalar joint ✕ ✓ ✕ ✕ S44z Dislocation finger/thumb NOS ✕ ✕ ✓ ✕ 
N099G Clicking talonavicular joint ✕ ✓ ✕ ✕ S45 Dislocation or subluxation of hip ✕ ✓ ✕ ✕ 
N099H Clicking other tarsal joint ✕ ✓ ✕ ✕ S450 Cls traumatic dislocation hip ✕ ✓ ✕ ✕ 
N099J Clicking 1st MTP joint ✕ ✓ ✕ ✕ S4500 Cls trmtc dslctn hip, unsp ✕ ✓ ✕ ✕ 
N099K Clicking lesser MTP joint ✕ ✓ ✕ ✕ S4501 Cls trmtc dslctn hip jt, post ✕ ✓ ✕ ✕ 
N099L Clicking IP joint of toe ✕ ✓ ✕ ✕ S4502 Cls trmtc obturator dslctn hip ✕ ✓ ✕ ✕ 
N09A Patellofemoral disorder ✕ ✓ ✕ ✕ S4503 Cls trmtc dslctn hip jt, anter ✕ ✓ ✕ ✕ 
N09AX Disorder of patella unspecified ✕ ✓ ✕ ✕ S450z Cls trmtc dislocation hip NOS ✕ ✓ ✕ ✕ 
N09B Osteophyte ✕ ✕ ✕ ✕ S451 Opn traumatic dislocation hip ✕ ✓ ✕ ✕ 
N09C Fistula of joint ✕ ✕ ✕ ✕ S4510 Opn trmtc dslctn hip, unsp ✕ ✓ ✕ ✕ 
N09y Calcification of joint ✕ ✕ ✕ ✕ S4511 Opn trmtc dslctn hip jt, post ✕ ✓ ✕ ✕ 
N09y0 Other joint dis.-site unspec. ✕ ✕ ✕ ✕ S4512 Opn trmtc obturator dslctn hip ✕ ✓ ✕ ✕ 
N09y1 Other joint dis.-shoulder ✕ ✕ ✓ ✕ S4513 Opn trmtc dslctn hip jt, anter ✕ ✓ ✕ ✕ 
N09y2 Other joint dis.-upper arm ✕ ✕ ✓ ✕ S451z Opn trmtc dislocation hip NOS ✕ ✓ ✕ ✕ 
N09y3 Other joint dis.-forearm ✕ ✕ ✓ ✕ S452 Cls trmtc subluxation hip jt ✕ ✓ ✕ ✕ 
N09y4 Other joint dis.-hand ✕ ✕ ✓ ✕ S4520 Cls trmtc sublux hip jt, unsp ✕ ✓ ✕ ✕ 
N09y5 Other joint dis.-pelvic/thigh ✕ ✓ ✕ ✕ S4521 Cls trmtc sublux hip jt, post ✕ ✓ ✕ ✕ 
N09y6 Other joint dis.-lower leg ✕ ✓ ✕ ✕ S4522 Cls trmtc sublux hip jt, ant ✕ ✓ ✕ ✕ 
N09y7 Other joint dis.-ankle/foot ✕ ✓ ✕ ✕ S453 Opn trmtc subluxation hip jt ✕ ✓ ✕ ✕ 
N09z0 Joint disord.NOS-site unspecif ✕ ✕ ✕ ✕ S4530 Opn trmtc sublux hip jt, unsp ✕ ✓ ✕ ✕ 
N09z1 Joint disord.NOS-shoulder ✕ ✕ ✓ ✕ S4531 Opn trmtc sublux hip jt, post ✕ ✓ ✕ ✕ 
N09z2 Joint disord.NOS-upper arm ✕ ✕ ✓ ✕ S4532 Opn trmtc sublux hip jt, anter ✕ ✓ ✕ ✕ 
N09z3 Joint disord.NOS-forearm ✕ ✕ ✓ ✕ S45z Dislocation of hip NOS ✕ ✓ ✕ ✕ 
N09z4 Joint disord.NOS-hand ✕ ✕ ✓ ✕ S46 Dislocation/subluxation knee ✕ ✓ ✕ ✕ 
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N09z5 Joint disord.NOS-pelvic/thigh ✕ ✓ ✕ ✕ S460 Acute meniscal tear medial ✕ ✓ ✕ ✕ 
N09z6 Joint disord.NOS-lower leg ✕ ✓ ✕ ✕ S4600 Ac meniscal tear,med,ant horn ✕ ✓ ✕ ✕ 
N09z7 Joint disord.NOS-ankle/foot ✕ ✓ ✕ ✕ S4601 Ac meniscal tear,med,post horn ✕ ✓ ✕ ✕ 
N1 Vertebral column syndromes ✓ ✕ ✕ ✓ S4602 Ac menscl tear,med,bckt hndle ✕ ✓ ✕ ✕ 
N10 Inflammatory spondylopathies ✓ ✕ ✕ ✕ S4603 Ac meniscal tear,med,radial ✕ ✓ ✕ ✕ 
N100 Ankylosing spondylitis ✓ ✕ ✕ ✕ S4604 Ac mnscl tr,med,periph,dtchmt ✕ ✓ ✕ ✕ 
N101 Spinal enthesopathy ✓ ✕ ✕ ✓ S4605 Ac mnscl tear,med,horiz clvge ✕ ✓ ✕ ✕ 
N102 Sacroiliitis NEC ✓ ✕ ✕ ✓ S461 Acute meniscal tear lateral ✕ ✓ ✕ ✕ 
N10y Other inflamm.spondylopathies ✓ ✕ ✕ ✓ S4610 Ac meniscal tear,lat,ant horn ✕ ✓ ✕ ✕ 
N10y0 Inflamm.spondylop.in dis. EC ✓ ✕ ✕ ✓ S4611 Ac meniscal tear,lat,post horn ✕ ✓ ✕ ✕ 
N10yz Other inflamm.spondylop.NOS ✓ ✕ ✕ ✓ S4612 Ac menscl tear,lat,bckt hndle ✕ ✓ ✕ ✕ 
N10z Spondylitis NOS ✓ ✕ ✕ ✓ S4613 Ac meniscal tear,lat,radial ✕ ✓ ✕ ✕ 
N11 Arthritis of spine ✓ ✕ ✕ ✓ S4614 Ac mnscl tr,lat,periph,dtchmt ✕ ✓ ✕ ✕ 
N110 Cervical spond.- no myelopathy ✓ ✕ ✕ ✓ S4615 Ac mnscl tear,lat,horiz clvge ✕ ✓ ✕ ✕ 
N1100 One lev Cx spondyl-no myelop ✓ ✕ ✕ ✓ S462 Other acute meniscus tear ✕ ✓ ✕ ✕ 
N1101 Two lev Cx spondyl-no myelop ✓ ✕ ✕ ✓ S463 Cls trm dslctn patello-fem jt ✕ ✓ ✕ ✕ 
N1102 Mult lev Cx spondyl-no myelop ✓ ✕ ✕ ✓ S4630 Cls trm dslctn pat-fem jt,lat ✕ ✓ ✕ ✕ 
N111 Cervical spond.+ myelopathy ✓ ✕ ✕ ✕ S4631 Cls trm dslctn pat-fem jt,med ✕ ✓ ✕ ✕ 
N1110 One lev Cx spondyl + myelop ✓ ✕ ✕ ✕ S464 Opn trm dslctn patello-fem jt ✕ ✓ ✕ ✕ 
N1111 Two lev Cx spondyl + myelop ✓ ✕ ✕ ✕ S4640 Opn trm dslctn pat-fem jt lat ✕ ✓ ✕ ✕ 
N1112 Mult lev Cx spondyl + myelop ✓ ✕ ✕ ✕ S4641 Opn trm dslctn pat-fem jt,med ✕ ✓ ✕ ✕ 
N1113 Cervical myelopathy ✓ ✕ ✕ ✕ S465 Other cls trm dslctn knee ✕ ✓ ✕ ✕ 
N112 Thoracic spond.-no myelopathy ✓ ✕ ✕ ✓ S4650 Cls trm dslctn knee, unspec ✕ ✓ ✕ ✕ 
N1120 One lev th spondyl-no myelop ✓ ✕ ✕ ✓ S4651 Cls trm dslctn knee jt, ant ✕ ✓ ✕ ✕ 
N1121 Two lev th spondyl-no myelop ✓ ✕ ✕ ✓ S4652 Cls trm dslctn knee jt, post ✕ ✓ ✕ ✕ 
N1122 Mult lev th spondyl-no myelop ✓ ✕ ✕ ✓ S4653 Cls trm dslctn knee jt, medial ✕ ✓ ✕ ✕ 
N1123 Dorsal spondylo w/o myelopath ✓ ✕ ✕ ✓ S4654 Cls trm dslctn knee jt,lateral ✕ ✓ ✕ ✕ 
N113 Thoracic spond.+ myelopathy ✓ ✕ ✕ ✕ S4655 Cls trm dslct knee jt,rotatory ✕ ✓ ✕ ✕ 
N1130 One lev th spondyl + myelop ✓ ✕ ✕ ✕ S4656 Cls trm dslctn, head fibula ✕ ✓ ✕ ✕ 
N1131 Two lev th spondyl + myelop ✓ ✕ ✕ ✕ S465z Cls trm dslctn knee NOS ✕ ✓ ✕ ✕ 
N1132 Mult lev th spondyl + myelop ✓ ✕ ✕ ✕ S466 Other opn trm dslctn knee ✕ ✓ ✕ ✕ 
N114 Degeneration of lumbar spine ✓ ✕ ✕ ✓ S4660 Opn trm dslctn knee, unspec ✕ ✓ ✕ ✕ 
N1140 One lev lumbsac spond-no myelo ✓ ✕ ✕ ✓ S4661 Opn trm dslctn knee jt, ant ✕ ✓ ✕ ✕ 
N1141 Two lev lumbsac spond-no myelo ✓ ✕ ✕ ✓ S4662 Opn trm dslctn knee jt, post ✕ ✓ ✕ ✕ 
N1142 Mult lev lumbsac spond-no myel ✓ ✕ ✕ ✓ S4663 Opn trm dslctn knee jt, medial ✕ ✓ ✕ ✕ 
N115 Lumbosacral spond.+ myelopathy ✓ ✕ ✕ ✕ S4664 Opn trm dslctn knee jt,lateral ✕ ✓ ✕ ✕ 
N1150 One lev lumbsac spond + myelop ✓ ✕ ✕ ✕ S4665 Opn trm dslct knee jt,rotatory ✕ ✓ ✕ ✕ 
N1151 Two lev lumbsac spond + myelop ✓ ✕ ✕ ✕ S4666 Opn trm dslctn, head fibula ✕ ✓ ✕ ✕ 
N1152 Mult lev lumbsac spond + myelo ✓ ✕ ✕ ✕ S466z Open dislocation knee NOS ✕ ✓ ✕ ✕ 
N116 Kissing spine ✓ ✕ ✕ ✕ S467 Cls trmtc sublux pat-fem jt ✕ ✓ ✕ ✕ 
N117 Ankylosing verteb.hyperostosis ✓ ✕ ✕ ✕ S4670 Cls trm sublux pat-fem jt,ltrl ✕ ✓ ✕ ✕ 
N118 Traumatic spondylopathy ✓ ✕ ✕ ✕ S4671 Cls trm sublux pat-fem jt,med ✕ ✓ ✕ ✕ 
N119 Cx spondylosis + radiculopathy ✓ ✕ ✕ ✓ S468 Opn trmtc sublux pat-fem jt ✕ ✓ ✕ ✕ 
N1190 One lev Cx spondyl + radiculop ✓ ✕ ✕ ✓ S4680 Opn trm sublux pat-fem jt,ltrl ✕ ✓ ✕ ✕ 
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N1191 Two lev Cx spondyl + radiculop ✓ ✕ ✕ ✓ S4681 Opn trm sublux pat-fem jt,med ✕ ✓ ✕ ✕ 
N1192 Mult lev Cx spondyl+radiculop ✓ ✕ ✕ ✓ S469 Cls trmtc sublux knee jt ✕ ✓ ✕ ✕ 
N11A Cx spondyl + vasc compression ✓ ✕ ✕ ✕ S4690 Cls trmtc sublux knee jt,unsp ✕ ✓ ✕ ✕ 
N11B Th spondyl + radiculop ✓ ✕ ✕ ✓ S4691 Cls trmtc sublux knee jt,ant ✕ ✓ ✕ ✕ 
N11B0 One lev th spondyl + radiculop ✓ ✕ ✕ ✓ S4692 Cls trmtc sublux knee jt,post ✕ ✓ ✕ ✕ 
N11B1 Two lev th spondyl + radiculop ✓ ✕ ✕ ✓ S4693 Cls trm sublux knee jt,medial ✕ ✓ ✕ ✕ 
N11B2 Mult lev th spondyl+radiculop ✓ ✕ ✕ ✓ S4694 Cls trmtc sublux knee jt,ltrl ✕ ✓ ✕ ✕ 
N11C Lumbsac spondyl + radiculopath ✓ ✕ ✕ ✓ S4695 Cls trm sublux knee jt,rotatry ✕ ✓ ✕ ✕ 
N11C0 1 lev lumbsac spond+radiculop ✓ ✕ ✕ ✓ S4696 Cls trmtc sublux,head fibula ✕ ✓ ✕ ✕ 
N11C1 2 lev lumbsac spond+radiculop ✓ ✕ ✕ ✓ S46A Opn trmtc sublux knee jt ✕ ✓ ✕ ✕ 
N11C2 Multi lev lumbsac spond+radicu ✓ ✕ ✕ ✓ S46A0 Opn trmtc sublux knee jt,unsp ✕ ✓ ✕ ✕ 
N11D0 Osteoarthritis of cervical spine ✓ ✕ ✕ ✓ S46A1 Opn trmtc sublux knee jt,ant ✕ ✓ ✕ ✕ 
N11D1 Osteoarthritis of thoracic spine ✓ ✕ ✕ ✓ S46A2 Opn trmtc sublux knee jt,post ✕ ✓ ✕ ✕ 
N11D2 Osteoarthritis of lumbar spine ✓ ✕ ✕ ✓ S46A3 Opn trm sublux knee jt,medial ✕ ✓ ✕ ✕ 
N11D3 Osteoarthritis of spine NOS ✓ ✕ ✕ ✓ S46A4 Opn trmtc sublux knee jt,ltrl ✕ ✓ ✕ ✕ 
N11y Other spondyloses/allied dis. ✓ ✕ ✕ ✓ S46A5 Opn trm sublux knee jt,rotatry ✕ ✓ ✕ ✕ 
N11y0 Brucella spondylitis ✓ ✕ ✕ ✕ S46A6 Opn trmtc sublux,head fibula ✕ ✓ ✕ ✕ 
N11y1 Enterobacterial spondylitis ✓ ✕ ✕ ✕ S46B Tear/articulr cart/knee,currnt ✕ ✓ ✕ ✕ 
N11y2 Neuropathic spondylopathy ✓ ✕ ✕ ✕ S46C Inj/multipl structures of knee ✕ ✓ ✕ ✕ 
N11z Osteoarthritis spine ✓ ✕ ✕ ✓ S46D Recurrent subluxation, patella ✕ ✓ ✕ ✕ 
N11z0 Spondylosis-no myelopathy,NOS ✓ ✕ ✕ ✓ S46z Dislocation of knee NOS ✕ ✓ ✕ ✕ 
N11z1 Spondylosis + myelopathy, NOS ✓ ✕ ✕ ✕ S47 Dislocation/sublux ankle ✕ ✓ ✕ ✕ 
N11zz Spondylosis NOS ✓ ✕ ✕ ✓ S470 Cls trmtc dislocation ankle jt ✕ ✓ ✕ ✕ 
N12 Intervertebral disc disorders ✓ ✕ ✕ ✓ S472 Cls trmtc sublux ankle jt ✕ ✓ ✕ ✕ 
N120 PID - prol cerv disc,no myelop ✓ ✕ ✕ ✓ S473 Opn trmtc sublux ankle jt ✕ ✓ ✕ ✕ 
N121 Thoracic disc displ.-no myelop ✓ ✕ ✕ ✓ S47z Dislocation of ankle NOS ✕ ✓ ✕ ✕ 
N122 Lumbar disc displacement ✓ ✕ ✕ ✓ S48 Dislocation/sublux foot ✕ ✓ ✕ ✕ 
N123 Intervertebral disc prol. NOS ✓ ✕ ✕ ✓ S480 Cls trmtc dislocation foot ✕ ✓ ✕ ✕ 
N124 Schmorl's nodes ✓ ✕ ✕ ✕ S4800 Cls trmtc dslctn foot,unsp ✕ ✓ ✕ ✕ 
N1240 Schmorl's nodes-unspec. region ✓ ✕ ✕ ✕ S4801 Cls trmtc tarsal dslctn,unsp ✕ ✓ ✕ ✕ 
N1241 Schmorl's nodes-thoracic regn. ✓ ✕ ✕ ✕ S4802 Cls trmtc dslctn,midtarsal jt ✕ ✓ ✕ ✕ 
N1242 Schmorl's nodes-lumbar region ✓ ✕ ✕ ✕ S4803 Cls trm dslc,tarso-metatrsl jt ✕ ✓ ✕ ✕ 
N124z Schmorl's nodes-region NOS ✓ ✕ ✕ ✕ S4804 Cls trm metatarsal dslctn,unsp ✕ ✓ ✕ ✕ 
N125 Cervical disc degeneration ✓ ✕ ✕ ✓ S4805 Cl trm dsl,mtatrso-phln jt,sgl ✕ ✓ ✕ ✕ 
N126 Thoracic disc degeneration ✓ ✕ ✕ ✓ S4806 Cl traum dslc toe, IPJ, single ✕ ✓ ✕ ✕ 
N127 Lumbar disc degeneration ✓ ✕ ✕ ✓ S4807 Cl tr dsl,mtatrs-phlng jt,mlti ✕ ✓ ✕ ✕ 
N128 Degenerative disc disease NOS ✓ ✕ ✕ ✓ S4808 Cl traum disloc toe,IPJ,multi ✕ ✓ ✕ ✕ 
N129 PID - prol i/v disc + myelop ✓ ✕ ✕ ✓ S4809 Cls trmtc dslctn,pantalar ✕ ✓ ✕ ✕ 
N1290 Unspec.disc disorder+myelop. ✓ ✕ ✕ ✕ S480A Cls trmtc dslctn,subtalar jt ✕ ✓ ✕ ✕ 
N1291 Cervical disc disord.+myelop. ✓ ✕ ✕ ✕ S480z Cls trmtc dslctn foot NOS ✕ ✓ ✕ ✕ 
N1292 Thoracic disc disord.+myelop. ✓ ✕ ✕ ✕ S481 Opn trmtc dslctn foot ✕ ✓ ✕ ✕ 
N1293 Lumbar disc disord.+myelopathy ✓ ✕ ✕ ✕ S4810 Opn trmtc dslctn foot,unsp ✕ ✓ ✕ ✕ 
N129z Disc disorder+myelopathy NOS ✓ ✕ ✕ ✕ S4811 Opn trmtc tarsal dslctn,unsp ✕ ✓ ✕ ✕ 
N12A Postlaminectomy syndrome ✓ ✕ ✕ ✕ S4812 Opn trmtc dslctn,midtarsal jt ✕ ✓ ✕ ✕ 
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N12A0 Postlaminectomy syndr.unspec. ✓ ✕ ✕ ✕ S4813 Opn trm dslc,tarso-metatrsl jt ✕ ✓ ✕ ✕ 
N12A1 Cervical postlaminectomy syndr ✓ ✕ ✕ ✕ S4814 Opn trm metatarsal dslc,unsp ✕ ✓ ✕ ✕ 
N12A2 Thoracic postlaminectomy syndr ✓ ✕ ✕ ✕ S4815 Op trm dsl,mtatrso-phln jt,sgl ✕ ✓ ✕ ✕ 
N12A3 Lumbar postlaminectomy syndr. ✓ ✕ ✕ ✕ S4816 Open traum disloc toe,IPJ,sing ✕ ✓ ✕ ✕ 
N12Az Postlaminectomy syndrome NOS ✓ ✕ ✕ ✕ S4817 Op tr dsl,mtatrso-phln jt,mlti ✕ ✓ ✕ ✕ 
N12B Disc prolapse with myelopathy ✓ ✕ ✕ ✕ S4818 Open traum disloc toe,IPJ,mult ✕ ✓ ✕ ✕ 
N12B0 Cx disc prolapse + myelopathy ✓ ✕ ✕ ✕ S4819 Opn trmtc dslctn,pantalar ✕ ✓ ✕ ✕ 
N12B1 Th disc prolapse + myelopathy ✓ ✕ ✕ ✕ S481A Opn trmtc dslctn,subtalar jt ✕ ✓ ✕ ✕ 
N12B2 Lu disc prolapse + myelopathy ✓ ✕ ✕ ✕ S481z Opn trmtc dslctn foot NOS ✕ ✓ ✕ ✕ 
N12C Disc prolapse + radiculopathy ✓ ✕ ✕ ✓ S482 Cls trmtc sublux,foot ✕ ✓ ✕ ✕ 
N12C0 Cx disc prolapse+radiculopathy ✓ ✕ ✕ ✓ S4820 Cls trmtc sublux,foot,unsp ✕ ✓ ✕ ✕ 
N12C1 Th disc prolapse+radiculopathy ✓ ✕ ✕ ✓ S4821 Cls trm sublux,tarsal jt,unsp ✕ ✓ ✕ ✕ 
N12C2 Lu disc prolapse+radiculopathy ✓ ✕ ✕ ✓ S4822 Cls trmtc sublux,midtarsal jt ✕ ✓ ✕ ✕ 
N12C3 Lu disc prol+caud eq compress ✓ ✕ ✕ ✕ S4823 Cls trm sublux,trso-mtatrsl jt ✕ ✓ ✕ ✕ 
N12C4 Prol lumb interv disc sciatic ✓ ✕ ✕ ✓ S4824 Cl tr sublx,mtatrs-phln jt,sgl ✕ ✓ ✕ ✕ 
N12D Narrowing disc space ✓ ✕ ✕ ✓ S4825 Cl traum sublux toe,IPJ,single ✕ ✓ ✕ ✕ 
N12z Other/unspec.disc disorders ✓ ✕ ✕ ✓ S4826 Cl tr sblx,mtatrs-phln jt,mlti ✕ ✓ ✕ ✕ 
N12z0 Other disc disorders unspecif. ✓ ✕ ✕ ✓ S4827 Cl trm sublux toe,IPJ,multi ✕ ✓ ✕ ✕ 
N12z1 Other cervical disc disorders ✓ ✕ ✕ ✓ S4828 Cls trmtc sublux,pantalar ✕ ✓ ✕ ✕ 
N12z2 Other thoracic disc disorders ✓ ✕ ✕ ✓ S4829 Cls trmtc sublux,subtalar jt ✕ ✓ ✕ ✕ 
N12z3 Other lumbar disc disorders ✓ ✕ ✕ ✓ S483 Opn trmtc sublux,foot ✕ ✓ ✕ ✕ 
N12z4 Cervical discitis ✓ ✕ ✕ ✓ S4830 Opn trmtc sublux,foot,unsp ✕ ✓ ✕ ✕ 
N12z5 Annular tear of cervical disc ✓ ✕ ✕ ✓ S4831 Opn trm sublux,tarsal jt,unsp ✕ ✓ ✕ ✕ 
N12z6 Resorption of cervical disc ✓ ✕ ✕ ✓ S4832 Opn trmtc sublux,midtarsal jt ✕ ✓ ✕ ✕ 
N12z7 Calcification of cervical disc ✓ ✕ ✕ ✕ S4833 Op trm sublux,tarso-mtatrsl jt ✕ ✓ ✕ ✕ 
N12z8 Thoracic discitis ✓ ✕ ✕ ✓ S4834 Op trm sublx mtatrs-phl jt,sgl ✕ ✓ ✕ ✕ 
N12z9 Annular tear of thoracic disc ✓ ✕ ✕ ✓ S4835 Opn trm sublux toe,IPJ,single ✕ ✓ ✕ ✕ 
N12zA Resorption of thoracic disc ✓ ✕ ✕ ✓ S4836 Op tr sblx,mtatrs-phln jt,mlti ✕ ✓ ✕ ✕ 
N12zB Calcification of thoracic disc ✓ ✕ ✕ ✕ S4837 Op traum sublux toe,IPJ,multi ✕ ✓ ✕ ✕ 
N12zC Lumbar discitis ✓ ✕ ✕ ✕ S4838 Opn trm sublux,pantalar ✕ ✓ ✕ ✕ 
N12zD Annular tear of lumbar disc ✓ ✕ ✕ ✓ S4839 Opn trm sublux,subtalar jt ✕ ✓ ✕ ✕ 
N12zE Resorption of lumbar disc ✓ ✕ ✕ ✓ S48z Dislocation of foot NOS ✕ ✓ ✕ ✕ 
N12zF Calcification of lumbar disc ✓ ✕ ✕ ✕ S490 Cls dslc cervical spine ✓ ✕ ✕ ✕ 
N12zG Infect intervert disc - pyogen ✓ ✕ ✕ ✕ S4900 Closed disloc.cerv.spine unsp. ✓ ✕ ✕ ✕ 
N12zH Cerv disc disord + radiculopth ✓ ✕ ✕ ✓ S4901 Cls dslc atlanto-occipital jnt ✓ ✕ ✕ ✕ 
N12zz Disc disorders NOS ✓ ✕ ✕ ✓ S4902 Cls dslc atlanto-axial joint ✓ ✕ ✕ ✕ 
N13 Other cervical disorders ✓ ✕ ✕ ✓ S4903 Closed dislocation C2/C3 ✓ ✕ ✕ ✕ 
N130 Cervical spinal stenosis ✓ ✕ ✕ ✓ S4904 Closed dislocation C3/C4 ✓ ✕ ✕ ✕ 
N1300 Idiopathic Cx spinal stenosis ✓ ✕ ✕ ✓ S4905 Closed dislocation C4/C5 ✓ ✕ ✕ ✕ 
N1301 Degenerativ Cx spinal stenosis ✓ ✕ ✕ ✓ S4906 Closed dislocation C5/C6 ✓ ✕ ✕ ✕ 
N1302 Iatrogenic Cx spinal stenosis ✓ ✕ ✕ ✓ S4907 Closed dislocation C6/C7 ✓ ✕ ✕ ✕ 
N1303 Cx spin stenos due to oth dis ✓ ✕ ✕ ✓ S4908 Closed dislocation C7/T1 ✓ ✕ ✕ ✕ 
N131 Cervicalgia ✓ ✕ ✕ ✓ S4909 Cl spnl dslc+cerv crd lsn,unsp ✓ ✕ ✕ ✕ 
N132 Cervicocranial syndrome ✓ ✕ ✕ ✓ S490A Cl spnl dslc+comp cerv crd lsn ✓ ✕ ✕ ✕ 
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N133 Cervicobrachial syndrome ✓ ✕ ✓ ✓ S490B Cls spnl dslc+ant cerv crd lsn ✓ ✕ ✕ ✕ 
N134 Brachial (cervical) neuritis ✕ ✕ ✓ ✓ S490C Cl spn dslc+cntrl cerv crd lsn ✓ ✕ ✕ ✕ 
N135 Torticollis unspecified ✓ ✕ ✕ ✓ S490D Cls spn dslc+post cerv crd lsn ✓ ✕ ✕ ✕ 
N1350 Intermittent torticollis ✓ ✕ ✕ ✓ S490x Closed disloc.mult.cerv.vert. ✓ ✕ ✕ ✕ 
N1351 Rheumatic torticollis ✓ ✕ ✕ ✓ S490z Closed disloc.cervic.vert.NOS ✓ ✕ ✕ ✕ 
N135z Stiff neck NOS ✓ ✕ ✕ ✓ S491 Open dislocation of neck ✓ ✕ ✕ ✕ 
N136 Panniculitis of neck ✓ ✕ ✕ ✕ S4910 Open disloc.cerv.spine unspec. ✓ ✕ ✕ ✕ 
N137 Cervical post.long.lig.ossific ✓ ✕ ✕ ✕ S4911 Open dslc atlanto-occipital jt ✓ ✕ ✕ ✕ 
N13y Other cervical syndromes ✓ ✕ ✕ ✓ S4912 Open dslc atlanto-axial jt ✓ ✕ ✕ ✕ 
N13y0 Cervical syndrome NEC ✓ ✕ ✕ ✓ S4913 Open dislocation C2/C3 ✓ ✕ ✕ ✕ 
N13y1 Klippel's disease ✓ ✕ ✕ ✕ S4914 Open dislocation C3/C4 ✓ ✕ ✕ ✕ 
N13y2 Crick in neck ✓ ✕ ✕ ✓ S4915 Open dislocation C4/C5 ✓ ✕ ✕ ✕ 
N13y3 Cervical root syndrome ✓ ✕ ✕ ✓ S4916 Open dislocation C5/C6 ✓ ✕ ✕ ✕ 
N13yz Other cervical syndromes NOS ✓ ✕ ✕ ✓ S4917 Open dislocation C6/C7 ✓ ✕ ✕ ✕ 
N13z Cervical and neck disorders NOS ✓ ✕ ✕ ✓ S4918 Open dislocation C7/T1 ✓ ✕ ✕ ✕ 
N14 Other/unspecif.back disorder ✓ ✕ ✕ ✓ S4919 Opn spnl dsl+cerv crd lsn,unsp ✓ ✕ ✕ ✕ 
N140 Spinal stenosis ✓ ✕ ✕ ✓ S491A Opn spn dslc+comp cerv crd lsn ✓ ✕ ✕ ✕ 
N1400 Spinal stenosis unspec.region ✓ ✕ ✕ ✓ S491B Opn spnl dslc+ant cerv crd lsn ✓ ✕ ✕ ✕ 
N1401 Thoracic spinal stenosis ✓ ✕ ✕ ✓ S491C Opn spn dslc+ctrl cerv crd lsn ✓ ✕ ✕ ✕ 
N1402 Lumbar spinal stenosis ✓ ✕ ✕ ✓ S491D Opn spnl dsl+post cerv crd lsn ✓ ✕ ✕ ✕ 
N1403 Idiopathic th spinal stenosis ✓ ✕ ✕ ✓ S491x Open disloc.mult.cerv.vertebra ✓ ✕ ✕ ✕ 
N1404 Degenerativ th spinal stenosis ✓ ✕ ✕ ✓ S491z Open disloc.cervical vert.NOS ✓ ✕ ✕ ✕ 
N1405 Iatrogenic th spinal stenosis ✓ ✕ ✕ ✓ S492 Cls dslc thoracic+lumbar spine ✓ ✕ ✕ ✕ 
N1406 Th spin stenos due to oth dis ✓ ✕ ✕ ✓ S4920 Cls dslc lumbar spine ✓ ✕ ✕ ✕ 
N1407 Idiopathic lu spinal stenosis ✓ ✕ ✕ ✓ S4921 Cls dslc thoracic vertebra ✓ ✕ ✕ ✕ 
N1408 Degenerativ lu spinal stenosis ✓ ✕ ✕ ✓ S4922 Cls spn dslc+thrc crd lsn,unsp ✓ ✕ ✕ ✕ 
N1409 Iatrogenic lu spinal stenosis ✓ ✕ ✕ ✓ S4923 Cls spnl dsl+comp thrc crd lsn ✓ ✕ ✕ ✕ 
N140A Lu spin stenos due to oth dis ✓ ✕ ✕ ✓ S4924 Cls spnl dslc+ant thrc crd lsn ✓ ✕ ✕ ✕ 
N140z Spinal stenosis NOS ✓ ✕ ✕ ✓ S4925 Cls spn dslc+cent thrc crd lsn ✓ ✕ ✕ ✕ 
N141 Acute back pain - thoracic ✓ ✕ ✕ ✓ S4926 Cls spn dslc+post thrc crd lsn ✓ ✕ ✕ ✕ 
N142 Acute back pain - lumbar ✓ ✕ ✕ ✓ S4927 Cl spn dsl+lmbr crd lsn unsp ✓ ✕ ✕ ✕ 
N1420 Lumbago with sciatica ✓ ✓ ✕ ✓ S4928 Cls spnl dsl+comp lmbr crd lsn ✓ ✕ ✕ ✕ 
N143 Acute back pain + sciatica ✓ ✓ ✕ ✓ S4929 Cls spnl dslc+ant lmbr crd lsn ✓ ✕ ✕ ✕ 
N144 Thoracic/lumbosacral neuritis ✓ ✕ ✕ ✓ S492A Cls spn dslc+cent lmbr crd lsn ✓ ✕ ✕ ✕ 
N1440 Thoracic neuritis, unspecified ✓ ✕ ✕ ✓ S492B Cls spnl dsl+post lmbr crd lsn ✓ ✕ ✕ ✕ 
N1441 Lumbosacral neuritis unspecif. ✓ ✕ ✕ ✓ S492C Cls spnl dslc+cauda equina lsn ✓ ✕ ✕ ✕ 
N144z Thoracic/lumbosac.neuritis NOS ✓ ✕ ✕ ✓ S492z Cls dslc thrcic+lmbr spine NOS ✓ ✕ ✕ ✕ 
N145 Acute back pain - unspecified ✓ ✕ ✕ ✓ S493 Open disloc.thoracic/lumbar ✓ ✕ ✕ ✕ 
N146 Disorders of the sacrum ✓ ✕ ✕ ✓ S4930 Open dislocation lumbar spine ✓ ✕ ✕ ✕ 
N1460 Lumbosacral ankylosis ✓ ✕ ✕ ✕ S4931 Opn dslc thoracic spine ✓ ✕ ✕ ✕ 
N1461 Sacroiliac ankylosis ✓ ✕ ✕ ✕ S4932 Opn spn dslc+thrc crd lsn,unsp ✓ ✕ ✕ ✕ 
N1462 Sacral ankylosis NOS ✓ ✕ ✕ ✕ S4933 Opn spnl dsl+comp thrc crd lsn ✓ ✕ ✕ ✕ 
N1463 Lumbosacral strain ✓ ✕ ✕ ✕ S4934 Opn spnl dslc+ant thrc crd lsn ✓ ✕ ✕ ✕ 
N1464 Sacroiliac instability ✓ ✕ ✕ ✓ S4935 Opn spn dslc+cent thrc crd lsn ✓ ✕ ✕ ✕ 
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N1465 Sacral instability NOS ✓ ✕ ✕ ✓ S4936 Opn spn dslc+post thrc crd lsn ✓ ✕ ✕ ✕ 
N1466 Sacroiliac disorder ✓ ✕ ✕ ✓ S4937 Op spn dsl+lmbr crd lsn unsp ✓ ✕ ✕ ✕ 
N146z Sacroiliac strain ✓ ✕ ✕ ✕ S4938 Opn spnl dsl+comp lmbr crd lsn ✓ ✕ ✕ ✕ 
N147 Disorders of the coccyx ✓ ✕ ✕ ✓ S4939 Opn spnl dslc+ant lmbr crd lsn ✓ ✕ ✕ ✕ 
N1470 Unspecified disorder of coccyx ✓ ✕ ✕ ✓ S493A Opn spn dslc+cent lmbr crd lsn ✓ ✕ ✕ ✕ 
N1471 Hypermobility of the coccyx ✓ ✕ ✕ ✓ S493B Opn spnl dsl+post lmbr crd lsn ✓ ✕ ✕ ✕ 
N1472 Coccygodynia ✓ ✕ ✕ ✓ S493C Opn spnl dslc+cauda equina lsn ✓ ✕ ✕ ✕ 
N147z Coccyx disorder NOS ✓ ✕ ✕ ✓ S493z Open disloc.thorac./lumbar NOS ✓ ✕ ✕ ✕ 
N148 Ankylosis/instab Cx,Th,Lu spin ✓ ✕ ✕ ✕ S494 Closed disloc.other vertebra ✓ ✕ ✕ ✕ 
N1480 Atlanto-occipital ankylosis ✓ ✕ ✕ ✕ S4940 Closed dislocation spine unsp. ✓ ✕ ✕ ✕ 
N1481 Atlanto-axial ankylosis ✓ ✕ ✕ ✕ S4941 Closed dislocation coccyx ✓ ✕ ✕ ✕ 
N1482 Cervical spine ankylosis ✓ ✕ ✕ ✕ S4942 Closed dislocation sacrum ✓ ✕ ✕ ✕ 
N1483 Cervico-thoracic ankylosis ✓ ✕ ✕ ✕ S494z Closed dislocation spine NOS ✓ ✕ ✕ ✕ 
N1484 Thoracic spine ankylosis ✓ ✕ ✕ ✕ S495 Open disloc.other vertebra ✓ ✕ ✕ ✕ 
N1485 Thoraco-lumbar ankylosis ✓ ✕ ✕ ✕ S4950 Open dislocation spine unspec. ✓ ✕ ✕ ✕ 
N1486 Lumbar spine ankylosis ✓ ✕ ✕ ✕ S4951 Open dislocation coccyx ✓ ✕ ✕ ✕ 
N1487 Atlanto-occipital instability ✓ ✕ ✕ ✕ S4952 Open dislocation sacrum ✓ ✕ ✕ ✕ 
N1488 Atlanto-axial instability ✓ ✕ ✕ ✕ S495z Open dislocation spine NOS ✓ ✕ ✕ ✕ 
N1489 Cervical spine instability ✓ ✕ ✕ ✕ S4960 Closed disloc sternoclavic. jt ✓ ✕ ✕ ✕ 
N148A Cervico-thoracic instability ✓ ✕ ✕ ✕ S4961 Cls trm dslc pelvis ✕ ✓ ✕ ✕ 
N148B Thoracic spine instability ✓ ✕ ✕ ✕ S4962 Cls trm dslc sterno-clav jt ✕ ✕ ✓ ✕ 
N148C Lumbar spine instability ✓ ✕ ✕ ✕ S4963 Cls trm dslc,stern-clav jt,ant ✕ ✕ ✓ ✕ 
N149 Back stiffness ✓ ✕ ✕ ✓ S4964 Cls trm dsl,stern-clav jt,post ✕ ✕ ✓ ✕ 
N14X Sacrococygeal disorders,NEC ✓ ✕ ✕ ✓ S4965 Cls trm dslc laryngl cartilage ✓ ✕ ✕ ✕ 
N14y Facet joint syndrome ✓ ✕ ✕ ✓ S4966 Cls trm dslc costo-vertebr jt ✓ ✕ ✕ ✕ 
N14z Back disorder/symptom NOS ✓ ✕ ✕ ✓ S4967 Cls trm dslc costo-chondral jt ✓ ✕ ✕ ✕ 
N1y Vertebral column disorders OS ✓ ✕ ✕ ✓ S496z Closed traumatic disloctn NOS ✕ ✕ ✕ ✕ 
N1y0 Rec atlantoax subl + myelopath ✓ ✕ ✕ ✕ S497 Other open trmtc dislocation ✕ ✕ ✕ ✕ 
N1y1 Fatigue fracture of vertebra ✓ ✕ ✕ ✕ S4970 Opn trm dslc sternum ✓ ✕ ✕ ✕ 
N1z Vertebral column disorder NOS ✓ ✕ ✕ ✓ S4971 Opn trm dslc pelvis ✕ ✓ ✕ ✕ 
N210 Adhesive capsulitis - shoulder ✕ ✕ ✓ ✓ S4972 Opn trm dslc sterno-clav jt ✕ ✕ ✓ ✕ 
N211 Rotator cuff shoulder syndrome ✕ ✕ ✓ ✓ S4973 Opn trm dslc,stern-clav jt,ant ✕ ✕ ✓ ✕ 
N2110 Rotator cuff syndrome unspecif ✕ ✕ ✓ ✓ S4974 Opn trm dsl,stern-clav jt,post ✕ ✕ ✓ ✕ 
N2111 Calcifying tendinitis shoulder ✕ ✕ ✓ ✕ S4975 Opn dslc laryngl cartilage ✓ ✕ ✕ ✕ 
N2112 Bicipital tenosynovitis ✕ ✕ ✓ ✓ S4976 Opn dslc costo-vertebr jt ✓ ✕ ✕ ✕ 
N2113 Supraspinatus tendinitis ✕ ✕ ✓ ✓ S4977 Opn trm dslc costo-chondral jt ✓ ✕ ✕ ✕ 
N2114 Part thickn rotator cuff tear ✕ ✕ ✓ ✕ S497z Open dislocation NOS ✕ ✕ ✕ ✕ 
N2115 Full thickn rotator cuff tear ✕ ✕ ✓ ✕ S498 Cls sublux cervical spine ✓ ✕ ✕ ✕ 
N2116 Subacromial bursitis ✕ ✕ ✓ ✓ S4980 Cls sublux cervical spine,unsp ✓ ✕ ✕ ✕ 
N2117 Subdeltoid bursitis ✕ ✕ ✓ ✓ S4981 Cls sublux atlanto-occiptl jt ✓ ✕ ✕ ✕ 
N2118 Bursitis of shoulder ✕ ✕ ✓ ✓ S4982 Cls sublux atlanto-axial jt ✓ ✕ ✕ ✕ 
N211z Painful arc syndrome ✕ ✕ ✓ ✓ S4983 Closed subluxation C2/C3 ✓ ✕ ✕ ✕ 
N212 Other shoulder affections NEC ✕ ✕ ✓ ✓ S4984 Closed subluxation C3/C4 ✓ ✕ ✕ ✕ 
N2120 Periarthritis of shoulder ✕ ✕ ✓ ✓ S4985 Closed subluxation C4/C5 ✓ ✕ ✕ ✕ 
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N2121 Scapulohumeral fibrositis ✕ ✕ ✓ ✓ S4986 Closed subluxation C5/C6 ✓ ✕ ✕ ✕ 
N2122 Subacromial impingement ✕ ✕ ✓ ✓ S4987 Closed subluxation C6/C7 ✓ ✕ ✕ ✕ 
N2123 Coracoid impingement ✕ ✕ ✓ ✓ S4988 Closed subluxation C7/T1 ✓ ✕ ✕ ✕ 
N2124 Impingement syndr of shoulder ✕ ✕ ✓ ✓ S4989 Cl spn sublx+cerv crd lsn,unsp ✓ ✕ ✕ ✕ 
N2125 Shoulder tendonitis ✕ ✕ ✓ ✓ S498A Cl spn sublx+comp cerv crd lsn ✓ ✕ ✕ ✕ 
N212z Other shoulder affect.NEC NOS ✕ ✕ ✓ ✓ S498B Cl spn sublux+ant cerv crd lsn ✓ ✕ ✕ ✕ 
N213 Enthesopathy of elbow region ✕ ✕ ✓ ✓ S498C Cl spn sublx+cntrl crv crd lsn ✓ ✕ ✕ ✕ 
N2130 Elbow enthesopathy unspecified ✕ ✕ ✓ ✓ S498D Cl spn sublux+post crv crd lsn ✓ ✕ ✕ ✕ 
N2131 Golfers elbow ✕ ✕ ✓ ✓ S498x Cls sublux mlti cerv vertebrae ✓ ✕ ✕ ✕ 
N2132 Lateral epicondylitis - elbow ✕ ✕ ✓ ✓ S498z Cls sublux cerv vertebra NOS ✓ ✕ ✕ ✕ 
N2133 Olecranon bursitis ✕ ✕ ✓ ✓ S499 Open sublux cerv spine ✓ ✕ ✕ ✕ 
N2134 Biceps tendinitis ✕ ✕ ✓ ✓ S4990 Open sublux cerv spine, unsp ✓ ✕ ✕ ✕ 
N2135 Triceps tendinitis ✕ ✕ ✓ ✓ S4991 Opn sublux atlanto-occipitl jt ✓ ✕ ✕ ✕ 
N213z Elbow enthesopathy NOS ✕ ✕ ✓ ✓ S4992 Open sublux atlanto-axial jt ✓ ✕ ✕ ✕ 
N214 Enthesopathy of wrist/carpus ✕ ✕ ✓ ✓ S4993 Open subluxation C2/C3 ✓ ✕ ✕ ✕ 
N2140 Bursitis of wrist ✕ ✕ ✓ ✓ S4994 Open subluxation C3/C4 ✓ ✕ ✕ ✕ 
N2141 Bursitis of hand ✕ ✕ ✓ ✓ S4995 Open subluxation C4/C5 ✓ ✕ ✕ ✕ 
N2142 Periarthritis of wrist ✕ ✕ ✓ ✓ S4996 Open subluxation C5/C6 ✓ ✕ ✕ ✕ 
N214z Wrist/carpus enthesopathy NOS ✕ ✕ ✓ ✓ S4997 Open subluxation C6/C7 ✓ ✕ ✕ ✕ 
N215 Enthesopathy of hip region ✕ ✓ ✕ ✓ S4998 Open subluxation C7/T1 ✓ ✕ ✕ ✕ 
N2150 Hip enthesopathy, unspecified ✕ ✓ ✕ ✓ S4999 Op spn sublx+cerv crd lsn,unsp ✓ ✕ ✕ ✕ 
N2151 Bursitis of hip ✕ ✓ ✕ ✓ S499A Op spn sublx+comp cerv crd lsn ✓ ✕ ✕ ✕ 
N2152 Gluteal tendinitis ✕ ✓ ✕ ✓ S499B Op spn sublux+ant cerv crd lsn ✓ ✕ ✕ ✕ 
N2153 Iliac crest spur ✕ ✓ ✕ ✓ S499C Op spn sublx+cntrl crv crd lsn ✓ ✕ ✕ ✕ 
N2154 Psoas tendinitis ✕ ✓ ✕ ✓ S499D Op spn sublux+post crv crd lsn ✓ ✕ ✕ ✕ 
N2155 Trochanteric tendinitis ✕ ✓ ✕ ✓ S499x Opn sublux mlti cerv vertebrae ✓ ✕ ✕ ✕ 
N2156 Adductor tendinitis ✕ ✓ ✕ ✓ S499z Opn sublux cerv vertebra NOS ✓ ✕ ✕ ✕ 
N2157 Trochanteric bursitis ✕ ✓ ✕ ✓ S49A Cls sublux thrcic+lumbar spine ✓ ✕ ✕ ✕ 
N2158 Snapping hip ✕ ✓ ✕ ✓ S49A0 Cls sublux lumbar spine ✓ ✕ ✕ ✕ 
N2159 Iliotibial band syndrome ✕ ✓ ✕ ✓ S49A1 Cls sublux thrcic spine ✓ ✕ ✕ ✕ 
N215A Ischial bursitis ✕ ✓ ✕ ✓ S49A2 Cl spn sublx+thrc crd lsn,unsp ✓ ✕ ✕ ✕ 
N215z Hip enthesopathy NOS ✕ ✓ ✕ ✓ S49A3 Cl spn sublx+comp thrc crd lsn ✓ ✕ ✕ ✕ 
N216 Enthesopathy of knee ✕ ✓ ✕ ✓ S49A4 Cl spn sublx+ant thrc crd lsn ✓ ✕ ✕ ✕ 
N2160 Bursitis of knee NOS ✕ ✓ ✕ ✓ S49A5 Cl spn sublx+cent thrc crd lsn ✓ ✕ ✕ ✕ 
N2161 Pes anserinus tendin./bursitis ✕ ✓ ✕ ✓ S49A6 Cl spn sublx+post thrc crd lsn ✓ ✕ ✕ ✕ 
N2162 Tibial collateral lig.bursitis ✕ ✓ ✕ ✓ S49A7 Cl spn sublx+lmbr crd lsn,unsp ✓ ✕ ✕ ✕ 
N2163 Fibular collat.lig.bursitis ✕ ✓ ✕ ✓ S49A8 Cl spn sublx+comp lmbr crd lsn ✓ ✕ ✕ ✕ 
N2164 Patellar tendinitis ✕ ✓ ✕ ✓ S49A9 Cl spn sublx+ant lmbar crd lsn ✓ ✕ ✕ ✕ 
N2165 Prepatellar bursitis ✕ ✓ ✕ ✓ S49AA Cl spn sublx+cent lmbr crd lsn ✓ ✕ ✕ ✕ 
N2166 Infrapatellar bursitis ✕ ✓ ✕ ✓ S49AB Cl spn sublx+post lmbr crd lsn ✓ ✕ ✕ ✕ 
N2167 Subpatellar bursitis ✕ ✓ ✕ ✓ S49AC Cl spn sublx+cauda equina lsn ✓ ✕ ✕ ✕ 
N2168 Biceps femoris tendinitis ✕ ✓ ✕ ✓ S49Az Cls sublux thrc+lmbr spine NOS ✓ ✕ ✕ ✕ 
N2169 Semimembranosus tendinitis ✕ ✓ ✕ ✓ S49B Opn sublux thrcic+lmbr vertbra ✓ ✕ ✕ ✕ 
N216z Suprapatellar bursitis ✕ ✓ ✕ ✓ S49B0 Open subluxation lumbar spine ✓ ✕ ✕ ✕ 
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N217 Tarsus enthesopathy ✕ ✓ ✕ ✓ S49B1 Opn sublux thoracic spine ✓ ✕ ✕ ✕ 
N2170 Enthesopathy of ankle unspec. ✕ ✓ ✕ ✓ S49B2 Op spn sublx+thrc crd lsn,unsp ✓ ✕ ✕ ✕ 
N2171 Enthesopathy of tarsus unspec. ✕ ✓ ✕ ✓ S49B3 Op spn sublx+comp thrc crd lsn ✓ ✕ ✕ ✕ 
N2172 Metatarsalgia NOS ✕ ✓ ✕ ✓ S49B4 Op spn sublx+ant thrc crd lsn ✓ ✕ ✕ ✕ 
N2173 Achilles bursitis ✕ ✓ ✕ ✓ S49B5 Op spn sublx+cent thrc crd lsn ✓ ✕ ✕ ✕ 
N2174 Achilles tendinitis ✕ ✓ ✕ ✓ S49B6 Op spn sublx+post thrc crd lsn ✓ ✕ ✕ ✕ 
N2175 Tibialis anterior tendinitis ✕ ✓ ✕ ✓ S49B7 Op spn sublx+lmbr crd lsn,unsp ✓ ✕ ✕ ✕ 
N2176 Tibialis posterior tendinitis ✕ ✓ ✕ ✓ S49B8 Op spn sublx+comp lmbr crd lsn ✓ ✕ ✕ ✕ 
N2177 Calcaneal spur ✕ ✓ ✕ ✓ S49B9 Op spn sublux+ant lmbr crd lsn ✓ ✕ ✕ ✕ 
N2178 Peroneal tendinitis ✕ ✓ ✕ ✓ S49BA Op spn sublx+cent lmbr crd lsn ✓ ✕ ✕ ✕ 
N2179 Plantar fasciitis ✕ ✓ ✕ ✓ S49BB Op spn sublx+post lmbr crd lsn ✓ ✕ ✕ ✕ 
N217A Posterior calcaneal exostosis ✕ ✓ ✕ ✓ S49BC Op spn sublx+cauda equina lsn ✓ ✕ ✕ ✕ 
N217B Anterior ankle impingement ✕ ✓ ✕ ✓ S49Bz Op sublx thrc+lmbr vertbra NOS ✓ ✕ ✕ ✕ 
N217C Fibular impingement ✕ ✓ ✕ ✓ S49C Closed sublux other vertebra ✓ ✕ ✕ ✕ 
N217z Ankle/tarsus enthesopathy NOS ✕ ✓ ✕ ✓ S49C0 Closed sublux spine, unsp ✓ ✕ ✕ ✕ 
N21y0 Anterior shin splints ✕ ✓ ✕ ✓ S49C1 Closed subluxation of coccyx ✓ ✕ ✕ ✕ 
N21y1 Posterior shin splints ✕ ✓ ✕ ✓ S49C2 Closed subluxation of sacrum ✓ ✕ ✕ ✕ 
N21z2 Adductor tendonitis ✕ ✓ ✕ ✓ S49Cz Closed subluxation spine NOS ✓ ✕ ✕ ✕ 
N21z3 Bone spur NOS ✕ ✕ ✕ ✕ S49D Open sublux other vertebra ✓ ✕ ✕ ✕ 
N21z4 Subungual exostosis ✕ ✕ ✕ ✕ S49D0 Open sublux spine, unspecified ✓ ✕ ✕ ✕ 
N21z5 Subungual exostosis great toe ✕ ✓ ✕ ✕ S49D1 Open subluxation of coccyx ✓ ✕ ✕ ✕ 
N21z6 Subungual exostosis lesser toe ✕ ✓ ✕ ✕ S49D2 Open subluxation of sacrum ✓ ✕ ✕ ✕ 
N2203 Finger trigger ✕ ✕ ✓ ✕ S49Dz Open subluxation of spine NOS ✓ ✕ ✕ ✕ 
N2204 De Quervains disease ✕ ✕ ✓ ✓ S49E Other closed traumatic sublux ✕ ✕ ✕ ✕ 
N2205 Other hand/wrist tenosynovitis ✕ ✕ ✓ ✓ S49E0 Cls trm sublux of sternum ✓ ✕ ✕ ✕ 
N2206 Tenosynovitis of ankle ✕ ✓ ✕ ✓ S49E1 Cls trm sublux of pelvis ✕ ✓ ✕ ✕ 
N2207 Tenosynovitis of foot ✕ ✓ ✕ ✓ S49E2 Cls trm sublux st-clav jt ✕ ✕ ✓ ✕ 
N220A Flexor tenosynovitis of wrist ✕ ✕ ✓ ✓ S49E3 Cls trm sublux,st-clav jt,ant ✕ ✕ ✓ ✕ 
N220B Flexor tenosynovitis of finger ✕ ✕ ✓ ✓ S49E4 Cls trm sublux,st-clav jt,post ✕ ✕ ✓ ✕ 
N220C Flexor tenosynovitis of thumb ✕ ✕ ✓ ✓ S49E5 Cls trm sublux laryngl cart ✓ ✕ ✕ ✕ 
N220D Extensor tenosynovitis of wrist ✕ ✕ ✓ ✓ S49E6 Cls trm sublux costo-vert jt ✓ ✕ ✕ ✕ 
N220E Extensor tenosynovitis-finger ✕ ✕ ✓ ✓ S49E7 Cls trm sublux costo-chond jt ✓ ✕ ✕ ✕ 
N220F Extensor tenosynovitis of thumb ✕ ✕ ✓ ✓ S49Ez Oth closed subluxation NOS ✕ ✕ ✕ ✕ 
N220G Acquired trigger thumb ✕ ✕ ✓ ✕ S49F Oth open traumatic subluxation ✕ ✕ ✕ ✕ 
N220H Achilles tenosynovitis ✕ ✓ ✕ ✓ S49F0 Opn trm sublux of sternum ✓ ✕ ✕ ✕ 
N220J Tibialis ant tenosynovitis ✕ ✓ ✕ ✓ S49F1 Opn trm sublux of pelvis ✕ ✓ ✕ ✕ 
N220K Tibialis post tenosynovitis ✕ ✓ ✕ ✓ S49F2 Opn trm sublux st-clav jt ✕ ✕ ✓ ✕ 
N220L Exten hal longus tenosynovitis ✕ ✓ ✕ ✓ S49F3 Opn trm sublux,st-clav jt,ant ✕ ✕ ✓ ✕ 
N220M Exten dig longus tenosynovitis ✕ ✓ ✕ ✓ S49F4 Opn trm sublux,st-clav jt,post ✕ ✕ ✓ ✕ 
N220N Peroneus longus tenosynovitis ✕ ✓ ✕ ✓ S49F5 Opn trm sublux laryngl cartlge ✓ ✕ ✕ ✕ 
N220P Peroneus brevis tenosynovitis ✕ ✓ ✕ ✓ S49F6 Opn trm sublux costo-verteb jt ✓ ✕ ✕ ✕ 
N220R Chron crep synovit hand/wrist ✕ ✕ ✓ ✕ S49F7 Opn trm sublux costo-chond jt ✓ ✕ ✕ ✕ 
N220S Synovitis of hip ✕ ✓ ✕ ✓ S49Fz Other open subluxation NOS ✕ ✕ ✕ ✕ 
N220z Synovitis of knee ✕ ✓ ✕ ✓ S49x Hand dislocation NOS ✕ ✕ ✓ ✕ 
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N221 Bunion ✕ ✓ ✕ ✕ S49X0 Traum pubic symph separation ✕ ✓ ✕ ✕ 
N2210 Infected bunion ✕ ✓ ✕ ✕ S49z Other dislocation NOS ✕ ✕ ✕ ✕ 
N2220 Beat elbow ✕ ✕ ✓ ✓ S4A #-dslc or subluxation shoulder ✕ ✕ ✓ ✕ 
N2221 Beat hand ✕ ✕ ✓ ✓ S4A0 Closed #-dslc shoulder ✕ ✕ ✓ ✕ 
N2222 Beat knee ✕ ✓ ✕ ✓ S4A00 Closed #-dslc shoulder joint ✕ ✕ ✓ ✕ 
N2223 Miners' elbow ✕ ✕ ✓ ✓ S4A01 Closed #-dslc acrom-clav joint ✕ ✕ ✓ ✕ 
N2224 Miners' knee ✕ ✓ ✕ ✓ S4A1 Open #-dslc shoulder ✕ ✕ ✓ ✕ 
N2225 Housemaids knee ✕ ✓ ✕ ✓ S4A10 Open #-dslc shoulder joint ✕ ✕ ✓ ✕ 
N224* Ganglion and synovial cyst ✕ ✕ ✕ ✕ S4A11 Open #-dslc acrom-clav joint ✕ ✕ ✓ ✕ 
N2240 Synovial cyst unspecified ✕ ✕ ✕ ✕ S4A2 Closed #-sublux shoulder ✕ ✕ ✓ ✕ 
N2241 Ganglion of joint ✕ ✕ ✕ ✕ S4A20 Closed #-sublux shoulder joint ✕ ✕ ✓ ✕ 
N2242 Ganglion of tendon sheath ✕ ✕ ✕ ✕ S4A21 Closed #-sublux acrom-clav jt ✕ ✕ ✓ ✕ 
N2243 Ganglion unspecified ✕ ✕ ✕ ✕ S4A3 Open #-sublux shoulder ✕ ✕ ✓ ✕ 
N2244 Cyst of bursa ✕ ✕ ✕ ✕ S4A30 Open #-sublux shoulder joint ✕ ✕ ✓ ✕ 
N2245 Ganglion of wrist ✕ ✕ ✓ ✕ S4A31 Open #-sublux acrom-clav joint ✕ ✕ ✓ ✕ 
N2246 Ganglion of knee ✕ ✓ ✕ ✕ S4B #-dslc/subluxation elbow ✕ ✕ ✓ ✕ 
N2247 Ganglion-superior tib-fib jnt ✕ ✓ ✕ ✕ S4B0 Closed #-dislocation elbow ✕ ✕ ✓ ✕ 
N2248 Ganglion of ankle ✕ ✓ ✕ ✕ S4B00 Closed #-dslc elbow joint ✕ ✕ ✓ ✕ 
N2249 Ganglion,flex tend sheath-fing ✕ ✕ ✓ ✕ S4B01 Cl #-disl sup rad-ulnar joint ✕ ✕ ✓ ✕ 
N224A Bakers cyst ✕ ✓ ✕ ✕ S4B1 Open #-dislocation elbow ✕ ✕ ✓ ✕ 
N224B Ganglion of hand ✕ ✕ ✓ ✕ S4B10 Open #-dislocation elbow joint ✕ ✕ ✓ ✕ 
N224C Ganglion of foot ✕ ✓ ✕ ✕ S4B11 Op #-discl sup rad-ulnar joint ✕ ✕ ✓ ✕ 
N224D Cyst of tendon sheath ✕ ✕ ✕ ✕ S4B2 Closed #-sublux elbow ✕ ✕ ✓ ✕ 
N224z Ganglion/synovial cyst NOS ✕ ✕ ✕ ✕ S4B20 Closed #-sublux elbow joint ✕ ✕ ✓ ✕ 
N225 Rupture of synovium ✕ ✕ ✕ ✕ S4B21 Cl #-sublx sup rad-ulnar joint ✕ ✕ ✓ ✕ 
N2250 Rupture of synovium unspecif. ✕ ✕ ✕ ✕ S4B3 Open #-sublux elbow ✕ ✕ ✓ ✕ 
N2251 Rupture of Bakers cyst - knee ✕ ✓ ✕ ✕ S4B30 Open #-sublux elbow joint ✕ ✕ ✓ ✕ 
N225z Rupture of synovium NOS ✕ ✕ ✕ ✕ S4B31 Op #-sublx sup rad-ulnar joint ✕ ✕ ✓ ✕ 
N226 Nontraumatic tendon subluxatn ✕ ✕ ✕ ✕ S4C #-dslc/subluxation of wrist ✕ ✕ ✓ ✕ 
N2260 Nontraum.unspec.tendon rupture ✕ ✕ ✕ ✕ S4C0 Closed fracture dslc of wrist ✕ ✕ ✓ ✕ 
N2261 Rotator cuff complete rupture ✕ ✕ ✓ ✕ S4C00 Cl #-disl distal rad-uln joint ✕ ✕ ✓ ✕ 
N2262 Biceps tendon rupture ✕ ✕ ✓ ✕ S4C01 Closed #-dsl radiocarpal joint ✕ ✕ ✓ ✕ 
N2263 Hand/wrist extensor tend.rupt. ✕ ✕ ✓ ✕ S4C02 Closed #-dslc mid carpal ✕ ✕ ✓ ✕ 
N2264 Hand/wrist flexor tendon rupt. ✕ ✕ ✓ ✕ S4C03 Closed #-dslc CMCJ ✕ ✕ ✓ ✕ 
N2265 Quadriceps tendon rupture ✕ ✓ ✕ ✕ S4C04 Closed #-dslc lunate (volar) ✕ ✕ ✓ ✕ 
N2266 Patellar tendon nontraum.rupt. ✕ ✓ ✕ ✕ S4C05 Closed #-dslc pri-lun(dors) ✕ ✕ ✓ ✕ 
N2267 Achilles tendon nontraum.rupt. ✕ ✓ ✕ ✕ S4C06 Cls #-dslc pri-lun trans-scphd ✕ ✕ ✓ ✕ 
N2268 Extensor dig communis rupture ✕ ✓ ✕ ✕ S4C0y Closed #-dslc other carpal ✕ ✕ ✓ ✕ 
N2269 Extensor poll longus rupture ✕ ✕ ✓ ✕ S4C1 Open fracture dslc wrist ✕ ✕ ✓ ✕ 
N226A Long head of biceps rupture ✕ ✕ ✓ ✕ S4C10 Open #-disl dstl rad-uln joint ✕ ✕ ✓ ✕ 
N226B Subluxation, long head-biceps ✕ ✕ ✓ ✕ S4C11 Open #-disloc radiocarpal jnt ✕ ✕ ✓ ✕ 
N226C Flex dig sublimis tend rupture ✕ ✕ ✓ ✕ S4C12 Open #-dslc mid carpal ✕ ✕ ✓ ✕ 
N226D Flex dig profund tend rupture ✕ ✕ ✓ ✕ S4C13 Open #-dslc CMCJ ✕ ✕ ✓ ✕ 
N226E Flex poll long tendon rupture ✕ ✕ ✓ ✕ S4C14 Open #-dslc lunate (volar) ✕ ✕ ✓ ✕ 
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N226F Tibialis posterior rupture ✕ ✓ ✕ ✕ S4C15 Open #-dslc pri-lun(dors) ✕ ✕ ✓ ✕ 
N226G Peroneus longus rupture ✕ ✓ ✕ ✕ S4C16 Opn #-dslc pri-lun trns-scaphd ✕ ✕ ✓ ✕ 
N226H Subluxation of peroneal tendon ✕ ✓ ✕ ✕ S4C1y Open #-dslc other carpal ✕ ✕ ✓ ✕ 
N226J Subluxation tendon wrist/hand ✕ ✕ ✓ ✕ S4C2 Closed #-sublux of the wrist ✕ ✕ ✓ ✕ 
N226K Dislocation tendon wrist/hand ✕ ✕ ✓ ✕ S4C20 Cl #-sblx distal rad-uln joint ✕ ✕ ✓ ✕ 
N226L Bowstringing tendon wrist/hand ✕ ✕ ✓ ✕ S4C21 Closed #-sublx radcarpal joint ✕ ✕ ✓ ✕ 
N226y Other foot/ankle tendon rupt. ✕ ✓ ✕ ✕ S4C22 Closed #-sublux mid carpal ✕ ✕ ✓ ✕ 
N226z Other nontraumatic tendon rupt ✕ ✕ ✕ ✕ S4C23 Closed #-sublux CMCJ ✕ ✕ ✓ ✕ 
N22y0 Short Achilles tendon ✕ ✓ ✕ ✕ S4C24 Closed #-sublux lunate (volar) ✕ ✕ ✓ ✕ 
N22y1 Calcification of tendon NOS ✕ ✕ ✕ ✕ S4C25 Cls #-sublux pri-lun (dorsal) ✕ ✕ ✓ ✕ 
N22y2 Abscess of tendon ✕ ✕ ✕ ✕ S4C26 Cls #-sublux pri-lun trns-scph ✕ ✕ ✓ ✕ 
N22y3 Abscess of bursa ✕ ✕ ✕ ✕ S4C2y Closed #-sublux other carpal ✕ ✕ ✓ ✕ 
N22y4 Synovial plica of knee ✕ ✓ ✕ ✕ S4C3 Open #-sublux of the wrist ✕ ✕ ✓ ✕ 
N22y5 Short tendon ✕ ✕ ✕ ✕ S4C30 Open #-sblx,dist rad-uln joint ✕ ✕ ✓ ✕ 
N22y6 Abscess of tendon-arm ✕ ✕ ✓ ✕ S4C31 Open #-sublux radcarpal joint ✕ ✕ ✓ ✕ 
N22y7 Abscess of tendon-forearm ✕ ✕ ✓ ✕ S4C32 Open #-sublux mid carpal ✕ ✕ ✓ ✕ 
N22y8 Abscess of tendon-hand ✕ ✕ ✓ ✕ S4C33 Open #-sublux CMCJ ✕ ✕ ✓ ✕ 
N22y9 Abscess of tendon-thigh ✕ ✓ ✕ ✕ S4C34 Open #-sublux lunate (volar) ✕ ✕ ✓ ✕ 
N22yA Abscess of tendon-leg ✕ ✓ ✕ ✕ S4C35 Open #-sublux pri-lun (dorsal) ✕ ✕ ✓ ✕ 
N22yB Abscess of tendon-foot ✕ ✓ ✕ ✕ S4C36 Op #-sublux pri-lun trns-scph ✕ ✕ ✓ ✕ 
N22yC Pyogenic infec - tendon sheath ✕ ✕ ✕ ✕ S4C3y Open #-sublux other carpal ✕ ✕ ✓ ✕ 
N22yD Tuberc infec - tendon sheath ✕ ✕ ✕ ✕ S4D #-dslc/sublux finger/thumb ✕ ✕ ✓ ✕ 
N22yE Abscess of bursa-shoulder ✕ ✕ ✓ ✕ S4D0 Closed #-disloc digit ✕ ✕ ✓ ✕ 
N22yF Abscess of bursa-elbow ✕ ✕ ✓ ✕ S4D00 Closed #-disloc digit, unsp ✕ ✕ ✓ ✕ 
N22yG Abscess of bursa-wrist ✕ ✕ ✓ ✕ S4D01 Closed #-disloc MPJ ✕ ✕ ✓ ✕ 
N22yH Abscess of bursa-hip ✕ ✓ ✕ ✕ S4D02 Closed #-disloc IPJ, unsp ✕ ✕ ✓ ✕ 
N22yJ Abscess of bursa-knee ✕ ✓ ✕ ✕ S4D03 Closed #-disloc DIPJ ✕ ✕ ✓ ✕ 
N22yK Abscess of bursa-ankle ✕ ✓ ✕ ✕ S4D04 Closed #-disloc PIPJ ✕ ✕ ✓ ✕ 
N22yL Abscess of bursa-foot ✕ ✓ ✕ ✕ S4D05 Closed #-disloc IPJ thumb ✕ ✕ ✓ ✕ 
N22yM Short Achilles tend - acquired ✕ ✓ ✕ ✕ S4D06 Closed #-dslc multiple digits ✕ ✕ ✓ ✕ 
N22yN Achilles degeneration ✕ ✓ ✕ ✕ S4D1 Open #-disloc digit ✕ ✕ ✓ ✕ 
N2300 Infective myositis-neck ✓ ✕ ✕ ✕ S4D10 Open #-disloc digit, unsp ✕ ✕ ✓ ✕ 
N2301 Infective myositis-back ✓ ✕ ✕ ✕ S4D11 Open #-disloc MPJ ✕ ✕ ✓ ✕ 
N2302 Infective myositis-shoulder ✕ ✕ ✓ ✕ S4D12 Open #-disloc IPJ, unsp ✕ ✕ ✓ ✕ 
N2303 Infective myositis-arm ✕ ✕ ✓ ✕ S4D13 Open #-disloc DIPJ ✕ ✕ ✓ ✕ 
N2304 Infective myositis-forearm ✕ ✕ ✓ ✕ S4D14 Open #-disloc PIPJ ✕ ✕ ✓ ✕ 
N2305 Infective myositis-hand ✕ ✕ ✓ ✕ S4D15 Open #-disloc IPJ thumb ✕ ✕ ✓ ✕ 
N2306 Infective myositis-pelvis ✕ ✓ ✕ ✕ S4D16 Open #-dslc multiple digits ✕ ✕ ✓ ✕ 
N2307 Infective myositis-thigh ✕ ✓ ✕ ✕ S4D2 Closed #-sublux digit ✕ ✕ ✓ ✕ 
N2308 Infective myositis-leg ✕ ✓ ✕ ✕ S4D20 Closed #-sublux digit, unsp ✕ ✕ ✓ ✕ 
N2309 Infective myositis-foot ✕ ✓ ✕ ✕ S4D21 Closed #-sublux MPJ ✕ ✕ ✓ ✕ 
N230A Muscle abscess ✕ ✕ ✕ ✕ S4D22 Closed #-sublux IPJ, unsp ✕ ✕ ✓ ✕ 
N230B Muscle abscess-neck ✓ ✕ ✕ ✕ S4D23 Closed #-sublux DIPJ ✕ ✕ ✓ ✕ 
N230C Muscle abscess-back ✓ ✕ ✕ ✕ S4D24 Closed #-sublux PIPJ ✕ ✕ ✓ ✕ 
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N230D Muscle abscess-shoulder ✕ ✕ ✓ ✕ S4D25 Closed #-sublux IPJ thumb ✕ ✕ ✓ ✕ 
N230E Muscle abscess-arm ✕ ✕ ✓ ✕ S4D26 Cls #-subluxation mlti digits ✕ ✕ ✓ ✕ 
N230F Muscle abscess-forearm ✕ ✕ ✓ ✕ S4D3 Open #-subluxation digit ✕ ✕ ✓ ✕ 
N230G Muscle abscess-hand ✕ ✕ ✓ ✕ S4D30 Open #-subluxation digit, unsp ✕ ✕ ✓ ✕ 
N230H Muscle abscess-pelvis ✕ ✓ ✕ ✕ S4D31 Open #-subluxation MPJ ✕ ✕ ✓ ✕ 
N230J Muscle abscess-thigh ✕ ✓ ✕ ✕ S4D32 Open #-subluxation IPJ, unsp ✕ ✕ ✓ ✕ 
N230K Muscle abscess-leg ✕ ✓ ✕ ✕ S4D33 Open #-subluxation DIPJ ✕ ✕ ✓ ✕ 
N230L Muscle abscess-foot ✕ ✓ ✕ ✕ S4D34 Open #-subluxation PIPJ ✕ ✕ ✓ ✕ 
N236 Dupuytrens contracture ✕ ✕ ✓ ✕ S4D35 Open #-subluxation IPJ thumb ✕ ✕ ✓ ✕ 
N2360 Dupuytren's disease of palm ✕ ✕ ✓ ✕ S4D36 Open #-sublux multiple digits ✕ ✕ ✓ ✕ 
N2361 Dupuyt dis-palm + nod no cont ✕ ✕ ✓ ✕ S4E #-dslc/subluxation hip ✕ ✓ ✕ ✕ 
N2362 Dupuyt dis-palm + contracture ✕ ✕ ✓ ✕ S4E0 Closed #-dslc, hip joint ✕ ✓ ✕ ✕ 
N2363 Dupuytren's disease-finger(s) ✕ ✕ ✓ ✕ S4E1 Open #-dslc, hip joint ✕ ✓ ✕ ✕ 
N2364 Dupuyt dis-fing + nod, no cont ✕ ✕ ✓ ✕ S4E2 Closed #-sublux, hip joint ✕ ✓ ✕ ✕ 
N2365 Dupuyt dis-finger(s) + contrac ✕ ✕ ✓ ✕ S4E3 Open #-sublux, hip joint ✕ ✓ ✕ ✕ 
N2366 Dupuyt dis-palm and finger(s) ✕ ✕ ✓ ✕ S4F #-dslc/subluxation knee ✕ ✓ ✕ ✕ 
N2367 Dup dis,palm+fing,+nod,no cont ✕ ✕ ✓ ✕ S4F0 Closed #-dslc, knee joint ✕ ✓ ✕ ✕ 
N2368 Dup dis,palm+fing,+contracture ✕ ✕ ✓ ✕ S4F1 Open #-dslc, knee joint ✕ ✓ ✕ ✕ 
N2370 Plantar fascial fibromatosis ✕ ✓ ✕ ✕ S4F2 Closed #-sublux, knee joint ✕ ✓ ✕ ✕ 
N2371 Knuckle pads ✕ ✕ ✓ ✕ S4F3 Open #-sublux, knee joint ✕ ✓ ✕ ✕ 
N2380 Contracture - pectoralis major ✓ ✕ ✕ ✕ S4F4 Cls #-dslc,patello-fem jt ✕ ✓ ✕ ✕ 
N2381 Contracture of triceps ✕ ✕ ✓ ✕ S4F5 Open #-dslc,patello-fem jt ✕ ✓ ✕ ✕ 
N2382 Contracture of biceps ✕ ✕ ✓ ✕ S4F6 Cls #-sublux,patello-fem jt ✕ ✓ ✕ ✕ 
N2383 Contracture of wrist flexor(s) ✕ ✕ ✓ ✕ S4F7 Open #-sublux,patello-fem jt ✕ ✓ ✕ ✕ 
N2384 Contracture - wrist extensor ✕ ✕ ✓ ✕ S4G #-dslc/subluxation ankle ✕ ✓ ✕ ✕ 
N2385 Contracture - flex poll longus ✕ ✕ ✓ ✕ S4G0 Closed #-dslc, ankle joint ✕ ✓ ✕ ✕ 
N2386 Contracture - thumb extensor ✕ ✕ ✓ ✕ S4G1 Open #-dslc, ankle joint ✕ ✓ ✕ ✕ 
N2387 Contracture-flex dig superfic ✕ ✕ ✓ ✕ S4G2 Closed #-sublux, ankle joint ✕ ✓ ✕ ✕ 
N2388 Contracture - flex dig profund ✕ ✕ ✓ ✕ S4G3 Open #-sublux, ankle joint ✕ ✓ ✕ ✕ 
N2389 Contracture-adductor pollicis ✕ ✕ ✓ ✕ S4H #-dslc/subluxation foot ✕ ✓ ✕ ✕ 
N238A Contract-oth intrin musc-hand ✕ ✕ ✓ ✕ S4H0 Closed #-dislocation foot ✕ ✓ ✕ ✕ 
N238B Contracture of iliopsoas ✕ ✓ ✕ ✕ S4H00 Closed #-dslc, subtalar joint ✕ ✓ ✕ ✕ 
N238C Contracture of rectus femoris ✕ ✓ ✕ ✕ S4H01 Closed #-dslc midtarsal jt ✕ ✓ ✕ ✕ 
N238D Contracture-adductor musc-hip ✕ ✓ ✕ ✕ S4H02 Cls #-dslc,tarsometatarsal jt ✕ ✓ ✕ ✕ 
N238E Contracture-abductor musc-hip ✕ ✓ ✕ ✕ S4H03 Cls #-dslc,metatrsphln jt,sgl ✕ ✓ ✕ ✕ 
N238F Contracture of hamstring(s) ✕ ✓ ✕ ✕ S4H04 Cls #-dslc,interphln jt,single ✕ ✓ ✕ ✕ 
N238G Contracture of quadriceps ✕ ✓ ✕ ✕ S4H05 Cls #-dslc,mtatrsophln jt,mlti ✕ ✓ ✕ ✕ 
N238H Contracture of tendo achilles ✕ ✓ ✕ ✕ S4H06 Cls #-dslc,interphln jt,mlti ✕ ✓ ✕ ✕ 
N238J Contracture-tibialis anterior ✕ ✓ ✕ ✕ S4H1 Open #-dslc, foot ✕ ✓ ✕ ✕ 
N238K Contracture-tibialis posterior ✕ ✓ ✕ ✕ S4H10 Open #-dslc, subtalar joint ✕ ✓ ✕ ✕ 
N238L Contracture-long toe flexor ✕ ✓ ✕ ✕ S4H11 Open #-dslc, midtarsal joint ✕ ✓ ✕ ✕ 
N238M Contracture-long toe extensor ✕ ✓ ✕ ✕ S4H12 Open #-dslc,tarsometatarsal jt ✕ ✓ ✕ ✕ 
N238N Contracture-intrin muscle-foot ✕ ✓ ✕ ✕ S4H13 Op #-dslc,mtatrsphln jt,single ✕ ✓ ✕ ✕ 
N23y2 Nontraumatic muscle rupture ✕ ✕ ✕ ✕ S4H14 Op #-dslc,interphln jt,single ✕ ✓ ✕ ✕ 
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N23y3 Divarication of recti ✕ ✕ ✕ ✕ S4H15 Opn #-dslc,metatrsphln jt,mlti ✕ ✓ ✕ ✕ 
N23y6 Palmar space infecn, thenar ✕ ✕ ✓ ✕ S4H16 Open #-dslc,interphln jt,mlti ✕ ✓ ✕ ✕ 
N23y7 Palmar space infecn, mid-palm ✕ ✕ ✓ ✕ S4H2 Closed #-sublux, foot ✕ ✓ ✕ ✕ 
N23y8 Palmar space infecn,hypo-thena ✕ ✕ ✓ ✕ S4H20 Closed #-sublux, subtalar jt ✕ ✓ ✕ ✕ 
N23yA Diastasis of muscle ✕ ✕ ✕ ✕ S4H21 Closed #-sublux, midtarsal jt ✕ ✓ ✕ ✕ 
N23yB Ischaemic infarction of muscle ✕ ✕ ✕ ✕ S4H22 Cls #-sublux,tarsometatarsl jt ✕ ✓ ✕ ✕ 
N23yD Muscle strain ✕ ✕ ✕ ✕ S4H23 Cl #-sublx,metatrsphln jt,sng ✕ ✓ ✕ ✕ 
N23yE Spasm of back muscles ✓ ✕ ✕ ✓ S4H24 Cl #-sublux,interphln jt,sngle ✕ ✓ ✕ ✕ 
N2405 Fibrositis of neck ✓ ✕ ✕ ✓ S4H25 Cl #-sublux,mtatrsphln jt,mlti ✕ ✓ ✕ ✕ 
N2406 Fibrositis arm ✕ ✕ ✓ ✓ S4H26 Cls #-sublux,interphln jt,mlti ✕ ✓ ✕ ✕ 
N2407 Hand rheumatism ✕ ✕ ✓ ✓ S4H3 Open #-sublux, foot ✕ ✓ ✕ ✕ 
N2410* Intercostal myalgia ✕ ✓ ✓ ✓ S4H30 Open #-sublux, subtalar joint ✕ ✓ ✕ ✕ 
N2431 Hypertrophy of knee fat pad ✕ ✓ ✕ ✕ S4H31 Open #-sublux,midtarsal jt ✕ ✓ ✕ ✕ 
N245* Ankle pain ✕ ✕ ✕ ✓ S4H32 Op #-sublux,tarsometatarsal jt ✕ ✓ ✕ ✕ 
N2450 Finger pain ✕ ✕ ✓ ✓ S4H33 Op #-sublux,MTP joint,single ✕ ✓ ✕ ✕ 
N2451 Foot pain ✕ ✓ ✕ ✓ S4H34 Opn #-sublux,interphln jt,sng ✕ ✓ ✕ ✕ 
N2452 Aching leg syndrome ✕ ✓ ✕ ✓ S4H35 Op #-sublx,mtatrsphln jt,mlti ✕ ✓ ✕ ✕ 
N2453 Pain in arm ✕ ✕ ✓ ✓ S4H36 Opn #-sublux,interphln jt,mlti ✕ ✓ ✕ ✕ 
N2454 Calf pain ✕ ✓ ✕ ✓ S4J Other #-dslc or subluxation ✕ ✕ ✕ ✕ 
N2455 Axillary pain ✕ ✕ ✓ ✓ S4J0 Other closed #-dislocation ✕ ✕ ✕ ✕ 
N2456 Tender heel pad ✕ ✓ ✕ ✓ S4J00 Closed #-dslc of sternum ✓ ✕ ✕ ✕ 
N2457 Shoulder pain ✕ ✕ ✓ ✓ S4J01 Closed #-dslc of pelvis ✕ ✓ ✕ ✕ 
N2459 Pain in buttock ✕ ✓ ✕ ✓ S4J02 Cls #-dslc st-clav jt,ant ✕ ✕ ✓ ✕ 
N2470 Swelling of calf ✕ ✓ ✕ ✕ S4J03 Cls #-dslc st-clav jt,post ✕ ✕ ✓ ✕ 
N2471* Leg cramps ✕ ✕ ✕ ✓ S4J1 Other open #-dislocation ✕ ✕ ✕ ✕ 
N247z* Hand cramps ✕ ✕ ✕ ✓ S4J10 Open #-dslc of sternum ✓ ✕ ✕ ✕ 
N3000 Acute osteomyelitis-site unsp. ✕ ✕ ✕ ✕ S4J11 Open #-dslc of pelvis ✕ ✓ ✕ ✕ 
N3001 Acute osteomyelitis-shoulder ✕ ✕ ✓ ✕ S4J12 Open #-dslc st-clav jt,ant ✕ ✕ ✓ ✕ 
N3002 Acute osteomyelitis-upper arm ✕ ✕ ✓ ✕ S4J13 Open #-dslc st-clav jt,post ✕ ✕ ✓ ✕ 
N3003 Acute osteomyelitis-forearm ✕ ✕ ✓ ✕ S4J2 Other closed #-sublux ✕ ✕ ✕ ✕ 
N3004 Acute osteomyelitis-hand ✕ ✕ ✓ ✕ S4J20 Closed #-sublux of sternum ✓ ✕ ✕ ✕ 
N3005 Thigh acute osteomyelitis ✕ ✓ ✕ ✕ S4J21 Closed #-sublux of pelvis ✕ ✓ ✕ ✕ 
N3006 Acute osteomyelitis-lower leg ✕ ✓ ✕ ✕ S4J22 Cls #-sublux st-clav jt,ant ✕ ✕ ✓ ✕ 
N3007 Foot - acute osteomyelitis ✕ ✓ ✕ ✕ S4J23 Cls #-sublux st-clav jt,post ✕ ✕ ✓ ✕ 
N300A Acute osteomyelitis-cerv spine ✓ ✕ ✕ ✕ S4J3 Other open #-subluxation ✕ ✕ ✕ ✕ 
N300B Acute osteomyelitis-thor spine ✓ ✕ ✕ ✕ S4J30 Open #-sublux of sternum ✓ ✕ ✕ ✕ 
N300C Acute osteomyelitis-lumb spine ✓ ✕ ✕ ✕ S4J31 Open #-sublux of pelvis ✕ ✓ ✕ ✕ 
N300D Acute osteomyelitis-sacrum ✓ ✕ ✕ ✕ S4J32 Open #-sublux st-clav jt,ant ✕ ✕ ✓ ✕ 
N300E Acute osteomyelitis-coccyx ✓ ✕ ✕ ✕ S4J33 Open #-sublux st-clav jt,post ✕ ✕ ✓ ✕ 
N300F Acute osteomyelitis-clavicle ✕ ✕ ✓ ✕ S4z Dislocation or subluxation NOS ✕ ✕ ✕ ✕ 
N300G Acute osteomyelitis-scapula ✕ ✕ ✓ ✕ S50 Sprain shoulder/upper arm ✕ ✕ ✓ ✕ 
N300H Acute osteomyelitis-humerus ✕ ✕ ✓ ✕ S500 Sprain acromio-clav ligament ✕ ✕ ✓ ✕ 
N300J Acute osteomyelitis-radius ✕ ✕ ✓ ✕ S501 Sprain, coraco-clav ligament ✕ ✕ ✓ ✕ 
N300K Acute osteomyelitis-ulna ✕ ✕ ✓ ✕ S502 Coracohumeral sprain ✕ ✕ ✓ ✕ 
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N300L Acute osteomyelitis-carp bone ✕ ✕ ✓ ✕ S503 Sprain infraspinatus tendon ✕ ✕ ✓ ✕ 
N300M Acute osteomyelitis-metacarpal ✕ ✕ ✓ ✕ S504 Rotator cuff sprain ✕ ✕ ✓ ✕ 
N300N Acute osteomyelit-phal fing/th ✕ ✕ ✓ ✕ S505 Sprain, subscapularis tendon ✕ ✕ ✓ ✕ 
N300P Acute osteomyelitis-pelvis ✕ ✓ ✕ ✕ S506 Sprain, supraspinatus tendon ✕ ✕ ✓ ✕ 
N300Q Acute osteomyelitis-femur ✕ ✓ ✕ ✕ S507 Sprain shoulder joint ✕ ✕ ✓ ✕ 
N300R Acute osteomyelitis-patella ✕ ✓ ✕ ✕ S5070 Sprain,shoulder joint,anterior ✕ ✕ ✓ ✕ 
N300S Acute osteomyelitis-tibia ✕ ✓ ✕ ✕ S5071 Sprain,shoulder jnt,posterior ✕ ✕ ✓ ✕ 
N300T Acute osteomyelitis-fibula ✕ ✓ ✕ ✕ S508 Sprain biceps tendon ✕ ✕ ✓ ✕ 
N300U Acute osteomyelitis-calcaneum ✕ ✓ ✕ ✕ S509 Sprain,long head biceps tendon ✕ ✕ ✓ ✕ 
N300V Acute osteomyelitis-talus ✕ ✓ ✕ ✕ S50A Sprain triceps tendon ✕ ✕ ✓ ✕ 
N300W Acute osteomyelitis oth tarsal ✕ ✓ ✕ ✕ S50w Shoulder strain ✕ ✕ ✓ ✕ 
N300X Acute osteomyelitis-metatarsal ✕ ✓ ✕ ✕ S50x Other upper arm sprain ✕ ✕ ✓ ✕ 
N300Y Acute osteomyelitis-phal toe ✕ ✓ ✕ ✕ S50X Spr/str oth/un part shl gir ✕ ✕ ✓ ✕ 
N3011 Chron.osteomyelitis-shoulder ✕ ✕ ✓ ✕ S50y Shoulder sprain NOS ✕ ✕ ✓ ✕ 
N3012 Chron.osteomyelitis-upper arm ✕ ✕ ✓ ✕ S50z Upper arm sprain NOS ✕ ✕ ✓ ✕ 
N3013 Chron.osteomyelitis-forearm ✕ ✕ ✓ ✕ S51 Forearm sprain ✕ ✕ ✓ ✕ 
N3014 Chron.osteomyelitis-hand ✕ ✕ ✓ ✕ S510 Sprn,elbw jt,rdl clltrl lgmnt ✕ ✕ ✓ ✕ 
N3015 Thigh - chronic osteomyelitis ✕ ✓ ✕ ✕ S511 Sprn,elbw jt,uln clltrl lgmnt ✕ ✕ ✓ ✕ 
N3016 Chron.osteomyelitis-lower leg ✕ ✓ ✕ ✕ S512 Radiohumeral sprain ✕ ✕ ✓ ✕ 
N3017 Foot - chronic osteomyelitis ✕ ✓ ✕ ✕ S513 Ulnohumeral sprain ✕ ✕ ✓ ✕ 
N301A Chronic osteomyelitis-Cx spine ✓ ✕ ✕ ✕ S51w Other elbow sprain ✕ ✕ ✓ ✕ 
N301B Chronic osteomyelitis-th spine ✓ ✕ ✕ ✕ S51x Other forearm sprain ✕ ✕ ✓ ✕ 
N301C Chronic osteomyelitis-lu spine ✓ ✕ ✕ ✕ S51y Elbow sprain NOS ✕ ✕ ✓ ✕ 
N301D Chronic osteomyelitis-sacrum ✓ ✕ ✕ ✕ S51z Forearm sprain NOS ✕ ✕ ✓ ✕ 
N301E Chronic osteomyelitis-coccyx ✓ ✕ ✕ ✕ S52 Sprain of wrist and hand ✕ ✕ ✓ ✕ 
N301F Brodie's abscess-cervic spine ✓ ✕ ✕ ✕ S520 Sprain wrist ligament ✕ ✕ ✓ ✕ 
N301G Brodie's abscess-thorac spine ✓ ✕ ✕ ✕ S5200 Wrist sprain unspecified ✕ ✕ ✓ ✕ 
N301H Brodie's abscess-lumbar spine ✓ ✕ ✕ ✕ S5201 Carpal joint sprain ✕ ✕ ✓ ✕ 
N301J Brodie's abscess-sacrum ✓ ✕ ✕ ✕ S5202 Sprn prox radcrp lgmnt non-sp ✕ ✕ ✓ ✕ 
N301K Brodie's abscess-coccyx ✓ ✕ ✕ ✕ S5203 Distal radioulnar joint sprain ✕ ✕ ✓ ✕ 
N3020 Unsp.osteomyelitis-site unspec ✕ ✕ ✕ ✕ S5204 Sprn radial collateral lgmnt ✕ ✕ ✓ ✕ 
N3021 Unsp.osteomyelitis-shoulder ✕ ✕ ✓ ✕ S5205 Sprn volar rad-carp lig non-sp ✕ ✕ ✓ ✕ 
N3022 Unsp.osteomyelitis-upper arm ✕ ✕ ✓ ✕ S5206 Sprn volar rad-carp lig sprfcl ✕ ✕ ✓ ✕ 
N3023 Unsp.osteomyelitis-forearm ✕ ✕ ✓ ✕ S5207 Sprn radio-scapho-cptate lgmnt ✕ ✕ ✓ ✕ 
N3024 Unsp.osteomyelitis-hand ✕ ✕ ✓ ✕ S5208 Sprain radio-lunate ligament ✕ ✕ ✓ ✕ 
N3025 Unsp.osteomyelitis-pelv/thigh ✕ ✓ ✕ ✕ S5209 Sprn radio-scapho-lunate lgmnt ✕ ✕ ✓ ✕ 
N3026 Unsp.osteomyelitis-lower leg ✕ ✓ ✕ ✕ S520A Sprn dorsal radio-carpal lgmnt ✕ ✕ ✓ ✕ 
N3027 Unsp.osteomyelitis-ankle/foot ✕ ✓ ✕ ✕ S520B Sprn ulnr carpal complx non-sp ✕ ✕ ✓ ✕ 
N302a Osteomyelitis of vertebra ✓ ✕ ✕ ✕ S520C Sprain ulnar-carpal meniscus ✕ ✕ ✓ ✕ 
N302A Infection of cervical spine ✓ ✕ ✕ ✕ S520D Sprn triangular fibrocartilage ✕ ✕ ✓ ✕ 
N302B Infection of thoracic spine ✓ ✕ ✕ ✕ S520E Sprain ulno-lunate ligament ✕ ✕ ✓ ✕ 
N302C Infection of lumbar spine ✓ ✕ ✕ ✕ S520F Sprn ulnar collateral lgmnt ✕ ✕ ✓ ✕ 
N302D Infection of sacrum ✓ ✕ ✕ ✕ S520G Sprn shrt intrnsc lgmnt non-sp ✕ ✕ ✓ ✕ 
N302E Infection of coccyx ✓ ✕ ✕ ✕ S520H Sprn scapho-trapezium lgmnt ✕ ✕ ✓ ✕ 
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N302F Infection of clavicle ✕ ✕ ✓ ✕ S520J Sprn luno-triquetral lgmnt ✕ ✕ ✓ ✕ 
N302G Infection of scapula ✕ ✕ ✓ ✕ S520K Sprain scapho-lunate ligament ✕ ✕ ✓ ✕ 
N302H Infection of humerus ✕ ✕ ✓ ✕ S520L Sprn volar intrcrp/V lgmnt ✕ ✕ ✓ ✕ 
N302J Infection of radius ✕ ✕ ✓ ✕ S520M Sprn dorsal intercarpal lgmnt ✕ ✕ ✓ ✕ 
N302K Infection of ulna ✕ ✕ ✓ ✕ S520z Wrist sprain NOS ✕ ✕ ✓ ✕ 
N302L Infection of carpal bone ✕ ✕ ✓ ✕ S521 Hand sprain ✕ ✕ ✓ ✕ 
N302M Infection of metacarpal ✕ ✕ ✓ ✕ S5210 Finger sprain ✕ ✕ ✓ ✕ 
N302N Infectn of phalanx finger/thum ✕ ✕ ✓ ✕ S5211 Carpometacarpal sprain ✕ ✕ ✓ ✕ 
N302P Infection of pelvis ✕ ✓ ✕ ✕ S5212 Metacarpophalangeal sprain ✕ ✕ ✓ ✕ 
N302Q Infection of femur ✕ ✓ ✕ ✕ S5213 Interphalangeal sprain ✕ ✕ ✓ ✕ 
N302R Infection of patella ✕ ✓ ✕ ✕ S5214 Midcarpal joint sprain ✕ ✕ ✓ ✕ 
N302S Infection of tibia ✕ ✓ ✕ ✕ S521z Hand sprain NOS ✕ ✕ ✓ ✕ 
N302T Infection of fibula ✕ ✓ ✕ ✕ S522 Sprain thumb ✕ ✕ ✓ ✕ 
N302U Infection of calcaneum ✕ ✓ ✕ ✕ S5220 Sprain thumb C.M.C.J ✕ ✕ ✓ ✕ 
N302V Infection of talus ✕ ✓ ✕ ✕ S5221 Sprn thumb MCPJ non specific ✕ ✕ ✓ ✕ 
N302W Infection of other tarsal bone ✕ ✓ ✕ ✕ S5222 Sprn thmb MCPJ rdl collat lgmt ✕ ✕ ✓ ✕ 
N302X Infection of metatarsal ✕ ✓ ✕ ✕ S5223 Sprn thmb MCPJ uln collat lgmt ✕ ✕ ✓ ✕ 
N302Y Infection of phalanx of toe ✕ ✓ ✕ ✕ S5224 Sprn thumb IPJ non specific ✕ ✕ ✓ ✕ 
N3030 Periostitis - site unspecified ✕ ✕ ✕ ✕ S5225 Sprn thmb IPJ rdl collat lgmt ✕ ✕ ✓ ✕ 
N3031 Periostitis - shoulder ✕ ✕ ✓ ✕ S5226 Sprn thmb IPJ uln collat lgmnt ✕ ✕ ✓ ✕ 
N3032 Periostitis - upper arm ✕ ✕ ✓ ✕ S523 Sprain finger ✕ ✕ ✓ ✕ 
N3033 Periostitis - forearm ✕ ✕ ✓ ✕ S5230 Sprain finger C.M.C.J. ✕ ✕ ✓ ✕ 
N3034 Periostitis - hand ✕ ✕ ✓ ✕ S5231 Sprn finger MCPJ non specific ✕ ✕ ✓ ✕ 
N3035 Periostitis - pelvic/thigh ✕ ✓ ✕ ✕ S5232 Sprn fngr MCPJ rdl collat lgmt ✕ ✕ ✓ ✕ 
N3036 Periostitis - lower leg ✕ ✓ ✕ ✕ S5233 Sprn fngr MCPJ uln collat lgmt ✕ ✕ ✓ ✕ 
N3037 Periostitis - ankle/foot ✕ ✓ ✕ ✕ S5234 Sprn finger PIPJ non specific ✕ ✕ ✓ ✕ 
N303A Periostitis, no osteomye-Cx sp ✓ ✕ ✕ ✕ S5235 Sprn fngr PIPJ rdl collat lgmt ✕ ✕ ✓ ✕ 
N303B Periostitis, no osteomye-th sp ✓ ✕ ✕ ✕ S5236 Sprn fngr PIPJ uln collat lgmt ✕ ✕ ✓ ✕ 
N303C Periostitis, no osteomye-lu sp ✓ ✕ ✕ ✕ S5237 Sprn finger DIPJ non specific ✕ ✕ ✓ ✕ 
N303D Periostitis, no osteomye-sacr ✓ ✕ ✕ ✕ S5238 Sprn fngr DIPJ rdl collat lgmt ✕ ✕ ✓ ✕ 
N303E Periostitis, no osteomye-coccy ✓ ✕ ✕ ✕ S5239 Sprn fngr DIPJ uln collat lgmt ✕ ✕ ✓ ✕ 
N304 Tuberculosis of spine (Pott's) ✓ ✕ ✕ ✕ S523A Volar plate injury finger MCPJ ✕ ✕ ✓ ✕ 
N3040 Tuberculosis of cervical spine ✓ ✕ ✕ ✕ S523B Volar plate injury finger PIPJ ✕ ✕ ✓ ✕ 
N3041 Tuberculosis of thoracic spine ✓ ✕ ✕ ✕ S523C Volar plate injury finger DIPJ ✕ ✕ ✓ ✕ 
N3042 Tuberculosis of lumbar spine ✓ ✕ ✕ ✕ S523D Volar plate injury thumb MCPJ ✕ ✕ ✓ ✕ 
N3043 Tuberculosis of sacrum/coccyx ✓ ✕ ✕ ✕ S523E Volar plate injury thumb IPJ ✕ ✕ ✓ ✕ 
N305 Tuberculosis of limb bones ✕ ✕ ✕ ✕ S523F Hyperextension injury of finger ✕ ✕ ✓ ✕ 
N3050 Tuberculosis-limb bone unspec. ✕ ✕ ✕ ✕ S524 Sprain tendon wrist or hand ✕ ✕ ✓ ✕ 
N3051 Tuberculosis-upper arm bone ✕ ✕ ✓ ✕ S5240 Sprain wrist extensors ✕ ✕ ✓ ✕ 
N3052 Tuberculosis-forearm bone ✕ ✕ ✓ ✕ S5241 Sprain wrist flexors ✕ ✕ ✓ ✕ 
N3053 Tuberculosis-pelvic/thigh bone ✕ ✓ ✕ ✕ S525 Sprain tendon of thumb ✕ ✕ ✓ ✕ 
N3054 Tuberculosis-lower leg bone ✕ ✓ ✕ ✕ S5250 Sprn,flxr pollicis longus tndn ✕ ✕ ✓ ✕ 
N3055 Tuberculosis-other limb bones ✕ ✕ ✕ ✕ S5251 Sprn,extnsr pollicis long tndn ✕ ✕ ✓ ✕ 
N3056 Tuberculosis-multipl.limb bone ✕ ✕ ✕ ✕ S526 Sprain tendon of finger ✕ ✕ ✓ ✕ 
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N305z Tuberculosis limb bones NOS ✕ ✕ ✕ ✕ S5260 Sprn,flxr digit superfic tndn ✕ ✕ ✓ ✕ 
N3060 Tuberculosis bone-site unspec. ✕ ✕ ✕ ✕ S5261 Sprn,flxr digit profundus tndn ✕ ✕ ✓ ✕ 
N3061 Tuberculosis bone-shoulder ✕ ✕ ✓ ✕ S5262 Sprn,extnsr digitorum tendon ✕ ✕ ✓ ✕ 
N3062 Tuberculosis bone-hand ✕ ✕ ✓ ✕ S52z Wrist and hand sprain NOS ✕ ✕ ✓ ✕ 
N3063 Tuberculosis bone-ankle/foot ✕ ✓ ✕ ✕ S53 Groin sprain ✕ ✓ ✕ ✕ 
N3070 Polio.osteopathy-site unspecif ✕ ✕ ✕ ✕ S530 Iliofemoral sprain ✕ ✓ ✕ ✕ 
N3071 Polio.osteopathy-shoulder ✕ ✕ ✓ ✕ S531 Ischiocapsular sprain ✕ ✓ ✕ ✕ 
N3072 Polio.osteopathy-upper arm ✕ ✕ ✓ ✕ S532 Sprain, hip joint ✕ ✓ ✕ ✕ 
N3073 Polio.osteopathy-forearm ✕ ✕ ✓ ✕ S533 Sprain quadriceps tendon ✕ ✓ ✕ ✕ 
N3074 Polio.osteopathy-hand ✕ ✕ ✓ ✕ S534 Sprain patellar tendon ✕ ✓ ✕ ✕ 
N3075 Polio.osteopathy-pelvic/thigh ✕ ✓ ✕ ✕ S535 Sprain, hamstring tendon ✕ ✓ ✕ ✕ 
N3076 Polio.osteopathy-lower leg ✕ ✓ ✕ ✕ S53w Other hip sprain ✕ ✓ ✕ ✕ 
N3077 Polio.osteopathy-ankle/foot ✕ ✓ ✕ ✕ S53x Other thigh sprain ✕ ✓ ✕ ✕ 
N3080 Subacute osteomyelitis-Cx spin ✓ ✕ ✕ ✕ S53y Hip sprain NOS ✕ ✓ ✕ ✕ 
N3081 Subacute osteomyelitis-th spin ✓ ✕ ✕ ✕ S53z Thigh sprain NOS ✕ ✓ ✕ ✕ 
N3082 Subacute osteomyelitis-lu spin ✓ ✕ ✕ ✕ S54 Knee sprain ✕ ✓ ✕ ✕ 
N3083 Subacute osteomyelitis-sacrum ✓ ✕ ✕ ✕ S540 Sprn/prt tr,knee,lat coll lgmt ✕ ✓ ✕ ✕ 
N3084 Subacute osteomyelitis-coccyx ✓ ✕ ✕ ✕ S5400 Sprn,knee jt,lat collat lgmt ✕ ✓ ✕ ✕ 
N30y1 Oth.inf.+bone dis-shoulder ✕ ✕ ✓ ✕ S5401 Part tear,knee,lat collat lgmt ✕ ✓ ✕ ✕ 
N30y2 Oth.inf.+bone dis-upper arm ✕ ✕ ✓ ✕ S541 Sprain med.collateral lig.knee ✕ ✓ ✕ ✕ 
N30y3 Oth.inf.+bone dis-forearm ✕ ✕ ✓ ✕ S5410 Sprn,knee jt,medial collat ✕ ✓ ✕ ✕ 
N30y4 Oth.inf.+bone dis-hand ✕ ✕ ✓ ✕ S5411 Part tear,knee,mdl collat lgmt ✕ ✓ ✕ ✕ 
N30y5 Oth.inf.+bone dis-pelvic/thigh ✕ ✓ ✕ ✕ S542 Sprain cruciate ligament knee ✕ ✓ ✕ ✕ 
N30y6 Oth.inf.+bone dis-lower leg ✕ ✓ ✕ ✕ S5421 Part tr,knee,ant cruciate lgmt ✕ ✓ ✕ ✕ 
N30y7 Oth.inf.+bone dis-ankle/foot ✕ ✓ ✕ ✕ S5422 Prt tr,knee,post cruciate lgmt ✕ ✓ ✕ ✕ 
N30z1 Bone infectn.NOS-shoulder ✕ ✕ ✓ ✕ S543 Sprain superior tibiofibular ✕ ✓ ✕ ✕ 
N30z2 Bone infectn.NOS-upper arm ✕ ✕ ✓ ✕ S544 Sprain plantaris tendon ✕ ✓ ✕ ✕ 
N30z3 Bone infectn.NOS-forearm ✕ ✕ ✓ ✕ S54w Other specified knee sprain ✕ ✓ ✕ ✕ 
N30z4 Bone infectn.NOS-hand ✕ ✕ ✓ ✕ S54x Other specified leg sprain ✕ ✓ ✕ ✕ 
N30z5 Bone infectn.NOS-pelvic/thigh ✕ ✓ ✕ ✕ S54x1 Sprain gastrocnemius ✕ ✓ ✕ ✕ 
N30z6 Bone infectn.NOS-lower leg ✕ ✓ ✕ ✕ S54y Knee sprain NOS ✕ ✓ ✕ ✕ 
N30z7 Bone infectn.NOS-ankle/foot ✕ ✓ ✕ ✕ S54z Leg sprain NOS ✕ ✓ ✕ ✕ 
N30z8 Costochondritis NOS ✓ ✕ ✕ ✓ S55 Sprain ankle/foot ✕ ✓ ✕ ✕ 
N3100 Paget's disease-cervical spine ✓ ✕ ✕ ✕ S550 Ankle sprain ✕ ✓ ✕ ✕ 
N3101 Paget's disease-thoracic spine ✓ ✕ ✕ ✕ S5500 Ankle sprain unspecified ✕ ✓ ✕ ✕ 
N3102 Paget's disease-lumbar spine ✓ ✕ ✕ ✕ S5501 Sprain, ankle joint, medial ✕ ✓ ✕ ✕ 
N3103 Paget's disease-sacrum ✓ ✕ ✕ ✕ S5502 Sprain ankle joint lateral ✕ ✓ ✕ ✕ 
N3104 Paget's disease-coccyx ✓ ✕ ✕ ✕ S5503 Distal tibiofibular sprain ✕ ✓ ✕ ✕ 
N3105 Paget's disease-clavicle ✕ ✕ ✓ ✕ S5504 Sprntndocalcan(Achilles tndn) ✕ ✓ ✕ ✕ 
N3106 Paget's disease-scapula ✕ ✕ ✓ ✕ S5505 Part tear,ankle,medial lgmt ✕ ✓ ✕ ✕ 
N3107 Paget's disease-humerus ✕ ✕ ✓ ✕ S5506 Part tear,ankle,lat lgmt ✕ ✓ ✕ ✕ 
N3108 Paget's disease-radius ✕ ✕ ✓ ✕ S550z Ankle sprain NOS ✕ ✓ ✕ ✕ 
N3109 Paget's disease-ulna ✕ ✕ ✓ ✕ S551 Foot sprain ✕ ✓ ✕ ✕ 
N310A Paget's disease-carpal bone ✕ ✕ ✓ ✕ S5510 Foot sprain unspecified ✕ ✓ ✕ ✕ 
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N310B Paget's disease-metacarpal ✕ ✕ ✓ ✕ S5511 Sprain, tarso-metatarsal joint ✕ ✓ ✕ ✕ 
N310C Paget's disease-phal, fing/th ✕ ✕ ✓ ✕ S5512 Sprn,metatarso-phalangeal jt ✕ ✓ ✕ ✕ 
N310D Paget's disease-pelvis ✕ ✓ ✕ ✕ S5513 Toe sprain ✕ ✓ ✕ ✕ 
N310E Paget's disease-femur ✕ ✓ ✕ ✕ S5514 Sprain, mid tarsal joint ✕ ✓ ✕ ✕ 
N310F Paget's disease-patella ✕ ✓ ✕ ✕ S5515 Sprain, flexor tendon, foot ✕ ✓ ✕ ✕ 
N310G Paget's disease-tibia ✕ ✓ ✕ ✕ S5516 Sprain extensor tendon foot ✕ ✓ ✕ ✕ 
N310H Paget's disease-fibula ✕ ✓ ✕ ✕ S551z Foot sprain NOS ✕ ✓ ✕ ✕ 
N310J Paget's disease-calcaneum ✕ ✓ ✕ ✕ S55z Ankle and foot sprain NOS ✕ ✓ ✕ ✕ 
N310K Paget's disease-talus ✕ ✓ ✕ ✕ S56 Sprain pelvic ligament ✕ ✓ ✕ ✕ 
N310L Paget's disease-oth tars bone ✕ ✓ ✕ ✕ S560 Sprain, lumbosacral ligament ✓ ✕ ✕ ✕ 
N310M Paget's disease-metatarsal ✕ ✓ ✕ ✕ S561 Sacroiliac ligament sprain ✓ ✕ ✕ ✕ 
N310N Paget's disease-phalanx of toe ✕ ✓ ✕ ✕ S5610 Sprn,ant sacro-iliac lgmt ✓ ✕ ✕ ✕ 
N310P Paget's disease-skull ✕ ✕ ✕ ✕ S5611 Sprn,post sacro-iliac lgmt ✓ ✕ ✕ ✕ 
N320 Vertebral epiphysitis ✓ ✕ ✕ ✕ S562 Sprain, sacrospinous ligament ✓ ✕ ✕ ✕ 
N3200 Juvenile spine osteochond.unsp ✓ ✕ ✕ ✕ S563 Sprain, sacrotuberous ligament ✓ ✕ ✕ ✕ 
N3201 Scheuermann's disease ✓ ✕ ✕ ✕ S564 Sprain, iliolumbar ligament ✓ ✕ ✕ ✕ 
N3202 Calve's vertebral osteochondr. ✓ ✕ ✕ ✕ S56y Other spec sacroiliac sprains ✓ ✕ ✕ ✕ 
N320z Juvenile spine osteochondr.NOS ✓ ✕ ✕ ✕ S56z Sacroiliac sprain NOS ✓ ✕ ✕ ✕ 
N321 Pelvis juvenile osteochondrop. ✕ ✓ ✕ ✕ S57 Sprain other parts of back ✓ ✕ ✕ ✕ 
N3210 Juv.osteochond.hip/pelvis unsp ✕ ✓ ✕ ✕ S570 Neck sprain ✓ ✕ ✕ ✕ 
N3211 Perthes dis. (femoral head) ✕ ✓ ✕ ✕ S5700 Neck sprain unspecified ✓ ✕ ✕ ✕ 
N3212 Ischiopubic synchondrosis ✕ ✓ ✕ ✕ S5701 Cervical ant.longit.lig.sprain ✓ ✕ ✕ ✕ 
N3213 Juvenile osteochond.-acetabul. ✕ ✓ ✕ ✕ S5702 Atlanto-axial joint sprain ✓ ✕ ✕ ✕ 
N3214 Juven.osteochond.-iliac crest ✕ ✓ ✕ ✕ S5703 Atlanto-occipital joint sprain ✓ ✕ ✕ ✕ 
N3215 Symphysis pubis osteochond. ✕ ✓ ✕ ✕ S5704 Whiplash injury ✓ ✕ ✕ ✕ 
N3216 Coxa plana ✕ ✓ ✕ ✕ S570z Neck sprain NOS ✓ ✕ ✕ ✕ 
N3217 Pseudocoxalgia ✕ ✓ ✕ ✕ S571 Thoracic sprain ✓ ✕ ✕ ✕ 
N321z Juv.osteochond.-hip/pelvis NOS ✕ ✓ ✕ ✕ S572 Lumbar sprain ✓ ✕ ✕ ✕ 
N322 Non tr.slipped upper fem.epiph ✕ ✓ ✕ ✕ S573 Sacrum sprain ✓ ✕ ✕ ✕ 
N3220 Non traumatic acute SUFE ✕ ✓ ✕ ✕ S5730 Sacral sprain unspecified ✓ ✕ ✕ ✕ 
N3221 Non traum acute-on-chron SUFE ✕ ✓ ✕ ✕ S5731 Sacrococcygeal sprain ✓ ✕ ✕ ✕ 
N3222 Non traumatic chronic SUFE ✕ ✓ ✕ ✕ S573z Sacrum sprain NOS ✓ ✕ ✕ ✕ 
N323 Juvenile osteochondritis -hand ✕ ✕ ✓ ✕ S574 Coccyx sprain ✓ ✕ ✕ ✕ 
N3230 Juven.osteochond.arm unspecif. ✕ ✕ ✓ ✕ S57z Back sprain NOS ✓ ✕ ✕ ✕ 
N3231 Juven.osteochond.hand unspecif ✕ ✕ ✓ ✕ S57z0 Pulled back muscle ✓ ✕ ✕ ✕ 
N3232 Panner's dis.(humerus capitul) ✕ ✕ ✓ ✕ S58 Complete tear, shoulder joint ✕ ✕ ✓ ✕ 
N3233 Kienbock's dis.(carpal lunate) ✕ ✕ ✓ ✕ S580 Cmplt tr,acromio-clav lgmt ✕ ✕ ✓ ✕ 
N3234 Humerus head juv. osteochondr. ✕ ✕ ✓ ✕ S581 Cmplt tr,coraco-clav lgmt ✕ ✕ ✓ ✕ 
N3235 Metacarpal head juv. osteoch. ✕ ✕ ✓ ✕ S58z Complete tear,shoulder jt NOS ✕ ✕ ✓ ✕ 
N3236 Burn's dis.(lower ulna) ✕ ✕ ✓ ✕ S59 Complete tear, elbow joint ✕ ✕ ✓ ✕ 
N3237 Radial head juven. osteochond. ✕ ✕ ✓ ✕ S590 Cmplt tr,elbw jt,lat coll lgmt ✕ ✕ ✓ ✕ 
N323z Juven.osteochond.-arm/hand NOS ✕ ✕ ✓ ✕ S591 Cmplt tr,elbw jt,mdl coll lgmt ✕ ✕ ✓ ✕ 
N324 Juvenile osteochondrosis - leg ✕ ✓ ✕ ✕ S59z Complete tear, elbow joint NOS ✕ ✕ ✓ ✕ 
N3240 Juvenile osteochondr.-leg unsp ✕ ✓ ✕ ✕ S5A Complete tear, wrist or hand ✕ ✕ ✓ ✕ 
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N3241 Kohler's dis.(prim.patell.ctr) ✕ ✓ ✕ ✕ S5A0 Complete tear wrist ligament ✕ ✕ ✓ ✕ 
N3242 Blount's dis.(proximal tibia) ✕ ✓ ✕ ✕ S5A00 Cmplt tr radial collat lgmt ✕ ✕ ✓ ✕ 
N3243 Sinding-Larsen's dis.(patella) ✕ ✓ ✕ ✕ S5A01 Cmp tr prox radcarp lgm non-sp ✕ ✕ ✓ ✕ 
N3244 Osgood-Schlatters dis.(tibia) ✕ ✓ ✕ ✕ S5A02 Cmp tr vlr rad-crp lgmt non-sp ✕ ✕ ✓ ✕ 
N324z Juvenile osteochondr.-leg,NOS ✕ ✓ ✕ ✕ S5A03 Cmp tr vlr rad-crp lgm superfc ✕ ✕ ✓ ✕ 
N325 Juvenile osteochondrosis-foot ✕ ✓ ✕ ✕ S5A04 Cmp tr rad-scpho-capitate lgmt ✕ ✕ ✓ ✕ 
N3250 Juvenile osteochond.-foot unsp ✕ ✓ ✕ ✕ S5A05 Cmplt tr rad-lunate lgmt ✕ ✕ ✓ ✕ 
N3251 Diaz's disease (astragalus) ✕ ✓ ✕ ✕ S5A06 Cmplt tr rad-scpho-lunate lgmt ✕ ✕ ✓ ✕ 
N3252 Sever's disease (calcaneum) ✕ ✓ ✕ ✕ S5A07 Cmplt tr dorsal rad-carp lgmt ✕ ✕ ✓ ✕ 
N3253 Freiberg's dis.(second metat.) ✕ ✓ ✕ ✕ S5A08 Cmpl tr uln carp cmplx non-sp ✕ ✕ ✓ ✕ 
N3254 Iselin's dis.(fifth metatars.) ✕ ✓ ✕ ✕ S5A09 Cmplt tr uln-carp meniscus ✕ ✕ ✓ ✕ 
N3255 Haglund's dis.(os tibiale ext) ✕ ✓ ✕ ✕ S5A0A Cmplt tr triang fibrocartilage ✕ ✕ ✓ ✕ 
N3256 Kohler's dis.(tarsal navicul.) ✕ ✓ ✕ ✕ S5A0B Cmplt tr ulno-lunate lgmt ✕ ✕ ✓ ✕ 
N325z Juvenile osteochond.-foot NOS ✕ ✓ ✕ ✕ S5A0C Cmplt tr uln collat lgmt ✕ ✕ ✓ ✕ 
N3270 Osteochondritis dissec-patella ✕ ✓ ✕ ✕ S5A0D Comp tr shrt intr lig non-sp ✕ ✕ ✓ ✕ 
N3271 Osteochondr diss-lat fem cond ✕ ✓ ✕ ✕ S5A0E Cmplt tr scapho-trapezium lgmt ✕ ✕ ✓ ✕ 
N3272 Other osteochondr dissec-knee ✕ ✓ ✕ ✕ S5A0F Cmplt tr luno-triquetral lgmt ✕ ✕ ✓ ✕ 
N3273 Osteochondr dissec-hum head ✕ ✕ ✓ ✕ S5A0G Cmplt tr scapho-lunate lgmt ✕ ✕ ✓ ✕ 
N3274 Osteochondr dissec-capitellum ✕ ✓ ✕ ✕ S5A0H Cmpl tr volar intercarp/V lgmt ✕ ✕ ✓ ✕ 
N3275 Osteochondr dissec-radial head ✕ ✕ ✓ ✕ S5A0J Cmplt tr dorsal intercarp lgmt ✕ ✕ ✓ ✕ 
N3276 Other osteochondr diss-elbow ✕ ✕ ✓ ✕ S5A0z Cmplt tr wrist lgmt NOS ✕ ✕ ✓ ✕ 
N3277 Osteochondritis dissec-wrist ✕ ✕ ✓ ✕ S5A1 Complete tear ligament thumb ✕ ✕ ✓ ✕ 
N3278 Osteochondr dissec-fem head ✕ ✓ ✕ ✕ S5A10 Cmp tr thmb MCPJ radl coll lgm ✕ ✕ ✓ ✕ 
N3279 Osteochondritis dissec-talus ✕ ✓ ✕ ✕ S5A11 Cmp tr thmb MCPJ uln coll lgmt ✕ ✕ ✓ ✕ 
N327y Osteochondr dissec-other site ✕ ✕ ✕ ✕ S5A12 Cmp tr thmb IPJ rad coll lgmt ✕ ✕ ✓ ✕ 
N328 Juv osteochondrosis of spine ✓ ✕ ✕ ✕ S5A13 Cmp tr thmb IPJ uln coll lgmt ✕ ✕ ✓ ✕ 
N32y Slipped radial epiphysis ✕ ✕ ✓ ✕ S5A1z Cmplt tr lgmt thumb NOS ✕ ✕ ✓ ✕ 
N32y0 Adult osteochondrosis of spine ✓ ✕ ✕ ✕ S5A2 Complete tear ligament finger ✕ ✕ ✓ ✕ 
N32y1 Kienbock's disease of adults ✕ ✕ ✓ ✕ S5A20 Cmp tr fngr MCPJ radl coll lgm ✕ ✕ ✓ ✕ 
N32yz Other spec.osteochondrop.NOS ✕ ✕ ✕ ✕ S5A21 Cmp tr fngr MCPJ uln coll lgmt ✕ ✕ ✓ ✕ 
N32z2 Osteochondritis of knee ✕ ✓ ✕ ✕ S5A22 Cmp tr fngr PIPJ rdl coll lgmt ✕ ✕ ✓ ✕ 
N3308 Local osteoporosis - Lequesne ✕ ✕ ✕ ✕ S5A23 Cmp tr fngr PIPJ uln coll lgmt ✕ ✕ ✓ ✕ 
N330B Vertebral osteoporosis ✓ ✕ ✕ ✕ S5A24 Cmpt tr fngr DIPJ rdl coll lgm ✕ ✕ ✓ ✕ 
N330C Osteoporosis localized spine ✓ ✕ ✕ ✕ S5A25 Cmp tr fngr DIPJ uln coll lgmt ✕ ✕ ✓ ✕ 
N331 Collapse of vertebra NOS ✓ ✕ ✕ ✕ S5A2z Cmplt tr lgmt finger NOS ✕ ✕ ✓ ✕ 
N3310 Collapse of thoracic vertebra ✓ ✕ ✕ ✕ S5Az Complete tear wrist/hand NOS ✕ ✕ ✓ ✕ 
N3311 Pathological # - lumbar vert. ✓ ✕ ✕ ✕ S5B Complete tear, hip ligament ✕ ✓ ✕ ✕ 
N3312 Postoophorc osteopor+path frct ✕ ✕ ✕ ✕ S5B0 Cmplt tr Iliofemoral lgmt ✕ ✓ ✕ ✕ 
N3313 Osteopor of disuse + path frct ✕ ✕ ✕ ✕ S5By Cmplt tr other hip lgmt ✕ ✓ ✕ ✕ 
N3314 Postsur malab osteop+path frct ✕ ✕ ✕ ✕ S5Bz Complete tear hip ligament NOS ✕ ✓ ✕ ✕ 
N3315 Drug-ind osteopor + path fract ✕ ✕ ✕ ✕ S5C Complete tear, knee ligament ✕ ✓ ✕ ✕ 
N3316 Idiopath osteopor + path fract ✕ ✕ ✕ ✕ S5C0 Cmplt tr,knee,lat collat lgmt ✕ ✓ ✕ ✕ 
N3317 Fract of bone in neoplast dis ✕ ✕ ✕ ✕ S5C1 Cmplt tr,knee,mdl collat lgmt ✕ ✓ ✕ ✕ 
N3318 Osteopor path # lumb vertebrae ✓ ✕ ✕ ✕ S5C2 Cmp tr,knee,post cruciate lgmt ✕ ✓ ✕ ✕ 
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N3319 Osteopor path # thor vertebrae ✓ ✕ ✕ ✕ S5C3 Cmpl tr,knee,ant cruciate lgmt ✕ ✓ ✕ ✕ 
N331A Osteopor path # cerv vertebrae ✓ ✕ ✕ ✕ S5Cy Cmplt tr,other knee lgmt ✕ ✓ ✕ ✕ 
N331B Postmenop osteopor+path fract ✕ ✕ ✕ ✕ S5Cz Cmplt tr,knee lgmt NOS ✕ ✓ ✕ ✕ 
N331C Pathological # cervical vert ✓ ✕ ✕ ✕ S5D Cmplt tr,ankle/foot lgmt ✕ ✓ ✕ ✕ 
N331D Collapsed vertebra NOS ✓ ✕ ✕ ✕ S5D0 Complete tear, ankle ligament ✕ ✓ ✕ ✕ 
N331E Collapse of cervical vertebra ✓ ✕ ✕ ✕ S5D00 Cmplt tr,ankle,mdl lgmt ✕ ✓ ✕ ✕ 
N331F Collapse of thoracic vertebra ✓ ✕ ✕ ✕ S5D01 Cmplt tr,ankle,lat lgmt ✕ ✓ ✕ ✕ 
N331G Collapse of lumbar vertebra ✓ ✕ ✕ ✕ S5D0z Cmplt tr,ankle lgmt NOS ✕ ✓ ✕ ✕ 
N331H Collap cerv vert due to osteop ✓ ✕ ✕ ✕ S5D1 Complete tear, foot ligament ✕ ✓ ✕ ✕ 
N331J Collap lumb vert due to osteo ✓ ✕ ✕ ✕ S5D10 Cmplt tr,mid tarsal jt lgmt ✕ ✓ ✕ ✕ 
N331K Coll thorac vert due osteopor ✓ ✕ ✕ ✕ S5D11 Cmplt tr,tarsometatarsal lgmt ✕ ✓ ✕ ✕ 
N331L Collap vert due osteopor NOS ✓ ✕ ✕ ✕ S5D12 Cmplt tr,metatarsophalan lgmt ✕ ✓ ✕ ✕ 
N331M Fragility # unsp osteoporosis ✕ ✕ ✕ ✕ S5D13 Cmplt tr,interphalan(toe)lgmt ✕ ✓ ✕ ✕ 
N331y Pathological fracture OS ✕ ✕ ✕ ✕ S5D1z Cmplt tr,foot lgmt NOS ✕ ✓ ✕ ✕ 
N331z Pathological fracture NOS ✕ ✕ ✕ ✕ S5Dz Cmplt tr,ankle/foot lgmt NOS ✕ ✓ ✕ ✕ 
N332 Cyst of bone ✕ ✕ ✕ ✕ S5E Cmplt tr,other lgmt,exc pelvis ✕ ✓ ✕ ✕ 
N3320 Bone cyst (localised),unspecif ✕ ✕ ✕ ✕ S5E0 Complete tear, jaw ligament ✕ ✕ ✕ ✕ 
N3321 Solitary bone cyst ✕ ✕ ✕ ✕ S5E1 Cmplt tr,thyroid region lgmt ✓ ✕ ✕ ✕ 
N3322 Aneurysmal bone cyst ✕ ✕ ✕ ✕ S5E2 Complete tear, rib ligament ✓ ✕ ✕ ✕ 
N3323 Monostotic fibrous dysplasia ✕ ✕ ✕ ✕ S5E20 Cmplt tr,chondrocostal jt lgmt ✓ ✕ ✕ ✕ 
N3324 Fibrous cortical defect ✕ ✕ ✕ ✕ S5E21 Cmplt tr,costal cartilage lgmt ✓ ✕ ✕ ✕ 
N332z Cyst of bone NOS ✕ ✕ ✕ ✕ S5E2z Cmplt tr,rib lgmt NOS ✓ ✕ ✕ ✕ 
N333 Hyperostosis of skull ✕ ✕ ✕ ✕ S5E3 Cmplt tr,sternum lgmt ✓ ✕ ✕ ✕ 
N3330 Hyperostosis interna frontalis ✕ ✕ ✕ ✕ S5E30 Cmplt tr,sternoclavicular lgmt ✕ ✕ ✓ ✕ 
N3331 Leontiasis ossium ✕ ✕ ✕ ✕ S5E31 Cmplt tr,chondrosternal lgmt ✓ ✕ ✕ ✕ 
N333z Hyperostosis of skull NOS ✕ ✕ ✕ ✕ S5E32 Cmpl tr,xiphoid cartilage lgmt ✓ ✕ ✕ ✕ 
N334 Avascular necrosis - bone ✕ ✕ ✕ ✕ S5E3z Cmplt tr,sternum lgmt NOS ✓ ✕ ✕ ✕ 
N3340 Avasc.bone necrosis site unsp. ✕ ✕ ✕ ✕ S5Ez Cmplt tr,other lgmt NOS ✕ ✕ ✕ ✕ 
N3341 Avasc.necrosis-head of humerus ✕ ✕ ✓ ✕ S5F Open division shoulder lgmt ✕ ✕ ✓ ✕ 
N3342 Avascular necrosis head-femur ✕ ✓ ✕ ✕ S5F0 Opn dvsn acromioclavic lgmt ✕ ✕ ✓ ✕ 
N3343 Femoral cond. avasc.necrosis ✕ ✓ ✕ ✕ S5F1 Opn dvsn coracoclavicular lgmt ✕ ✕ ✓ ✕ 
N3344 Avascular necrosis-talus ✕ ✓ ✕ ✕ S5Fz Open dvsn shoulder lgmt NOS ✕ ✕ ✓ ✕ 
N3345 Avascular necrosis, capitellum ✕ ✓ ✕ ✕ S5G Open division elbow ligament ✕ ✕ ✓ ✕ 
N3346 Avasc necrosis, lat fem cond ✕ ✓ ✕ ✕ S5G0 Opn dvsn elbow,lat collat lgmt ✕ ✕ ✓ ✕ 
N3347 Avascular necrosis-other bone ✕ ✕ ✕ ✕ S5G1 Opn dvsn elbow,mdl collat lgmt ✕ ✕ ✓ ✕ 
N3348 Idiopath asep necrosis of bone ✕ ✕ ✕ ✕ S5G2 Opn division radhumeral lgmt ✕ ✕ ✓ ✕ 
N334A Osteonecr due to prev trauma ✕ ✕ ✕ ✕ S5G3 Open dvsn ulnohumeral lgmt ✕ ✕ ✓ ✕ 
N334B Osteonecrosis in caisson dis ✕ ✕ ✕ ✕ S5Gy Open dvsn other elbow lgmt ✕ ✕ ✓ ✕ 
N334C Osteonecr due haemoglobinopath ✕ ✕ ✕ ✕ S5Gz Open division elbow lgmt NOS ✕ ✕ ✓ ✕ 
N335 Osteitis condensans ✓ ✕ ✕ ✕ S5H Open division wrist/hand lgmt ✕ ✕ ✓ ✕ 
N3350 Osteitis condensans ilii ✓ ✕ ✕ ✕ S5H0 Open division wrist ligament ✕ ✕ ✓ ✕ 
N336 Tietze's disease ✓ ✕ ✕ ✓ S5H00 Open dvsn wrist lgmt,single ✕ ✕ ✓ ✕ 
N3372 Algodystrophy of hand ✕ ✕ ✓ ✕ S5H01 Open dvsn wrist lgmts,multiple ✕ ✕ ✓ ✕ 
N3373 Algodystrophy of knee ✕ ✓ ✕ ✕ S5H0z Open division wrist lgmt NOS ✕ ✕ ✓ ✕ 
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N3374 Algodystrophy of foot ✕ ✓ ✕ ✕ S5H1 Open division thumb ligament ✕ ✕ ✓ ✕ 
N338 Malunion/nonunion of fracture ✕ ✕ ✕ ✕ S5H10 Opn dvs thmb MCPJ,rdl coll lgm ✕ ✕ ✓ ✕ 
N3380 Malunion of fracture ✕ ✕ ✕ ✕ S5H11 Opn dvs thmb MCPJ,uln coll lgm ✕ ✕ ✓ ✕ 
N3381 Pseudoarthrosis-fract.nonunion ✕ ✕ ✕ ✕ S5H12 Opn dvs thmb IPJ,rdl coll lgmt ✕ ✕ ✓ ✕ 
N3382 Hypertrophic non-union of # ✕ ✕ ✕ ✕ S5H13 Opn dvs thmb IPJ,uln coll lgmt ✕ ✕ ✓ ✕ 
N3383 Atrophic non-union of fracture ✕ ✕ ✕ ✕ S5H1z Open division thumb lgmt NOS ✕ ✕ ✓ ✕ 
N3384 Angular mal-union of fracture ✕ ✕ ✕ ✕ S5H2 Open division finger ligament ✕ ✕ ✓ ✕ 
N3385 Rotational mal-union of # ✕ ✕ ✕ ✕ S5H20 Opn dvs fngr MCPJ,rdl coll lgm ✕ ✕ ✓ ✕ 
N3386 Delayed union of fracture ✕ ✕ ✕ ✕ S5H21 Opn dvs fngr MCPJ,uln coll lgm ✕ ✕ ✓ ✕ 
N338z Fracture malunion/nonunion NOS ✕ ✕ ✕ ✕ S5H22 Opn dvs fngr PIPJ,rdl coll lgm ✕ ✕ ✓ ✕ 
N339 Residual foreign body in bone ✕ ✕ ✕ ✕ S5H23 Opn dvs fngr PIPJ,uln coll lgm ✕ ✕ ✓ ✕ 
N33A0 Bony pelvic pain ✕ ✓ ✕ ✓ S5H24 Opn dvs fngr DIPJ,rdl coll lgm ✕ ✕ ✓ ✕ 
N33A1 Clavicle pain ✕ ✕ ✓ ✓ S5H25 Opn dvs fngr DIPJ,uln coll lgm ✕ ✕ ✓ ✕ 
N33z2 Chondromalacia NOS ✕ ✕ ✕ ✕ S5H2z Open division fngr lgmt NOS ✕ ✕ ✓ ✕ 
N33zE Costochondritis ✓ ✕ ✕ ✓ S5Hz Open dvsn wrist/hand lig NOS ✕ ✕ ✓ ✕ 
N33zz Costochondritis NOS ✓ ✕ ✕ ✓ S5J Open division hip ligament ✕ ✓ ✕ ✕ 
N34 Fallen arches ✕ ✓ ✕ ✓ S5J0 Open division iliofemoral lgmt ✕ ✓ ✕ ✕ 
N340 Pes planus - acquired ✕ ✓ ✕ ✓ S5Jy Other spec opn dvsn hip lgmt ✕ ✓ ✕ ✕ 
N3400 Hypermobile flat foot ✕ ✓ ✕ ✓ S5Jz Open division hip ligament NOS ✕ ✓ ✕ ✕ 
N3401 Rigid flat foot ✕ ✓ ✕ ✓ S5K Open division ligament knee ✕ ✓ ✕ ✕ 
N3402 Peroneal spastic flat foot ✕ ✓ ✕ ✕ S5K0 Opn dvsn lat collat lgmt knee ✕ ✓ ✕ ✕ 
N341 Talipes planus - acquired ✕ ✓ ✕ ✓ S5K1 Opn dvsn mdl collat lgmt knee ✕ ✓ ✕ ✕ 
N34z Flat foot NOS ✕ ✓ ✕ ✓ S5K2 Opn dvs post cruciate lgm knee ✕ ✓ ✕ ✕ 
N35 Acquired deformities of toe ✕ ✓ ✕ ✕ S5K3 Opn dvs ant cruciate lgmt knee ✕ ✓ ✕ ✕ 
N350 Hallux valgus - acquired ✕ ✓ ✕ ✕ S5K4 Opn dvsn,sup tibiofibular lgmt ✕ ✓ ✕ ✕ 
N351 Hallux varus - acquired ✕ ✓ ✕ ✕ S5Ky Open division other knee lgmt ✕ ✓ ✕ ✕ 
N352 Hallux rigidus - acquired ✕ ✓ ✕ ✕ S5Kz Open division knee lgmt NOS ✕ ✓ ✕ ✕ 
N353 Hallux malleus ✕ ✓ ✕ ✕ S5L Open division lgmt ankle/foot ✕ ✓ ✕ ✕ 
N354 Other hammer toe - acquired ✕ ✓ ✕ ✕ S5L0 Open division ankle ligament ✕ ✓ ✕ ✕ 
N355 Claw toe - acquired ✕ ✓ ✕ ✕ S5L00 Open division ankle,mdl lgmt ✕ ✓ ✕ ✕ 
N356 Clawing of great toe ✕ ✓ ✕ ✕ S5L01 Open division ankle,lat lgmt ✕ ✓ ✕ ✕ 
N357 Crossover toe ✕ ✓ ✕ ✕ S5L02 Open dvsn calcaneofibular lgmt ✕ ✓ ✕ ✕ 
N358 Mallet toe ✕ ✓ ✕ ✕ S5L03 Opn dvs dstl tibiofibular lgmt ✕ ✓ ✕ ✕ 
N359 Bunionette ✕ ✓ ✕ ✕ S5L0z Open division ankle lgmt NOS ✕ ✓ ✕ ✕ 
N35A Over-riding 5th toe ✕ ✓ ✕ ✕ S5L1 Open division foot ligament ✕ ✓ ✕ ✕ 
N35y Other acquired toe deformity ✕ ✓ ✕ ✕ S5L10 Open dvsn,mid tarsal jt lgmt ✕ ✓ ✕ ✕ 
N35z Acquired toe deformity NOS ✕ ✓ ✕ ✕ S5L11 Open dvsn tarsometatarsal lgmt ✕ ✓ ✕ ✕ 
N36 Other acquired limb deformity ✕ ✕ ✕ ✕ S5L12 Open dvsn metatarsophalan lgmt ✕ ✓ ✕ ✕ 
N360 Acquir.forearm def.ex.fingers ✕ ✕ ✓ ✕ S5L13 Open dvsn interphalan(toe)lgmt ✕ ✓ ✕ ✕ 
N3600 Acquired forearm deform.unspec ✕ ✕ ✓ ✕ S5L1z Open division foot lgmt NOS ✕ ✓ ✕ ✕ 
N3601 Cubitus valgus - acquired ✕ ✕ ✓ ✕ S5Lz Open dvsn ankle/foot lgmt NOS ✕ ✓ ✕ ✕ 
N3602 Cubitus varus - acquired ✕ ✕ ✓ ✕ S5M Open division pelvic ligament ✕ ✓ ✕ ✕ 
N3603 Acquired valgus wrist deform. ✕ ✕ ✓ ✕ S5M0 Open division symphysis pubis ✕ ✓ ✕ ✕ 
N3604 Acquired varus wrist deformity ✕ ✕ ✓ ✕ S5M1 Open dvsn sacrotuberous lgmt ✓ ✕ ✕ ✕ 
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N3605 Wrist drop - acquired ✕ ✕ ✓ ✕ S5M2 Open dvsn sacrospinous lgmt ✓ ✕ ✕ ✕ 
N3606 Claw hand - acquired ✕ ✕ ✓ ✕ S5M3 Open division sacroiliac lgmt ✓ ✕ ✕ ✕ 
N3607 Club hand - acquired ✕ ✕ ✓ ✕ S5M30 Open dvsn ant sacro-iliac lgmt ✓ ✕ ✕ ✕ 
N360z Acquired forearm deformity NOS ✕ ✕ ✓ ✕ S5M31 Opn dvsn post sacro-iliac lgmt ✓ ✕ ✕ ✕ 
N361 Mallet finger ✕ ✕ ✓ ✕ S5M3z Open dvsn sacroiliac lgmt NOS ✓ ✕ ✕ ✕ 
N362 Other acquired finger deform. ✕ ✕ ✓ ✕ S5M4 Open division iliolumbar lgmt ✓ ✕ ✕ ✕ 
N3620 Acquired finger deformity unsp ✕ ✕ ✓ ✕ S5M5 Open division lumbosacral lgmt ✓ ✕ ✕ ✕ 
N3621 Boutonniere finger deformity ✕ ✕ ✓ ✕ S5My Othr spec opn dvsn pelvic lgmt ✕ ✓ ✕ ✕ 
N3622 Swan-neck finger deformity ✕ ✕ ✓ ✕ S5Mz Open division pelvic lgmt NOS ✕ ✓ ✕ ✕ 
N3623 Flexion deformity of finger ✕ ✕ ✓ ✕ S5N Opn dvsn,lgmt other part back ✓ ✕ ✕ ✕ 
N3624 Extension deformity of finger ✕ ✕ ✓ ✕ S5N0 Open dvsn, neck ligament ✓ ✕ ✕ ✕ 
N3625 Deviation of finger ✕ ✕ ✓ ✕ S5N1 Open division,thoracic lgmt ✓ ✕ ✕ ✕ 
N3626 Rotational deformity of finger ✕ ✕ ✓ ✕ S5N2 Open division, lumbar ligament ✓ ✕ ✕ ✕ 
N362z Acquired finger deformity NOS ✕ ✕ ✓ ✕ S5N3 Open division, sacrum ligament ✓ ✕ ✕ ✕ 
N363 Acquired deformities of hip ✕ ✓ ✕ ✕ S5Nz Open divisn, back ligament NOS ✓ ✕ ✕ ✕ 
N3630 Acquired hip deformity unspec. ✕ ✓ ✕ ✕ S5P Open division, other ligament ✕ ✕ ✕ ✕ 
N3631 Coxa valga - acquired ✕ ✓ ✕ ✕ S5P0 Open division, jaw ligament ✕ ✕ ✕ ✕ 
N3632 Coxa vara - acquired ✕ ✓ ✕ ✕ S5P00 Opn dvsn,temporomandibulr lgmt ✕ ✕ ✕ ✕ 
N3633 Acq internal femoral torsion ✕ ✓ ✕ ✕ S5P0z Opn dvsn,jaw ligament NOS ✕ ✕ ✕ ✕ 
N3634 Persistent femoral anteversion ✕ ✓ ✕ ✕ S5P1 Opn dvsn,thyroid region lgmt ✓ ✕ ✕ ✕ 
N3635 Acq external femoral torsion ✕ ✓ ✕ ✕ S5P10 Opn dvsn,cricoarytenoid lgmt ✓ ✕ ✕ ✕ 
N363z Acquired hip deformity NOS ✕ ✓ ✕ ✕ S5P11 Opn dvsn,cricothyroid ligament ✓ ✕ ✕ ✕ 
N364 Acquired genu valgum/varum ✕ ✓ ✕ ✕ S5P12 Opn dvsn,thyroid cartilge lgmt ✓ ✕ ✕ ✕ 
N3640 Knock knee ✕ ✓ ✕ ✕ S5P1z Opn dvsn,thyroid regn lgmt NOS ✓ ✕ ✕ ✕ 
N3641 Bow legged ✕ ✓ ✕ ✕ S5P2 Open division, rib ligament ✓ ✕ ✕ ✕ 
N364z Acquired genu valgum/varum NOS ✕ ✓ ✕ ✕ S5P20 Opn dvsn,chondrocost jnt lgmt ✓ ✕ ✕ ✕ 
N365 Genu recurvatum - acquired ✕ ✓ ✕ ✕ S5P21 Opn dvsn,costal cartilage lgmt ✓ ✕ ✕ ✕ 
N366 Acquired knee deformity NOS ✕ ✓ ✕ ✕ S5P2z Opn dvsn,rib ligament NOS ✓ ✕ ✕ ✕ 
N3660 Flexion deformity of knee ✕ ✓ ✕ ✕ S5P3 Opn dvsn,sternal ligament ✓ ✕ ✕ ✕ 
N367 Other acquir.ankle/foot deform ✕ ✓ ✕ ✕ S5P30 Opn dvsn,sternoclavicular lgmt ✕ ✕ ✓ ✕ 
N3670 Acquir.ankle/foot deform.unsp. ✕ ✓ ✕ ✕ S5P31 Opn dvsn,chondrosternal lgmt ✓ ✕ ✕ ✕ 
N3671 Acquired equinovarus-clubfoot ✕ ✓ ✕ ✕ S5P32 Opn dvsn,xiphoid cartilge lgmt ✓ ✕ ✕ ✕ 
N3672 Acquired equinus foot deform. ✕ ✓ ✕ ✕ S5P3z Opn dvsn,sternal ligament NOS ✓ ✕ ✕ ✕ 
N3673 Aquired cavus foot deformity ✕ ✓ ✕ ✕ S5Pz Open division, other lig NOS ✕ ✕ ✕ ✕ 
N3674 Acquired claw foot ✕ ✓ ✕ ✕ S5Q Rupture tendon upper arm ✕ ✕ ✓ ✕ 
N3675 Acquired cavovarus foot deform ✕ ✓ ✕ ✕ S5Q0 Rupture infraspinatus tendon ✕ ✕ ✓ ✕ 
N3676 Other acquir.calcaneus deform. ✕ ✓ ✕ ✕ S5Q1 Rupture subscapularis tendon ✕ ✕ ✓ ✕ 
N3677 Acquired talipes NEC ✕ ✓ ✕ ✕ S5Q2 Rupture supraspinatus tendon ✕ ✕ ✓ ✕ 
N3678 Acquired varus heel ✕ ✓ ✕ ✕ S5Q3 Rupture long head biceps tendn ✕ ✕ ✓ ✕ 
N3679 Acquired valgus heel ✕ ✓ ✕ ✕ S5Q4 Rupture biceps tendon ✕ ✕ ✓ ✕ 
N367A Plantar flexion-midtarsal jnt ✕ ✓ ✕ ✕ S5Q5 Rupture triceps tendon ✕ ✕ ✓ ✕ 
N367B Plantar flex contracture-TMTJ ✕ ✓ ✕ ✕ S5Q6 Inj tendon rotator cuff should ✕ ✕ ✓ ✕ 
N367C Flexion contracture-MTPJ ✕ ✓ ✕ ✕ S5Qz Rupture tendon upper arm NOS ✕ ✕ ✓ ✕ 
N367D Extension contracture-MTPJ ✕ ✓ ✕ ✕ S5R Rupture tendon forearm/wrist ✕ ✕ ✓ ✕ 
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N367E Flexion contracture-toe joint ✕ ✓ ✕ ✕ S5R0 Rupture wrist extensors ✕ ✕ ✓ ✕ 
N367F Acq plantar-flexed forefoot ✕ ✓ ✕ ✕ S5R1 Rupture wrist flexors ✕ ✕ ✓ ✕ 
N367G Acq plantar-flexed first ray ✕ ✓ ✕ ✕ S5Rz Rupture tendon hand/wrist NOS ✕ ✕ ✓ ✕ 
N367H Acq plantar-flexed fifth ray ✕ ✓ ✕ ✕ S5S Rupture tendon of thumb ✕ ✕ ✓ ✕ 
N367J Acquired dorsiflexed forefoot ✕ ✓ ✕ ✕ S5S0 Rupture flexor pollicis longus ✕ ✕ ✓ ✕ 
N367K Acquired dorsiflexed first ray ✕ ✓ ✕ ✕ S5S1 Rupture extnsr pollicis longus ✕ ✕ ✓ ✕ 
N367L Acquired supinated forefoot ✕ ✓ ✕ ✕ S5S2 Mallet thumb+clsd tndn injury ✕ ✕ ✓ ✕ 
N367M Acquired pronated forefoot ✕ ✓ ✕ ✕ S5Sz Rupture tendon thumb NOS ✕ ✕ ✓ ✕ 
N367N Acquired forefoot adductus ✕ ✓ ✕ ✕ S5T Rupture tendon of finger ✕ ✕ ✓ ✕ 
N367P Acquired forefoot abductus ✕ ✓ ✕ ✕ S5T0 Rupt flexr digit superfic tndn ✕ ✕ ✓ ✕ 
N367Q Serpentine foot ✕ ✓ ✕ ✕ S5T1 Rupt flex digit profundus tndn ✕ ✕ ✓ ✕ 
N367z Acquired ankle/foot deform.NOS ✕ ✓ ✕ ✕ S5T2 Rupt extensor digit tndn ✕ ✕ ✓ ✕ 
N368 Other knee deformity ✕ ✓ ✕ ✕ S5T3 Mallet finger+cls tndn injury ✕ ✕ ✓ ✕ 
N3680 Acq internal tibial torsion ✕ ✓ ✕ ✕ S5Tz Rupture tendon of finger NOS ✕ ✕ ✓ ✕ 
N3681 Acq external tibial torsion ✕ ✓ ✕ ✕ S5U Rupture tendon thigh ✕ ✓ ✕ ✕ 
N3682 Chronic instability of knee ✕ ✓ ✕ ✕ S5U0 Rupture quadriceps tendon ✕ ✓ ✕ ✕ 
N36A Drop foot ✕ ✓ ✕ ✕ S5U1 Rupture hamstring tendon ✕ ✓ ✕ ✕ 
N36y Torsion tibia ✕ ✓ ✕ ✕ S5U2 Rupture patellar tendon ✕ ✓ ✕ ✕ 
N36y0 Acquired unequal leg length ✕ ✓ ✕ ✕ S5Uz Rupture upper leg tendon NOS ✕ ✓ ✕ ✕ 
N36y1 Acquired unequal arm length ✕ ✕ ✓ ✕ S5V Rupture tendon leg or foot ✕ ✓ ✕ ✕ 
N36y3 Deformity of clavicle ✕ ✕ ✓ ✕ S5V0 Rupture achilles tendon ✕ ✓ ✕ ✕ 
N36y4 Deformity of scapula ✕ ✕ ✓ ✕ S5V1 Rupture plantaris tendon ✕ ✓ ✕ ✕ 
N36y5 Deformity of humerus ✕ ✕ ✓ ✕ S5V2 Rupture foot flexor tendon ✕ ✓ ✕ ✕ 
N36y6 Deformity of radius ✕ ✕ ✓ ✕ S5V3 Rupture foot extensor tendon ✕ ✓ ✕ ✕ 
N36y7 Deformity of ulna ✕ ✕ ✓ ✕ S5Vz Rupture tendon leg/foot NOS ✕ ✓ ✕ ✕ 
N36y8 Deformity of carpal bone ✕ ✕ ✓ ✕ S5W Other specified tendon rupture ✕ ✕ ✕ ✕ 
N36y9 Deformity of metacarpal ✕ ✕ ✓ ✕ S5y0 Septal cartilage nose sprain ✕ ✕ ✕ ✕ 
N36yA Deformity of phalanx - fing/th ✕ ✕ ✓ ✕ S5y1 Jaw sprain ✕ ✕ ✕ ✕ 
N36yB Deformity of pelvis ✕ ✓ ✕ ✕ S5y10 Jaw sprain, unspecified ✕ ✕ ✕ ✕ 
N36yC Deformity of femur ✕ ✓ ✕ ✕ S5y11 Temporomandibular sprain ✕ ✕ ✕ ✕ 
N36yD Deformity of patella ✕ ✓ ✕ ✕ S5y1z Jaw sprain NOS ✕ ✕ ✕ ✕ 
N36yE Deformity of tibia ✕ ✓ ✕ ✕ S5y3 Rib sprain ✓ ✕ ✕ ✕ 
N36yF Deformity of fibula ✕ ✓ ✕ ✕ S5y30 Rib sprain unspecified ✓ ✕ ✕ ✕ 
N36yG Deformity of calcaneum ✕ ✓ ✕ ✕ S5y31 Chondrocostal joint sprain ✓ ✕ ✕ ✕ 
N36yH Deformity of talus ✕ ✓ ✕ ✕ S5y32 Costal cartilage sprain ✓ ✕ ✕ ✕ 
N36yJ Deformity of other tarsal bone ✕ ✓ ✕ ✕ S5y3z Rib sprain NOS ✓ ✕ ✕ ✕ 
N36yK Deformity of metatarsal ✕ ✓ ✕ ✕ S5y4 Sternum sprain ✓ ✕ ✕ ✕ 
N36yL Deformity of phalanx of toe ✕ ✓ ✕ ✕ S5y40 Sternum sprain unspecified ✓ ✕ ✕ ✕ 
N36yM Old amputee NOS ✕ ✕ ✕ ✕ S5y41 Sternoclavicular sprain ✕ ✕ ✓ ✕ 
N36yz Acquired limb deformity NEC ✕ ✕ ✕ ✕ S5y42 Chondrosternal sprain ✓ ✕ ✕ ✕ 
N36z Drop foot ✕ ✓ ✕ ✕ S5y43 Xiphoid cartilage sprain ✓ ✕ ✕ ✕ 
N37 Curvature of spine ✓ ✕ ✕ ✕ S5y4z Sternum sprain NOS ✓ ✕ ✕ ✕ 
N370 Adolescent postural kyphosis ✓ ✕ ✕ ✕ S5y5 Pelvis sprain or complete tear ✕ ✓ ✕ ✕ 
N371 Acquired kyphosis ✓ ✕ ✕ ✕ S5y50 Sprain of pelvis, unspecified ✕ ✓ ✕ ✕ 
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N3710 Acquired postural kyphosis ✓ ✕ ✕ ✕ S5y51 Sprain symphysis pubis ✕ ✓ ✕ ✕ 
N3711 Radiation kyphosis ✓ ✕ ✕ ✕ S5y52 Cmpl tear,symphysis pubis lgmt ✕ ✓ ✕ ✕ 
N3712 Post-laminectomy kyphosis ✓ ✕ ✕ ✕ S5y53 Cmpl tear,sacrotuberous lgmt ✓ ✕ ✕ ✕ 
N3713 Kyphosis due to oth treatment ✓ ✕ ✕ ✕ S5y54 Cmpl tear,sacrospinous lgmt ✓ ✕ ✕ ✕ 
N371z Acquired kyphosis NOS ✓ ✕ ✕ ✕ S5y55 Cmpl tear,sacroiliac lgmt ✓ ✕ ✕ ✕ 
N372 Acquired lordosis ✓ ✕ ✕ ✕ S5y56 Cmpl tear,iliolumbar lgmt ✓ ✕ ✕ ✕ 
N3720 Acquired postural lordosis ✓ ✕ ✕ ✕ S5y57 Cmpl tear,lumbosacral lgmt ✓ ✕ ✕ ✕ 
N3721 Post-laminectomy lordosis ✓ ✕ ✕ ✕ S5y5z Sprain of pelvis NOS ✕ ✓ ✕ ✕ 
N3722 Other post-surgical lordosis ✓ ✕ ✕ ✕ S5yX Spr/str oth/unsp parts thor ✓ ✕ ✕ ✕ 
N372z Acquired lordosis NOS ✓ ✕ ✕ ✕ S5z Ligament sprain NOS ✕ ✕ ✕ ✕ 
N373 Kyphoscoliosis and scoliosis ✓ ✕ ✕ ✕ S6 Intracranial inj.excl.+skull # ✕ ✕ ✕ ✕ 
N3730 Idiopathic scoliosis ✓ ✕ ✕ ✕ S64 Head injury ✕ ✕ ✕ ✕ 
N3731 Idiopathic kyphoscoliosis ✓ ✕ ✕ ✕ S6401 Minor head injury ✕ ✕ ✕ ✕ 
N3732 Resolving infant.idiopath.scol ✓ ✕ ✕ ✕ S646 Head injury ✕ ✕ ✕ ✕ 
N3733 Progressive infant.idiop.scol. ✓ ✕ ✕ ✕ S6460 Minor head injury ✕ ✕ ✕ ✕ 
N3734 Radiation scoliosis ✓ ✕ ✕ ✕ S7 Injury To Chest ✓ ✕ ✕ ✕ 
N3735 Thoracogenic scoliosis ✓ ✕ ✕ ✕ S72x Crushedchest ✓ ✕ ✕ ✕ 
N3736 Postural scoliosis ✓ ✕ ✕ ✕ S77 Injury To Chest ✓ ✕ ✕ ✕ 
N3737 Adolescent idiopath scoliosis ✓ ✕ ✕ ✕ S797 InjuryToChest ✓ ✕ ✕ ✕ 
N3738 Post-surgical scoliosis ✓ ✕ ✕ ✕ S8* Laceration of head/neck/trunk ✕ ✕ ✕ ✕ 
N3739 Scoliosis due to oth treatment ✓ ✕ ✕ ✕ S83 Other open wound of head ✕ ✕ ✕ ✕ 
N373z Kyphoscoliosis or scoliosis NOS ✓ ✕ ✕ ✕ S830 Open wound of scalp ✕ ✕ ✕ ✕ 
N374 Spine curvature+other condits. ✓ ✕ ✕ ✕ S831 Open wound scalp+complication ✕ ✕ ✕ ✕ 
N3740 Curvature of spine unspecified ✓ ✕ ✕ ✕ S8343 Open wound of eyebrow ✕ ✕ ✕ ✕ 
N3741 Kyphosis + other condition ✓ ✕ ✕ ✕ S84 Open wound of neck ✓ ✕ ✕ ✕ 
N3742 Lordosis + other condition ✓ ✕ ✕ ✕ S852 Open wound of front wall of thorax ✓ ✕ ✕ ✕ 
N3743 Scoliosis + other condition ✓ ✕ ✕ ✕ S8z Laceration ✕ ✕ ✕ ✕ 
N3744 Kyphosis in skeletal dysplasia ✓ ✕ ✕ ✕ S9 Laceration of arm ✕ ✕ ✓ ✕ 
N3745 Neuromuscular kyphosis ✓ ✕ ✕ ✕ S90 Open wound shoulder/upper limb ✕ ✕ ✓ ✕ 
N3746 Osteoporotic kyphosis ✓ ✕ ✕ ✕ S9000 Open wound of shoulder region ✕ ✕ ✓ ✕ 
N3747 Lordosis in skeletal dysplasia ✓ ✕ ✕ ✕ S900z Opn wound shoulder+up limb,NOS ✕ ✕ ✓ ✕ 
N3748 Lordosis in hip disease ✓ ✕ ✕ ✕ S9010 Open wound shoulder+complicat. ✕ ✕ ✓ ✕ 
N3749 Neuromuscular lordosis ✓ ✕ ✕ ✕ S902 Tendon inj + open wound arm ✕ ✕ ✓ ✕ 
N374A Scoliosis in skelet dysplasia ✓ ✕ ✕ ✕ S9020 Open wound shoulder+tendon inv ✕ ✕ ✓ ✕ 
N374B Neuromuscular scoliosis ✓ ✕ ✕ ✕ S9021 Open wound scapular+tendon inv ✕ ✕ ✓ ✕ 
N374C Scoliosis in neurofibromatosis ✓ ✕ ✕ ✕ S9022 Open wound axillary+tendon inv ✕ ✕ ✓ ✕ 
N374D Scoliosis in conn tiss anomal ✓ ✕ ✕ ✕ S9023 Open wound upper arm+tendon ✕ ✕ ✓ ✕ 
N374E Flatback syndrome ✓ ✕ ✕ ✕ S9025 Complete dvsn,biceps tendon ✕ ✕ ✓ ✕ 
N374W Lordosis, unspecified ✓ ✕ ✕ ✕ S9026 Complete dvsn,triceps tendon ✕ ✕ ✓ ✕ 
N374X Other+unspecified kyphosis ✓ ✕ ✕ ✕ S9028 Partial division biceps tendon ✕ ✕ ✓ ✕ 
N374z Spine curvature+other cond.NOS ✓ ✕ ✕ ✕ S9029 Partial dvsn,triceps tendon ✕ ✕ ✓ ✕ 
N37y Other curvatures of spine ✓ ✕ ✕ ✕ S902x Mult.opn.wnd.upper arm+tendon ✕ ✕ ✓ ✕ 
N37z Curvature of spine NOS ✓ ✕ ✕ ✕ S902z Opn.wound upper arm+tendon NOS ✕ ✕ ✓ ✕ 
N37z0 Acquired hunchback ✓ ✕ ✕ ✕ S9030 Degloving injury,shoulder area ✕ ✕ ✓ ✕ 
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N37zz Curvature of spine NOS ✓ ✕ ✕ ✕ S906 Traumat amp at shoulder joint ✕ ✕ ✓ ✕ 
N380 Acquired deformity of nose ✕ ✕ ✕ ✕ S91 Open Wound - Wrist ✕ ✕ ✓ ✕ 
N381 Other acquired head deformity ✕ ✕ ✕ ✕ S9100 Open wound of forearm ✕ ✕ ✓ ✕ 
N382 Acquired deformity of neck ✓ ✕ ✕ ✕ S9101 Open wound of elbow ✕ ✕ ✓ ✕ 
N383 Acquired chest/rib deformity ✓ ✕ ✕ ✕ S9102 Open wound wrist unspecified ✕ ✕ ✓ ✕ 
N3830 Acquired chest deformity unsp. ✓ ✕ ✕ ✕ S9103 Open wound of wrist, volar ✕ ✕ ✓ ✕ 
N3831 Acquired rib deformity unsp. ✓ ✕ ✕ ✕ S9104 Open wound of wrist, dorsal ✕ ✕ ✓ ✕ 
N3832 Acquired pectus carinatum ✓ ✕ ✕ ✕ S911 Open wound lower arm+complic. ✕ ✕ ✓ ✕ 
N3833 Acquired pectus excavatum ✓ ✕ ✕ ✕ S9111 Open wound elbow+complication ✕ ✕ ✓ ✕ 
N383z Acquired chest/rib deform.NOS ✓ ✕ ✕ ✕ S9112 Open wound wrist+complication ✕ ✕ ✓ ✕ 
N384 Acquired spondylolisthesis ✓ ✕ ✕ ✕ S912 Open wound lowr arm+tendon inj ✕ ✕ ✓ ✕ 
N3840 Dysplastic spondylolisthesis ✓ ✕ ✕ ✕ S9120 Open wound forearm+tendon inv. ✕ ✕ ✓ ✕ 
N3841 Isthmic spondylolisthesis ✓ ✕ ✕ ✕ S9121 Open wound elbow+tendon inv. ✕ ✕ ✓ ✕ 
N3842 Degenerative spondylolisthesis ✓ ✕ ✕ ✕ S9122 Open wound wrist+tendon inv. ✕ ✕ ✓ ✕ 
N3843 Pedicular spondylolisthesis ✓ ✕ ✕ ✕ S9123 Cmpl dvs extensor tendon wrist ✕ ✕ ✓ ✕ 
N385 Acquired deformity spine NOS ✓ ✕ ✕ ✕ S9124 Cmpl dvs flexor tendon wrist ✕ ✕ ✓ ✕ 
N386 Pelvic obliquity ✕ ✓ ✕ ✕ S9125 Part dvs extensor tendon wrist ✕ ✕ ✓ ✕ 
N387 Cauliflower ear ✕ ✕ ✕ ✕ S9126 Part dvs flexor tendon wrist ✕ ✕ ✓ ✕ 
N388 Spondylolysis ✓ ✕ ✕ ✕ S912z Opn.wnd.lower arm+tendon NOS ✕ ✕ ✓ ✕ 
N38y0 Acquired clavicle deformity ✕ ✕ ✓ ✕ S9131 Degloving injury, elbow area ✕ ✕ ✓ ✕ 
N390 Nonallopathic lesion-head reg ✕ ✕ ✕ ✓ S9132 Degloving injury wrist, volar ✕ ✕ ✓ ✕ 
N391 Nonallopathic lesion-cervical ✓ ✕ ✕ ✓ S9133 Degloving injury wrist, dorsum ✕ ✕ ✓ ✕ 
N392 Nonallopathic lesion-thoracic ✓ ✕ ✕ ✓ S91z Opn.wnd.elb./forearm/wrist NOS ✕ ✕ ✓ ✕ 
N393 Nonallopathic lesion-lumbar ✓ ✕ ✕ ✓ S92 Open wound hand excl.finger(s) ✕ ✕ ✓ ✕ 
N394 Nonallopathic lesion-sacral ✓ ✕ ✕ ✓ S920 Open wound hand-no complic. ✕ ✕ ✓ ✕ 
N395 Nonallopathic lesion-pelvic ✕ ✓ ✕ ✓ S9200 Open wound of hand, palm ✕ ✕ ✓ ✕ 
N396 Nonallopathic lesion-legs ✕ ✓ ✕ ✓ S9201 Open wound of hand, dorsum ✕ ✕ ✓ ✕ 
N397 Nonallopathic lesion-arms ✕ ✕ ✓ ✓ S921 Open wound hand+complication ✕ ✕ ✓ ✕ 
N398 Nonallopathic lesion-rib cage ✓ ✕ ✕ ✓ S922 Open wound hand+tendon involv. ✕ ✕ ✓ ✕ 
N399 Nonallopathic lesion-abd.+oth. ✕ ✕ ✕ ✓ S9220 Cmpl dvs extensor tendon hand ✕ ✕ ✓ ✕ 
N3y01 Subluxatn complex (vertebral) ✓ ✕ ✕ ✕ S9221 Cmpl dvs flexor tendon hand ✕ ✕ ✓ ✕ 
N3y02 Sublux stenos of neural canal ✓ ✕ ✕ ✕ S9222 Part dvs extensor tendon hand ✕ ✕ ✓ ✕ 
N3y03 Osseous stenos of neural canal ✓ ✕ ✕ ✕ S9223 Partial dvs flexor tendon hand ✕ ✕ ✓ ✕ 
N3y04 Connect tiss sten neural canal ✓ ✕ ✕ ✕ S923 Degloving injury hand ✕ ✕ ✓ ✕ 
N3y05 Intervert disc sten neur canal ✓ ✕ ✕ ✕ S9230 Degloving injury hand, palmar ✕ ✕ ✓ ✕ 
N3y06 Oss/sublx sten intervert foram ✓ ✕ ✕ ✕ S9231 Degloving injury hand, dorsum ✕ ✕ ✓ ✕ 
N3y07 Con tis/disc sten intervrt for ✓ ✕ ✕ ✕ S924 Severe multi tiss damage hand ✕ ✕ ✓ ✕ 
Nyu21 [X]Other primary coxarthrosis ✕ ✓ ✕ ✕ S925 Massive multi tiss damage hand ✕ ✕ ✓ ✕ 
Nyu22 [X]Oth dysplastic coxarthrosis ✕ ✓ ✕ ✕ S92z Open wound hand excl.fing.NOS ✕ ✕ ✓ ✕ 
Nyu23 [X]Oth post-traum coxarthrosis ✕ ✓ ✕ ✕ S93 Open wound of finger(s) or thumb ✕ ✕ ✓ ✕ 
Nyu24 [X]Oth 2ndry coxarthrsis,bilat ✕ ✓ ✕ ✕ S9300 Open wound finger ✕ ✕ ✓ ✕ 
Nyu25 [X]Unilat primary gonarthrosis ✕ ✓ ✕ ✕ S9302 Open wound thumb ✕ ✕ ✓ ✕ 
Nyu26 [X]Oth post-traum gonarthrosis ✕ ✓ ✕ ✕ S932 Open wound finger+tendon inj. ✕ ✕ ✓ ✕ 
Nyu27 [X]Oth 2ndry gonarthrsis,bilat ✕ ✓ ✕ ✕ S9322 Cmpl dvsn,both flxr tendons ✕ ✕ ✓ ✕ 
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Nyu28 [X]Unilat second gonarthrosis ✕ ✓ ✕ ✕ S9323 Cmpl dvsn,ext digit tendon ✕ ✕ ✓ ✕ 
Nyu29 [X]O p arthros/1st crpmtcrp jt ✕ ✕ ✓ ✕ S932A Part dvsn both flxr tendons ✕ ✕ ✓ ✕ 
Nyu2A [X]O p-trm arthro/1st cpmcp jt ✕ ✕ ✓ ✕ S932B Part dvsn,ext digit tendon ✕ ✕ ✓ ✕ 
Nyu2B [X]O 2ndy arthros/1st cmc j,bi ✕ ✕ ✓ ✕ S937 Open wound finger damage nail ✕ ✕ ✓ ✕ 
Nyu2C [X]O 2ndry arthros/1st cpmcp j ✕ ✕ ✓ ✕ S93z Open wound finger NOS ✕ ✕ ✓ ✕ 
Nyu2D [X]Other specified arthrosis ✕ ✕ ✕ ✕ S942 Mult./unsp.opn.wnd.arm+tendon ✕ ✕ ✓ ✕ 
Nyu2E [X]Oth secondary coxarthrosis ✕ ✓ ✕ ✕ S9504 Traumatic amputation thumb tip ✕ ✕ ✓ ✕ 
Nyu30 [X]Oth deformity/hallux(acqd) ✕ ✓ ✕ ✕ S96 Traumatic amputation of finger(s) ✕ ✕ ✓ ✕ 
Nyu31 [X]Oth hammer toe(s)(acquired) ✕ ✓ ✕ ✕ S960 Traumat.amput.finger-no compl. ✕ ✕ ✓ ✕ 
Nyu32 [X]Oth deformits/toe(s)(acqd) ✕ ✓ ✕ ✕ S9605 Tr ampufingermultiple ✕ ✕ ✓ ✕ 
Nyu33 [X]Oth acqd deforms/ankle+foot ✕ ✓ ✕ ✕ S9606 Traumatic amputation finger tip ✕ ✕ ✓ ✕ 
Nyu34 [X]Oth spcf acqd deform/limbs ✕ ✕ ✕ ✕ S97 Traumatic amputation arm/hand ✕ ✕ ✓ ✕ 
Nyu35 [X]Other derangements/patella ✕ ✓ ✕ ✕ S9y Open wound upper limb OS ✕ ✕ ✓ ✕ 
Nyu36 [X]Other disorders of patella ✕ ✓ ✕ ✓ SA Laceration - leg ✕ ✓ ✕ ✕ 
Nyu37 [X]Other meniscus derangements ✕ ✓ ✕ ✕ SA0 Open wound hip and thigh ✕ ✓ ✕ ✕ 
Nyu38 [X]O spontn disrptn/lig(s)knee ✕ ✓ ✕ ✕ SA00 Open wound hip/thigh-no compl. ✕ ✓ ✕ ✕ 
Nyu39 [X]Oth intrnl derangemnts/knee ✕ ✓ ✕ ✕ SA1 Open wound knee/leg/ankle ✕ ✓ ✕ ✕ 
Nyu3B [X]O spcf joint derangmnts,NEC ✕ ✕ ✕ ✕ SA100 Open wound of knee ✕ ✓ ✕ ✕ 
Nyu3C [X]Other instability of joint ✕ ✕ ✕ ✕ SA101 Open wound of leg ✕ ✓ ✕ ✕ 
Nyu3D [X]Other spcfd joint disorders ✕ ✕ ✕ ✕ SA110 Open wound knee+complication ✕ ✓ ✕ ✕ 
Nyu3E [X]Disorder of patella, unspec ✕ ✓ ✕ ✓ SA131 Degloving injury lower leg ✕ ✓ ✕ ✕ 
Nyu5 [X]Deforming dorsopathies ✓ ✕ ✕ ✕ SA17 Open Wound - Ankle ✕ ✓ ✕ ✕ 
Nyu50 [X]Other secondary kyphosis ✓ ✕ ✕ ✕ SA1z Open wound knee/leg/ankle NOS ✕ ✓ ✕ ✕ 
Nyu51 [X]Other+unspecified kyphosis ✓ ✕ ✕ ✕ SA2 Open wound foot excl.toe(s) ✕ ✓ ✕ ✕ 
Nyu52 [X]Other lordosis ✓ ✕ ✕ ✕ SA203 Open wound heel ✕ ✓ ✕ ✕ 
Nyu53 [X]Other idiopathic scoliosis ✓ ✕ ✕ ✕ SA2z Open wound foot NOS ✕ ✓ ✕ ✕ 
Nyu54 [X]Other secondary scoliosis ✓ ✕ ✕ ✕ SA3 Open wound of toe(s) ✕ ✓ ✕ ✕ 
Nyu55 [X]Other forms of scoliosis ✓ ✕ ✕ ✕ SA31 Open wound toe(s)+complication ✕ ✓ ✕ ✕ 
Nyu56 [X]Other fusion of spine ✓ ✕ ✕ ✕ SA3z Open wound of toe(s) NOS ✕ ✓ ✕ ✕ 
Nyu57 [X]O recur atlantoaxl subluxtn ✓ ✕ ✕ ✕ SA7z Traumatic amputation - leg NOS ✕ ✓ ✕ ✕ 
Nyu58 [X]Oth recur vertebrl subluxtn ✓ ✕ ✕ ✕ SC00 Late effect-#skull/face bones ✕ ✕ ✕ ✕ 
Nyu59 [X]Oth spcf deform dorsopaths ✓ ✕ ✕ ✕ SC01 Late effect-#spine-no cord les ✓ ✕ ✕ ✕ 
Nyu5A [X]Lordosis, unspecified ✓ ✕ ✕ ✕ SC010 Late effect # cervic vertebra ✓ ✕ ✕ ✕ 
Nyu5B [X]Spin osteochondrosis, unsp ✓ ✕ ✕ ✕ SC011 Late effect # thoracic vert ✓ ✕ ✕ ✕ 
Nyu6 [X]Spondylopathies ✓ ✕ ✕ ✓ SC012 Late effect # lumbar vertebra ✓ ✕ ✕ ✕ 
Nyu60 [X]Oth infectv spondylopathies ✓ ✕ ✕ ✕ SC02 Late effect-#arm ✕ ✕ ✓ ✕ 
Nyu61 [X]Oth spcf inflam spondylpath ✓ ✕ ✕ ✕ SC03 Late effect-# neck of femur ✕ ✓ ✕ ✕ 
Nyu62 [X]Oth spondylosis+myelopathy ✓ ✕ ✕ ✕ SC04 Late effect-other #leg ✕ ✓ ✕ ✕ 
Nyu63 [X]O spondylosis+radiculopathy ✓ ✕ ✕ ✕ SC09 Late effect-traumatic amputatn ✕ ✕ ✕ ✕ 
Nyu64 [X]Other spondylosis ✓ ✕ ✕ ✓ SC0X Seq oth fract thorax/pelvis ✓ ✕ ✕ ✕ 
Nyu65 [X]Other spcfd spondylopathies ✓ ✕ ✕ ✓ SC0z Delayed union of fracture ✕ ✕ ✕ ✕ 
Nyu66 [X]Spondylpth/o inf+paras d CE ✓ ✕ ✕ ✕ SD097 SuperficialInjury:Neck ✓ ✕ ✕ ✕ 
Nyu67 [X]Collapsd vertebra in dis CE ✓ ✕ ✕ ✕ SD0y Superficial injury of head NOS ✕ ✕ ✕ ✕ 
Nyu68 [X]Spondylpthy/oth diseases CE ✓ ✕ ✕ ✓ SD0y0 Superficial injury of face NOS ✕ ✕ ✕ ✕ 
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Nyu7 [X]Other dorsopathies ✓ ✕ ✕ ✓ SD1y1 Sup inj chst w NOS-no mj op wd ✓ ✕ ✕ ✕ 
Nyu70 [X]Oth cervicl disc displacmnt ✓ ✕ ✕ ✓ SD1y4 Supl inj bk NOS-no mj opn wnd ✓ ✕ ✕ ✕ 
Nyu71 [X]Oth cervicl disc degeneratn ✓ ✕ ✕ ✓ SD2y0 Superfic injury shoulder NOS ✕ ✕ ✓ ✕ 
Nyu72 [X]Oth cervical disc disorders ✓ ✕ ✕ ✓ SD2y1 Superficial injury of scapular NOS ✕ ✕ ✓ ✕ 
Nyu73 [X]Lumb+o intrvrt disc d+mylop ✓ ✕ ✕ ✕ SD3 Superf.inj.elbow/forearm/wrist ✕ ✕ ✓ ✕ 
Nyu74 [X]Lumb+o intvt disc d+radiclp ✓ ✕ ✕ ✓ SD3y0 Superficial injury of elbow NOS ✕ ✕ ✓ ✕ 
Nyu75 [X]O spc intervert disc displm ✓ ✕ ✕ ✓ SD3y1 Superficial injury of forearm NOS ✕ ✕ ✓ ✕ 
Nyu76 [X]O spc intrvrtbl disc degenr ✓ ✕ ✕ ✓ SD3y2 Superficial injury of wrist NOS ✕ ✕ ✓ ✕ 
Nyu77 [X]O spcf intrvrtbrl disc diso ✓ ✕ ✕ ✓ SD4 Superf.inj.handexcl.fingers ✕ ✕ ✓ ✕ 
Nyu78 [X]Sacrococygeal disorders,NEC ✓ ✕ ✕ ✓ SD4y Superf.inj.-handNOSnoinf. ✕ ✕ ✓ ✕ 
Nyu79 [X]Oth specified dorsopathies ✓ ✕ ✕ ✓ SD4z Superf.inj.-hand NOS+infect. ✕ ✕ ✓ ✕ 
Nyu7A [X]Other dorsalgia ✓ ✕ ✕ ✓ SD5 Superficial injury finger(s) ✕ ✕ ✓ ✕ 
Nyu7B [X]Cervical disc disord, unsp ✓ ✕ ✕ ✓ SD5z Superfic.inj.-finger NOS+inf. ✕ ✕ ✓ ✕ 
NyuA0 [X]Other bursitis of elbow ✕ ✕ ✓ ✓ SD6 Superficial inj.leg excl.foot ✕ ✓ ✕ ✕ 
NyuA1 [X]Other bursitis of knee ✕ ✓ ✕ ✓ SD6y Superfic.injury-legNOSnoinf ✕ ✓ ✕ ✕ 
NyuA2 [X]Other bursitis of hip ✕ ✓ ✕ ✓ SD6y2 SuperficialinjuryofkneeNOS ✕ ✓ ✕ ✕ 
NyuAB [X]Other shoulder lesions ✕ ✕ ✓ ✓ SD6y3 Superficial injury lwr leg NOS ✕ ✓ ✕ ✕ 
NyuAC [X]O enthespath/lw limb,exc ft ✕ ✓ ✕ ✓ SD6y4 Superficial injury of ankle NOS ✕ ✓ ✕ ✕ 
NyuAD [X]Other enthesopathy of foot ✕ ✓ ✕ ✓ SD7y0 Superficial injury of foot NOS ✕ ✓ ✕ ✕ 
NyuAJ [X]Enthesopathy lowr limb,unsp ✕ ✓ ✕ ✓ SD7y1 Superficial injury of toe NOS ✕ ✓ ✕ ✕ 
NyuD0 [X]O juv osteochndrsis/hp+pelv ✕ ✓ ✕ ✕ SE00 Contusion forehead ✕ ✕ ✕ ✕ 
NyuD1 [X]O juv osteochndrsis/up limb ✕ ✕ ✓ ✕ SE01 Contusion cheek ✕ ✕ ✕ ✕ 
R01z1 [D]Growing pains - limbs ✕ ✕ ✕ ✓ SE08 Other contusion neck ✓ ✕ ✕ ✕ 
R0224 [D]Loc swell mass/lump up limb ✕ ✕ ✓ ✕ SE0z Contusion face scalp+neck NOS ✓ ✕ ✕ ✕ 
R0225 [D]Loc swell mass/lump low limb ✕ ✓ ✕ ✕ SE11 Contusioneyelids+perioc tiss ✕ ✕ ✕ ✕ 
R0229 [D]Foot lump ✕ ✓ ✕ ✕ SE20 Contusion breast ✓ ✕ ✕ ✕ 
R022A [D]Shoulder lump ✕ ✕ ✓ ✕ SE21 Contusion chest wall ✓ ✕ ✕ ✕ 
R022B [D]Lump on hand ✕ ✕ ✓ ✕ SE22z Contusion abdominal wall NOS ✕ ✕ ✕ ✕ 
R022C [D]Lump on knee ✕ ✓ ✕ ✕ SE23 Contusion back ✓ ✕ ✕ ✕ 
R022D [D]Lump on leg ✕ ✓ ✕ ✕ SE231 Contusion buttock ✕ ✓ ✕ ✕ 
R022F [D]Lump on thigh ✕ ✓ ✕ ✕ SE232 Contusion of lower back ✓ ✕ ✕ ✕ 
R022G [D]Finger lump ✕ ✕ ✓ ✕ SE233 Contusion of coccyx ✓ ✕ ✕ ✕ 
R022H [D]Wrist lump ✕ ✕ ✓ ✕ SE23z Contusion back NOS ✓ ✕ ✕ ✕ 
R022K [D]Buttock swelling ✕ ✓ ✕ ✕ SE241 Contusion penis ✕ ✕ ✕ ✕ 
R04 [D]Head and neck symptoms ✓ ✕ ✕ ✓ SE242 Contusion scrotum or testis ✕ ✕ ✕ ✕ 
R0400 [D]Facial pain ✕ ✕ ✕ ✓ SE25 Contusion of pelvic region ✕ ✓ ✕ ✕ 
R040z [D]Jaw pain ✕ ✕ ✕ ✓ SE3 Arm bruise ✕ ✕ ✓ ✕ 
R042 [D]Neck swelling/mass/lump ✓ ✕ ✕ ✕ SE30 Contusion shoulder or upper arm ✕ ✕ ✓ ✕ 
R0420* [D]Swelling face ✕ ✕ ✕ ✕ SE300 Contusion shoulder area ✕ ✕ ✓ ✕ 
R0422 [D]Lump in head or neck ✓ ✕ ✕ ✕ SE303 Contusion upper arm ✕ ✕ ✓ ✕ 
R04z* [D]Head and neck other sympt. ✕ ✕ ✕ ✓ SE31 Contusion elbow or forearm ✕ ✕ ✓ ✕ 
R04zz [D]Head and neck symptoms NOS ✓ ✕ ✕ ✓ SE310 Contusion forearm area ✕ ✕ ✓ ✕ 
R065 [D]Chest pain ✓ ✕ ✕ ✓ SE311 Contusion elbow area ✕ ✕ ✓ ✕ 
R0650 [D] Retrosternal chest pain ✓ ✕ ✕ ✓ SE31z Contusion elbow and forearm NOS ✕ ✕ ✓ ✕ 
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R0652 [D]Anterior chest wall pain ✓ ✕ ✕ ✓ SE320 Contusion hand excluding finger ✕ ✕ ✓ ✕ 
R0659 [D]Parasternal chest pain ✓ ✕ ✕ ✓ SE321 Contusion wrist ✕ ✕ ✓ ✕ 
R065A [D]Musculoskeletal chest pain ✓ ✕ ✕ ✓ SE322 Contusion hand palm ✕ ✕ ✓ ✕ 
R065B [D]Non cardiac chest pain ✓ ✕ ✕ ✓ SE323 Contusion hand dorsum ✕ ✕ ✓ ✕ 
R065C [D]Retrosternal chest pain ✓ ✕ ✕ ✓ SE32z Contusion wrist and hand NOS ✕ ✕ ✓ ✕ 
R065D [D]Central chest pain ✓ ✕ ✕ ✓ SE330 Contusion finger unspecified ✕ ✕ ✓ ✕ 
R065z [D]Chest pain NOS ✓ ✕ ✕ ✓ SE33z Contusion finger NOS ✕ ✕ ✓ ✕ 
R066 [D]Swelling mass lump chest ✓ ✕ ✕ ✕ SE3z Contusion upper limb NOS ✕ ✕ ✓ ✕ 
R0661 [D]Chest lump ✓ ✕ ✕ ✕ SE4 Leg bruise ✕ ✓ ✕ ✕ 
R090B [D]Groin pain ✕ ✓ ✕ ✓ SE40 Contusion hip and thigh ✕ ✓ ✕ ✕ 
R090C [D]Loin pain ✓ ✕ ✕ ✓ SE400 Contusion hip ✕ ✓ ✕ ✕ 
R090G [D] Pelvic pain ✕ ✓ ✕ ✓ SE401 Contusion thigh ✕ ✓ ✕ ✕ 
R090J [D]Right upper quadrant pain ✓ ✕ ✕ ✓ SE41 Bruise - knee/lower leg ✕ ✓ ✕ ✕ 
R090K [D]Left upper quadrant pain ✓ ✕ ✕ ✓ SE410 Contusion lower leg ✕ ✓ ✕ ✕ 
R1300 [D]Skull/head x-ray abnormal ✕ ✕ ✕ ✕ SE411 Contusion knee ✕ ✓ ✕ ✕ 
Ryu04 [X]Other chest pain ✓ ✕ ✕ ✓ SE42 Contusnankle+footexc toe(s) ✕ ✓ ✕ ✕ 
S0 Fracture of skull ✕ ✕ ✕ ✕ SE420 Contusion foot ✕ ✓ ✕ ✕ 
S00 Parietal bone fracture ✕ ✕ ✕ ✕ SE421 Contusion ankle ✕ ✓ ✕ ✕ 
S00z #Skull vault NOS ✕ ✕ ✕ ✕ SE42z Contusion ankle and foot NOS ✕ ✓ ✕ ✕ 
S01 Temporal bone fracture ✕ ✕ ✕ ✕ SE43 Contusion toe ✕ ✓ ✕ ✕ 
S010 Cls # bse skl wtout intrcr inj ✕ ✕ ✕ ✕ SE45 Contusion lower limb NOS ✕ ✓ ✕ ✕ 
S011 Cls # base skl wth intrcrn inj ✕ ✕ ✕ ✕ SE46 Traumatic haematoma ✕ ✕ ✕ ✕ 
S01z #Base of skull NOS ✕ ✕ ✕ ✕ SF021 Crush injury larynx ✓ ✕ ✕ ✕ 
S02 Fracture of face bones ✕ ✕ ✕ ✕ SF100 Crush injury penis ✕ ✕ ✕ ✕ 
S020 Closed fracture nose ✕ ✕ ✕ ✕ SF101 Crush injury scrotum and testis ✕ ✕ ✕ ✕ 
S021 Open fracture nose ✕ ✕ ✕ ✕ SF10z Crush injuryext genitalia NOS ✕ ✕ ✕ ✕ 
S022 Fracture of lower jaw, closed ✕ ✕ ✕ ✕ SF110 Crushinjuryback ✓ ✕ ✕ ✕ 
S023 Fracture of lower jaw, open ✕ ✕ ✕ ✕ SF111 Crush injury buttock ✕ ✓ ✕ ✕ 
S0230 Open # mandible (site unsp) ✕ ✕ ✕ ✕ SF2 Crush injury of arm ✕ ✕ ✓ ✕ 
S0238 Op#mandible-bodyother+unspec. ✕ ✕ ✕ ✕ SF20z Crushinjuryshlder+uparmNOS ✕ ✕ ✓ ✕ 
S024 Fracture of upper jaw, closed ✕ ✕ ✕ ✕ SF210 Crushinjuryforearm ✕ ✕ ✓ ✕ 
S0240 Closed fracture maxilla ✕ ✕ ✕ ✕ SF22 Crush injury wrist or hand ✕ ✕ ✓ ✕ 
S0241 Closed fracture zygoma ✕ ✕ ✕ ✕ SF220 Crush injuryhandexcl fingers ✕ ✕ ✓ ✕ 
S025 Fracture of upper jaw, open ✕ ✕ ✕ ✕ SF23 Crush injury finger(s) ✕ ✕ ✓ ✕ 
S0250 Open fracture maxilla ✕ ✕ ✕ ✕ SF230 Closed crush injury finger ✕ ✕ ✓ ✕ 
S0251 Open fracture zygoma ✕ ✕ ✕ ✕ SF231 Closed crush injury thumb ✕ ✕ ✓ ✕ 
S027 Open orbital blow-out fracture ✕ ✕ ✕ ✕ SF233 Open crush injury finger ✕ ✕ ✓ ✕ 
S028 Fracture of skull+facial bones ✕ ✕ ✕ ✕ SF234 Open crush injury thumb ✕ ✕ ✓ ✕ 
S0280 Fracture of nasal bones ✕ ✕ ✕ ✕ SF2y Crush injury arm multiple sites ✕ ✕ ✓ ✕ 
S0281 Fracture of orbital floor ✕ ✕ ✕ ✕ SF3 Crush injury lower limb ✕ ✓ ✕ ✕ 
S0282 Fracture/malar+maxillary bones ✕ ✕ ✕ ✕ SF300 Crushinjurythigh ✕ ✓ ✕ ✕ 
S0283 Fracture of mandible ✕ ✕ ✕ ✕ SF301 Crushinjuryhip ✕ ✓ ✕ ✕ 
S02A Le Fort I fracture maxilla ✕ ✕ ✕ ✕ SF304 Closed crush injury hip ✕ ✓ ✕ ✕ 
S02B Le Fort II fracture maxilla ✕ ✕ ✕ ✕ SF310 Crushinjurylowerleg ✕ ✓ ✕ ✕ 
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S02C Le Fort III fracture maxilla ✕ ✕ ✕ ✕ SF311 Crush injury knee ✕ ✓ ✕ ✕ 
S02x1 #Orbit NOS - closed ✕ ✕ ✕ ✕ SF320 Crush injury foot ✕ ✓ ✕ ✕ 
S02z #Facial bone NOS ✕ ✕ ✕ ✕ SF321 Crush injury ankle ✕ ✓ ✕ ✕ 
S03 Other/unqualif.skull fractures ✕ ✕ ✕ ✕ SF32z Crush injury ankle and foot NOS ✕ ✓ ✕ ✕ 
S030 Closed #skull NOS - no i/c inj ✕ ✕ ✕ ✕ SF33 Crush injury toe(s) ✕ ✓ ✕ ✕ 
S031 Closed #skull NOS + i/c inj. ✕ ✕ ✕ ✕ SJ30 Cervicalnerverootinjury ✓ ✕ ✕ ✕ 
S032 Open #skull NOS - no i/c inj. ✕ ✕ ✕ ✕ SJ305 Cervical nerve root injury - C6 ✓ ✕ ✕ ✕ 
S033 Open #skull NOS + i/c inj. ✕ ✕ ✕ ✕ SJ306 Cervical nerve root injury - C7 ✓ ✕ ✕ ✕ 
S03z Skull fracture NOS ✕ ✕ ✕ ✕ SJ34 Brachialplexusinjury ✓ ✕ ✓ ✕ 
S04 Multiple skull fractures ✕ ✕ ✕ ✕ SJ43 Latrl cutaneous branch T12 inj ✓ ✕ ✕ ✕ 
S040 Mult.#skull,closed-no i/c inj. ✕ ✕ ✕ ✕ SJ513 Open injury median nerve ✕ ✕ ✓ ✕ 
S041 Mult.#skull,closed + i/c inj. ✕ ✕ ✕ ✕ SJ52 Ulnarnerveinjury ✕ ✕ ✓ ✕ 
S042 Mult.#skull,open-no i/c inj. ✕ ✕ ✕ ✕ SJ520 Closedinjuryulnarnerve ✕ ✕ ✓ ✕ 
S043 Mult.#skull,open + i/c inj. ✕ ✕ ✕ ✕ SJ528 Inj/ulnar nerve/wrist+hand lev ✕ ✕ ✓ ✕ 
S044 Mult fractur inv skul+fac bone ✕ ✕ ✕ ✕ SJ534 Inj/radial nerv/wrist+hand lev ✕ ✕ ✓ ✕ 
S04z Mult.skull+other bone # NOS ✕ ✕ ✕ ✕ SJ56 Digital nerve injury ✕ ✕ ✓ ✕ 
S0z Fracture of skull NOS ✕ ✕ ✕ ✕ SJ564 Opn injdigital nerve in fingr ✕ ✕ ✓ ✕ 
S1 Fracture of neck and trunk ✓ ✕ ✕ ✕ SJ566 Injury of digital nerve of thumb ✕ ✕ ✓ ✕ 
S10 #Spine - no cord lesion ✓ ✕ ✕ ✕ SJ60 Sciaticnerveinjury ✕ ✓ ✕ ✕ 
S100 Closed # cervical spine ✓ ✕ ✕ ✕ SJ63 Peroneal nerve injury ✕ ✓ ✕ ✕ 
S1000 Clsd # unsp cerv vertebra ✓ ✕ ✕ ✕ SJ642 Cls inj lat cutan nerve thigh ✕ ✓ ✕ ✕ 
S1001 Closed fracture atlas ✓ ✕ ✕ ✕ SJB0 Injury/ulnarnerve/upparmlev ✕ ✕ ✓ ✕ 
S1002 Closed fracture axis ✓ ✕ ✕ ✕ SK0y1 Compartment syndrome forearm ✕ ✕ ✓ ✕ 
S1003 Clsd # third cerv vertebra ✓ ✕ ✕ ✕ SK0y5 Compartmentsyndromeleg ✕ ✓ ✕ ✕ 
S1004 Clsd # fourth cerv vertebra ✓ ✕ ✕ ✕ SK100 Other cheek injuries ✕ ✕ ✕ ✕ 
S1005 Clsd # fifth cerv vertebra ✓ ✕ ✕ ✕ SK101 Other ear injuries ✕ ✕ ✕ ✕ 
S1006 Clsd # sixth cerv vertebra ✓ ✕ ✕ ✕ SK103 Other lip injuries ✕ ✕ ✕ ✕ 
S1007 Clsd # seventh cerv vertebra ✓ ✕ ✕ ✕ SK104 Other mouth injuries ✕ ✕ ✕ ✕ 
S1008 Cls # atlas-isol arch/art prcs ✓ ✕ ✕ ✕ SK105 Other nose injuries ✕ ✕ ✕ ✕ 
S1009 Clsd # atlas, comminuted ✓ ✕ ✕ ✕ SK109 Scalp injury ✕ ✕ ✕ ✕ 
S100A Clsd # axis, odontoid process ✓ ✕ ✕ ✕ SK10x Other face injuries ✕ ✕ ✕ ✕ 
S100B Clsd # axis, spondylolysis ✓ ✕ ✕ ✕ SK10y Other neck injuries ✓ ✕ ✕ ✕ 
S100C Clsd # axis, spinous process ✓ ✕ ✕ ✕ SK10z Other face/neck injuries NOS ✓ ✕ ✕ ✕ 
S100D Clsd # axis, transvrse process ✓ ✕ ✕ ✕ SK11 Othertrunkinjuries ✓ ✕ ✕ ✕ 
S100E Clsd # axis, posterior arch ✓ ✕ ✕ ✕ SK110 Other chest wall injuries ✓ ✕ ✕ ✕ 
S100F Clsd # axis, tricolumnar ✓ ✕ ✕ ✕ SK112 Other interscapular injuries ✕ ✕ ✓ ✕ 
S100G Clsd # cerv vert, burst ✓ ✕ ✕ ✕ SK113 Other buttock injuries ✕ ✓ ✕ ✕ 
S100H Clsd # cerv vert, wedge ✓ ✕ ✕ ✕ SK114 Other back injuries ✓ ✕ ✕ ✕ 
S100J Cls # cerv vert, spondylolysis ✓ ✕ ✕ ✕ SK115 Other abdominal wall injuries ✕ ✕ ✕ ✕ 
S100K Cls # cerv vert, spinous prcss ✓ ✕ ✕ ✕ SK116 Other flank injuries ✓ ✕ ✕ ✕ 
S100L Cls # cerv vert, trnsvrse prcs ✓ ✕ ✕ ✕ SK117 Other groin injuries ✕ ✓ ✕ ✕ 
S100M Cls # cerv vert, post arch ✓ ✕ ✕ ✕ SK11z OthertrunkinjuriesNOS ✓ ✕ ✕ ✕ 
S100N Cls # cerv vert, tricolumnar ✓ ✕ ✕ ✕ SK121 Other scapular region injuries ✕ ✕ ✓ ✕ 
S100x Multiple clsd # cerv vert ✓ ✕ ✕ ✕ SK122 Other shoulder injuries ✕ ✕ ✓ ✕ 
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S100z Clsd # cerv spine NOS ✓ ✕ ✕ ✕ SK12z Othershould/upperarminj.NOS ✕ ✕ ✓ ✕ 
S101 Open fracture cervical spine ✓ ✕ ✕ ✕ SK13 Other elbow/forearm/wrist inj. ✕ ✕ ✓ ✕ 
S1010 Open # unsp cerv vertebra ✓ ✕ ✕ ✕ SK130 Other elbow injuries ✕ ✕ ✓ ✕ 
S1011 Open fracture atlas ✓ ✕ ✕ ✕ SK131 Injury arm ✕ ✕ ✓ ✕ 
S1012 Open fracture axis ✓ ✕ ✕ ✕ SK132 Other wrist injuries ✕ ✕ ✓ ✕ 
S1013 Open # third cerv vertebra ✓ ✕ ✕ ✕ SK133 Unspecified injury of wrist ✕ ✕ ✓ ✕ 
S1014 Open # fourth cerv vertebra ✓ ✕ ✕ ✕ SK14 Other hand injury (exc.finger) ✕ ✕ ✓ ✕ 
S1015 Open # fifth cerv vertebra ✓ ✕ ✕ ✕ SK140 Unspecified injury of hand ✕ ✕ ✓ ✕ 
S1016 Open # sixth cerv vertebra ✓ ✕ ✕ ✕ SK15 Other finger injuries ✕ ✕ ✓ ✕ 
S1017 Open # seventh cerv vert ✓ ✕ ✕ ✕ SK150 Other finger injuries unsp. ✕ ✕ ✓ ✕ 
S1018 Opn # atlas-isol arch/art prcs ✓ ✕ ✕ ✕ SK151 Otherfingernailinjuries ✕ ✕ ✓ ✕ 
S1019 Open # atlas, comminuted ✓ ✕ ✕ ✕ SK152 Other thumb injuries unsp. ✕ ✕ ✓ ✕ 
S101A Open # axis, odontoid prcss ✓ ✕ ✕ ✕ SK154 Finger injury ✕ ✕ ✓ ✕ 
S101B Open # axis, spondylolysis ✓ ✕ ✕ ✕ SK15z Other finger injuries NOS ✕ ✕ ✓ ✕ 
S101C Open # axis, spinous procss ✓ ✕ ✕ ✕ SK160 Other hip injuries ✕ ✓ ✕ ✕ 
S101D Opn # axis, trnsvrse process ✓ ✕ ✕ ✕ SK161 Other thigh injuries ✕ ✓ ✕ ✕ 
S101E Open # axis, posterior arch ✓ ✕ ✕ ✕ SK17 Injury toe ✕ ✓ ✕ ✕ 
S101F Open # axis, tricolumnar ✓ ✕ ✕ ✕ SK170 Other knee injury ✕ ✓ ✕ ✕ 
S101G Open # cerv vert, burst ✓ ✕ ✕ ✕ SK171 Other leg injury ✕ ✓ ✕ ✕ 
S101H Open # cerv vert, wedge ✓ ✕ ✕ ✕ SK172 Other ankle injury ✕ ✓ ✕ ✕ 
S101J Opn # cerv vert, spondylolysis ✓ ✕ ✕ ✕ SK173 Other foot injury ✕ ✓ ✕ ✕ 
S101K Opn # cerv vert, spinous prcs ✓ ✕ ✕ ✕ SK174 Calf injury ✕ ✓ ✕ ✕ 
S101L Opn # cerv vert, trnsvrse prcs ✓ ✕ ✕ ✕ SK175 Injury of lower leg ✕ ✓ ✕ ✕ 
S101M Opn # cerv vert, post arch ✓ ✕ ✕ ✕ SK17z Knee/leg/ankle/foot injury NOS ✕ ✓ ✕ ✕ 
S101N Opn # cerv vert, tricolumnar ✓ ✕ ✕ ✕ SK1D0 Inj/adductor musc+tendon/thigh ✕ ✓ ✕ ✕ 
S101x Multiple open # cerv vert ✓ ✕ ✕ ✕ SK1E Inj/musc+tendon/lower leg levl ✕ ✓ ✕ ✕ 
S101z Open # cerv spine NOS ✓ ✕ ✕ ✕ SK1x8 Multiple open wounds of lower leg ✕ ✓ ✕ ✕ 
S102 Closed fracture thoracic vertebra ✓ ✕ ✕ ✕ SP04 Hipprosthesisloose ✕ ✓ ✕ ✕ 
S1020 Clsd # thoracic vert, burst ✓ ✕ ✕ ✕ SP04a Dislocation hip joint prosthes ✕ ✓ ✕ ✕ 
S1021 Clsd # thoracic vert wedge ✓ ✕ ✕ ✕ SP04z Hip prosthesis loose ✕ ✓ ✕ ✕ 
S1022 Cls # thorc vert-spondylolysis ✓ ✕ ✕ ✕ SR10 Fracture involv head with neck ✓ ✕ ✕ ✕ 
S1023 Clsd # thor vert-spinous prcss ✓ ✕ ✕ ✕ SR100 Cls fract invol head with neck ✓ ✕ ✕ ✕ 
S1024 Clsd # thorc vert-trnsvrs prcs ✓ ✕ ✕ ✕ SR101 Op fract invol head with neck ✓ ✕ ✕ ✕ 
S1025 Clsd # thorc vert - post prcs ✓ ✕ ✕ ✕ SR11 Fractr inv thrx wth lw bck+plv ✓ ✕ ✕ ✕ 
S1026 Clsd # thorc vert - tricolumnr ✓ ✕ ✕ ✕ SR12 Fractur inv mult reg/1 upp lmb ✕ ✕ ✓ ✕ 
S102y Othr spec clsd # thorac vert ✓ ✕ ✕ ✕ SR120 Cl fr in mult reg one upp limb ✕ ✕ ✓ ✕ 
S102z Clsd # thorac vert NOS ✓ ✕ ✕ ✕ SR121 Op fr in mult reg one upp limb ✕ ✕ ✓ ✕ 
S103 Open # thoracic vertebra ✓ ✕ ✕ ✕ SR13 Fractur inv multi reg/1 lw lmb ✕ ✓ ✕ ✕ 
S1030 Open # thorac vert, burst ✓ ✕ ✕ ✕ SR14 Fract inv mult reg/both lw lmb ✕ ✓ ✕ ✕ 
S1031 Open # thorac vert, wedge ✓ ✕ ✕ ✕ SR140 Cl fr inv mult reg both lw lmb ✕ ✓ ✕ ✕ 
S1032 Opn # thorc vert-spondylolysis ✓ ✕ ✕ ✕ SR141 Op fr inv mult reg both lw lmb ✕ ✓ ✕ ✕ 
S1033 Opn # thorc vert-spinous prcs ✓ ✕ ✕ ✕ SR15 Frct inv mult reg/up lmb+l lmb ✕ ✕ ✕ ✕ 
S1034 Opn # thorc vert-trnsvrse prcs ✓ ✕ ✕ ✕ SR150 Cl fr in mult reg up + low lmb ✕ ✕ ✕ ✕ 
S1035 Opn # thor vert-posterior arch ✓ ✕ ✕ ✕ SR151 Op fr in mult reg up + low lmb ✕ ✕ ✕ ✕ 
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S1036 Opn # thor vert-tricolumnar ✓ ✕ ✕ ✕ SR16 Fract/thorx wth lw bck+plv+lmb ✓ ✓ ✕ ✕ 
S104 Closed fracture lumbar vertebra ✓ ✕ ✕ ✕ SR160 Cl fract/th wth lw bck+plv+lmb ✓ ✓ ✕ ✕ 
S1040 Clsd # lumbar vert, burst ✓ ✕ ✕ ✕ SR161 Op fract/th wth lw bck+plv+lmb ✓ ✓ ✕ ✕ 
S1041 Clsd # lumbar vert wedge ✓ ✕ ✕ ✕ SR20 Disloc,sprns+strns inv hd+neck ✓ ✕ ✕ ✕ 
S1042 Cls # lumbr vert-spondylolysis ✓ ✕ ✕ ✕ SR21 Disl sprn+strn/thrx+lw bck+plv ✓ ✕ ✕ ✕ 
S1043 Cls # lumbr vert-spinous prcss ✓ ✕ ✕ ✕ SR22 Disl,sprn+strn/mult reg up lmb ✕ ✕ ✓ ✕ 
S1044 Cls # lumbr vert-trnsvrse prcs ✓ ✕ ✕ ✕ SR23 Disl sprns+strns/mlt rg lw lmb ✕ ✓ ✕ ✕ 
S1045 Cls # lumb vert-posterior arch ✓ ✕ ✕ ✕ SR24 Disl,sprn+strn/mlt reg u+l lmb ✕ ✕ ✕ ✕ 
S1046 Clsd # lumb vert - tricolumnar ✓ ✕ ✕ ✕ Syu1 [X]Injuries to the neck ✓ ✕ ✕ ✕ 
S105 Open fracture lumbar vertebra ✓ ✕ ✕ ✕ Syu12 [X]Superf inj neck part unsp ✓ ✕ ✕ ✕ 
S1050 Open # lumbar vert, burst ✓ ✕ ✕ ✕ Syu15 [X]Fract oth spec cervic vert ✓ ✕ ✕ ✕ 
S1051 Open # lumbar vert, wedge ✓ ✕ ✕ ✕ Syu16 [X]Fracture other parts neck ✓ ✕ ✕ ✕ 
S1052 Opn # lumb vert, spondylolysis ✓ ✕ ✕ ✕ Syu17 [X]Disloc oth unsp parts neck ✓ ✕ ✕ ✕ 
S1053 Opn # lumb vert, spinous prcs ✓ ✕ ✕ ✕ Syu18 [X]Spr/str jt/lg ot/un pt neck ✓ ✕ ✕ ✕ 
S1054 Opn # lumb vert, trnsvrse prcs ✓ ✕ ✕ ✕ Syu31 [X]Sup inj ab/low back/peluns ✓ ✕ ✕ ✕ 
S1055 Opn # lumb vert,posterior arch ✓ ✕ ✕ ✕ Syu3L [X]Unsp inj abd/low back/pelv ✓ ✕ ✕ ✕ 
S1056 Opn # lumb vert, tricolumnar ✓ ✕ ✕ ✕ Syu4 [X]Inj to shoulder/upper arm ✕ ✕ ✓ ✕ 
S106 Closed fracture sacrum ✓ ✕ ✕ ✕ Syu44 [X]Fract should/upp arm unsp ✕ ✕ ✓ ✕ 
S1060 Clsd compression # sacrum ✓ ✕ ✕ ✕ Syu46 [X]Spr/str oth/un part shl gir ✕ ✕ ✓ ✕ 
S1061 Clsd vertical # of sacrum ✓ ✕ ✕ ✕ Syu4E [X]Unspecif inj should/up arm ✕ ✕ ✓ ✕ 
S107 Open fracture sacrum ✓ ✕ ✕ ✕ Syu5 [X]Inj to elbow & forearm ✕ ✕ ✓ ✕ 
S1070 Opn compression # sacrum ✓ ✕ ✕ ✕ Syu54 [X]Fract of forearm unspecif ✕ ✕ ✓ ✕ 
S1071 Open vertical # sacrum ✓ ✕ ✕ ✕ Syu5F [X]Oth spec inj elbow/forearm ✕ ✕ ✓ ✕ 
S108 Closed fracture pelvis coccyx ✓ ✕ ✕ ✕ Syu5G [X]Unspecif inj elbow/forearm ✕ ✕ ✓ ✕ 
S109 Open fracture pelvis, coccyx ✓ ✕ ✕ ✕ Syu6 [X]Injuries to the wrist and hand ✕ ✕ ✓ ✕ 
S10A Fracture of neck ✓ ✕ ✕ ✕ Syu63 [X]Fract other carpal bone(s) ✕ ✕ ✓ ✕ 
S10A0 Fracture/1st cervical vertebra ✓ ✕ ✕ ✕ Syu64 [X]Fract other metacarpal bone ✕ ✕ ✓ ✕ 
S10A1 Fracture/2nd cervical vertebra ✓ ✕ ✕ ✕ Syu65 [X]Frac oth uns part wrist/hnd ✕ ✕ ✓ ✕ 
S10A2 Multip fracture/cervical spine ✓ ✕ ✕ ✕ Syu66 [X]Spr/str ot/uns prt wris/hnd ✕ ✕ ✓ ✕ 
S10B Fracture/lumbar spine+pelvis ✓ ✕ ✕ ✕ Syu6C [X]Inj int mus/tn ot finwt/hd ✕ ✕ ✓ ✕ 
S10B0 Fracture of lumbar vertebra ✓ ✕ ✕ ✕ Syu6M [X]Unsp injury wrist and hand ✕ ✕ ✓ ✕ 
S10B1 Fracture of sacrum ✓ ✕ ✕ ✕ Syu7 [X]Injuries to the hip and thigh ✕ ✓ ✕ ✕ 
S10B2 Fracture of coccyx ✓ ✕ ✕ ✕ Syu72 [X]Fract other parts of femur ✕ ✓ ✕ ✕ 
S10B3 Fracture of ilium ✕ ✓ ✕ ✕ Syu8 [X]Inj to knee and lower leg ✕ ✓ ✕ ✕ 
S10B4 Fracture of acetabulum ✕ ✓ ✕ ✕ Syu80 [X]Contus oth uns part low leg ✕ ✓ ✕ ✕ 
S10B5 Fracture of pubis ✕ ✓ ✕ ✕ Syu84 [X]Sprn/str oth unsp part knee ✕ ✓ ✕ ✕ 
S10B6 Mult fractur/lumbar spine+pelv ✓ ✕ ✕ ✕ Syu9 [X]Injuries to the ankle and foot ✕ ✓ ✕ ✕ 
S10x Closed # spine, unspecif ✓ ✕ ✕ ✕ Syu94 [X]Fracture of other tarsal bones ✕ ✓ ✕ ✕ 
S10y Open # spine, unspecif ✓ ✕ ✕ ✕ Syu96 [X]Sprn/str oth/unsp part foot ✕ ✓ ✕ ✕ 
S10z #Spine - no cord lesion - NOS ✓ ✕ ✕ ✕ Syu9B [X]Inj oth mus/ten,ank/foot lv ✕ ✓ ✕ ✕ 
S11 #Vertebra + cord lesion ✓ ✕ ✕ ✕ Syu9C [X]Inj uns mus/ten of ank/foot ✕ ✓ ✕ ✕ 
S110 Closed cervical #+cord lesion ✓ ✕ ✕ ✕ SyuB0 [X]Disl/spr/str uns jt/lig trk ✓ ✕ ✕ ✕ 
S1100 Clsd # C1-C4 unspec cord les ✓ ✕ ✕ ✕ SyuB8 [X]Unspecif inj leg lev unsp ✕ ✓ ✕ ✕ 
S1101 Clsd # C1-C4 complete cord les ✓ ✕ ✕ ✕ SyuBJ [X]Inj unsp muscle+tendon trnk ✓ ✕ ✕ ✕ 
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Read 
Code 
Read Term Axial Lower 
Limb 
Upper 
Limb 
Clinician 
Defined 
Read 
Code 
Read Term Axial Lower 
Limb 
Upper 
Limb 
Clinician 
Defined 
S1102 Clsd # C1-C4 ant cord lesion ✓ ✕ ✕ ✕ SyuBK [X]Dsl spr/stn uns jnt+lig arm ✕ ✕ ✓ ✕ 
 
*Codes with multiple clinical terms where alternate terms are located in more than one of the three regions specified in the RRC criteria (axial, upper limb or lower limb). !
A5.3 Somatic symptoms Read code list
Table A5.4 Somatic symptom Read codes.
Physical symptom Read 
code
Clinical term
Irritable bowel 
syndrome
J521 Irritable bowel syndrome
J5210 Irritable bowel syndrome with diarrhoea
Fatigue/tiredness 1682 Fatigue
R0071 [D]Fatigue
168 Tiredness symptom
1683 Tired all the time
1688 Exhaustion
R0075 [D]Tiredness
Headache R040 [D]Headache
R040z [D]Pain in head NOS
1BA8 Temporal headache
1BAZ Headache site NOS
1BB3 Shooting headache
1BB2 Throbbing headache
1BBZ Headache character NOS
1BA4 Bilateral headache
1BA3 Unilateral headache
1BA2 Generalised headache
1BA5 Frontal headache
1BA6 Occipital headache
1BA7 Parietal headache
1BA9 Sinus headache
1B1G C/O - a headache
E2781 Tension headache
1BB Headache character
1BB1 Aching headache
1BB4 Morning headache
1BB5 Heavy head
Eu454 [X]Persistent somatoform pain disorder (P) Psychogenic headache (S)
Fyu5D Cervicogeneic headache
F2626 [X]Tension-type headache
Fyu5E [X]Chronic headache disorder
F26 Migraine
F260 Classical migraine
F261 Common migraine
F2610 Atypical migraine
F2611 Sick headache
F261z Common migraine NOS
F262 Migraine variants
F2620 Cluster headache
F2621 Horton's (histamine) neuralgia
F2626 [X]Tension type headache
F2623 Basilar migraine
F2624 Ophthalmic migraine
F2625 Periodic migrainous neuralgia
F2627 Chronic paroxysmal hemicrania
F262z Migraine variant NOS
F26y Other forms of migraine
F26y0 Hemiplegic migraine
F26y1 Ophthalmoplegic migraine
F26y2 Status migrainosus
F26y3 Complicated migraine
F26yz Other forms of migraine NOS
F26z Migraine NOS
K584 Premenstrual tension syndrome (P) Migraine - menstrual (S)
Numbness/tingling R0206 [D]Numbess
1B44 Has numbness
R0203 [D]Tingling of skin
1B43 Has tingling sensation
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Physical symptom Read 
code
Clinical term
Pain/cramps in the 
abdomen 
R090 [D]Abdominal pain
R0904 [D]Abdominal cramps
R090D [D]Abdominal migraine
Ryu11 [X]Other and unspecified abdominal pain
R090z [D]Abdominal pain NOS
R090N [D]Nonspecific abdominal pain
R090z [D]Abdominal pain NOS
1968 Abdominal discomfort
1969 Abdominal pain
19690 Abdominal wall pain
196A Type of GIT pain NOS
196 Abdominal pain type
197A Generalised abdominal pain
Upper abdominal pain 197B Upper abdominal pain
R0905 [D]Epigastric pain
Dizziness R0040 [D]Dizziness
1B5 Incoordination symptom (P) Dizziness symptom (S)
1B52 Unsteadiness present
1B51 No incoordination
1B54 Giddiness present
1B55 Dizziness on standing up
1B5Z Incoordination symptom NOS
R0042 [D]Light-headedness
R0043 [D]Vertigo NOS
Insomnia E2741 Transient insomnia
1B1B Cannot sleep - insomnia
1B1B0 Initial insomnia
1B1B1 Middle insomnia
1B1B2 Late insomnia
E2742 Persistent insomnia
R0052 [D]Insomnia NOS
R005 [D]Sleep disturbances
R0050 [D]Sleep disturbance, unspecified
R0054 [D]Hypersomnia NOS
R005z [D]Sleep dysfunction NOS
1B1Q Poor sleep pattern
Depression Eu32z [X]Depression NOS
E281 Chronic depression
E2B0 Postviral depression
1JJ Suspected depression
1B1U Symptoms of depression
E2003 Anxiety with depression
9H90 Depression annual review
9H92 Deperssion interim review
Eu412 [X]Mixed anxiety and depressive disorder
8BK0 Depression management programme
Eu341 [X]Dysthymia
Eu32z [X]Depressive episode, unspecified
E130 Reactive depressive psychosis
E204 Neurotic depression reactive type
E113 Recurrent major depressive episode
E112 Single major depressive episode
Eu32 [X]Depressive episode
Eu33 [X]Recurrent depressive disorder
Eu315 [X]Bipolar affective disorder current episode severe depression with psyc 
symp
Eu314 [X]Bipolar affective disorder current episode severe depression no 
psychot symptoms
Eu313 [X]Bipolar affective disorder cur episode mild or moderate depression
Nausea R0700 [D]Nausea
198 Nausea
1982 Nausea present
1983 Morning nausea
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Physical symptom Read 
code
Clinical term
Nausea (cont) 1984 Upset stomach
198Z Nausea NOS
Constipation 19C Constipation
19C2 Constipated
19CZ Constipation NOS
E2645 Psychogenic constipation
J520 Constipation - functional
J5200 Acute constipation
J5201 Chronic constipation with overflow
J5202 Chronic constipation without overflow
J5204 Chronic constipation
J520z Constipation NOS
Nervousness R2y2 [D]Nervousness
E205 Neurasthenia - nervous debility
E200 Anxiety states
E2000 Anxiety state unspecified
E2001 Panic disorder
E2002 Generalised anxiety disorder
E2004 Chronic anxiety
E2005 Recurrent anxiety
E200z Anxiety state NOS
E202 Phobic anxiety
E2020 Phobia unspecified
Eu515 [X]Nightmares
Eu41 [X]Other anxiety disorder
Eu410 [X]Panic disorder (episodic paroxysmal anxiety)
Eu411 [X}Generalised anxiety disorder
Eu413 [X}Other mixed anxiety disorders
Eu41y [X]Other specified anxiety disorders
Eu41z [X]Anxiety disorder, unspecifie
Chest pain 182 Chest pain
1822 Central chest pain
1823 Precordial pain
1824 Anterior chest wall pain
1826 Parasternal pain
1827 Painful breathing - pleurodynia
1828 Atypical chest pain
1829 Retrosternal pain
182B Rib pain
182B0 Costal margin chest pain
182C Chest wall pain
182Z Chest pain NOS
R065 [D]Chest pain
R0650 [D]Chest pain, unspecified
R0651 [D]Precordial pain
R0652 [D]Anterior chest wall pain
R0653 [D]Painful respiration NOS
1825 Pleuritic pain
R0654 [D]Pleuritic pain
R0655 [D]Pleurodynia
R0656 [D]Chest discomfort
R0657 [D]Chest pressure
R0658 [D]Chest tightness
R0659 [D]Parasternal chest pain
R065A [D]Musculoskeletal chest pain
R065B [D]Non-cardiac chest pain
R065C [D]Retrosternal chest pain
R065D [D]Central chest pain
R065z [D]Chest pain NOS
Fever 165 Temperature symptoms
1652 Feels hot/feverish
1653 Fever with sweating
1657 Hot flushes
165Z Temperature symptom NOS
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Physical symptom Read 
code
Clinical term
Diarrhoea J43z Other non-infective gastroenteritis 
19F Diarrhoea symptoms
19F2 Diarrhoea
19F3 Spurious (overflow) diarrhoea
19FZ Diarrhoea symptom NOS
J525 Functional diarrhoea
E2643 Psychogenic diarrhoea
19G Diarrhoea and vomiting
Eu453 [X]Somatoform autonomic dysfunction (P) Psychogenic diarrhoea (S)
J4z Non-infective gastroenteritis NOS
J4zz Non-infective gastroenteritis NOS
Dry mouth 1927 Dry mouth
J0770 Salivary hyposecretion
Itching 1D15 C/O: itching
Eu45y [X]Other somatoform disorders (P) Psychogenic pruritis (S)
M18z Pruritis NOS
Wheezing R0609 [D]Wheezing
1737 Wheezing
R060E [D]Mild wheeze
R060G [D]Severe wheeze
R060F [D]Moderate wheeze
R060H [D]Very severe wheeze
Raynaud’s 
phenomenon 
G7301 Raynaud’s phenomenon 
G730 Raynaud’s syndrome
G7300 Raynaud’s disease
G730z Raynaud’s syndrome NOS
Ringing in ears 1C23 Ringing in ear
F583 Tinnitus
F5830 Unspecified tinnitus
F5831 Subjective tinnitus
F583z Tinnitus NOS
F5832 Objective tinnitus
1C23 Tinnitus symptoms
1C22 Buzzing in ear
1C24 Hissing in ear
1C25 Roaring in ear
1C2Z Tinnitus symptom NOS
Vomiting R0701 [D]Vomiting
199 Vomiting
1992 Vomiting
199z Vomiting NOS
J16y5 Functional vomiting
J162 Persistent vomiting
J1620 Cyclical vomiting
J1621 Habit vomiting
J162z Persistent vomiting NOS
Eu505 [X]Psychogenic vomiting
E2754 Psychogenic vomiting NOS
E2642 Cyclical vomiting - psychogenic
Heartburn R071 [D]Heartburn
R0711 [D]Waterbrash
R0710 [D]Pyrosis
R071z [D]Heartburn NOS
1955 Heartburn symptom
J10y4 Gastro-oesophageal reflux
J16y4 Dyspepsia
195 Indigestion symptoms
1953 Waterbrash
1954 Indigestion
1957 Gastric reflux
1958 Undiagnosed dyspepsia
195Z Indigestion symptom NOS
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Physical symptom Read 
code
Clinical term
Oral ulcers J082 Mouth ulcer
J0820 Minor aphthous ulcer
J0821 Major aphthous ulcer
J0822 Recurrent aphthous ulcer
J082z Oral aphthae NOS
Loss of/change in 
taste 
ZV415 [V]Problem with smell or taste
1924 Loss of taste
R0112 [D]Parageusia
R011z [D]Smell or taste disorder NOS
192A Bad taste in mouth
Seizures 667T Daily seizures
R003z [D]Convulsion NOS
F132z Myoclonus NOS
F2516 Grand mal seizure
E2015 Hysterical seizures
667V Many seizures in a day
R0034 [D]Nocturnal seizure
667S 1 to 7 seizures a week
667Q 1-12 seizures a year
667R 2-4 seiaures a month
F2514 Epileptic seizures - tonic
F2512 Epileptic seizures - clonic
F2503 Epileptic seizures - akinetic
F2502 Epileptic seizures - atonic
F2513 Epileptic seizures - myoclonic
F2556 Simple partial epileptic seizure
Shortness of breath R0608 [D}Shortness of breath
173 Shortness of breath symptom
1738 Difficulty breathing
1739 Shortness of breath
R060A [D]Dyspnoea
2322 O/E - dyspnoea
Loss of appetite R0300 [D]Appetite loss
1612 Appetite loss - anorexia
E2756 Non-organic loss of appetite
Eu50y [X]Psychogenic loss of appetite
Rash 1D14 C/O: a rash
2114 O/E - a rash
M2y42 Vesicular eruption
2227 O/E - rash present
2F0 O/E - discoid rash
R021 [D]Rash and other nonspecific skin eruption
R021z [D]Rash and other nonspecific skin eruption NOS
Easy bruising 16B2 Bruises easily
Hair loss M2400 Alopecia unspecified
1N02 C/O: hair loss
M240 Alopecia
M240z Alopecia NOS
Frequent urination 1A1 Micturition frequency
1A12 Frequency of micturition
1A1Z Micturition frequency NO
Painful urination 1A55 Dysuria
R081 [D]Dysuria
R0810 [D]Painful urination
R0811 [D]Strangury
R081z [D]Dysuria NOS
E2653 Psychogenic dysuria
Muscle weakness 2832 O/E - paresis (weakness)
1B3 Motor symptoms
R0072 [D]Asthenia NOS
Bladder spasms R0832 [D]Urge incontinence
1A26 Urge incontinence of urine
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Physical symptom Read 
code
Clinical term
Hearing difficulties F59 Hearing loss
F590 Conductive hearing loss
F591 Sensorineural hearing loss
F592 Mixed conductive and sensorineural deafness
F594 High frequency deafness
F595 Low frequency deafness
F957 Mild acquired hearing loss
F598 Moderate acquired hearing loss
F599 Severe acquired hearing loss
F59A Profound acquired hearing loss
F59y Other specified forms of hearing loss
F59z Deafness NOS
1C12 Hearing difficulty
1C13 Deafness
1C131 Unilateral deafness
1C132 Partial deafness
1C133 Bilateral deafness
1C16 Deteriorating hearing
1C1Z Hearing symptom NOS
ZV412 [V]Problems with hearing
Dry eyes 1B88 Dry eyes
F4F14 Dry eye syndrome
Hives/welts M28z Urticaria NOS
Muscle pain N2410 Muscle pain
Blurred vision R48y0 Blurred vision NOS
Thinking/remembering 
problem (cognitive 
impairment)
28E Cognitive decline
E2A10 Mild memory disturbance
Sun sensitivity No associated Read codes found on systematic and semantic searching of Read 
code browser.Waking unrefreshed
A92
A5.4 Read codes for FM/CWP differential diagnoses
Table A5.5 Fibromyalgia differential diagnosis Read codes.
Differential diagnosis Read 
code
Clinical term
Rheumatoid arthritis N04* Inflammatory arthropathy
Systemic lupus 
erythematosus
N000* Systemic lupus erythematosus
Muscle pain N2410 Muscle pain
Polymyalgia rheumatica N20* Polymyalgia rheumatica
Ankylosing spondylitis N100* Ankylosing spondylitis
N0450 Juvenile ankylosing spondylitis
Sjögren’s N002* Sicca (Sjogren's) syndrome
Hypothyroidsim C04* Hypothyroidism
C052* Chronic lymphocytic thyroiditis (Hashimotos's disease)
*A search was made for consultations coded with these codes and all daughter codes below them in the Read code 
hierarchy.
A5.5 Frequent attendance in RRCs aged 45+
Table A5.6 Percentage of cases/controls aged 45+ also non-musculoskeletal frequent attenders (top 
10%).
Number (%) of patients also frequent attenders
RRC - All RRC - Clinician RRC - Rohrbeck Controls
Top 10% non-MS FAs*
n
2,412 (34%) 2,075 (35%) 1,105 (37%) 996 (9%)
7,190 5,980 3,009 10,977
*non-MS FAs: non-musculoskeletal frequent attenders
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A5.6 Ambiguous codes sensitivity analysis
Methods
From the list of 5,182 unique musculoskeletal Read codes 584 were unable to be identified as 
specifically regional or generalised and were therefore classified as ambiguous. Codes classified 
as ambiguous represented broad clinical terms with the potential to represent either regional or 
generalised musculoskeletal conditions. In order to establish whether inclusion of ambiguous 
codes influenced the patients returned by the RRC criteria, a sensitivity analysis was performed to 
compare the prevalence of RRCs returned when ambiguous codes were included or excluded.
The cases identified by all regional musculoskeletal codes or the clinician defined code set were 
included in the sensitivity analysis. RRCs identified using the Rohrbeck-2007 code list were not 
included since the code list was predefined. Controls were defined by the presence or regional 
pain only and were therefore also not included in the sensitivity analysis.
Ambiguous codes were incorporated into the criteria (see table 5.1) by adapting the final criterion 
as follows:
At least four consultations for regional musculoskeletal complaints in total during the five year 
period: correlates with four consultations for either regional musculoskeletal complaints  or 
ambiguous musculoskeletal codes during the five year period.
Results
The results of the sensitivity analysis for the inclusion of ambiguous codes is shown in Table A5.7. 
The inclusion of the ambiguous codes appears to have only a small influence on the number of 
patients returned. Total prevalence increases by between 6 and 9 per 10,000 of the population 
with the inclusion of ambiguous codes. The addition of ambiguous codes has a greater influence 
on prevalence in the higher age groups and the female gender, with prevalence increases of 
between 20 and 28 per 10,000 population in women over 65. Overall however, the differences are 
minimal with a similar pattern observed for both groups of cases.
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Table A5.7 Prevalence (per 10,000 population) for RRC-all and RRC-clinician including and excluding 
ambiguous codes.
RRC-all RRC-clinician
Regional codes only Including ambiguous 
codes
Regional codes only Including ambiguous 
codes
Female Male Total Female Male Total Female Male Total Female Male Total
<14
15–24
25–44
45–64
65–75
75+
Total
31 41 36 31 43 37 22 13 17 22 13 17
340 266 303 345 268 306 205 103 154 208 104 156
873 627 749 880 632 755 648 426 536 652 429 539
1,704 1,190 1,447 1,718 1,196 1,457 1,420 959 1,189 1,433 964 1,198
2,098 1,574 1,847 2,119 1,584 1,862 1,810 1,338 1,583 1,830 1,344 1,597
2,298 1,785 2,102 2,326 1,805 2,128 1,808 1,513 1,695 1,829 1,524 1,713
1,173 807 993 1,184 814 1,002 942 624 785 951 627 792
Discussion
The inclusion of ambiguous codes has only a small influence on patients returned. The marginal 
increases in prevalence observed when ambiguous codes are included suggest that these 585 
codes are not used frequently. 
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Chapter 6 appendix
A6.1 Comparison of two- and three-region RRCs
Table A6.1 Comparison of 2- and 3-region RRC-clinician and RRC-Rohrbeck patients and controls on 
age, gender, recorded somatic symptoms, MS and non-MS consultation count and proportion who are 
in the top 10% of attenders (non-MS consultations only) for the years 2005–2009 in the fully registered 
CiPCA population. 
Patient group 
(identified from fully 
registered patients in 
CiPCA population 
2005–2009)
Mean 
age 
(sd)
Number 
female (%)
Mean 
somatic 
symptom 
count (sd)
Mean non-
MS 
consultation 
count (sd)
Mean MS 
consultation 
count (sd)
% also 
non-MS 
FAs (top 
10%)
Total
RRC-clinician-3 60 (15) 2,117 (60%) 3.04 (2.24) 44 (28) 12 (7) 37% 3,507
RRC-clinician-2 59 (17) 2,343 (62%) 2.73 (2.07) 38 (24) 10 (6) 29% 3,800
RRC-Rohrbeck-3 61 (15) 1,211 (62%) 3.06 (2.36) 44 (28) 14 (8) 39% 1,946
RRC-Rohrbeck-2 61 (16) 1,051 (67%) 2.67 (2.15) 39 (23) 11 (7) 30% 1,577
Control 46 (21) 10,215 (50%) 1.22 (1.35) 20 (17) 2 (2) 7% 20,499
MS: musculoskeletal
FA: Frequent attender
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A6.2 Non-specific generalised pain
a. RRC-clinician
Table A6.2 Comparison of RRC-clinician and patients recorded with non-specific pain codes (and the 
overlap between the two groups) on age, gender, recorded somatic symptoms, MS and non-MS 
consultation count and proportion who are in the top 10% of attenders (non-MS consultations only) for 
the years 2005–2009 in the fully registered CiPCA population. 
Somatic 
symptom count
Consultation count
Non-MS MS
Patient group 
(identified from 
fully registered 
patients in CiPCA 
population 
2005–2009)
Mean 
age 
(sd)
% 
female
% 
FAs 
Mean 
(sd)
Median
(IQ)
Mean 
(sd)
Median 
(IQ)
Mean 
(sd)
Median 
(IQ)
Total
 A. RRC-clinician 59 (16) 61% 33% 2.9 (2.2) 2 (1, 4) 41 (26) 36 (22, 53) 11 (7) 9 (6, 13) 7,307
B. NS 60 (18) 67% 27% 2.4 (2.1) 2 (1, 3) 37 (25) 32 (19, 48) 8 (7) 6 (3, 11) 6,466
C. RRC not NS 58 (16) 58% 29% 2.7 (2.0) 2 (1, 4) 38 (25) 33 (21, 50) 10 (6) 8 (6, 12) 5,504
D. RRC also NS 63 (15) 71% 44% 3.6 (2.4) 3 (2, 5) 48 (28) 43 (29, 61) 14 (8) 12 (9, 17) 1,803
E. NS not RRC 58 (19) 65% 21% 2.0 (1.8) 2 (1, 3) 32 (22) 28 (16, 43) 6 (5) 5 (3, 7) 4,463
NS: non-specific pain consulter (including OA)
MS: musculoskeletal
FA: Top 10% non-musculoskeletal frequent attender
b. RRC-Rohrbeck
Table A6.3 Comparison of RRC-Rohrbeck and patients recorded with non-specific pain codes (and the 
overlap between the two groups) on age, gender, recorded somatic symptoms, MS and non-MS 
consultation count and proportion who are in the top 10% of attenders (non-MS consultations only) for 
the years 2005–2009 in the fully registered CiPCA population. 
Somatic 
symptom count
Consultation count
Non-MS MS
Patient group 
(identified from 
fully registered 
patients in CiPCA 
population 
2005–2009)
Mean 
age 
(sd)
% 
female
% 
FAs 
Mean 
(sd)
Median
(IQ)
Mean 
(sd)
Median 
(IQ)
Mean 
(sd)
Median 
(IQ)
Total
 A. RRC-Rohrbeck 61 (15) 64% 35% 2.9 (2.3) 2 (1, 4) 42 (26) 37 (24, 54) 12 (8) 11 (7, 15) 3,523
B. NS 60 (18) 67% 27% 2.4 (2.1) 2 (1, 3) 37 (25) 32 (19, 48) 8 (7) 6 (3, 11) 6,466
C. RRC not NS 60 (16) 61% 31% 2.6 (2.1) 2 (1, 4) 39 (25) 34 (22, 52) 11 (6) 9 (7, 14) 2,594
D. RRC also NS 65 (14) 74% 47% 3.6 (2.5) 3 (2, 5) 49 (28) 45 (30, 62) 16 (9) 14 (10, 19) 929
E. NS not RRC 59 (18) 65% 24% 2.3 (2.0) 2 (1, 3) 35 (24) 30 (18, 46) 7 (6) 5 (3, 9) 5,537
NS: non-specific pain consulter (including OA)
MS: musculoskeletal
FA: Top 10% non-musculoskeletal frequent attender
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